<SEC-DOCUMENT>0001804220-20-000030.txt : 20201105
<SEC-HEADER>0001804220-20-000030.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105074826
ACCESSION NUMBER:		0001804220-20-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGENERON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000872589
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133444607
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19034
		FILM NUMBER:		201288738

	BUSINESS ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591
		BUSINESS PHONE:		9148477000

	MAIL ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REGENERON PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regn-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee,d:bab647050bc248e3930163531a1d57d8--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:regn="http://www.regeneron.com/20200930" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>regn-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml80LTEtMS0xLTA_72f9f22f-0c1c-4a84-96ff-ba4ac61d6b55">0000872589</ix:nonNumeric><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml81LTEtMS0xLTA_f822bcf2-b253-480e-91ce-cb59ad43922a">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml85LTEtMS0xLTA_a325aded-0187-4155-995a-a005fb60923f">2020</ix:nonNumeric><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml8xMC0xLTEtMS0w_f9fab79e-8ea1-4261-8dad-1852c0535ed2">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml8xMS0xLTEtMS0w_54756975-9833-4ec3-8c18-906b32cc1e0b">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="regn-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i92bcdb9b7b864199b967467d316c3c36_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0883093cd35746e1a9961ef2b396311a_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i00959df13c4a47889ab1b2afc9be2d60_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734f13176346421b8ee85411fad81c78_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093941038ceb4a2e8821227dedd1ed05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35263a3519634adea7dcab66a8b1e11c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1dd19a4363b42258975d1bb4365b864_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3235f9163fb4412faece41710cd7e880_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c115ff83ee44b0aa8d8f69f486f45c4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i482f52a211724b65982994e352203f86_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81303cd78a934bbda788e5640aace50b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06871b3ff554800abeeb70d0b62897f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3352f230c1452e890cc614c8897783_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f16611576d448be82f57639682001f2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035f917b860a4f768fe2549dd9543867_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic91b3ef18aaa4ad4a4bf04dc6109978e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecf127247f14d498c30b360496d431a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e9d4d4034b4d7f982d34bd64567768_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic722d7b117f44dfea29c3cd481f51536_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577c609c14224e14bab80ff04411fadc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd60199c2fea4aa6b05d646072ecd355_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0ffcf9d201484c9266a9e0eb9c3699_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1496d62f31ce472a895a9f7ee128dcde_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675c01e82a4f4e03aae9d3f62c0f88a1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5209c4293dba429294a909ce19bcd10f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a442e00aba438eaf835e73a520b7c9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63987c408794f65bf06da42ebd33fdb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e316c4afa634ebfae1c7f8337aa165f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78089fb22ef5491881366c4ba92689ec_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9579d06815ca4b268c93324679499313_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4525169eade14ddd931acd9ebfcd8ca6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia498f71e843b46caa332f9386b2a8a77_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406ac9ba980e4136af01f1c5b4139a6f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i133407deeda04cfcaaca9a0f8b8ce3a7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07264113e8534e54adbff64a62edf458_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b811303f2b4ac48bf302278623bcec_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a8e33e4c564462baa741028cfca1b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e212993795477f8b66d1a401e7449b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35565fb3ae5b4966af577b02b5b1a8a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4784f44bf1f04a1592918d8d7ba96743_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926e5a0e99ba4804814d49ee066a7499_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce1551350fe413883e19b37029324a2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a21886017f4e2184b5ab2de327322b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd8de61d5594cc0a90ae1aa4ec131cd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68fbf82feee845b8bd4480b59aa72864_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5381a9cd688d4fc8a51b1cdde15f6dbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30a2465e1c142e4b97306dd631b2630_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1dbcf1c58b04386b0b8628caf87d9d6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2525fcd8b64f424981d34550a4882b28_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad3302f7141c4de7a1b4ad4a9e1248f3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a59ed42376b439fa09f3f52339203c4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ba7e0bbf404b678cc2a4e9a17e6a98_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e52cf5b7084ff6bdac52905e07508d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81df8d94688a4785b4fcdee55b999ff5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e9062cb41a4ef582967a70ea3d968a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7663889c931a45829c5bd7a59fc6c036_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28eccdf14bd4f3db6fe4948f581213b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31fbe348fcbf489c8e3bce16aba7c016_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida39a32e51e34d42b313e6250995a791_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if627925a7144416dad03494b413c8c61_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d32369eb9904de592697e700da19318_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5854d26eafb49958a08f5eb2ce7d9a0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6aecf582e764d5c8603bb9cedda4ca8_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5e669d94774805aabf0020dadd0d57_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377c1ec369d2482fa9a2758786c551a2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0559295694514aa8be74a966d65f6235_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687d1a3db056417a8c3ae24d7fd80e51_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5368714b52465da523e0607775d0ec_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d3f5064b5a48e29625e4a30f388481_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b26cf777144ecea7d36c98690e9db2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c759feb874484d9c65a0976149d579_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a79bd68191745689351c05a41d63699_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8204fd099a854ea1a40d19bf4c7433b9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940f4ab7445647329c8c94c4fc6ca764_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idedb24cf92424d13afb7f8971ec77486_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8409743b587499c9431d97cf882be4a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1f38aa9fd24905a4230a517daef524_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e068d5db5e440bb019a77918a1f513_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c0d06309ba48f3842f3304738d7c4e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208259b9728c4fb78df67ba613da6db2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93ab20c00413412fb90e7a9897470fa0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if260882197374baea06d232c9dbdae20_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a06a306ebb4c579cddd781e1b375c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe190863af84a0296aa289188b4b233_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee18f385dd8849668c5be259e457682c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00f8b9e2a0b49449c6f19540f28b731_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936c971cd6804e7ab94e27735c0fdef9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia007c7f6d5ed4efca99a88aa3102d6a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib420108285b94badbb732b426062abd7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4a936fac9948ef8229a2a83ad922ea_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60df2d7f3b5418e8a6614f237c06dd7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341faabd353947de903f5e3eff280493_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24811c1ea905459f8e11c86cf166e750_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d26b43c17754b828848943ea0e32972_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2384b7830806480cbeaa6244e94a5866_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd7679bb2cb437b89a2c91b4e76a30b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51906d645bca4b2ca7899fcbd47e0874_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0ba82258c54e758ead2a40321a3329_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedbfb2b1ebb640c1b73cd3e30e74c02f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6d86539ab6438a81f9d17a87d8108d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a52597c51f5412492f6c132bf465821_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc6f6996a634c0e9b097ac2f58e752b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fc78e9a3304a3bac95b0cf117279a6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c30004e4fe94ba4875ced4b468677a8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7289e9b303ae482ab10a155371fd403e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2d6a85606748b6ae2be54b2683aae9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4274b29daf4675ab09b5e77fa76d58_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf0ca2aae29d4d96bd94dc0a09fb6e08_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbbdbae70a344ee9bc01b9143fdf9a7e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b7e691f7dab4bb58c1c0765d7ddc72a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfabd1b7b627426f9a33e66492f38481_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b02c0994812409f96b2fbccef842513_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5aac854b44a486b905645bbb8b852d8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1323fcbcb772436a8c497dcb0925c29a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8fab8149afc476fbcd010d6fac8dfc3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72da8bc596c7486cb41228ce22a460c6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4ff746cc404cf9a2e0326b7e30ecb8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913cae035ec5417db5bb2235faaa5b0c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf58700054b74965a4154a14e0348fc2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id287f840c8b942fb96eb5ac0f597ff16_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i259fa8cda2034a8485dd4d98ae1d54b9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210976468f6d4beea437d37b4aa63663_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0e0f96f1723947e68a27075b552c4719_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e9eead3dd34158b0429a505019d3f1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c5788ee66d4e5e89464da41cc6269a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d16524c09f42f9bc5b0d1c70c5817e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793d1c60fb2e41319710da444819bf38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66079e1a96d94e1eab04aea3ea86a08b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ae37db927b4fae8c60dc4bbeea1188_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77597e8bfdd64fe2bae163eb8fec1490_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7440ca289f91448e86b7140c31a5c495_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3b75b9f9ab41f6b1c862dcdff343eb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629b8945a2b244738e800fb84f2b891d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7992d88a42314fd9959ab26fd254bdc4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a403650d89b4cdbacb41612bdcdc2fa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bc77d612f847c88293dde238e89d6f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858f26c124514e65930d2a7c4d3ae840_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f34054df8504a19a5ad1c41cc47fff2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieccb4e85845442c5b68026da6ae50775_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7812846c7af642bf8c717b3128434e3f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50af2d0e293b46ddb00a3419f1912ad6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f305f8e6ace47fd86b9631dd499da4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50af2638268242f6b59b88d1b6a5770b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39afe508e4c415cbb06cf308ee47ccb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e99f703b684f02a5aa414ea753d8aa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e216705cab94a00b9676a165f2bcefa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d68f82974548b4bee81aecd0a90d14_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e8d4c3b1834a21843449aa8b585d68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975f4a743b164615bd2ef7edf00f00b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c2a84796d544b182e6e74ceb73a585_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155a77df03774a34b4015dc1801c5b18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30550b7dd2b49b4b69c045354a6a07f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e159ae1bc03421c808cd526f3c49fb0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ae24fdf2ba43769cc7901206518a12_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4206c910554d81af805977f3002947_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09a1e9f85cf481ab3cc770922ba3391_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f74bf2738be48258c23b0dcbdaa12ea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f86c58c4b574796881d49e37d000bae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice9e38a9d51f4fbaa964316765d51ca0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424392c0a0484adfafb25cbcffa01a84_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife607ecedd0549008b720df4da98fba3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524b4d40e946437f9cc3badd5234eca4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249d2b86432a4c65bd64b122b30b44a1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd85c66a10c44e869a10593d3b0aae6e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903692403a774f48bb520b2c3aaa8879_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c8625c815b4033956a9b3202d3f56e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1288473dda949c38b342de4f098cc6d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125e5e85d95a405e8280fe383b98b6c0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3725af6673294f5aa8ee78886c09a9af_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9269fb1edbc04cd1ac5f2238658e8872_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789f27d056fe4015b571c9fc45b1bdc3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfa0b97e54d49f7a24ff6f66c316d8b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89320920064f41bf969faeb62c0e0007_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7075e6f52bc44235a553c88375786049_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f314f4872f04da6b2b01389f0883f09_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd6be8d9b3e4d459a816ed46de88b98_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if734d160735a4b25bcf2df8175aebb38_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647137868b2d4017a026a60b257f74d9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b9876c37a342a39a55d03fb7cd497c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768f3f67a5ad413cb73fbc810de0d72b_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie52e1228322949d0906b14737878fbb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18ea0893a48f488d8f88308c3e9ee61b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ac5fc163d3459aa29a0f7e270b195c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62eefa1863e47f7a276818d52328f65_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a032ed700df48e8b4754328ea168c43_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa95e30f69814af0a60388d1bb9f88a6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd823974b604b1390f3616a69d17bd6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc38fd53dce24fa3abe9de323809035c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33902f27fb464f2788858727dc0f48f4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd88b5df537c46f0a7f3172ab2b40960_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e78e3764fb346d9abe7fb4037bb0528_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aef510b4bff453f8d176f79acb15431_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba52ce52c05f40beba9639ea3d78c7d3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e6521a7a684a99872680a1548d3d37_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01db19eff4ba44168b83edd0617cc0bb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f67f970eb284b439ef2084a5ddf0c4e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc03aab082174d41aa16b8adf809207e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042578dd0f7942d0837b6e77eecbd085_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17ddd9842744aaea31d03825f513ff8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0d66d038e84724bc6951ccc43d25a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b24fd379cb345f092d697825567373e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796be097beaf45008b0b52db759c841c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab077eab2b448d4bc8e7af35fdefa59_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5351df69b749490991f52fb2919ecaa6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1febd6b0737446ebac35bb01d092f15_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7058246a9659451f88d94beb0d3ec13e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae545194ff24904a88dd0e9092398b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe3f67d977694fb89ca3de52695ce285_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf58477014064d2aa4d6dc03bb6963ed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85be8c3176d432ca84c44b9cab50dde_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bf72d6126149e4abf801ce66065da4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic184b458c91d499fa1a5711477b97f68_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478c123cbdf04a5693d39fe47d38ee54_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36638689867843109daff532397d136a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8b16b9d02f4c5db91ce70d178e3e91_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa227b8deba441693b33a2fbafddb8e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab2a78eec84461897d6a611b6915df8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9825a846e164e5ea7cfe55e771e11b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f5db47717d49e1844b3f7b3174f1dd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0ade14d07348fea114a6a08fedda5a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f33ed3e59d44118a5a40e3435d58ef8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9d9e2ee1494f5f9a4f9463de7838e6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66510b4d5ffc47b6a9f4b37c4c429ca3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54c03b4823b4871926f13634d87caab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9207f4bbca3f4cf89c0781ee2963e848_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafbbe3c8ece417ea95836d71b2b8d9c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia323b61d6ca54592b8470bc4a3c536af_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f643a7609c4ebfbb43b0e1032cdde6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c6215466c64dd8a803be94b251edda_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id810e98c23264dd7862faff8c51896f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92d56f793334c729cbf51da9cc2bb80_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6371d5d148549828b6707ade5b5f0ea_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id99617e0fbe44be4ba82c4083676868b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911314304b514431af13b55d5a2dc5ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d63c24f0218414e9990379ad00300cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c8ceb313d6d4253941c222abbdda87d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad0c140dee94620bf61713792c263c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d30029d14449749b125424cd027e65_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6ef393ea1f41409b5056fb005e2f77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ac96ed0be24de7b4d78a4154650332_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a8bbfcd7a24b5b824f96ad7338a054_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i713f9254ad4e48be9e5d986625994aa4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13644cdf2ce34c7c8c816531c17bffac_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cbc42470c77425ba7013c4d8b733291_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4de3948dc24c89953087647ee69972_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88b69bb3d8246e492ef775636b3be4e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e7fa786500484f9ecd6a1394da0446_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9dbf1de37814cc591de5f5dfd7367a5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d60d80740cb4c3d8c3264e5a536bb75_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c4643a0fbe4860b2b92747ba930b68_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbc67414a3f4b75a4caa66eca345086_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5b3e8bce4a477b86a941cc7530a23e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06ce8aa5e2b4cc09ea1c19bd54664cc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ca96a034d34a608df2c5923fa76c90_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d96bb16db141e2a860d5637be2962e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2506ac5a2034c828fe5038d9beb37ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541eacb289b24268a93f9d97ac19b713_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e6ac37be9848dda98174ec211537bb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c906750bd44ebfa1472014377a3aa1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358f15a0dd6d48b29acf4a71f823027f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c52905678f44008a79f2f04de098ce4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52447f425dcf49d6b1e10676a99f4280_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b2946c537042c89d7783ab07d85448_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0579df393aca4a968868c9bb40a1ab0e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68f420c9c13e4e23a601c1b506fa4a4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e0aead3d7445da8371fd938402c091_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e14cefc3db84553880f64ccb1fa43bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86accf19d5314b94b2f97f98ad733968_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e0b94218008446f83e54c839d26d417_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5e6f8e04c640e9a3a58b970d0b5099_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i322b98f3dc874456add467767aaa4162_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278d21029b334fdfa0462d06cf1f3130_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e8ef1954ceb4ec99864b1fe9544ceef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7feff46efcfb423cb246abcc1bb4d36a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18805c870e4245d592672c40510db7b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8876032e074445d89ddad2131dd29fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fd969b6c884737a5442b5de99684a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8593ca7502ee42d499fd89567506b6c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31d2a9dd29b41c98f55f6c5305d8e3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8532b49a5daa42f2a3875d2512dbd140_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c2c6d2774a4997916504acf5a44d4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb07d4899f3445b83edd542e47de881_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i490a6a8ff60443ed968309024d4e02ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9093b35e7b624c38a7f019c21a2e9a5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc12bd1bc93d4447ae534aa38c459530_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e42d73bc9440fcb7dfe671ce0e5ccd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771b1c5b394f47639c3f9bdf6695758d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d06b9c5853e400a9847d748ae198625_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:BridgeFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:CommonStockHeldBySanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c14da02ab04b15a697c1f976f6c63b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied42ff47bb2e4f48ad72135de84e2827_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b56bd9207547a3a35c46fed3f56b79_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00da91153ab4285948986d4a8528f33_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5a33a1ef064741af1b75d4df1e7b8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14491178e814761b044424a9d90cc57_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136244d2dc724edcbda67477d4375855_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb343771e004b36a23994024299f080_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7a7a7f0ec7b41ccb9e296ec34a49d62_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76fb63f2f534fd586e297b9d26b3169_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a462a19f724c93b0ad3e5e3df53fa2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>regn:claim</xbrli:measure></xbrli:unit><xbrli:context id="ib4162e2d3ffa40cab347875d0e8141e1_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A165PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ec0cbb09134d05af796df3d6121770_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A741PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-26</xbrli:startDate><xbrli:endDate>2016-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e0c80c71e941b48916ad1f5287ba31_D20170728-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-28</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841077884f1e4957adca717303635407_I20190214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b28b11bf97045e493c30eaae17baf6a_D20200716-20200716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-16</xbrli:startDate><xbrli:endDate>2020-07-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibab647050bc248e3930163531a1d57d8_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80Mjk_58f0a0bf-34d5-4bf0-9602-3e559fba7c2d">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF8xLTAtMS0xLTA_c5335e6e-77a9-4d79-b5be-4b75108965e7">&#9746;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF8yLTEtMS0xLTAvdGV4dHJlZ2lvbjo5Y2NkNTUxNTJhZmU0ZWJjYTRmNTY1OTZmOWE5ZTFkNl8zNQ_d66f8683-eaa7-4ecd-9a7e-1bdd67ec5872">September 30, 2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF80LTAtMS0xLTA_d3b39f47-0c21-4128-ae19-9cc314338c0f">&#9744;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from __________ to __________</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:29.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjVjNjY0YTMyZDYzNDIzMjhmNTdhM2UxMjAyYTZmODMvdGFibGVyYW5nZTpiNWM2NjRhMzJkNjM0MjMyOGY1N2EzZTEyMDJhNmY4M18wLTEtMS0xLTAvdGV4dHJlZ2lvbjpjYmVlMGNiMmZhN2Q0ZjFkOTY1MjVlYTkzMGIwYmZiNF8yOQ_e64552e6-c047-4acb-ac2f-6e5d170a020d">0-19034</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzA_24c2e955-0270-42bb-8e49-f8933fa9371f">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YzZmMDkxOTU5MzkxNGEwNzg5OTQ1YTljNjEzZDJhMjkvdGFibGVyYW5nZTpjNmYwOTE5NTkzOTE0YTA3ODk5NDVhOWM2MTNkMmEyOV8wLTAtMS0xLTA_c784eb22-5944-4d5c-8497-bdd2bf6c1fc5">New York</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YzZmMDkxOTU5MzkxNGEwNzg5OTQ1YTljNjEzZDJhMjkvdGFibGVyYW5nZTpjNmYwOTE5NTkzOTE0YTA3ODk5NDVhOWM2MTNkMmEyOV8wLTItMS0xLTA_82936c0f-3c92-4f76-97e0-a93ae7c82cbe">13-3444607</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV80_d221b722-52ac-4548-b07b-228997f4d670">777 Old Saw Mill River Road</ix:nonNumeric>,  <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV85_327b173d-3a91-40cc-9943-ac19aa21ef61">Tarrytown</ix:nonNumeric>,  <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV8xNA_22e2d912-b9f4-41a3-8996-3e3841830428">New York</ix:nonNumeric>  <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV8xOA_7f678782-385f-4100-94f9-64c3748aaf93">10591-6707</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzE_63ecf41c-da74-4aa6-8c1e-65b819a228d5">914</ix:nonNumeric>) <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzI_c49574ff-42b6-4839-a768-3b8d7f6a5a26">847-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:41.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTAtMS0xLTA_b407dadb-040d-464d-9159-a00fb3f8c6c6">Common Stock - par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTEtMS0xLTA_bd4c3c10-4003-4d1a-991d-e90dcc9f3342">REGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTItMS0xLTA_bb550cc1-caa3-4211-af77-81cb4e22aa3a">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:87.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjZhZGU0NTZjMTEwNDY2YjgwODhhOTU2NjQwZDdlYTUvdGFibGVyYW5nZTpiNmFkZTQ1NmMxMTA0NjZiODA4OGE5NTY2NDBkN2VhNV8wLTEtMS0xLTA_17241d0c-97cf-4799-b82b-384792cc6c1e">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjZhZGU0NTZjMTEwNDY2YjgwODhhOTU2NjQwZDdlYTUvdGFibGVyYW5nZTpiNmFkZTQ1NmMxMTA0NjZiODA4OGE5NTY2NDBkN2VhNV8yLTEtMS0xLTA_1ba8ca45-95d4-4953-bb36-9a80796fd415">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:13.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTAtMS0xLTA_590d193e-4173-4641-ac91-c00108cd2d12">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTEwLTEtMS0w_dd373a9a-ad21-4819-a8b4-afb03dc728f8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTEzLTEtMS0w_eea0c0b1-440a-4aa5-96e2-948357767dfa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:86.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ODRkNWEyODVmMDA4NDhlNWE4OGY3NzdmMTEzNjVmYWUvdGFibGVyYW5nZTo4NGQ1YTI4NWYwMDg0OGU1YTg4Zjc3N2YxMTM2NWZhZV8yLTItMS0xLTA_aaec1fd4-5f03-4320-bd2c-4ee8f2411618">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr></table></div><div style="text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the registrant's classes of common stock as of October&#160;23, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.526%"><tr><td style="width:1.0%"></td><td style="width:47.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92bcdb9b7b864199b967467d316c3c36_I20201023" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NWU0MzZiYmMwNmNmNGEwNDhiMzIwMDYzYWEzOTQ0NzgvdGFibGVyYW5nZTo1ZTQzNmJiYzA2Y2Y0YTA0OGIzMjAwNjNhYTM5NDQ3OF8xLTItMS0xLTA_b6572723-9c09-4005-9e83-12fc0ef28d03">1,848,970</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0883093cd35746e1a9961ef2b396311a_I20201023" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NWU0MzZiYmMwNmNmNGEwNDhiMzIwMDYzYWEzOTQ0NzgvdGFibGVyYW5nZTo1ZTQzNmJiYzA2Y2Y0YTA0OGIzMjAwNjNhYTM5NDQ3OF8yLTItMS0xLTA_5b9f4b5f-a9a2-4396-aff9-3f749a82c9db">104,857,294</ix:nonFraction></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page Numbers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_13">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_16">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_16">eptember</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_16"> 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_16">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19">Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_19">3</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22">Condensed Consolidated Statements of Stockholders' Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_22">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_25">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_28">7</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_67">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_67">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_67">27</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_94">Item 3. </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_94">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_97">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_97">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_97">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_100">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_100">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_103">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_103">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_103">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_106">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_106">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_106">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_109">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_109">85</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_112">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_112">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_112">86</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_115">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_115">87</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "Regeneron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron Genetics Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," and "ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ibab647050bc248e3930163531a1d57d8_13"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="ibab647050bc248e3930163531a1d57d8_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNC0xLTEtMS0w_d0f1dbd0-69ae-4555-839f-1cefa7a89d02">1,573.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNC0zLTEtMS0w_12780a71-08c6-4a8c-9068-4d889d73cfda">1,617.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNS0xLTEtMS0w_58cadfc7-7a91-40a1-ac03-63ba45ace6e3">1,452.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNS0zLTEtMS0w_9afdbc36-8aa6-4d51-8b66-c75fd62cda8e">1,596.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - trade, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNi0xLTEtMS0w_593e8c6d-5328-45c3-b4f5-3a4eed4a3d89">3,092.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNi0zLTEtMS0w_91d61c17-eee6-466c-90d0-5e7725c2e189">2,100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNy0xLTEtMS0w_30c21a6d-1a6c-4f01-b4e9-b3a3622743f0">460.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNy0zLTEtMS0w_d6f30eae-5a76-43b1-b1f6-46451118fb13">260.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOC0xLTEtMS0w_6e0b07d1-1c8e-4529-99c9-f6f824d0674e">486.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOC0zLTEtMS0w_cbf092cf-ad34-4788-b57a-5dafd3b86666">425.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOS0xLTEtMS0w_91c4c2b2-155c-4e63-95c9-f101b26bbfdd">1,801.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOS0zLTEtMS0w_89a4e396-e040-4441-a7bf-22011c3df3a8">1,415.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTAtMS0xLTEtMA_058aa582-2ced-47c7-9086-d2983cca835b">230.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTAtMy0xLTEtMA_1556f97f-a4ab-455a-8a5c-5825ee46187a">273.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTEtMS0xLTEtMA_a1297450-8fc6-49bb-8350-243af7af43b5">9,097.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTEtMy0xLTEtMA_c10d7cab-e006-4e6c-8c8e-cc3001da188d">7,689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTMtMS0xLTEtMA_356eb508-8a83-475b-9ab6-22f3d5e36bee">2,875.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTMtMy0xLTEtMA_f75d6544-38de-40e1-8397-d2e523d206e3">3,256.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTQtMS0xLTEtMA_7e3769dd-7339-46a7-9f5f-528f617b5e19">3,138.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTQtMy0xLTEtMA_44fb101d-36c6-4b26-aeda-5985c01b7909">2,890.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTUtMS0xLTEtMA_de167732-9ad6-44f1-9a22-e51a0ed361e6">804.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTUtMy0xLTEtMA_ac1ff09d-2f8a-4299-9366-7220a7443a25">824.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTYtMS0xLTEtMA_dcbb75b8-d373-4368-a25b-a1f728724d46">168.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTYtMy0xLTEtMA_60ca65ce-c853-4fc6-9ec8-72648327789c">144.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTctMS0xLTEtMA_3c1812ae-9e0c-4172-bd8e-f0ee902f9a19">16,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTctMy0xLTEtMA_525c854d-91ca-4540-b336-c7d5b6b30e89">14,805.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjEtMS0xLTEtMA_166f6777-7c1e-4758-92fe-081f880e28ef">443.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjEtMy0xLTEtMA_7a612afa-eb91-4c60-a5fb-f72bd3e0b531">418.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjItMS0xLTEtMA_db6fd910-654b-4ddb-aa58-51c06fcdf835">1,303.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjItMy0xLTEtMA_19394bb9-ee18-4be2-80e4-b583cf80c5b2">1,211.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjQtMS0xLTEtMA_0eb1315a-f6ad-453a-b896-0521e0def60f">409.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjQtMy0xLTEtMA_e6abb9be-1195-47c6-8427-2739df6490ff">310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734f13176346421b8ee85411fad81c78_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjUtMS0xLTEtMA_20574258-eb96-4cea-b452-0a9d82ebe67a">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjUtMy0xLTEtMA_af3f8842-1440-4fcd-8171-f8f8dcd37952">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjYtMS0xLTEtMA_076500ed-14b5-40a3-b051-fe727cc1d500">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjYtMy0xLTEtMA_da49c2c6-5046-4c4b-b9e3-87d124e2cd02">85.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjctMS0xLTEtMA_0735c538-abff-4cab-9c55-efda342ab62f">2,337.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjctMy0xLTEtMA_1e47bf59-f84f-4080-8aba-ae2dd621f2f4">2,096.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjgtMS0xLTEtNjg5_8232e958-75c6-4be8-a7b6-464076a17e5b">1,978.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjgtMy0xLTEtNjg5_306fb074-c9ca-4c79-bfec-0d9b07cafce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjktMS0xLTEtMA_8fa03f2c-4c31-4f5c-b194-4d07a27615e2">716.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjktMy0xLTEtMA_e6e0849f-e12c-46dc-974a-86c2304d4ea6">713.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzAtMS0xLTEtMA_4ab74318-7d0a-449c-9cd8-171506407c35">37.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzAtMy0xLTEtMA_9d8bec7e-46f3-4515-87cf-6af2756bdc7a">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734f13176346421b8ee85411fad81c78_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzEtMS0xLTEtMA_93a4e5dd-ff41-4036-b7dc-5adcabd313d9">67.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzEtMy0xLTEtMA_f9b2da60-3fea-4112-aedc-878cbfc3007e">77.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzItMS0xLTEtMA_ef3eb7e4-6cc1-42f7-b1fd-f0ee73a994fb">367.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzItMy0xLTEtMA_5689a075-3af3-462a-a6f8-adb5389a2231">482.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzMtMS0xLTEtMA_9dbb0073-7cbe-4f91-b753-fa72cc800ea1">454.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzMtMy0xLTEtMA_72709fcb-c36e-479f-a73f-37998e038834">317.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzQtMS0xLTEtMA_ff69b1af-65eb-433d-8a39-1d07226884d1">5,958.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzQtMy0xLTEtMA_48ce4a28-b66b-479c-89a9-194dce738e16">3,715.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzIy_1be8e282-4aa8-43b3-88e0-af48fb87ab00"><ix:nonFraction unitRef="usdPerShare" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzIy_ea391c57-9adf-48b9-af31-a7276e864259">.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzM2_b2b05b7c-92b6-434e-b626-4cf479b2c12a"><ix:nonFraction unitRef="shares" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzM2_d08d20ac-6979-478d-bc89-476a455df8b6">30,000,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_1df1fa31-56da-44ef-99fa-1770f89105ef"><ix:nonFraction unitRef="shares" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_2b1433f0-4c66-4e59-93d4-236189bcc98a"><ix:nonFraction unitRef="shares" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_3ca4765c-5fcd-45a5-897c-c9e2c120568a"><ix:nonFraction unitRef="shares" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_42b5b262-fc60-4024-a732-65d0a3d32a6d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMS0xLTEtMA_faf99f04-6799-480c-8790-a9b22c479885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMy0xLTEtMA_13f5aef5-ff11-42b2-bc31-52766ab0efd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Stock, convertible, $<ix:nonFraction unitRef="usdPerShare" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzMz_b4a0c588-0649-4253-9a75-cd1e1fdd95b3"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzMz_b629aedc-935c-40e1-8e13-1522d5040997">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzQ3_1bea6414-a168-4dd9-a05b-d5d19a8791ef"><ix:nonFraction unitRef="shares" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzQ3_68ad7584-eaf3-4503-b0e0-5a792458562d">40,000,000</ix:nonFraction></ix:nonFraction> shares authorized; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_1d5eb95a-79c9-4b7a-a7f6-ead2f98e4674"><ix:nonFraction unitRef="shares" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_223d7a4d-541a-470a-b7c2-e31654ce8f3e"><ix:nonFraction unitRef="shares" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_6cbd5075-f26b-4eda-9f05-045bf27293f3"><ix:nonFraction unitRef="shares" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_7f739371-1e42-4e12-aa20-1651d766d31f">1,848,970</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in 2020 and 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMS0xLTEtMA_54926f44-474c-41a7-9662-41e730d3e772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMy0xLTEtMA_f24a54db-bf37-4c7e-9d65-e9fe7b7e654a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzE5_10b3cc76-40c9-4e3a-baf0-6c1edae44e84"><ix:nonFraction unitRef="usdPerShare" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzE5_2fbce3b6-3b70-46dc-92eb-719ffb8a645e">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzMz_5ef93481-ce85-4f21-88b1-b4bbade60ded"><ix:nonFraction unitRef="shares" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzMz_c91cd6e9-4fb4-4248-b352-e39ddb672121">320,000,000</ix:nonFraction></ix:nonFraction> shares authorized; shares issued - <ix:nonFraction unitRef="shares" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0Xzcx_b39ba46d-363b-4a61-8053-8e44bcbdcd5d">120,516,837</ix:nonFraction> in 2020 and <ix:nonFraction unitRef="shares" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0Xzg2_7d32c138-169d-4b65-a53b-1964f22c9cf4">113,288,103</ix:nonFraction> in 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMS0xLTEtMA_2a31078e-feda-46e3-a900-c59ebc5389a0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMy0xLTEtMA_d9603f74-9103-4f3a-8d71-3e66d598e850">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDAtMS0xLTEtMA_bd358afa-746a-4422-9dd0-ce30ffa0f936">6,592.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDAtMy0xLTEtMA_e77159e9-bf91-4c38-8e65-eaebe12fe380">4,428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDEtMS0xLTEtMA_24967643-8d6c-4e40-9dd0-e326a33e9be2">9,743.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDEtMy0xLTEtMA_abab785f-7ff5-49a6-b38b-690e8e4defdd">7,379.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDItMS0xLTEtMA_6cdc903b-7a72-471d-83ba-c58bf6b9cf0b">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDItMy0xLTEtMA_d3b76e8d-559f-4d78-ae88-9f675bf8959b">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjAyZTg0MjkwNjc3ODQ3ZjI5ZTQ1Mzg5ZTVkMTEyMzBkXzI5_cc82cd51-1763-4fee-aeb6-742c6f77c5e7">15,741,824</ix:nonFraction> shares in 2020 and <ix:nonFraction unitRef="shares" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjAyZTg0MjkwNjc3ODQ3ZjI5ZTQ1Mzg5ZTVkMTEyMzBkXzUx_b2ec0c78-9546-4675-a34b-4b5c4e2da4af">4,860,123</ix:nonFraction> shares in 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMS0xLTEtMA_994ea7c8-cefa-49be-95c4-e3a4eef37971">6,242.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMy0xLTEtMA_0b79cfb1-53c7-470a-afc1-63f9422db740">739.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDQtMS0xLTEtMA_a53bd4e7-a137-44bc-9c5c-aa435f86450f">10,125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDQtMy0xLTEtMA_8e09cd73-59c4-45e8-a0a7-d03046eaf54e">11,089.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDUtMS0xLTEtMA_f8253dde-cac2-475a-acc8-084276ef895c">16,084.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDUtMy0xLTEtMA_b224501b-17ee-4d50-b1aa-45958dae3155">14,805.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 12.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC0yLTEtMS0w_c239af0e-67e9-4cf1-a29c-ef31d69282bc">1,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC00LTEtMS0w_bd04e293-9e1a-4ba7-b4c6-2d811006f02a">1,238.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC02LTEtMS0w_85a5efee-b1a8-4905-8425-d897c9f9023a">3,945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC04LTEtMS0w_76bc5f45-48ad-4e86-a3bf-93d36ef5c709">3,548.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1dd19a4363b42258975d1bb4365b864_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS0yLTEtMS0w_f893519b-83e2-4814-b649-4cc7944b182c">353.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS00LTEtMS0w_a41baa19-87f1-4ce1-887b-133ffd7c7235">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3235f9163fb4412faece41710cd7e880_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS02LTEtMS0w_de1d9330-e7c8-4150-9a63-4eeeed108112">869.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS04LTEtMS0w_db545b8c-c874-4188-9eb4-849ef04efc19">232.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c115ff83ee44b0aa8d8f69f486f45c4_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi0yLTEtMS0w_3da64126-1ba9-4ecb-975e-d54aebec446e">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482f52a211724b65982994e352203f86_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi00LTEtMS0w_ebe16145-5127-491a-9cfc-cd5a58a207d2">293.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81303cd78a934bbda788e5640aace50b_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi02LTEtMS0w_aa3921bd-1f4a-45cc-ac9a-8eead314071d">825.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi04LTEtMS0w_c7ef803f-e96c-4323-8247-9135190f1a77">834.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06871b3ff554800abeeb70d0b62897f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy0yLTEtMS0w_9aac8d32-0343-41ca-ba80-4b74bcc57295">158.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy00LTEtMS0w_52183e32-9552-4418-ad77-9fbfac69483d">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3352f230c1452e890cc614c8897783_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy02LTEtMS0w_cefaf36a-7fe3-461d-acfc-a20e944ef57b">433.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f16611576d448be82f57639682001f2_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy04LTEtMS0w_de41301e-80d0-45e3-a684-aec034202498">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC0yLTEtMS0w_26bbc1be-19c5-4167-acec-d412ab5f99a9">2,294.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC00LTEtMS0w_3202c102-6afb-4975-b4e5-e17c3e3063c7">1,743.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC02LTEtMS0w_9fe33893-3e6a-49ee-a1d5-57f93c306f23">6,074.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC04LTEtMS0w_0ced2f3f-617e-4110-a628-144c6623ec05">4,694.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtMi0xLTEtMA_b1779a7a-d588-4c1d-a55e-b3e0898b4586">684.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtNC0xLTEtMA_34f9d3be-132c-4605-ad16-3813aab8e5a5">526.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtNi0xLTEtMA_3a723b48-214f-4792-be5a-2abaaa52fcc7">1,990.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtOC0xLTEtMA_35e74652-8fd0-42a6-adba-2828333c5586">1,897.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItMi0xLTEtMA_05bf44d8-dc82-4222-b578-e27fd2500f74">326.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItNC0xLTEtMA_fa262ee9-b14b-4c17-ae3e-9d4ff8fdbaec">304.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItNi0xLTEtMA_bb1af597-4eb0-4ca6-b057-e211963c1ce2">1,042.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItOC0xLTEtMA_55969fb0-3e3d-4341-9f72-9c8772873ba6">890.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtMi0xLTEtMA_3cd5011d-a6c0-4053-ad72-5f85fe955016">131.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtNC0xLTEtMA_a5705949-560c-4010-ad23-a921d0d2abd4">115.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtNi0xLTEtMA_00bdf20d-c27e-43f1-8f31-487903e633e3">312.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtOC0xLTEtMA_e7052d69-fffd-44d4-884d-55d387bb2d33">253.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035f917b860a4f768fe2549dd9543867_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtMi0xLTEtMA_479ebbb1-8a0e-4c76-9285-9f91df9204f6">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtNC0xLTEtMA_e050a474-7442-4e0a-aef6-ac0486fcf28b">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic91b3ef18aaa4ad4a4bf04dc6109978e_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtNi0xLTEtMA_15616b0c-3009-4919-abc1-485c0d7a9d3c">454.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtOC0xLTEtMA_ca4869e5-e294-4501-96f5-35076ee67837">289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtMi0xLTEtMA_9d354ebf-565f-4e09-b522-8c5e4739f141">44.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtNC0xLTEtMA_90f8ec72-f2d6-4be4-a4d3-a3daded341db">50.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtNi0xLTEtMA_804679f2-1bfc-4f70-bbd3-48262f4b612f">135.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtOC0xLTEtMA_fed1e58f-31d5-4a9b-879a-b0a2aa2400a6">171.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtMi0xLTEtMA_06bda02b-880b-4f54-90c8-c84f9b5f2734">1,240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtNC0xLTEtMA_87c71931-0418-45da-99b8-3a13065bd767">1,005.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtNi0xLTEtMA_ddce5579-808f-492c-91bc-88ef53831cc6">3,664.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtOC0xLTEtMA_91d2d3cf-a20f-4e7e-9424-98761e90429f">3,160.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtMi0xLTEtMA_f2e1df29-638a-4e46-87aa-28f928180e8e">1,053.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtNC0xLTEtMA_e4023517-54da-4473-9db2-826e4b34dc84">738.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtNi0xLTEtMA_3b13b1fc-2055-41fa-9bcb-126d9fdf93b7">2,409.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtOC0xLTEtMA_ac5fdb20-754f-413f-bd83-d41714048131">1,534.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtMi0xLTEtMA_42c5b1a7-a6e7-4d33-a53b-8b603de26a30">28.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtNC0xLTEtMA_d66e3a5c-ada1-48f9-97e1-90c600ca2dcc">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtNi0xLTEtMA_c717d372-86d0-4d3b-8e18-bd00cfba82fd">218.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtOC0xLTEtMA_52cc3a5d-cabe-4f59-95d7-38ece97db440">28.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItMi0xLTEtMA_6da2213e-38e8-4bd0-b164-3d380c92b14d">26.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItNC0xLTEtMA_7b9fa7f4-f139-4a06-b71c-44357c901755">7.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItNi0xLTEtMA_808adc97-f53d-4c0b-af9e-75b2ce337ae3">42.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItOC0xLTEtMA_a5176385-f5f7-40a5-aab6-a419cbb754df">23.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtMi0xLTEtMA_c614e75c-dfab-4cfb-ad9e-ae798ebd472a">54.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtNC0xLTEtMA_1c270f1b-f5f2-467b-80fc-2a9c25f61394">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtNi0xLTEtMA_d838d070-ff8b-44bb-b8f9-993899104d71">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtOC0xLTEtMA_e94e51cd-fb5b-4547-bf52-f413794d221b">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtMi0xLTEtMA_81303265-67a9-44dc-90aa-77bf8653d711">998.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtNC0xLTEtMA_49baa6ba-d31d-42ad-bf16-16aa2cb3d40d">768.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtNi0xLTEtMA_b2a2e04d-0589-456c-89be-e765ad7c7c82">2,585.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtOC0xLTEtMA_7b265d94-874c-49a7-bb21-ce07573db81c">1,539.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctMi0xLTEtMA_d60e2c7a-cff9-490d-b52c-05c64bcf1c00">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctNC0xLTEtMA_793e337d-e021-450e-8a6d-fd631fcf20e0">98.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctNi0xLTEtMA_b59a7a2f-5a93-49e0-9335-082e61572426">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctOC0xLTEtMA_537ec8be-15a1-479d-8081-61d29bc1a740">215.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktMi0xLTEtMA_49a6e178-28a5-4ae3-8ae7-275589249cba">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktNC0xLTEtMA_3aa85e40-b4ad-48fd-b682-80cc2abb660f">669.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktNi0xLTEtMA_0ffc34b8-aed4-4766-b5b0-07994bbeb0d1">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktOC0xLTEtMA_222b42bf-dc84-4d59-b75d-c399fcc64ba9">1,323.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtMi0xLTEtMA_039aed97-1e89-4612-89c4-3d31733e9a70">7.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtNC0xLTEtMA_4e347043-02f3-4044-8728-9ef1ca4e2b55">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtNi0xLTEtMA_fd7eac92-a076-478e-bb83-28ea9c09acec">21.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtOC0xLTEtMA_71073d6b-39b5-4567-a87f-a66d99a424c4">12.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItMi0xLTEtMA_3b934267-5cae-4ed0-b2e3-2337c62a23fc">7.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItNC0xLTEtMA_6216e80b-d152-4750-9add-a84ac881f894">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItNi0xLTEtMA_1bff6f55-574a-4ac8-87c6-fc77e8b88593">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItOC0xLTEtMA_8f0ce353-882c-4a68-a071-587329a72ba2">11.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtMi0xLTEtMA_f6981412-e0a5-4324-8e2b-e731118c2987">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtNC0xLTEtMA_57091313-a9da-4700-aa97-d3c84d99dd84">109.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtNi0xLTEtMA_459ab687-9f2c-41ee-a95f-a34080275346">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtOC0xLTEtMA_2534a12f-558c-4239-9802-4b039ed2a633">109.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtMi0xLTEtMA_af2ed847-03e8-4235-8013-ac4965a1af72">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtNC0xLTEtMA_8e67165f-9982-4993-8eb6-ea42d0a930ea">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtNi0xLTEtMA_ceedf006-d512-4b78-913b-69ff24246285">116.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtOC0xLTEtMA_48bdf911-3af8-4b9e-8a39-311861ca1bab">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtMi0xLTEtMA_5289126f-6fb8-4317-8a20-3b14e1c926d5">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtNC0xLTEtMA_b4bc9de7-47d5-4fc8-828d-ad64642d5f83">669.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtNi0xLTEtMA_3a73fac8-4509-43b2-b2c5-3b2d52e2b4e8">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtOC0xLTEtMA_e7e94548-fb16-4105-80c4-a2068a401b72">1,323.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtMi0xLTEtMA_e816b252-889f-471b-b55a-49655e44ee08">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtNC0xLTEtMA_4003d20c-a08b-48cd-8c20-5b18c6fb842f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtNi0xLTEtMA_93960eea-9a28-43e4-9fe4-9719bc86b1b1">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtOC0xLTEtMA_cf293fe8-111f-468a-912d-5f7b4dd72cdb">31.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtMi0xLTEtMA_4359e042-090c-4a32-9b03-0b05b58f5e37">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtNC0xLTEtMA_f08ebe7b-6ec9-498b-8a04-29298d140670">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtNi0xLTEtMA_be4b855b-7378-4611-83e8-263f5efd11e4">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtOC0xLTEtMA_4951d90f-a7c8-4e27-8861-744c62d539ef">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItMi0xLTEtMA_7d591e5b-3de2-452c-acfc-7cca91b46d5a">837.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItNC0xLTEtMA_825f331c-5ca4-4046-965c-3a983cf4d421">670.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItNi0xLTEtMA_26405fe3-7d4b-40a1-b0b7-01e3d8087eea">2,373.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItOC0xLTEtMA_c1462bb7-93ab-4816-adf5-6d9c9e883ebd">1,352.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.996%"><tr><td style="width:1.0%"></td><td style="width:34.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0yLTEtMS0w_e8e3e16a-ecfe-4042-a8f7-709377aa0ac1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi00LTEtMS0w_243f5a8f-7921-41e4-b503-861b3d6a4b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi02LTEtMS0w_2387245a-c705-4924-be1e-5106aa76cb2d">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi04LTEtMS0w_bbeb83e7-bed4-4038-a1ee-fc6964af7bc3">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecf127247f14d498c30b360496d431a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xMC0xLTEtMA_35258cd2-d622-404e-80c3-24e90e07e853">4,428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e9d4d4034b4d7f982d34bd64567768_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xMi0xLTEtMA_83bccf6f-a191-4308-8578-b731f2e6ee2c">7,379.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic722d7b117f44dfea29c3cd481f51536_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xNC0xLTEtMA_b77d0848-7c80-4c02-b022-05128d9697d7">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xNi0xLTEtMA_d0345aba-d9f6-43a4-b435-605add861316">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xOC0xLTEtMA_33ea1a2b-9308-4b44-9061-0f7face0f663">739.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0yMC0xLTEtMA_e0e476a9-5868-493f-a93c-44496ef18020">11,089.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy02LTEtMS0w_2457f55f-a958-4e91-bb56-9a542868105a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy0xMC0xLTEtMA_b283433f-6bf7-49eb-8306-a19d60ff8516">817.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy0yMC0xLTEtMA_e684881c-411b-4e19-beed-909e89b662aa">817.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC02LTEtMS0w_e859f055-1bea-4dc6-a9d1-d138eae6c734">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC0xMC0xLTEtMA_b912e933-37ca-4b30-906a-1fbbce002e63">155.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC0yMC0xLTEtMA_79ad39d7-bd91-432f-973b-d3124e3fe90a">155.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xMC0xLTEtMA_c6ba00f1-6956-428b-8dd4-1df7f97ed99d">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331" decimals="-5" format="ixt:zerodash" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xNi0xLTEtMA_672b6d17-3545-40e6-aedd-a123edeeb255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xOC0xLTEtMA_57bbbd09-002b-4481-b48b-d64f8ad77b61">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0yMC0xLTEtMA_2789379e-a701-4495-ab39-43bf0547e9e9">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0xNi0xLTEtMA_d9c64854-3342-4479-87fc-5f4993441eeb">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0xOC0xLTEtMA_896e0bfa-a58a-4ba8-b1d9-3f94d7094927">336.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0yMC0xLTEtMA_c6c2b6cc-d2a1-43ad-8204-681671cd1f83">336.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNy0xMC0xLTEtMA_68379b91-fc80-4559-b525-284f38d1dbd7">108.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNy0yMC0xLTEtMA_a0157dfd-f1b9-47e7-83c5-d945221597db">108.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd60199c2fea4aa6b05d646072ecd355_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOC0xMi0xLTEtMA_30dc04ab-96c9-45a9-8e5a-0953b0e48eef">624.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOC0yMC0xLTEtMA_9d119506-b6ec-40f1-9a75-e3938303a41d">624.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb0ffcf9d201484c9266a9e0eb9c3699_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOS0xNC0xLTEtMA_54f52d57-0cd7-4f7e-a376-820bc25fc477">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOS0yMC0xLTEtMA_b650aff9-7b15-42a3-8ac6-c54f906bab86">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMi0xLTEtMA_1c2e5115-d256-4177-b513-06ae13866f30">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtNC0xLTEtMA_3ca0af34-7448-4e12-a861-44a7b82f4c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1496d62f31ce472a895a9f7ee128dcde_I20200331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtNi0xLTEtMA_1b4d4d92-0c26-4a84-8054-ece2687cb643">116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1496d62f31ce472a895a9f7ee128dcde_I20200331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtOC0xLTEtMA_291f61dc-e532-4b25-9252-a37df2498e3e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675c01e82a4f4e03aae9d3f62c0f88a1_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTAtMS0xLTA_d6179d7c-a11c-4b87-b5fc-42d5001d8bbe">5,211.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5209c4293dba429294a909ce19bcd10f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTItMS0xLTA_32f0a801-c5fc-405f-aa78-079528aba727">8,004.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2a442e00aba438eaf835e73a520b7c9_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTQtMS0xLTA_c44eb738-6c60-477e-95ed-cdeff6354f02">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if63987c408794f65bf06da42ebd33fdb_I20200331" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTYtMS0xLTA_d046ee5e-d7df-4e9f-a868-e4c1e3a2631f">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if63987c408794f65bf06da42ebd33fdb_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTgtMS0xLTA_ade170bd-a685-4ba8-9464-cd45a6bcbc77">1,073.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e316c4afa634ebfae1c7f8337aa165f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMjAtMS0xLTA_4e22b8b1-c50a-4e39-bbcf-da3e42e726b8">12,133.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtNi0xLTEtMA_f11e8639-d1d3-413b-966e-2e0d6f39c526">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtMTAtMS0xLTA_ac0e8d07-ec14-4aed-ba6b-7655b1d90b42">1,355.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtMjAtMS0xLTA_910c19aa-d557-4a07-b7d6-ae4a4fd2532a">1,355.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItNi0xLTEtMA_1bfefd88-e4ba-463f-8abb-d2c778c29e90">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItMTAtMS0xLTA_b17e5729-f961-4f3b-8bcd-b68f6a24d6af">416.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItMjAtMS0xLTA_20e835ef-ac5f-4ad8-b75b-78f0830ef36f">416.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTAtMS0xLTA_220cd128-408c-4367-a37d-7cd6a0d5d576">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630" decimals="-5" format="ixt:zerodash" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTYtMS0xLTA_f230793d-c76e-4fea-97c9-07ca4971de97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTgtMS0xLTA_d3f7d2ac-79e8-43f5-a8fe-eaccadd75832">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMjAtMS0xLTA_8c736f90-347d-4c2f-818d-cb3add7191e3">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMTYtMS0xLTA_2e75f7b1-8a23-4fda-a298-5eac0b48b416">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMTgtMS0xLTA_c14976ae-5aa0-4d71-b9ba-ea26045a3538">5,071.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMjAtMS0xLTA_35c2bbbb-0799-450c-9006-4b815254dfdc">5,071.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTUtMTAtMS0xLTA_78234bad-e369-4797-86f0-9429f842b65a">105.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTUtMjAtMS0xLTA_f1b83fae-cb31-424e-bc17-056103bd8b5c">105.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78089fb22ef5491881366c4ba92689ec_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTYtMTItMS0xLTA_52c89546-f4af-41c5-b49b-283405a6b0e1">897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTYtMjAtMS0xLTA_501ea93c-f1ba-441e-b1f8-3b5f2aedee9e">897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9579d06815ca4b268c93324679499313_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTctMTQtMS0xLTA_f71419f8-4355-4d88-9edb-4a53d6c71355">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTctMjAtMS0xLTA_f1329863-2d00-4c5e-9206-34c9be6cda62">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4525169eade14ddd931acd9ebfcd8ca6_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMi0xLTEtMA_4ba83225-dd81-48da-8607-2143ae773089">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4525169eade14ddd931acd9ebfcd8ca6_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtNC0xLTEtMA_ee9cf9e2-33ee-4f47-9bd9-28778e3890c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtNi0xLTEtMA_34913bc9-4cb2-4491-8d86-c893a387131f">119.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtOC0xLTEtMA_59b70bd0-271e-41bc-8f35-1106ba687197">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia498f71e843b46caa332f9386b2a8a77_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTAtMS0xLTA_d6c5b17a-4560-46d1-9323-a853e52cea0d">6,263.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406ac9ba980e4136af01f1c5b4139a6f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTItMS0xLTA_05efc902-80ae-429d-a544-b4862972c0d0">8,901.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133407deeda04cfcaaca9a0f8b8ce3a7_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTQtMS0xLTA_15ee1ed3-c871-43c8-a535-752df8b91f59">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i07264113e8534e54adbff64a62edf458_I20200630" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTYtMS0xLTA_74cfe647-c088-4f08-9fc9-0e2f80a36cec">15.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07264113e8534e54adbff64a62edf458_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTgtMS0xLTA_e842d5c6-5462-4506-af1d-2baca1463fa2">6,142.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b811303f2b4ac48bf302278623bcec_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMjAtMS0xLTA_2202c474-5aa8-4ae3-806f-d6e83f11e546">9,057.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktNi0xLTEtMTgz_8a269d7c-db5f-4bfc-96a5-921f0bf9634c">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktMTAtMS0xLTE4Mw_57c2145d-1c61-49b6-9233-ef73cef7fa6e">297.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktMjAtMS0xLTE4Mw_50ad8363-f83f-44d3-8c8e-f0e8c9544583">297.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtNi0xLTEtMTgz_f49deebf-1b76-4977-9a13-74be967640d7">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtMTAtMS0xLTE4Mw_8f47e52f-faa4-43d8-9f5c-6d4bf847d93d">80.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtMjAtMS0xLTE4Mw_c4ba8758-69dd-40cf-8fba-8a1819d7c6c0">80.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTAtMS0xLTE4Mw_008eebb3-2ebf-4bab-924b-060a7751cb74">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTYtMS0xLTE4Mw_5fe307ce-ccd5-4ff7-8daf-5d17f15b8a9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTgtMS0xLTE4Mw_c9b9a631-633e-4472-bdb8-49385f4cc836">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMjAtMS0xLTE4Mw_6c212db3-af06-414a-bb19-6569bf5cc7fd">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMTYtMS0xLTE4Mw_6eebe03d-468f-438e-ac64-c449e2668709">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMTgtMS0xLTE4Mw_6f246869-9421-440f-826e-3bd77aa42032">100.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMjAtMS0xLTE4Mw_0967e828-768d-4904-9938-f773c296b21f">100.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTAtMS0xLTE4Mw_40e6b3c1-82d5-4e80-b532-0a500a78f55f">104.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMjAtMS0xLTE4Mw_3031d30b-9515-4bb9-a08f-4feb1942745b">104.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a8e33e4c564462baa741028cfca1b5_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMTItMS0xLTE4Mw_d7c65831-fb9f-4044-89c7-6f7696ba82f2">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMjAtMS0xLTE4Mw_b13136bc-b242-4f0d-a8d4-f6e2a54b2351">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86e212993795477f8b66d1a401e7449b_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMTQtMS0xLTE4Mw_32128392-6a6a-4469-ac33-b3241c794389">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMjAtMS0xLTE4Mw_7f1ad5ed-55d9-4c9a-85cd-14ceca3540d3">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMi0xLTEtMTg3_beafbfc8-4999-4a09-a9ad-a5bac507eed6">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtNC0xLTEtMTg3_1a705af3-98d0-4db6-b4b6-836c6b92efc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtNi0xLTEtMTg3_1d0eb87b-6dcd-4628-889a-8258a340c4e9">120.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtOC0xLTEtMTg3_f33d2e73-b0f6-4be5-870f-9b694186ed12">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35565fb3ae5b4966af577b02b5b1a8a6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTAtMS0xLTE4Nw_e174faa0-0582-4b75-b256-5536994dfe8c">6,592.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4784f44bf1f04a1592918d8d7ba96743_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTItMS0xLTE4Nw_c384a80e-f656-4a18-b3be-3145c4b2f78a">9,743.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926e5a0e99ba4804814d49ee066a7499_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTQtMS0xLTE4Nw_69706770-48bf-48be-bda6-fb6c50055e70">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5ce1551350fe413883e19b37029324a2_I20200930" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTYtMS0xLTE4Nw_d7c35db2-9355-45c5-b831-7f606efc7cd2">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ce1551350fe413883e19b37029324a2_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTgtMS0xLTE4Nw_3746f862-cd76-4e0b-8b12-be1e50697ad3">6,242.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMjAtMS0xLTE4Nw_fc338b90-677f-447a-8305-bf58e09cd87c">10,125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.996%"><tr><td style="width:1.0%"></td><td style="width:34.464%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="63" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20a21886017f4e2184b5ab2de327322b_I20181231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMi0xLTEtMA_85810b28-2136-4262-bda5-86d4c9fdc0f5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a21886017f4e2184b5ab2de327322b_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtNC0xLTEtMA_620a6add-1c4b-41b8-acba-ee925943704c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtNi0xLTEtMA_7b518509-ee16-473d-83a8-43e0a3682d01">111.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtOC0xLTEtMA_6070c6e0-cf99-4949-91ed-2dd7278edf38">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd8de61d5594cc0a90ae1aa4ec131cd_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTAtMS0xLTA_dfdf2d71-9590-456e-a1c8-63292a06b2a7">3,911.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68fbf82feee845b8bd4480b59aa72864_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTItMS0xLTA_9aa6b131-a3d3-4dc3-85e6-0e49d0f66aec">5,254.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5381a9cd688d4fc8a51b1cdde15f6dbc_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTQtMS0xLTA_5bff65e0-1ea2-4c27-9f37-585cd2ed484e">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTYtMS0xLTA_74747450-fe1d-48b2-9b6e-b42ebc97192f">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTgtMS0xLTA_dca25a98-bb16-4421-b073-67fcfd44663d">396.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30a2465e1c142e4b97306dd631b2630_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMjAtMS0xLTA_2b5a521a-8d39-4cd5-86ac-609b07226548">8,757.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1dbcf1c58b04386b0b8628caf87d9d6_D20190101-20190331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtNi0xLTEtMA_15337737-04c4-4e7e-b28b-42a5cd8a6de7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMTAtMS0xLTA_6783b697-66d1-4e3e-96b8-5da27814bc59">140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMjAtMS0xLTA_e0862901-3ebf-4e5a-a414-478b518e4fd3">140.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMTAtMS0xLTA_171ff380-ecc4-49df-9783-d625e5c2bd48">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMjAtMS0xLTA_b036f360-c5af-466f-ae13-e342a2b3b243">10.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTAtMS0xLTA_ec0fdf19-c470-409e-95c4-4a98e663767a">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTYtMS0xLTA_261d4f26-7352-48df-9a2f-6ef482dd93d2">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTgtMS0xLTA_5de97b75-45e9-4aad-835a-4b7633ce6d76">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMjAtMS0xLTA_d1b102e9-944c-469a-89a8-e4ce47705a2b">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMTYtMS0xLTA_5ee42d8a-0632-4b44-9ac2-df01ae85ba23">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMTgtMS0xLTA_6b532b1b-91d3-498b-be50-90ff0224c357">54.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMjAtMS0xLTA_47241791-c9b4-4137-a770-b637d88bd80e">54.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjgtMTAtMS0xLTA_0512710d-40d3-498a-a3f6-aa2a5a1d18ac">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjgtMjAtMS0xLTA_32d49ce2-e405-4d62-a63a-a8ff88c03524">114.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment upon adoption of new accounting standard</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2525fcd8b64f424981d34550a4882b28_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjktMTItMS0xLTA_ed956283-4f32-40b9-95aa-a29b2a3a4eda">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3302f7141c4de7a1b4ad4a9e1248f3_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjktMjAtMS0xLTA_9617cd2e-3f96-4fa9-aeda-106885512b2e">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a59ed42376b439fa09f3f52339203c4_D20190101-20190331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzAtMTItMS0xLTA_a79d1264-f087-43b8-bca5-523f34965ccc">461.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzAtMjAtMS0xLTA_6a4a524d-9506-49b0-a456-8bc1ed1de4e0">461.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ba7e0bbf404b678cc2a4e9a17e6a98_D20190101-20190331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzEtMTQtMS0xLTA_28b49a1c-3e3f-4db9-9fd9-7e323513f31d">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzEtMjAtMS0xLTA_59ffaa73-bc9f-4c25-b4eb-539b492dbbe1">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69e52cf5b7084ff6bdac52905e07508d_I20190331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMi0xLTEtMA_4f5a11b0-a8be-4538-81ee-7f2c59ad8d51">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e52cf5b7084ff6bdac52905e07508d_I20190331" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItNC0xLTEtMA_a3620e75-f625-4221-bd9f-1de14e08a3c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81df8d94688a4785b4fcdee55b999ff5_I20190331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItNi0xLTEtMA_9dc05046-1084-49fc-982e-e166976087a0">111.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81df8d94688a4785b4fcdee55b999ff5_I20190331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItOC0xLTEtMA_d4773826-94ef-41a2-91af-59003725db50">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e9062cb41a4ef582967a70ea3d968a_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTAtMS0xLTA_08966f29-40b4-43b0-bb52-f43072e1184b">4,160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7663889c931a45829c5bd7a59fc6c036_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTItMS0xLTA_64e4d32d-a168-4ccc-a134-11acab72949d">5,725.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28eccdf14bd4f3db6fe4948f581213b_I20190331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTQtMS0xLTA_2227144d-f27a-4a3f-ad5a-2ecc66a84170">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i31fbe348fcbf489c8e3bce16aba7c016_I20190331" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTYtMS0xLTA_1a1004d3-ff3f-4173-aff1-45761fed403c">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31fbe348fcbf489c8e3bce16aba7c016_I20190331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTgtMS0xLTA_6f3806c3-9bab-434f-bac0-0dc5760a2c79">444.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida39a32e51e34d42b313e6250995a791_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMjAtMS0xLTA_d7c4c713-93e1-43a1-abb6-409c1286e3f7">9,444.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if627925a7144416dad03494b413c8c61_D20190401-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtNi0xLTEtMA_4ac6bcbd-169d-43b1-b500-5346cfcddff6">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtMTAtMS0xLTA_62a7fe06-a363-4d46-aa21-9b367cd60d19">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtMjAtMS0xLTA_24f667ba-7d09-4f2f-b0f4-0a2fb67524eb">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if627925a7144416dad03494b413c8c61_D20190401-20190630" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtNi0xLTEtMA_77e62739-2793-418b-b023-20e3673a226a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtMTAtMS0xLTA_19a1e491-e863-484b-8293-164c1a17f948">29.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtMjAtMS0xLTA_9d538802-3f9a-4c0d-99e3-e8d6f9e8eb49">29.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMTAtMS0xLTA_b32bcdcd-0bd6-4c3f-8822-12cb5b8f62d3">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5854d26eafb49958a08f5eb2ce7d9a0_D20190401-20190630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMTgtMS0xLTA_03d4efb4-c02f-475c-9521-f51b4644dff8">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMjAtMS0xLTA_57fbf4a0-a246-4483-b73f-da6360825aaa">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzYtMTAtMS0xLTA_4d4026de-ccf6-4dfc-a9f5-f76f74130f3d">109.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzYtMjAtMS0xLTA_0d82ecf5-fbcf-4478-abff-84267a02341a">109.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6aecf582e764d5c8603bb9cedda4ca8_D20190401-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzctMTItMS0xLTA_436b2eae-8292-40ef-8481-daca6c0dfbc2">193.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzctMjAtMS0xLTA_1626b1dd-673c-4bde-a124-9af2f1bb6db8">193.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e5e669d94774805aabf0020dadd0d57_D20190401-20190630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzgtMTQtMS0xLTA_11f8329b-54b4-4238-b594-6fd53e155b9d">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzgtMjAtMS0xLTA_11f61342-a293-4a00-aee0-28d8b00ad245">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i377c1ec369d2482fa9a2758786c551a2_I20190630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMi0xLTEtMA_89679985-f391-42b3-9c18-914951432bf4">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377c1ec369d2482fa9a2758786c551a2_I20190630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktNC0xLTEtMA_b4278fcf-a284-4b08-a633-9027e3cfb0fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0559295694514aa8be74a966d65f6235_I20190630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktNi0xLTEtMA_3aec0d5a-946b-4c28-add6-b87869f1d252">111.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0559295694514aa8be74a966d65f6235_I20190630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktOC0xLTEtMA_2f0810ce-acd8-4292-a012-607eb2b0c19d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687d1a3db056417a8c3ae24d7fd80e51_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTAtMS0xLTA_aaead11f-2d62-4b61-baea-b07cce97b4c6">4,263.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5368714b52465da523e0607775d0ec_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTItMS0xLTA_b96c9387-bd86-46e8-8555-54ebb7bf6a93">5,918.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d3f5064b5a48e29625e4a30f388481_I20190630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTQtMS0xLTA_61706fa3-2a16-4465-81f7-0a94966002a1">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTYtMS0xLTA_b22e73c7-b170-43f0-8940-e09ddb511926">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTgtMS0xLTA_0d205916-8951-4eae-b269-f8f5bece59cc">441.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b26cf777144ecea7d36c98690e9db2_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMjAtMS0xLTA_aa5bb63e-d48b-48d5-a154-f9e6261a40d2">9,755.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtNi0xLTEtMTk2_e62b0047-b014-4c79-9c52-e5dd1a863168">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtMTAtMS0xLTE5Ng_e777c010-2d4d-494b-a692-c9402597f1dd">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtMjAtMS0xLTE5Ng_4f4101b3-3a99-4858-992c-aa1427977ea6">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktNi0xLTEtMTk2_3c12bc7f-0b50-4d3b-a766-d9eb901f5fe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktMTAtMS0xLTE5Ng_14db3bc7-60a1-4b4a-bc4a-d0ca0af02362">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktMjAtMS0xLTE5Ng_81f639bf-bd49-4f96-8518-e8f9dcee9a1f">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMTAtMS0xLTE5Ng_d061d05a-6910-40b3-a3c2-a7f7b705478e">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMTgtMS0xLTE5Ng_4884a963-290b-4275-8b2e-cfdd7bae4ab0">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMjAtMS0xLTE5Ng_b3632944-e320-41d5-a1f4-193085927828">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMTYtMS0xLTE5Ng_9d2e5445-ef2e-4216-9b6a-f1a081a67594">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMTgtMS0xLTE5Ng_61418293-39ce-409d-a8c1-6da30d22d7a2">48.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMjAtMS0xLTE5Ng_ff9d60ca-3f46-4384-b060-b26d1779de4e">48.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of Class A Stock to Common Stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3a79bd68191745689351c05a41d63699_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMi0xLTEtMjUx_dc3de400-e903-4d37-8d91-f46c9f0c4f7f">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItNi0xLTEtMjUx_301f4ed9-3d51-4236-8102-7584cdb4232c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMjAtMS0xLTI1MQ_616c440d-c01f-4991-9a73-9428d7f15e4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMTAtMS0xLTE5Ng_a414b0e7-087f-458f-8ae3-68fff290c5bb">112.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMjAtMS0xLTE5Ng_97141f2f-5b85-47e6-a7f0-b44b203b2766">112.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8204fd099a854ea1a40d19bf4c7433b9_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTQtMTItMS0xLTE5Ng_a91bc911-1552-449a-8840-043f3ec41a54">669.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTQtMjAtMS0xLTE5Ng_8a7d0ad3-5622-42e7-9b96-43f7671fc079">669.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940f4ab7445647329c8c94c4fc6ca764_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTUtMTQtMS0xLTE5Ng_2023c794-cb40-41e2-a58c-556e60cdabdc">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTUtMjAtMS0xLTE5Ng_dd22382c-4b85-4978-a22c-8c0120f0b529">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idedb24cf92424d13afb7f8971ec77486_I20190930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMi0xLTEtMTk2_e2d9b042-212a-48f3-b93e-bb7e6766b08a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idedb24cf92424d13afb7f8971ec77486_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtNC0xLTEtMTk2_6ea8684a-22d4-4a4c-b28e-76d7fde9eb4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtNi0xLTEtMTk2_456fd602-2f63-4de5-aced-aedd279f1571">112.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtOC0xLTEtMTk2_2653df92-3239-4ae5-8f20-bd439ba7810f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8409743b587499c9431d97cf882be4a_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTAtMS0xLTE5Ng_767c8a55-9fd1-452d-bb6b-153ae0d5670b">4,388.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1f38aa9fd24905a4230a517daef524_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTItMS0xLTE5Ng_91895f70-1f70-44ba-b3bb-4fb7b1dc01e3">6,587.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e068d5db5e440bb019a77918a1f513_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTQtMS0xLTE5Ng_79144c4e-e477-4d69-b2e6-951a7fd810cd">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24c0d06309ba48f3842f3304738d7c4e_I20190930" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTYtMS0xLTE5Ng_49f4e6c0-1d54-47f3-9cd3-b641405905fc">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24c0d06309ba48f3842f3304738d7c4e_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTgtMS0xLTE5Ng_8dc7f6d3-0a58-476f-bce9-b0684094a5fc">488.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMjAtMS0xLTE5Ng_3bdcfd83-60a3-4d02-b0e0-622c93b87303">10,504.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="63" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMy0yLTEtMS0w_dfb9d71f-8181-4d00-bb92-885ca28ecb0e">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMy00LTEtMS0w_3c083c20-1a75-49c5-9b16-e90ec410d96c">1,323.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNS0yLTEtMS0w_af9f821a-c85f-419d-a925-d44f0d10a834">174.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNS00LTEtMS0w_34099cbb-7fc8-4d30-a6ee-5e40c305ace3">156.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNi0yLTEtMS0w_ec611798-385c-48a9-af6a-28c1a4084c46">310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNi00LTEtMS0w_6e0de783-d1d9-4d11-b49c-be4fb91ad16e">330.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNy0yLTEtMS0w_d7639f07-53b2-4cc9-99cf-45a61c9d949e">111.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNy00LTEtMS0w_01869839-7a7f-40f7-a38e-4535002604fd">113.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfOC0yLTEtMS0w_85adc75c-d8e9-4575-9d73-14efceb02548">117.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfOC00LTEtMS0w_03122a7b-a281-4a3e-971d-6aacc6d31262">110.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in Sanofi, trade, and other accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTAtMi0xLTEtMA_49fb3036-7ae7-463a-91df-44161fb14021">1,275.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTAtNC0xLTEtMA_2f2c6fa8-a389-40f4-9cb8-8b2cb5eb099f">464.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTEtMi0xLTEtMA_c941c38c-9348-45d3-a617-05ddd57b0a1f">402.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTEtNC0xLTEtMA_33ebdc16-1669-490c-830b-7b22925a9f8b">227.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTItMi0xLTEtMA_13b6cc0b-7614-4c0a-836c-817384829dc1">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTItNC0xLTEtMA_44fc92b3-a505-4da6-90f4-f7f4db02e953">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTMtMi0xLTEtMA_413334af-97eb-4a35-b732-3738f0bd5123">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTMtNC0xLTEtMA_721dd523-f869-4da4-89ce-e3585ee9f4b6">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable, accrued expenses, and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTQtMi0xLTEtMA_90abec40-7657-494e-bbf4-4e9b159a99c1">80.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTQtNC0xLTEtMA_ac14f253-1315-4969-ac9c-c1aa18fbd99e">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTUtMi0xLTEtMA_13786f1f-88a9-4d79-ac41-d0554421c896">976.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTUtNC0xLTEtMA_835e34bb-e612-4e7b-8893-9e0f87b3c900">318.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTYtMi0xLTEtMA_b1f7ab23-2e80-44af-a8a8-6e21bd5a7c5f">1,387.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTYtNC0xLTEtMA_ffdf97a9-8316-4b9f-bbb3-b28fa4076db6">1,642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable and other securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTktMi0xLTEtMA_09f2dc39-86a3-4a5c-afa2-372b3b98c40f">2,642.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTktNC0xLTEtMA_3f7d3d1f-5cc1-43c1-8192-a5e30cb28b04">2,834.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales or maturities of marketable and other securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjAtMi0xLTEtMA_3a4ed476-f4f5-4fce-9aaa-9f1e2e38a241">3,330.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjAtNC0xLTEtMA_f57ce5a3-0594-4509-8c44-75c4949fa8c7">1,306.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjEtMi0xLTEtMA_fd4c0c9e-0fd0-4b85-95a0-5ea67623cb4d">453.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjEtNC0xLTEtMA_ee75bc93-4091-49ea-b804-bd3e646828f9">290.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjItMi0xLTEtMA_74aa7c19-675d-4b86-8ed9-bd0e9444fa2f">234.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjItNC0xLTEtMA_53d2fc05-69d4-46bd-9265-1b3d01f4056f">1,819.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtMi0xLTEtMTY3Mw_6681e119-b90b-4b30-bc58-e08ebb7c90d0">1,981.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtNC0xLTEtMjcxNA_ebec76ad-0a07-4242-b4e6-bec8af050d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bridge loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtMi0xLTEtMA_03e9489f-690d-461f-9328-7268d765f3f6">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtNC0xLTEtMA_50477354-2892-4b89-b3b3-d5d90304c93b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of bridge loan facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtMi0xLTEtMTY1OQ_c5f99b1e-3d82-4cb7-b565-ad4c5600ca61">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtNC0xLTEtMTY2Mw_86c5b9a6-9bea-4c09-9024-ca97f542fe95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtMi0xLTEtMA_0542ea34-d222-4088-8491-5485ce65f16c">2,471.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtNC0xLTEtMA_58b8ee6b-8b19-4960-ad6f-271d49dceb7a">163.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments in connection with Common Stock tendered for employee tax obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjctMi0xLTEtMA_9edc6dbf-0435-4c04-aa47-e4e5e9ec912d">652.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjctNC0xLTEtMA_6631c457-8d67-4474-9bbc-af3e8c1cd538">40.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjgtMi0xLTEtMA_720de301-1fed-483e-b3f1-76e13e19ecca">5,465.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjgtNC0xLTEtMA_66f2be34-3443-46d3-986e-87770e31c5a1">29.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjktMi0xLTEtMA_3fb13b0f-297a-4d3d-b725-1d8924e5b89f">1,665.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjktNC0xLTEtMA_1cf83679-f590-4519-a076-a68fbbc7c4ab">93.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzEtMi0xLTEtMA_6b299691-3b5d-4737-a955-a069ea368817">43.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzEtNC0xLTEtMA_0027a135-9d8e-48e6-a1e1-859630c721ab">82.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzMtMi0xLTEtMA_bb1950fc-59cc-431b-b315-25653dd98b19">1,630.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30a2465e1c142e4b97306dd631b2630_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzMtNC0xLTEtMA_42eb7be2-849a-492d-948d-a8e55c4a8637">1,480.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzUtMi0xLTEtMA_4dbd7b54-81ea-4abf-aa9a-5020ce877edf">1,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzUtNC0xLTEtMA_6c01f66a-22c4-498c-8a1f-b03c6161e6c3">1,397.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_28"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><div><span><br/></span></div><div id="ibab647050bc248e3930163531a1d57d8_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYxOQ_71f7fe77-63d4-4575-a067-639d7ea185a3" continuedAt="i7b51577ab9ef48ad80789e4fda618d9d" escape="true">Interim Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i7b51577ab9ef48ad80789e4fda618d9d" continuedAt="i36d8de5ae9574b88a42495747d6a7b7c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyMw_5cdb53d8-7316-43bd-94f9-57e297a4eff7" continuedAt="i5b58164f42d84db79724cf43be6b6884" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b58164f42d84db79724cf43be6b6884">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2019 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we changed the presentation of cost reimbursements from collaborators who are not deemed to be our customers from collaboration revenue to a reduction of the corresponding operating expense (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, either Research and development or Selling, general, and administrative) incurred by us. We also changed the presentation of amounts recognized in connection with up-front and development milestone payments received from collaboration revenue to other operating income. We made these changes in presentation because we believe the new presentation is preferable, as it better reflects the nature of the Company&#8217;s costs incurred and revenues earned pursuant to arrangements with collaborators and enhances the comparability of our financial statements with industry peers.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation has been applied retrospectively. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyNg_210cdbf5-cae4-471b-b16c-a8bfd2e845ce" continuedAt="i8086c098050f4a3c8f08ad42e52288e1" escape="true">The tables below present the impact of the change on the Company&#8217;s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company&#8217;s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company&#8217;s previously-filed Consolidated Statements of Stockholders&#8217; Equity.  </ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><ix:continuation id="i8086c098050f4a3c8f08ad42e52288e1" continuedAt="i75032bc46a704d82aa7bc585f268d7f0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:46.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Balance Sheet Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi0yLTEtMS0w_b6cccf5a-2ef7-407d-8653-0020b62e94e4">1,086.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231" decimals="-5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi00LTEtMS0w_50231bda-3586-4c97-b504-dfca7f31eb0d">124.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi02LTEtMS0w_c0eedf4f-fa52-4768-9884-a1d45ae2228a">1,211.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy0yLTEtMS0w_396a67ea-cec1-4010-bacb-ad21622c4ec0">395.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if260882197374baea06d232c9dbdae20_I20191231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy00LTEtMS0w_fa6a5833-1df7-4ac4-8a26-cf0e2d3e0128">85.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy02LTEtMS0w_014a2dfb-0dfd-4150-a9dc-27924b99b854">310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (current)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a06a306ebb4c579cddd781e1b375c6_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC0yLTEtMS0w_a7046ae1-f416-45eb-82a5-3a1ca958f59b">196.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe190863af84a0296aa289188b4b233_I20191231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC00LTEtMS0w_36205649-63b4-4d82-9c25-19214bb31c55">124.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC02LTEtMS0w_2212a20c-f8fc-4b5d-9770-2911f05ed2d3">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS0yLTEtMS0w_e775f7b3-864b-44ea-9fab-5806740315e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS00LTEtMS0w_81a2b824-8b65-4254-802e-951c157dea2a">85.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS02LTEtMS0w_7f3e2dda-862c-4a15-aded-3c10cc10713c">85.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi0yLTEtMS0w_76f93769-56f7-43f7-84e5-88ba1ab86404">509.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if260882197374baea06d232c9dbdae20_I20191231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi00LTEtMS0w_203ca74c-7ff6-4bca-80ee-196f6f4745a3">482.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi02LTEtMS0w_a00cc79d-d22c-472d-842c-2952e697005c">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (noncurrent)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a06a306ebb4c579cddd781e1b375c6_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy0yLTEtMS0w_e2796d9e-4f06-4a34-9a04-8168f6600f2a">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe190863af84a0296aa289188b4b233_I20191231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy00LTEtMS0w_9881e2f3-22f2-47b1-987c-8818dc40083b">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy02LTEtMS0w_f436a8ca-5870-40ec-9e7e-8ad9969f2c10">77.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC0yLTEtMS0w_adb77fda-0a38-434c-a65d-0e362d4fbd0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if260882197374baea06d232c9dbdae20_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC00LTEtMS0w_c8792565-f57b-4d8b-abb6-61e0e8525d2a">482.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC02LTEtMS0w_0c8460c9-ad25-4004-895d-10f0c3d2130e">482.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS0yLTEtMS0w_5f2b24a8-a93b-46c3-bc71-2251dd767da4">286.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS00LTEtMS0w_73433392-a444-4de6-b2e2-64933224ab48">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS02LTEtMS0w_e03c2c03-5f53-47dd-a120-be8ce60f5ae2">317.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i36d8de5ae9574b88a42495747d6a7b7c"><ix:continuation id="i75032bc46a704d82aa7bc585f268d7f0"><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18f385dd8849668c5be259e457682c_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0yLTEtMS0w_a99ef078-d84d-4631-9591-83a0ba1bf089">404.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic00f8b9e2a0b49449c6f19540f28b731_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi00LTEtMS0w_e1ce017a-cdb2-4f78-9694-ac5fb6a945f0">229.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi02LTEtMS0w_f0ba655e-2671-4185-a374-776ca833139b">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936c971cd6804e7ab94e27735c0fdef9_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi04LTEtMS0w_8f8a580b-7c43-40a1-9ad3-2642dc9e7938">999.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia007c7f6d5ed4efca99a88aa3102d6a6_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0xMC0xLTEtMA_af57cc9d-a267-4a98-b906-b04879c29f66">766.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0xMi0xLTEtMA_dfcb25f1-7a47-48ad-96cc-6efc6790c697">232.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib420108285b94badbb732b426062abd7_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0yLTEtMS0w_b4217b40-3f7e-4614-9820-3050b9d28c85">302.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief4a936fac9948ef8229a2a83ad922ea_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy00LTEtMS0w_2a092e41-8a95-4f8b-8100-b90de90f9277">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482f52a211724b65982994e352203f86_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy02LTEtMS0w_56380e75-c185-4969-af7d-4aaabdc25cdb">293.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60df2d7f3b5418e8a6614f237c06dd7_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy04LTEtMS0w_44918eae-6961-43cc-9db0-a9303d653122">868.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i341faabd353947de903f5e3eff280493_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0xMC0xLTEtMA_786a5c55-06f9-4a0d-9b99-412f6149d1ed">33.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0xMi0xLTEtMA_0acf6829-3c1a-4554-bd10-8f4587163e83">834.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24811c1ea905459f8e11c86cf166e750_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0yLTEtMS0w_ab49b12b-6585-4855-a807-9d6792f5c446">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d26b43c17754b828848943ea0e32972_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC00LTEtMS0w_c2606ffd-92c4-4ba0-bcf5-17304dda1627">66.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC02LTEtMS0w_9b8f835f-0dfe-43e2-8e76-c487617d9b6b">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2384b7830806480cbeaa6244e94a5866_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC04LTEtMS0w_e98726fc-efc2-4500-95d7-218238d5a495">278.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cd7679bb2cb437b89a2c91b4e76a30b_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0xMC0xLTEtMA_5199cdf0-d153-4927-8c8d-ff8049a48d9d">199.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f16611576d448be82f57639682001f2_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0xMi0xLTEtMA_071f82a9-e51d-40d6-8a94-2936a4755308">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0yLTEtMS0w_992b5a6b-7878-4fcb-8e65-fe8696b15d97">2,048.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS00LTEtMS0w_623799c9-6525-407a-ae21-4500c1a2e919">304.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS02LTEtMS0w_f2608b91-0289-4059-a193-571a33410955">1,743.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS04LTEtMS0w_a0104f39-fe5d-42df-81ea-8a2b5983c55e">5,693.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0xMC0xLTEtMA_3d20ce9d-f18f-4ce2-8519-c42251bc4a9e">999.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0xMi0xLTEtMA_2042b809-0ca4-4e5c-8135-96773531b801">4,694.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0yLTEtMS0w_17d1be19-656a-47e9-84c6-201ab575e595">663.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy00LTEtMS0w_267e6e58-78ec-4206-b30b-f95890722b2b">137.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy02LTEtMS0w_c66e1e3b-87f8-47c9-a754-d88af638b689">526.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy04LTEtMS0w_ffe26c2e-f48e-4b38-9b67-837af91715c9">2,353.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0xMC0xLTEtMA_483f82d9-033e-43a1-bacf-72126d8d7a53">455.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0xMi0xLTEtMA_d6290db7-6180-4756-961a-d98236feb91a">1,897.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0yLTEtMS0w_d1656827-0c36-497c-bf82-a22b7be40c0d">419.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC00LTEtMS0w_ad05a51e-de80-41af-8706-8f3846b15e06">115.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC02LTEtMS0w_cef040cd-8b9f-43a4-a07a-74519f37187a">304.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC04LTEtMS0w_cfa8fbd0-993b-45c9-ac42-c875417b70e4">1,248.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0xMC0xLTEtMA_6d72f4d8-7c68-4aba-b785-1832b45a86b8">357.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0xMi0xLTEtMA_5365a784-aa54-4a0d-9028-d2f2abae3419">890.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51906d645bca4b2ca7899fcbd47e0874_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0yLTEtMS0w_8875b4bc-d1e8-49d9-b133-5bef0bc77943">110.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f0ba82258c54e758ead2a40321a3329_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS00LTEtMS0w_7d3a4f35-8ba3-47b2-9d76-857b51e3e357">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS02LTEtMS0w_c61e7260-5c62-4c3e-8cf9-9073d91bed73">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedbfb2b1ebb640c1b73cd3e30e74c02f_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS04LTEtMS0w_51d3f690-56b3-4847-a6f3-2f27f6225774">304.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f6d86539ab6438a81f9d17a87d8108d_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0xMC0xLTEtMA_043c0646-8748-45f2-bfa5-f6a6c6450916">14.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0xMi0xLTEtMA_d9a92e9e-e287-48ad-bf98-e183d59c1f93">289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMi0xLTEtMA_2f9c926a-7d45-4aed-bb14-da179dd6118c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtNC0xLTEtMA_d22d8fe7-25ba-4871-82b5-3f34b1bcc1b4">50.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtNi0xLTEtMA_7e4c25d7-4150-4154-8958-290eab98433f">50.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtOC0xLTEtMA_30005e13-92f7-48ac-ac30-a873301905e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMTAtMS0xLTA_f493e873-3846-48e6-91ea-47cd408755db">171.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMTItMS0xLTA_0ee20c27-7a1c-4ed4-abfe-7af9cb3d6d96">171.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMi0xLTEtMA_a12db32b-be2a-47ef-bbd4-e59f8ad67862">1,309.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtNC0xLTEtMA_1e50bc46-5bc1-462b-aa49-b4ca380be6d6">304.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtNi0xLTEtMA_ed089f25-dacf-45a8-8da1-afdf43132ba7">1,005.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtOC0xLTEtMA_d1171a50-8eb1-4be1-b039-367fbf762319">4,159.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMTAtMS0xLTA_3157a891-fabb-4fc8-9bbe-12666caa6240">999.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMTItMS0xLTA_264d0616-fee4-423a-8529-c6afa2fa896a">3,160.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.</span></div></td></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:46.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Flows Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy0yLTEtMS0w_d33cdd5b-87af-48d4-9316-50b14c33e24e">375.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy00LTEtMS0w_350de7bd-263e-4850-9dc7-35b37336a870">209.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy02LTEtMS0w_721dd523-f869-4da4-89ce-e3585ee9f4b6">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable, accrued expenses, and other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC0yLTEtMS0w_878d291b-dd19-4c44-871b-c02fb476d31a">119.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC00LTEtMS0w_9e897a55-5bce-4dab-aeb4-7d16d766088d">209.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC02LTEtMS0w_ac14f253-1315-4969-ac9c-c1aa18fbd99e">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYzMQ_68de30cc-2d64-4982-a2ab-85e8f4bc1aa9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyMA_adef3e3f-ea8d-48c7-9665-823df3a7bd3f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_34"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="regn:ProductSalesandConcentrationRiskTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzQ0_e29045fa-c5a2-4d2f-90d7-eed52527e9cd" continuedAt="ia17e0b1e00614385b5e16fecdda901ea" escape="true">Product Sales</ix:nonNumeric></span></div><ix:continuation id="ia17e0b1e00614385b5e16fecdda901ea"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzkw_d188e176-a73e-4f1f-8fea-e3ced16b6ce1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.461%"><tr><td style="width:1.0%"></td><td style="width:42.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a52597c51f5412492f6c132bf465821_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi0yLTEtMS0w_de4845f7-7d53-46df-a5d6-290f5f546a39">1,318.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc6f6996a634c0e9b097ac2f58e752b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi00LTEtMS0w_019e14dd-6364-4547-b1d2-7379ac2edd2d">1,187.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fc78e9a3304a3bac95b0cf117279a6_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi02LTEtMS0w_52291d83-e2b0-407e-8494-3c689fea19b5">3,604.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c30004e4fe94ba4875ced4b468677a8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi04LTEtMS0w_acbfe5ae-87bf-4f5d-81bd-9fe33448ce26">3,422.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7289e9b303ae482ab10a155371fd403e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy0yLTEtMS0w_ab0e6607-58d4-481f-b3db-ee5601dc3384">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2d6a85606748b6ae2be54b2683aae9_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy00LTEtMS0w_a76197bc-237f-47c4-904e-1df4489be232">47.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4274b29daf4675ab09b5e77fa76d58_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy02LTEtMS0w_431386e8-1764-473e-b5f1-f926b04aec3e">196.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf0ca2aae29d4d96bd94dc0a09fb6e08_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy04LTEtMS0w_bfedbd4d-5fe7-4c30-9021-3354579203db">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbbdbae70a344ee9bc01b9143fdf9a7e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNC0yLTEtMS0w_eeab2b3a-cdc4-4d32-807c-5b66f336b085">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7e691f7dab4bb58c1c0765d7ddc72a_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNC02LTEtMS0w_2ada5c66-6d60-4834-8f1b-6030c198dc7d">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfabd1b7b627426f9a33e66492f38481_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS0yLTEtMS0xNzE4_4a99a258-22dc-4aa6-af0b-bcb3a344d09e">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b02c0994812409f96b2fbccef842513_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS00LTEtMS0xNzIx_b4b0b185-eda8-4a8f-b5f7-83be5e35e49d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5aac854b44a486b905645bbb8b852d8_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS02LTEtMS0xNzI0_070e04ce-f3c5-4cad-8501-fc4714e87220">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1323fcbcb772436a8c497dcb0925c29a_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS04LTEtMS0xNzI3_6185d894-53df-4857-a556-3f9528b60e18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fab8149afc476fbcd010d6fac8dfc3_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS0yLTEtMS0w_efd6ac90-e520-4ba1-a9fb-ceec4f67a1c6">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72da8bc596c7486cb41228ce22a460c6_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS00LTEtMS0w_de67da9e-01ca-4694-a75b-ce6dfd2215eb">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4ff746cc404cf9a2e0326b7e30ecb8_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS02LTEtMS0w_cd470544-1236-48a1-a78b-205b7a2a9eff">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913cae035ec5417db5bb2235faaa5b0c_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS04LTEtMS0w_3aad05ac-e2a6-40ec-932a-c1c8fce7ab09">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf58700054b74965a4154a14e0348fc2_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi0yLTEtMS0w_fed5e3a0-27ba-41f2-96a8-2cbe0ab7af56">1,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id287f840c8b942fb96eb5ac0f597ff16_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi00LTEtMS0w_beef9c7c-3d22-4d98-a4ee-d9fe4fed30e9">1,238.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i259fa8cda2034a8485dd4d98ae1d54b9_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi02LTEtMS0w_0ef48ace-f085-4b2d-9349-be83634a9128">3,945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210976468f6d4beea437d37b4aa63663_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi04LTEtMS0w_ed57d318-95ac-47c0-bedf-a0f1f71c041d">3,548.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2020 and 2019. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzYy_3fc99624-787a-40bf-a09b-9d1592063d30" continuedAt="i3f21e7471b244505bfd2e198256212d7" escape="true">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><ix:continuation id="i3f21e7471b244505bfd2e198256212d7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:45.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e0f96f1723947e68a27075b552c4719_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi0yLTEtMS0w_e00c54ad-fd80-4a92-8689-a2934433bbe1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30e9eead3dd34158b0429a505019d3f1_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi00LTEtMS0w_7ec4cf90-49f4-4626-b402-7ea241f66c46">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93c5788ee66d4e5e89464da41cc6269a_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi02LTEtMS0w_f32ea93b-4be9-4e13-acab-78867a7b4293">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63d16524c09f42f9bc5b0d1c70c5817e_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi04LTEtMS0w_6db8f366-e919-4009-8f12-1bde8cf9885e">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i793d1c60fb2e41319710da444819bf38_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy0yLTEtMS0w_44222c18-0f9b-4444-bd94-f8242e62edf6">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66079e1a96d94e1eab04aea3ea86a08b_D20190701-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy00LTEtMS0w_704a55ef-c4c9-40a6-a8e9-50d9b9a7270e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89ae37db927b4fae8c60dc4bbeea1188_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy02LTEtMS0w_74810e15-b7a3-40fb-a634-7db57c946fbc">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77597e8bfdd64fe2bae163eb8fec1490_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy04LTEtMS0w_cd644c1e-8cb0-4607-bb9c-b74fb0da427f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div id="ibab647050bc248e3930163531a1d57d8_37"></div><div style="margin-bottom:8pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDU_a9c8bacc-1130-4f96-9ffb-79356dda9a46" continuedAt="ib01df0099c974fcba41ea49ac4cc5ce9" escape="true">Collaboration, License, and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="ib01df0099c974fcba41ea49ac4cc5ce9" continuedAt="i38efe0d87bc8435ebced60d83343d937"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDY_8bb06e26-1528-4ee8-bcfc-3ec55e9db07b" continuedAt="i2cac615ea0db4d18b16d07f23ad79d18" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize product candidates and utilize our technology platforms. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDc_2c309fd4-ba73-45ea-9a37-e922e05c6527" continuedAt="i7bd954d7aea34d88bfff0f83f5da692b" escape="true">In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. </ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i38efe0d87bc8435ebced60d83343d937" continuedAt="i5dc3770f204e48d2a559756360744971"><ix:continuation id="i2cac615ea0db4d18b16d07f23ad79d18" continuedAt="i2d44601941204d0ea5836484109b15ae"><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><ix:continuation id="i7bd954d7aea34d88bfff0f83f5da692b" continuedAt="ic55062ff4d224e1fa94fc3044b8d5781"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are entitled to reimbursement of all or a portion of the research and development expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred. In connection with the commercialization phase of our collaborative arrangements, we may be obligated to perform commercialization-related activities on behalf of the collaboration. If we are reimbursed for all or a portion of costs incurred for the commercialization-related activities, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are obligated to use commercially reasonable efforts to supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator; however, recognition of such cost reimbursements is deferred until the product is sold by our collaborator to third-party customers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2d44601941204d0ea5836484109b15ae">Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for such quarter. These estimates are reconciled to actual results in the subsequent fiscal quarter, and collaboration revenue is adjusted accordingly, as necessary.</ix:continuation>  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i5dc3770f204e48d2a559756360744971" continuedAt="ib0fadb37e9b54ca88e42497e99e1ae65"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><ix:continuation id="ic55062ff4d224e1fa94fc3044b8d5781" continuedAt="i6bd750987005428e8d6d80c321fd6a24"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440ca289f91448e86b7140c31a5c495_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy00LTEtMS0w_744df0ca-1423-4970-9547-c794dee5ca0a">212.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3b75b9f9ab41f6b1c862dcdff343eb_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy02LTEtMS0w_5a2451a6-6e60-441d-bb8d-66b88faca7b9">94.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629b8945a2b244738e800fb84f2b891d_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy04LTEtMS0w_00943ec6-9932-457f-adb3-45fbe918fc49">555.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7992d88a42314fd9959ab26fd254bdc4_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy0xMC0xLTEtMA_fa080ccf-5c7b-4c47-8f07-a561039ec3a1">105.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC00LTEtMS02OTY0_884b3748-f00e-4b4e-87f6-bff466ee9f7f">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a403650d89b4cdbacb41612bdcdc2fa_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC02LTEtMS02OTYx_b985136f-e419-4c5b-af7b-a043a0c54d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bc77d612f847c88293dde238e89d6f_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC04LTEtMS02OTY5_db8efe0c-f198-4c52-9875-515dee411337">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858f26c124514e65930d2a7c4d3ae840_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC0xMC0xLTEtNjk1Ng_b142b4e1-cd6a-4e29-a5e1-36f0ee9a8672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f34054df8504a19a5ad1c41cc47fff2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC00LTEtMS0w_9461da00-7fd8-485d-8afc-8be663e46c99">94.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieccb4e85845442c5b68026da6ae50775_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC02LTEtMS0w_b568d400-7282-4221-8fcb-884f541a25a8">85.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7812846c7af642bf8c717b3128434e3f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC04LTEtMS0w_cff26084-0691-4307-b446-0918c65c0894">275.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50af2d0e293b46ddb00a3419f1912ad6_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC0xMC0xLTEtMA_bda05ae7-061d-4378-87cc-cc77e9fcb322">143.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f305f8e6ace47fd86b9631dd499da4c_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS00LTEtMS0w_eea2f547-e475-48f6-ad7c-39a451c79065">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50af2638268242f6b59b88d1b6a5770b_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS02LTEtMS0w_7ea77717-f0fd-4414-8f2b-e87d315ee8e7">60.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39afe508e4c415cbb06cf308ee47ccb_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS04LTEtMS0w_7e820851-2cb5-4d26-8266-7a3e895361cc">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e99f703b684f02a5aa414ea753d8aa_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS0xMC0xLTEtMA_167f830e-fe95-425b-89cb-740cd4b98d5d">216.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e216705cab94a00b9676a165f2bcefa_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi00LTEtMS0w_4eee9c29-d3f6-4366-b9c8-d1a51abf0fce">17.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4d68f82974548b4bee81aecd0a90d14_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi02LTEtMS0w_e39b8c56-8870-4119-8c83-d87625169ccf">10.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e8d4c3b1834a21843449aa8b585d68_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi04LTEtMS0w_ede3123e-7f92-4856-9903-e76339a24c62">59.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975f4a743b164615bd2ef7edf00f00b0_D20190101-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi0xMC0xLTEtMA_daef76fd-19bd-4058-a479-422d5eae014b">29.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c2a84796d544b182e6e74ceb73a585_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy00LTEtMS0w_7562a8dc-2930-44ef-bed1-24e2053ef54e">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155a77df03774a34b4015dc1801c5b18_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy02LTEtMS0w_211a088f-033c-4cea-b821-949be6f0fcf6">111.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30550b7dd2b49b4b69c045354a6a07f_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy04LTEtMS0w_7e2a8c75-d865-44f3-96e3-a6591ee7432e">260.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e159ae1bc03421c808cd526f3c49fb0_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy0xMC0xLTEtMA_3b1502aa-b704-4c27-a2ab-66c849cb875c">349.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ae24fdf2ba43769cc7901206518a12_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtNC0xLTEtMA_47c594f8-3a6a-42a1-ae16-87b4c92198b3">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e4206c910554d81af805977f3002947_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtNi0xLTEtMA_1b6ca553-eded-46e6-9b40-2522db3685a9">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib09a1e9f85cf481ab3cc770922ba3391_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtOC0xLTEtMA_f1455444-f792-4572-9173-ca813a5b8084">17.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f74bf2738be48258c23b0dcbdaa12ea_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtMTAtMS0xLTA_1effb4f0-4234-481e-9c8f-47d3725ff3ac">16.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f86c58c4b574796881d49e37d000bae_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtNC0xLTEtMA_358ae22b-b410-4e56-b4c4-4350a56687a5">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9e38a9d51f4fbaa964316765d51ca0_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtNi0xLTEtMA_642284cf-ef21-4da8-b0fe-bc08d9f96f6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i424392c0a0484adfafb25cbcffa01a84_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtOC0xLTEtMA_fb956469-b99f-4cc1-81ff-506944013e86">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife607ecedd0549008b720df4da98fba3_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtMTAtMS0xLTA_60bdf886-c9bf-4c26-a1e3-fb83f6c77009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524b4d40e946437f9cc3badd5234eca4_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItNC0xLTEtMA_151f086f-4c77-4986-b9e2-84f64fa8c50b">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249d2b86432a4c65bd64b122b30b44a1_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItNi0xLTEtMA_7e98a21d-f587-4d76-bed4-100a4d0bff3e">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd85c66a10c44e869a10593d3b0aae6e_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItOC0xLTEtMA_93a75ebb-c78e-4fd7-8267-12db21d795e6">136.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903692403a774f48bb520b2c3aaa8879_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItMTAtMS0xLTA_4225e2a8-84be-42a7-9d62-0d7aa0548c26">120.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c8625c815b4033956a9b3202d3f56e_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtNC0xLTEtMA_8f92827c-f8f2-4bb6-935e-13cfeacffc76">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1288473dda949c38b342de4f098cc6d_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtNi0xLTEtMA_dd070612-f61e-4e52-84e2-6bc618ebca7e">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i125e5e85d95a405e8280fe383b98b6c0_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtOC0xLTEtMA_802b51c5-7436-42ce-bcf7-39e229c731c2">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3725af6673294f5aa8ee78886c09a9af_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfSellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtMTAtMS0xLTA_030f0875-dd56-449f-875a-c9c28137238c">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9269fb1edbc04cd1ac5f2238658e8872_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtNC0xLTEtMA_098ed103-353d-4a5f-b903-3f9a951925dd">31.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i789f27d056fe4015b571c9fc45b1bdc3_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtNi0xLTEtMA_76ba87b6-5d99-4132-a8ca-c34defdeea33">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bfa0b97e54d49f7a24ff6f66c316d8b_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtOC0xLTEtMA_5da45898-7eb1-462f-9c2b-3537b88725f9">86.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89320920064f41bf969faeb62c0e0007_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtMTAtMS0xLTA_b6899adb-aa17-4b14-bd16-195dfa352cab">51.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7075e6f52bc44235a553c88375786049_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtNC0xLTEtMA_ca6fd9b9-5016-490e-bdc7-5bf3c2dd02f3">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f314f4872f04da6b2b01389f0883f09_D20190701-20190930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtNi0xLTEtMA_0369dcd9-52b6-44c1-a1d2-4a6f11ca7f37">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd6be8d9b3e4d459a816ed46de88b98_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtOC0xLTEtMA_dda28939-f0a6-4bd4-8319-ccaed8cb8fc3">57.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if734d160735a4b25bcf2df8175aebb38_D20190101-20190930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtMTAtMS0xLTA_cd4acc1d-4ea9-488e-8f4a-f87efab75e13">73.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 and Note 10 for information regarding Sanofi's sale of our Common Stock during the second quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the companies' Antibody License and Collaboration Agreement (the "LCA"), following receipt of the first positive Phase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate ("Shared Phase 3 Trial Costs") are generally shared <ix:nonFraction unitRef="number" contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930" decimals="INF" name="regn:PercentageOfTrialCostsBorneByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDUzOA_0e34b4a1-e713-4c68-97ee-3bc536514d36">80</ix:nonFraction>% by Sanofi and <ix:nonFraction unitRef="number" contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930" decimals="INF" name="regn:PercentageOfTrialCostsBorneByEntity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDU1NQ_03277c11-421a-49a7-9a73-63bfd16a3a88">20</ix:nonFraction>% by Regeneron. All other agreed-upon worldwide development expenses incurred by both companies are funded by Sanofi. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Refer to the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below for further details regarding the Letter Agreement and Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products developed under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. See discussion below related to the development and commercialization of Praluent </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="ib0fadb37e9b54ca88e42497e99e1ae65" continuedAt="i31042e604a7543368c391dab56095f42"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective April 1, 2020. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $<ix:nonFraction unitRef="usd" contextRef="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIwOTQ2Mjc5MjUwMTQ_8883698c-27be-426c-ba4b-8231ccb89140">50.0</ix:nonFraction>&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk1ODU_1e8629dc-438f-4036-b485-c39db6bb2059">1.0</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930" format="ixt-sec:durwordsen" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk2MjY_122e92ca-837a-41f6-858d-9202bbea9599">twelve-month</ix:nonNumeric> basis. We are entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk1OTk_d1e3020e-0c10-4e72-81fa-a84b9bd366b0">200.0</ix:nonFraction>&#160;million in additional sales milestone payments from Sanofi.  </span></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="regn:ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMTA_89fb03e0-b6fe-4b55-8276-7b2998f0327c" continuedAt="i35c2e8d96cc44039b9b5e0da182ab5fa" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"></td><td style="width:48.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647137868b2d4017a026a60b257f74d9_I20200930" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMi0yLTEtMS0w_3d16af4d-5ecf-4582-94d9-1b27b5520240">453.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b9876c37a342a39a55d03fb7cd497c_I20191231" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMi00LTEtMS0w_c7f6b155-d4a3-496e-ac91-b7ed336bef97">272.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647137868b2d4017a026a60b257f74d9_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMy0yLTEtMS0w_ac7233d0-aca0-4561-9817-17086c46dfc5">433.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b9876c37a342a39a55d03fb7cd497c_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMy00LTEtMS0w_dc93b195-efd9-437c-b9a4-fdbf900f975e">328.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 is the last quarter for which Sanofi and the Company will share profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a <ix:nonFraction unitRef="number" contextRef="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401" decimals="INF" name="regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNjgwMA_4bdea737-5e65-461c-a8f7-24e30c1b826d">5</ix:nonFraction>% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to <ix:nonFraction unitRef="number" contextRef="i768f3f67a5ad413cb73fbc810de0d72b_D20200401-20200401" decimals="INF" name="regn:PercentageOfRoyaltyPaymentThatCanBeOffset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNzkyMg_065cdc8d-efcb-4c24-b20a-17d28d314cd9">50</ix:nonFraction>% of any Praluent royalty payment owed to Regeneron). The parties will each bear <ix:nonFraction unitRef="number" contextRef="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401" decimals="INF" name="regn:LossContingencyPercentageOfDamagesResponsibleFor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfODAwNA_54465ded-0fdd-4adf-b882-c80b423f4f55">50</ix:nonFraction>% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration is governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company ("IO Development Activities") under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. If Sanofi exercises its option to license rights to a BCMAxCD3 Program antibody or MUC16xCD3 Program antibody thereunder, it will co-develop these drug candidates with the Company through product approval. Sanofi will fund development costs up front for a BCMAxCD3 Program antibody and we will reimburse half of the total development costs for such antibody from our share of future IO Collaboration profits to the extent they are sufficient for this purpose. In addition, we and Sanofi will share equally, on an ongoing basis, the development costs for a MUC16xCD3 Program antibody. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the IO License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab), an antibody targeting the receptor known as programmed cell death protein 1 (PD-1). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. Pursuant to the Letter Agreement, the Libtayo development budget was increased and the Company has agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to the Libtayo development and Dupilumab/Itepekimab Eligible Investments incurred in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i31042e604a7543368c391dab56095f42" continuedAt="i7d899bcddba4475c81386a584b0feaaa"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods through September 30, 2020 by selling certain shares of our Common Stock directly or indirectly owned by Sanofi; if Sanofi desires to sell such shares, we may elect to purchase, in whole or in part, such shares from Sanofi. See Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States and the parties equally share profits and losses from worldwide sales. </span></div><ix:continuation id="i35c2e8d96cc44039b9b5e0da182ab5fa" continuedAt="id20084a458594f86a90d035d61d477d1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"></td><td style="width:48.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMi0yLTEtMS0w_ab787d91-6b9d-4327-9f5f-0635ea8a9c84">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231" decimals="-5" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMi00LTEtMS0w_0b299b60-92e9-4662-9743-f8b0107ade58">16.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMy0yLTEtMS0w_ee89babf-b13c-4855-a2ed-6b71306885a1">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMy00LTEtMS0w_0e6c768c-31fa-4e93-a63a-7785df64cccc">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfNC0yLTEtMS0w_f8529c72-326c-4179-ba6b-9ebca410489e">441.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfNC00LTEtMS0w_d688a391-5deb-4fcb-bc04-bc4489e08c27">558.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="-5" format="ixt:numdotdecimal" name="regn:UnsatisfiedObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTE1MzU_1406b577-0f83-4b07-b99f-4a89e8384c95">951.0</ix:nonFraction>&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><ix:continuation id="i6bd750987005428e8d6d80c321fd6a24" continuedAt="ie97986e4ca9d40a6832c21888c398ff3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.422%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ea0893a48f488d8f88308c3e9ee61b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi00LTEtMS0w_cf302205-e140-4722-bbb0-35ade1237e20">287.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ac5fc163d3459aa29a0f7e270b195c_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi02LTEtMS0w_9c34ba9b-492d-4e12-b376-24b400bf9b73">275.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62eefa1863e47f7a276818d52328f65_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi04LTEtMS0w_7d66321e-a392-4c92-8971-1cd64dde8e9d">772.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a032ed700df48e8b4754328ea168c43_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi0xMC0xLTEtMA_33443449-a87c-456f-985c-22f03307dcb9">793.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa95e30f69814af0a60388d1bb9f88a6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy00LTEtMS0w_955dfca7-92ab-4029-838e-43344dfcbd24">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd823974b604b1390f3616a69d17bd6_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy02LTEtMS0w_4a349ee6-e157-4324-9f0a-3beabff51da9">18.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc38fd53dce24fa3abe9de323809035c_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy04LTEtMS0w_797b2bf7-cda0-4e2b-9e31-63a2da7afb6e">52.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33902f27fb464f2788858727dc0f48f4_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy0xMC0xLTEtMA_5857c0fd-c792-47b2-9804-3fcb6cf08aa5">41.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd88b5df537c46f0a7f3172ab2b40960_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC00LTEtMS0w_28fedd43-bfbf-4062-8d75-a910a69c48a3">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e78e3764fb346d9abe7fb4037bb0528_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC02LTEtMS0w_a4bf2b1b-dad4-4d33-8074-0df5f0f92cdb">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aef510b4bff453f8d176f79acb15431_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC04LTEtMS0w_469566b8-9edf-4ef1-9612-ab7c6240b73c">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba52ce52c05f40beba9639ea3d78c7d3_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC0xMC0xLTEtMA_bcfc279c-dbd5-4fd8-b447-72978844d8ff">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e6521a7a684a99872680a1548d3d37_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS00LTEtMS0w_6ac8ba05-700b-46e7-90fc-c1e5b2c06ad4">12.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01db19eff4ba44168b83edd0617cc0bb_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS02LTEtMS0w_4a7f3fca-34cc-4dc2-b8ad-c64ad752e229">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f67f970eb284b439ef2084a5ddf0c4e_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS04LTEtMS0w_2170ef48-deda-48d6-b366-b91c64ae5d00">26.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc03aab082174d41aa16b8adf809207e_D20190101-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS0xMC0xLTEtMA_16427b29-776c-446a-954a-7c0803476838">13.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042578dd0f7942d0837b6e77eecbd085_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfOtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi00LTEtMS0w_c65c9533-ede2-4c1f-bdc7-6771615fb52c">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17ddd9842744aaea31d03825f513ff8_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfOtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi02LTEtMS0w_1f41d730-1ccd-4cf9-b826-592273b79b12">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0d66d038e84724bc6951ccc43d25a5_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfOtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi04LTEtMS0w_487cbeec-ea5a-40a1-95d2-3de4517bda44">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b24fd379cb345f092d697825567373e_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfOtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi0xMC0xLTEtMA_7d9b2522-a594-4145-b4eb-35aa208ec4fb">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between <ix:nonFraction unitRef="number" contextRef="i796be097beaf45008b0b52db759c841c_D20200101-20200930" decimals="3" name="regn:RevenuebasedonpercentageofannualsalesinJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIyNDk_4dccc00a-33a2-4177-9cab-35d9ccc61143">33.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idab077eab2b448d4bc8e7af35fdefa59_D20200101-20200930" decimals="3" name="regn:RevenuebasedonpercentageofannualsalesinJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIyNTY_9ac88637-eb5f-421e-9dd5-ebfa5a686ae2">40.0</ix:nonFraction>% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. In addition, the Company and Bayer share the funding of agreed-upon EYLEA development costs. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i7d899bcddba4475c81386a584b0feaaa" continuedAt="i2dd3a645abb244a29d11732ae4c0da08"><ix:continuation id="id20084a458594f86a90d035d61d477d1" continuedAt="ied7ebd198b7f42978588be8dc2571528"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"></td><td style="width:48.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5351df69b749490991f52fb2919ecaa6_I20200930" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMi0yLTEtMS0w_f988f7d4-4276-4825-a2ac-d047a7898b1d">299.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1febd6b0737446ebac35bb01d092f15_I20191231" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMi00LTEtMS0w_bf67ca46-2a32-4746-8065-42812a9f18db">311.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5351df69b749490991f52fb2919ecaa6_I20200930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMy0yLTEtMS0w_70795f4f-3325-4774-91ce-b0a455a430bf">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1febd6b0737446ebac35bb01d092f15_I20191231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMy00LTEtMS0w_6b508f78-a7c5-4acb-9ee3-0cd35fcdc0df">123.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company and Teva entered into a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan. The Company is also responsible for the manufacture and supply of fasinumab globally.</span></div><ix:continuation id="ie97986e4ca9d40a6832c21888c398ff3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:33.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.606%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi00LTEtMS0w_fc9279f5-a3bc-4f36-93e6-9a93c567079b">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7058246a9659451f88d94beb0d3ec13e_D20190701-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi02LTEtMS0w_7a952c69-70e1-4e94-ad69-d7a8d49571f1">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae545194ff24904a88dd0e9092398b3_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi04LTEtMS0w_27926c0c-ec4c-41af-8515-e08eea4afb66">82.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe3f67d977694fb89ca3de52695ce285_D20190101-20190930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi0xMC0xLTEtMA_c99f13f1-eb9c-4095-b225-5c7c12f8f2d2">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf58477014064d2aa4d6dc03bb6963ed_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy00LTEtMS0w_2b8f0b75-cf31-4e1e-865a-d3c8f288a505">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic85be8c3176d432ca84c44b9cab50dde_D20190701-20190930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy02LTEtMS0w_3310c870-7925-4c62-acbc-087f614a484b">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bf72d6126149e4abf801ce66065da4_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy04LTEtMS0w_28e02546-38ba-4803-a827-014a12babc0d">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic184b458c91d499fa1a5711477b97f68_D20190101-20190930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy0xMC0xLTEtMA_cf6ec5a5-c2ef-4591-bc34-90630de65248">68.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="ied7ebd198b7f42978588be8dc2571528"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"><tr><td style="width:1.0%"></td><td style="width:54.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMi0yLTEtMS0w_38b2e504-7cf4-4a33-b4d1-a44effb759f6">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36638689867843109daff532397d136a_I20191231" decimals="-5" name="us-gaap:AccountsAndNotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMi00LTEtMS0w_d4650ebe-509b-4da1-af83-6829698ff8a8">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMy0yLTEtMS0w_5652d9d0-3fc2-48a1-a932-577dbc1b55d4">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36638689867843109daff532397d136a_I20191231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMy00LTEtMS0w_e8cc66a4-4479-4a90-afcc-f774bdd2f5f4">114.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930" decimals="-5" format="ixt:numdotdecimal" name="regn:UnsatisfiedObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTM2NTM_920ee32d-4a91-48aa-a87f-465a91ab165d">130.3</ix:nonFraction>&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either we or Intellia select pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at our option or Intellia&#8217;s option, as applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i2dd3a645abb244a29d11732ae4c0da08" continuedAt="i454dd449d67e41d798c551966ba570f6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gene edited products. In connection with the agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="regn:CollaborativeArrangementUpfrontPaymentMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUxNzY_84c9e19d-134a-4b7f-b19a-9c83c8bd5656">70.0</ix:nonFraction>&#160;million up-front payment, which was recorded to Research and development expense in the second quarter of 2020, and purchased <ix:nonFraction unitRef="shares" contextRef="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUyOTc_fab32658-d3a3-4300-a128-3ef6dbc4c35e">925,218</ix:nonFraction> shares of Intellia common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedAtCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzNjc_659310ba-8706-4616-b7e8-7d0f10adcc8e">30.0</ix:nonFraction>&#160;million. The amount paid in excess of the fair market value of the shares purchased, or $<ix:nonFraction unitRef="usd" contextRef="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTU0NTA_b5cbc141-7388-415b-a94b-87ceae82201c">15.0</ix:nonFraction>&#160;million, was also recorded to Research and development expense in the second quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">e. Biomedical Advanced Research Development Authority ("BARDA")</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i454dd449d67e41d798c551966ba570f6">In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement ("OTA") with BARDA, pursuant to which the U.S. Department of Health and Human Services ("HHS") is obligated to fund <ix:nonFraction unitRef="number" contextRef="i6e8b16b9d02f4c5db91ce70d178e3e91_I20200331" decimals="INF" name="regn:PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTU4MDc_bfd06ea7-be4e-4bf5-b9b2-e02180c8ee26">80</ix:nonFraction>% of certain of our costs incurred for certain research and development activities related to COVID-19 treatments. In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished REGN-COV2 to the U.S. government. The agreement could result in payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="regn:MaximumTransactionAgreementPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDk0NzgwMjM0MzU0MQ_95128095-2fe7-44fa-9b7b-0f5a294bc8b6">450.2</ix:nonFraction>&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish and storage activities. See Note 2 for REGN-COV2 net product sales recognized in connection with this agreement during the three months ended September 30, 2020.</ix:continuation> </span></div><div id="ibab647050bc248e3930163531a1d57d8_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzg1_4e56942b-68e2-47ea-b24a-fff1cda862a0" continuedAt="i1a171c9b50714d8a8f97637246732991" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="i1a171c9b50714d8a8f97637246732991"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's basic net income per share amounts have been computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzky_528d453a-aa90-4223-b954-3faa242c0dcd" continuedAt="i0056ca383a8c4b3b9832a3fbfe65655f" escape="true">The calculations of basic and diluted net income per share are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><ix:continuation id="i0056ca383a8c4b3b9832a3fbfe65655f"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:42.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi0yLTEtMS0w_49a6e178-28a5-4ae3-8ae7-275589249cba">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi00LTEtMS0w_3aa85e40-b4ad-48fd-b682-80cc2abb660f">669.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi02LTEtMS0w_0ffc34b8-aed4-4766-b5b0-07994bbeb0d1">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi04LTEtMS0w_222b42bf-dc84-4d59-b75d-c399fcc64ba9">1,323.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS0yLTEtMS0w_f6981412-e0a5-4324-8e2b-e731118c2987">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS00LTEtMS0w_57091313-a9da-4700-aa97-d3c84d99dd84">109.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS02LTEtMS0w_459ab687-9f2c-41ee-a95f-a34080275346">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS04LTEtMS0w_2534a12f-558c-4239-9802-4b039ed2a633">109.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffa227b8deba441693b33a2fbafddb8e_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy0yLTEtMS0w_15a8dd81-78a9-4092-8077-e372ade81dc9">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ab2a78eec84461897d6a611b6915df8_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy00LTEtMS0w_8e30ead8-e75e-46f9-85ac-32c693863c24">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9825a846e164e5ea7cfe55e771e11b5_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy02LTEtMS0w_70f3d513-99c4-404a-b941-8d1e49e9efd8">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7f5db47717d49e1844b3f7b3174f1dd_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy04LTEtMS0w_98f4c1e5-e7bc-4818-a879-43f3bb99609a">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife0ade14d07348fea114a6a08fedda5a_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC0yLTEtMS0w_1093fad9-63b4-4f28-a5fc-f64054dd2b89">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f33ed3e59d44118a5a40e3435d58ef8_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC00LTEtMS0w_4f5ce628-183e-4b49-83fa-44066c55e0f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9d9e2ee1494f5f9a4f9463de7838e6_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC02LTEtMS0w_1b2dc336-5cfb-4114-94f5-99b63c768d8b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66510b4d5ffc47b6a9f4b37c4c429ca3_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC04LTEtMS0w_c068f51c-ec9c-44a3-94b9-364cbec65a56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS0yLTEtMS0w_17d8d3f9-d847-4be2-a719-e68c18824d25">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS00LTEtMS0w_cdfea998-08c1-43bb-9123-72260aa85f91">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS02LTEtMS0w_dbfc10b4-dae0-4e8e-bf26-f1383f431394">116.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS04LTEtMS0w_5a80aa04-9ee1-4787-a95d-f8512e8ec771">114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtMi0xLTEtMA_039aed97-1e89-4612-89c4-3d31733e9a70">7.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtNC0xLTEtMA_4e347043-02f3-4044-8728-9ef1ca4e2b55">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtNi0xLTEtMA_fd7eac92-a076-478e-bb83-28ea9c09acec">21.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtOC0xLTEtMA_71073d6b-39b5-4567-a87f-a66d99a424c4">12.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItMi0xLTEtMA_3b934267-5cae-4ed0-b2e3-2337c62a23fc">7.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItNC0xLTEtMA_6216e80b-d152-4750-9add-a84ac881f894">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItNi0xLTEtMA_1bff6f55-574a-4ac8-87c6-fc77e8b88593">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItOC0xLTEtMA_8f0ce353-882c-4a68-a071-587329a72ba2">11.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzg3_ff30ba46-a168-4bf3-b0d3-c25c68e16167" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive, include the following: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.964%"><tr><td style="width:1.0%"></td><td style="width:33.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib54c03b4823b4871926f13634d87caab_D20200701-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi0yLTEtMS0w_86de6484-5d85-45dc-be14-379ce94748e0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9207f4bbca3f4cf89c0781ee2963e848_D20190701-20190930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi00LTEtMS0w_a05513a1-e386-48a7-b42e-57f15f2cd679">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icafbbe3c8ece417ea95836d71b2b8d9c_D20200101-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi02LTEtMS0w_c8b108ca-be71-4b5d-8b27-d21697f503db">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia323b61d6ca54592b8470bc4a3c536af_D20190101-20190930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi04LTEtMS0w_c57e916e-33bb-487f-a4ca-cd90c3750342">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78f643a7609c4ebfbb43b0e1032cdde6_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy0yLTEtMS0w_2fe251fe-0f7e-4b02-877c-a727d730fc2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60c6215466c64dd8a803be94b251edda_D20190701-20190930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy00LTEtMS0w_df928c5f-5e82-41c6-b8bc-dddb5a324d00">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id810e98c23264dd7862faff8c51896f0_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy02LTEtMS0w_6a79d869-c649-47bf-8899-59a9b5bbf895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if92d56f793334c729cbf51da9cc2bb80_D20190101-20190930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy04LTEtMS0w_3de6dc70-428d-4426-8175-8928cba5ee07">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_43"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1Mg_55d23157-fda5-4db1-bcf5-2330dd13e9f3" continuedAt="i5189bc020ba0492daa869651c5998a13" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i5189bc020ba0492daa869651c5998a13" continuedAt="i461c5800f5d741df9dbed72a57258aa2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of September&#160;30, 2020 and December&#160;31, 2019 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1OA_ba57d6b4-24c0-4b8a-a93a-f79a40056ede" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:46.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi0yLTEtMS0w_bc224c04-60c3-448e-8497-c4d7d760d63b">2,796.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi00LTEtMS0w_aff25c92-db44-4be8-80ad-53ee60278dff">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi02LTEtMS0w_8208a845-21d0-417b-b2c6-0c77aae40a75">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi04LTEtMS0w_16e17ae5-85c2-4741-b74d-e062385ab2e5">2,836.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy0yLTEtMS0w_23a971b2-0013-4649-abac-dc34dda84b86">133.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy00LTEtMS0w_45da744d-9392-403a-868e-0e2c81730d5e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy02LTEtMS0w_5f34c7ed-ed0c-495c-9e57-95c2117cdad1">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy04LTEtMS0w_1dfc23b3-60e2-46f0-9aaa-c8a49a7cc4d3">134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC0yLTEtMS0w_a09eaa1b-50c3-44f0-8beb-46bf6c69a702">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC00LTEtMS0w_4cbe6d27-6c1d-4cac-bb30-804f11e980a8">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC02LTEtMS0w_f1af3fdc-7943-4971-b785-d2dbe530d647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC04LTEtMS0w_d8c8c86a-7585-4ec6-9047-a0f668d5fd67">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS0yLTEtMS0w_ef7832a4-2b1a-473e-8add-13d239e6afa0">390.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS00LTEtMS0w_49260689-545a-488d-8d47-e2563c2c77ec">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS02LTEtMS0w_7d42a829-471a-48c4-87bb-d860adc57321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS04LTEtMS0w_c4ea5e71-2d74-478d-bd54-f7e4116988d5">390.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi0yLTEtMS0w_c54c7974-767d-47a7-a15f-3aa08fa79bab">122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi00LTEtMS0w_9f46754a-bc07-4419-8a01-b9e527b01d1f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi02LTEtMS0w_147c74ef-57fc-46dd-a7c9-569c417b6354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi04LTEtMS0w_312763a5-5eec-4d3e-87e3-b1fb9fcd838f">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy0yLTEtMS0w_c2edd589-8e4b-4618-afb0-2deaa3d028e2">3,508.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy00LTEtMS0w_aa5e6834-7c63-42d4-a069-1cc24b9ba6ed">42.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy02LTEtMS0w_f2c9ed1a-4f48-43b2-b98b-11993a392c4e">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy04LTEtMS0w_1591fb6b-ccd5-42b0-931f-4e5627bd7c9c">3,550.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtMi0xLTEtMA_3034a7af-77d4-43d6-b40f-5bdff9163ebc">3,960.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtNC0xLTEtMA_f97ed72f-72f8-44f0-a241-d1da9885681e">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtNi0xLTEtMA_95f73b76-b5af-4e7d-8a09-b2fe2873b266">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtOC0xLTEtMA_d9e0f885-5f4c-4247-899f-110feb1742e6">3,988.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtMi0xLTEtMA_3e299a8b-7e7f-499d-9c73-f69c318ed62f">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtNC0xLTEtMA_24b8679e-0c09-4435-a913-8007e7a47a5b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtNi0xLTEtMA_127b2df5-c768-486a-bf27-71437307ddf8">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtOC0xLTEtMA_b99589ee-00ab-4065-b6f8-d7a94607807c">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItMi0xLTEtMA_381f6891-66ca-4fb2-b2a2-6bb2a475af36">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItNC0xLTEtMA_4e386c68-ca83-4cda-855a-7972c768a1c8">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItNi0xLTEtMA_2164f30c-d412-4b7a-b4d8-14527cd6bd11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItOC0xLTEtMA_18b3f5c8-8f06-4df9-a14d-dfb1491156f1">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad0c140dee94620bf61713792c263c0_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtMi0xLTEtMA_2397fb3c-098a-4775-a8be-191f9724314c">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad0c140dee94620bf61713792c263c0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtNC0xLTEtMA_f81bf4f9-b0fd-4c9f-9e43-5503cee7a530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad0c140dee94620bf61713792c263c0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtNi0xLTEtMA_9a0d7f35-225e-4b7c-bd9f-2cc6cab39b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad0c140dee94620bf61713792c263c0_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtOC0xLTEtMA_6d45c7e3-d519-4476-9975-aacb7e519060">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtMi0xLTEtMA_067de385-4363-48c1-bfaa-faa59fecc84a">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtNC0xLTEtMA_2be8bd64-e09b-4042-b334-905f8ea8694a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtNi0xLTEtMA_18170bfb-5c0b-46c1-935b-ae4cac3fb847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtOC0xLTEtMA_10f06e0e-6767-4212-8bc9-b70b3ae3e5b5">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtMi0xLTEtMA_6cd784c8-cae6-4888-b285-f5e1f74c55a1">4,206.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtNC0xLTEtMA_7aeea5bf-3208-49ca-9ffc-950f88b9975f">28.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtNi0xLTEtMA_c618b874-d0de-4c05-9034-8d50da9fd259">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtOC0xLTEtMA_38c81f0e-6ca0-45b8-8c66-ece16d3170b5">4,234.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2020 mature at various dates through September 2025. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ2NQ_bef4f88c-db60-454c-b113-10e5e7cb3d76" continuedAt="ica33b30ee9ef44b7b939268c2f694b50" escape="true">The fair values of available-for-sale debt security investments by contractual maturity consist of the following:</ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><ix:continuation id="ica33b30ee9ef44b7b939268c2f694b50"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.473%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMi0yLTEtMS0w_ac37617b-2e0b-426e-9b8f-fb29711f78a8">1,452.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMi00LTEtMS0w_1c679924-d36d-45ec-9608-e457c073fb68">1,596.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMy0yLTEtMS0w_130d47f1-a037-484d-9ffd-6eff15313799">2,097.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMy00LTEtMS0w_9bfa3e20-bf2a-4df0-ac63-88902d4255ac">2,638.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfNS0yLTEtMS0w_d7ee0960-c18f-4af4-81bc-baa53a9be510">3,550.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfNS00LTEtMS0w_6a9d2592-68fe-4274-a28e-7cbb30f46bc5">4,234.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1OQ_1def1142-a0de-4a8c-b9f9-6ab8a8f20d4e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:29.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0xLTEtMS0w_9b020b6e-342d-4de7-a6c9-f9fa4d22837b">560.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0zLTEtMS0w_3d8c90e8-b129-42dd-a5f1-55bdfd8d24c3">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi01LTEtMS0w_d68d2987-0238-4425-aae0-b3caa49dbae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi03LTEtMS0w_65c04b9a-2151-4cd0-8328-893ec4886986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi05LTEtMS0w_b6e3ce3e-dab3-4bdd-96e3-e70a3f814f53">560.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20d30029d14449749b125424cd027e65_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0xMS0xLTEtMA_8cd0e5ab-784a-4a80-acd1-96edf9bf1713">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0xLTEtMS00MzM3_3cbd2af5-8c5e-4232-8aa4-7e34eb1dc731">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0zLTEtMS00MzQz_11455d62-7e22-4abc-8b29-af5e0c2b1e84">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy01LTEtMS00MzQz_f6635596-5c45-4920-9d6d-f089118ea8fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy03LTEtMS00MzQz_80b8e055-16ca-40dc-962f-2cbd2c1e9af0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy05LTEtMS00MzQz_5f0ce256-3bbc-4aae-bce6-331e01a6c4eb">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0xMS0xLTEtNDM0Nw_48f61464-b052-4c92-9857-f3a85428ed0d">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0xLTEtMS02MjQ5_12777726-50da-4ae5-820f-55886984f752">606.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0zLTEtMS02MjQ5_5644751e-fd20-4081-b7c2-4177615abc64">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC01LTEtMS02MjQ5_09a3d7a2-c7c1-4933-85d3-5d6fa7eef484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC03LTEtMS02MjQ5_0f34a777-3a3a-4b72-99ad-43d0e2751038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC05LTEtMS02MjQ5_e3be4efb-23f3-42cf-9496-d4a2fdc71099">606.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0xMS0xLTEtNjI0OQ_d33bb72e-e66c-4038-9f5f-fed4582ffb7f">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0xLTEtMS0w_af59aee3-9a02-4ee7-9ce4-262660a93109">257.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0zLTEtMS0w_fff6ae9a-323c-4d7a-a46a-1b2d0b7d9109">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS01LTEtMS0w_cb73cb3f-2216-4d04-b5d1-f735340f2fc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS03LTEtMS0w_f425a2df-0354-4a79-82fd-6556dc3a5bbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS05LTEtMS0w_a7a0a6c9-eb02-42c6-93c8-6a321c174019">257.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0xMS0xLTEtMA_8f88dfee-2489-480b-a6db-175113eec6b8">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0xLTEtMS0w_51467151-080c-4a19-8869-56ec304d8fc2">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0zLTEtMS0w_3e0ca3f7-a949-4fbe-815a-d172bc03bf7a">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi01LTEtMS0w_c15699c6-8d21-4bff-8ed7-ce0d8b04bc14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi03LTEtMS0w_3a140942-339b-4a4c-bb27-448deba72615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi05LTEtMS0w_941b6946-e496-4262-812e-ee0c79cf2a75">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0xMS0xLTEtMA_bf7944b1-5c97-43b9-a909-f343a8f912b2">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0xLTEtMS0w_fd406e06-fe62-4db4-a0ee-414f1b6c8387">274.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0zLTEtMS0w_1fecf9d4-2248-49b6-8bff-b7644c127d9c">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy01LTEtMS0w_9eb47902-9f3b-48a0-a891-374c2c553d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy03LTEtMS0w_0d3d6756-57c0-4a28-8fd7-302d97dec13f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy05LTEtMS0w_1587a70b-a435-458e-88b6-f5dfb1ab8acf">274.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0xMS0xLTEtMA_4eed56ef-010c-4a20-bba8-ecded8af88ab">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i461c5800f5d741df9dbed72a57258aa2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2020, realized gains on sales of marketable securities were not material. For the nine months ended September&#160;30, 2020, realized gains were $<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTAyNA_28441ade-0d34-4db1-bebd-0595fff0ad2f">28.5</ix:nonFraction>&#160;million. Realized losses were not material for the three and nine months ended September&#160;30, 2020. There were <ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTA5Mg_695d82e4-2e0b-4800-8bc7-9301432dd55b"><ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTA5Mg_d1c5f41b-181d-4ee1-a65e-34a24012c6c0">no</ix:nonFraction></ix:nonFraction> realized losses on sales of marketable securities, and realized gains were not material, for the three and nine months ended September&#160;30, 2019.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the three and nine months ended September&#160;30, 2020 and 2019, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities (as described above).</span></div></ix:continuation><div id="ibab647050bc248e3930163531a1d57d8_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTMzMQ_b6d94ba9-f075-4283-a8fd-11d49447c7b6" continuedAt="i67078c805d214e98bf21eb490e6937c8" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i67078c805d214e98bf21eb490e6937c8" continuedAt="i300702ee6536472eb9d3d81a102efef9"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTM0Mg_d18b205a-f81a-412c-ad39-066e1639e2f8" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:48.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ac96ed0be24de7b4d78a4154650332_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy0xLTEtMS0w_912ea7ac-5347-458e-ba75-4518571935ed">2,836.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a8bbfcd7a24b5b824f96ad7338a054_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy0zLTEtMS0w_5c0dac2e-cdcc-4765-a9d8-16cd4461816c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713f9254ad4e48be9e5d986625994aa4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy01LTEtMS0w_fa810c44-910b-46d5-bc9a-5e28817dd7f6">2,836.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13644cdf2ce34c7c8c816531c17bffac_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC0xLTEtMS0w_9b9a26a1-6827-4d85-b075-e9912c918f59">134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cbc42470c77425ba7013c4d8b733291_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC0zLTEtMS0w_9b7c2189-8474-46cd-81b3-95200bd5de96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4de3948dc24c89953087647ee69972_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC01LTEtMS0w_a223bf10-8e2a-4f7b-bf89-c9e17aa1ddde">134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88b69bb3d8246e492ef775636b3be4e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS0xLTEtMS0w_050f4aae-a3d5-47b8-8516-1796114caa5d">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e7fa786500484f9ecd6a1394da0446_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS0zLTEtMS0w_8bb94fd2-84bd-4212-9914-b91066a80839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dbf1de37814cc591de5f5dfd7367a5_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS01LTEtMS0w_1ccd0929-5a85-46e6-9b60-cc5ce091f9fc">66.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d60d80740cb4c3d8c3264e5a536bb75_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi0xLTEtMS0w_f38a4768-f3e1-41b2-a3c8-60f036ae5642">390.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c4643a0fbe4860b2b92747ba930b68_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi0zLTEtMS0w_722b651b-aca1-4204-a6ad-d491e286d5ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc67414a3f4b75a4caa66eca345086_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi01LTEtMS0w_16b1ec33-7888-44fa-ba0b-25960be652e6">390.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5b3e8bce4a477b86a941cc7530a23e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy0xLTEtMS0w_87f5b52c-c429-4607-8785-f7667a53a935">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06ce8aa5e2b4cc09ea1c19bd54664cc_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy0zLTEtMS0w_6e29668b-9a96-48e9-864d-5660a2da8066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ca96a034d34a608df2c5923fa76c90_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy01LTEtMS0w_34281c87-b807-4e3a-b6d1-3dcdbb30d112">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d96bb16db141e2a860d5637be2962e_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC0xLTEtMS0w_1bfefff1-2409-4403-ab48-c57e060cd3cc">41.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2506ac5a2034c828fe5038d9beb37ee_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC0zLTEtMS0w_dc4e296b-cff9-411e-8bd5-2228b1ff033f">41.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541eacb289b24268a93f9d97ac19b713_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC01LTEtMS0w_84d55a29-12e0-4dc8-9a60-9e9b8b68186d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e6ac37be9848dda98174ec211537bb_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS0xLTEtMS0w_fcdb6c63-af05-4fe2-ac2e-bad0708572c7">736.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c906750bd44ebfa1472014377a3aa1_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS0zLTEtMS0w_d754f54a-71f8-4d0d-a249-65e680c804ef">720.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358f15a0dd6d48b29acf4a71f823027f_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS01LTEtMS0w_cc970b9f-36c5-4b20-89eb-70b22da582a3">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c52905678f44008a79f2f04de098ce4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtMS0xLTEtMA_885cc521-e81f-4eea-a830-2b25eda7c3d9">4,328.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52447f425dcf49d6b1e10676a99f4280_I20200930" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtMy0xLTEtMA_bf380caa-a7f8-4443-8c09-adb4271d3cfe">761.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b2946c537042c89d7783ab07d85448_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtNS0xLTEtMA_d4adc954-c4ae-4561-8b92-9ef6d02628cf">3,566.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0579df393aca4a968868c9bb40a1ab0e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtMS0xLTEtMA_9fb89ffe-909a-4cbf-9f0c-245fa4f2855a">3,988.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f420c9c13e4e23a601c1b506fa4a4b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtMy0xLTEtMA_230b65c9-6ba3-492d-be64-3c126b08fbf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e0aead3d7445da8371fd938402c091_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtNS0xLTEtMA_811cc567-cf49-47d7-8737-143d35bdf1d4">3,988.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e14cefc3db84553880f64ccb1fa43bb_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtMS0xLTEtMA_21a30101-beb9-4ab8-8bb3-88165f13efbe">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86accf19d5314b94b2f97f98ad733968_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtMy0xLTEtMA_b17ae861-2a5e-4cea-8554-7bf3755857e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0b94218008446f83e54c839d26d417_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtNS0xLTEtMA_22d23ad0-8c36-425d-b057-53685c115b32">54.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5e6f8e04c640e9a3a58b970d0b5099_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtMS0xLTEtMA_0cf29101-e92f-41c1-885a-84d902da422a">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322b98f3dc874456add467767aaa4162_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtMy0xLTEtMA_0b92671e-fa13-41a0-b344-80fbd658de58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278d21029b334fdfa0462d06cf1f3130_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtNS0xLTEtMA_e403da01-03e6-497a-96d0-0a8e70260a52">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e8ef1954ceb4ec99864b1fe9544ceef_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctMS0xLTEtMA_0585637d-18bd-4b3a-b6ad-d8fc08869d7f">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7feff46efcfb423cb246abcc1bb4d36a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctMy0xLTEtMA_f916f3f5-4618-4e68-8db3-dce0f488e1d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18805c870e4245d592672c40510db7b3_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctNS0xLTEtMA_bc09bd66-cf69-4215-a812-3dbda83bcd77">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8876032e074445d89ddad2131dd29fe_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtMS0xLTEtMA_b9c8632a-8773-46ad-a09c-3ca90ae2eabe">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45fd969b6c884737a5442b5de99684a5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtMy0xLTEtMA_629f9c94-5909-4cde-a7f6-f1da064090ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8593ca7502ee42d499fd89567506b6c1_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtNS0xLTEtMA_ff96a303-9be5-4d17-a6b5-5b9e33e25180">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31d2a9dd29b41c98f55f6c5305d8e3e_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktMS0xLTEtMA_2f554497-31cb-451b-87de-6798bc8d4b65">61.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8532b49a5daa42f2a3875d2512dbd140_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktMy0xLTEtMA_42177700-8a03-4f55-8cad-245c7a10079a">61.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c2c6d2774a4997916504acf5a44d4a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktNS0xLTEtMA_7287d166-26e5-4b0b-84ce-0eb958a52bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb07d4899f3445b83edd542e47de881_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtMS0xLTEtMA_f6399c14-5b2b-4e90-b654-02a7294e369f">557.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490a6a8ff60443ed968309024d4e02ed_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtMy0xLTEtMA_820249aa-444e-46e6-a3b0-24982d54ef41">557.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9093b35e7b624c38a7f019c21a2e9a5b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtNS0xLTEtMA_51a2599c-8ba0-49f3-8aa6-48e6d0021ecf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc12bd1bc93d4447ae534aa38c459530_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtMS0xLTEtMA_98baa00e-1557-48c7-b61d-db9f9318c59a">4,853.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e42d73bc9440fcb7dfe671ce0e5ccd_I20191231" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtMy0xLTEtMA_b82ef7be-8cac-4395-a483-0ab239b1564b">618.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771b1c5b394f47639c3f9bdf6695758d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtNS0xLTEtMA_ec56398b-67ac-4a15-8072-40ef910ad5d9">4,234.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of September&#160;30, 2020 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfODY1_6670e409-3892-4ec9-bdda-3eb88cc2df2b">37.5</ix:nonFraction> million of net unrealized losses and $<ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfODcy_50b6d84a-7d5f-406b-8be7-f62a4463679c">133.8</ix:nonFraction> million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfOTk2_e38a4760-c6ee-4274-9ed6-fe4e9086c585">15.7</ix:nonFraction>&#160;million of net unrealized gains and $<ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTAwMw_9804e89f-e90b-4db9-b1da-62242e63d73d">58.4</ix:nonFraction>&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i300702ee6536472eb9d3d81a102efef9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2020 and December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTE3MA_33eb8029-85c1-4681-a39e-05f301d8d413">60.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTE3Nw_58b72aff-cc28-47a6-a98d-11945489f030">55.6</ix:nonFraction>&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt (see Note 8 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for additional details) was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTIwOTQ2Mjc5MDc4NzI_dc91bd7f-89fd-4fa1-9559-aa1ae05e9d79">1.929</ix:nonFraction>&#160;billion as of September&#160;30, 2020, and was determined based on Level 2 inputs.</span></div></ix:continuation><div id="ibab647050bc248e3930163531a1d57d8_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RleHRyZWdpb246MWJmMmFhMDYzMmU4NDQ2NmFmYWQ3NzRiMzFkMTA2ZjVfMjMx_580bafc3-d2ef-4b6c-80df-7cd59b984da6" continuedAt="i515b2e370e0b40209e47f74a04c7abb9" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i515b2e370e0b40209e47f74a04c7abb9"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RleHRyZWdpb246MWJmMmFhMDYzMmU4NDQ2NmFmYWQ3NzRiMzFkMTA2ZjVfMjMw_3f1898b7-a5e7-474c-aef7-b52387049c82" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:47.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMi0xLTEtMS0w_a4623781-deed-40e0-96f5-b0288af83576">400.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMi0zLTEtMS0w_bdcc74b9-c85a-4d38-a49e-3edb82415330">216.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMy0xLTEtMS0w_5da2187d-de5a-4f5b-8a7e-b99a19d60787">715.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMy0zLTEtMS0w_29083808-e0c8-4714-8626-87e7edd14b11">727.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNC0xLTEtMS0w_91f3f1a9-a761-4ac1-9b1d-68775e538db7">132.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNC0zLTEtMS0w_dc7bc3e8-1372-4282-a52a-108140378e7e">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNS0xLTEtMS0w_edbd8fd2-37d6-416a-98f5-162196ee0afc">553.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNS0zLTEtMS0w_7bc6bdf4-59a5-49b8-96eb-5f0e0a2521a4">400.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNi0xLTEtMS0w_be1efed4-f7e1-4cee-9822-778fe73d8209">1,801.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNi0zLTEtMS0w_8596f320-39e8-41dc-a90a-d176cf4443dd">1,415.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred (see Note 3).</span></div></ix:continuation><div id="ibab647050bc248e3930163531a1d57d8_52"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTQ2NA_984df62a-521d-4b25-8fc8-454d3dbe5ab4" continuedAt="i3337048771b74b5b8df07461c886193b" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i3337048771b74b5b8df07461c886193b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Loan Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 10, we purchased shares of our Common Stock from Sanofi, in connection with Sanofi's secondary offering of our Common Stock held by Sanofi, with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $<ix:nonFraction unitRef="usd" contextRef="i8d06b9c5853e400a9847d748ae198625_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMjkx_8bba3f3e-d09f-42eb-bcc3-09db42a6d4f7">1.5</ix:nonFraction>&#160;billion senior unsecured 364-day bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $<ix:nonFraction unitRef="usd" contextRef="ie7c14da02ab04b15a697c1f976f6c63b_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDg4MTg_c144c130-4d4b-414b-bca8-1750c413c5e3">1.250</ix:nonFraction>&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $<ix:nonFraction unitRef="usd" contextRef="ied42ff47bb2e4f48ad72135de84e2827_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDg5MDc_84e82512-8241-475b-bd8e-734fbdc00600">750</ix:nonFraction>&#160;million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above. The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="ie7c14da02ab04b15a697c1f976f6c63b_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDk0MDE_418e4fe9-6e54-4d6d-aa0e-4c114b249f41">1.750</ix:nonFraction>% per year and will mature on September 15, 2030. The 2050 Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="ied42ff47bb2e4f48ad72135de84e2827_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDk1MDQ_0a0d9cf4-a1f5-4928-85c7-504f874c23b4">2.800</ix:nonFraction>% per year and will mature on September 15, 2050. Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes for the three months ended September&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie7b56bd9207547a3a35c46fed3f56b79_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTI2NDQzODM3MzEyMDA_99cc90fa-fed4-4060-9963-67393f8c1573">6.4</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at <ix:nonFraction unitRef="number" contextRef="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfNDk0NzgwMjMzNDAxNg_7a44ac75-04f0-4909-9fef-d70c7b53f7aa">100</ix:nonFraction>% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831" decimals="INF" name="regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfNDk0NzgwMjMzNDAyMg_73dc0a71-55f5-4209-95b7-4a36f37fcf35">101</ix:nonFraction>% of the principal amount plus accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_55"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfNDk0NzgwMjMyNzg0OQ_1a46e65a-6da0-4a9d-bc7f-68df972a1ce5" continuedAt="i42488d9f32fb4aee984c61a59f575db7" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i42488d9f32fb4aee984c61a59f575db7" continuedAt="i4b4546287f19402a816182e6567a4004"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTMx_20bed819-7eb6-47c9-9e55-39079e11436f">15.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTM4_6dbff6e7-c2c4-459d-922b-bf9c82672e06">12.9</ix:nonFraction>% for the three months ended September&#160;30, 2020 and 2019, respectively, and <ix:nonFraction unitRef="number" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTk3_bb67990c-6112-414a-a655-2e5d807c6139">8.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfNDM5ODA0NjUxMjI4Mg_bfe1cfa4-3d37-491d-9700-b339d05e25d0">14.0</ix:nonFraction>% for the nine months ended September&#160;30, 2020 and 2019, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate for the three and nine months ended September&#160;30, 2019 was positively impacted, compared to the U.S. federal statutory rate, primarily by federal tax credits for research activities, the foreign-derived intangible income deduction, and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, partly offset by the taxation of certain global intangible low-taxed income and the non-deductible Branded Prescription Drug Fee.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b4546287f19402a816182e6567a4004">The Company believes it is reasonably possible that its unrecognized tax benefits as of September&#160;30, 2020 may decrease within the next twelve months, and, as a result, positively impact our effective tax rate, as a result of expected settlement of audits and statute of limitation lapses.</ix:continuation> </span></div><div id="ibab647050bc248e3930163531a1d57d8_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjgyMQ_43de4ce7-7d14-46a1-bfce-30f342d00ce1" continuedAt="i9570b790a7854ba9bbad93bf5d7fcdfa" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i9570b790a7854ba9bbad93bf5d7fcdfa" continuedAt="iddbe0cc048b64348ac47b663314d8e89"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$<ix:nonFraction unitRef="usd" contextRef="ie00da91153ab4285948986d4a8528f33_I20191130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMTU0_caae9c17-0a72-4b86-b310-1fd18a880239">1.0</ix:nonFraction> billion&#160;of our Common Stock. The share repurchase program permits the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. </span></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfNDk0NzgwMjMyOTMwMA_2bb27795-69e2-429d-82fc-04ec983308e5" continuedAt="i8abc877b92d2483fa347d5228eaf511a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"></td><td style="width:46.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMS0yLTEtMS0yODY3_011d16e8-8bbe-4188-80e1-69ac0d28fd94">179,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMS0yLTEtMS0w_9e6b3e11-69e3-4c92-a11a-6cfa63d54f82">898,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMi0yLTEtMS0yODcw_fe2a1085-91f4-4514-a9af-2a517d5bacd9">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMi0yLTEtMS0w_cfa63f5f-ed95-46a5-9b08-a5696215b121">373.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="iddbe0cc048b64348ac47b663314d8e89" continuedAt="iebac6e3011fe4465b42556824885ab1d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8c5a33a1ef064741af1b75d4df1e7b8c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfNDM5ODA0NjUxMzk0NQ_f03b3761-e9fd-479c-a371-c6e42428ab2e">372.7</ix:nonFraction> million which remained available for share repurchases under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, effective January 2018, we have agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments by selling our Common Stock directly or indirectly owned by Sanofi. <ix:continuation id="i8abc877b92d2483fa347d5228eaf511a" continuedAt="i864b02d5b00a47bea0b08b545c567325">The table below summarizes the&#160;shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.</ix:continuation></span></div><div style="text-align:center"><ix:continuation id="i864b02d5b00a47bea0b08b545c567325"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"></td><td style="width:50.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy0xLTEtMS0w_d5b3ad98-9e54-48b4-a680-1ad1a1c48ba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib14491178e814761b044424a9d90cc57_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy0zLTEtMS0w_5a748173-330a-4a61-919d-35f67bd88b6a">103,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy01LTEtMS0w_d61723ce-c2c8-480a-98cd-23a482d057d0">77,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy03LTEtMS0w_d4edc703-8a62-4a33-a8a7-ea078287c179">210,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC0xLTEtMS0w_ec9d25d1-3d29-4fb7-a6b1-709126efc455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib14491178e814761b044424a9d90cc57_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC0zLTEtMS0w_19c7debc-c9f7-45ac-b2e2-e9e101aea10b">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC01LTEtMS0w_c99bc10d-6c95-49ae-b219-63850798b570">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC03LTEtMS0w_c64b2a12-56c4-414e-b7ad-79ed80d1640e">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupilumab/Itepekimab:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (in cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy0xLTEtMS0w_2f7b7f96-a45f-414b-931d-24a67bd516f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy0zLTEtMS0w_642344dc-814e-4960-8ac2-f3516a65d88b">69,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy01LTEtMS0w_56a35008-d74d-4434-9044-b09268e67a15">171,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy03LTEtMS0w_1e51bd38-398e-4edc-9a08-d65bee5cd97a">93,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC0xLTEtMS0w_ce43e54d-f8bb-4932-b047-15642811f31d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC0zLTEtMS0w_d9792f18-a130-40b9-a686-c7c7fe6dd871">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC01LTEtMS0w_1608b234-1c45-4a36-b71b-49536d0859c1">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC03LTEtMS0w_8a8a5969-3b5a-4b16-9165-53e4b42f6cd7">29.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="regn:Maximumsharesthecollaboratorcouldsell" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMTkwOA_5d9776b6-9eed-465e-9094-a2c39dbdeda9">279,766</ix:nonFraction> shares of our Common Stock remained available for sale by Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments incurred in periods through September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iebac6e3011fe4465b42556824885ab1d">In May 2020, a secondary offering of <ix:nonFraction unitRef="shares" contextRef="i136244d2dc724edcbda67477d4375855_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjIwNA_eddba0d6-46b8-4a49-bc73-4784f23ece73">13,014,646</ix:nonFraction> shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased <ix:nonFraction unitRef="shares" contextRef="i7fb343771e004b36a23994024299f080_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjM1Mg_7c64b122-af2b-46de-b4dc-b462b71d650e">9,806,805</ix:nonFraction> shares directly from Sanofi for an aggregate purchase amount of $<ix:nonFraction unitRef="usd" contextRef="i7fb343771e004b36a23994024299f080_D20200501-20200531" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjQxOQ_0b3d5feb-b676-49dc-a56a-4c9ae1f19c7f">5</ix:nonFraction>&#160;billion (the "Stock Purchase"). See Note 8 for additional information. As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than <ix:nonFraction unitRef="shares" contextRef="id7a7a7f0ec7b41ccb9e296ec34a49d62_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjU3Nw_0ad345b4-2df2-4256-913c-85a36eefaed9">400,000</ix:nonFraction> shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (which Sanofi has used, and may continue to use, for the funding of certain development costs described above).</ix:continuation> </span></div><div id="ibab647050bc248e3930163531a1d57d8_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzYy_abca14d2-7b28-49c5-b49e-97e364fce184" continuedAt="i85104b413157491399ad897bdea611b3" escape="true">Statement of Cash Flows</ix:nonNumeric></span></div><ix:continuation id="i85104b413157491399ad897bdea611b3" continuedAt="i5360391f0c174c56aa98ac2eef6dc33a"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzUy_9bacf486-9f5e-45dc-9dca-d9d940be1d36" escape="true"><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzU0_e8d00293-e69a-4f44-bd27-124adb8b1d65" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:58.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.172%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMi0yLTEtMS0w_d0f1dbd0-69ae-4555-839f-1cefa7a89d02">1,573.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMi00LTEtMS0w_3d5ea15e-81f3-4d3a-ace8-4be94d23d94d">1,384.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMy0yLTEtMS0w_0bc097b6-d85e-4983-ba57-385128ea3372">13.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMy00LTEtMS0w_21737ee2-817a-4ee0-8ba7-e7465cb39bc2">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfNC0yLTEtMS0w_9fb5cac8-05b6-47e1-92c9-7da085c1a708">1,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfNC00LTEtMS0w_4d22686f-c447-462e-9c81-fd9baaee66d9">1,397.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i5360391f0c174c56aa98ac2eef6dc33a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNDk0NzgwMjMyNjM2OQ_826a5ccb-0060-4977-9406-37d163fdc38b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:26.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi0xLTEtMS04MzIx_1e97403c-752b-4fec-af46-f9fb4d3ed422">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76fb63f2f534fd586e297b9d26b3169_D20190101-20191231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi0zLTEtMS04MzIx_183e3396-602f-4838-92f8-88a0a87c6cef">133.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi01LTEtMS04MzIx_19df2f17-b192-4de0-8443-d3d0a704cabd">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a462a19f724c93b0ad3e5e3df53fa2_D20180101-20181231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi03LTEtMS04MzIx_9a117a56-185a-454d-b0f2-3a76fef958ea">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibab647050bc248e3930163531a1d57d8_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNDk0NzgwMjM3ODU2Nw_5fbdf5c4-f83c-4a22-8368-f9a5ad9bcfa6" continuedAt="i6444829142de4f1cac27d5d8785bc71c" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="i6444829142de4f1cac27d5d8785bc71c" continuedAt="i67d0a0a4b9244157b2fed41caf4d8261"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. <ix:nonNumeric contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMjgxODk_f3fc9873-74b3-449d-ac15-ede78e7f6c7e" escape="true">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</ix:nonNumeric> The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2020 and December&#160;31, 2019, the Company had accruals for loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNTcy_5ad98fb1-2e44-41ab-b135-c55d2ca5ede8">132.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNTc5_eea6a69e-dac3-40f8-afd1-e2d695f95592">100.0</ix:nonFraction> million, respectively. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to '287 Patent and '163 Patent</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to patent infringement litigation initiated by the Company involving its European Patent No. 1,360,287 (the "'287 Patent") and its European Patent No. 2,264,163 (the "'163 Patent"). Each of these patents concerns genetically engineered mice capable of producing chimeric antibodies that are part human and part mouse. Chimeric antibody sequences can be used to produce high-affinity fully human monoclonal antibodies. In these proceedings, the Company claims infringement of several claims of the '287 Patent and the '163 Patent (as applicable), and seeks, among other types of relief, an injunction and an account of profits in connection with the defendants' infringing acts, which may include, among other things, the making, use, keeping, sale, or offer for sale of genetically engineered mice (or certain cells from which they are derived) that infringe one or more claims of the '287 Patent and the '163 Patent (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2013, the Company commenced patent infringement litigation against Kymab Ltd in the English High Court of Justice, Chancery Division, Patents Court, in London, asserting the '287 Patent and '163 Patent. Following a trial to adjudicate the claims of infringement and counterclaims of invalidity of the '287 Patent and the '163 Patent, the court issued a final judgment on February 1, 2016, finding that the asserted claims of the '287 and '163 Patents are novel, not obvious, and infringed by Kymab's genetically engineered mice. However, the court invalidated the '287 and '163 Patents on the ground of insufficiency. On appeal, the Court of Appeal (Civil Division of England and Wales) reversed the English High Court's decision and held that the '287 Patent and '163 Patent are both valid and infringed by Kymab and subsequently issued a final order, which enjoined Kymab from infringing the '287 Patent and '163 Patent (subject to certain exceptions) and required Kymab to destroy or deliver to a third party all products and antibodies and cells engineered to produce antibodies which infringe the '287 Patent and '163 Patent (subject to certain exceptions). On June 24, 2020, the Supreme Court of the United Kingdom overturned the decision of the Court of Appeal on validity and held that the '287 and '163 Patents are each invalid on the ground of insufficiency. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8 and July 13, 2016, notices of opposition against the '163 Patent were filed in the European Patent Office (the "EPO") by Merus N.V. and Kymab and Novo Nordisk A/S, respectively. The notices assert, as applicable, lack of novelty, lack of inventive step, and insufficiency. Following an oral hearing before the Opposition Division of the EPO on February 5&#8211;7, 2018, the Opposition Division upheld the '163 Patent without amendments. Kymab, Merus, and Novo Nordisk each filed a notice of appeal of the Opposition Division's decision on February 9, 2018, May 25, 2018, and June 26, 2018, respectively. On January 7, 2019, Merus withdrew its appeal of the '163 Patent in the EPO in connection with the previously reported global settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i67d0a0a4b9244157b2fed41caf4d8261" continuedAt="i1dea985b1a874835a071cca3daf033a4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and seeks a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that <ix:nonFraction unitRef="claim" contextRef="ib4162e2d3ffa40cab347875d0e8141e1_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzM0MA_9f57c55a-58a2-4568-ba0c-4e1981cfaa93">two</ix:nonFraction> claims of the '165 Patent and <ix:nonFraction unitRef="claim" contextRef="i76ec0cbb09134d05af796df3d6121770_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzM3Mw_439709c1-d31d-45e2-a92d-5f5f2c2d82af">one</ix:nonFraction> claim of the '741 Patent were not invalid. The jury also found that <ix:nonFraction unitRef="claim" contextRef="ib4162e2d3ffa40cab347875d0e8141e1_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="regn:LossContingencyClaimsInvalidNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzQ0NA_75bda83f-28cf-43cf-92a7-f40188a16b4a">two</ix:nonFraction> claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit has been scheduled for December 9, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2016, Amgen filed a lawsuit against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi-Synthelabo Limited, Aventis Pharma Limited, Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the English High Court of Justice, Chancery Division, Patents Court, in London, seeking a declaration of infringement of Amgen's European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, by Praluent.&#160;The lawsuit also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On February 8, 2017, the court temporarily stayed this litigation on terms mutually agreed by the parties. On October 22, 2020, the court lifted the stay upon application by the Company and the Sanofi defendants, and the case will proceed in due course.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germany. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 25, 2016, Amgen filed a lawsuit for infringement of the '124 Patent against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the Regional Court of D&#252;sseldorf, Germany (the "D&#252;sseldorf Regional Court"), seeking a permanent injunction, an accounting of marketing activities, a recall of Praluent and its removal from distribution channels, and damages. On November 14, 2017, the D&#252;sseldorf Regional Court issued a decision staying the infringement proceedings until a decision of the Opposition Division of the EPO concerning the pending opposition filed by the Company, Sanofi, and several other opponents against the '124 Patent (as discussed below). Following Amgen's request to reopen the proceedings in light of the issuance of the Preliminary Opinion (as defined below), the D&#252;sseldorf Regional Court held an oral hearing on September 11, 2018 and ruled on December 10, 2018 that the infringement proceedings would be reopened. On July 11, 2019, the D&#252;sseldorf Regional Court found that Praluent infringes the '124 Patent and granted an injunction prohibiting the Company and Sanofi's manufacture, sale, and marketing of Praluent in Germany (the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i1dea985b1a874835a071cca3daf033a4" continuedAt="i9ee76931de3e47ccbedd074b58bbabf9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">"July 11 Decision"). Amgen subsequently enforced the injunction and, as a result, commercialization of Praluent in Germany has been discontinued. On July 12, 2019, the Company and Sanofi appealed the July 11 Decision to the Higher Regional Court of D&#252;sseldorf (the "Higher Regional Court"). An oral hearing on the merits of the appeal to the Higher Regional Court (originally scheduled for April 2, 2020) has been rescheduled for November 5, 2020. On August 5, 2019 and October 31, 2019, the Higher Regional Court denied the Company and Sanofi's requests for a stay of preliminary enforcement of the July 11 Decision pending the appeal on the merits. On November 3, 2020, Amgen filed a motion withdrawing this lawsuit without prejudice.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">France. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2016, Amgen filed a lawsuit for infringement of the '124 Patent in the Tribunal de grande instance in Paris, France against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi Chimie (subsequently added as a defendant). Amgen is seeking the prohibition of allegedly infringing activities with a &#8364;<ix:nonFraction unitRef="eur" contextRef="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926" decimals="INF" format="ixt:numdotdecimal" name="regn:LossContingencyDamagesSoughtPerUnitProduced" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTEzNjA_76406eef-adf4-4d94-be63-e30eee48f920">10,000</ix:nonFraction> penalty per drug unit of Praluent produced in violation of the court order sought by Amgen; an appointment of an expert for the assessment of damages; disclosure of technical (including supply-chain) and accounting information to the expert and the court; provisional damages of &#8364;<ix:nonFraction unitRef="eur" contextRef="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTE2NDI_1bb89f51-a380-408a-8642-08f06ea075b4">10.0</ix:nonFraction> million (which would be awarded on an interim basis pending final determination); reimbursement of costs; publication of the ruling in three newspapers; and provisional enforcement of the decision to be issued, which would ensure enforcement of the decision (including any provisional damages) pending appeal. Amgen is not seeking a preliminary injunction in this proceeding at this time. On April 10, 2017, the Company and the Sanofi parties filed briefs seeking invalidation of certain of the claims of the '124 Patent, and Amgen filed a response on July 28, 2017. Oral hearing on this infringement lawsuit (originally scheduled for February 12, 2019) has yet to be rescheduled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Netherlands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2019, Amgen initiated a lawsuit alleging infringement of the Dutch designation of the '124 Patent in the District Court of The Hague in the Netherlands, against Sanofi-Aventis Netherlands B.V. and Sanofi-Aventis Groupe S.A. The Company has not been named as a defendant in this action. Amgen alleges, among other things, patent infringement based on the production, importation, and commercialization of Praluent (alirocumab) in the Netherlands. Amgen's requests are made on an accelerated basis and include, among other things, a request for a permanent injunction, damages, an order for customer information, a recall order, a destruction order, and an order for costs. A trial has been scheduled for February 12, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Italy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, Amgen filed a lawsuit for infringement of the Italian designation of the '124 Patent in the Tribunale di Milano - Enterprise Chamber in Milan, Italy, against Sanofi-Aventis Groupe S.A., Sanofi Chimie, and Sanofi SpA. The Company has not been named as a defendant in this action. Amgen alleges that the production, importation, and commercialization of Praluent (alirocumab) in Italy infringes the '124 Patent. The writ of summons filed by Amgen seeks, among other things, a declaration of infringement, a permanent injunction, withdrawal of product from the market, and damages. On June 24, 2020, Amgen also filed a preliminary injunction motion against the Sanofi parties. On August 12, 2020, the court denied Amgen's preliminary injunction motion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Spain. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, Amgen also filed a lawsuit alleging infringement of the Spanish designation of the '124 Patent in the Juzgado de lo Mercantil No. 5 (Commercial Court) in Barcelona, Spain, against Sanofi-Aventis, S.A. The Company was not named as a defendant in this action. Amgen alleged, among other things, patent infringement based on the manufacture, offering for sale, introduction into the market, use, and importation or possession of Praluent (alirocumab) in Spain. Amgen sought, among other things, a permanent injunction, withdrawal of Praluent from the market, seizure and destruction of Praluent from the market and in storage, and damages in the form of lost profits and costs and expenses. On May 12, 2020, the court stayed this lawsuit until October 30, 2020 on terms mutually agreed by the parties. On October 30, 2020, the stay was automatically lifted. On November 2, 2020, Amgen filed a motion withdrawing this lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPO Proceedings. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '124 Patent is also subject to opposition proceedings in the EPO seeking to invalidate certain of its claims, which were initiated by Sanofi on February 24, 2016 and, separately, by the Company, Sanofi, and several other opponents on November 24, 2016. On December 13, 2017, the Opposition Division of the EPO issued a preliminary, non-binding opinion (the "Preliminary Opinion") regarding the validity of the '124 Patent, indicating that it currently considers the claims of a new request filed by Amgen in response to the opposition to satisfy the requirements for patentability. An oral hearing on the oppositions against the '124 Patent was held on November 28&#8211;30, 2018, at which the Opposition Division upheld the validity of the '124 Patent's claims in amended form. The Company and Sanofi filed notices of appeal to the Technical Board of Appeal (the "TBA") of the EPO on November 30, 2018. An oral hearing before the TBA was held on October 28&#8211;29, 2020, at which the TBA ruled that the '124 Patent claims directed to compositions of matter and medical use were invalid based on a lack of inventive step.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i9ee76931de3e47ccbedd074b58bbabf9" continuedAt="iaf0c297174474d57a3b54bc95b18ce75"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2017, Amgen filed a lawsuit for infringement of Amgen's Japanese Patent Nos. 5,906,333 (the "'333 Patent") and 5,705,288 (the "'288 Patent") in the Tokyo District Court Civil Division (the "Tokyo District Court") against Sanofi K.K. Amgen's complaint alleges that manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) infringe the '333 and '288 Patents. The complaint further seeks a permanent injunction, disposal of product, and court costs. The Company has not been named as a defendant in this litigation. On January 17, 2019, the Tokyo District Court upheld the validity of the '333 Patent and '288 Patent and ordered a permanent injunction against Sanofi K.K. to stop manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) and to dispose of all product. However, the Tokyo District Court stayed the enforcement of such injunction pending appeal to the Intellectual Property High Court of Japan (the "IPHC"). On January 30, 2019, Sanofi K.K. appealed the Tokyo District Court's decision in the infringement proceedings to the IPHC. Following an oral hearing on October 30, 2019, the IPHC affirmed the Tokyo District Court's decision in the infringement proceedings. Sanofi K.K. appealed the IPHC's decision in the infringement proceedings to the Supreme Court of Japan on November 12, 2019. On April 24, 2020, the Supreme Court of Japan declined to hear the appeal filed by Sanofi K.K. in the infringement proceedings and the injunction issued by the Tokyo District Court became effective. Sanofi K.K. subsequently complied with the injunction and, as a result, the commercialization of Praluent in Japan has been discontinued. On March 31, 2020, Amgen filed a related lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the finding of infringement of the '333 Patent and the '288 Patent. The Company has not been named as a defendant in this damages action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation filed a lawsuit against Amgen and Immunex Corporation, a wholly owned subsidiary of Amgen, in the United States District Court for the District of Massachusetts seeking a declaratory judgment that the Company's and the other plaintiffs' Commercializing of Dupixent does not directly or indirectly infringe U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. On May 1, 2017, the Company and the other plaintiffs filed a notice of voluntary dismissal of this action without prejudice.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of the '487 Patent. On July 28 and 31, 2017, the same parties filed <ix:nonFraction unitRef="claim" contextRef="i00e0c80c71e941b48916ad1f5287ba31_D20170728-20170731" decimals="INF" format="ixt-sec:numwordsen" name="regn:GainContingencyInterPartesReviewFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTg3NDg_59ffa07f-98c3-48fc-a45c-062b2c269eec">two</ix:nonFraction> additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). On October 4, 2017, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a decision on the first IPR petition and declined to institute an IPR proceeding to review the validity of the '487 Patent. On February 15, 2018, the PTAB issued two decisions instituting the Company's and Sanofi's Additional IPR Petitions on all claims of the '487 Patent for which review had been requested. Oral hearings on the Additional IPR Petitions before the PTAB were held on November 14, 2018. On February 14, 2019, the PTAB issued final written decisions on the Additional IPR Petitions, invalidating all <ix:nonFraction unitRef="claim" contextRef="i841077884f1e4957adca717303635407_I20190214" decimals="INF" name="regn:GainContingencyClaimsInvalidatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTk1MDM_1eaa218b-daf3-4372-ace0-3c49e9c7a588">17</ix:nonFraction> claims of the '487 Patent as obvious based on one of the Additional IPR Petitions while declining to hold the challenged claims of the '487 Patent invalid based on the other. In April 2019, the parties filed notices of appeal with the Federal Circuit appealing the PTAB's respective adverse final written decisions on the Additional IPR Petitions, and oral argument was held on August 5, 2020. On October 13, 2020, the Federal Circuit affirmed the PTAB's decision on the Additional IPR Petition that invalidated all 17 claims of the '487 Patent as obvious.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. Immunex is not seeking an injunction in this proceeding at this time. On June 21, 2017, the court denied a motion to dismiss Immunex's complaint previously filed by the Company and the Sanofi parties. On June 28, 2017, the Company and the Sanofi parties filed an answer to Immunex's complaint and counterclaims against Immunex and Amgen (which was amended on October 31, 2017 to, among other things, add an inequitable conduct allegation), and Immunex and Amgen filed an answer to the counterclaims on July 28, 2017. A combined hearing on the construction of certain disputed claim terms of the '487 Patent and the Company and the Sanofi parties' motion </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="iaf0c297174474d57a3b54bc95b18ce75" continuedAt="i40e011480d9d46b9be21f0a6f90eb12b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for summary judgment on the issue of indefiniteness of the '487 Patent claims was held on July 12, 2018. On August 24, 2018, the court issued an order denying this motion and construed the disputed claim terms as proposed by Amgen. On February 28, 2019, the court granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. The original patent term of the Immunex patents is set to expire in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), treble damages, costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated <ix:nonFraction unitRef="claim" contextRef="i4b28b11bf97045e493c30eaae17baf6a_D20200716-20200716" decimals="INF" format="ixt-sec:numwordsen" name="regn:GainContingencyInterPartesReviewFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMjY3MzU_2dca5b6b-9807-4e12-acdc-60a80b4f66eb">two</ix:nonFraction> IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended. The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceedings Relating to fasinumab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unless otherwise noted, dollars in millions, except per share data)</span></div></div><ix:continuation id="i40e011480d9d46b9be21f0a6f90eb12b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. A trial has been scheduled to commence in late November or early December 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the oppositions against the '048 Patent was held on November 29&#8211;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. An oral hearing before the TBA has been scheduled for July 29, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGN-COV2</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allele seeks a judgment of patent infringement of the '221 Patent, a judgment that such infringement was willful, and an award of monetary damages (together with interest), treble damages, costs and expenses of the lawsuit, and attorneys' fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. An oral hearing on the motion to dismiss was held on October 7, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Demand</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, is evaluating this demand letter.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="ibab647050bc248e3930163531a1d57d8_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements.&#160;Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.&#160;These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators&#8217; ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators (collectively, "Regeneron&#8217;s Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and our product candidates and research and clinical programs now underway or planned, including without limitation EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(aflibercept) Injection, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(dupilumab) Injection, Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(cemiplimab) Injection, Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(alirocumab) Injection, Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(sarilumab) Injection, Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(atoltivimab, maftivimab, and odesivimab-ebgn), REGN-COV2, fasinumab, evinacumab, garetosmab, pozelimab, Regeneron's oncology programs (including its costimulatory bispecific portfolio), Regeneron's earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and product candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Inmazeb, REGN-COV2, fasinumab, evinacumab, garetosmab, pozelimab, and odronextamab; the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products (such as EYLEA, Dupixent, Libtayo, Praluent, and Kevzara), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and product candidates; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's Products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's Products and product candidates; our ability to manufacture and manage supply chains for multiple products and product candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and product candidates; the availability and extent of reimbursement of Regeneron&#8217;s Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's agreement with Roche relating to REGN-COV2, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA, Dupixent, and Praluent described further in Note 12 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 12 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.&#160;These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.&#160;In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part II, Item 1A. "Risk Factors," which could cause actual events and results to differ materially from those indicated by such forward-looking statements. We do not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious diseases. Our commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to be an integrated, multi-product biotechnology company that provides patients and medical professionals with important options for preventing and treating human diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information is summarized as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:43.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain revisions have been made to the previously reported revenues for the periods ended September 30, 2019. See Note 1 to our Condensed Consolidated Financial Statements for further details.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:28.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease Area</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA (aflibercept) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular age-related macular degeneration ("wet AMD")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic macular edema ("DME")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macular edema following retinal vein occlusion ("RVO"), which includes macular edema following central retinal vein occlusion ("CRVO") and macular edema following branch retinal vein occlusion ("BRVO")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myopic choroidal neovascularization ("mCNV")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic retinopathy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular glaucoma ("NVG")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in adults and adolescents)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyposis ("CRSwNP")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced cutaneous squamous cell carcinoma ("CSCC")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:28.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease Area</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent (alirocumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-lowering in heterozygous familial hypercholesterolemia ("HeFH") or clinical atherosclerotic cardiovascular disease ("ASCVD") (in adults)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular risk reduction in patients with established cardiovascular disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara (sarilumab) Solution for Subcutaneous Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis ("RA") (in adults)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rilonacept) Injection for Subcutaneous Use</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Auto-inflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome ("MWS") </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ziv-aflibercept) Injection for Intravenous Infusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic colorectal cancer ("mCRC")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td></tr><tr style="height:5pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note: Refer to "Net Product Sales of Regeneron-Discovered Products" section below for information regarding whether net product sales for a particular product are recorded by us, Bayer, or Sanofi</span></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Refer to label information in each territory for specific indication</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Bayer (outside the United States)</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketed as Libtayo (cemiplimab-rwlc) Injection in the United States</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi prior to April 2020. Effective April 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States. Pursuant to the April 2020 agreement, Sanofi pays us a royalty on net product sales of Praluent outside the United States. Refer to "Collaboration, License, and Other Agreements" section below for further details.</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Rest of world. Checkmark in this column indicates that the product has received marketing approval in at least one country outside of the United States, European Union ("EU"), or Japan</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Approval in Japan is for adults and adolescents 15 years of age and older</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Pursuant to a 2015 amended and restated ZALTRAP agreement, Sanofi is solely responsible for the development and commercialization of ZALTRAP, and Sanofi pays us a percentage of aggregate net product sales of ZALTRAP</span></div></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> No longer marketed by Sanofi in Japan due to injunction (see Note 12 to our Condensed Consolidated Financial Statements for further details)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales of Regeneron-Discovered Products</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.050%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Product Sales Recorded by Regeneron</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Total Sales)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Product Sales Recorded by Regeneron</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Total Sales)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,706.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,422.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,537.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. The Company records its share of profits/losses in connection with sales of EYLEA outside the United States.</span></div></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of Libtayo in the United States. Sanofi records net product sales of Libtayo outside the United States and global net product sales of Dupixent, Kevzara, and ZALTRAP. The Company records its share of profits/losses in connection with (i) sales of Libtayo outside the United States, and (ii) global sales of Dupixent and Kevzara. Sanofi pays the Company a percentage of net sales of ZALTRAP.</span></div></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, Regeneron records net product sales of Praluent in the United States. Also effective April 1, 2020, Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales. Previously, Sanofi recorded global net product sales of Praluent and the Company recorded its share of profits/losses in connection with such sales. Refer to "Products" section above and "Collaboration, License, and Other Agreements - Sanofi" section below for further details.</span></div></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of REGN-COV2 in connection with our agreement with the U.S. government. Refer to "Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BARDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">" below for further details.  </span></div></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Percentage not meaningful</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs in Clinical Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All 24 of our product candidates in clinical development, including the five U.S. Food and Drug Administration ("FDA") approved products which we are investigating in additional indications, were discovered in our research laboratories and are summarized in the table below. We believe that our ability to develop product candidates is enhanced by the application of our&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platforms. We continue to invest in the development of enabling technologies to assist in our efforts to identify, develop, manufacture, and commercialize new product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development (including any post-approval studies), uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes to drug pricing and reimbursement regulations and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, and changes in the competitive landscape affecting a product candidate. The planning, execution, and results of our clinical programs are significant factors that can affect our operating and financial results. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators conduct clinical trials in multiple countries across the world. The COVID-19 pandemic and the restrictions adopted around the globe to reduce the spread of the disease have impacted and will continue to impact our clinical development programs. We continue to evaluate the impact of the COVID-19 pandemic on an individual trial basis and oversee trial management while also working to ensure patient safety and provide sufficient supply of product candidates for the studies.&#160;At this time, we expect fully enrolled clinical studies to remain generally on track. However, the ongoing pandemic continues to impact clinical trial execution in many regions across the world for us and our collaborators. The ultimate impact (including possible delays in recruiting and/or obtaining data) resulting from the COVID-19 pandemic will depend, among other factors, on the extent of the pandemic in the areas with study sites and patient populations. It is possible that the COVID-19 pandemic may cause clinical disruptions beyond those we have described. In addition, there may be delays in the timing of regulatory review and other projected milestones discussed in the table below.&#160; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part II, Item 1A. "Risk Factors" for a description of these and other risks and uncertainties that may affect our clinical programs, including those related to the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.786%"><tr><td style="width:1.0%"></td><td style="width:15.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ophthalmology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-dose formulation in wet AMD </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retinopathy of prematurity </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("ROP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by Ministry of Health, Labour and Welfare ("MHLW") for NVG in Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-dose formulation in wet AMD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-filled syringe approved by European Commission ("EC")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-dose formulation in DME</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology &amp; Inflammatory Diseases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-4R alpha subunit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grass allergy</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis in pediatrics (6 months&#8211;5 years of age) (Phase 2/3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis in pediatrics (6&#8211;11 years of age) (EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by FDA for expanded atopic dermatitis indication in pediatrics (6&#8211;11 years of age) </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EC decision for expanded atopic dermatitis indication in pediatrics (6&#8211;11 years of age) (fourth quarter 2020)</span></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peanut allergy</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma in pediatrics (6&#8211;11 years of age)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by National Medical Products Administration ("NMPA") in China for adults with atopic dermatitis</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report results from Phase 3 study for atopic dermatitis in pediatric patients (6 months&#8211;5 years of age) (2022)</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eosinophilic esophagitis </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("EoE")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in adults</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, adolescents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and pediatrics</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") recommended approval for an additional indication in children aged 6 to 11 with atopic dermatitis</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submit supplemental Biologics License Application ("sBLA") and Marketing Authorization Application ("MAA") for asthma in pediatrics (6&#8211;11 years of age) (first quarter 2021)</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease ("COPD") </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bullous pemphigoid (Phase 2/3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic spontaneous urticaria</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Phase 3 trial for asthma in children aged 6 to 11 years met its primary and key secondary endpoints</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report results from Part B of the Phase 3 study in adults and adolescents with EoE (2022)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prurigo nodularis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allergic bronchopulmonary aspergillosis ("ABPA")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report results from Phase 2 study in peanut allergy (fourth quarter 2020)</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by MHLW for CRSwNP in Japan</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved by FDA and MHLW for 300 mg auto-injector</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resubmit sBLA for 200 mg auto-injector (fourth quarter 2020)</span></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.786%"><tr><td style="width:1.0%"></td><td style="width:15.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Part A of the Phase 3 trial in adult and adolescent patients with EoE met both co-primary endpoints</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report results from Phase 3 chronic spontaneous urticaria and prurigo nodularis studies (second half 2021) </span></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Presented results from Phase 2a trial in grass allergy</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 3 studies in chronic inducible urticaria, chronic sinusitis without nasal polyposis, and allergic fungal rhinosinusitis (fourth quarter 2020)</span></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiated second confirmatory Phase 3 trial in COPD</span></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 3 study in hand and foot atopic dermatitis (first half 2021)</span></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevzara (sarilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-6R</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polyarticular-course juvenile idiopathic arthritis ("pcJIA")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Phase 3 studies in COVID-19 patients did not meet primary and key secondary endpoints</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic juvenile idiopathic arthritis ("sJIA")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued clinical development in polymyalgia rheumatica and giant cell arteritis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3500)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-33</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued further clinical development in atopic dermatitis due to lack of efficacy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 3 study in COPD (fourth quarter 2020)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COPD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN1908-1909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to Feld1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat allergy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report results from Phase 2 study in cat allergic asthmatics (first half 2021)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5713-5714-5715</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Betv1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Birch allergy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 3 study in birch allergy (first half 2021)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7257</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL2Rg</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplastic anemia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:81pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.786%"><tr><td style="width:1.0%"></td><td style="width:15.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Libtayo (cemiplimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(h)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PD-1</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solid tumors and advanced hematologic malignancies</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basal cell carcinoma ("BCC") <br/>(potentially pivotal study)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line non-small cell lung cancer ("NSCLC"), monotherapy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line NSCLC, monotherapy (U.S. and EU)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Phase 3 monotherapy trial in first-line NSCLC met primary endpoint. Independent Data Monitoring Committee ("IDMC") recommended stopping the trial early due to highly significant improvement in overall survival. </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA decision on sBLA (target action date of February 28, 2021) and EC decision on regulatory submission (mid-2021) for first-line NSCLC, monotherapy</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced CSCC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line NSCLC, chemotherapy combination</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced BCC (U.S. and EU)</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoadjuvant CSCC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second-line cervical cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA decision on sBLA (target action date of March 3, 2021) and EC decision on regulatory submission (mid-2021) for advanced BCC </span></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjuvant CSCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed patient enrollment in Phase 3 first-line NSCLC chemotherapy combination study</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Phase 2 study in BCC demonstrated clinically-meaningful and durable responses</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim analysis from Phase 3 study in cervical cancer (2021)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Presented positive data from pivotal NSCLC and BCC studies at the European Society for Medical Oncology ("ESMO") Virtual Congress 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Odronextamab (REGN1979)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting CD20 and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain B-cell malignancies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-cell non-Hodgkin lymphoma ("B-NHL") (potentially pivotal study)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expanded potentially pivotal Phase 2 program with different subtypes of NHL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report updated results from initial study in certain B-cell malignancies (fourth quarter 2020)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple myeloma </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report updated results from initial study in multiple myeloma (fourth quarter 2020)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiple myeloma </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platinum-resistant ovarian cancer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.786%"><tr><td style="width:1.0%"></td><td style="width:15.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5678</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting two distinct MET epitopes</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MET-altered advanced NSCLC </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN3767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to LAG-3 </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solid tumors and advanced hematologic malignancies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN6569</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to GITR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solid tumors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular/Metabolic Diseases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Praluent (alirocumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PCSK9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Homozygous familial hypercholesterolemia ("HoFH")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in pediatrics</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH in adults (U.S.)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported results from Phase 3 study in adult patients with HoFH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA decision on sBLA for HoFH in adults (target action date of April 4, 2021)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeFH in pediatrics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evinacumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN1500)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to ANGPTL3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refractory hypercholesterolemia (both HeFH and non-FH)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH (U.S. and EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> published positive results from Phase 3 trial in HoFH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA decision on BLA (target action date of February 11, 2021) and EC decision on MAA for HoFH (first half 2021)</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severe hypertriglyceridemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pozelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3918)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to C5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paroxysmal nocturnal hemoglobinuria ("PNH")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate combination program with Alnylam's cemdisiran (fourth quarter 2020)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CD55-deficient protein-losing enteropathy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 3 program in PNH (next 12 months)</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garetosmab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN2477)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Activin A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fibrodysplasia ossificans progressiva </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("FOP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)(e) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(potentially pivotal study)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported results from Phase 2 study in FOP </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further review trial data and determine next steps for the program</span></td></tr><tr style="height:75pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paused dosing in the open-label portion of the Phase 2 study in FOP based on reports of serious adverse events</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.786%"><tr><td style="width:1.0%"></td><td style="width:15.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to leptin receptor ("LEPR")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generalized lipodystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5381</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to NPR1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Heart failure</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pain</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fasinumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(l)(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN475)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to NGF</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Osteoarthritis pain of the knee or hip</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported top-line results from Phase 3 trials in osteoarthritis pain of the knee or hip</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report additional longer-term safety results from Phase 3 studies in osteoarthritis pain of the knee or hip (first half 2021)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued actively treating patients following recommendation from the IDMC that the program should be terminated</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continue discussions with regulatory authorities and determine next steps for the program (first half 2021)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN-COV2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> (REGN10933-10987)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to SARS-CoV-2 virus</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 multi-dose safety study</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 treatment in non-hospitalized patients (Phase 2/3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 prevention</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adults with mild-to-moderate COVID-19 who are at high risk for poor outcomes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported that Phase 2/3 trial in non-hospitalized patients with COVID-19 met primary and key secondary endpoints</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA decision on EUA for COVID-19 (fourth quarter 2020)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 treatment in hospitalized patients (Phase 2/3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 treatment in hospitalized patients (RECOVERY trial)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted request to FDA for an Emergency Use Authorization ("EUA") for COVID-19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete Phase 3 portion of COVID-19 study in non-hospitalized patients and submit BLA (first half 2021)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDMC recommended further enrollment of hospitalized patients requiring high-flow oxygen or mechanical ventilation be placed on hold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two papers published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> describing REGN-COV2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:13pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 1: For purposes of the table above, a program is classified in Phase 1, 2, or 3 clinical development after recruitment for the corresponding study or studies has commenced</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 2: We have discontinued further clinical development of REGN5069, an antibody to GFR&#945;3, which was previously being studied in osteoarthritis pain of the knee</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Sanofi</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Bayer outside of the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted orphan drug designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA granted Breakthrough Therapy designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi did not opt-in to or elected not to continue to co-develop the product candidate. Under the terms of our agreement, Sanofi is entitled to receive royalties on any future sales of the product candidate.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(g) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We and the Biomedical Advanced Research Development Authority ("BARDA") of the U.S. Department of Health and Human Services ("HHS") are parties to agreements whereby HHS provides certain funding to support research and development of this product candidate</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Studied as monotherapy and in combination with other antibodies and treatments</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Information in this column relates to U.S., EU, and Japan regulatory submissions only</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi prior to April 2020. Effective April 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States. Refer to "Collaboration, License, and Other Agreements" section below for further details.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> As described in the section preceding the table above and Part II, Item 1A. "Risk Factors," development timelines may be further subject to change as a result of the impact of the COVID-19 pandemic</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(l) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Teva and Mitsubishi Tanabe Pharma</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Conducted with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the National Institutes of Health ("NIH")</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Roche </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the continued success in commercializing EYLEA and Dupixent. We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators. Also, our research and development activities outside our collaborations, the costs of which are not reimbursed, are expected to expand and require additional resources. We also expect to incur substantial costs related to the commercialization of our marketed products. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our marketed products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits or losses from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such product(s) and whether or when they may become profitable.</span></div><div id="ibab647050bc248e3930163531a1d57d8_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information - Clinical Development Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGN-COV2</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our end-to-end antibody technologies to discover and develop brand new therapeutic antibodies for COVID-19. The Company is advancing REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat infection from the SARS-CoV-2 virus. The use of our two-antibody "cocktail" is intended to diminish the risk of viral escape by effectively binding to the virus's critical spike protein in two separate, non-overlapping locations. In April 2020, the Company moved its leading neutralizing antibodies into pre-clinical and clinical-scale cell production lines, and in June 2020, initiated its first clinical trial of REGN-COV2. Following a positive review from the IDMC of REGN-COV2 Phase 1 safety results in an initial cohort, the program advanced to late-stage clinical trials (see table above for further details). The REGN-COV2 clinical program consists of the following separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic and asymptomatic COVID-19 patients, uninfected people with close exposure to a COVID-19 patient (such as the patient's housemate), and healthy volunteers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we submitted a request to the FDA for an EUA for REGN-COV2 in patients with mild-to-moderate COVID-19 who are at high risk for poor outcomes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced positive results from the ongoing Phase 2/3 seamless trial in non-hospitalized patients with COVID-19, showing that REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits, and/or physician office/telemedicine visits). The trial met the primary and key secondary endpoints. In September 2020, we had announced initial data from the trial showing that REGN-COV2 reduced viral load and time to alleviate symptoms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the IDMC for the REGN-COV2 treatment trials for COVID-19 recommended that the current hospitalized patient trial be modified. Specifically, based on a potential safety signal and an unfavorable risk/benefit profile at this time, the IDMC recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending collection and analysis of further data on patients already enrolled. The IDMC also recommended continuing enrollment of hospitalized patients requiring either no or low-flow oxygen as the risk/benefit remains acceptable in these cohorts. Finally, the IDMC recommended continuation of the outpatient trial (described further above) without modification.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we and the University of Oxford announced that the RECOVERY trial in the UK will evaluate REGN-COV2. The RECOVERY trial, which is a Phase 3 open-label trial in patients hospitalized with COVID-19, will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own. The trial is being coordinated by researchers at the University of Oxford. The RECOVERY IDMC is aware of the IDMC recommendations made in connection with the REGN-COV2 treatment trials (described above), and will be discussing the impact, if any, on the RECOVERY trial.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inmazeb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved Inmazeb for the treatment of infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in adult and pediatric patients, including newborns of mothers who have tested positive for the infection. In connection with this approval, we were also granted a material threat medical countermeasure priority review voucher by the FDA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fasinumab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we announced that two Phase 3 trials, FACT OA1 and FACT OA2, achieved the co-primary endpoints for fasinumab 1 mg monthly, demonstrating significant improvements in pain and physical function over placebo at week 16 and week 24, respectively. Fasinumab 1 mg monthly also showed nominally significant benefits in physical function in both trials and pain in one trial, when compared to the maximum FDA-approved prescription doses of non-steroidal anti-inflammatory drugs for osteoarthritis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FACT OA1 trial included an additional treatment arm, fasinumab 1 mg every two months, which showed numerical benefit over placebo, but did not reach statistical significance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In initial safety analyses from the Phase 3 trials, there was an increase in arthropathies reported with fasinumab. In a sub-group of patients from one Phase 3 long-term safety trial, there was an increase in joint replacement with fasinumab 1 mg monthly treatment during the off-drug follow-up period, although this increase was not seen in the other trials to date. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also announced that we discontinued actively treating patients with fasinumab, which at such time only involved dosing in an optional second-year extension phase of one trial. This followed a recommendation from the fasinumab program's IDMC that the program should be terminated, based on available evidence to date. We will continue to gather long-term safety data, which we expect to report in 2021, along with our decision on next steps for the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Garetosmab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we notified clinical investigators to pause dosing of garetosmab in the ongoing Phase 2 LUMINA-1 trial in patients with the ultra-rare genetic disorder FOP. The decision was based on reports of fatal serious adverse events in the trial during the open-label portion during which all patients received active treatment. These deaths are being further investigated to understand if they are related to garetosmab treatment. During the 28-week double-blind treatment period, there were no deaths in the trial.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also shared this update with the trial's IDMC and relevant regulatory authorities, and will conduct a review of the trial data to date to better understand the benefit/risk profile of garetosmab in people with FOP. The Company announced top-line 28-week results from the LUMINA-1 trial earlier this year; this is the only active trial evaluating garetosmab.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreements Related to COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2020, the Company announced an expansion of its Other Transaction Agreement ("OTA") with BARDA, pursuant to which HHS is obligated to fund 80% of certain of our costs incurred for certain research and development activities related to COVID-19 treatments. In July 2020, the Company also announced an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished REGN-COV2 to the U.S. government. This agreement could result in payments to the Company of up to $450.2 million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish and storage activities. See "Results of Operations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">" below for REGN-COV2 net product sales recognized in connection with this agreement during the three months ended September 30, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Roche</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a collaboration agreement with Roche to develop, manufacture, and distribute REGN-COV2. We will continue to lead global development activities for REGN-COV2, and the parties will jointly fund the ongoing Phase 3 prevention and Phase 1 healthy volunteer safety studies, as well as any mutually agreed additional new global studies to evaluate further the potential of REGN-COV2 in treating or preventing COVID-19. Roche will be responsible for securing regulatory approvals outside the United States, following the initial EMA approval (if any), and conducting any additional studies specifically required for approval by regulators outside the United States.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, each party is obligated to dedicate a certain amount of manufacturing capacity to REGN-COV2 each year. We will distribute the product in the United States and Roche will distribute the product outside of the United States. The parties will share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product delivered by each party. Any profit sharing will commence after product manufactured by Roche receives regulatory approval and is supplied to the market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration, License, and Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of 13,014,646 shares of our Common Stock held by Sanofi was completed. We also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5 billion. Pursuant to the offering and purchase, Sanofi disposed of all of its shares of common stock in Regeneron, other than 400,000 shares that it retained as of the closing of these transactions (see further details below regarding Sanofi's use of these shares for the funding of certain development costs).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we were collaborating with Sanofi on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). See discussion below for updates related to the development and commercialization of Praluent effective April 1, 2020. Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), following receipt of the first positive Phase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate are generally shared 80% by Sanofi and 20% by us. All other agreed-upon development costs incurred by both companies are funded 100% by Sanofi. We are obligated to reimburse Sanofi for 50% of worldwide development expenses that were fully funded by Sanofi and 30% of shared Phase 3 trial-related costs based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Sanofi entered into a letter agreement (the "Letter Agreement") amending the LCA in connection with, among other matters, the allocation of additional funds to certain proposed activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Pursuant to the Letter Agreement, we have agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to the Dupilumab/Itepekimab Eligible Investments for the quarterly periods commencing on January 1, 2018 and ending on September 30, 2020 by selling certain shares of our Common Stock directly or indirectly owned by Sanofi. Refer to the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below for further details regarding the Letter Agreement and this funding arrangement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement, Sanofi records product sales for commercialized products, and Regeneron has the right to co-commercialize such products on a country-by-country basis. We have exercised our option to co-commercialize Dupixent in the United States and in certain countries outside the United States. We currently anticipate commencing co-commercialization of Dupixent in such countries outside the United States in 2021. We supply certain commercial bulk product to Sanofi. We and Sanofi equally share profits and losses from sales within the United States. We and Sanofi share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us), and share losses outside the United States at 55% (Sanofi)/45% (us). In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0 million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0 billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $200.0 million in additional milestone payments from Sanofi, including the second sales milestone in the amount of $50.0 million, when such sales outside the United States exceed $1.5 billion on a rolling twelve-month basis. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company will share profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Sanofi on the development and commercialization of antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration is governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement (the "Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement (the "IO License and Collaboration Agreement"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company ("IO Development Activities") under the original 2015 Immuno-oncology Discovery and Development Agreement (the "2015 IO Discovery Agreement") to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. The Amended IO Discovery Agreement provided for Sanofi's payment of $461.9 million to the Company as consideration for (x) the termination of the 2015 IO Discovery Agreement, (y) the prepayment for certain IO Development Activities regarding the BCMAxCD3 Program and the MUC16xCD3 Program, and (z) the reimbursement of costs incurred by the Company under the 2015 IO Discovery Agreement during the fourth quarter of 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended IO Discovery Agreement, the Company is required to conduct development activities with respect to (i) the BCMAxCD3 Program through the earlier of clinical proof-of-concept or the expenditure of $70.0 million (the "BCMAxCD3 Program Costs Cap") and (ii) the MUC16xCD3 Program through the earlier of clinical proof-of-concept or the expenditure of $50.0 million (the "MUC16xCD3 Program Costs Cap"); provided that under certain circumstances, Sanofi will have the option to increase the MUC16xCD3 Program Costs Cap to $70.0 million by making a payment to the Company in the amount of $20.0 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Amended IO Discovery Agreement, we are primarily responsible for conducting the IO Development Activities (other than certain clinical trials that may be funded separately by Sanofi), including antibody development, preclinical activities, toxicology studies, manufacture of clinical supplies, filing of Investigational New Drug Applications ("INDs"), and clinical development through proof-of-concept. We are obligated to reimburse Sanofi for half of the development costs they funded that are attributable to clinical development of antibody product candidates under the Amended IO Discovery Agreement from our share of profits from commercialized IO Collaboration products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the BCMAxCD3 Program and the MUC16xCD3 Program, when (i) clinical proof-of-concept is established, (ii) the applicable Program Costs Cap is reached, or (iii) in certain other limited circumstances, Sanofi will have the option to license rights to the product candidate and other antibodies targeting the same targets for, with regard to BCMAxCD3, immuno-oncology indications, and with regard to MUC16xCD3, all indications, pursuant to the IO License and Collaboration Agreement, as amended. If Sanofi does not exercise its option to license rights to a product candidate, we will retain the exclusive right to develop and commercialize such product candidate and Sanofi will receive a royalty on sales. Pursuant to the Amended IO Discovery Agreement, the parties agreed that (i) if Sanofi exercises its option with respect to a BCMAxCD3 Program antibody, Sanofi will lead the development and global commercialization of such BCMAxCD3 Program antibody; and (ii) if Sanofi exercises its option with respect to a MUC16xCD3 Program antibody, (x) we will lead the development of such MUC16xCD3 Program antibody and commercialization of such MUC16xCD3 Program antibody within the United States and (y) Sanofi will lead the commercialization of such MUC16xCD3 Program antibody outside of the United States. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi exercises its option to license rights to a BCMAxCD3 Program antibody or MUC16xCD3 Program antibody thereunder, it will co-develop these drug candidates with us through product approval under the terms of the IO License and Collaboration Agreement. Sanofi will fund development costs up front for a BCMAxCD3 Program antibody and we will reimburse half of the total development costs for such antibody from our share of future IO Collaboration profits to the extent they are sufficient for this purpose. In addition, we and Sanofi will share equally, on an ongoing basis, the development costs for a MUC16xCD3 Program antibody. Each party will have the right to co-commercialize licensed products in countries where it is not the lead commercialization party. The parties will share equally in profits and losses in connection with the commercialization of collaboration products. We are obligated to use commercially reasonable efforts to supply clinical requirements of each drug candidate under the IO License and Collaboration Agreement until commercial supplies of that IO drug candidate are being manufactured.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the IO License and Collaboration Agreement, the parties are also co-developing and co-commercializing Libtayo, an antibody targeting PD-1. We have principal control over the development of Libtayo, and the parties share equally, on an ongoing basis, development and commercialization expenses for Libtayo. Under the Letter Agreement, we have agreed to allow Sanofi to satisfy in whole or in part its funding obligation with respect to Libtayo development costs for the quarterly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods commencing on October 1, 2017 and ending on September 30, 2020 by selling certain shares of our Common Stock directly or indirectly owned by Sanofi. As of September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="ie52e1228322949d0906b14737878fbb8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="regn:Maximumsharesthecollaboratorcouldsell" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF83OS9mcmFnOjM1Mjg5ODIzOTczNzRmMTI4MDg3MDAwNzcxODgzNTNhL3RleHRyZWdpb246MzUyODk4MjM5NzM3NGYxMjgwODcwMDA3NzE4ODM1M2FfMTIwOTQ2Mjc5NDMzOTQ_5d9776b6-9eed-465e-9094-a2c39dbdeda9">279,766</ix:nonFraction> shares of our Common Stock remained eligible for sale by Sanofi in order to satisfy its funding obligations with respect to Libtayo development costs and/or, as noted above, Dupilumab/Itepekimab Eligible Investments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi desires to sell shares of our Common Stock during the term of the Letter Agreement to satisfy a portion or all of its funding obligations for the Libtayo development and/or, as noted above, Dupilumab/Itepekimab Eligible Investments, we may elect to purchase, in whole or in part, such shares from Sanofi. If we do not elect to purchase such shares, Sanofi may sell the applicable number of shares (subject to certain daily and quarterly limits) in one or more open-market transactions. Refer to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Antibody"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section above for a description of share transactions related to Dupilumab/Itepekimab Eligible Investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Libtayo, we lead commercialization activities in the United States, while Sanofi leads commercialization activities outside of the United States and the parties equally share profits from worldwide sales. Sanofi has exercised its option to co-commercialize Libtayo in the United States. We will be entitled to a milestone payment of $375.0 million in the event that global sales of certain licensed products targeting PD-1 (including Libtayo), together with sales of any other products licensed under the IO License and Collaboration Agreement and sold for use in combination with any of such licensed products targeting PD-1, equal or exceed $2.0 billion in any consecutive twelve-month period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EYLEA outside the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2006, we and Bayer have been parties to a license and collaboration agreement for the global development and commercialization outside the United States of EYLEA. Under the agreement, we and Bayer collaborate on, and share the costs of, the development of EYLEA. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, we are entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net sales through 2021, and thereafter, the companies will share equally in profits and losses from the sales of EYLEA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to reimburse Bayer for 50% of the development costs that it has incurred under the agreement from our share of the collaboration profits (including payments to us based on sales in Japan). The reimbursement payment in any quarter will equal 5% of the then outstanding repayment obligation, but never more than our share of the collaboration profits in the quarter unless we elect to reimburse Bayer at a faster rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we retain exclusive commercialization rights to EYLEA and are entitled to all profits from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fasinumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a collaboration agreement with Teva to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation ("MTPC"). In connection with the agreement, Teva made a $250.0 million non-refundable up-front payment. We lead global development activities, and the parties share equally, on an ongoing basis, development costs under a global development plan. As of September&#160;30, 2020, we had earned an aggregate of $120.0 million of development milestones from Teva and we are entitled to receive up to an aggregate of $340.0 million in additional development milestones and up to an aggregate of $1.890 billion in contingent payments upon achievement of specified annual net sales amounts. We are responsible for the manufacture and supply of fasinumab globally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we will lead commercialization activities, and the parties will share equally in any profits or losses in connection with commercialization of fasinumab. In the territory outside of the United States, Teva will lead commercialization activities and we will supply product to Teva at a tiered purchase price, which is calculated as a percentage of net sales of the product (subject to adjustment in certain circumstances).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Odronextamab (REGN1979)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with Zai Lab Limited to develop and commercialize odronextamab in mainland China, Hong Kong, Taiwan, and Macau (the "Zai Territories"). In connection with the agreement, Zai made a $30.0 million non-refundable up-front payment to the Company. We will continue to lead global development activities for odronextamab, and Zai will be responsible for funding a portion of the global development costs for certain clinical trials. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the manufacture and supply of clinical and commercial product of odronextamab to Zai. If odronextamab is commercialized in the Zai Territories, we will supply the product to Zai at a tiered purchase price, which is calculated as a percentage of net sales of the product (subject to adjustment in certain circumstances), and are eligible to receive up to $160.0 million in additional regulatory and sales milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. In May 2020, we expanded our existing collaboration with Intellia Therapeutics, Inc. to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene edited products. In connection with the agreement, we made a $70.0 million up-front payment and purchased 925,218 shares of Intellia common stock for an aggregate purchase price of $30.0 million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $15.0 million, were recorded to Research and development expense in the second quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2015, we and BARDA entered into an agreement pursuant to which HHS provides certain funding to develop, test, and manufacture a treatment for Ebola virus infection. In July 2020, HHS exercised its option under the existing agreement to provide up to $344.6 million of additional funding for the manufacture and supply of Inmazeb. We expect to deliver a pre-specified number of Inmazeb treatment doses over the course of approximately six years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See "Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BARDA" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">section above for information related to our COVID-19 agreement.</span></div><div id="ibab647050bc248e3930163531a1d57d8_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of New York in 1988 and publicly listed in 1991. Our principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and our telephone number at that address is (914) 847-7000. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our Internet website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission ("SEC"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and other interested parties should note that we use our media and investor relations website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://newsroom.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our social media channels to publish important information about Regeneron, including information that may be deemed material to investors. We encourage investors and other interested parties to review the information we may publish through our media and investor relations website and the social media channels listed on our media and investor relations website, in addition to our SEC filings, press releases, conference calls, and webcasts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our websites and social media channels is not included as a part of, or incorporated by reference into, this report.</span></div><div id="ibab647050bc248e3930163531a1d57d8_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Three and Nine Months Ended September&#160;30, 2020 and 2019 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain revisions have been made to the previously reported September 30, 2019 amounts below in connection with changing the presentation of certain amounts earned from collaborators; see Note 1 to our Condensed Consolidated Financial Statements for further details.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:43.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales in the United States:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,422.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi and Bayer collaboration revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of Praluent in the United States were recorded by Sanofi prior to April 1, 2020 </span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of EYLEA in the United States increased for the three and nine months ended September&#160;30, 2020, compared to the same periods in 2019, due to higher sales volume partly offset by an increase in sales-related deductions primarily due to higher rebates and discounts. Overall U.S. EYLEA demand was lower in April 2020 due to the impact of the COVID-19 pandemic compared to the same period of 2019. While we observed an increase in U.S. EYLEA demand during the subsequent months of the second and third quarters of 2020 relative to April 2020, we are unable to predict whether there will be additional adverse impact on net product sales if shelter-in-place, social distancing, and other similar measures are reintroduced or imposed in additional geographies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Refer to "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section above for further details. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September&#160;30, 2020, net product sales of REGN-COV2 were recorded in connection with our agreement with the U.S. government. Refer to "Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BARDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">" section above for further details.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi Collaboration Revenue</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:47.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Antibody</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immuno-oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by us in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi provides us with an estimate of our share of the profits or losses from commercialization of antibodies for the most recent fiscal quarter; these estimates are reconciled to actual results in the subsequent fiscal quarter, and our portion of the profits or losses is adjusted accordingly, as necessary. During the three and nine months ended September&#160;30, 2020, the change in our share of profits in connection with commercialization of antibodies, compared to the same periods of 2019, was driven by higher Dupixent profits and, to a lesser extent, our new agreement with Sanofi under which, effective April 1, 2020, we are no longer sharing in losses with Sanofi in connection with the commercialization of Praluent (see further information below). The increase in reimbursements for manufacturing of commercial supplies is primarily driven by higher Dupixent sales, as revenue recognition for such cost reimbursements is deferred until the product is sold by Sanofi to third-party customers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's share of profits in connection with the commercialization of Dupixent, Praluent (through March 31, 2020), and Kevzara is summarized below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.380%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent, Praluent, and Kevzara net product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits  </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits as a percentage of Dupixent, Praluent, and Kevzara net product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Global net product sales of Dupixent and Kevzara are recorded by Sanofi. The quarter ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses in connection with Sanofi's global net sales and the related commercialization of Praluent (see further details below); therefore, the quarter ended March 31, 2020 was the last quarter for which net product sales of Praluent were included in the table above. </span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States. Under the new agreement, Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States, and will pay the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0 billion on a rolling twelve-month basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Collaboration Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:52.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by us in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States is summarized below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:52.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA net product sales outside the United States </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profit from sales outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.3</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit as a percentage of EYLEA net product sales outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bayer records net product sales of EYLEA outside the United States. Bayer provides us with an estimate of our share of the profit, including the percentage of sales in Japan that we earned, from commercialization of EYLEA outside the United States for the most recent fiscal quarter; these estimates are reconciled to actual results in the subsequent fiscal quarter, and our portion of the profit or loss is adjusted accordingly, as necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue increased during the three and nine months ended September 30, 2020, compared to the same periods of 2019, primarily due to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of revenue in connection with our agreements with BARDA related to funding of certain development activities for antibodies for the treatment of COVID-19 and Inmazeb for the treatment of Ebola; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effective April 1, 2020, Sanofi's reimbursement for manufacturing commercial supplies of Praluent and royalties of 5% on Sanofi&#8217;s net product sales of Praluent outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except headcount data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average headcount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Includes costs incurred as well as cost reimbursements from collaborators who are not deemed to be our customers</span></div></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of goods sold includes costs in connection with producing commercial supplies for products that are sold by Regeneron in the United States (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">i.e.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> for which we record net product sales) and any royalties we are obligated to pay on such sales, period costs for our Limerick manufacturing facility, and amounts we are obligated to pay to Sanofi for its share of Libtayo U.S. gross profits</span></div></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of collaboration and contract manufacturing includes costs we incur in connection with producing commercial drug supplies for collaborators and others</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses included a total of $101.2 million and $117.1 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $310.5 million and $330.8 million for the nine months ended September&#160;30, 2020 and 2019, respectively, of non-cash compensation expense related to equity awards granted under our long-term incentive plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our estimates of direct research and development expenses by clinical development program and other significant categories of research and development expenses. Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, including costs related to preclinical research activities, clinical trials, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse. Indirect research and development expenses have not been allocated directly to each program, and primarily consist of costs to compensate personnel, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects. Clinical manufacturing costs primarily consist of costs to manufacture bulk drug product for clinical development purposes as well as related external drug filling, packaging, and labeling costs. Clinical manufacturing costs also includes pre-launch commercial supplies which did not meet the criteria to be capitalized as inventory.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fasinumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evinacumab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara (sarilumab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front payments related to license and collaboration agreements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product candidates in clinical development and other research programs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab supplies and other research and development costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and other operating costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manufacturing costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses by collaborators</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain prior year amounts have been reclassified to conform to the current year's presentation</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the nine months ended September&#160;30, 2020 included $85.0 million in aggregate up-front payments made in connection with our collaboration agreement with Intellia (see "Collaboration, License, and Other Agreements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intellia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Research and development expenses for the nine months ended September&#160;30, 2019 included a $400.0 million up-front payment to Alnylam.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses included non-cash compensation expense of $55.9 million and $60.0 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $169.5 million and $178.0 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development, uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes in the competitive landscape affecting a product candidate, and other risks and uncertainties described in Part II, Item 1A. "Risk Factors" (including those relating to the disruptions caused by the COVID-19 pandemic). There is also variability in the duration and costs necessary to develop a pharmaceutical product, potential opportunities and/or uncertainties related to future indications to be studied, and the estimated cost and scope of the projects. The lengthy process of seeking FDA and other applicable approvals, and subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources. Any failure by us to obtain, or delay in obtaining, regulatory approvals could materially adversely affect our business. We are unable to reasonably estimate if our product candidates in clinical development will generate material product revenues and net cash inflows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased for the nine months ended September&#160;30, 2020, compared to the same period in 2019, primarily due to higher headcount-related costs, an increase in commercialization-related expenses for EYLEA and Libtayo, higher contributions to independent not-for-profit patient assistance organizations, additional accruals for loss contingencies associated with ongoing litigation, and, effective April 1, 2020, no longer receiving Praluent-related cost reimbursements from Sanofi for Regeneron-incurred expenses. Selling, general, and administrative expenses also included non-cash compensation expense of $35.9 million and $40.8 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $114.4 million and $122.3 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold increased for the nine months ended September 30, 2020, compared to the same period in 2019, primarily in connection with higher product sales including (i) our obligation to pay Sanofi its share of Libtayo U.S. gross profits and (ii) third-party royalties. These increases were partly offset by lower period costs for our Limerick commercial manufacturing facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Collaboration and Contract Manufacturing</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration and contract manufacturing increased for the three and nine months ended September&#160;30, 2020, compared to the same periods in 2019, primarily due to the recognition of manufacturing costs associated with higher sales of Dupixent and recognition of costs in connection with manufacturing ex-U.S. commercial supplies of Praluent for Sanofi under our new agreement (see "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above for further details). In addition, Cost of collaboration and contract manufacturing increased for the nine months ended September&#160;30, 2020, compared to the same period in 2019, due to process validation costs in connection with manufacturing Inmazeb under our BARDA agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating (Income) Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating (income) expense, net, includes recognition of a portion of amounts previously deferred in connection with up-front and development milestone payments, as applicable, received in connection with Sanofi IO, Teva, and MTPC collaborative arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, for the three months ended September&#160;30, 2020, compared to the same period in 2019, was negatively impacted by the recognition of unrealized losses on equity securities. In addition, interest expense for the three months ended September 30, 2020, compared to the same period in 2019, increased as a result of the 2020 bridge loan facility and issuance of senior notes (as described below). Other income (expense), net, for the nine months ended September&#160;30, 2020, compared to the same period in 2019, was primarily affected by the positive impact of the recognition of unrealized gains on equity securities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:46.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except effective tax rate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities. Our effective tax rate for the three and nine months ended&#160;September&#160;30, 2019&#160;was positively impacted, compared to the U.S. federal statutory rate, primarily by federal tax credits for research activities, the foreign-derived intangible income deduction, and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, partly offset by the taxation of certain global intangible low-taxed income and the non-deductible Branded Prescription Drug Fee.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:44.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,471.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,097.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,689.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,408.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,759.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,592.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we also had borrowing availability of $750.0&#160;million under a revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash for the Nine Months Ended September&#160;30, 2020 and 2019</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:48.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,665.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,758.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income for the nine months ended September&#160;30, 2020 included a $50.0&#160;million sales-based milestone related to Sanofi sales of antibodies outside the United States (see "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above for further details) and $85.0 million up-front payments made to Intellia pursuant to our collaboration agreements. Our net income for the nine months ended September&#160;30, 2020 also included $133.8 million related to unrealized gains (net) on equity securities (included in other non-cash items). As of September 30, 2020, Sanofi, trade, and other accounts receivables increased by $1.275 billion, compared to December 31, 2019, primarily as a result of extending payment terms to certain of our EYLEA customers due to the COVID-19 pandemic. Deferred taxes as of September 30, 2020 decreased by $117.9 million, compared to December 31, 2019, primarily due to non-cash compensation expense and unrealized gains (net) on equity securities as described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of marketable securities during the nine months ended September&#160;30, 2020 included proceeds in connection with funding our stock repurchase from Sanofi (as described below). Capital expenditures during the nine months ended September&#160;30, 2020 included costs associated with (i) the expansion of our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, including construction of a fill/finish facility and related equipment, and (ii) laboratory expansion and renovations at our Tarrytown, New York facilities. We expect to incur capital expenditures of $570 million to $600 million for the full year of 2020 primarily in connection with these projects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we paid an aggregate of $5.5 billion to purchase shares of our Common Stock, a portion of which was funded with the proceeds from a $1.5&#160;billion senior unsecured 364-day bridge loan facility. See additional information under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below. During the three months ended September 30, 2020, we issued and sold $2.0 billion aggregate principal amount of senior unsecured notes and used a portion of the net proceeds to repay in full the bridge loan facility. See additional information under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuance of Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of Common Stock, in connection with exercises of employee stock options, were&#160;$2.5 billion during the nine months ended September&#160;30, 2020, compared to&#160;$163.5 million&#160;during the nine months ended September&#160;30, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. The share repurchase program permits the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. We plan to finance the share repurchase program with available cash.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, we repurchased&#160;898,991 shares of our Common Stock under the program and recorded the cost of the shares received, or&#160;$373.3 million, as Treasury Stock. As of September&#160;30, 2020, the Company had $372.7 million which remained available for share repurchases under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," effective January 7, 2018, we agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to Libtayo development and/or Dupilumab/Itepekimab Eligible Investments incurred in periods through September 30, 2020 by selling shares (of which 279,766 shares remained available to be sold as of September&#160;30, 2020) of our Common Stock directly or indirectly owned by Sanofi. During the nine months ended September 30, 2020, Sanofi elected to sell, and we elected to purchase (by issuing a credit towards the amount owed by Sanofi), 77,677 shares of the Company's Common Stock to satisfy Sanofi's funding obligation related to Libtayo development costs. Consequently, we recorded $41.7 million related to the shares received as Treasury Stock during the nine months ended September 30, 2020. In addition, during the nine months ended September 30, 2020, Sanofi elected to sell, and we elected to purchase (in cash), 171,471 shares of the Company's Common Stock in connection with Sanofi's funding obligation for Dupilumab/Itepekimab Eligible Investments. Consequently, we recorded the cost of the shares received, or $93.3 million, as Treasury Stock during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," in May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares of our Common Stock directly from Sanofi for an aggregate purchase amount of $5 billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (which Sanofi has used, and may continue to use, for the funding of certain Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments as described above). </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the Stock Purchase with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $1.5&#160;billion senior unsecured 364-day bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. As described below, the Bridge Facility was repaid in August 2020 following the issuance and sale of the Company's senior unsecured notes.  </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $750&#160;million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above, including accrued interest and related fees and expenses in connection therewith. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes accrue interest at the rate of 1.750% per year and will mature on September 15, 2030. The 2050 Notes accrue interest at the rate of 2.800% per year and will mature on September 15, 2050. Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year, commencing on March 15, 2021, until their respective maturity dates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div><div id="ibab647050bc248e3930163531a1d57d8_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our critical accounting policies and use of estimates are presented in Part II, Item&#160;7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 (filed February 7, 2020).&#160;Except as described in Note 1 to our Condensed Consolidated Financial Statements included in this report, there were no material changes to our critical accounting policies and use of estimates during the nine months ended September&#160;30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Impact of Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the future adoption of recently issued accounting standards is not expected to have a material impact on the Company's financial position or results of operations.</span></div><div id="ibab647050bc248e3930163531a1d57d8_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 (filed February 7, 2020). There have been no material changes to our market risks or to our management of such risks as of September&#160;30, 2020. </span></div><div id="ibab647050bc248e3930163531a1d57d8_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  CONTROLS AND PROCEDURES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ibab647050bc248e3930163531a1d57d8_100"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ibab647050bc248e3930163531a1d57d8_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.  LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the information set forth in Note 12 to our Condensed Consolidated Financial Statements included in this report.</span></div><div id="ibab647050bc248e3930163531a1d57d8_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an environment that involves a number of significant risks and uncertainties. We caution you to read the following risk factors, which have affected, and/or in the future could affect, our business, prospects, operating results, and financial condition. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, prospects, operating results, and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this report and should also be considered by our investors. For purposes of this section, references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators under our collaboration agreements with them, unless otherwise stated or required by the context. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, we are subject to a number of risks that if realized could materially harm our business, prospects, operating results, and financial condition. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in this "Risk Factors" section. Please carefully consider all of the information in this Form 10-Q, including the full set of risks set forth in this "Risk Factors" section, and in our other filings with the U.S. Securities and Exchange Commission before making an investment decision regarding Regeneron.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be further adversely affected by the effects of the COVID-19 pandemic, including those impacting our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers, as well as the demand for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the development, manufacturing, and potential commercialization of REGN-COV2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of EYLEA and Dupixent. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of our products are dependent on the availability and extent of reimbursement from third-party payors, including private payors and government programs such as Medicare and Medicaid, which could change due to various factors such as the drug price control measures recently announced by the Trump administration.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our products is subject to significant competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                     </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Development Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious complications or side effects in connection with the use or development of our products or product candidates could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our products are intended to be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Market Exclusivity Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect the confidentiality of our trade secrets, and our patents or other means of defending our intellectual property may be insufficient to protect our proprietary rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents or proprietary rights of others may restrict our development, manufacturing, and/or commercialization efforts and subject us to patent litigation and other proceedings that could find us liable for damages.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products, including EYLEA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our products and to advance our clinical pipeline. As we increase our production in anticipation of potential regulatory approval for our product candidates (such as REGN-COV2), our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our products approved for marketing and could jeopardize our clinical development programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to manufacture products may be impaired if any of our or our collaborators&#8217; manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party service or supply failures, failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, or failures at the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our collaborators&#8217; failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks from the improper conduct of our employees, agents, contractors, or collaborators, including those relating to potential non-compliance with relevant laws and regulations such as the Foreign Corrupt Practices Act.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax liabilities and risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential liability related to the personal information we collect from individuals, data brokers, or research institutions or obtain from clinical trials sponsored by us or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our collaborations with Sanofi or Bayer are terminated or breached, our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Factors &#8211; Risks Related to Employees, Information Technology, Financial Results and Liquidity, and Our Common Stock</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on our key personnel and will be harmed if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness could adversely impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is extremely volatile.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing shareholders may be able to exert significant influence over matters requiring shareholder approval and over our management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*       *       *</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. It has since spread around the world, including the United States; and, in March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. This pandemic has adversely affected or has the potential to adversely affect, among other things, the economic and financial markets and labor resources of the countries in which we operate; our manufacturing and supply chain operations, research and development efforts, commercial operations </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and sales force, administrative personnel, third-party service providers, and business partners and customers; and the demand for our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has resulted in travel and other restrictions to reduce the spread of the disease, including governmental orders across the globe, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, maintain social distancing, and order cessation of non-essential travel. As a result of these developments, we have implemented work-from-home policies for a significant part of our employees (except those deemed critical, including those working in our laboratories and manufacturing facilities). The effects of shelter-in-place and social distancing orders, government-imposed quarantines, and work-from-home policies may further negatively impact productivity, disrupt our business, and delay our clinical programs and development timelines beyond the delays we have already experienced and disclosed, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Such restrictions and limitations may also further negatively impact our access to regulatory authorities (which are affected, among other things, by applicable travel restrictions and may be delayed in responding to inquiries, reviewing filings, and conducting inspections); our ability to perform regularly scheduled quality checks and maintenance; and our ability to obtain services from third-party specialty vendors and other providers or</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to access their expertise as fully and timely as needed.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic may also result in the loss of some of our key personnel, either temporarily or permanently. In addition, our sales and marketing efforts have been negatively impacted and may be further negatively impacted by postponement or cancellation of face-to-face meetings and restrictions on access by non-essential personnel to hospitals or clinics to the extent such measures slow down adoption or further commercialization of our marketed products. The demand for our marketed products may also be adversely impacted by the restrictions and limitations adopted in response to the COVID-19 pandemic, particularly to the extent they affect the patients' ability or willingness to start or continue treatment with our marketed products. Any of the foregoing factors may result in lower net product sales of our marketed products. For example, net product sales of EYLEA in the United States decreased for the three months ended June 30, 2020, compared to the same period in 2019, due in part to the impact of the COVID-19 pandemic. See Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations" for a discussion of our net product sales. Demand for some or all of our marketed products may continue to be reduced while the shelter-in-place or social distancing orders are in effect and, as a result, some of our inventory may become obsolete and may need to be written off, impacting our operating results. These and similar, and perhaps more severe, disruptions in our operations may materially adversely impact our business, operating results, and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarantines, shelter-in-place, social distancing, and similar government orders (or the perception that such orders, shutdowns, or other restrictions on the conduct of business operations could occur) related to COVID-19 or other infectious diseases are impacting personnel at our research and manufacturing facilities, our suppliers, and other third parties on which we rely, and are also impacting the availability or cost of materials produced by or purchased from such parties, resulting in supply chain strains or disruptions that may become material. While some materials may be obtained from more than one supplier, port closures and other restrictions resulting from the COVID-19 pandemic could materially disrupt our supply chain or limit our ability to obtain sufficient materials for the production, including fill/finish, of our products and development of our product candidates as well as our research efforts. If microbial, viral (including COVID-19), or other contaminations are discovered in our products, product candidates, the materials used for their production, or in our facilities, or in the facilities of our collaborators, third-party contract manufacturers, or other contractors or suppliers, the affected facilities may need to be closed or may otherwise be affected for an extended period of time, or the contamination may result in other delays or disruptions in our direct or indirect supply chain. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, infections and deaths related to COVID-19 have disrupted and may continue to disrupt the United States' healthcare and healthcare regulatory systems.  Such disruptions could divert healthcare resources away from, or materially delay, FDA review and potential approval of our product candidates and new indications for our marketed products.  It is unknown how long these disruptions could continue.  In addition, some of our clinical trials have been and may continue to be affected by the COVID-19 pandemic. This impact includes delays in site initiation and patient enrollment due to prioritization of hospital resources toward the COVID-19 pandemic and patients' inability to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, has been and may continue to be delayed or disrupted. For example, as noted above in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Overview - Programs in Clinical Development," the ongoing COVID-19 pandemic continues to impact clinical trial execution in many regions across the world for us and our collaborators. We will continue to evaluate the adverse impact of the COVID-19 pandemic on an individual trial basis. The disruptions caused by the COVID-19 pandemic may further negatively impact the progress of our clinical trials, including the readouts of trial results, the timing of regulatory review, and any anticipated program milestones. Further, while we continue to focus on developing a novel therapy to address the COVID-19 pandemic, our research programs and the development of our other product candidates may need to be further de-prioritized. Any elongation or de-prioritization of our research and development programs and clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates, which would increase our operating expenses and may have a material adverse effect on our operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it recently caused significant disruption of global financial markets and could cause more economic disruption in the future. This disruption, if sustained or recurrent, could make it more difficult for us to access capital if needed. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of this pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic adversely affects our business, prospects, operating results, or financial condition, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face risks related to the development, manufacturing, and potential commercialization of REGN-COV2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the recent global outbreak of COVID-19, we are pursuing the development and manufacturing of REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat infection from the SARS-CoV-2 virus. While we recently announced positive results from the ongoing Phase 2/3 seamless trial in non-hospitalized patients with COVID-19, there are multiple ongoing clinical trials to evaluate the and efficacy of REGN-COV2 and there is no assurance of favorable results from any ongoing or future clinical trials or the timing of their completion. For example, in October 2020, the IDMC for the REGN-COV2 treatment trials recommended that further enrollment of hospitalized patients requiring high-flow oxygen or mechanical ventilation be placed on hold. It is possible that the FDA and other regulatory authorities may not approve REGN-COV2 for the treatment of COVID-19, or that any marketing approvals, if granted, may have significant limitations on its use. Further, other parties may be successful in developing a more effective treatment for COVID-19. As a result, we may never successfully commercialize REGN-COV2. The intense public interest, including speculation by the media, in the development of REGN-COV2 has caused significant volatility in our stock price, which we expect to continue as data and other information from the ongoing and any future clinical trials evaluating REGN-COV2 and third-party product candidates for the treatment or prevention of COVID-19 as well as any regulatory actions become public.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also face risks related to our significant investment in the development, supply, allocation, distribution, pricing, and potential commercialization of REGN-COV2. Given the severity and urgency of the COVID-19 pandemic, we have committed significant capital and resources to fund and supply clinical trials and to accelerate and scale up the production of REGN-COV2, which involves a complex manufacturing process that is both resource- and time-sensitive. We expect our investment in the development and manufacture of REGN-COV2 to continue through 2021 and beyond, although the magnitude of our investment will be subject to clinical data results, the duration of the COVID-19 pandemic, and other factors, including regulatory outcomes. If we are unable to obtain regulatory approvals, or if we make a strategic decision to discontinue development of REGN-COV2 or are otherwise not successful in the commercialization of REGN-COV2, we will be unable to recoup our significant expenses incurred to date and in the future related to the development and production of REGN-COV2. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our internal manufacturing capacity will likely not be sufficient to cover the demand for REGN-COV2 if we receive regulatory approval or are otherwise authorized to market this therapy. While we have entered into a collaboration agreement with Roche to develop, manufacture, and distribute REGN-COV2, we cannot be certain that the technology transfer process required to allow Roche to manufacture REGN-COV2 will be completed in the expected time frame or at all nor can we be certain that this collaboration will result in the anticipated increase in the current manufacturing and distribution capacity for REGN-COV2 or that any increased manufacturing and distribution capacity will be sufficient. We and Roche also face challenges related to the allocation of existing and future supply of REGN-COV2, particularly with respect to geographic distribution. As supplies of REGN-COV2 are expected to remain constrained, it is possible that the U.S. government may limit or restrict our ability to distribute and commercialize REGN-COV2 outside of the United States. In addition, as a result of the emergency situations in many countries, there is a heightened risk that REGN-COV2 may be subject to adverse governmental actions in certain countries. The U.S. government may exercise or assert certain rights with respect to our inventions, products, or product candidates. For example, under the Defense Production Act, the U.S. government may, among other things, require domestic industries to provide essential goods and services needed for the national defense, such as drug material or other supplies needed to treat COVID-19 patients, which could require us to allocate manufacturing capacity in a way that impacts our regular operations. In addition, our agreements with the U.S. government contain provisions granting the U.S. government certain rights relating to products, product candidates, and related inventions (as applicable) covered by those agreements. For example, in July 2020, we entered into an agreement to manufacture and deliver REGN-COV2 to the U.S. government. Among other rights, this agreement gives the U.S. government the right to require us to grant a non-exclusive license to applicable inventions to a third party if such action is deemed necessary to alleviate certain health or safety needs. This right may be triggered if we, for example, do not manufacture or supply sufficient product to address such needs. If the U.S. government exercises or asserts any such rights or imposes these or similar measures with respect to our products, product candidates, or related inventions (including REGN-COV2), it may adversely impact our business and results of operations. Foreign governments (including the government of Ireland, where we have manufacturing facilities) may have similar rights or attempt </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to assert any such rights. Further, we have observed and are likely to continue to face significant public attention and scrutiny over the complex decisions made regarding the REGN-COV2 development program, including any allocation, distribution, or pricing decisions with respect to REGN-COV2. If we are unable to successfully manage these risks, we could face significant reputational harm, which could negatively affect our stock price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of EYLEA and Dupixent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA net sales represent a substantial portion of our revenues and this concentration of our net sales in a single product makes us substantially dependent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on that product. For the nine months ended September&#160;30, 2020 and 2019, EYLEA net sales in the United States represented 59% and 73% of our total revenues, respectively. If we were to experience difficulty with the commercialization of EYLEA in the United States or if Bayer were to experience any difficulty with the commercialization of EYLEA outside the United States (including as a result of the COVID-19 pandemic discussed above), or if we and Bayer are unable to maintain current marketing approvals of EYLEA, we may experience a reduction in revenue and may not be able to sustain profitability, and our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have been increasingly dependent on our share of profits from the commercialization of Dupixent under our Antibody Collaboration with Sanofi. If we or Sanofi were to experience any difficulty with the commercialization of Dupixent or if we or Sanofi are unable to maintain current marketing approvals of Dupixent, we may experience a reduction in revenue and our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the degree of commercial success of our marketed products will continue to depend on many factors, including the following (as applicable):</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on our business and the demand for our marketed products, as well as its continued impact on, among other things, our employees, collaborators, suppliers, and other third parties on which we rely, our ability to continue to manage our supply chain, and the global economy (as further discussed above under "Risks Related to the COVID-19 Pandemic - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of the commercial strategy in and outside the United States for the marketing of our products, including pricing strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient coverage of, and reimbursement for, our marketed products by third-party payors, including Medicare and Medicaid in the United States and other government and private payors in the United States and foreign jurisdictions, as well as U.S. and foreign payor restrictions on eligible patient populations and the reimbursement process (including drug price control measures that may be introduced in the United States by various federal and state authorities);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our collaborators' ability to maintain sales of our marketed products in the face of competitive products and to differentiate our marketed products from competitive products, including as applicable product candidates currently in clinical development; and, in the case of EYLEA, the existing and potential new competition for EYLEA (discussed further under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" below) and the willingness of retinal specialists and patients to start or continue treatment with EYLEA or to switch from another product to EYLEA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious complications or side effects in connection with the use of our marketed products, as discussed under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and successfully monitoring commercial manufacturing arrangements for our marketed products with third parties who perform fill/finish or other steps in the manufacture of such products to ensure that they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending proceedings relating to EYLEA, Dupixent, and Praluent (described further in Note 12 to our Condensed Consolidated Financial Statements included in this report), as well as other risks relating to our marketed products associated with intellectual property of other parties and pending or future litigation relating thereto (as discussed under "Risks Related to Intellectual Property and Market Exclusivity" below);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of the pending government proceedings and investigations and other matters described in Note 12 to our Condensed Consolidated Financial Statements included in this report (including the civil complaint filed against us on June 24, 2020 in the U.S. District Court for the District of Massachusetts by the U.S. Attorney's Office for the District of Massachusetts); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and studies of other products that could implicate an entire class of products or are perceived to do so; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of existing and new health care laws and regulations currently being considered or implemented in the United States, including price reporting and other disclosure requirements of such laws and regulations and the potential impact of such requirements on physician prescribing practices and payor coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More detailed information about the risks related to the commercialization of our marketed products is provided in the risk factors below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or they commercialize for the products' currently approved indications in the United States, EU, and other countries where such products are approved. If we or our collaborators fail to maintain regulatory compliance for such products' currently approved indications (including because the product does not meet the relevant endpoints of any required post-approval studies, or for any of the reasons discussed below under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition. Failure to comply may also subject us to sanctions, product recalls, or withdrawals of previously approved marketing applications. See also "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our marketed products in the United States are dependent, in large part, on the availability and extent of reimbursement from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid. Sales of our marketed products in other countries are dependent, in large part, on similar reimbursement mechanisms and programs in those countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenues and profitability will be adversely affected in a material manner if such third-party payors do not adequately defray or reimburse the cost of our marketed products to patients. If these entities do not provide coverage and reimbursement with respect to our marketed products or provide an insufficient level of coverage and reimbursement, such products may be too costly for many patients to afford them, and physicians may not prescribe them. Many third-party payors cover only selected drugs, or may prefer selected drugs, making drugs that are not covered or preferred by such payors more expensive for patients. Third-party payors may also require prior authorization for reimbursement, or require failure on another type of treatment before covering a particular drug, particularly with respect to higher-priced drugs. As our currently marketed products and product candidates are biologics, bringing them to market may cost more than bringing traditional, small-molecule drugs to market due to the complexity associated with the research, development, production, supply, and regulatory review of such products. Given cost sensitivities in many health care systems (which will likely be exacerbated as a result of the COVID-19 pandemic), our currently marketed products and product candidates are likely to be subject to continued pricing pressures, which may have an adverse impact on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order for private insurance and governmental payors (such as Medicare and Medicaid in the United States) to reimburse the cost of our marketed products, we must maintain, among other things, our FDA registration and our National </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug Code, formulary approval by pharmacy benefits managers, and recognition by insurance companies and the Centers for Medicare &amp; Medicaid Services (the "CMS"). There is no certainty that we will be able to obtain or maintain the applicable requirements for reimbursement (including relevant formulary coverage, as discussed further below) of our current and future marketed products, which may have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other third-party payors (including pharmacy benefit management companies) are challenging the prices charged for healthcare products and increasingly limiting, and attempting to limit, both coverage and level of reimbursement for prescription drugs, such as by requiring outcomes-based or other pay-for-performance pricing arrangements. They are also imposing restrictions on eligible patient populations and the reimbursement process, including by means of required prior authorizations and utilization management criteria, such as step therapy (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requiring the use of less costly medications before more costly medications are approved for coverage). Some states are also considering legislation that would control the prices and reimbursement of prescription drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any prescription drug for which supplemental rebates are not being paid. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform measures in the future that will impose additional constraints on prices and reimbursements for our marketed products; this trend may be further accelerated as a result of the COVID-19 pandemic.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation and policies designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. At the federal level, some of the Trump administration's prior budget proposals contained drug price control measures that may be included in future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B (such as EYLEA); to allow some states to negotiate drug prices under Medicaid; and to eliminate cost sharing for generic drugs for low-income patients. Additionally, on May 11, 2018, President Trump laid out his administration's "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs" to reduce the cost of prescription drugs while preserving innovation and cures. The HHS has been soliciting feedback on some of these measures and may implement others impacting our business under its existing authority. CMS has also recently sought public comment on how best to leverage its authority provided under the Competitive Acquisition Program and introduce competition into Medicare Part B by allowing CMS to bring on vendors to negotiate payment amounts for Medicare Part B drugs. In addition, since January 1, 2019, CMS has allowed Medicare Advantage ("MA") plans to use step therapy for Part B drugs (such as EYLEA).&#160; On October 25, 2018, President Trump announced that CMS was evaluating a program that proposes to set the Medicare payment amount for Part B single-source drugs and biologics to more closely align with international drug prices (also referred to as reference or international price index ("IPI") drug pricing) and pay physicians and hospitals participating in such program a set drug add-on payment for administered drugs. CMS also issued an advance notice of proposed rulemaking that requested public comment on the proposed program, which is contemplated to initially cover fifty percent of Medicare Part B spending on separately payable Part B drugs (such as EYLEA), with the IPI-based price for each such drug to be phased in over a period of five years; notice of proposed rulemaking on this program is pending review by the Office of Management and Budget. In addition, in September 2020, President Trump signed an executive order entitled "Lowering Drug Prices by Putting America First" (the "MFN Executive Order"). The MFN Executive Order provides that it is "the policy of the United States that the Medicare program should not pay more for costly Part B or Part D prescription drugs or biological products than the most-favored-nation price" within the member countries of the Organization for Economic Co-operation and Development (the "MFN Price"); and directs the Secretary of the HHS to implement rulemaking to test a payment model pursuant to which Medicare would pay no more than the MFN Price for certain drugs covered by Medicare Parts B and D. While the scope, details, and implementation of these contemplated executive actions (including whether and how their mechanism may differ from that of the proposed IPI drug pricing program discussed above) are not clear, this continues to signal that the U.S. administration intends to pursue new measures to constrain drug costs and Medicare payments for drugs. Similarly, various members of the current U.S. Congress and 2020 presidential candidates have indicated that lowering drug prices continues to be a legislative and political priority, and some have introduced proposals aimed at drug pricing. At the state level, legislatures are becoming increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and price and marketing cost disclosure and transparency measures. In some cases, these measures are designed to encourage importation from other countries and bulk purchasing. A reduction in the availability or extent of reimbursement from U.S. government programs (including as a result of the proposals, initiatives, and developments described above) could have a material adverse effect on the sales of EYLEA or our other marketed products. Economic pressure on state budgets may also have a similar impact. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pharmacy benefit management companies often develop formularies to reduce their cost for medications. The breadth of the products covered by formularies varies considerably from one pharmacy benefit management company to another. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our marketed products. If our marketed products are not included within an adequate number of formularies, adequate reimbursement levels are not provided, the eligible insured patient population for our products is limited, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a key payor refuses to provide reimbursement for our products in a particular jurisdiction altogether, this could have a material adverse effect on our and our collaborators' ability to commercialize the applicable product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain foreign countries, pricing, coverage, and level of reimbursement of prescription drugs are subject to governmental control, and we and our collaborators may be unable to obtain coverage, pricing, and/or reimbursement on terms that are favorable to us or necessary for us or our collaborators to successfully commercialize our marketed products in those countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country, and may take into account the clinical effectiveness, cost, and service impact of existing, new, and emerging drugs and treatments. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Our results of operations may suffer if we or our collaborators are unable to market our products in foreign countries or if coverage and reimbursement for our marketed products in foreign countries is limited or delayed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our products and product candidates is subject to significant competition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial competition in the biotechnology and pharmaceutical industries from biotechnology, pharmaceutical, and chemical companies. Many of our competitors have substantially greater research, preclinical and clinical product development and manufacturing capabilities, as well as financial, marketing, and human resources, than we do. Our smaller competitors may also enhance their competitive position if they acquire or discover patentable inventions, form collaborative arrangements, or merge with larger pharmaceutical or biotechnology companies. There is significant actual and potential future competition for each of our marketed products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA faces significant competition in the marketplace. For example, EYLEA competes in one or more of its approved indications with other VEGF inhibitors, including Novartis and Genentech/Roche's Lucentis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ranibizumab) and Novartis' Beovu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brolucizumab). Ophthalmologists are also using off-label, third-party repackaged versions of Genentech/Roche's approved VEGF antagonist, bevacizumab, for the treatment of certain of EYLEA's indications, and we are aware of another company developing an ophthalmic formulation of such product. In DME and RVO, EYLEA also competes with intravitreal implants of corticosteroids. We are also aware of a number of companies working on the development of product candidates and extended delivery devices for the potential treatment of one or more of EYLEA's indications, including those that act by blocking VEGF and VEGF receptors (including therapies designed to extend the treatment interval) and/or other targets (such as Ang2). In addition, we are aware of several companies developing biosimilar versions of EYLEA and other approved anti-VEGF treatments. Other potentially competitive products in development include products for use in combination with EYLEA and/or other anti-VEGF treatments, small-molecule tyrosine kinase inhibitors, gene therapies, and other eye-drop formulations, devices, and oral therapies. There also is a risk that third parties repackage ZALTRAP for off-label use and sale for the treatment of diseases of the eye, even though ZALTRAP has not been manufactured and formulated for use in intravitreal injections. We are aware of claims by third parties, including those based on published clinical data, alleging that ZALTRAP may be safely administered to the eye.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for Dupixent's current and potential future indications is also competitive. In atopic dermatitis, there are several topical ointments or agents either approved or in development. In addition, a number of companies are developing antibodies against IL-13, IL-13Ra1, OX40, IL-31R, and/or IL-1alpha. Several companies are also studying JAK inhibitors for atopic dermatitis. In asthma, competitors to Dupixent include antibodies against the IL-5 ligand or the IL-5 receptor or immunoglobulin E; and some of these antibodies, if approved in this indication, may also compete with Dupixent in CRSwNP. There are several other potentially competitive products in development that may compete with Dupixent in asthma, as well as potential future indications, including antibodies against thymic stromal lymphopoietin ("TSLP"), the IL-33 ligand, or the IL-33 receptor (ST2). Dupixent also faces competition from orally administered small molecule agents and inhaled products in asthma and potential future indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Libtayo also faces significant competition. There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1, including Merck's Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Bristol-Myers Squibb's Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), Roche's Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab), and AstraZeneca's Imfinzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(durvalumab).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is also significant actual and potential future competition for other products marketed or otherwise commercialized by us and/or our collaborators under our collaboration agreements with them. For example, there are several companies that are marketing and/or developing antibodies or other molecules (such as small interfering RNA molecules, or siRNAs) against </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PCSK9 and IL-6 and/or IL-6R, which currently (or, for product candidates in development, may in the future if approved) compete with Praluent and Kevzara, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our other late-stage and earlier-stage clinical candidates in development are all fully human antibodies. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> technology, other antibody generation technologies, and other late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies using various technologies, including antibody generation technologies and other approaches such as RNA interference (RNAi) and chimeric antigen receptor T cell (CAR-T cell) technologies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of antibody-based products against targets that are also the targets of our early- and late-stage product candidates. We are also aware of other companies developing or marketing small molecules that may compete with our antibody-based product candidates in various indications, if such product candidates obtain regulatory approval in those indications. If any of these or other competitors announces a successful clinical study involving a product that may be competitive with one of our product candidates or the grant of marketing approval by a regulatory agency for a competitive product, such developments may have an adverse effect on our business or future prospects. In addition, the first product to reach the market in a therapeutic area is often at a significant competitive advantage relative to later entrants to the market. Accordingly, the relative speed with which we, or our collaborators, can develop our product candidates, complete the clinical trials and approval processes, and, if such product candidates are approved for marketing and sale, supply commercial quantities to the market is expected to continue to be an important competitive factor. Due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for a product against any particular target, which may have a material adverse effect on our business or future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have established our own sales and marketing organization for EYLEA in the United States for its currently approved indications, we have no sales, marketing, commercial, or distribution capabilities for EYLEA outside the United States. Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate, as in effect from time to time) for sales, marketing, and distribution of EYLEA in countries outside the United States.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of our Antibody Collaboration and our IO Collaboration, we and Sanofi co-commercialize Dupixent and Libtayo in the United States. As a result, we rely in part on Sanofi's sales and marketing organization in the United States for these products. If we and Sanofi fail to coordinate our United States sales and marketing efforts effectively, sales of any of such products may be materially affected. Sanofi also maintains other important responsibilities relating to Dupixent in the United States. For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product. We also rely on Sanofi for sales, marketing, and distribution of Dupixent and Libtayo in countries outside the United States. Effective April 1, 2020, we and Sanofi amended the Antibody Collaboration to remove Praluent from the LCA such that, among other things, the LCA no longer governs the development, manufacture, or commercialization of Praluent. Effective as of the same date, we and Sanofi entered into the Praluent Cross License &amp; Commercialization Agreement whereby we, at our sole cost, are solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States; and Sanofi pays us a 5% royalty on Sanofi's net product sales of Praluent outside the United States until March 31, 2032. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are unsuccessful in continuing to commercialize the marketed products subject to such collaborations, or if Bayer or Sanofi terminate their respective collaborations with us, our business, prospects, operating results, and financial condition would be materially impaired. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities. Therefore, termination of the Bayer collaboration agreement, our Antibody Collaboration, or our IO Collaboration would create substantial new and additional risks to the successful commercialization of the applicable products, particularly outside the United States. For additional information regarding our collaborations with Bayer and Sanofi, see "Risks Related to Our Reliance on Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to develop EYLEA and commercialize EYLEA outside the United States in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below and "Risks Related to Our Reliance on Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of products we commercialize in the United States and our collaborators' sales of products they commercialize under our collaboration agreements with them in the United States and other countries (which impact our share of any profits or losses from the commercialization of these products under the relevant collaboration agreements and, therefore, our results of operations) may be reduced if the applicable product is imported into those countries from lower priced markets, whether legally or illegally (a practice known as parallel trading or reimportation). Parallel traders (who may repackage or otherwise alter the original product or sell it through alternative channels such as mail order or the Internet) take advantage of the price differentials between markets arising from factors including sales costs, market conditions (such as intermediate trading stages), tax rates, or national regulation of prices. Under our arrangement with Bayer, pricing and reimbursement for EYLEA outside the United States is the responsibility of Bayer. Similarly, under our Antibody Collaboration and IO Collaboration with Sanofi, pricing and reimbursement for the products commercialized thereunder outside the United States are the responsibility of Sanofi. Prices for our marketed products in jurisdictions outside the United States are based on local market economics and competition and are likely to differ from country to country. In the United States, prices for pharmaceuticals are generally higher than in the bordering nations of Canada and Mexico and sales of our marketed products in the United States may be reduced if the applicable product marketed in those bordering nations is imported into the United States. In addition, there are proposals to legalize the import of pharmaceuticals from outside the United States into the United States. If such proposals were implemented, our future revenues derived from sales of our marketed products could be reduced. Parallel-trading practices also are of particular relevance to the EU, where they have been encouraged by the current regulatory framework. These types of imports may exert pressure on the pricing of our marketed products in a particular market or reduce sales recorded by us or our collaborators, thereby adversely affecting our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if clinical trials demonstrate the safety and effectiveness of any of our product candidates for a specific disease and the necessary regulatory approvals are obtained, the commercial success of any of our product candidates or new indications for our marketed products will depend upon, among other things, their acceptance by patients, the medical community, and third-party payors and on our and our collaborators' ability to successfully manufacture, market, and distribute those products in substantial commercial quantities or to establish and manage the required infrastructure to do so, including large-scale information technology systems and a large-scale distribution network. Establishing and maintaining sales, marketing, and distribution capabilities are expensive and time-consuming. Even if we obtain regulatory approval for our product candidates or new indications, if they are not successfully commercialized, we will not be able to recover the significant investment we have made in developing such products and our business, prospects, operating results, and financial condition would be severely harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products may also be adversely affected by guidelines or recommendations to healthcare providers, administrators, payors, and patient communities that result in decreased use of our products. Such guidelines or recommendations may be published not only by governmental agencies, but also professional societies, practice management groups, private foundations, and other interested parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are delivered either by intravenous infusion or by intravitreal or subcutaneous injections, which are generally less well received by patients than tablet or capsule delivery and this could adversely affect the commercial success of those products if they receive marketing approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell EYLEA, Libtayo, Praluent, and ARCALYST in the United States to several distributors and specialty pharmacies, as applicable. Under this distribution model, the distributors and specialty pharmacies generally take physical delivery of product and generally sell the product directly to healthcare providers or other pharmacies (as applicable). For the nine months ended September&#160;30, 2020, our gross product sales of such products to two customers accounted on a combined basis for 86% of our total gross product revenue. We expect this significant customer concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue for the foreseeable future. Our ability to generate and grow sales of these products will depend, in part, on the extent to which our distributors and specialty pharmacies are able to provide adequate distribution of these products to healthcare providers. Although we believe we can find additional distributors, if necessary, our revenue during any period of disruption could suffer and we might incur additional costs. In addition, these customers are responsible for a significant portion of our net trade accounts receivable balances. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us, or any failure to pay for the products we have shipped to them could adversely affect our results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited commercial capabilities outside the United States and do not currently have an organization for the sales, marketing, and distribution of marketed products outside the United States. We will need to establish commercial capabilities outside the United States if we decide to co-commercialize a product outside the United States. For example, we recently exercised our option under the Antibody Collaboration to co-commercialize Dupixent in certain jurisdictions outside the United States. In addition, there may be other circumstances in which we need to establish commercial capabilities outside the United States, including because we decide to commercialize a particular product independently; we are unable to find an appropriate collaborator; or our existing collaborator decides not to opt in, decides to opt out, or breaches its obligations to us with respect to a particular product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize or co-commercialize any products outside the United States, we must build our sales, marketing, distribution, managerial, and other non-technical capabilities in the relevant markets or make arrangements with third parties to perform these services, which would likely be expensive and time consuming and could delay product launch or the co-commercialization of a product in one or more markets outside the United States. We cannot be certain that we will be able to successfully develop commercial capabilities outside the United States within an acceptable time frame or at all. These and other difficulties relating to commercializing our products outside the United States may severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot sell or market products without regulatory approval. If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications of our marketed products (or are materially delayed in doing so), the value of our Company and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we (which, for purposes of this risk factor, includes our collaborators, unless otherwise stated or required by the context) must obtain and maintain approval from the FDA for each drug we intend to sell. Obtaining FDA approval is typically a lengthy and expensive process, and approval is highly uncertain. We cannot predict with certainty if or when we might submit for regulatory approval for any of our product candidates currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. The FDA has substantial discretion in the approval process (including with respect to setting specific conditions for submission) and may either refuse to accept an application for substantive review or may form the opinion after review of an application that the application is insufficient to allow approval of a product candidate. If the FDA does not accept our application for review or approve our application, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit the data before it will reconsider our application. Depending on the extent of these or any other studies that might be required, approval of any applications that we submit may be delayed significantly, or we may be required to expend more resources. It is also possible that any such additional studies, if performed and completed, may not be considered sufficient by the FDA to make our applications approvable. If any of these outcomes occur, we may be forced to delay or abandon our applications for approval.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances (such as when we use a biomarker-based test to identify and enroll specific patients in a clinical trial), regulatory approval of a companion diagnostic to our therapeutic product candidate may be required as a condition to regulatory approval of the therapeutic product candidate. We may need to rely on third parties to provide companion diagnostics for use with our product candidates. Such third parties may be unable or unwilling on terms acceptable to us to provide such companion diagnostics or to obtain timely regulatory approval of such companion diagnostics, which could negatively impact regulatory approval of our product candidates or may result in increased development costs or delays.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require us to conduct additional clinical trials after granting approval of a product. Its ability to do so has been enhanced by the Food and Drug Administration Amendments Act of 2007, pursuant to which the FDA has the explicit authority to require postmarketing studies (also referred to as post-approval or Phase 4 studies), labeling changes based on new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety information, and compliance with FDA-approved risk evaluation and mitigation strategies. Post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other data about our marketed products (or data about products similar to our marketed products that implicate an entire class of products or are perceived to do so) may result in changes in product labeling, restrictions on use, product withdrawal or recall, loss of approval, or lower sales of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the FDA policies under the Prescription Drug User Fee Act, the FDA system of review times for new drugs includes standard review and priority review. Standard review can be accomplished in a 10-month time frame from the time the application is filed by the FDA (filing date), which typically occurs approximately 60 days following submission of the application by the applicant. The FDA has stated the goal to act on 90% of standard new molecular entity ("NME") New Drug Application ("NDA") and original BLA submissions within 10 months of the filing date. A priority review designation is given to drugs that treat a serious condition and offer major advances in treatment, or provide a treatment where no adequate therapy exists, and may also be afforded to a human drug application based on a priority review voucher. The FDA has stated the goal to act on 90% of priority NME NDA and original BLA submissions within six months of the filing date. However, the FDA's review goals are subject to change and the duration of the FDA's review depends on a number of factors, including the number and types of other applications that are submitted to the FDA around the same time period or are pending. Even if any of our applications receives a priority review designation, we may not ultimately be able to obtain approval of our application within a time frame consistent with the FDA's stated review goals or at all, and such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA enforces Good Clinical Practices ("GCPs") and other regulations through periodic inspections of trial sponsors, clinical research organizations ("CROs"), principal investigators, and trial sites. If we or any of the third parties conducting our clinical studies are determined to have failed to fully comply with GCPs, the study protocol or applicable regulations, the clinical data generated in those studies may be deemed unreliable. This could result in non-approval of our product candidates by the FDA, or we or the FDA may decide to conduct additional inspections or require additional clinical studies, which would delay our development programs, require us to incur additional costs, and could substantially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a new drug or biologic product, the FDA requires that the facilities at which the product will be manufactured or advanced through the supply chain be in compliance with current Good Manufacturing Practices, or cGMP, requirements and regulations governing the manufacture, shipment, and storage of the product. These cGMP requirements and regulations are not prescriptive instructions on how to manufacture products, but rather a series of principles that must be observed during manufacturing; as a result, their implementation may not be clearly delineated and may present a challenging task. Manufacturing product candidates in compliance with these regulatory requirements is complex, time-consuming, and expensive. To be successful, our products must be manufactured in compliance with regulatory requirements, and at competitive costs. If we or any of our third-party manufacturers, product packagers, labelers, or other parties performing steps in the supply chain are unable to maintain regulatory compliance, the FDA can impose regulatory sanctions, including, among other things, refusal to approve a pending application for a new drug or biologic product, or revocation of a pre-existing approval. For additional information, see "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Our business, prospects, operating results, and financial condition may be materially harmed as a result of noncompliance with the requirements and regulations described in this paragraph.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regular way drug approval process, the FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and available alternatives. If we are granted an EUA for any of our product candidates </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(such as REGN-COV2),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we would be able to commercialize any such product candidate prior to FDA approval. However, there is no guarantee that the FDA will grant an EUA for any of our product candidates; in addition, the FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long an EUA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (if it is granted with respect to any of our product candidates)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would remain in effect for any such product candidate. Such revocation could adversely impact our business in a variety of ways, including by having to absorb related manufacturing and overhead costs as well as potential inventory write-offs if regulatory approval is not obtained timely or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FDA and other regulatory agency regulations in the United States, we are subject to a variety of foreign regulatory requirements governing human clinical trials, manufacturing, marketing and approval of drugs, and commercial sale and distribution of drugs in foreign countries. The foreign regulatory approval process is similarly a lengthy and expensive process, the result of which is highly uncertain, and foreign regulatory requirements include all of the risks associated with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approval as well as country specific regulations. We and our collaborators must maintain regulatory compliance for the products we or they commercialize in foreign jurisdictions.&#160;From time to time, we may hold a product's marketing approval in a jurisdiction outside the United States where we may have less experience and where our regulatory capabilities may be more limited.&#160;In addition, actions by a regulatory agency in a country or region with respect to a product candidate may have an impact on the approval process for that product candidate in another country or region. Foreign regulatory authorities often also have the authority to require post-approval studies, which involve various risks similar to those described above, and may ask for additional data in order to begin a clinical study. Whether or not we obtain FDA approval for a product in the United States, we must obtain approval of the product by the comparable regulatory authorities in foreign countries before we can market that product or any other product in those countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described above, we must conduct extensive testing of our product candidates and new indications of our marketed products before we can obtain regulatory approval to market and sell them. We need to conduct both preclinical animal testing and human clinical trials. Conducting such studies is a lengthy, time-consuming, and expensive process. These tests and trials may not achieve favorable results for many reasons, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events (or side effects) caused by or connected with exposure to the product candidate (or prior or concurrent exposure to other products or product candidates), difficulty in enrolling and maintaining subjects in a clinical trial, clinical trial design that may not make it possible to enroll a sufficient number of patients to achieve a statistically significant result or the desired level of statistical significance, lack of sufficient supplies of the product candidate or comparator drug, and the failure of clinical investigators, trial monitors, contractors, consultants, or trial subjects to comply with the trial plan, protocol, or applicable regulations related to the FDA's Good Laboratory Practice requirements ("GLPs") or GCPs. A clinical trial may also fail because it did not include and/or retain a sufficient number of patients to detect the endpoint being measured or reach statistical significance. A clinical trial may also fail because the dose(s) of the investigational drug included in the trial were either too low or too high to determine the optimal effect of the investigational drug in the disease setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to reevaluate any drug candidate that does not test favorably and either conduct new studies, which are expensive and time consuming, or abandon that drug development program. If preclinical testing yields unfavorable results, product candidates may not advance to clinical trials.  The failure of clinical trials to demonstrate the safety and effectiveness of our clinical candidates for the desired indication(s) would preclude the successful development of those candidates for such indication(s), in which event our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our products and product candidates (such as Libtayo and Dupixent) are studied in combination with agents and treatments developed by us or our collaborators. There may be additional risks and unforeseen safety issues resulting from such combined administration, any of which may materially adversely impact clinical development of these product candidates and our ability to obtain regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful development of our current and future product candidates is uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small minority of all research and development programs ultimately result in commercially successful drugs. Clinical trials may not demonstrate statistically sufficient effectiveness and safety to obtain the requisite regulatory approvals for these product candidates in these indications. Many companies in the biopharmaceutical industry, including our Company, have suffered significant setbacks in clinical trials, even after promising results have been obtained in earlier trials. In a number of instances, we have terminated the development of product candidates due to a lack of or only modest effectiveness, and clinical trials evaluating our product candidates failed to meet the relevant endpoints. For example, in August 2017, we reported that the Phase 3 study evaluating suptavumab, an antibody to RSV, did not meet its primary endpoint of preventing medically-attended RSV infections in infants; as a result, we have discontinued further clinical development of this antibody. Moreover, even if we obtain positive results from preclinical testing or clinical trials, we may not achieve the same success in future trials, or the FDA and analogous foreign regulatory authorities may deem the results insufficient for an approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our clinical trials are conducted under the oversight of IDMCs. These independent oversight bodies are made up of external experts who review the progress of ongoing clinical trials, including available safety and efficacy data, and make recommendations concerning a trial's continuation, modification, or termination based on interim, unblinded data. Any of our ongoing clinical trials may be discontinued or amended in response to recommendations made by responsible IDMCs based on their review of such interim trial results. For example, in August 2020, we discontinued actively treating patients with fasinumab (which at such time only involved dosing in an optional second-year extension phase of one trial) following a recommendation from the responsible IDMC that the program be terminated based on available evidence to date. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommended termination or material modification of any of our ongoing late-stage clinical trials by an IDMC could negatively impact the future development of our product candidate(s), and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying our antibody-based product candidates in a wide variety of indications in clinical trials. Many of these trials are exploratory studies designed to evaluate the safety profile of these compounds and to identify what diseases and uses, if any, are best suited for these product candidates. These product candidates may not demonstrate the requisite efficacy and/or safety profile to support continued development for some or all of the indications that are being, or are planned to be, studied, which would diminish our clinical "pipeline" and could negatively affect our future prospects and the value of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Various illnesses, injuries, and discomforts have been reported from time-to-time during clinical trials of our product candidates and new indications for our marketed products. It is possible that as we test our drug candidates or new indications in larger, longer, and more extensive clinical programs, or as use of these drugs becomes more widespread if they receive regulatory approval, illnesses, injuries, and discomforts that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients after approval. If additional clinical experience indicates that any of our product candidates or new indications for our marketed products has many side effects or causes serious or life-threatening side effects, the development of the product candidate may be delayed or fail, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to EYLEA, there are many potential safety concerns associated with significant blockade of VEGF that may limit our ability to further successfully commercialize EYLEA. These serious and potentially life-threatening risks, based on clinical and preclinical experience of VEGF inhibitors, include bleeding, intestinal perforation, hypertension, proteinuria, congestive heart failure, heart attack, and stroke. Other VEGF blockers have reported side effects that became evident only after large-scale trials or after marketing approval when large numbers of patients were treated. There are risks inherent in the intravitreal administration of drugs like aflibercept (such as intraocular inflammation ("IOI"), sterile and culture positive endophthalmitis, corneal decomposition, retinal detachment, and retinal tear), which can cause injury to the eye and other complications. The side effects previously reported for EYLEA include conjunctival hemorrhage, macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters. In addition, commercialization of EYLEA or our other products may be impacted by actions of third parties on which we rely, such as manufacturers of syringes or other devices used in the administration of our products. For example, in February 2018, we issued a letter to healthcare professionals providing updated guidance relating to reports of IOI following EYLEA injections. In this letter, we noted that while our review did not identify any association of IOI rates with the EYLEA drug itself, an association was seen with certain batches of the syringe that were included in specific lots of final packaged EYLEA kits. These and other complications or issues or side effects could harm further development and/or commercialization of EYLEA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dupixent and Libtayo are being studied in additional indications, as shown in the table under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Overview - Programs in Clinical Development." There is no guarantee that marketing approval of Dupixent or Libtayo (as applicable) in any of these indications will be successfully obtained. The side effects previously reported for Dupixent include hypersensitivity reactions, conjunctivitis and keratitis, injection-site reactions, eye and eyelid inflammation, cold sores, oropharyngeal pain, and eosinophilia; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. These and other complications or side effects could harm further development and/or commercialization of Dupixent and Libtayo (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also are risks inherent in subcutaneous injections (which are used for administering most of our antibody-based products and product candidates), such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects. These and other complications or side effects could harm further development and/or commercialization of our antibody-based products and product candidates utilizing this method of administration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of recombinant proteins frequently causes an immune response, resulting in the creation of antibodies against the therapeutic protein. The antibodies can have no effect or can totally neutralize the effectiveness of the protein, or require that higher doses be used to obtain a therapeutic effect. In some cases, the antibody can cross-react with the patient's own proteins, resulting in an "auto-immune" type disease. Whether antibodies will be created can often not be predicted from preclinical or clinical experiments, and their detection or appearance is often delayed, so neutralizing antibodies may be detected at a later date, in some cases even after pivotal clinical trials have been completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to continue to develop suitable product formulations or manufacturing processes to support large-scale clinical testing of our product candidates, including our antibody-based product candidates, we may be unable to supply necessary materials for our clinical trials, which would delay or prevent the development of our product candidates. Similarly, if we are unable, directly or through our collaborators or third parties, to supply sufficient quantities of our products or develop formulations of our product candidates suitable for commercial use, we will be unable to obtain regulatory approval for those product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products are used and some of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system. For example, in the United States and the EU, EYLEA is approved in the 2mg pre-filled syringe. The success of our products and product candidates may depend to a significant extent on the performance of such devices, some of which may be novel or comprised of complex components. Given the increased complexity of the review process when approval of the product and device is sought under a single marketing application and the additional risks resulting from a product candidate's designation as a combination product discussed below, our product candidates used with such drug-delivery devices may be substantially delayed in receiving regulatory approval or may not be approved at all. The FDA review process and criteria for such applications are not well established, which could also lead to delays in the approval process. In addition, some of these drug-delivery devices may be provided by single-source, third-party providers or our collaborators. In any such case, we may be dependent on the sustained cooperation of those third-party providers or collaborators to supply and manufacture the devices; to conduct the studies and prepare related documentation required for approval or clearance by the applicable regulatory agencies; and to continue to meet the applicable regulatory and other requirements to maintain approval or clearance once it has been received. In addition, other parties may allege that our drug-delivery devices infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 12 to our Condensed Consolidated Financial Statements. Failure to successfully develop or supply the devices, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or the third-party providers to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in a product or product candidate reaching the market. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop or supply and manufacture these devices, or to gain or maintain their approval, could adversely affect sales of the related products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic, or device. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Although a single marketing application is generally sufficient for the approval, clearance, or licensure of a combination product, the FDA may determine that separate marketing applications are necessary. In addition, submitting separate marketing applications may be necessary to receive some benefit that accrues only from approval under a particular type of application. This could significantly increase the resources and time required to bring a particular combination product to market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Market Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires using sensitive and proprietary technology and other information that we protect as trade secrets. We seek to prevent improper disclosure of these trade secrets through confidentiality agreements and other means. If our trade secrets are improperly disclosed, by our current or former employees, our collaborators, or otherwise, it could help our competitors and adversely affect our business. We will be able to protect our proprietary rights only to the extent that our proprietary technologies and other information are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biotechnology companies, including our Company, involves complex legal and factual questions and, therefore, enforceability cannot be predicted with certainty. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented. Patent applications filed outside the United States may be challenged by other parties, for example, by filing third-party observations that argue against patentability or an opposition. Such opposition proceedings are increasingly common in the EU and are costly to defend. For example, our European Patent No. 2,264,163 is the subject of opposition proceedings in the European Patent Office (the "EPO") (currently pending before its Boards of Appeal), as described in Note 12 to our Condensed Consolidated Financial Statements included in this report. We have pending patent applications in the United States Patent and Trademark Office (the "USPTO"), the EPO, and the patent offices of other foreign jurisdictions, and it is likely that we will need to defend patents from challenges by others from time to time in the future. Certain of our U.S. patents may also be challenged by parties who file a request for post-grant review or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review under the America Invents Act of 2011 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination. For example, on February 11, 2020, anonymous parties filed two requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of two of our patents - U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent"). The '226 Patent concerns methods for manufacturing VEGF antagonist fusion proteins, including aflibercept, and the '992 Patent concerns formulations and vials containing VEGF antagonist fusion proteins, including aflibercept. The USPTO has granted both requests to initiate reexamination proceedings. Post-grant proceedings are increasingly common in the United States and are costly to defend. Our patent rights may not provide us with a proprietary position or competitive advantages against competitors. Furthermore, even if the outcome is favorable to us, the enforcement of our intellectual property rights can be extremely expensive and time consuming.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently hold issued trademark registrations and have trademark applications pending in the United States and other jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our&#160;trademarks&#160;to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering, or using&#160;trademarks that infringe, dilute or otherwise violate our trademark rights, our business could be adversely affected.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others (including those relating to trademarks, copyrights, and trade secrets). Other parties may allege that they own blocking patents to our products in clinical development or even to products that have received regulatory approval and are being or have been commercialized, either because they claim to hold proprietary rights to the composition of a product or the way it is manufactured or the way it is used. Moreover, other parties may allege that they have blocking patents to antibody-based products made using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, or any other of our technologies, either because of the way the antibodies are discovered or produced or because of a proprietary composition covering an antibody or the antibody's target.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been in the past, are currently, and may in the future be involved in patent litigation and other proceedings involving patents and other intellectual property. For example, we and/or Sanofi are currently party to patent infringement proceedings initiated by Amgen against us and/or Sanofi relating to Praluent and patent infringement proceedings relating to Dupixent, as described in Note 12 to our Condensed Consolidated Financial Statements. In addition, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 12 to our Condensed Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are aware of patents and pending patent applications owned by others that respectively claim antibodies to IL-4R and methods of treating conditions including atopic dermatitis and asthma with such antibodies; antibodies to IL-6R and methods of treating conditions including rheumatoid arthritis with such antibodies; antibodies to PCSK9 and methods of treating hypercholesterolemia with such antibodies; and antibodies to PD-1 and methods of treating cancer with such antibodies. In addition to Dupixent (dupilumab), Libtayo (cemiplimab), Praluent (alirocumab), and Kevzara (sarilumab), our late-stage antibody-based pipeline includes fasinumab, an antibody to NGF; evinacumab, an antibody to ANGPTL3; garetosmab, an antibody to Activin A; pozelimab, an antibody to C5; odronextamab, a bispecific antibody targeting CD20 and CD3; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat infection from the SARS-CoV-2 virus.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not believe that any of our products or our late-stage antibody-based product candidates infringe any valid claim in these patents or patent applications,</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these other parties could initiate lawsuits for patent infringement and assert that their patents are valid and cover our products or our late-stage antibody-based product candidates, similar to the patent infringement proceedings referred to above. Further, we are aware of a number of patent applications of others that, if granted with claims as currently drafted, may cover our current or planned activities. It could be determined that our products and/or actions in manufacturing or selling our products or product candidates infringe such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent holders could assert claims against us for damages and seek to prevent us from manufacturing, selling, or developing our products or product candidates, and a court may find that we are infringing validly issued patents of others. In the event that the manufacture, use, or sale of any of our products or product candidates infringes on the patents or violates other proprietary rights of others, we may be prevented from pursuing product development, manufacturing, and commercialization of those drugs and may be required to pay costly damages. In addition, in the event that we assert our patent rights against other parties that we believe are infringing our patent rights, such parties may challenge the validity of our patents and we may become the target of litigation, which may result in an outcome that is unfavorable to us. Any of these adverse developments may materially harm our business, prospects, operating results, and financial condition. In any event, legal disputes are likely to be costly and time consuming to defend.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to obtain licenses to patents when, in our judgment, such licenses are needed or advisable. For example, in August 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb &amp; Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo. If any licenses are required, we may not be able to obtain such licenses on commercially reasonable terms, if at all. The failure to obtain any such license could prevent us from developing or commercializing any one or more of our products or product candidates, which could severely harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical and biotechnology industries, the majority of an innovative product's commercial value is usually realized during the period in which it has market exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product's sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our late-stage product candidates or other clinical candidates are approved for marketing in the United States or elsewhere, market exclusivity for those products will generally be based upon patent rights and/or certain regulatory forms of exclusivity. As described above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the scope and enforceability of our patent rights may vary from country to country. The failure to obtain patent and other intellectual property rights, or limitations on the use, or the loss, of such rights could materially harm us. Absent patent protection or regulatory exclusivity for our products, it is possible, both in the United States and elsewhere, that generic, biosimilar, and/or interchangeable versions of those products may be approved and marketed, which would likely result in substantial and rapid reductions in revenues from sales of those products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the federal Patient Protection and Affordable Care Act (the "PPACA"), there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-approved biological product. The PPACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened if, for example, the PPACA is amended.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the EU has had an established regulatory pathway for biosimilars since 2005.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increased likelihood of biosimilar competition has increased the risk of loss of innovators' market exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. Due to this risk, and uncertainties regarding patent protection, it is not possible to predict the length of market exclusivity for any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particular product we currently or may in the future commercialize with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. We are aware of several companies developing biosimilar versions of EYLEA. In the United States, the regulatory exclusivity period for EYLEA (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period during which no biosimilar product can be approved by the FDA) expires on November 18, 2023, with the possibility of an additional six months of regulatory exclusivity (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, until May 18, 2024) if the FDA grants pediatric exclusivity based on our completion of certain studies evaluating EYLEA in pediatric patients with retinopathy of prematurity and submission of the data from these studies to the FDA no later than 15 months before the date on which regulatory exclusivity would otherwise expire. The loss of market exclusivity for a product (such as EYLEA) would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing and Supply</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Rensselaer, New York and Limerick, Ireland. Manufacturing facilities operated by us and by third-party contract manufacturers engaged by us would be inadequate to produce the active pharmaceutical ingredients of our current marketed products and our product candidates in sufficient clinical quantities if our clinical pipeline advances as planned. For example, our internal manufacturing capacity will likely not be sufficient to cover the demand for REGN-COV2, our novel investigational antibody "cocktail" treatment designed to prevent and treat infection from the SARS-CoV-2 virus, if we receive regulatory approval or are otherwise authorized to market this therapy. In addition to expanding our internal capacity, we intend to continue to rely on our collaborators, and may also rely on contract manufacturers, to produce commercial quantities of drug material needed for commercialization of our products. For example, as described in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," in August 2020, we announced a collaboration agreement with Roche to develop, manufacture, and distribute REGN-COV2. We cannot be certain that the technology transfer process required to allow Roche to manufacture REGN-COV2 will be completed in the expected time frame or at all nor can we be certain that this collaboration will result in the anticipated increase in the current manufacturing and distribution capacity for REGN-COV2 or that any increased manufacturing and distribution capacity will be sufficient. As we increase our production in anticipation of potential regulatory approval for our product candidates, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes. We rely entirely on other parties and our collaborators for filling and finishing services, including with respect to drug-delivery devices (such as a pre-filled syringe, patch pump, auto-injector, or other delivery system). Generally, in order for other parties to perform any step in the manufacturing and supply chain, we must transfer technology to the other party, which can be time consuming and may not be successfully accomplished without considerable cost and expense, or at all. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. If for any reason they are unable to do so, and as a result we are unable to directly or through other parties manufacture and supply sufficient commercial and clinical quantities of our products on acceptable terms, or if we should encounter delays or other difficulties with our collaborators, contract manufacturers, warehouses, shipping, testing laboratories, or other parties involved in our supply chain which adversely affect the timely manufacture and supply of our products or product candidates, our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing manufacturing facilities in Rensselaer, New York and Limerick, Ireland, we may lease, operate, purchase, or construct additional facilities to conduct expanded manufacturing or other related activities in the future. Expanding our manufacturing capacity to supply commercial quantities of the active pharmaceutical ingredients for our marketed products and our product candidates if they are approved for marketing, and to supply clinical drug material to support the continued growth of our clinical programs, will require substantial additional expenditures, time, and various regulatory approvals and permits. This also holds true for establishing fill/finish capabilities in the future, for which we have taken initial steps. Further, we will need to hire and train significant numbers of employees and managerial personnel to staff our expanding manufacturing and supply chain operations, as well as any future fill/finish activities. Start-up costs can be large, and scale-up entails significant risks related to process development and manufacturing yields. In addition, we may face difficulties or delays in developing or acquiring the necessary production equipment and technology to manufacture sufficient quantities of our product candidates at reasonable costs and in compliance with applicable regulatory requirements. The FDA and analogous foreign regulatory authorities must determine that our existing and any expanded manufacturing facilities and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any future fill/finish activities comply, or continue to comply, with cGMP requirements for both clinical and commercial production and license them, or continue to license them, accordingly, and such facilities must also comply with applicable environmental, safety, and other governmental permitting requirements. We may not successfully expand or establish sufficient manufacturing or any future fill/finish capabilities or manufacture our products economically or in compliance with cGMPs and other regulatory requirements, and we and our collaborators may not be able to build or procure additional capacity in the required timeframe to meet commercial demand for our product candidates if they receive regulatory approval, and to continue to meet the requirements of our clinical programs. This would interfere with our efforts to successfully commercialize our marketed products, and could also delay or require us to discontinue one or more of our clinical development programs. As a result, our business, prospects, operating results, and financial condition could be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue to manufacture products in our Rensselaer, New York and Limerick, Ireland facilities and at additional facilities (if any) in the future (including our ability to conduct any fill/finish activities in the future), the ability of our collaborators to manufacture products at their facilities, and our ability to utilize other third parties to produce our products, to supply raw materials or other products, or to perform fill/finish services or other steps in our manufacture and supply chain, depends on our and their ability to operate without infringing the patents or other intellectual property rights of others. Other parties may allege that our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain (which may be located in jurisdictions outside the United States), infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 12 to our Condensed Consolidated Financial Statements. A judicial or regulatory decision in favor of one or more parties making such allegations could directly or indirectly preclude the manufacture of our products to which those intellectual property rights apply on a temporary or permanent basis, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our manufacturing facilities primarily to produce bulk product for commercial supply of our marketed products and clinical and preclinical candidates for ourselves and our collaborations. We also plan to use such facilities to produce bulk product for commercial supply of new indications of our marketed products and new product candidates if they are approved for marketing. If our clinical candidates are discontinued or their clinical development is delayed, if the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. In addition, if we or our collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, as well as at our collaborators' facilities. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, contaminations, fire, natural disasters, acts of war or terrorism, or other problems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates are very difficult to manufacture. As our products and product candidates are biologics, they require processing steps that are more difficult than those required for most chemical pharmaceuticals. Accordingly, multiple steps are needed to control the manufacturing processes. Problems with these manufacturing processes, even minor deviations from the normal process or from the materials used in the manufacturing process (which may not be detectable by us or our collaborators in a timely manner), could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims, and insufficient inventory. Also, the complexity of our manufacturing process may make it difficult, time-consuming, and expensive to transfer our technology to our collaborators or contract manufacturers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain raw materials or other products necessary for the manufacture and formulation of our marketed products and product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers. In addition, we rely on certain third parties or our collaborators to perform filling, finishing, distribution, laboratory testing, and other services related to the manufacture of our marketed products and product candidates, and to supply various raw materials and other products. We would be unable to obtain these raw materials, other products, or services for an indeterminate period of time if any of these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contaminations, business interruptions, or labor shortages or disputes (in each case, including as a result of the COVID-19 pandemic). In any such circumstances, we may not be able to engage a backup or alternative supplier or service provider in a timely manner or at all. This, in turn, could materially and adversely affect our or our collaborators' ability to manufacture or supply marketed products and product candidates, which could materially and adversely affect our business and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin. There are certain regulatory restrictions on using these biological source materials. If we or our collaborators are required to substitute for these sources to comply with such regulatory requirements, our clinical development or commercial activities may be delayed or interrupted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators and other third-party providers are required to maintain compliance with cGMPs, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm such compliance. Changes of suppliers or modifications of methods of manufacturing may require amending our application(s) to the FDA or such comparable foreign agencies and acceptance of the change by the FDA or such comparable foreign agencies prior to release of product(s). Because we produce multiple products and product candidates at our facilities in Rensselaer, New York and Limerick, Ireland, there are increased risks associated with cGMP compliance. Our inability, or the inability of our collaborators and third-party fill/finish or other service providers, to demonstrate ongoing cGMP compliance could require us to engage in lengthy and expensive remediation efforts, withdraw or recall product, halt or interrupt clinical trials, and/or interrupt commercial supply of any marketed products, and could also delay or prevent our obtaining regulatory approval for our product candidates or new indications for our marketed products. Any delay, interruption, or other issue that arises in the manufacture, fill/finish, packaging, or storage of any drug product or product candidate as a result of a failure of our facilities or the facilities or operations of our collaborators or other third parties to pass any regulatory agency inspection or maintain cGMP compliance could significantly impair our ability to develop, obtain approval for, and successfully commercialize our products, which would substantially harm our business, prospects, operating results, and financial condition. Any finding of non-compliance could also increase our costs, cause us to delay the development of our product candidates, result in delay in our obtaining, or our not obtaining, regulatory approval of product candidates or new indications for our marketed products, and cause us to lose revenue from any marketed products, which could be seriously detrimental to our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacturing, marketing, and sale of drugs for use in people expose us to product liability risk. Any informed consent or waivers obtained from people who enroll in our clinical trials may not protect us from liability or the cost of litigation. We may also be subject to claims by patients who use our approved products, or our product candidates if those product candidates receive regulatory approval and become commercially available, that they have been injured by a side effect associated with the drug. Even in a circumstance in which we do not believe that an adverse event is related to our products or product candidates, the related investigation may be time consuming or inconclusive and may have a negative impact on our reputation or business. We may face product liability claims and be found responsible even if injury arises from the acts or omissions of third parties who provide fill/finish or other services. To the extent we maintain product liability insurance in relevant periods, such insurance may not cover all potential liabilities or may not completely cover any liability arising from any such litigation. Moreover, in the future we may not have access to liability insurance or be able to maintain our insurance on acceptable terms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the marketing and promotion of our products, which must comply with the Food, Drug, and Cosmetic Act and applicable FDA implementing standards. The FDA's review of promotional activities includes healthcare provider-directed and direct-to-consumer advertising as well as sales representatives' communications. The FDA may take enforcement action for promoting unapproved uses of a product or other violations of its advertising laws and regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, we are subject to health care "fraud and abuse" laws, such as the federal False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. Federal and state anti-kickback laws prohibit, among other things, payments or other remuneration to induce or reward someone to purchase, prescribe, endorse, or recommend a product that is reimbursed under federal or state healthcare programs. If we provide payments or other remuneration to a healthcare professional to induce the prescribing of our products, we could face liability under state and federal anti-kickback laws. Recently, the Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the federal anti-kickback statute.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as off-label uses, that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Rebate program. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment. Even if it is determined that we have not violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would harm our business, prospects, operating results, and financial condition. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be challenged under one or more of such laws. As described further in Note 12 to our Condensed Consolidated Financial Statements included in this report, we are party to a civil complaint filed in June 2020 by the U.S. Attorney's Office for the District of Massachusetts concerning our support of 501(c)(3) organizations that provide financial assistance to patients; and we are cooperating with a pending government investigation concerning certain other business activities. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion in any such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">proceedings or investigations could harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the PPACA, the federal government requires that pharmaceutical manufacturers record any "transfers of value" made to U.S. prescribers and certain other healthcare providers and teaching hospitals. Information provided by companies is aggregated and posted annually on an "Open Payments" website, which is managed by CMS, the agency responsible for implementing these disclosure requirements. We continue to dedicate significant resources to comply with these requirements and need to be prepared to comply with additional reporting obligations outside of the United States that may apply in the future. The PPACA also includes various provisions designed to strengthen fraud-and-abuse enforcement, such as increased funding for enforcement efforts and the lowering of the intent requirement of the federal anti-kickback statute and criminal health care fraud statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, several states have legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Many of these requirements and standards are new or uncertain, and the penalties for failure to comply with these requirements may be unclear. If we are found not to be in full compliance with these laws, we could face enforcement actions, fines, and other penalties, and could receive adverse publicity, which would harm our business, prospects, operating results, and financial condition. Additionally, access to such data by fraud-and-abuse investigators and industry critics may draw scrutiny to our collaborations with reported entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our business activities outside of the United States are subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission, or SEC, and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to expand internationally, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated biotechnology company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, infectious agents (such as viruses, bacteria, and fungi), radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changing rules and regulations of various federal and state governmental authorities as well as the stock exchange on which our Common Stock is listed. These entities, including the SEC and The NASDAQ Stock Market LLC, have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional requirements and regulations in response to laws enacted by Congress, including the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that expressly authorized or required the SEC to adopt additional rules in these areas, a number of which have yet to be fully implemented. Our efforts to comply with these requirements and regulations have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management's time from other business activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of our business, including research and development, manufacturing, marketing, pricing, sales, intellectual property rights, and the framework for dispute resolution and asserting our rights against others, are subject to extensive legislation and regulation. Changes in applicable federal and state laws and agency regulations could have a materially negative impact on our business. These include:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the FDA and foreign regulatory processes for new therapeutics that may delay or prevent the approval of any of our current or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign cGMPs that may make it more difficult and costly for us to maintain regulatory compliance and/or manufacture our marketed product and product candidates in accordance with cGMPs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, the PPACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government could carry out significant changes in legislation, regulation, and government policy (including with respect to the possible repeal of all or portions of the PPACA, government reimbursement changes and drug price control measures, and changes in the existing treaty and trade relationships with other countries), as evidenced by statements and actions of President Trump and certain members of Congress (including those discussed above under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"). While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our products could adversely affect our business. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we have filed or may file or cause other regulatory delays, which could materially and adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and conduct business outside the United States and we plan to expand these activities. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, which include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfamiliar foreign laws or regulatory requirements or unexpected changes to those laws or requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other laws and regulatory requirements to which our business activities abroad are subject, such as the FCPA and the U.K. Bribery Act (discussed in greater detail above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">");</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the political or economic condition of a specific country or region;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the value of foreign currency versus the U.S. dollar;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), and other trade barriers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in attracting and retaining qualified personnel; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in the conduct of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, effective January 31, 2020, the United Kingdom commenced an exit from the EU, commonly referred to as "Brexit." During a transition period (set to expire on December 31, 2020), the British government will continue to negotiate the terms of the United Kingdom's future relationship with the EU. The outcome of these negotiations is uncertain, and we do not know to what extent Brexit will ultimately impact the business and regulatory environment in the United Kingdom, the rest of the EU, or other countries. We have large-scale manufacturing operations in Limerick, Ireland and have also established an office in the vicinity of London. Changes impacting our ability to conduct business in the United Kingdom or other EU countries, or changes to the regulatory regime applicable to our operations in those countries (such as with respect to the approval of our product candidates), may materially and adversely impact our business, prospects, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional tax liabilities related to our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in the United States and various foreign jurisdictions. Significant judgment is required in determining our worldwide tax liabilities, and our effective tax rate is derived from a combination of the applicable statutory rates in the various jurisdictions in which we operate. We record liabilities that involve significant management judgment for uncertain tax positions. The Internal Revenue Service or other domestic or foreign taxing authorities may disagree with our interpretation of tax law as applied to the operations of Regeneron and its subsidiaries or with the positions we may take with respect to particular tax issues on our tax returns. Consequently, our reported effective tax rate and our after-tax cash flows may be materially and adversely affected by tax assessments or judgments in excess of accrued amounts we have estimated in preparing our financial statements. Further, our effective tax rate may also be adversely affected by numerous other factors, including changes in the mix of our profitability from country to country, changes in tax laws and regulations, and tax effects of the accounting for stock-based compensation (which depend in part on the price of our stock and, therefore, are beyond our control). Recommendations by the Organization for Economic Co-operation and Development and the European Union Anti-Tax Avoidance Directive require companies to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny. Even though we regularly assess the information provided to tax authorities in determining the appropriateness of our tax reserves, such tax authorities could take a position that is contrary to our expectations, and the result could adversely affect our provision for income tax and our current rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the personal information we collect from individuals, data brokers, or research institutions or obtain from clinical trials sponsored by us or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most U.S. health care providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act. For example, as part of our human genetics initiative, our wholly-owned subsidiary, Regeneron Genetics Center LLC, has entered into collaborations with research institutions, including the Geisinger Health System, which are subject to such regulations. Regeneron is not currently classified as a covered entity or business associate under HIPAA and thus is not subject to its requirements or penalties. However, we could be prosecuted under HIPAA's criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered health care provider or research institution that has not satisfied HIPAA's requirements for disclosure of individually identifiable health information. There are instances where we collect and maintain sensitive personally identifiable information, which may include health information outside of the scope of HIPAA. This information may be received throughout the clinical trial process, in the course of our research collaborations, directly from individuals who enroll in our patient assistance programs, and from our own employees in a pandemic response process (such as in connection with the COVID-19 pandemic). In the case of a breach of personal information we may be subject to state breach notification laws requiring notification of affected individuals and state regulators. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient assistance programs and product marketing activities as part of which we collect California resident personal data are subject to the California Consumer Privacy Act of 2018 (the "CCPA"). The CCPA is a consumer protection law that provides California residents with personal data privacy rights and became effective on January 1, 2020. The CCPA requires us, among other things, to update our notices and develop new processes internally and with our partners. There are fines, penalties, and a private right of action resulting from non-compliance with the CCPA. Several other U.S. states have introduced similar consumer protection laws that may go into effect in the near future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our clinical trial programs and research collaborations outside the U.S. (such as our consortium with a group of companies to fund the generation of genetic exome sequence data from the UK Biobank health resource) implicate international data protection laws, including the European Union's General Data Protection Regulation (the "GDPR"). The GDPR has created a range of new compliance obligations, including increased transparency requirements and new data subject rights. Violations of the GDPR carry significant financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher)). In addition to the GDPR, certain EU Member States have issued or will be issuing their own implementation legislation. While we continue to monitor these developments, there remains some uncertainty surrounding the legal and regulatory environment for these evolving privacy and data protection laws. Complying with varying jurisdictional requirements could increase the costs and complexity of compliance, including the risk of substantial financial penalties for insufficient notice and consent, failure to respond to data subject rights requests, lack of a legal basis for the transfer of personal information out of the EU, or improper processing of personal data under the GDPR. Failure by our collaborators to comply with the strict rules on the transfer of personal data outside of the EU into the U.S. may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business and could create liability for us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, health privacy laws, data breach notification laws, consumer protection laws, data localization laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals' health and other personal information. Moreover, individuals about whom we or our collaborators obtain health or other personal information, as well as the providers and third parties who share this information with us, may have statutory or contractual limits that impact our ability to use and disclose the information. We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Claims that we have violated individuals' privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any collaborators fail to comply with applicable federal, state, local, or foreign regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators' ability to commercialize our products and could harm, prevent, or substantially increase the cost of marketing and sales of any affected products that we are able to commercialize. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is a risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on funding and support from Sanofi to develop, manufacture, and commercialize certain of our products and product candidates. With respect to the products that we are co-developing with Sanofi under our Antibody Collaboration (currently consisting of Dupixent, Kevzara, and itepekimab), Sanofi funds a significant portion of development expenses incurred in connection with the development of these products. In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are developing MUC16xCD3 Program antibodies (such as REGN4018) and BCMAxCD3 Program antibodies (such as REGN5458 and REGN5459) under the amended and restated IO Discovery and Development Agreement with Sanofi and Sanofi has the right to elect to co-develop these antibodies under our IO Collaboration. If Sanofi does not elect to co-develop MUC16xCD3 Program antibodies or BCMAxCD3 Program antibodies under our IO Collaboration, or opts out of their development under our IO Collaboration, we will be required to fund and conduct on our own all such efforts to support those product candidates, unless we enter into arrangements with other parties.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi elects to co-develop BCMAxCD3 Program antibodies and/or MUC16xCD3 Program antibodies under our IO Collaboration, Sanofi will initially fund the development expenses incurred in connection with the development of BCMAxCD3 Program antibodies, for which Sanofi will be the principal controlling party, and half of the development expenses incurred in connection with the clinical development of MUC16xCD3 Program antibodies, for which we will be the principal controlling party. Under our IO Collaboration, Sanofi also funds half of the development expenses incurred in connection with the clinical development of Libtayo, subject to an agreed-upon development budget. In addition, if Sanofi elects to co-develop BCMAxCD3 Program antibodies, Sanofi will lead much of the clinical development efforts and assist with obtaining and maintaining regulatory approval. We also rely on Sanofi to lead commercialization efforts outside the United States for Libtayo. Following regulatory approval, we will rely on Sanofi to lead (i) the commercialization efforts in the United States for BCMAxCD3 Program antibodies and (ii) the commercialization efforts outside the United States for MUC16xCD3 Program antibodies and BCMAxCD3 Program antibodies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi terminates the Antibody Collaboration or the IO Collaboration or fails to comply with its payment obligations under any of our collaborations, our business, prospects, operating results, and financial condition would be materially harmed. We would be required to either expend substantially more resources than we have anticipated to support our research and development efforts, which could require us to seek additional funding that might not be available on favorable terms or at all, or materially cut back on such activities. If Sanofi does not perform its obligations with respect to the product candidates that it elects to co-develop, our ability to develop, manufacture, and commercialize these product candidates will be significantly adversely affected. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities for products commercialized under our Antibody Collaboration or our IO Collaboration (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Antibody Collaboration or the IO Collaboration would create substantial new and additional risks to the successful development and commercialization of the products subject to such collaborations, particularly outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on Bayer with respect to the commercialization of EYLEA outside the United States. Bayer is responsible for obtaining and maintaining regulatory approval outside the United States, as well as providing all sales, marketing, and commercial support for the product outside the United States. In particular, Bayer has responsibility for selling EYLEA outside the United States using its sales force and, in Japan, in cooperation with Santen pursuant to a Co-Promotion and Distribution Agreement, as in effect from time to time, with Bayer's Japanese affiliate. If Bayer and, in Japan, Santen do not perform their obligations in a timely manner, or at all, our ability to commercialize EYLEA outside the United States will be significantly adversely affected. Bayer has the right to terminate its collaboration agreement with us at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination. If Bayer were to terminate its collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek another collaboration that might not be available on favorable terms or at all, and could cause significant issues for the commercialization of EYLEA outside the United States and result in substantial additional costs and/or lower revenues to us. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Bayer collaboration agreement would create substantial new and additional risks to the successful commercialization of EYLEA outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and clinical development of our product candidates. We also depend, or will depend, on some of these third parties in connection with the commercialization of our marketed products and our product candidates and new indications for our marketed products if they are approved for marketing. If any of our existing collaborators or service providers breaches or terminates its agreement with us or does not perform its development or manufacturing services under an agreement in a timely manner (including as a result of its inability to perform due to financial or other relevant constraints) or in compliance with applicable GMPs, GLPs, or GCP standards, we could experience additional costs, delays, and difficulties in the manufacture or development of, or in obtaining approval by regulatory authorities for, or successfully commercializing our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators rely on third-party service providers to support the distribution of our marketed products and for many other related activities in connection with the commercialization of these marketed products. Despite our or our collaborators' arrangements with them, these third parties may not perform adequately. If these service providers do not perform their services adequately, sales of our marketed products will suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Related to Employees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on certain of our executive officers, other key members of our senior management team, and our Chairman. If we are not able to retain (or for any other reason lose the services of) any of these persons, our business may suffer. In particular, we depend on the services of P. Roy Vagelos, M.D., the Chairman of our board of directors; Leonard S. Schleifer, M.D., Ph.D., our President and Chief Executive Officer; and George D. Yancopoulos, M.D., Ph.D., our President and Chief Scientific Officer. We are also highly dependent on the expertise and services of other senior management members leading our research, development, manufacturing, and commercialization efforts. There is intense competition in the biotechnology industry for qualified scientists and managerial personnel in the research, development, manufacture, and commercialization of drugs. We may not be able to continue to attract and retain the qualified personnel necessary to continue to advance our business and achieve our strategic objectives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Technology Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex, and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. These systems are also critical to enable remote working arrangements, which have been growing in importance due in part to the COVID-19 pandemic and our implementation of work-from-home policies for a significant part of our employees. The size and complexity of our computer systems make us potentially vulnerable to IT system breakdowns, internal and external malicious intrusion, and computer viruses and ransomware, which may impact product production and key business processes. We also have outsourced significant elements of our information technology infrastructure and operations to third parties, which may allow them to access our confidential information and may also make our systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by such third parties or others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our systems are potentially vulnerable to data security breaches - whether by employees or others - which may expose sensitive data to unauthorized persons. Data security breaches could lead to the loss of trade secrets or other intellectual property, result in demands for ransom or other forms of blackmail, or lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage or extortion) and expertise, including by organized criminal groups, "hacktivists," nation states, and others. As a company with an increasingly global presence, our systems are subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such disruptions and breaches of security could result in legal proceedings, liability under laws that protect the privacy of personal information, disruptions to our operations, and damage to our reputation, which could have a material adverse effect on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Results, Liquidity, and Need for Additional Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot sustain profitability, our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot sustain profitability, we may be unable to continue our operations. In the absence of substantial revenue from the sale of products on an ongoing basis, including our net product sales of EYLEA and funding we receive under our collaboration agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), or from other sources, the amount, timing, nature, or source of which cannot be predicted, we may incur substantial losses again as we conduct our research and development activities, commercialize our approved products, and prepare for possible commercialization of our other product candidates and new indications of our marketed products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend substantial resources for research and development, including costs associated with clinical testing of our product candidates and new indications of our marketed products, the commercialization of products, and capital expenditures. We believe our existing capital resources and borrowing availability under our revolving credit facility, together with funds generated by our current and anticipated EYLEA net product sales and funding we are entitled to receive under our collaboration agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), will enable us to meet our anticipated operating needs for the foreseeable future. However, one or more of our collaboration agreements may terminate, our revenues may fall short of our projections or be delayed, or our expenses may increase, any of which could result in our capital being consumed significantly faster than anticipated. Our expenses may increase for many reasons, including expenses in connection with the commercialization of our marketed products and the potential commercial launches of our product candidates and new indications for our marketed products, manufacturing scale-up, expenses related to clinical trials testing of antibody-based product candidates we are developing on our own (without a collaborator), and expenses for which we are responsible in accordance with the terms of our collaboration agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our existing capital resources and our current and anticipated revenues will be sufficient to meet our operating needs. We may require additional financing in the future and we may not be able to raise additional funds on acceptable terms or at all. For example, there is no guarantee that we will have the ability to pay the principal amount due on the Notes at maturity or redeem, repurchase, or refinance the Notes prior to maturity on acceptable terms or at all. In addition, in March 2017, we completed a $720.0 million lease financing for our existing corporate headquarters and other rentable area consisting of approximately 150 acres of predominately office buildings and laboratory space located in Tarrytown, New York, which will become due and payable in full on the five-year anniversary of the closing date unless extended with the consent of all the participants and subject to certain other conditions. Our ability to refinance or to obtain additional financing could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. Volatility in the financial markets could increase borrowing costs or affect our ability to raise capital. If additional financing is necessary and we obtain it through the sale of equity securities, such sales will likely be dilutive to our shareholders. Debt financing arrangements may require us to pledge certain assets or enter into covenants that would restrict our business activities or our ability to incur further indebtedness and may be at interest rates and contain other terms that are not favorable to our shareholders. Should we require and be unable to raise sufficient funds (i) to complete the development of our product candidates, (ii) to successfully commercialize our product candidates or new indications for our marketed products if they obtain regulatory approval, and (iii) to continue our manufacturing and marketing of our marketed products, we may face delay, reduction, or elimination of our research and development or preclinical or clinical programs and our commercialization activities, which would significantly limit our potential to generate revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our indebtedness could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have certain indebtedness and contingent liabilities, including milestone and royalty payment obligations. As of September 30, 2020, we had an aggregate of $2.695 billion of outstanding indebtedness under the Notes and the lease financing facility. We may also incur additional debt in the future. Any such indebtedness could:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development, and mergers and acquisitions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to competitors that have less debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in foreign currency exchange rates could have a material adverse effect on our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue from outside of the United States will increase as our products, whether marketed or otherwise commercialized by us or our collaborators, gain marketing approval in such jurisdictions. Our primary foreign currency exposure relates to movements in the Japanese yen, euro, British pound sterling, Canadian dollar, and Australian dollar. If the U.S. dollar weakens against a specific foreign currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase, having a negative impact. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive impact. Therefore, significant changes in foreign exchange rates can impact our operating results and the financial condition of our Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $1.573 billion in cash and cash equivalents and $4.328 billion in marketable securities (including $777.6 million in equity securities). Our investments consist primarily of debt securities, including investment-grade corporate bonds. These fixed-income investments are subject to external factors that may adversely affect their market value or liquidity, such as interest rate, liquidity, market, and issuer credit risks, including actual or anticipated changes in credit ratings. The equity securities we hold may experience significant volatility and may decline in value or become worthless if the issuer experiences an adverse development. Furthermore, our equity investments could be subject to dilution (and decline in value) as a result of the issuance of additional equity interests by the applicable issuer. If any of our investments suffer market price declines, such declines may have an adverse effect on our financial condition and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The elimination of LIBOR could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the United Kingdom regulator that regulates the London Interbank Offered Rate ("LIBOR") announced its intention to phase out LIBOR rates by the end of 2021. No consensus exists as to what rate or rates may become accepted alternatives to LIBOR or whether LIBOR rates will cease to be published or supported before or after 2021. A transition away from&#160;LIBOR&#160;as a benchmark for establishing the applicable interest rate may&#160;adversely&#160;affect our outstanding variable-rate indebtedness and interest rate swaps, as well as floating-rate debt securities we hold. For example, if a published U.S. dollar LIBOR rate is unavailable after 2021, the rent payments for the leased facilities in Tarrytown, New York and interest for borrowings (if any) with an interest rate based on the LIBOR rate under our revolving credit facility, all of which are indexed to LIBOR, will be determined using various alternative methods, any of which may result in interest obligations which are more than, or do not otherwise correlate over time with, the payments that would have been made on such debt if U.S. dollar LIBOR was available in its current form.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is extremely volatile.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been significant volatility in our stock price and generally in the market prices of biotechnology companies' securities. Various factors and events may have a significant impact on the market price of our Common Stock. These factors include, by way of example:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, Dupixent, and Libtayo, as well as our overall operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of, and the market share for, our marketed products, especially EYLEA, Dupixent, and Libtayo;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of technological innovations or product candidates by us or competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims by others that our products or technologies infringe their patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges by others to our patents in the EPO and in the USPTO;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety or effectiveness of any of our marketed products or product candidates or new indications for our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement actions, decisions, or recommendations by government authorities, insurers, or other organizations (such as health maintenance organizations and pharmacy benefit management companies) affecting the coverage, reimbursement, or use of any of our marketed products or competitors' products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital as needed on favorable terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with collaborators or key customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology industry or in government regulation of healthcare, including those relating to compounding (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a practice in which a pharmacist, a physician, or, in the case of an outsourcing facility, a person under the supervision of a pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">large sales of our Common Stock by our executive officers or other employees, directors, or significant shareholders (or the expectation of any such sales);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax rates, laws, or interpretation of tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrivals and departures of key personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repurchase our Common Stock under any share repurchase program on favorable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity that results from the rebalancing of stock indices in which our Common Stock is included, or the inclusion or exclusion of our Common Stock from such indices; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors identified in these "Risk Factors"; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by the investment community or our shareholders of any of the foregoing factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Common Stock has been, and could continue to be, subject to wide fluctuations in response to these and other factors, including the sale or attempted sale of a large amount of our Common Stock in the market. As discussed in greater detail under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below, a large percentage of our Common Stock is owned by a small number of our principal shareholders. As a result, the public float of our Common Stock (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the portion of our Common Stock held by public investors, as opposed to the Common Stock held by our directors, officers, and principal shareholders) may be lower than the public float of other large public companies with broader public ownership. Therefore, the trading price of our Common Stock may fluctuate significantly more than the stock market as a whole. These factors may exacerbate the volatility in the trading price of our Common Stock and may negatively impact your ability to liquidate your investment in Regeneron at the time you wish at a price you consider satisfactory. Broad market fluctuations may also adversely affect the market price of our Common Stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation, which may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A small number of our shareholders beneficially own a substantial amount of our Common Stock. As of September&#160;30, 2020, our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 39.0% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of September&#160;30, 2020. If our significant shareholders or we sell substantial amounts of our Common Stock in the public market, or there is a perception that such sales may occur, the market price of our Common Stock could fall. Sales of Common Stock by our significant shareholders also might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors previously authorized a share repurchase program to repurchase up to $1.0 billion of our Common Stock (of which $372.7 million remained available as of September&#160;30, 2020). Any share repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, our results of operations and financial condition, the price of our Common Stock on the NASDAQ Global Select Market, and other factors that we may deem relevant. We can provide no assurance that we will continue to repurchase shares of our Common Stock at favorable prices, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing shareholders may be able to exert significant influence over matters requiring shareholder approval and over our management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A Stock, who are generally the shareholders who purchased their stock from us before our initial public offering, are entitled to ten votes per share, while holders of Common Stock are entitled to one vote per share. As of September&#160;30, 2020, holders of Class A Stock held 15.0% of the combined voting power of all shares of Common Stock and Class A Stock then outstanding. These shareholders, if acting together, would be in a position to significantly influence the election of our directors and the vote on certain corporate transactions that require majority or supermajority approval of the combined classes, including mergers and other business combinations. This may result in our taking corporate actions that other shareholders may not consider to be in their best interest and may affect the price of our Common Stock. As of September&#160;30, 2020:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current executive officers and directors beneficially owned 8.5% of our outstanding shares of Common Stock, assuming conversion of their Class A Stock into Common Stock and the exercise of all options held by such persons which are exercisable within 60 days of September&#160;30, 2020, and 19.8% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by such persons which are exercisable within 60 days of September&#160;30, 2020; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 39.0% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of September&#160;30, 2020. In addition, these five shareholders plus our Chief Executive Officer held approximately 46.2% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by our Chief Executive Officer which are exercisable within 60 days of September&#160;30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, our by-laws, and the New York Business Corporation Law contain various provisions that could have the effect of delaying or preventing a change in control of our Company or our management that shareholders may consider favorable or beneficial. Some of these provisions could discourage proxy contests and make it more difficult for shareholders to elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock. These provisions include:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorization to issue "blank check" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under the New York Business Corporation Law, in addition to certain restrictions which may apply to "business combinations" involving our Company and an "interested shareholder," a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon. See the risk factor above captioned "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our existing shareholders may be able to exert significant influence over matters requiring shareholder approval and over our management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the January 2014 amended and restated investor agreement between us and Sanofi, as amended, Sanofi is bound by certain "standstill" provisions, which contractually prohibit Sanofi from seeking to directly or indirectly exert control of our Company or acquiring more than 30% of our Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the later of the fifth anniversaries of the expiration or earlier termination of our License and Collaboration Agreement with Sanofi relating to our Antibody Collaboration or our ZALTRAP collaboration agreement with Sanofi, each as amended; (ii) our announcement recommending acceptance by our shareholders of a tender offer or exchange offer that, if consummated, would constitute a change of control involving us; (iii) the public announcement of any definitive agreement providing for a change of control involving us; (iv) the date of any issuance of shares of Common Stock by us that would result in another party having more than 10% of the voting power of our outstanding Class A Stock and Common Stock (taken together) unless such party enters into a standstill agreement containing certain terms substantially similar to the standstill obligations of Sanofi; or (v) other specified events, such as a liquidation or dissolution of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, pursuant to our 2016 ANG2 license and collaboration agreement with Bayer (which was terminated on November 1, 2018 by agreement of the parties but whose "standstill" provisions continue to be in effect as described below), Bayer is bound by certain "standstill" provisions, which contractually prohibit Bayer from seeking to influence the control of our Company or acquiring more than 20% of our outstanding Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) November 1, 2023; (ii) the public announcement of a tender offer, exchange offer, or other proposal that would constitute a change of control of our Company; (iii) the acquisition by a third party or a group of third parties (other than by Dr. Schleifer or his affiliates) of more than 20% of the voting power of our outstanding Class A Stock and Common Stock (taken together); (iv) the issuance of shares of capital stock to another party (other than to an underwriter in a public offering) that would result in such party's having more than 7% of the voting power of our outstanding Class A Stock and Common Stock (taken together) unless such third party enters into a standstill agreement containing terms substantially similar to the standstill obligations of Bayer; or (v) other specified events, such as a liquidation or dissolution of our Company. A similar "standstill" prohibition applies to Bayer pursuant to our 2014 PDGFR-beta license and collaboration agreement with Bayer (which agreement was terminated on July 31, 2017 by agreement of the parties but whose "standstill" provisions continue to be in effect until July 31, 2022 unless they expire earlier upon the occurrence of certain specified events).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, pursuant to the 2016 collaboration agreement between us and Teva, Teva and its affiliates are bound by certain "standstill" provisions, which contractually prohibit them from seeking to directly or indirectly exert control of our Company or acquiring more than 5% of our Class A Stock and Common Stock (taken together). This prohibition will remain in place until the earliest of (i) the fifth anniversary of the expiration or earlier termination of the agreement; (ii) our announcement recommending acceptance by our shareholders of a tender offer or exchange offer that, if consummated, would constitute a change of control involving us; (iii) the public announcement of any definitive agreement providing for a change of control involving us; (iv) the acquisition by a third party or a group of third parties of more than 30% of the voting power of our outstanding Class A Stock and Common Stock (taken together); (v) the date of any issuance of shares of capital stock by us that would result in another party having more than 10% of the voting power of our outstanding Class A Stock and Common Stock (taken together) unless such party enters into a standstill agreement containing certain terms substantially similar to the standstill obligations of Teva; or (vi) other specified events, such as a liquidation or dissolution of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Change in Control Severance Plan and the employment agreement with our Chief Executive Officer, each as amended and restated, provide for severance benefits in the event of termination as a result of a change in control of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. Also, equity awards issued under our long-term incentive plans may become fully vested in connection with a "change in control" of our Company, as defined in the plans. These contractual provisions may also have the effect of deterring, delaying, or preventing an acquisition or other change in control.</span></div><div id="ibab647050bc248e3930163531a1d57d8_109"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted equity awards granted under one of our long-term incentive plans, during the three months ended September 30, 2020. Refer to Part I, Item 2. "Liquidity and Capital Resources" for further information.</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of a Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/1/2020&#8211;7/31/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,117,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2020&#8211;9/30/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,677,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is related to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock awards or restricted stock units granted under one of our long-term incentive plans.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.380%"><tr><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">Indenture, dated August 12, 2020, between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">Regeneron Pharmaceuticals, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">"</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm">")</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-1.htm"> and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">First Supplemental Indenture, dated August 12, 2020, between the Registrant and U.S. Bank National Association. (Incorporated by reference from the Form 8-K for the Registrant, filed August 12, 2020.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">Form of 1.750% Senior Note due 2030 (included in Exhibit 4.2).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/872589/000110465920093924/tm2027319d1_ex4-2.htm">Form of 2.800% Senior Note due 2050 (included in Exhibit 4.2).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex101x09302020x10q.htm">Base Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex102x09302020x10q.htm">Project Agreement, dated as of July 6, 2020, by and between the Registrant and Advanced Technology International.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex103x09302020x10q.htm">License Agreement, dated as of August 18, 2020, by and among the Registrant, F. Hoffman-La Roche Ltd, and Genentech, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex311x09302020x10q.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex312x09302020x10q.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex32x09302020x10q.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2020 and 2019; (iii) the Registrant's Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2020 and 2019; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="ibab647050bc248e3930163531a1d57d8_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibab647050bc248e3930163531a1d57d8_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGENERON PHARMACEUTICALS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Duly Authorized Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>regn-ex101x09302020x10q.htm
<DESCRIPTION>BASE AGREEMENT BY AND BETWEEN THE REGISTRANT AND ATI
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6e83dc7d5cfd461ab7794fe52340835e_1"></div><div style="min-height:72pt;width:100%"><div style="padding-right:52pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div style="padding-right:52pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div><div style="padding-right:52pt;text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div><div style="margin-top:4.55pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">BASE AGREEMENT </font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">BETWEEN</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVANCED TECHNOLOGY INTERNATIONAL (ATI) </font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">315 SIGMA DRIVE</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">SUMMERVILLE, SC 29486 </font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">AND</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regeneron Pharmaceuticals, Inc.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">777 Old Saw Mill River Road</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tarrytown, NY 10591</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO.&#58; 2020-504</font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authority&#58; MCDC Other Transaction Agreement (OTA) No. W15QKN-16-9-1002 and 10 U.S.C. &#167; 2371b, Section 815 of the 2016 National Defense Authorization Act (NDAA), Public Law (P.L.) 114-92.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_4"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 2 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:11.6pt;padding-right:69.1pt;text-align:justify;text-indent:0.05pt"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">This Agreement </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">is </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">entered into between the Advanced Technology International hereinafter referred </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">to as </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">the &#34;Consortium Management Finn (CMF),&#34; and </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%;text-decoration:underline">Regeneron Pharmaceuticals. Inc</font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">, hereinafter referred </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">to </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">as &#34;Project Agreement Holder.&#34; This Agreement constitutes the entire understanding and agreement between the </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">parties </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">with </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">respect </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">to the </font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">su</font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">bject </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">matter hereof and supersedes all prior representations and </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">agreements. </font><font style="color:#464646;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:118%">It </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">shall </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">not be varied </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">except by an instrument in writing of subsequent date duly executed by </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">an </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">authorized representative </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">of </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">each </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">of </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">the parties. </font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">The </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">validity, construction, scope and performance of this Agreement </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">shall </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">be governed </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">by the </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">laws </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">of the </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">state </font><font style="color:#363636;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">o</font><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">f </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">South Carolina, </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">excluding its choice of </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">laws </font><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:118%">rules.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.304%"><tr><td style="width:1.0%"></td><td style="width:44.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVANCED TECHNOLOGY INTERNATIONAL</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#47;s&#47; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Signature)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#47;s&#47; Robert Landry&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Signature)</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Name &#38; Title)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Robert Landry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Vice President, Finance and Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Name &#38; Title)</font></div><div><font><br></font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 6 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Date)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">July 6 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(Date)</font></div></td></tr></table></div><div style="height:58pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_10"></div><hr style="page-break-after:always"><div style="min-height:67.59pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 3 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article I.</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">SCOPE OF THE AGREEMENT</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 1.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Background</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 1.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_13" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Definitions</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_22" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 1.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_22" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_22" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Scope</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_25" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 1.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_25" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_25" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Goals&#47;Objectives</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_28" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 1.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_28" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_28" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Reports</a></font></div><div style="margin-top:6pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article II.   TERM</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">The Term of this Agreement</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Termination of this Agreement by Mutual Agreement</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_34" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Termination Provisions</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Termination Cost</a></font></div><div style="margin-top:6.05pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Close-out Procedure.</a></font></div><div style="margin-top:6.1pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 2.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_40" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Stop Work</a></font></div><div style="margin-top:6pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article III.  MANAGEMENT OF THE PROJECT</font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 3.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">The Medical CBRN Defense Consortium (MCDC)</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 3.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">The following MCDC decisions are subject to the ACC-NJ approval</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 3.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_43" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Management and Project Structure</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_46" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 3.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_46" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_46" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Modifications</a></font></div><div style="margin-top:6.05pt;padding-left:9.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article IV. AGREEMENT ADMINISTRATION</a></font></div><div style="margin-top:6.1pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article V.   OBLIGATION AND PAYMENT</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Obligation</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Project Payments</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_49" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Accounting System Requirements</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_52" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_52" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_52" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Invoicing Instructions</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Advance Payments&#58;</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_58" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Limitation of Funds</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_61" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 5.07</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_61" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_61" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Financial Records and Reports</a></font></div><div style="margin-top:6pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_61" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article VI.  NONTRADITIONAL DEFENSE&#47;COST SHARING</a></font></div><div style="margin-top:6.15pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article VII.  DISPUTES</font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.01&#160;&#160;&#160;&#160;General</font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 7.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Dispute Resolution Procedures</a></font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:20.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 7.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_64" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Limitation of Liability and Damages</a></font></div><div style="margin-top:4.2pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article VIII.  CONFIDENTIAL INFORMATION</a></font></div><div style="height:81.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.59pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 4 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Definitions</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Exchange of Information</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_67" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Authorized Disclosure</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Return of Proprietary Information</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Term</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 8.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Flow Down</a></font></div><div style="margin-top:6pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article IX.  PUBLICATION AND ACADEMIC RIGHTS</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 9.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Use of Information</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 9.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_70" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Publication or Public Disclosure of Information</a></font></div><div style="margin-top:6pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article X.   PATENT RIGHTS</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Definitions</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Allocation of Principal Rights</a></font></div><div style="margin-top:6.05pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_76" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Invention Disclosure, Election of Title, and Filing of Patent Application</a></font></div><div style="margin-top:6.1pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Conditions When the Government May Obtain Title</a></font></div><div style="margin-top:6.25pt;padding-left:96.45pt;padding-right:61.45pt;text-indent:-76.45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:124%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:124%;text-decoration:none">Section 10.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:124%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_79" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:124%;text-decoration:none">Minimum Rights to the MCDC PAH and Protection of the MCDC PAH&#8217;s Right to File</a></font></div><div style="margin-top:5.1pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Action to Protect the Government&#8217;s Interest</a></font></div><div style="margin-top:6.05pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.07</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Lower Tier Agreements</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.08</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_82" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Reporting on Utilization of Subject Inventions</a></font></div><div style="margin-top:6.1pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.09</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Preference for American Industry</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.10</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">March-in Rights</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.11</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Opportunity to Cure</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.12</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_85" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Background Information</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 10.13</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Survival Rights</a></font></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XI. DATA RIGHTS</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_88" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Definitions</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_91" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_91" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_91" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Data Categories</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_94" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_94" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_94" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Allocation of Principal Rights</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_97" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_97" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_97" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Marking of Data</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Copyright</a></font></div><div style="margin-top:6.05pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Data First Produced by the Government</a></font></div><div style="margin-bottom:6.85pt;margin-top:6.1pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.07</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_100" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Prior Technology</a></font></div><div style="margin-top:4.2pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.08</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Lower Tier Agreements</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 11.09</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Survival Rights</a></font></div><div style="height:81.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.59pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 5 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XII.</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_103" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">EXPORT CONTROL</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XIII.   TITLE AND DISPOSITION OF PROPERTY</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 13.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Definitions</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 13.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Title to Property</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 13.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Government Furnished Property</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_106" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XIV.   CIVIL RIGHTS ACT</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_109" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XV.</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_109" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_109" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">NO SMALL BUSINESS AFFILIATION</a></font></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_109" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XVI.  ANTITRUST</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_109" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XVII.  SECURITY &#38; OPSEC</a></font></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XVIII. SAFETY</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XIX.   REPRESENTATIONS AND WARRANTIES</a></font></div><div style="margin-top:6.05pt;padding-left:19.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 19.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Representations and Warranties of All Parties</a></font></div><div style="margin-top:6.1pt;padding-left:19.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 19.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_121" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Limitations</a></font></div><div style="margin-top:6.05pt;padding-left:8.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XX.</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">LIABILITY OF THE PARTIES</a></font></div><div style="margin-top:6.1pt;padding-left:19.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 20.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Waiver of Liability</a></font></div><div style="margin-top:6.05pt;padding-left:19.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 20.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Damages</a></font></div><div style="margin-top:6.1pt;padding-left:19.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 20.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Extension of Waiver of Liability</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 20.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Applicability</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 20.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Limitation of Liability</a></font></div><div style="margin-top:6.15pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XXI.  GENERAL PROVISIONS</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Fees</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.02</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Waiver</a></font></div><div style="margin-top:6pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.03</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_124" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section Headings</a></font></div><div style="margin-top:6.15pt;padding-left:20.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.04</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Severability</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.05</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Force Majeure</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.06</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Regulatory Affairs</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.07</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Radioactive Materials</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.08</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_127" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Recombinant DNA</a></font></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.09</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Required Compliance for Use of Laboratory Animals</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.10</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Required Compliance for Use of Human Subjects</a></font></div><div style="margin-bottom:1pt;margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.11</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Required Compliance for use of Human Anatomical Substances</a></font></div><div style="margin-top:4.2pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.12</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_130" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Compliance with current Good Manufacturing Processes (cGMP)</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.13</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Registration with Select Agent Program</a></font></div><div style="height:81.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.59pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 6 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:6.15pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.14</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_133" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Duty-Free Entry</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 21.15</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Follow-On Production</a></font></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XXII. ASSIGNMENT OF AGENCY</a></font></div><div style="margin-top:6pt;padding-left:20pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Section 22.01</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a><a href="#i6e83dc7d5cfd461ab7794fe52340835e_139" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Assignment</a></font></div><div style="margin-top:6.15pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_142" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XXIII. ORDER OF PRECEDENCE</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_142" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Article XXIV.EXECUTION</a></font></div><div style="margin-top:6pt;padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><a href="#i6e83dc7d5cfd461ab7794fe52340835e_145" style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:none">Attachment I &#8211; Assurance of Compliance with Title VI of the Civil Rights Act of 1964</a></font></div><div><font><br></font></div><div style="height:81.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_13"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 7 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article I.&#160;&#160;&#160;&#160;SCOPE OF THE AGREEMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.01 Background</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Army Contracting Command-New Jersey (ACC-NJ) is entering into a Section 815 Prototype Other Transaction Agreement (OTA) with the Medical CBRN Defense Consortium, c&#47;o Advanced Technology International 315 Sigma Drive, Summerville, SC 29486. The Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) through the Joint Program Executive Office for Chemical and Biological Defense (JPEO- CBD) seeks to collaborate with the MCDC to carry out a coordinated research and development program. An OTA is being proposed with the purpose of conducting Research and Development into medical, pharmaceutical, and diagnostic technologies to enhance mission effectiveness of military personnel. The MCDC was formed in response to the Government&#8217;s expressed interest to engage with an industry consortium comprised of traditional and nontraditional government contractors, small and large businesses, for-profit and not-for-profit entities, academic organizations and their affiliates for the purpose of entering into an OTA for prototype projects.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the OTA and associated awards, the Government, along with the non-government members from the MCDC, shall perform coordinated planning and research and development prototype efforts designed to encompass the areas contained within the scope of this OTA as listed in Article I, Section 1.03.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.02 Definitions</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Academic Research Institution&#8221; means accredited institutions (colleges, universities or other educational institutions) of higher learning in the U.S.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Agreement&#8221; refers to the Base Agreement between the Medical CBRN Defense Consortium (MCDC) Consortium Management Firm (CMF) Advanced Technology International (ATI) and the Project Agreement Holder.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Agreements Officer (AO)&#8221; is the U.S. Army Contracting Command &#8211; New Jersey&#8217;s warranted Contracting Officer authorized to sign the final OTA for the Government.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Agreements Officer Representative (AOR)&#8221; is the individual designated by the Government on a per project basis to monitor all technical aspects and assist in agreement administration of the specific project&#59; the AOR shall only assist in agreement administration of the specific project to the extent delegated such administration authority in writing in the AOR delegation letter by the responsible Agreements Officer.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Basket&#8221; is an electronic file containing proposals that have been submitted by MCDC Members in response to Requests for Prototype Proposals (RPP), reviewed by the Government, and favorably evaluated in accordance with the procedures outlined in Section 1.03 of this Article.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Cash Contribution&#8221; means a MCDC member organization&#8217;s financial resources expended to conduct a project awarded under this Agreement. The cash contribution can be derived from MCDC member organization funds or outside sources or may also come from non-federal contract or grant revenues or from profit or fee on a federal procurement contract. A MCDC member organization&#8217;s own source of funds may include corporate retained earnings, current or prospective Independent Research and Development (IR&#38;D) funds or any other indirect cost pool allocation. New or concurrent IR&#38;D funds can be utilized as a cash contribution provided those funds identified by the MCDC member organization are to be spent on the conduct of a project&#8217;s Statement of Work. Prior IR&#38;D will not be considered as part of the MCDC member organization&#8217;s cash or in kind contributions nor will fee be considered on the Project Awards that include cost sharing. Cash contributions include the funds a MCDC member organization will spend for labor (including benefits and direct overhead), materials, new equipment (prorated if appropriate), subcontractor efforts expended on a project, and restocking the parts and material consumed under a project.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Consortium Management Firm (CMF)&#8221; refers to the organization acting on behalf of the MCDC to execute and administer the efforts under the Other Transaction Agreement for this program as defined in the specific agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_16"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 8 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entered into between the MCDC and the CMF. The current CMF is Advanced Technology International (ATI). The MCDC reserves the right to replace the CMF at any time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Cost Share&#8221; means resources expended by the PAH on the proposed project SOW and subject to the direction of the AOR. There are two kinds of cost share&#58; cash contribution and in-kind contribution. Cost Share may only be proposed and collected on cost-reimbursement type agreements.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Contracting Activity&#8221; means an element of an agency designated by the agency head and delegated broad authority regarding acquisition functions. It also means elements or another agency designated by the director of a defense agency which has been delegated contracting authority through its agency charter.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:61.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Date of Completion&#8221; is the date on which all work is completed or the date on which the period of performance ends.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Development&#8221; means the systematic use, under whatever name, of scientific and technical knowledge in the design, development, test, or evaluation of an existing or potential new technology, product or service (or of an improvement in an existing technology, product or service) for the purpose of meeting specific performance requirements or objectives. Development includes the research functions of design engineering, prototyping, and engineering testing.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.95pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Effective Date&#8221; means the date when this Agreement is signed and executed by the Agreements Officer for the Government.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Government&#8221; means the US Government and its departments and agencies.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Government Fiscal Year&#8221; means the period commencing on October 1 and ending September 30 of the following calendar year.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.55pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;In Kind Contribution&#8221; means the MCDC member organization&#8217;s nonfinancial resources expended by the MCDC member organization to conduct a project, such as wear and tear on in-place capital assets like machinery or the prorated value of space used for the conduct of a project, and the reasonable fair market value (appropriately prorated) of equipment, materials, and other property used in the conduct of the project.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;JPM-MCS&#8221; means the Joint Project Manager-Medical Countermeasure Systems Office created for the advanced development of medical countermeasures for chemical and biological defense. The JPM-MCS is also the program management office for this overall effort. The JPM-MCS includes an array of stakeholders involved in the development of prototype hardware, software, and system technologies.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Milestone&#8221; means a scheduled event signifying the completion of a major deliverable or a set of related deliverables.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.75pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Medical CBRN Defense Consortium&#8221; is the consortium formed by industry in response to the Government&#8217;s expressed interest to quickly provide the warfighter with safe and effective chemical, biological, radiological, and nuclear countermeasures. The MCDC is comprised of Traditional and Nontraditional Defense Contractors,  including small and large (other than small) businesses, for profit, and not for profit entities, and academic research institutions. The MCDC was originally named the National Chemical and Biologic Defense Consortium.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;MCDC Executive Committee&#8221; is the Executive Committee, comprised of Traditional and Nontraditional Defense Contractors, including small and large businesses, for profit and not for profit entities, and academic research institutions.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;MCDC Members&#8221; means the Nontraditional and Traditional Defense Contractors, including small and large businesses, for profit and not for profit entities, and Academic Research Institutions that are members in good standing of the MCDC.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_19"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 9 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Nontraditional Defense Contractor&#8221; with respect to applicable authority, means an entity that is not currently performing and has not performed, for at least the one-year period preceding the solicitation of sources by the Department of Defense for the procurement or transaction, any contract or subcontract for the Department of Defense that is subject to full coverage under the cost accounting standards prescribed pursuant to section 1502 of title 41 and the regulations implementing such section.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other Transaction Agreement (OTA)&#8221; refers to the Section 815 Other Transaction Agreement between the Government and the MCDC by its Consortium Management Firm, Advanced Technology International, Agreement No. W15QKN-16-9-1002.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other Transactions for Prototype Projects&#8221; refers to this type of Other Transaction Agreement (OTA). Section 815 of Public Law 114-92 authorizes the use of OTAs, under the authority of 10 U.S.C. 2371(b), under certain circumstances for prototype projects directly relevant to enhancing the mission effectiveness of military personnel and supporting the platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the armed forces. This type of OTA is treated by DoD as an acquisition instrument, commonly referred to as an &#8220;other transaction&#8221; for a prototype project or Section 815 &#8220;other transaction&#8221;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Parties&#8221; means the Consortium Management Firm, Advanced Technology International, and the Project Agreement Holder where collectively identified and &#8220;Party&#8221; where each entity is individually identified.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Payable Milestone&#8221; means that once a milestone has been met (see definition of &#8220;milestone&#8221;), the Government can approve payment to the MCDC of a predetermined dollar amount in relation to performance of a particular project under the Other Transaction Agreement.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Program Manager&#8221; means the Technical Administrator for the Program (located at the JPM-MCS) responsible for Government oversight of the MCDC OTA program.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Project&#8221; refers to the scope of work being completed under a Project Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Project Agreement (PA)&#8221; means that agreement between the MCDC, by its CMF, and the MCDC member entity whose proposal is evaluated and competitively selected by the Government for funding, establishing the scope of work, terms and conditions for the MCDC member entity performance and payment under the Government funded project. Project Agreements shall comply with all provisions contained within the OTA and any other supporting documents referenced therein. The Project Agreement is initiated by the CMF based on the Technical Direction Letter sent by the Government to the CMF.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Project Agreement Holder (PAH)&#8221; means the MCDC member entity issued a Project Agreement by the CMF.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Technical Direction Letter (TDL)&#8221; is a Government document to be issued to the CMF reflecting the Government's decision to select and fund all or part of a particular proposal submitted by a MCDC member or team of MCDC members through the RPP process conducted under this OTA. The TDL shall establish the scope of work, terms and conditions for performance and payment and include the MCDC member proposal selected for Government funding. Where a specific Government agency laboratory, test facility, center or other location will be used by the MCDC member entity in performance of the Project Agreement, it will be identified and the cost of such use, whether Government-contributed or MCDC member reimbursed, will be identified in the TDL.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;United States Army Contracting Command &#8211; New Jersey Contracting Activity&#8221; (ACC-NJ) means the contracting activity who is designated as the lead Government organization in charge of executing the Program.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;White Paper&#8221; means a document limited to a few pages prepared and submitted by a MCDC member(s) in response to a Government solicitation issued under the terms and conditions of the OTA that briefly describes and summarizes a technology idea or concept for an indicated research area in a Government-specified format. The White Papers are evaluated by the Government to determine whether submission of a full proposal on the summarized concept or idea might be warranted. To the extent that a MCDC member(s) desires to include </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 10 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proprietary information in the white paper it shall be identified and marked in accordance with the terms for protection of information under Article VIII. Confidential Information.</font></div><div style="text-align:justify"><font><br></font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_22"></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.03 Scope</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government in conjunction with the MCDC member entities shall perform a coordinated research and development program designed to support the DoD&#8217;s medical, pharmaceutical, and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. The mission of JPM-MCS is to provide the</font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. military forces and the nation safe, effective, and innovative medical solutions to counter Chemical Biological Radiological and Nuclear (CBRN) threats. Under the OTA and associated Project Agreements, the Government along with the Consortium member entities, shall perform coordinated planning and research and development prototype efforts in support of the JPM-MCS mission through the development of products in three (3) major Medical Countermeasure Systems (MCS) objective areas&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:80.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">Detection&#58; Systems and devices to identify CBRN agents and assist in making medical decisions</font></div><div style="padding-left:80.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.5pt">Prevention&#58; Prophylaxis, pretreatment, and post-exposure prophylaxis</font></div><div style="padding-left:80.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treatment&#58; Therapeutics (post-exposure, post-symptomatic)</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government will determine which endeavors to pursue and projects to fund. At any time throughout the term of the OTA, the Government may address the needs for the desired MCS objective areas or other related Government needs as they arise. The MCDC and the Government agree that other organizations and agencies within the U.S. Government may participate in the collaborative activities through a Memorandum of Agreement or other such arrangement. It is anticipated that these other organizations may include JPEO-CBD and DTRA.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Request for Prototype Proposal (RPP) Process&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the Government identifies a need under one of the MCS objective areas above, the Government will issue a Request for Prototype Proposal (RPP). The RPP will include a Request for White Papers (RWP) and&#47;or a Request for Prototype Proposal (RPP) to the Consortium Management Firm (CMF). Due dates will be indicated for each. The CMF shall in turn issue a similar request to MCDC&#8217;s member entities, for which the Government will review and evaluate all responses. The Government will be solely responsible for evaluation of the white papers and&#47;or proposal submissions, as applicable. If the RPP includes a RWP, only members submitting white papers will be permitted to submit full proposal submissions. Based on the evaluation of the white papers, the Government will make a recommendation on whether the member should or should not submit a full proposal submission. Any member submitting a white paper, regardless of the Government&#8217;s recommendation, may submit a proposal.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCDC member white papers and proposals shall be submitted to the CMF in accordance with the RPP instructions which will include evaluation criteria and a Statement of Work (SOW) template on the due date indicated in the RPP. The CMF will review white paper and proposal submissions for completeness and format compliance. The CMF shall in turn prepare and transmit MCDC&#8217;s member&#8217;s white papers and proposals to the Government for evaluation. The Government will be responsible for technical evaluation and selection of the projects from the proposals submitted. The CMF will assess the reasonableness and completeness of the cost estimates and then provide a formal assessment to the Government. The Government Agreement Officer will review this assessment and make the final determination regarding whether the negotiated project cost is fair and reasonable. All Project Agreements will be subject to discussions&#47;negotiations and proposal updates, as appropriate, prior to execution.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once all steps are complete, the Government will issue a Technical Direction Letter (TDL) to the CMF for the authorization and execution of the selected project to be performed by the selected MCDC&#8217;s member entity(ies). Once the CMF receives notification of selection of a project for funding via TDL, the CMF will enter into a Project Agreement with the MCDC member.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A modification will be included with the TDL, which will include the funding for the negotiated and agreed-upon project. After receipt of the TDL and review and execution of the funding modification, the CMF shall enter into a Project Agreement (PA) with MCDC member whose project was selected. MCDC CMF shall administer the </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 11 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government-funded Project Agreements. The Government's designated Agreements Officer Representative (AOR) for the specific project will supervise the technical work performed by MCDC&#8217;s member entity in execution of the</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_25"></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PA. The Government reserves the right to revise the terms and conditions of these projects in accordance with Article III, Section 3.04.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Placement in the Electronic &#8220;Basket File&#8221;&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qualifying proposals, not eligible for current funding, may be entered into an electronic basket and subject to award for up to thirty-six (36) months. The RPP will contain the available ratings and their definitions to be assigned to proposals as a result of the technical evaluation as well as which specific ratings will qualify a proposal for inclusion in the Basket. The Government reserves the right to determine which, if any, proposals are to be selected according to the published criteria.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once in the Basket, a proposal may be identified for award by the Government based on Government need and availability of funding. The Government reserves the right to 1.) request that the MCDC member who submitted the identified proposal, scale or otherwise adjust the original proposal, and to 2.) fund all or part of the identified proposal. The MCDC member will have an opportunity to update their proposal, as applicable, if selected from the basket. The Government will review any updated information provided by the MCDC member and&#47;or CMF. Upon the Government&#8217;s decision to fund such a proposal from the Basket, the CMF will receive notification of the award decision through a TDL whereupon the CMF will enter into a Project Agreement with the indicated MCDC member as required.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A selected proposal will reside in the Basket for thirty-six (36) months from the date the corresponding RPP is closed unless funded or the submitting MCDC member requests in writing beforehand to have it removed.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBIR Phase III Project Requests</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It will be incumbent upon the MCDC member, on their own with some general support and guidance from the CMF, to find a Government Technical POC with both (1) available funding and (2) an interest in furthering technology developed under a current or prior SBIR project. Upon doing so, the Government Technical POC will coordinate the feasibility of placing the award under the OTA with the Government AO and OTA Program Manager and the following areas will be considered when making a determination for appropriateness of award under the OTA&#58;</font></div><div style="margin-top:6.1pt;padding-left:44.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.55pt">How the proposed effort derives from, extends, or logically concludes efforts performed under prior SBIR funding agreements&#59;</font></div><div style="margin-top:5.95pt;padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.55pt">How the proposed effort fits within the definition of a prototype effort related to medical, pharmaceutical, and diagnostic technologies to enhance mission effectiveness of military personnel in accordance with the statutory requirement&#59;</font></div><div style="margin-top:6.05pt;padding-left:44.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.55pt">How the proposed effort fits within the overall scope of work and the goals and objectives of the OTA.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the Government AO and the OTA Program Manager determine it is appropriate to award the SBIR Phase III under the OTA, the Government AO will send a proposal request to the MCDC member through the CMF, as is standard for any Government request under the OTA. The CMF will provide a cost analysis summary to the Government Agreements Officer (AO) for consideration in the Government&#8217;s award determination. The Government will evaluate the proposal, conduct any necessary negotiations through the CMF, and make an award determination. If the Government makes the determination to award to the MCDC member, the Government AO will issue a TDL letter to the CMF, resulting in the issuance of a Project Agreement between the CMF and MCDC member.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBIR Phase III awards under this Agreement shall include the Data Rights provisions and Data Rights granted to the MCDC member contained within Article XI of this Agreement. All administrative, reporting, and other aspects of awards made for SBIR Phase III efforts under this Agreement will be in accordance with the terms and conditions of the OTA. MCDC Members must have been awarded and performed under a previous SBIR Phase I and&#47;or Phase II contract in order to qualify for SBIR Phase III award under this Agreement.</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 12 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.04 Goals&#47;Objectives</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_28"></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following goals&#47;objectives will be pursued through the execution of the OTA&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:62.95pt;padding-right:60.85pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerate the development of mission critical technologies in the areas of concern from applied research into advanced development.</font></div><div style="padding-left:62.95pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deliver therapeutic MCM prototypes targeting viral, bacterial, and  biological toxin targets of interest to the DOD. MCM prototypes are drug products that have completed all or part of the activities required to support FDA licensure. This may include meeting warfighter requirements of protection against an aerosolized route of exposure.</font></div><div style="padding-left:62.95pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deliver enabling technologies that will support the development and regulatory review of MCM prototypes. The enabling technologies can include animal models of viral, bacterial or biological toxin disease and pathogenesis (multiple routes of exposure), assays, diagnostic technologies or other platform technologies applicable to development and regulatory review of MCM.</font></div><div style="padding-left:62.95pt;padding-right:60.95pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop prototype candidates for the prophylaxis, treatment and diagnosis of Chemical threats. This will include diagnosis of, and prophylaxis and treatment for, exposure to traditional and emerging chemical nerve agent threats, as well as other emerging chemical threat agents other than nerve agents.</font></div><div style="padding-left:62.95pt;padding-right:60.65pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop prototype candidates for the prophylaxis, treatment and diagnosis of Radiological and Nuclear threats. This will include prototype candidates for diagnosis of, and prophylaxis and treatment for Acute Radiation Syndrome.</font></div><div style="padding-left:62.95pt;padding-right:60.85pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop soldier-carried autoinjector delivery devices for single drug administration. Develop soldier- carried autoinjector delivery devices for administration of two or more drugs.</font></div><div style="padding-left:62.95pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop vaccine-manufacturing platforms that offer early stage manufacturing flexibility and diversity using a deep knowledge of protein(s) expression in a biological system that is reproducible and scalable, and preferably with direct FDA experience. The goal is to manufacture and test identified protective molecule(s) and target molecule(s) (along with associated reagents and standards) in multiple scalable, flexible manufacturing platforms encompassing a diverse array of manufacturing systems (e.g., insect, mammalian, live viral, plant, </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">E.coli</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, yeast, etc.) for use in appropriate animal model(s) and in Phase 1 trials.</font></div><div style="padding-left:62.95pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%;padding-left:14.55pt">Pharmaceutical development will address the FDA Animal Rule, as appropriate.</font></div><div style="padding-left:62.95pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Utilize adjuvants and excipients supporting the ability to develop up to 300,000 equivalent doses within 60 days at clinical quality.</font></div><div style="padding-left:62.95pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Support a family of systems diagnostic approach that increases the speed, accuracy, and confidence of agent identification and disease diagnosis. Diagnostic areas include those for organisms that circulate freely and at relatively high numbers at or near the onset of symptoms, organisms that circulate in low numbers early in infection but then integrate with host cells, organisms that have significant genomic diversity from strain to strain, and non-BW agents such as toxins&#47;chemical agents&#47;radiological agents that do not replicate and require low quantities to cause illness.</font></div><div style="padding-left:62.95pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Support the Defense Biological Products Assurance Office (formally the Critical Reagents Program), the principal DoD resource of high quality, validated, and standardized biological reference materials, reagents, and assays, as necessary.</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DoD Advanced Development and Manufacturing Capabilities&#58; To facilitate lessons learned and to ensure DoD MCM product development schedules are not impacted, the consortium will consider Advanced Development and Manufacturing (ADM) capability contractors for biologics manufacturing activities for monoclonal antibodies, vaccines, and recombinant proteins may utilize the DoD funded facility.</font></div><div style="padding-left:62.9pt;padding-right:60.95pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue collaborative research with non-traditional technology providers in a manner that enables effective transition of technologies to Government prototyping programs during any phase of life cycle support (affordability, manufacturability, sustainment, etc.).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.05&#160;&#160;&#160;&#160;Reports</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:26.9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCDC member organizations conducting projects in accordance with this Agreement shall maintain records of the activities performed and funding expended under the projects and the results of any studies analyses, tests, and other investigations conducted. Based on the progress of the funded projects and other </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 13 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:26.9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information known to the AO or authorized designee, the MCS Program Office shall review the relevant projects throughout the period to determine if any changes to planning or budget are required. If such a change is expected which will cause a need to modify the OTA, the Technical Direction Letter or an individual Project Agreement may be modified to incorporate such changes. The AO is the only authorized representative of the Government who may make modifications to the OTA. PAHs shall submit the following reports to the CMF who will review and provide one cumulative report detailing status of all funded projects to the MCS Program Office.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_31"></div><div style="margin-top:4.15pt;padding-left:26.95pt;padding-right:60.65pt;text-align:justify"><font><br></font></div><div style="padding-left:26.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.) Project Agreement Quarterly Report. The report will have two major sections&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.65pt;text-align:justify;text-indent:-16.7pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.27pt">Technical Status Report. The technical status report will detail technical progress to date and report on all problems, technical issues or major developments during the reporting period. Each of the topics described below shall be addressed for the effort performed&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:62.95pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of actual accomplishments with the goals and objectives of the project established for the period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99.65pt;text-indent:-54.75pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:43.09pt">Reasons why established goals and objectives were not met, if appropriate.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other pertinent information including, when appropriate, analysis and explanation of cost variances.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:62.95pt;padding-right:60.65pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cumulative chronological list of written publications in technical journals. Include those in press as well as manuscripts in preparation and planned for later submission. Indicate likely journals, authors, and titles.</font></div><div><font><br></font></div><div style="padding-left:99.6pt;text-indent:-54.7pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:43.04pt">Papers presented at meetings, conferences, seminars, etc.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.7pt;text-align:justify;text-indent:-19.45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.25pt">Business Status Report. The business status report shall provide summarized details of the resource status of the Project Agreement, including the status of the contributions by all participants. This report will include a quarterly accounting of current expenditures. Any major deviations from the agreed to project plans shall be explained with discussion of proposed actions to address the deviations. The report will also include an accounting of interest earned on Government Funds, if any. It is not expected that any interest will accrue under the Project Agreement(s), as milestone payments will be tracked and adjusted accordingly. In any event, the Government reserves the right to require interest amounts in excess of $250 per year to be remitted to the US Treasury.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.) Annual Technical Report. Annual technical reports are required for projects whose periods of performance are greater than one year. The PAH&#8217;s report will provide a concise and factual discussion of the significant accomplishments and progress during the year covered by the report.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:26.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.) Final Technical Report.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Final Technical Report (FTR). A Final Technical Report shall be submitted to the CMF within thirty (30) calendar days of the completion of the Project Agreement. This report will provide a comprehensive, cumulative, and substantive summary of the progress and significant accomplishments achieved during the total period of the effort. Each of the topics described above shall be addressed as appropriate for the effort performed. Upon receipt, the AOR will review and provide any comments within 30 days. If necessary, the PAH will update the FTR within 30 days of receipt of AOR&#8217;s comments. Once the CMF has informed PAH that the FTR has been approved by the AOR, the PAH shall forward a copy of the FTR to the Defense Technical Information Center, Attn. DTIC-O, 8725 John J. Kingman Road, Suite 0944, Fort Belvoir, VA 22060-6218.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:60.6pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Format. The cover and title page shall be Standard Form (SF) 298, Report Documentation Page. Item 13 of the form should contain a 100 to 200 word abstract summarizing technical progress during the reporting </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 14 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. Style should be third person singular using past tense. Jargon, special symbols or notations, subscripts, mathematical symbols or foreign alphabet letters are not permitted. All pages should be prepared for acquisition and distribution by the Defense Technical Information Center (DTIC). All pages should be good quality for copying purposes. The report shall be prepared in accordance with American National Standards Institute (ANSI) document Z39.18-1987, &#34;Scientific and Technical Reports&#58; Organization, Preparation, and Production,&#34; which may be obtained from American National Standards Institute Incorporated, 1430 Broadway, New York, NY, 10018. The FTR front page shall be marked in a conspicuous place with a distribution statement to denote the extent of its availability for distribution, release, and disclosure without additional approvals or authorizations.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_34"></div><div style="margin-top:4.15pt;padding-left:52.15pt;padding-right:60.75pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:44.95pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.) Final Business Status Report. The final business status report shall provide summarized details of the resource status of the Project Agreement, including the status of the contributions by all participants. This report will include a final accounting of cumulative expenditures. If a project is terminated prior to the end of a quarter or a year and sufficient funding is available, the PAH, through the CMF, must submit a final technical and business status report in the same format as detailed herein.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;padding-right:61.45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note&#58; Deficiencies in regulatory reports must be adequately assessed by the Government, MCDC and the individual performer, or consortium as a whole, to come to resolution.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article II.&#160;&#160;&#160;&#160;TERM</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.01 The Term of this Agreement</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of performance for this Agreement is from the effective date, which is the date of last signature, to April 7, 2036. If at any time funds expended exceed the amount obligated on a Project Agreement prior to the expiration of the term, the Parties have no obligation to continue performance and may elect to cease their efforts at that point. Provisions of this Agreement, which, by their express terms or by necessary implication, apply for periods of time other than specified in Article II herein, shall be given effect, notwithstanding this Article.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.02 Termination of this Agreement by Mutual Agreement</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the rights and obligations with respect to proprietary information and&#47;or specific intellectual property agreements between or amongst the Government, the CMF and the MCDC member organizations, unless extended by mutual written agreement of the Parties, this Agreement shall automatically terminate by written agreement of  the Parties. Unless otherwise directed by the AO through the CMF, individual Project Agreements pursuant to this Agreement shall also terminate upon the termination of this Agreement.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.03 Termination Provisions</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to a reasonable determination that the program, or a project funded under the program, will not produce beneficial results commensurate with the expenditure of resources, the Government may terminate performance of work under this OTA or a specific project, in whole or in part, if the AO determines that a termination is in the Government&#8217;s interest. The AO shall terminate by delivering to the MCDC through its CMF a Notice of Termination specifying the extent of termination and the effective date.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After receipt of a Notice of Termination, and except as directed by the CMF, the PAH shall immediately proceed with the following obligations, regardless of any delay in determining or adjusting any amounts due&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:49.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Stop work and direct its subawardees to stop work as specified in the notice.</font></div><div style="margin-top:0.25pt;padding-left:49.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.75pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Place no further subagreements or orders (referred to as orders in this clause) for materials, services, or facilities, except as necessary to complete the continued portion of the project.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:0.44pt;text-indent:49.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Terminate all orders to the extent they relate to the work terminated.</font></div><div><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_37"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 15 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:54pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Assign to the Government, as directed by the AO, all right, title, and interest of the PAH under the orders terminated, in which case the Government shall have the right to settle or to pay any termination settlement proposal arising out of those terminations.</font></div><div style="margin-top:0.15pt;padding-left:54pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:54pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) With approval or ratification to the extent required by the AO, the CMF may settle all outstanding liabilities and termination settlement proposals arising from the termination of orders&#59; the approval or ratification will be final for purposes of this clause.</font></div><div style="margin-top:0.15pt;padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Provide CMF, and&#47;or obtain from the subawardees under the terminated portion of the Agreement a transfer of title to the following where applicable and deliver to the Government --</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:85.5pt;padding-right:60.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The fabricated or unfabricated parts, work in process, completed work, supplies, and other material produced or acquired for the work terminated&#59; and</font></div><div style="margin-top:0.25pt;padding-left:85.5pt"><font><br></font></div><div style="padding-left:85.5pt;padding-right:60.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) The completed or partially completed plans, drawings, information, and other property that, if the order had been completed, would have been required to be furnished to the Government.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Complete performance of any work not terminated, if applicable.</font></div><div style="margin-top:0.4pt;padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Take any action that may be necessary, or that the AO may direct through the CMF, for the protection and preservation of the property related to this project that is in the possession of the PAH(s) or any subawardee and in which the Government has or may acquire an interest.</font></div><div style="margin-top:0.2pt;padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) Use commercially reasonable efforts to sell, as directed or authorized by the CMF, any property of the types referred to under Article II. Section 2.03 Termination Provisions, (6)(i) and (ii)&#59; provided, however, that the PAH&#58;</font></div><div style="margin-top:0.05pt;padding-left:54pt"><font><br></font></div><div style="padding-left:85.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) is not required to extend credit to any purchaser and</font></div><div style="margin-top:0.25pt;padding-left:85.5pt"><font><br></font></div><div style="padding-left:85.5pt;padding-right:60.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) may arrange for the subawardee who was performing the terminated work to acquire the property under the conditions prescribed by, and at prices approved by, the CMF.</font></div><div style="margin-top:0.3pt;padding-left:54pt"><font><br></font></div><div style="padding-left:85.5pt;padding-right:61.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) will in no event be required to continue with such efforts for more than three (3) months after notice by the CMF to sell or disposition such property.</font></div><div style="margin-top:0.15pt;padding-left:54pt"><font><br></font></div><div style="padding-left:54pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) The PAH has no obligation to continue to cost share on the terminated project or terminated portion of the project.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.9pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement for at least 1&#47;3 cost share of the total project cost by the PAH is assessed prior to award. In the event that during the course of the performance of the Project Agreement any of the parties to the Project Agreement believe the cost sharing funds available will be insufficient, the PAH shall notify the CMF within twenty-five (25) days of the event that gave rise to the insufficient cost sharing funds. CMF will notify the Government within five</font></div><div style="margin-top:0.1pt;padding-left:8.9pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) days of receiving such notice from the PAH. The Government will determine whether it is in its best interest to either renegotiate the scope and&#47;or terms of the Project Agreement to meet the cost share requirement or terminate the Project Agreement in whole or in part.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of any transfer or disposition of project property will be applied to reduce any payments to be made by the Government under that particular project, including credited to the price or cost of the work, or paid in any other manner directed by the CMF.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a termination of the Project Agreement, the Government shall have patent rights as described in Article X, Patent Rights, and rights in Data as described in Article XI, Data Rights. Failure of the PAH and Government to agree to an equitable adjustment shall be resolved pursuant to Article VII, Disputes.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_40"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 16 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.04 Termination Cost</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CMF will negotiate with the Government and PAH in good faith equitable reimbursement for work performed toward accomplishment of the task or tasks of individual projects. The Government will allow full credit for the Government share of the obligations properly incurred by a PAH prior to termination. Costs incurred by a PAH during a suspension or after termination of a project are not allowable unless the CMF expressly authorizes them in either the notices of suspension, termination, or subsequently. Other PAH&#8217;s costs incurred during a suspension or after termination which are necessary and not reasonably avoidable are allowable if&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:26.95pt;padding-right:61pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The costs result from obligations which were properly incurred by the PAH before the effective date of the suspension or termination, are not in anticipation of it, and in the case of a termination, are non-cancellable&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27pt;padding-right:60.95pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">The costs would be allowable if the project was not suspended or the award expired normally at the end of the funding period in which the termination takes effect.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.05 Close-out Procedure.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Government funds an individual Project Agreement and then subsequently terminates the agreement or the requirements of the agreement are met, the following closeout procedures apply&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:26.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Definitions.</font></div><div><font><br></font></div><div style="padding-left:49.5pt;padding-right:61pt;text-indent:-31.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)        &#8220;Closeout&#8221; &#8211; the process by which the Government and CMF determine that all applicable administrative actions and all required work have been completed by the PAH.</font></div><div style="margin-top:0.55pt;padding-left:49.5pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.8pt;text-indent:-31.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)       &#8220;Date of Completion&#8221; &#8211; the date on which all work is completed or the date on an amendment thereto on which the period of performance ends.</font></div><div style="margin-top:0.05pt;padding-left:49.5pt;text-indent:-31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:60.85pt;text-indent:-31.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)      &#8220;Disallowed costs&#8221; &#8211; those charges that the Government or its representative determines to be unallowable, in accordance with the terms and conditions stated in this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.95pt;padding-right:61pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Upon request, the Government shall make prompt payments to the PAH through the CMF for allowable reimbursable costs under the MCS Project Agreement being closed out.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:26.95pt;padding-right:60.95pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The PAH shall immediately refund any balance of unobligated (unencumbered) cash that the CMF has paid and that is not authorized to be retained by the PAH for use in the performance of the Project Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.95pt;padding-right:60.65pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">The CMF shall obtain from the PAH within 90 calendar days after the date of completion of an MCS Project Agreement all financial, performance, and other reports required as a condition of the MCS Project Agreement. The CMF may grant extensions when requested by the PAH.</font></div><div><font><br></font></div><div style="padding-left:26.95pt;padding-right:61pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">When authorized, the CMF shall make a settlement for any upward or downward adjustments to the Government&#8217;s share of costs after these reports are received based on final, actual expenditures in accordance with the Termination Costs provision of the Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:29.5pt;text-indent:-20.55pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.56pt">Quick close-out procedures similar to FAR 42.708 shall be followed.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The PAH shall account for any property received from the Government.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.06 Stop Work</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As directed by the AO, the CMF may, at any time, by written order to the PAH, require the PAH to stop all, or any part, of the work called for under this Agreement or any Project Agreement for a period of 90 days after the written order is delivered to the PAH, and for any further period to which the parties may agree. The order shall be </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 17 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifically identified as a stop-work order issued under this section. Upon receipt of the order, the PAH shall immediately comply with its terms and take all reasonable steps to minimize the incurrence of costs allocable to the work covered by the order during the period of work stoppage. Within a period of 90 days after a stop-work is delivered to the PAH, or within any extension of that period to which the parties shall have agreed, the CMF shall either&#58;</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_43"></div><div style="margin-top:4.15pt;padding-left:18pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)     Cancel the stop-work order&#59; or</font></div><div style="margin-top:6.05pt;padding-left:22.5pt;text-indent:-3.65pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)     Terminate the work covered by the Project Agreement as provided in Article II, Term and Termination.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a stop work order issued under this clause is canceled, the PAH shall resume work. The CMF shall make an equitable adjustment in the delivery schedule or Project Agreement estimated cost&#47;price, or both, and the Government&#8217;s share of the Project Agreement shall be modified, in writing, accordingly, if&#8212;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">The stop-work order results in an increase in the time required for, or in the PAH&#8217;s cost properly allocable to, the performance of any part of the Project Agreement&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">The PAH asserts its right to the adjustment within 30 days after the end of the period of work stoppage&#59; provided, that, if the Government decides the facts justify the action, the Government through the MCDC CMF may receive and act upon a proposal submitted at any time before final payment under the Project Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a stop work order is not canceled and the work covered by the Project Agreement is terminated in accordance with Article II, the MCDC CMF shall work with the PAH to negotiate an equitable reimbursement in accordance with Article II. Section 2.03, Termination Provisions.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article III. MANAGEMENT OF THE PROJECT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.01 The Medical CBRN Defense Consortium (MCDC)</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCDC, as defined in the OTA, was formed to work with the Government and provide input in developing technologies to support the Department of Defense&#8217;s (DoD) medical, pharmaceutical, and diagnostic requirements as related to enhancing the mission effectiveness of military personnel ultimately resulting in fully executed research and development prototype projects selected by the Government. Every Member in this MCDC is independent of the other, and there is no affiliation between the MCDC members within the definition of 13 C.F.R. 121.103 of the Federal Small Business Regulations and no such affiliation is intended either by the formation or implementation of the MCDC.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As appointed by the MCDC Executive Committee, the CMF has the authority to execute the Other Transaction Agreement (OTA) on behalf of the MCDC and has the responsibility for day to day overall administration of this Agreement, subject to the supervision of the MCDC Executive Committee.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.02 The following MCDC decisions are subject to the ACC-NJ approval&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:62.9pt;padding-right:60.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Changes to the MCDC Articles of Collaboration if such changes substantially alter the relationship of the MCDC and the Government as originally agreed upon when the OTA was executed&#59;</font></div><div style="padding-left:62.9pt;padding-right:60.85pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Changes to, or elimination of, any ACC-NJ funding allocation to any MCDC Member as technically and&#47;or financially justified.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.03 Management and Project Structure</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical and project management of the coordinated research program established under this Agreement shall be accomplished through the management structures and processes detailed in this Article.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government competitively selected the MCDC, organized by its Consortium Management Firm Advanced Technology International, a Section 501(c)(3) nonprofit organization. MCDC has entered into an agreement with Advanced Technology International authorizing Advanced Technology International to enter into this OTA as the </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 18 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:8.9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consortium manager, engage in overall day to day management of the MCDC under the guidance of and as designated by the MCDC Executive Committee, including technical, programmatic, reporting, financial, administrative and contractual matters and administer Project Agreements required for performance under this OTA.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_46"></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As established by funded projects under the OTA, the Government Program Manager shall fully participate in the appropriate program technical meetings held by the MCDC. The AORs and Other Government personnel, as deemed appropriate, also may participate in the technical portion of these meetings.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.04 Modifications</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of scheduled meetings, end of program reviews, or at any time during the term of the OTA, research progress or results may indicate that a change in the OTA&#8217;s scope, objectives or Term would be beneficial to program objectives. Recommendations for modifications, including justifications to support any changes to the OTA Scope, will be documented in a letter and submitted by the PAH to the CMF, who will then forward it to the Program Manager with a copy to the AO. This documentation letter will detail the technical, chronological, and financial impact of the proposed modification to the OTA. The Program Manager shall be responsible for the review and verification of any recommendations to revise or otherwise modify the OTA Scope or other proposed changes to the terms and conditions of the OTA and subsequently this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to projects the Government determines to fund as a result of the RPP process specified in the Agreement Scope, any PAH recommendations for modifications, including justifications to support any changes to the funded projects, will be documented in a letter and submitted by the CMF to the AO with a copy to the Government Agreements Officer Representative designated for the particular project. The AO shall be responsible for review of proposed changes and for all modifications to the terms and conditions of the project awards. The CMF shall modify the Project Agreement(s) in the event of any such modifications or changes to the project.</font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of Projects</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.9pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Performance of the work on each project is subject to the technical direction of the AOR designated in the Project Agreement. For the purposes of this clause, technical direction includes the following&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Direction to the PAH, which shifts work emphasis between work areas or tasks, requires pursuit of certain lines of inquiry, fills in details or otherwise serves to accomplish the objectives described in the statement of work&#59;</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.95pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Guidelines to the PAH that assist in the interpretation of drawings, specifications or technical portions of work description.</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:61pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.12pt">Review and, where required by the Project Agreement, approval of technical reports, drawings, specifications, or technical information to be delivered by the PAH under the Project Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AOR shall monitor the PAH&#8217;s performance with respect to compliance with the technical requirements of the Project Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.9pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Technical direction must be within the general scope of work stated in the Project Agreement. Technical direction may not be used to</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.12pt">Assign additional work under the Project Agreement&#59;</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.85pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.55pt">Increase or decrease the estimated Project Agreement cost, fee (if any), or the time required for the project performance&#59;</font></div><div style="margin-top:0.05pt;padding-left:62.95pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.12pt">Change any of the terms, conditions or specifications of the Project Agreement&#59; or</font></div><div style="padding-left:62.95pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.55pt">Accept non-conforming work.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, no verbal or written request, notice, authorization, direction or order received by the PAH shall be binding upon the MCDC, CMF or Government, or serve as the basis for a change in the Project Agreement cost or any other provision of the Project Agreement, unless issued (or confirmed) in writing by the MCDC CMF Contractual Representative designated in the Project Agreement.</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_49"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 19 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The PAH shall immediately notify the MCDC CMF Contractual Representative whenever a written change notification has been received from anyone other than the MCDC CMF Contractual Representative, which would affect any of the terms, conditions, cost, schedules, etc. of the Project Agreement, and the PAH is to perform no work or make any changes in response to any such notification or make any claim on the MCDC through its CMF or Government, unless the MCDC CMF Contractual Representative directs the PAH, in writing, to implement such change notification.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article IV.&#160;&#160;&#160;&#160;AGREEMENT ADMINISTRATION</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:49pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative and contractual matters under this Agreement shall be referred to the following representatives of the parties&#58;</font></div><div style="margin-top:0.05pt;padding-left:152.95pt;padding-right:240.5pt;text-indent:-144pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:230%">MCDC&#58;&#160;&#160;&#160;&#160;Advanced Technology International </font></div><div style="margin-top:0.05pt;padding-left:152.95pt;padding-right:240.5pt;text-indent:-144pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </font></div><div style="padding-left:152.95pt;padding-right:240.5pt;text-indent:-144pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sr. Contracts Manager</font></div><div style="padding-left:152.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">315 Sigma Drive</font></div><div style="padding-left:9pt;padding-right:274.75pt;text-indent:143.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summerville, SC 29486 </font></div><div style="padding-left:9pt;padding-right:274.75pt;text-indent:143.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:9pt;padding-right:274.75pt;text-indent:143.95pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Project Agreement Holder&#58;&#160;&#160;&#160;&#160;______________________</font></div><div style="padding-left:128.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:128.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:128.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:128.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:128.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________</font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:11.35pt;padding-right:83pt;text-align:justify;text-indent:-2.55pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">Each party may change its representatives named in this Article by written notification to the other parties. Agreements Officer Representative (AOR)&#58; AOR will be designated by the Government on a per project basis.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article V.&#160;&#160;&#160;&#160;OBLIGATION AND PAYMENT</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.01 Obligation&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.85pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as specified in Article VII&#58; Disputes, the CMF&#8217;s liability to make payments to the PAH is limited only to those funds obligated under the Project Agreement(s). The CMF may incrementally fund the Project Agreement(s). If modification becomes necessary in performance of projects, pursuant to Article V of this Agreement, the CMF and the PAH shall establish and execute a revised Schedule of Payable Milestones consistent with the current Project Agreement.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.02 Project Payments&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.85pt;padding-right:61.1pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detailed instructions for project payments will be included in the Technical Direction Letter to be issued by the CMF on a project by project basis.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.03 Accounting System Requirements&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.85pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the submission of invoices, the PAH shall have and maintain an established accounting system which complies with Generally Accepted Accounting Principles (GAAP) and the requirements of this Agreement. The PAH shall ensure that appropriate arrangements have been made for receiving, distributing and accounting for Federal funds under this Agreement. Consistent with this stipulation, an acceptable accounting system will be one  in which all cash receipts and disbursements are controlled and documented properly.</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_52"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 20 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04 Invoicing Instructions&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project Payable Milestones&#58; The PAH shall segregate and track all individual project costs separately and shall document the accomplishments of each Payable Milestone under each Project Agreement. A Payable Milestones report shall be detailed on a project basis and submitted with each request to the AOR or designee for approval.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04 a. Payment Method Types</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project Agreements will be issued as either a fixed price milestone payment method or a cost reimbursement milestone payment method as described below.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:62.95pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Fixed Price Milestone Payment Method&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments shall be made in accordance with the Payable Milestone Schedule of each Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. The Payable Milestone Schedule may be revised as appropriate and deemed necessary by issuance of a bilateral modification to the Project Agreement. Quarterly reviews by the AOR and the CMF will assess the need for revisions to the Payable Milestone Schedule. An acceptable invoice for adjustable fixed price milestone payments is one that (on the invoice or on the Payable Milestone Report)&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:98.95pt;text-indent:-22.93pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">contains the date of invoice and the Base Agreement number and Project Agreement number&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:98.95pt;padding-right:60.85pt;text-indent:-25.7pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">identifies any associated technical milestones and the progress toward completion of each milestone&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:99pt;text-indent:-28.47pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.5pt">lists the milestone cost negotiated and contained in each Project Agreement</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:63pt;padding-right:60.75pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.39pt">Cost Reimbursable Milestone Payment Method (with not to exceed ceiling)&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment is contingent upon satisfactory progress toward completion of milestones as delineated in Project Agreement. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (ii) below, either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each Project Task Assignment)&#58;</font></div><div><font><br></font></div><div style="padding-left:99pt;text-indent:-27.53pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.1pt">contains the date of invoice and the Base Agreement number and Project Agreement number&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:98.95pt;padding-right:60.85pt;text-indent:-30.2pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">identifies any associated technical milestones and the progress toward completion of each milestone&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:98.95pt;padding-right:60.85pt;text-indent:-32.97pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">includes a description of supplies and services, labor costs, subcontractor costs, material costs, travel costs, other direct costs, and extended totals&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:98.95pt;padding-right:60.85pt;text-indent:-32.43pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">indicates the current period and cumulative man-hours and costs incurred through the period indicated on the invoice&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:98.95pt;text-indent:-29.71pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.05pt">contains the following certification statement&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:80.95pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;I certify that the amounts invoiced are for costs incurred in accordance with the agreement, the work reflected has been performed, and prior payment has not been received.&#8221;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:80.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized Signature __________________________</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:62.95pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.96pt">Cost Plus Fixed Fee Milestone Payment Method (with not to exceed ceiling)&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment is contingent</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_55"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 21 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:63pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon satisfactory progress toward completion of milestones as delineated in Project Agreement. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. The PAH will normally fund any costs incurred above this maximum amount. Either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each Project Agreement)&#58;</font></div><div><font><br></font></div><div style="padding-left:103.5pt;padding-right:60.9pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   contains the date of invoice and the Base t Agreement number and Project Agreement number&#59;</font></div><div style="margin-top:0.05pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.5pt;padding-right:60.85pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)    identifies any associated technical milestones and the progress toward completion of each milestone&#59;</font></div><div style="margin-top:0.5pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:103.5pt;padding-right:60.85pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   includes a description of supplies and services, labor costs, subcontractor costs, material costs, travel costs, other direct costs, fixed fee and extended totals&#59;</font></div><div style="margin-top:0.05pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.5pt;padding-right:60.85pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)   indicates the current period and cumulative man-hours and costs incurred through the period indicated on the invoice&#59; and</font></div><div style="margin-top:0.5pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:103.5pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   contains the following certification statement&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:80.95pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;I certify that the amounts invoiced are for costs incurred in accordance with the agreement, the work reflected has been performed, and prior payment has not been received.&#8221;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:80.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized Signature __________________________</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:63pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Reimbursable, Cost Sharing Milestone Payment Method (with not to exceed ceiling)&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment is contingent upon satisfactory progress toward completion of milestones as delineated in Project Agreement and acceptable cost share. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (ii) below, either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each Project Agreement)&#58;</font></div><div><font><br></font></div><div style="padding-left:103.5pt;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)      contains the date of invoice and the Base Agreement number and Project Agreement number&#59;</font></div><div style="margin-top:0.5pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:103.5pt;padding-right:60.85pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   identifies any associated technical milestones and the progress toward completion of each milestone&#59;</font></div><div style="margin-top:0.05pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:103.5pt;padding-right:60.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   includes a report of the cost share expended towards the accomplishment of the SOW tasks and&#47;or milestones. This cost share report may be attached to the invoice if contractor practices make inclusion of such information on the invoice itself impractical. If the cost share report is separate from the invoice, it must be signed by an authorized representative. This cost share report must contain a breakout of the cost share by cost element similar to the level of detail required on the invoice and any in-kind contributions. The preferred method of reporting cost share is to provide an invoice for actual cost incurred with a value for the cost shared amount and the value to be reimbursed by the Government through the CMF&#59;</font></div><div style="margin-top:0.55pt;padding-left:103.5pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:103.5pt;padding-right:60.95pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)  includes a description of supplies and services, labor costs, subcontractor costs, material costs, travel costs, other direct costs, and extended totals&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_58"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 22 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:99pt;padding-right:60.9pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   indicates the current period and cumulative man-hours and costs incurred through the period indicated on the invoice&#59; and</font></div><div style="margin-top:0.5pt;padding-left:99pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:99pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)  contains the following certification statement&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:81pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;I certify that the amounts invoiced are for costs incurred in accordance with the agreement, the work reflected has been performed, and prior payment has not been received.&#8221;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:81pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized Signature __________________________</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04 b.&#160;&#160;&#160;&#160;Submission of Invoices</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invoices may be submitted no more frequently than monthly. The PAH shall submit invoices and any necessary supporting documentation via email to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          .</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Cost type Project Agreements, the PAH&#8217;s final invoice (completion invoice) will be clearly indicated as such and shall indicate the cumulative amounts incurred and billed to completion, and a written certification of the total hours expended. Actual project costs incurred and cost share performance, if applicable, of each project shall be reported and reviewed each quarter.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04 c. Payment Terms</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms are NET 30 days after CMF&#8217;s receipt of an acceptable invoice. An acceptable invoice is one that meets the conditions described in Article V Section 5.04a. Payment Method Types.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.05 Advance Payments&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a per project basis, advance payments may be approved by the AO. If the AO has approved advance payments, there will be a requirement to establish a separate interest bearing account. The PAH sets up and maintains funds in a separate interest bearing account unless one of the following applies&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:62.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The PAH receives less than $120,000 in Federal awards per year&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:62.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The best reasonably available interest bearing account would not expect to earn interest in excess of</font></div><div style="padding-left:63pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$250 per year on such cash advances&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:63pt;padding-right:60.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">The depository would require an average or minimum balance so high that it would not be feasible within the expected cash resources for the project&#59; or</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:63pt;padding-right:60.9pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">The advance payments are made one time to reduce financing costs for large up-front expenditures and the fund will not remain in the PAH&#8217;s account for any significant period of time.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a separate interest bearing account is set up, any interest earned should be remitted annually to the CMF. CMF shall forward the funds to the Government as directed by the AO. Interest payments shall be made payable to the U.S. Treasury.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.06 Limitation of Funds&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth in Article VII, the Government's financial liability will not exceed the amount obligated for projects and available for payment.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_61"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 23 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.07 Financial Records and Reports&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall maintain adequate records to account for Federal funds received under this Agreement and shall maintain adequate records to account for Project Agreement funding provided under this Agreement, should cost sharing procedures be implemented for funding a particular project. PAH's relevant financial records are available and subject to examination or audit on behalf of the ACC-NJ for a period not to exceed five (5) years after final payment of the PAH's project. The AO or designee shall have direct access to sufficient records and information of the PAH to ensure full accountability for all funding under this Agreement. Such audit, examination or access shall be performed during business hours on business days upon prior written notice and shall be subject to the security requirements of the audited party. Any audit required during the course of the program may be conducted by the Government using Government auditors or, at the request of the PAH, by the requesting PAH's external CPA accounting firm at the expense of the requesting PAH.</font></div><div style="margin-top:0.1pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AGREEMENT</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article VI.&#160;&#160;&#160;&#160;NONTRADITIONAL DEFENSE&#47;COST SHARING</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with provisions of 10 USC 2371b, Section 815 of the 2016 National Defense Authorization Act, P.L. 114-92, which provides the Department of Defense (DoD) authority to enter into transactions </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other than </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts, grants, or cooperative agreements, the Department of Defense (DoD) has the authority to make awards that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or the improvement of platforms, systems, components, or materials in use by the armed forces. Section 815 revised the definition for  the term &#8216;nontraditional defense contractor&#8217; as defined in Article I. Section 1.01, Definitions.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each MCDC Member Organization must meet the definition of a Nontraditional Defense Contractor or have at least one Nontraditional Defense Contractor participating to a significant extent in the performance of an awarded Project Agreement. Examples of what might be considered a significant extent or significant contribution include, but may not be limited to supplying new key technologies or products, accomplishing a significant amount of the effort, or in some other way causing a material reduction in the cost or schedule or increase in the performance.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant Nontraditional Defense Contractor participation cannot be fulfilled, the Member Organization must provide at least one third cost share of the value of the Project Agreement awarded to the Member Organization. Proposals that fail to comply with this requirement will not be awarded under the OTA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost Sharing is not required under this Other Transaction Agreement for projects that contain significant nontraditional defense contractor participation. Where both Parties agree, cost sharing may be considered on a per project basis under terms and conditions to be agreed to by the Parties and in accordance with the &#8220;Other Transactions&#8221; (OT) Guide For Prototype Projects dated January 2001. For traditional Government contractors without a significant nontraditional defense contractor teaming partner, a one third cost share of the project costs is required as described in the &#8220;Other Transaction&#8221; (OT) Guide For Prototype Projects dated January 2001. For traditional Government contractors with significant nontraditional defense contractor participation, cost sharing is not required for Projects under this OTA.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the period of performance of any Project Agreement, the Government AO and AOR will actively monitor Nontraditional Defense Contractor participation and&#47;or cost sharing to ensure compliance with this provision in accordance with implementation guidance from HQDA and&#47;or OSD. The PAH will be given the opportunity to become compliant with the guidance should they be found non-compliant. Failure to comply may result in termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_64"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 24 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;padding-right:408.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:231%">Article VII. DISPUTES Section 7.01 General</font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this Article, &#8220;Parties&#8221; means the CMF, the PAH and the Government where collectively identified and &#8220;Party&#8221; where each entity is individually identified. The Parties shall communicate with one another in good faith and in a timely and cooperative manner when raising issues under this Article.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.02 Dispute Resolution Procedures</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disagreement, claim or dispute among the Parties concerning questions of fact or law arising from or in connection with this Agreement and whether or not involving an alleged breach of this Agreement, may be raised only under this Article.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever disputes, disagreements, or misunderstandings arise, the Parties shall attempt to resolve the issue(s) involved by discussion and mutual agreement as soon as practicable. In no event shall a dispute, disagreement or misunderstanding which arose more than three (3) months prior to the notification made under this article constitute the basis for relief under this article unless the ACC-NJ, Center Director for Emerging Technologies, in the interest of justice, waives this requirement.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failing resolution by mutual agreement, the aggrieved Party shall document the dispute, disagreement, or misunderstanding by notifying the other Party in writing documenting the relevant facts, identifying unresolved issues, specifying the clarification or remedy sought, and documenting the rationale as to why the clarification&#47;remedy is appropriate. Within ten (10) working days after providing notice to the other Party, the aggrieved Party may, in writing, request a decision by the ACC-NJ, Center Director for Emerging Technologies. The other Party shall submit a written position on the matter(s) in dispute within thirty (30) calendar days after being notified that a decision has been requested. The ACC-NJ, Center Director for Emerging Technologies, will conduct a review of the matter(s) in dispute and render a decision in writing within thirty (30) calendar days of receipt of such position. Any such decision is final and binding, unless a Party shall, within thirty (30) calendar days request further review as provided by this article.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If requested within thirty (30) calendar days of the ACC-NJ, Center Director for Emerging Technologies&#8217; decision, further review will be conducted by the Chair of the MCDC Executive Committee and the ACC-NJ Associate Director. In the event of a decision, or in absence of a decision within sixty (60) calendar days of referral to the Chair of the MCDC Executive Committee and the ACC-NJ, Associate Director (or such other period as agreed to by the parties), either party may pursue any right or remedy provided by law, including but not limited to the right to seek extraordinary relief under Public Law 85-804. Alternatively, the parties may agree to explore and establish an Alternate Disputes Resolution procedure to resolve this dispute.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.03 Limitation of Liability and Damages</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall the liability of the MCDC PAH or any other entity performing research activities under a Project Agreement exceed the funding such entity has received for their performance of the specific Project Agreement under which the dispute arises.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Party shall be liable to any other Party for consequential, punitive, special and incidental damages or other indirect damages, whether arising in contract (including warranty), tort (whether or not arising from the negligence of a Party) or otherwise, except to the extent such damages are caused by a Party's willful misconduct&#59; Notwithstanding the foregoing, claims for contribution toward third-party injury, damage, or loss are not limited, waived, released, or disclaimed.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_67"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 25 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article VIII.&#160;&#160;&#160;&#160;CONFIDENTIAL INFORMATION</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.01&#160;&#160;&#160;&#160;Definitions</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">&#8220;Disclosing Party&#8221; means CMF, MCDC PAHs, or the Government who discloses Confidential Information as contemplated by the subsequent Paragraphs.</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">&#8220;Receiving Party&#8221; means CMF, MCDC PAHs, or the Government who receives Confidential Information disclosed by a Disclosing Party.</font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">&#8220;Confidential Information&#8221; means information and materials of a Disclosing Party which are designated as confidential or as a Trade Secret in writing by such Disclosing Party, whether by letter or by use of an appropriate stamp or legend, prior to or at the same time any such information or materials are disclosed by such Disclosing Party to the Receiving Party. Notwithstanding the foregoing, materials and other information which are orally, visually, or electronically disclosed by a Disclosing Party, or are disclosed in writing without an appropriate letter, stamp, or legend, shall constitute Confidential Information or a Trade Secret if such Disclosing Party, within thirty (30) calendar days after such disclosure, delivers to the Receiving Party a written document or documents describing the material or information and indicating  that it is confidential or a Trade Secret, provided that any disclosure of information by the Receiving Party prior to receipt of such notice shall not constitute a breach by the Receiving Party of its obligations under this Paragraph. &#8220;Confidential Information&#8221; includes any information and materials considered a Trade Secret by the PAH. &#8220;Trade Secret&#8221; means all forms and types of financial, business, scientific, technical, economic, or engineering or otherwise proprietary information, including, but not limited to, patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes, whether tangible or intangible, and whether or how stored, compiled, or memorialized physically, electronically, graphically, photographically, or in writing if -</font></div><div><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.96pt">The owner thereof has taken reasonable measures to keep such information secret&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">The information derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable through proper means by, the public.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.02&#160;&#160;&#160;&#160;Exchange of Information&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Government nor MCDC on behalf of the MCDC member entities or PAHs nor the CMF shall be obligated to transfer Confidential Information independently developed by the Government or the MCDC member entities or PAHs or the CMF absent an express written agreement between the Parties involved in the exchange providing the terms and conditions for such disclosure.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.03 Authorized Disclosure&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Receiving Party agrees, to the extent permitted by law, that Confidential Information shall remain the property of the Disclosing Party (no one shall disclose unless they have the right to do so), and that, unless otherwise agreed to by the Disclosing Party, Confidential Information shall not be disclosed, divulged, or otherwise communicated by it to third parties or used by it for any purposes other than in connection with specified project efforts and the licenses granted in Article X, Patent Rights, and Article XI, Data Rights, provided that the duty to protect such &#8220;Confidential Information&#8221; and &#8220;Trade Secrets&#8221; shall not extend to materials or information that&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Are received or become available without restriction to the Receiving Party under a proper, separate agreement,</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">Are not identified with a suitable notice or legend per Article VIII entitled &#34;Confidential Information&#34; herein,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Are lawfully in possession of the Receiving Party without such restriction to the Receiving Party at the time of disclosure thereof as demonstrated by prior written records,</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Are or later become part of the public domain through no fault of the Receiving Party,</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_70"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 26 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:45pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)      Are received by the Receiving Party from a third party having no obligation of confidentiality to the Disclosing Party that made the disclosure,</font></div><div style="margin-top:0.5pt;padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)    Are developed independently by the Receiving Party without use of Confidential Information as evidenced by written records,</font></div><div style="margin-top:0.1pt;padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)     Are required by law or regulation to be disclosed&#59; provided, however, that the Receiving Party has provided written notice to the Disclosing Party promptly so as to enable such Disclosing Party to seek a protective order or otherwise prevent disclosure of such information.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.04 Return of Proprietary Information&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the request of the Disclosing Party, the Receiving Party shall promptly return all copies and other tangible manifestations of the Confidential Information disclosed. As used in this section, tangible manifestations include human readable media as well as magnetic and digital storage media.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.05 Term&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Receiving Party under this Article shall continue for a period of seven (7) years from conveyance of the Confidential Information.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.06 Flow Down</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall flow down the requirements of this Article VIII to their respective personnel, member entities, agents, subawardees (including employees) at all levels, receiving such Confidential Information under this OTA.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article IX.&#160;&#160;&#160;&#160;PUBLICATION AND ACADEMIC RIGHTS</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.01 Use of Information.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of this Article, &#8220;Parties&#8221; means the PAH and the Government where collectively identified and &#8220;Party&#8221; where each entity is individually identified.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of Article VIII, Confidential Information, Article IX, Publication and Academic Rights, and Article XI Data Rights, the PAH and the Government shall have the right to publish or otherwise disclose information and&#47;or data developed by the Government and&#47;or the respective MCDC PAH under the Research Project. The PAH and the Government (and its employees) shall include an appropriate acknowledgement of the sponsorship of the Research Projects by the Government and the MCDC PAH in such publication or disclosure.  The Parties shall have only the right to use, disclose, and exploit any such data and Confidential Information in accordance with the rights held by them pursuant to this Agreement.  Notwithstanding the above, the Parties shall not be deemed authorized by this paragraph, alone, to disclose any Confidential Information of the Government or the PAH.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 9.02 Publication or Public Disclosure of Information</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:44.95pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.96pt">Classified Project Agreements</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a release of Confidential Information or Trade Secrets is for a classified Project Agreement, the provisions of the DoD Security Agreement (DD Form 441) and the DoD Contract Security Classification Specification (DD Form 254) apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_73"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 27 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:27pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)   Review or Approval of Technical Information for Public Release.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)       At least 30 days prior to the scheduled release date PAH shall submit to the CMF a copy of the information to be released. In turn, CMF shall submit to the Government AOR a copy of the information to be released.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government AOR is hereby designated as the approval authority for the AO for such releases.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)         Where the PAH is an Academic Research Institution performing fundamental research on campus. PAH shall provide papers and publications for provision to the CMF for provision to the Government AOR for review and comment 30 days prior to formal paper&#47;publication submission. However, if that Academic Research Institution incorporates into its research results or publications artifacts produced by and provided to these institutions on behalf of other (non-educational institution) MCDC PAHs (or has authors listed on the paper who are not employees or students of the Academic Research Institution) then the procedures in Section 9.02(a) ABOVE must be followed.</font></div><div style="margin-top:0.05pt;padding-left:45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)      Parties to this Agreement are responsible for assuring that an acknowledgment of government support will appear in any publication of any material based on or developed under this OTA, using the following acknowledgement terms&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:81pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Effort sponsored by the U.S. Government under Other Transaction number W15QKN-16-9-1002 between the MCDC, and the Government</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The US Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Parties to this Agreement are also responsible for assuring that every publication of material based on or developed under this project contains the following disclaimer&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:81pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The views and conclusions contained herein are those of the authors and should not be  interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.</font></div><div><font><br></font></div><div style="padding-left:45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall flowdown these requirements to its subawardees, at all tiers.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)   Notices. To avoid disclosure of Confidential Information or Trade Secrets belonging to an MCDC member entity or PAH and&#47;or the Government and the loss of patent rights as a result of premature public disclosure of patentable information, the PAH that is proposing to publish or disclose such information shall provide advance notice to the MCDC, through its CMF, and identify such other parties as may have an interest in such Confidential Information. The CMF shall notify such parties at least &#91;* * *&#93; prior to any PAH&#8217;s submission for publication or disclosure, together with any and all materials intended for publication or disclosure relating to technical reports, data, or information developed by the parties during the term of and pursuant to this Agreement. The Government must notify the MCDC, through its CMF, of any objection to disclosure within this &#91;* * *&#93; period, or else the PAH, shall be deemed authorized to make such disclosure.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:45pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  Filing of Patent Applications.   During the course of any such &#91;* * *&#93; period, the PAH shall</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.85pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    provide notice to the CMF as to whether it desires that a patent application be filed on any invention disclosed in such materials. In the event that a PAH and&#47;or the Government desires that such a patent be filed, the PAH or the Government proposing to publish or disclose such materials agrees to withhold publication and disclosure of such materials until the occurrence of the first of the following&#58;</font></div><div><font><br></font></div><div style="padding-left:63pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)   Filing of a patent application covering such invention, or</font></div><div style="margin-top:0.05pt;padding-left:63pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:63pt;padding-right:60.9pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Written agreement, from the AO and the CMF (on behalf of the PAH to whom such Confidential Information belong) that no patentable invention is disclosed in such materials.</font></div><div><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_76"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 28 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:63pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)   Further, during the course of any such &#91;* * *&#93; period, the PAH shall notify the AO and the</font></div><div style="padding-left:63pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government, through the CMF, if PAH believes any of its Confidential Information have been included in the proposed publication or disclosure and shall identify the specific Confidential Information or Trade Secrets that need to be removed from such proposed publication. The Government and the CMF on behalf of the PAH proposing the publication or disclosure of such materials agrees to remove from the proposed publication or disclosure all such Confidential Information so identified by the CMF.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article X.&#160;&#160;&#160;&#160;PATENT RIGHTS</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.01 Definitions</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Invention&#8221; means any invention or discovery which is or may be patentable or otherwise protectable under Title 35 of the United States Code.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Made&#8221; when used in relation to any invention means the conception or first actual reduction to practice of such invention.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Practical application&#8221; means to manufacture, in the case of a composition of product&#59; to practice, in the case of a process or method, or to operate, in the case of a machine or system&#59; and in each case, under such conditions as to establish that the invention is capable of being utilized and that its benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Subject Invention&#8221; means any invention of the MCDC&#8217;s PAH or its subcontractors of any tier conceived or first actually reduced to practice in the performance of work on a Project Agreement under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Background Invention&#34; means any invention, or improvement to any invention, other than a Subject Invention, made by a PAH (or their subcontractors of any tier) that was conceived, designed, developed, produced, and&#47;or actually reduced to practice prior to performance of the Agreement or outside the scope of work performed under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.02 Allocation of Principal Rights</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH, or its subcontractor to the extent such is proper assignee of the invention, shall retain the entire right, title, and interest throughout the world to each Subject Invention consistent with the provisions of this Article, Executive Order 12591 and 35 U.S.C &#167; 202. In the event that a PAH consists of more than one entity or person, those entities or persons may allocate such right, title interest between themselves or others as they may agree in writing. With respect to any Subject Invention in which the PAH retains title, the Government shall have a non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the United States the Subject Invention throughout the world. The PAH may elect to provide full or partial rights that it has retained to other parties. The Government shall have the right to use any products or processes used for test and evaluation (including materials for testing or assays) in any other project pursued on behalf of the U.S. Government.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.03 Invention Disclosure, Election of Title, and Filing of Patent Application</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:63.05pt;text-indent:-18.15pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.49pt">The PAH shall disclose each Subject Invention to the  CMF within &#91;* * *&#93; after the inventor</font></div><div style="padding-left:44.9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discloses it in writing to his company personnel responsible for patent matters. The disclosure to the CMF shall be in the form of a written report and shall identify the Agreement under which the invention was made and the identity of the inventor(s). It shall be sufficiently complete in technical detail to convey a clear understanding to the extent known at the time of the disclosure, of the nature, purpose, operation, and the physical, chemical, biological or electrical characteristics of the invention. The disclosure shall also identify any publication, sale, or public use of the invention and whether a manuscript describing the invention has been submitted for publication and, if so, whether it has been accepted for publication at the time of disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_79"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 29 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:45pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)   If the PAH determines that it does not intend to retain title to any such invention, the PAH shall notify the CMF, in writing, within &#91;* * *&#93; of disclosure. However, in any case where publication, sale or public use has initiated the one (1) year statutory period wherein valid patent protection can still be obtained in the United States, the period for such notice may be shortened by the ACC-NJ through CMF to a date that is no more than &#91;* * *&#93; prior to the end of the project.</font></div><div style="padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.55pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)  The PAH shall file its initial patent application on a Subject Invention to which it elects to retain title within &#91;* * *&#93; after election of title or, if earlier, prior to the end of the statutory period wherein valid patent protection can be obtained in the United States after a publication, or sale, or public use.  The  MCDC PAH may elect to file patent applications in additional countries (including the European Patent Office and the Patent Cooperation Treaty) within either &#91;* * *&#93; of the corresponding initial patent application or &#91;* * *&#93; from the date permission is granted by the Commissioner of Patents and Trademarks to file foreign patent applications, where such filing has been prohibited by a Secrecy Order.</font></div><div style="margin-top:0.55pt;padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)   After considering the position of the CMF on behalf of the PAH, a request for extension of the time for disclosure election, and filing under this Article IX, paragraph C, may be approved by ACC-NJ, which ACC-NJ approval shall not be unreasonably withheld.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.04&#160;&#160;&#160;&#160;Conditions When the Government May Obtain Title</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:61.45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon written request to the CMF, the PAH shall convey to the Government title to any Subject Invention under any of the following conditions&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:44.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">If the PAH fails to disclose or elects not to retain title to the Subject Invention within the times specified in Section 10.03 of this Article X, Patent Rights&#59; provided, that the Government may only request title within &#91;* * *&#93; after learning of the failure of the PAH to disclose or elect within the specified times.</font></div><div><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">In those countries in which the PAH fails to file patent applications within the times specified in Section 10.03 of this Article X, Patent Rights&#59; provided, that if the PAH has filed a patent application in a country after times specified in Section 10.03 of this Article X, Patent Rights, but prior to its receipt of the written request by the Government through the CMF, the PAH shall continue to retain title in that country&#59; or</font></div><div><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">In any country in which the PAH decides not to continue the prosecution of any application for, to pay the maintenance fees on, or defend in reexamination or opposition proceedings on, a patent on a Subject Invention.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.05&#160;&#160;&#160;&#160;Minimum Rights to the MCDC PAH and Protection of the MCDC PAH&#8217;s Right to File</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties agree that&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:44.9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.44pt">The PAH shall retain a non-exclusive, royalty-free license throughout the world in each Subject Invention to which the Government obtains title, except if the PAH fails to disclose the invention within the times specified in Section 10.03 of this Article X, Patent Rights. PAH's license extends to the domestic (including Canada) subsidiaries and affiliates, if any, of the PAH within the corporate structure of which the PAH is a party and includes the right to grant licenses of the same scope to the extent that PAH was legally obligated to do so at the time the Project Agreement was funded. The license is transferable only with the approval of the Government, except when transferred to the successor of that part of the business to which the invention pertains. Government approval for license transfer shall not be unreasonably withheld.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:44.9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.44pt">The PAH domestic license may be revoked or modified by the Government to the extent necessary to achieve expeditious practical application of the Subject Invention pursuant to an application for an exclusive license submitted consistent with appropriate provisions at 37 CFR Part 404. This license shall not be revoked in that field of use or the geographical areas in which the PAH has achieved practical application and continues to make the benefits of the invention reasonably accessible to the public. The license in any foreign country may be revoked or modified at the discretion of the Government to the extent </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 30 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:44.9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the PAH, its licensees, or the subsidiaries or affiliates have failed to achieve practical application in that foreign country.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_82"></div><div style="margin-top:4.15pt;padding-left:44.95pt;padding-right:60.85pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)    Before revocation or modification of the license, the Government shall furnish the CMF, and the CMF shall forward to the PAH, a written notice of the Government's intention to revoke or modify the license, and the PAH shall be allowed &#91;* * *&#93; (or such other time as may be authorized for good cause shown) after the notice to show cause why the license should not be revoked or modified.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.06&#160;&#160;&#160;&#160;Action to Protect the Government&#8217;s Interest</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)   The PAH shall execute or have executed and promptly deliver to CMF all instruments necessary to (i) establish or confirm the rights the Government has throughout the world in those Subject Inventions to which the PAH elects to retain title, and (ii) convey title to the Government when requested under Section 10.04 of this Article X, Patent Rights, and to enable the Government to obtain patent protection throughout the world in that Subject Invention.</font></div><div style="padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)   The PAH agrees to require, by written agreement, that its employees working on Project Agreements, other than clerical and non-technical employees, agree to disclose promptly in writing, to personnel identified as responsible for the administration of patent matters and in a format acceptable to the CMF, each Subject Invention made under this Agreement in order that the CMF on behalf of the PAH can comply with disclosure provisions of Section 10.03 of the Article X, Patent Rights, and to execute all papers necessary to file the patent applications on the Subject Invention and to establish the Government&#8217;s rights in the Subject Invention. The PAH acknowledges and shall instruct its employees, through employee agreements or other suitable educational programs, on the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars.</font></div><div style="padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)   The PAH shall notify the CMF of any decision not to continue the prosecution of a patent application, pay maintenance fees, or defend in a reexamination or opposition proceedings on a patent, in any country, not less than &#91;* * *&#93; before the expiration of the response period required by the relevant patent office.</font></div><div style="padding-left:45pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)   The PAH shall include, within the specification of any United States patent application and any patent issuing thereon covering a Subject Invention, the following statement&#58; &#8220;This invention was made with U.S. Government support under Agreement No. W15QKN-16-9-1002 awarded by the ACC-NJ to the MCDC. The Government has certain rights in the invention.&#8221;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.07&#160;&#160;&#160;&#160;Lower Tier Agreements</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:68.1pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall include the Article X, Patent Rights, suitably modified to identify the parties, in all lower tier agreements, regardless of tier, for experimental, development, or research work.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.08&#160;&#160;&#160;&#160;Reporting on Utilization of Subject Inventions</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall submit, on request during the term of the Project Agreement, periodic reports no more frequently than annually on the utilization of a Subject Invention or on efforts at obtaining such utilization that are being made by the PAH or its licensees or assignees. Such reports shall include information regarding the status of development date of first commercial sale or use, gross royalties received by the PAH, and such other data and information as the agency may reasonably specify. The PAH also agrees to provide additional reports as may be requested by the Government, through CMF, in connection with any march-in proceedings undertaken by the Government in accordance with Section 10.10 of this Article X, Patent Rights. Consistent with 35 U.S.C. &#167; 205, the Government agrees it shall not disclose such information to persons outside the Government without permission of the MCDC on behalf of the PAHs.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_85"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 31 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.09 Preference for American Industry</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision of the Article X, Patent Rights, the PAH is not to grant to any person the exclusive right to use or sell any Subject Invention in the United States or Canada unless such person agrees that any product embodying the Subject Invention or produced through the use of the Subject Invention shall be manufactured substantially in the United States or Canada. However, in individual cases, the requirements for such an agreement may be waived by the Government upon a showing by the PAH that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that, under the circumstances, domestic manufacture is not commercially feasible.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.10 March-in Rights</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH agrees that, with respect to any Subject Invention in which its PAH has retained title, the Government, through CMF, has the right to require the PAH to obtain and grant a non-exclusive license to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, and if the PAH refuses such a request, the Government has the right to grant such a licensee itself if the Government determines that&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:61.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Such action is necessary because the PAH or assignee has not taken effective steps, consistent with the intent of this Agreement, to achieve practical application of the Subject Invention&#59;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:61.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Such action is necessary to alleviate health or safety needs which are not reasonably satisfied by the PAH, assignee, or their licensees&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Such action is necessary to meet requirements for public use and such requirements are not reasonably satisfied by the PAH, assignee, or licensees&#59; or</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Such action is necessary because the Agreement required by Section 10.09 of this Article X, Patent Rights, has not been obtained or waived or because a licensee who has the exclusive right to use or sell any Subject Invention in the United States is in the breach of such Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.11 Opportunity to Cure</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of this Article X, Patent Rights, provide that the Government may gain title or license to a Subject Invention by reason of the PAH&#8217;s action, or failure to act, within the times required by this Article X, Patent Rights. Prior to claiming such rights (including any rights under Article X, Section 10.10 March-In Rights), the Government will give written notice to MCDC, through its CMF, and CMF will convey such written notice to PAH, of the Government's intent, and afford the PAH a reasonable time to cure such action or failure to act. The length of the cure period will depend on the circumstances, but in no event will be more than 60 days. PAH may also use the cure period to show good cause why the claiming of such title or right would be inconsistent with the intent of this Agreement in light of the appropriate timing for introduction of the technology in question, the relative funding and participation of the parties in the development, and other factors.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.12 Background Information</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no event shall the provisions set forth in this Article X apply to any Background Inventions or Patents. The PAHs or their subcontractors shall retain the entire right, title, and interest throughout the world to each such Inventions and Patents that each party has brought through MCDC to the project issued under this Agreement and the Government shall not have any rights under this Agreement. Projects to be funded under this Agreement will list Background Inventions and Patents anticipated to be used on the project&#59; such listing may be amended by the parties as appropriate to reflect changes in such plans.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_88"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 32 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 10.13&#160;&#160;&#160;&#160;Survival Rights</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of this Article X shall survive termination of this Agreement under Article II.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the terms of this Article, differing rights in patents may be negotiated among the Parties to each individual project on a case-by-case basis.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XI.&#160;&#160;&#160;&#160;DATA RIGHTS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This is a Data Rights Clause specifically tailored for this OTA to address respective rights of the Government and MCDC on behalf of its actual or prospective MCDC PAHs to such Data as is owned, developed, to be developed or used by an actual or prospective MCDC member entity or PAH (1) as identified in a MCDC member entity(ies) proposal submitted to the Government through the CMF in response to a competitive Government OTA call for proposals, and (2) when such proposal is selected by the Government for funded performance and the Project Agreement is issued by the CMF to that MCDC member entity for performance of such Government OTA project.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.01 Definitions</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:25.75pt;text-align:justify;text-indent:-16.85pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.19pt">&#8220;Commercial Computer Software&#8221; as used in the Article is defined in DFARS 252-227-7014(a)(1) (Jun 1995).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Commercial Computer Software License&#8221; means the license terms under which commercial computer software and Data (as defined in this OTA) is sold or offered for sale, lease or license to the general public.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.44pt">&#8220;Computer Data Base&#8221; as used in this Agreement, means a collection of data recorded in a form capable of being processed by a computer. The term does not include computer software.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Computer program&#8221; as used in this Agreement means a set of instructions, rules, or routines in a form that is capable of causing a computer to perform a specific operation or series of operations.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Computer software&#8221; as used in this Agreement means computer programs, source code, source code listings, object code listings, design details, algorithms, processes, flow charts, formulae and related material that would enable the software to be reproduced, recreated or recompiled. Computer software does not include computer data bases or computer software documentation.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Computer software documentation&#8221; means owner&#8217;s manuals, user&#8217;s manuals, installation instructions, operating instructions, and other similar items, regardless of storage medium, that explain the capabilities of the computer software or provide instructions for using the software.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Data&#8221; as used in this Article of the Agreement, means computer software, computer software documentation, form, fit and function data, and technical data as defined in this Article.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Form, fit and function data&#8221; means technical data that describes the required overall physical, functional and performance characteristics (along with the qualification requirements, if applicable) of an item, component, or process to the extent necessary to permit identification of physically and functionally interchangeable items.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.55pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">&#8220;Government purpose rights&#8221; means the rights to use, modify, duplicate or disclose the &#8220;Data&#8221; licensed with such rights under this OTA within the Government for United States Government purposes only&#59; and to release or disclose data outside the Government to any authorized persons pursuant to an executed non-disclosure agreement for such persons use, modification, or reproduction for United States Government purposes only. United States Government purposes include Foreign Military Sales purposes. Under this Agreement, the period of Government purpose rights shall be no less than ten (10) years and during such time the MCDC member entity or PAH developing or providing such Data to the Government with government purpose rights shall have the sole and exclusive right to use such Data for commercial purposes. In the event this Data is used to perform another project issued to that MCDC member entity or PAH under this OTA during this ten (10) year period, the period of </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 33 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:8.95pt;padding-right:60.55pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government purpose rights shall be extended an additional ten (10) years starting with the date of completion of performance of the additional project.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_91"></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:68.1pt;text-indent:-0.05pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) &#8220;Limited rights&#8221; as used in this Article is as defined in DFARS 252.227-7013(a)(13) (Nov 1995).</font></div><div style="margin-top:0.1pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) &#8220;Restricted rights&#8221; as used in this Article is as defined in DFARS 252.227-7014(a)(14) (Jun 1995).</font></div><div style="margin-top:0.5pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12) &#8220;Specially Negotiated License Rights&#8221; are those rights to Data that have been specifically negotiated between the Government and the MCDC on behalf of the member entity or PAH whose proposal is selected by the Government under a call for proposals issued under the OTA.</font></div><div style="margin-top:0.1pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13) &#8220;Technical data&#8221; means recorded information, regardless of the form or method of the recording, of a scientific or technical nature (including computer software documentation). The term does not include computer software or data incidental to contract administration, such as financial and&#47;or management information.</font></div><div style="margin-top:0.55pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14) &#8220;Unlimited rights&#8221; as used in this Article is as defined n DFARS 252.227-7013(a)(16).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.02&#160;&#160;&#160;&#160;Data Categories</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Category A is the Data developed and paid for totally by private funds, or the PAH's (or its subcontractor's) IR&#38;D funds and it is Data to which the PAH (or its subcontractor) retains all rights. Category A Data shall include, but not be limited to,</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.96pt">Data as defined in this Article and any designs or other material provided by the PAH for a project under this Agreement which was not developed in the performance of work under that project, and for which the PAH retains all rights.</font></div><div><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">Any initial Data or technical, marketing, or financial Data provided at the onset of the project by any of the MCDC member entities or PAHs. Such Data shall be marked &#8220;Category A&#8221; and any rights to be provided to the Government for such Data under a specific project shall be as identified in the proposal submitted to the Government and included into the Technical Direction Letter and CMF issued Project Agreements.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Category B is any Data developed under this OTA with mixed funding, i.e. development was accomplished partially with costs charged to a PAH&#8217;s indirect cost pools and&#47;or costs not allocated to a PAH&#8217;s Project Agreement under this OTA, and partially with Government funding under this OTA. Any Data developed outside of this OTA whether or not developed with any Government funding in whole or in part under a Government agreement, contract or subcontract shall have the rights negotiated under such prior agreement, contract or subcontract&#59; the Government shall get no additional rights in such Data.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:9pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Category C is any Data developed exclusively with Government funds under this OTA. Research and Development performed was not accomplished exclusively or partially at private expense. Under this category,</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:45pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">the Government will have Government Purpose Rights in Data developed exclusively with Government funds under a project funded by the Government under this OTA that is&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:72pt;padding-right:60.85pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   Data pertaining to an item, component, or process which has been or will be developed exclusively with Government funds&#59;</font></div><div style="margin-top:0.15pt;padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:60.7pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   Studies, analyses, test data, or similar data produced for this contract, when the study, analysis, test, or similar work was specified as an element of performance&#59;</font></div><div style="margin-top:0.3pt;padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;padding-right:61.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)   Data created in the performance of the OTA that does not require the development, manufacture, construction, or production of items, components, or processes&#59;</font></div><div><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_94"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 34 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:72pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)  Form, fit, and function data&#59;</font></div><div style="margin-top:0.25pt;padding-left:72pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)   Data necessary for installation, operation, maintenance, or training purposes (other than detailed manufacturing or process data)&#59;</font></div><div style="margin-top:0.15pt;padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)  Corrections or changes to technical data furnished to the Contractor by the Government&#59;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government can only order such Data as is developed under the OTA project where the order request is made within one (1) year following OTA project completion. In the event the Government orders such Data, it shall pay the PAH the reasonable costs for all efforts to deliver such requested Data, including but not limited to costs of locating such Data, formatting, reproducing, shipping, and associated administrative costs.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;text-align:justify;text-indent:3.8pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)     The Government shall have unlimited rights in Data</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:76.5pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   Otherwise publicly available or that has been released or disclosed by PAH without restrictions on further use, release or disclosure, other than a release or disclosure resulting from the sale, transfer, or other assignment of interest in the Data to another party or the sale or transfer of some or all of a business entity or its assets to another party&#59;</font></div><div style="margin-top:0.2pt;padding-left:76.5pt"><font><br></font></div><div style="padding-left:76.5pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Data in which the Government has obtained unlimited rights under another Government contract or as a result of negotiations&#59; or</font></div><div style="margin-top:0.3pt;padding-left:76.5pt"><font><br></font></div><div style="padding-left:76.5pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Data furnished to the Government, under this or any other Government contract or subcontract thereunder, with&#8212;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:94.5pt;padding-right:60.85pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Government Purpose Rights or limited rights and the restrictive condition(s) has&#47;have expired&#59; or</font></div><div style="margin-top:0.15pt;padding-left:94.5pt"><font><br></font></div><div style="padding-left:94.5pt;padding-right:60.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Government purpose rights and the PAH's exclusive right to use such Data for commercial purposes under such contract or subcontract has expired.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    However, any Data developed outside of this OTA whether or not developed with any Government funding in whole or in part under a Government agreement, contract or subcontract shall have the rights negotiated under such prior agreement, contract or subcontract&#59; the Government shall get no additional rights in such Data.</font></div><div style="margin-top:0.2pt;padding-left:49.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  Further, the Government's rights to Commercial Computer Software and Data licensed under a Commercial Computer Software License under this OTA, and the treatment of Data relating thereto, shall be as set forth in the Commercial Computer Software License.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)   The parties to this Agreement understand and agree that the CMF shall require PAHs stamp all documents in accordance with this Article and that the Freedom of Information Act (FOIA) and Trade Secrets Act (TSA) apply to Data.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.03&#160;&#160;&#160;&#160;Allocation of Principal Rights</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:23.15pt;text-align:justify;text-indent:-14.2pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:2.54pt">The Government shall have no rights to Category A Data.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The Government shall have immediate Government Purpose Rights to Category B or C Data upon delivery or project or Agreement completion (whichever is earlier), except that</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_97"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 35 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:49.5pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) where the PAH whose Data it is, is a small business as defined under the Small Business Innovation research Program (SBIR) under 15 U.S.C. 638, and such data was developed under a project designated by the Government in the RPP as an SBIR program project, such PAH automatically shall be entitled to a delay in the start of the Government Purpose Rights period for at least five (5) years from project completion, or such longer period as may be negotiated among the Government and MCDC on behalf of the PAH, and</font></div><div style="margin-top:0.05pt;padding-left:49.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The CMF, at the request of small business or an other than small business MCDC member entity or PAH, may request on such member entity's or PAH's behalf a delay of the start of Government Purpose Rights in Category B or C Data for a period not to exceed five (5) years from project or Agreement completion (whichever is earlier). Such requests will only be made in those cases where the CMF has provided information from the affected actual or prospective PAH demonstrating the need for this additional restriction on Government use and shall be submitted to the ACC-NJ AO for approval, which approval shall not be unreasonably withheld. In the event of any dispute regarding approval of this request, the parties agree to treat this as a dispute and shall follow the provisions of Article VII, Disputes.</font></div><div style="margin-top:0.55pt;padding-left:49.5pt"><font><br></font></div><div style="padding-left:49.5pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) for Article XI.Section 11.02 3(c) Category C Data, the Government shall have only the rights established under prior agreements.</font></div><div style="margin-top:0.05pt;padding-left:49.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) for Article XI.Section 11.02 3(d) Category C Data, the Government shall only have the rights set forth in the Commercial Computer Software Data license agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Data that will be delivered, furnished, or otherwise provided to the Government as specified in a specific project award funded under this Agreement, in which the Government has previously obtained rights, shall be delivered, furnished, or provided with the pre-existing rights, unless (a) the parties have agreed otherwise, or (b) any restrictions on the Government&#8217;s rights to use, modify, reproduce, release, perform, display, or disclose the data have expired or no longer apply.</font></div><div style="margin-top:0.05pt;padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Each proposal submitted by the MCDC member entities in response to a Government call for proposals under this OTA shall include a list of the Category A, B and C Data to be used or developed under the proposal if selected. Rights in such Data shall be as established under the terms of this Agreement, unless otherwise asserted in the proposal and agreed to by the Government. The Government AO will incorporate the list of Category A, B and C Data and the identified rights therefor in the award document.</font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following issuance of a Technical Direction Letter and subsequent CMF issuance of the Project Agreement to the Government selected MCDC member entity (the PAH), the PAH shall update the list to identify any additional, previously unidentified, Data if such Data will be used or generated in the performance of the funded work. Rights in such Data shall be as established under the terms of this Agreement, unless otherwise asserted in a supplemental listing and agreed to by the Government.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.04 Marking of Data</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.65pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for Data delivered with unlimited rights, Data to be delivered under this Agreement subject to restrictions on use, duplication or disclosure shall be marked with the following legend&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.95pt;text-align:justify;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use, duplication, or disclosure is subject to the restrictions as stated in the Agreement between the U.S. Government and the MCDC, Agreement No. W15QKN-16-9-1002, Project Title and the MCDC Project Agreement with &#91;insert name of company&#93; No.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not anticipated that any Category A Data will be delivered to the Government under this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event commercial computer software and Data is licensed under a commercial computer software license under this OTA, a Special License rights marking legend shall be used as agreed to by the parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government shall have unlimited rights in all unmarked Data. In the event that a PAH learns of a release to the Government of its unmarked Data that should have contained a restricted legend, the CMF on behalf of the member</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_100"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 36 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entity or PAH will have the opportunity to cure such omission going forward by providing written notice to the Government AO within three (3) months of the erroneous release.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.05 Copyright</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAHs reserve the right to protect by copyright original works developed under this Agreement. All such copyrights will be in the name of the individual PAH. The PAH(s) hereby grant to the U.S. Government a non- exclusive, non-transferable, royalty-free, fully paid-up license to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, for governmental purposes, any copyrighted materials developed under this agreement, and to authorize others to do so.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event Data is exchanged with a notice indicating that the Data is protected under copyright as a published, copyrighted work and it is also indicated on the Data that such Data existed prior to, or was produced outside of this Agreement, the Party receiving the Data and others acting on its behalf may reproduce, distribute, and prepare derivative works for the sole purpose of carrying out that Party&#8217;s responsibilities under this Agreement with the written permission of the Copyright holder.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copyrighted Data that existed or was produced outside of this Agreement and is unpublished - having only been provided under licensing agreement with restrictions on its use and disclosure - and is provided under this Agreement shall be marked as unpublished copyright in addition to the appropriate license rights legend restricting its use, and treated in accordance with such license rights legend markings restricting its use.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAHs are responsible for affixing appropriate markings indicating the rights of the Government on all Data delivered under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government agrees not to remove any copyright notices placed on Data and to include such notices on all reproductions of the Data.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.06 Data First Produced by the Government&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As to Data first produced by the Government in carrying out the Government&#8217;s responsibilities under this OTA and which Data would embody trade secrets or would comprise commercial or financial information that is privileged or confidential if obtained from the CMF on behalf of any PAH, such Data will, to the extent permitted by law, be appropriately marked with a suitable notice or legend and maintained in confidence by the CMF and any PAH to whom disclosed for three (3) years after the development of the information, with the express understanding that during the aforesaid period such Data may be disclosed and used by the CMF or any PAH, including its respective employees or subcontractors of any tier, (under suitable protective conditions) by or on behalf of the Government  for Government purposes only.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.07 Prior Technology</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">Government Prior Technology&#58; In the event it is necessary for the Government to furnish the CMF or any MCDC member entity or PAH, including their respective employees or their subcontractors of any tier, with Data which existed prior to, or was produced outside of this Agreement, and such Data is so identified with a suitable notice or legend, the Data will be maintained in confidence and disclosed and used only for the purpose of carrying out their responsibilities under this Agreement. Data protection will include proprietary markings and handling, and the signing of non-disclosure agreements by CMF, PAHs, PAH subcontractors of any tier and their respective employees to whom such Data is provided for use under the OTA. Upon completion of activities under this Agreement, such Data will be disposed of as requested by the Government.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">CMF and PAH Prior Technology&#58; In the event it is necessary for the CMF or any PAH to furnish the Government with Data which existed prior to, or was produced outside of this Agreement, and such Data embodies trade secrets or comprises commercial or financial information which is privileged or confidential, and such Data is so identified with a suitable notice or legend, the Data will be maintained in confidence and disclosed and used by the Government and such Government Contractors or contract employees that the Government may hire on a temporary or periodic basis only for the purpose of carrying out the Government&#8217;s responsibilities under this </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 37 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. Data protection will include proprietary markings and handling, and the signing of nondisclosure agreements by such Government Contractors or contract employees. Neither the CMF nor any PAH shall be obligated to provide Data that existed prior to, or was developed outside of this Agreement to the Government.  Upon completion of activities under this Agreement, such Data will be disposed of as requested by the CMF on behalf of itself or PAHs.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_103"></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.8pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)     Oral and Visual Information&#58; If information which the PAH (including their subcontractors of any tier and their respective employees) considers to embody trade secrets or to comprise commercial or financial information which is privileged or confidential is expressly disclosed orally or visually directly to the Government and&#47;or CMF, the exchange of such information must be memorialized in tangible, recorded form and marked with a suitable notice or legend, and furnished to the Government and&#47;or CMF within ten (10) calendar days after such oral or visual disclosure, or the Government and&#47;or CMF shall have no duty to limit or restrict, and shall not incur any liability for any disclosure and use of such information. Upon Government and&#47;or CMF request, additional detailed information about the exchange will be provided subject to restrictions on use and disclosure.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:9pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)     Disclaimer of Liability&#58; Notwithstanding the above, neither the Government nor the CMF shall be restricted in, nor incur any liability for, the disclosure and use of&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:49.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)     Data not identified with a suitable notice or legend as set forth in this Article&#59; nor</font></div><div style="margin-top:0.5pt;padding-left:49.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify;text-indent:40.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)   Information contained in any Data for which disclosure and use is restricted under Article VIII entitled &#8220;Confidential Information&#8221; above, if such information is or becomes generally known without breach of the above, is properly known to the Government or CMF or is generated by the Government or CMF independent of carrying out responsibilities under this Agreement, is rightfully received from a third party without restriction, or is included in Data which the PAH has furnished, or is required to furnish to the Government or CMF without restriction on disclosure and use.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)      Marking of Data&#58; Any Data delivered under this Agreement shall be marked with a suitable notice or legend.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the Paragraphs in this Article, differing rights in Data may be negotiated among the Parties to each individual project on a case-by-case basis.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.08 Lower Tier Agreements</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall include this Article, suitably modified to identify the parties, in all subcontracts or lower tier agreements, regardless of tier, or experimental, developmental, or research work.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 11.09 Survival Rights</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of this Article shall survive termination of this Agreement under Article II.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the terms of this in this Article, differing rights in data may be negotiated among the Parties to each individual Technology Project Agreement on a case-by-case basis.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XII. EXPORT CONTROL</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export Control</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:59.15pt;text-indent:-14.25pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:2.59pt">Information subject to Export Control Laws&#47;International Traffic in Arms Regulation (ITAR)&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:44.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Law 90-629, &#171; Arms Export Control Act, &#187; as amended (22 U.S.C. 2751 et. seq.) requires that all unclassified technical data with military application may not be exported lawfully without an approval, authorization, or license under EO 12470 or the Arms Export Control Act and that such data require an approval, authorization, or license under EO 12470 or the Arms Export Control Act. For purposes of making this determination, the Military Critical Technologies List (MCTL) shall be used as general </font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 38 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:44.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guidance. All documents determined to contain export controlled technical data will be marked with the following notice&#58;</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_106"></div><div style="margin-top:4.15pt;padding-left:44.95pt;padding-right:61pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">WARNING-</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> this document contains technical data whose export is restricted by the Arms Export Control Act (Title 22, U.S.C., and Sec 2751, et seq.) or the Export Administration Act of 1979, as amended, Title 50, U.S.C., App. 2401 et seq. Violations of these export laws are subject to severe criminal penalties. Disseminate in accordance with provision of DOD Directive 5230.25.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:59.25pt;text-indent:-14.3pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:2.64pt">Flowdown.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall include this Article, suitably modified, to identify all Parties, in all Project Agreements or lower tier agreements. This Article shall, in turn, be included in all sub-tier subcontracts or other forms of lower tier agreements, regardless of tier.</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XIII. TITLE AND DISPOSITION OF PROPERTY</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.01 Definitions</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:61pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Article, &#8220;property&#8221; means any tangible personal property other than property actually consumed during the execution of work under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.02 Title to Property</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant items of property are expected to be acquired under this Agreement by the PAH. Title to any item of property valued $10,000.00 or less that is acquired by the PAH pursuant to a Project Agreement with the MCDC, in performance of the project issued to the PAH under this OTA shall vest in the PAH upon acquisition with no further obligation of the Parties unless otherwise determined by the Government AO. Should any item of property with an acquisition value greater than $10,000.00 be required, the PAH through the CMF shall obtain prior written approval of the Government AO. Title to this property shall also vest in the MCDC member entity or PAH upon acquisition. That PAH shall be responsible for the maintenance, repair, protection, and preservation of all such property at its own expense. Property acquired pursuant to this clause shall not be considered as in exchange for services in performance of the project, but shall be considered a Government contribution to the project.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 13.03 Government Furnished Property</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government may provide the PAH Government Furnished Property (GFP) to facilitate the performance of individual projects under this Other Transaction Agreement. Such GFP will be specifically identified to a particular project and incorporated into the applicable Project Agreement. The GFP shall be utilized only for the performance of that individual project unless a specific exception is made in writing by the Agreements Officer.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall assume the risk of and be responsible for any loss or destruction of, or damage to, any Government Furnished Property while in its possession or control, with the exception of reasonable wear and tear or reasonable and proper consumption. All property shall be returned at the end of the Project Agreement in as good as condition as when received with the exception of said reasonable wear and tear or in accordance with the provisions of the Project Agreement regarding its use. The PAH shall obtain explicit written authorization for any transfer or disposition of Government Furnished Property.</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XIV. CIVIL RIGHTS ACT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement and any resulting Project Agreement is subject to the compliance requirements of Title VI of the Civil Rights Act of 1964 as amended (42 U.S.C. 2000-d) relating to nondiscrimination in Federally assisted programs. It is the responsibility of each PAH to assure the PAH has signed an Assurance of Compliance with the nondiscriminatory provisions of the Act (Attachment 1).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_109"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 39 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XV.&#160;&#160;&#160;&#160;NO SMALL BUSINESS AFFILIATION</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XVI.&#160;&#160;&#160;&#160;ANTITRUST</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the MCDC Articles of Collaboration, members agree to comply with all applicable U.S. laws, including U.S. antitrust laws. The MCDC is recognized under the National Cooperative Research and Production Act of 1993 and the MCDC will be similarly filing under the Act.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XVII.&#160;&#160;&#160;&#160;SECURITY &#38; OPSEC</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:68.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All PAH shall comply with DFARS 252.204-7012 (Oct 2016)&#58; Safeguarding Covered Defense Information and Cyber Incident Reporting when applicable.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:49pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covered Defense Information (CDI) will be identified at the Project Agreement level. The MCDC Member shall comply with DFARS 252.204-7012 (Oct 2016)&#58; Safeguarding Covered Defense Information and Cyber Incident Reporting, which includes implementing on its covered contractor information systems the security requirements specified by DFARS 252.204-7012. Nothing in this paragraph shall be interpreted to foreclose the MCDC Member's right to seek alternate means of complying with the security requirements in National Institute of Standards and Technology (NIST) Special Publication (SP) 800-171 (as contemplated in DFARS 252.204-7008 (Compliance with Safeguarding Covered Defense Information Controls) (Oct 2016) and DFARS 252.204-7012 (Safeguarding Covered Defense Information and Cyber Incident Reporting (Oct 2016)).</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work performed by a PAH under a Project Agreement may involve access to Controlled Unclassified Information (CUI). All Controlled Unclassified Information (CUI) developed under this Agreement will be managed in accordance with DoD Manual 5200.01, Volume 4 dated February 24, 2012. Contractor personnel shall comply with applicable Technology Protection Plans (TPP), Interim Program Protection Plans (IPPP) and&#47;or Program Protection Plans (PPP). If a project involves a Controlled Unclassified Information (CUI) effort, the below listed Department of Defense Directives, Federal Acquisition Regulation (FAR) and the Defense Federal Acquisition Regulation Supplement (DFARS), and ARDEC clauses will be incorporated into the Project Agreements by reference with the same force and effect as if they were given in full text.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:45.75pt;padding-right:60.6pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Each project Scope of Work will be provided by the Agreements Officer Representative (AOR) to the Joint Project Manager- Medical Countermeasure Systems Office for dissemination to the appropriate Fort Detrick COMSEC officer prior to award for review.</font></div><div style="padding-left:45.75pt;padding-right:60.6pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Each project Scope of Work will be subject to Ft. Detrick policy and procedure according to DoD 5220.22- M, (National Industrial Security Program Operating Manual, NISPOM), as deemed applicable and appropriate during the security review process and prior to award. Additional COMSEC requirements may be required at other locations&#47;facilities (based on service&#47;command requirements).</font></div><div style="padding-left:45.75pt;padding-right:60.7pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Specific applicable policies, instructions, and regulations will be identified in each project. Throughout the life of the Agreement, if any policy, instruction, or regulation is replaced or superseded, the replacement or superseding version shall apply. The following is a snapshot of key regulatory documents, policies, regulations, etc. that may be applicable at time of project award.</font></div><div style="margin-top:0.05pt;padding-left:63.8pt;text-indent:-18.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">DoDM 5200.01 DoD Information Security Program, 24 Feb 12</font></div><div style="padding-left:63.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.72pt">DoD 5200.2-R Personnel Security Regulation, Jan 87</font></div><div style="padding-left:63.8pt;text-indent:-18.1pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.34pt">DoDD 5220.22 National Industrial Security Program, 28 Feb 06</font></div><div style="margin-top:0.05pt;padding-left:63.75pt;padding-right:60.85pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">DoDI 5200.01, Information Security Program and Protection of Sensitive Compartmented  Information, 24 Feb 2012</font></div><div style="margin-top:0.05pt;padding-left:63.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.29pt">DoD 5400.7-R, DOD Freedom of Information Act, Sept 98</font></div><div style="padding-left:63.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.39pt">DoDD 2000.12, Antiterrorism Program, 18 Aug 03</font></div><div style="margin-top:0.05pt;padding-left:63.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.72pt">FAR Clause 4.402, Safeguarding Classified Information Within Industry</font></div><div style="padding-left:63.75pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.72pt">FAR Clause 52.204-2, Security Requirements, Aug 1996</font></div><div><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_112"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 40 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:45pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)  For all Project Agreements, the following statement shall be flowed to the MCDC member entities unless otherwise stated within the Project Agreements.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)   Classification guidance for requirement - &#8220;The security level for this agreement is UNCLASSIFIED.&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)  Anti-Terrorism Level I Training. This provision is for PAH employees with an area of performance within an Army controlled installation, facility or area. All PAH employees requiring access to  Army installations, facilities and controlled access areas shall complete AT Level I awareness training within sixty (60)-calendar- days after project start date or effective date of incorporation of this requirement into the project, whichever is applicable. PAH(s) shall submit certificates of completion for each affected employee and PAH employee, to the AOR or to the Agreements Officer, if an AOR is not assigned, within thirty (30)-calendar-days after completion of training by all employees or personnel. AT level I awareness training is available at the following website&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;atlevel1.dtic.mil&#47;at</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)  Access and General Protection&#47;Security Policy and Procedures. This standard language text is for PAH employees with an area of performance within an Army controlled installation, facility or area. PAH employees shall comply with applicable installation, facility and area commander installation&#47;facility access and local security policies and procedures (provided by government representative). The PAH also shall provide all information required for background checks to meet installation access requirements to be accomplished by installation Provost Marshal Office, Director of Emergency Services or Security Office. The PAH workforce must comply with all personal identity verification requirements as directed by DOD, HQDA and&#47;or local policy. In addition to the changes otherwise authorized by the changes clause of this agreement, should the Force Protection Condition (FPCON) at any individual facility or installation change, the Government may require changes in PAH security matters or processes.</font></div><div style="padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.65pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)  Anti-Terrorism Awareness Training for PAH Personnel Traveling Overseas. This standard language text requires U.S.-based PAH employees to make available and to receive Government provided area of responsibility (AOR) specific AT awareness training as directed by AR 525-13. Specific AOR training content is directed by the combatant commander with the unit Anti-terrorism Officer (ATO) being the local point of contact.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)  iWATCH Training. This standard language is for PAH employees with an area of performance within an Army- controlled installation, facility or area. PAH(s) shall brief all employees on the local iWATCH program (training standards provided by the requiring activity ATO). This local developed training will be used to inform employees of the types of behavior to watch for and instruct employees to report suspicious activity to the AOR. This training shall be completed within sixty (60)-calendar-days of a Project Agreement award and within sixty (60)-calendar- days of new employees&#8217; commencing performance with the results reported to the AOR NLT thirty (30)-calendar-days after Project Agreement award.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)  Impact on PAH performance during increased FPCON during periods of increased threat. During FPCONs Charlie and Delta, services may be discontinued &#47; postponed due to higher threat. Services will resume when FPCON level is reduced to Bravo or lower.</font></div><div style="padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)  Random Antiterrorism Measures Program (RAMP) participation. PAH personnel working on an installation are subject to participation in Installation RAMP security program (e.g. vehicle searches, wearing of ID badges, etc.).</font></div><div style="margin-top:0.55pt;padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.55pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) PAH Employees Who Require Access to Government Information Systems. All PAH employees with access to a government information system must be registered in the ATCTS (Army Training Certification Tracking System) at commencement of services, and must successfully complete the DOD Information Assurance Awareness prior to access to the IS and then annually thereafter.</font></div><div style="margin-top:0.1pt;padding-left:45pt;text-indent:-18pt"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 41 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)  For projects that Require an OPSEC Standing Operating Procedure&#47;Plan. The PAH shall develop an OPSEC Standard Operating Procedure (SOP)&#47;Plan within ninety (90)-calendar-days of project award to be reviewed and approved by the responsible Government OPSEC officer, per AR 530-1, Operations Security.</font></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_115"></div><div style="margin-top:4.15pt;padding-left:45.7pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This plan will be submitted by MCDC on behalf of the PAH(s) to the AO for coordination of approvals. This SOP&#47;Plan will include the Government's critical information, why it needs to be protected, where it is located, who is responsible for it and how to protect it. In addition, MCDC shall identify an individual who will be an OPSEC Coordinator. MCDC will ensure this individual becomes OPSEC Level II certified per AR 530-1.</font></div><div><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13) For projects that Require OPSEC Training. Per AR 530-1, Operations Security, new PAH employees assigned by the PAH(s) to perform under a MCDC Project Agreement must complete Level I OPSEC awareness training within thirty (30)-calendar-days of their reporting for duty. All PAH employees performing under an OPSEC-designated project must complete annual Level I OPSEC awareness training. Level I OPSEC awareness training is available at the following website&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;cdsetrain.dtic.mil&#47;opsec&#47;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)  For Information assurance (IA)&#47;information technology (IT) training. All PAH employees must complete the DoD IA awareness training before issuance of network access and annually thereafter. All PAH(s) working IA&#47;IT functions must comply with DoD and Army training requirements in DoDD 8570.01, DoD 8570.01-M and AR 25-2 within six (6) months of employment.</font></div><div style="padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)  For information assurance (IA)&#47;information technology (IT) certification. Per DoD 8570.01-M , DFARS 252.239-7001 and AR 25-2, the PAH employees supporting IA&#47;IT functions shall be appropriately certified upon Project Agreement award. The baseline certification as stipulated in DoD 8570.01-M must be completed upon Project Agreement award.</font></div><div style="padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.65pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For PAH personnel authorized to accompany the Force. DFARS Clause 252.225-7040, Contractor Personnel Authorized to Accompany U.S. Armed Forces Deployed Outside the United States. The clause shall be used in projects that authorize PAH personnel to accompany U.S. Armed Forces deployed outside the U.S. in contingency operations&#59; humanitarian or peacekeeping operations&#59; or other military operations or exercises, when designated by the combatant commander. The clause discusses the following AT&#47;OPSEC related topics&#58; required compliance with laws and regulations, pre-deployment requirements, required training (per combatant command guidance) and personnel data required.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.6pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17) For projects requiring Performance or Delivery in a Foreign Country, DFARS Clause 252.225-7043, Antiterrorism&#47;Force Protection for Defense Contractors Outside the U.S. The clause shall be used in projects that require performance or delivery in a foreign country. This clause applies to both contingencies and non-contingency support. The key AT requirement is for non-local national PAH personnel to comply with theater clearance requirements and allows the combatant commander to exercise oversight to ensure the PAH&#8217;s compliance with combatant commander and subordinate task force commander policies and directives.</font></div><div style="margin-top:0.5pt;padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For projects requiring the PAH to obtain U.S. Government Common Access Cards, installation badges, and&#47;or access passes, the PAH shall return all issued U.S. Government Common Access Cards, installation badges, and&#47;or access passes to the AOR when the project is completed or when the PAH employee no longer requires access to the installation or facility.</font></div><div style="padding-left:45pt;text-indent:-22.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19) For projects that require access to Potential Critical Program Information (PCPI) &#47; Critical Program Information (CPI)&#58;</font></div><div style="padding-right:60.85pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_118"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 42 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:63pt;padding-right:60.6pt;text-align:justify;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) The PAH shall comply with the associated Interim Program Protection Plan (IPPP) &#47; Program Protection Plan (PPP) &#47; or Technology Protection Plan (TPP). The PAH shall comply with DOD, DA and AMC technology protection requirements in DODI 5200.39, AR 70-1, DA PAM 70-3 and AMC- R-380-13.</font></div><div><font><br></font></div><div style="padding-left:45pt;padding-right:60.65pt;text-align:justify;text-indent:-22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20) Work by the Consortium Management Firm (CMF) and Project Agreement Holder&#47;Consortium Member (PAH) under Project Agreements may involve access to Controlled Unclassified Information (CUI) as well as information classified as &#8220;Confidential&#8221;, &#8220;Secret&#8221;, or &#8220;Top Secret&#8221;. The CMF and the PAH and their employees who work on such Project Agreements shall comply with (1) the Security Agreement (DD Form 441), including the National Industrial Security Program Operation Manual (DOD 5220.22M), (2) any revisions to that manual that may be issued, and (3) the Agreement security classification specification (DD form 254) if included, and all security requirements including but not limited to OPSEC plans and those security requirements specific to the individual projects. During the course of this Agreement the Parties may determine that information developed by the PAH and&#47;or the Government pursuant to this Agreement shall be treated as classified. Such information shall be classified in accordance with DOD 5220.22M.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:63pt;padding-right:60.85pt;text-align:justify;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Each project Scope of Work will be provided by the AOR to the AOR&#8217;s local Security Office prior to award for review. For classified efforts that Security Office will provide the overall Security Classification Specification (DD Form 254). The PAH will be responsible for providing a copy of any Subcontract Security Classification Specification (DD Form 254) to lower tier awards.</font></div><div style="margin-top:0.55pt;padding-left:63pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:63pt;padding-right:60.7pt;text-align:justify;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)  If a Project Agreement involves a classified effort or a Controlled Unclassified Information (CUI) effort, Department of Defense Directives, Federal Acquisition Regulation (FAR) and the Defense Federal Acquisition Regulation Supplement (DFARS) clauses by reference, and local clauses will be incorporated with the same force and effect as if they were given in full text shall be incorporated into this agreement.</font></div><div style="margin-top:0.05pt;padding-left:63pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:63pt;padding-right:60.8pt;text-align:justify;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Specific applicable policies, instructions, and regulations will be identified in each Project Agreement. Throughout the life of the Project Agreement, if any policy, instruction, or regulation is replaced or superseded, the replacement or superseding version shall apply.</font></div><div style="margin-top:0.55pt;padding-left:63pt;text-indent:-13.5pt"><font><br></font></div><div style="padding-left:63pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Agreement Structure</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:81pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)    Research and Development under these Project Agreements will be in accordance with the Other Transaction Agreement (OTA) between the United States Army Contracting Command &#8211; New Jersey (ACC-NJ) and the MCDC in care of its Consortium Management Firm (CMF), Advanced Technology International (ATI).</font></div><div style="padding-left:81pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:81pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)   Within the Project Agreements, sharing of classified information will be on a need to know basis as directed in required Project Agreements.</font></div><div style="margin-top:0.05pt;padding-left:81pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii)   Upon Project Agreement completion or termination, the PAH must&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Return ALL classified information received or generated under the Project Agreement&#59;</font></div><div style="margin-top:0.05pt;padding-left:81pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Destroy all of the classified information&#59; or,</font></div><div style="padding-left:81pt;padding-right:249.1pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:232%">(3) Request retention for a specified period of time </font></div><div style="padding-left:0.44pt;padding-right:249.1pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flowdown for OPSEC&#47;Security Requirements&#58;</font></div><div style="padding-right:249.1pt;text-align:justify"><font><br></font></div><div style="padding-left:9.05pt;padding-right:60.65pt;text-align:justify;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCDC shall include the aspects of this Article as they pertain to each project requirement. Each project will include specific OPSEC &#47; Security requirements within each SOW and RPP. The requirements delineated  within each project, in turn, shall be included in all sub-tier subcontracts or other forms of lower-tier agreements, regardless of tier.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_121"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 43 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XVIII. SAFETY</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall adhere to all local, state, and federal rules and regulations required in maintaining a safe and non- hazardous occupational environment throughout the duration of the project. At a minimum, the PAH shall provide the following reports and materials on an as needed basis&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accident&#47;Incident Report</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The PAH shall report immediately any major accident&#47;incident (including fire) resulting in any one or more of the following&#58; causing one or more fatalities or one or more disabling injuries&#59; damage of Government property exceeding $10,000&#59; affecting program planning or production schedules&#59; degrading the safety of equipment under a project, such as personnel injury or property damage may be involved&#59; identifying a potential hazard requiring corrective action. The PAH shall prepare the report (DI-SAFT-81563) for each incident.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Safety Data Sheets (MSDS)&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall prepare and maintain MSDS for all materials used and generated under this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental Requirements include the following&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pollution Prevention&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration should be given to alternative materials and processes in order to eliminate, reduce, or minimize hazardous waste being generated. This is to be accomplished while minimizing item cost and risk to item performance.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Compliance</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; All activities must be in compliance with Federal, State, and local environmental  laws and regulations, Executive orders, treaties, and agreements. The PAH shall evaluate the environmental consequences and identify the specific types and amounts of hazardous waste being generated during the conduct of efforts undertaken under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hazardous Waste Report&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH shall evaluate the environmental consequences and identify the specific types and amounts of hazardous waste being generated during this Agreement. The PAH shall submit a Hazardous Waste Report IAW DI-MGMT-80899.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disposal Instructions for Residual&#47;Scrap Materials</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The PAH shall dispose of all residual and scrap materials generated from this Agreement, including high explosives. The PAH shall specify the anticipated quantities, methods, and disposal costs.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XIX. REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 19.01 Representations and Warranties of All Parties</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Party to this Agreement represents and warrants to the other Parties that (1) it is free to enter into this Agreement&#59; (2) in so doing, it will not violate any other agreement to which it is a party&#59; and (3) it has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 19.02 Limitations</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as expressly provided herein, no party to this Agreement makes any warranty, express or implied, either in fact or by operation of law, by statute or otherwise, relating to (1) any research conducted under this agreement, or (2) any invention conceived and&#47;or reduced to practice under this agreement, or (3) any other intellectual property developed under this Agreement, and each party to this Agreement specifically disclaims any implied warranty of merchantability or warranty of fitness for a particular purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_124"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 44 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XX. LIABILITY OF THE PARTIES</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 20.01 Waiver of Liability</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the activities undertaken pursuant to this Agreement, no Party shall make any claim against the others, employees of the others, the others&#8217; related entities (e.g., Government, contractors, subcontractors, etc.), or employees of the others&#8217; related entities for any injury to or death of its own employees or employees of its related entities, or for damage to or loss of its own property or that of its related entities, whether such injury, death, damage or loss arises through negligence or otherwise, except in the case of willful misconduct.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 20.02 Damages</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Parties shall not be liable to each other for consequential, punitive, special and incidental damages or other indirect damages, whether arising in contract (including warranty), tort (whether or not arising from the negligence of a Party) or otherwise, except to the extent such damages are caused by a Party's willful misconduct&#59; Notwithstanding the foregoing, claims for contribution toward third-party injury, damage, or loss are not limited, waived, released, or disclaimed.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 20.03 Extension of Waiver of Liability</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH agrees to extend the waiver of liability as set forth above subawardees at any tier under an Project Agreement by requiring them, by contract or otherwise, to agree to waive all claims against the Parties to this Agreement.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 20.04 Applicability</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the other provisions of this article, this Waiver of Liability shall not be applicable to&#58;</font></div><div style="margin-top:0.05pt;padding-left:27pt;padding-right:60.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Claims between the PAH and the CMF regarding a material breach, noncompliance, or nonpayment of funds&#59;</font></div><div style="margin-top:0.05pt;padding-left:27pt;padding-right:60.9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Claims for damage caused by willful misconduct&#59; and</font></div><div style="margin-top:6.05pt;padding-left:27pt;text-indent:1.15pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Intellectual property claims.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 20.05&#160;&#160;&#160;&#160;Limitation of Liability</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In no case shall the CMF, or the PAH&#8217;s financial liability exceed the amount obligated by the Government or committed as a Cash Contribution or In-kind Contribution by a MCDC member entity under a Project Agreement. Nothing in this Article shall be construed to create the basis of a claim or suit where none would otherwise exist.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XXI.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.01&#160;&#160;&#160;&#160;Fees</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PAH will not be constrained from the payment of an appropriate fee or profit for the effort being conducted on a Project Agreement when cost share is not being contributed. The fees shall be specific to the individual Project Agreements and negotiated on project by project basis.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.02&#160;&#160;&#160;&#160;Waiver</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No waiver of any rights shall be effective unless assented to in writing by the party (Government, MCDC, CMF, or PAH) to be charged, and the waiver of any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.03&#160;&#160;&#160;&#160;Section Headings</font></div><div><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_127"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 45 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:9pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The headings and subheadings of the sections of this Agreement are intended for convenience of reference only and are not intended to be a part of, or to affect the meaning or interpretation of this Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.04 Severability</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision&#59; Provided that no such severability shall be effective if the result of such action materially changes the economic benefit of this Agreement to the Parties.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.05 Force Majeure</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No failure or omission by the CMF or the MCDC PAH in the performance of any obligation of this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from any cause or causes beyond the control of the Parties, including but not limited to, the following&#58; acts of God&#59; Acts or omissions of any Government&#59; Any rules, regulations or orders issued by any Governmental authority or by any officer, department, and agency or instrumentality thereof&#59; fire&#59; storm&#59; flood&#59; earthquake&#59; accident&#59; war&#59; rebellion&#59; insurrection&#59; riot&#59; and invasion and provided that such failure or omission resulting from one of the above causes is cured as soon as is practicable after the occurrence of one or more of the above mentioned causes.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.06 Regulatory Affairs</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development and production of medical products and processes fall under the purview of the Food and Drug Administration (FDA) and research on these products involving animal or human studies is regulated by other laws, directives, and regulations. Project Awards under this Agreement that involve work in support of or related to FDA regulatory approval will address contingencies for Government access to regulatory rights in the event of product development abandonment or failure. Efforts conducted under this OTA shall be done ethically and in accordance with all applicable laws, directives, and regulations.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Government shall ensure performance includes regulatory expertise and guidance for candidate medical countermeasure development efforts&#58;</font></div><div style="padding-left:45pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">This includes allowing the government to discuss&#47;negotiate in partnership with the consortium how to assume appropriate risk in regulatory strategies. The government will review, negotiate, and come to consensus with the PAH on product-specific risk-based decisions.</font></div><div style="padding-left:44.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAHs will use all regulatory programs to accelerate the pace of candidate medical countermeasure development, including fast-track status, and as appropriate meeting requirements for priority review vouchers, applying for breakthrough therapy and accelerated approval as appropriate (see FDA Guidance for Industry&#58; Expedited Programs for Serious Conditions &#8211; Drugs and Biologics).</font></div><div style="padding-left:44.95pt;padding-right:60.9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAH will provide FDA submissions to the government such as all documentation requested by FDA and all proposals to FDA.</font></div><div style="padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAH will allow the government to monitor all FDA communications by listening to teleconferences and attending meetings.</font></div><div style="padding-left:44.95pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAH will allow the government to attend regulatory site visits and audits, and actively participate in all third-party audits.</font></div><div style="padding-left:44.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAH will comply with Quality Assurance according to negotiated standards with the government on reports, material for Interim Fielding Capability (such as Emergency Use Authorization or Expanded Access Protocols), product for trials, prototypes, etc.</font></div><div style="margin-top:0.05pt;padding-left:44.95pt;padding-right:60.8pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.39pt">PAH will provide strategies to address contingencies that could arise from regulatory directives, and regulatory failures.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.07 Radioactive Materials</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAH shall ensure compliance with the provisions of Title 10 CFR 21. This regulation establishes procedures and requirements for implementation of Section 206 of the Energy Reorganization Act of 1974.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.08 Recombinant DNA</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_130"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 46 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAH shall ensure that all work involving the use of recombinant DNA will be in compliance with guidance provided at the following website&#58; </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www4.od.nih.gov&#47;oba</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (National Institutes of Health &#91;NIH&#93; Guidelines for Research Involving Recombinant DNA Molecules).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.09 Required Compliance for Use of Laboratory Animals</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provisions contained in this award or incorporated by reference herein, the PAH is expressly forbidden to use or subcontract for the use of laboratory animals in any manner whatsoever without the express written approval of the US Army Medical Research and Materiel Command, Animal Care and Use Office,. The PAH shall receive written approval to begin research under the applicable protocol proposed for a Project Agreement from the US Army Medical Research and Materiel Command, Animal Care and Use Office under separate letter to the PAH and Principal Investigator. A copy of this approval will be provided to the ACC-NJ for the official file. Non-compliance with any provision of this clause may result in the termination of award. Information  is&#160;&#160;&#160;&#160;provided&#160;&#160;&#160;&#160;at&#160;&#160;&#160;&#160;the&#160;&#160;&#160;&#160;following&#160;&#160;&#160;&#160;website </font><font style="color:#3953a4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;mrmc.amedd.army.mil&#47;index.cfm&#63;pageid&#61;Research_Protections.acuro_regulations</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The PAH will conduct advanced development&#47;pivotal studies including human safety studies, animal efficacy studies or clinical studies required for approval using validated endpoints, and other studies as deemed necessary by the FDA for licensure of the candidate product in adherence to current Good Laboratory Practice regulations, current Good Clinical Practice regulations, and all other applicable FDA regulations in the conduct of non-clinical and clinical studies as defined by FDA guidance (21 CFR Parts 210-211).</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.10 Required Compliance for Use of Human Subjects</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research under this award involving the use of human subjects may not begin until the U.S. Army Medical  Research and Materiel Command's Office of Research Protections, Human Research Protections Office (HRPO) approves the protocol in accordance with 45 CFR Part 46. Written approval to begin research or subcontract for the use of human subjects under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to ACC-NJ for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award. Information is provided at the following website&#58; </font><font style="color:#3953a4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;mrmc.amedd.army.mil&#47;index.cfm&#63;pageid&#61;Research_Protections.hrpo</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.11 Required Compliance for use of Human Anatomical Substances</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research at funded institutions using human anatomical substances may not begin until the U.S. Army Medical Research and Materiel Command's Office of Research Protections, Human Research Protections Office (HRPO) approves the protocol. Written approval to begin research or subcontract for the use of human anatomical substances under the applicable protocol proposed for this award will be issued from the US Army Medical Research and Materiel Command, HRPO, under separate letter to the funded institution and the Principal Investigator. A copy of this approval will be provided to ACC-NJ, from the CMF, for the official file. Non-compliance with any provision of this clause may result in withholding of funds and or the termination of the award. Information is provided at the following web site&#58; </font><font style="color:#3953a4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;mrmc.amedd.army.mil&#47;index.cfm&#63;pageid&#61;Research_Protections.hrpo</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.12 Compliance with current Good Manufacturing Processes (cGMP)</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing Standards as appropriate for the level of prototype Material used for clinical trials, pivotal non- clinical studies, consistency lots, and other uses as defined in regulatory plans should be compliant with current Good Manufacturing Processes (cGMP) as defined by FDA guidance (21 CFR Parts 210-211). If at any time during the life of the award, the PAH fails to comply with cGMP in the manufacturing, processing and packaging of this product and such failure results in a material adverse effect on the safety, purity or potency of the product (a material failure) as identified by the FDA, the PAH shall have thirty (30) calendar days from the time such material failure is identified to cure such material failure.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_133"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 47 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.4pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.13 Registration with Select Agent Program</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where required, consortium members performing studies and tasks using select biological agent or toxins should be registered with the program with the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS) or the Animal and Plant Health Inspection Services (APHIS), U.S. Department of Agriculture (USDA), as applicable, before performing work, in accordance with 42 CFR 73. No Government funds can be used for work involving Select Agents, as defined in 42 CFR 73, if the final registration certificate is denied. Listings of select agents and toxins, biologic agents and toxins, and overlap agents or toxins as well as information about the registration process, can be obtained on the Select Agent Program Web site at http&#58;&#47;&#47;www.cdc.gov&#47;od&#47;sap&#47;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.14 Duty-Free Entry</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:22.65pt;text-indent:-13.7pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.61pt">Definitions</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As used in this clause &#8211;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:60.95pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#8220;Component,&#8221; means any item supplied to the Government as part of an end product or of another component.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) &#8220;Customs territory of the United States&#8221; means the 50 States, the District of Columbia, and Puerto Rico.</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#8220;Eligible product&#8221; means &#8211;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) &#8220;Designated country end product&#8221; as defined in the Trade Agreements clause&#59;</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:60.8pt;text-align:justify;text-indent:-27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) &#8220;Free Trade Agreement country end product&#8221; other than a &#8220;Bahrainian end product&#8221; or a &#8220;Moroccan end product&#8221; as defined in the Buy American Act &#8211; Free Trade Agreements &#8211; Balance of Payments Program&#59; or</font></div><div style="padding-left:72pt;padding-right:60.95pt;text-align:justify;text-indent:-27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) &#8220;Canadian end product&#8221; as defined in Alternate I of the Buy American Act &#8211; Free Trade Agreements &#8211; Balance of Payments Program.</font></div><div style="padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) &#8220;Qualifying country&#8221; and &#8220;qualifying country end product&#8221; have the meanings given in the Trade Agreements clause, the Buy American Act and Balance of Payments Program clause, or the Buy American Act&#8212;Free Trade Agreements&#8212;Balance of Payments Program.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:26.95pt;padding-right:60.75pt;text-align:justify;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Except as provided in paragraph (i) of this clause, or unless supplies were imported into the customs territory of the United States before the date of a Project Agreement or the applicable subcontract, the price of this Agreement shall not include any amount for duty on-</font></div><div style="padding-left:45pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) End items that are eligible products or qualifying country end products&#59;</font></div><div style="padding-left:45pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Components (including, without limitation, raw materials and intermediate assemblies) produced or made in qualifying countries, that are to be incorporated in U.S &#8211; made end products to be delivered under an Project Agreement&#59; or</font></div><div style="margin-top:0.1pt;padding-left:45pt;padding-right:60.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Other supplies for which the PAH estimates that duty will exceed $200 per shipment into the customs territory of the Unites States</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The PAH shall &#8211;</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.7pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Claim duty-free entry only for supplies that the PAH intends to deliver to the Government under an Project Agreement, either as end items or components of end items&#59; and</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)  Pay duty on supplies, or any portion thereof, that are diverted to nongovernmental use, other than &#8211;</font></div><div style="padding-left:40.5pt;text-indent:5.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i) Scrap or salvage&#59; or</font></div><div style="padding-left:45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Competitive sale made, directed, or authorized by the Agreements Officer.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27pt;padding-right:60.85pt;text-indent:-18.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.39pt">Except as the PAH may otherwise agree, the Government will execute duty-free entry certificates and will afford such assistance as appropriate to obtain the duty-free entry of supplies &#8211;</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.9pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  For which no duty is included in the Project Agreement price in accordance with paragraph (b) of this clause&#59; and</font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)  For which shipping documents bear the notation specified in paragraph (e) of this clause.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27pt;padding-right:60.95pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">For foreign supplies for which the Government will issue duty-free entry certificates in accordance with this clause, shipping documents submitted to Customs shall &#8211;</font></div><div style="margin-top:0.05pt;padding-left:27pt;text-indent:-0.01pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) Consign the shipments to the appropriate &#8211;</font></div><div style="padding-left:40.5pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)   Military department in care of the PAH, including the PAH&#8217;s delivery address&#59; or</font></div><div style="margin-top:0.05pt;padding-left:40.5pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)  Military installation&#59; and</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_136"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 48 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:27pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Include the following information&#58;</font></div><div style="padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)    Prime Agreement number and, if applicable, delivery order number.</font></div><div style="padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)   Number of the subcontract for foreign supplies, if applicable.</font></div><div style="margin-top:0.05pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)  Identification of the carrier.</font></div><div style="margin-top:0.05pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) (A) For direct shipments to a U.S. military installation, the notation&#58; &#8220;UNITED STATES GOVERNMENT DEPARTMENT OF DEFENSE Duty-Free Entry to be claimed pursuant to Section XXII, Chapter 98, Subchapter VIII, Item 9808.00.30 of the Harmonized Tariff Schedule of the United States. Upon arrival of shipment at the appropriate port of entry, District Director of Customs, please release shipment under 19 CFR Part 142 and notify Commander, Defense Contract management Agency (DCMA) New York, ATTN&#58; Customs Team, DCMAE-GNTF, 207 New York Avenue, Staten Island, New York, 10305-5013, for execution of Customs Form 7501, 7501A, or 7506 and any required duty-free entry certificates.&#8221;</font></div><div style="margin-top:0.1pt;padding-left:67.5pt;padding-right:60.85pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B) If the shipment will be consigned to other than a military installation, e.g., a domestic contractor&#8217;s plant, the shipping document notation shall be altered to include the name and address of the contractor, agent, or broker who will notify Commander, DCMA New York, for execution of the duty- free certificate. (If the shipment will be consigned to a contractor&#8217;s plant and no duty-free entry certificate is required due to a trade agreement, the PAH shall claim duty-free entry under the applicable trade agreement and shall comply with the U.S. Customs Service requirements. No notification to Commander, DCMA New York, is required.)</font></div><div style="margin-top:0.05pt;padding-left:63pt;padding-right:60.95pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)  Gross weight in pounds (if freight is based on space tonnage, state cubic feet in addition to gross shipping weight.)</font></div><div style="padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(vi)  Estimated value in U.S. dollars.</font></div><div style="padding-left:63pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii) Activity address number of the contract administration office administering the prime contract, e.g., for DCMA Dayton, S3605A.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f)   Preparation of customs forms.</font></div><div style="margin-top:0.05pt;padding-left:31.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)(i) Except for shipments consigned to a military installation, the PAH shall &#8211;</font></div><div style="padding-left:85.5pt;padding-right:60.9pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">Prepare any customs forms required for the entry of foreign supplies into the customs territory of the United States in connection with this Agreement&#59; and</font></div><div style="margin-top:0.05pt;padding-left:85.5pt;padding-right:60.8pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">Submit the completed customs forms to the District Director of Customs, with a copy to DCMA NY for execution of any required duty-free entry certificates.</font></div><div style="padding-left:54pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) Shipments consigned directly to a military installation will be released in accordance with sections </font></div><div style="padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          10.101 and 10.102 of the U.S. Customs regulations.</font></div><div style="margin-top:0.05pt;padding-left:49.5pt;padding-right:61.45pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) For shipments containing both supplies that are to be accorded duty-free entry and supplies that are not, the PAH shall identify on the customs forms those items that are eligible for duty-free entry.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(g)   The PAH shall &#8211;</font></div><div style="padding-left:45pt;padding-right:60.65pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Prepare (if the PAH is a foreign supplier), or shall instruct the foreign supplier to prepare, a sufficient number of copies of the bill of lading (or other shipping document) so that at least two of the copies accompanying the shipment will be available for use by the District Director of Customs at the port of entry&#59;</font></div><div style="margin-top:0.05pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) Consign the shipment as specified in paragraph (e) of this clause&#59; and</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3) Mark on the exterior of all packages &#8211;</font></div><div style="margin-top:0.05pt;padding-left:40.5pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) &#8220;UNITED STATES GOVERNMENT, DEPARTMENT OF DEFENSE&#8221;&#59; and</font></div><div style="padding-left:40.5pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) The activity address number of the contract administration office administering the prime Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27pt;padding-right:60.75pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)  The PAH through the MCDC CMF shall notify the ACO in writing of any purchase of eligible products of qualifying country supplies to be accorded duty-free entry, that are to be imported into the customs territory of the United States for delivery to the Government or for incorporation in end items to be delivered to the Government. The PAH through the MCDC CMF shall furnish the notice to the ACO immediately upon award to the supplier and shall include in the notice &#8211;</font></div><div style="padding-left:27pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)The PAH&#8217;s name, address, and Commercial and Government Entity (CAGE) code&#59;</font></div><div style="margin-top:0.05pt;padding-left:27pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Prime Agreement number and Project Agreement number&#59;</font></div><div style="padding-left:27pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3) Total dollar value of the prime Agreement or Project Agreement number&#59;</font></div><div style="padding-left:27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4) Date of the last scheduled delivery under the prime Agreement or Project Agreement number&#59;</font></div><div style="margin-top:0.05pt;padding-left:27pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Foreign supplier&#8217;s name and address&#59;</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_139"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 49 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4.15pt;padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Number of the subcontract for foreign supplies&#59;</font></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7) Total dollar value of the subcontract for foreign supplies&#59;</font></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8) Date of the last scheduled delivery under the subcontract for foreign supplies&#59;</font></div><div style="margin-top:0.05pt;padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) List of items purchased&#59;</font></div><div style="padding-left:40.5pt;padding-right:60.85pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) An agreement that the PAH will pay duty on supplies, or any portion thereof, that are diverted to nongovernmental use other than &#8211;</font></div><div style="margin-top:0.05pt;padding-left:40.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Scrap of salvage&#59; or</font></div><div style="margin-top:0.05pt;padding-left:40.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii) Competitive sale made, directed, or authorized by the Agreements Officer&#59;</font></div><div style="padding-left:22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11) Country or origin&#59; and</font></div><div style="padding-left:22.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12) Scheduled delivery date(s).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:27pt;padding-right:60.9pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)  This clause does not apply to purchases of eligible products or qualifying country supplies in connection with this Agreement if &#8211;</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:60.8pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The supplies are identical in nature to supplies purchased by the PAH or any subcontractor in connection with its commercial business&#59; and</font></div><div style="padding-left:45pt;padding-right:60.7pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) It is not economical or feasible to account for such supplies so as to ensure that the amount of the supplies for which duty-free entry is claimed does not exceed the amount purchased in connection with this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(j)    The PAH shall &#8211;</font></div><div style="padding-left:40.5pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1) Insert the substance of this clause, including this paragraph (j), in all subcontracts for &#8211;</font></div><div style="padding-left:54pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Qualifying country components&#59; or</font></div><div style="margin-top:0.05pt;padding-left:54pt;text-indent:-0.05pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Nonqualifying country components for which the PAH estimates that duty will exceed $200 per unit&#59;</font></div><div style="padding-left:54pt;padding-right:60.8pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Require subcontractors to include the number of this Agreement on all shipping documents submitted to Customs for supplies for which duty-free entry is claimed pursuant to this clause&#59; and</font></div><div style="padding-left:54pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3) Include in applicable subcontracts &#8211;</font></div><div style="margin-top:0.05pt;padding-left:67.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The name and address of the ACO for this Agreement&#59;</font></div><div style="padding-left:67.5pt;padding-right:60.75pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) The name, address, and activity address number of the contract administration office specified in this Agreement&#59; and</font></div><div style="margin-top:0.05pt;padding-left:67.5pt;text-indent:-13.5pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) The information required by paragraphs (h)(1), (2), and (3) of this clause.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9.1pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 21.15 Follow-On Production</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9.05pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 U.S.C. &#167; 2371b, Section 815 authorizes the use of a follow-on production contract (FAR) or transaction (OTA). In order to be eligible for follow-on production, the following criteria is required&#58; (1) the follow-on shall be awarded to the same participants named in the Project Agreement&#59; (2) competitive procedures were used to award the Project Agreement in question&#59; and (3) the Project Agreement was successfully completed. This Agreement was the result of competitive procedures, and competitive procedures are used to award individual projects under this Agreement. The Agreements Officer shall be responsible for documenting whether or not a Project Agreement was successfully completed. Follow-on production efforts shall be strictly limited to the scope of the successfully completed prototype. This Agreement will not be used to award follow-on production efforts&#59; Government customers will be responsible for working with their contracting personnel.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Project Agreements shall include the following statement&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.05pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;In accordance with 10 U.S.C. &#167; 2371b(f), and upon a determination that this competitively awarded prototype project has been successfully completed, this prototype project may result in the award of a follow-on production contract or transaction without the use of competitive procedures.&#34;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:9.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XXII. ASSIGNMENT OF AGENCY</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9.05pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 22.01 Assignment.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.05pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither this Agreement nor any rights or obligations of any party hereunder shall be assigned or otherwise transferred by either party without the prior written consent of the other party.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_142"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 50 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XXIII. ORDER OF PRECEDENCE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any inconsistency between the general terms of this Agreement, the inconsistency shall be resolved by giving precedence in the following order&#58; (1) the Agreement&#59; (2) Attachments to the Agreement&#59; (3) the Project Agreement documentation (including but not limited to the PAH proposal selected for funding by the Government). In any event, specifically negotiated Project Agreement terms will govern over general terms of this Agreement.</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.95pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Article XXIV. EXECUTION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.75pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement constitutes the entire Agreement of the Parties and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions among the Parties, whether oral or written, with respect to the subject matter hereof. This Agreement may be revised only by written consent of the PAH and the CMF Contracting Representative designated in this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i6e83dc7d5cfd461ab7794fe52340835e_145"></div><hr style="page-break-after:always"><div style="min-height:67pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#464646;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Page 51 of 51&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:4pt;padding-left:15.45pt;padding-right:67.45pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Attachment I &#8211; Assurance of Compliance with Title VI of the Civil Rights Act of 1964</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:145.65pt;padding-right:197.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:134%">Statement of Assurance of Compliance with Title VI of the Civil Rights Act of 1964</font></div><div style="padding-left:124.65pt;padding-right:176.5pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:113%">For MCDC Member Organizations</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">The</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;text-decoration:underline"> &#160;&#160;&#160;&#160;Regeneron Pharmaceuticals, Inc.&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">hereby agrees that it will comply with the provisions of the Title VI Civil Rights Act of 1964 as amended (42 U.S.C 2000-d) and all requirements imposed pursuant thereto, to the end that, in accordance with Title VI of that Act and the Regulation, no person in the United States shall, on the ground of race, color, or national origin, be</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:109%">excluded from participation in, be denied the benefits of, or be otherwise subjected to discrimination</font></div><div style="padding-left:9pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under any MCDC Project for which the MCDC member organization receives Federal financial  assistance from the Government.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.6pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The MCDC member organization agrees that compliance with this assurance constitutes a condition of continued receipt of Federal financial assistance, and that it is binding upon the MCDC member organization, its successors, transferees and assignees for the period during which such assistance is provided.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.65pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The MCDC member organization further recognizes and agrees that the United States shall have the right to seek judicial enforcement of this assurance.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:60.7pt;text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The person or persons whose signature(s) appear(s) below is&#47;are authorized to sign this assurance, and commit the MCDC member organization to the above provisions.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:101%">Signature of Authorized Official</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:102%">Title of Authorized Official</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:102%">Name of MCDC Member Organization</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="padding-left:8.95pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:101%">Date</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#5d5d5d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:7%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>regn-ex102x09302020x10q.htm
<DESCRIPTION>PROJECT AGREEMENT BY AND BETWEEN THE REGISTRANT AND ATI
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iaa383481d5794ed7bcdc614b8587edf4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 10.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt;text-align:center"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:66px;width:652px"></div><div style="margin-top:4.5pt;padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROJECT AGREEMENT NO.&#58;&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:13.8pt;padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MCDC BASE AGREEMENT NO.&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2020-504</font></div><div><font><br></font></div><div style="padding-left:50pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROJECT TITLE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MCDC2008-005&#59; Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2</font></div><div><font><br></font></div><div style="padding-left:121.95pt;padding-right:134.15pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTIES&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advanced Technology International (&#8220;MCDC CMF&#8221;) and Regeneron Pharmaceuticals, Inc. (&#8220;Project Agreement Holder&#8221;)</font></div><div><font><br></font></div><div style="padding-left:49.95pt;padding-right:71.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Project Agreement is awarded under the authority of MCDC Base Agreement No. 2020-504, and herein incorporates all the terms and conditions thereof, as such terms and conditions are modified by the terms of the Statement Of Work attached hereto as Exhibit A (the &#8220;Statement of Work&#8221; or &#8220;SOW&#8221;). The parties agree that, to the extent any terms or conditions of the Statement of Work conflict with the terms and conditions of MCDC Base Agreement No. 2020-504, the terms and conditions of the Statement of Work shall apply and take precedence.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">PAYMENT METHOD</font></div><div style="padding-left:50pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">The Payment Method for this Project Agreement is Firm Fixed Price with a not to exceed ceiling.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">TERM OF THE PROJECT AGREEMENT</font></div><div style="padding-left:50pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The period of performance for this Project Agreement is from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">the effective date, which is the date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">of the last signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">June 30, 2021.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">OBLIGATION</font></div><div style="padding-left:49.95pt;padding-right:71.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The MCDC CMF&#8217;s liability to make payments to the Project Agreement Holder is limited to only those funds obligated under this Project Agreement or by modification to the Project Agreement. MCDC CMF may incrementally fund this Project Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">TOTAL FIRM FIXED PRICE</font></div><div style="padding-left:50pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total firm fixed price for the services to be provided by the Project Agreement Holder is as follows&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:86pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Total Firm Fixed Price&#160;&#160;&#160;&#160;$450,262,000</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">TOTAL FUNDING</font></div><div style="padding-left:50pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total amount of funding currently available for payment and allotted to this Project Agreement is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">$450,262,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">MILESTONE PAYMENT SCHEDULE</font></div><div style="padding-left:50pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Project Agreement Holder shall document the accomplishments of each Project Payable Milestone under each Project Agreement. Acceptance of Milestones shall be contingent upon approval from the Government Agreements Officer Representative (AOR) detailed in Clause No. 9, Technical and Administrative Representatives. Milestone payments will be paid in the amount indicated in the attached Milestone Payment Schedule (Attachment A).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">APPROACH TO MEETING THE OTHER TRANSACTION AUTHORITY</font></div><div style="padding-left:49.95pt;padding-right:71.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accordance with provision contained in 10 USC 2371b governing the use Other Transaction Agreements each MCDC Member Organization must meet at least one of the following conditions&#58; have at least one nontraditional defense contractor or nonprofit research institution participating to a significant extent in the performance of an awarded Project Agreement&#59; all significant participants in the Project Agreement other than the Federal Government are small businesses (including small businesses participating in a program described under section 9 of the Small Business Act (15 U.S.C. 638)) or nontraditional defense contractors&#59; or provide a cost share of no less than one third of the value of the Project Agreement awarded to the Member Organization. The Project Agreement Holder&#8217;s approach to meeting the Other Transaction Authority requirement is identified below. Throughout the period of performance of any Project Agreement, the CMF and the Government will actively monitor the award to ensure compliance with this provision in accordance with implementation guidance from Headquarters &#8211; Department of the Army (HQDA) and&#47;or Office of the Secretary of Defense (OSD). The Project Agreement Holder will be given the opportunity to become compliant with the guidance should they be found non-compliant. Failure to comply may result in termination.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:50pt;padding-right:71.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The warranties and representations submitted as part of the proposal are hereby incorporated into this Project Agreement. The Project Agreement Holder was proposed as a nontraditional defense contractor and determined to be providing a significant contribution.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">STATEMENT OF WORK</font></div><div style="padding-left:49.95pt;padding-right:71.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Statement of Work, Attachment A, provides a detailed description of the work to be accomplished and reports and deliverables required by this Project Agreement. All changes to Attachment A must be incorporated via written modification to this Project Agreement. Additional guidance on report requirements is in Attachment B, Report Requirements.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:9pt">TECHNICAL AND ADMINISTRATIVE REPRESENTATIVES</font></div><div style="padding-left:50pt;padding-right:71.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following technical and contractual representatives of the Parties are hereby designated for this Project Agreement. Either party may change their designated representatives by written notification to the other.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:38.151%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MCDC CMF Contractual Representative&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contracts Administrator</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advanced Technology International</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">315 Sigma Drive</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">Summerville, SC 29486</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Email&#58;  </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration:underline">Government Technical Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%">&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreements Officer Representative (AOR)&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;</font></td></tr></table></div><div style="padding-left:72pt"><font><br></font></div><div id="iaa383481d5794ed7bcdc614b8587edf4_7"></div><div style="margin-bottom:6pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.614%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%;text-decoration:underline">Project Agreement Holder&#8217;s Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:105%">&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Technical Representative&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Contractual Representative&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">777 Old Saw Mill River Rd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">777 Old Saw Mill River Rd</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tarrytown, NY 10591</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tarrytown, NY 10591</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">MARKING OF DELIVERABLES</font></div><div style="padding-left:50pt;padding-right:92.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any Data delivered under this Project Agreement, by the Project Agreement Holder, shall be marked with a suitable notice or legend.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">SECURITY ADMINISTRATION</font></div><div style="padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">The security level for this project is UNCLASSIFIED.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">ATTACHMENTS</font></div><div style="padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Attachments listed herein are hereby incorporated by reference into this Project Agreement.</font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.34pt">Statement of Work, &#8220;Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2&#8221;</font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt">Report Requirements</font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt">Technical Direction Letter (TDL) RPP-20-08 Regeneron</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">GOVERNMENT FURNISHED PROPERTY</font></div><div style="padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">At this time, Government Furnished Property is not provided for use under this Project Agreement.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">PATENT RIGHTS AND DATA RIGHTS</font></div><div style="padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Please reference Section 7 of Attachment A, Statement of Work.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">FOLLOW-ON PRODUCTION PROVISION</font></div><div style="padding-left:50pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Please reference Section 1 of Attachment A, Statement of Work.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">SECURITY &#38; OPSEC</font></div><div style="padding-left:50pt;padding-right:92.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The below language shall be used as Paragraph 6 of Article XVII in Regeneron&#8217;s Base Agreement&#58;</font></div><div style="padding-left:50pt;padding-right:76.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Access and General Protection&#47;Security Policy and Procedures. This standard language text is applicable to ALL PAH employees working on critical program information or covered defense information related to Operation Warp Speed (OWS), and to those with an area of performance within an Army controlled installation, facility or area. PAH employees shall comply with applicable installation, facility and area commander installation&#47;facility access and local security policies and procedures (provided by government representative). The PAH also shall provide all information required for background checks necessary to access critical program information or covered defense information related to OWS, and to meet installation access requirements to be accomplished by installation Provost Marshal Office, Director of Emergency Services or Security Office. The PAH workforce must comply with all personal identity verification requirements as directed by DOD, HQDA and&#47;or local policy. In addition to the changes otherwise authorized by the changes clause of this agreement, should the Force Protection Condition (FPCON) at any individual facility or installation change, the Government may require changes in PAH security matters or processes.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:68pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%;padding-left:3pt">ENTIRE AGREEMENT</font></div><div style="padding-left:50pt;padding-right:56.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Project Agreement and the MCDC Base Agreement under which it is issued constitute the entire understanding and agreement between the parties with respect to the subject matter hereof.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:50pt;padding-right:56.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided herein (including in the SOW), all Terms and Conditions of the MCDC Base Agreement and its modifications remain unchanged and in full force and effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:449.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:11%">  </font></div><div><font><br></font></div><div style="text-align:center"><img alt="image_11a.jpg" src="image_11a.jpg" style="height:97px;width:736px"></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:36pt;padding-right:92.8pt"><font style="color:#2b2b2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">The Project Agreement Holder is required to sign this document and </font><font style="color:#1a181a;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">return </font><font style="color:#2b2b2d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">to Advanced Technology International to finalize this action.</font></div><div style="padding-right:92.8pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.895%"><tr><td style="width:1.0%"></td><td style="width:53.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regeneron Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advanced Technology International</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; Robert Landry&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Robert Landry&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Vice President- Finance and Chief Financial Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Jul 6, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6 July 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Statement of Work</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This page intentionally left blank. See separate document for Attachment A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.3pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Statement of Work</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RPP #&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RPP-20-08</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Identifier&#58; MCDC OTA 2008-005, W15QKN-16-9-1002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consortium Member&#58; Regeneron Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Title of Proposal&#58; Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.0&#160;&#160;&#160;&#160;INTRODUCTION, SCOPE, AND OBJECTIVES</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. Preamble</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. (referred to herein as &#8220;Regeneron&#8221;, &#8220;Offeror&#8221;, &#8220;Contractor&#8221; or &#8220;Recipient&#8221;) has demonstrated experience with rapid scale-up of biopharmaceutical programs.&#160; Our excellent history of receiving development scale processes from Research and Development (R&#38;D) laboratories, and then expanding to clinical or commercial Good Manufacturing Practice (GMP) scale production, is well documented. &#91;* * *&#93; We have consistently demonstrated our ability to expedite the delivery of high quality, safe and efficacious products (Ebola therapeutic) in partnership with the Government (anti-MERS, anti-Ebola).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fully human monoclonal antibodies (mAbs) are molecules with high potency, predictable Pharmacokinetics (PK), and limited off-target toxicity, and thus provide attractive types of therapeutics for emerging diseases. Importantly, we have repeatedly demonstrated that candidate mAb-based drugs to prevent and&#47;or treat emerging infections, can be rapidly obtained from Regeneron&#8217;s proprietary VelocImmune&#174; mice. Further, our ability to concurrently generate isogenic cell lines that are optimized for rapid antibody scale up and manufacturing using our proprietary Chemistry, Manufacturing, and Controls (CMC) platform technologies, have facilitated both testing of our mAbs in preclinical models and subsequent development of these mAbs into drugs suitable for human testing. In the process of completing many of these activities we have collaborated with other entities (including BARDA, Research Institutes, Government Laboratories and Universities). Our manufacturing has been designed to be paired with our proprietary VelocImmune&#174; R&#38;D technology, that is a proven process to rapidly take a research concept from the bench, into large scale production, with the ability to delivery medicines to patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Government has advised Regeneron that it is appropriate for the project described in this Project Agreement to be performed through the Medical CBRN Defense Consortium (MCDC), under the authority of the MCDC Other Transaction Agreement No. W15QKN-16-9-1002. &#160;Regeneron is amenable to performing the project pursuant to such authority, based on the advice of the Government, and due to the unprecedented circumstances of the Coronavirus Disease 2019 (COVID-19) pandemic and, accordingly, the parties have entered into this Project Agreement.&#160;</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. Overall Objectives and Scope</font></div><div style="padding-left:25pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This project is defined by discrete work segments for the continuous manufacture of drug substance, formulated drug substance and filled, packaged and labeled drug product, in accordance with a mutually agreed schedule.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to this project, Regeneron will manufacture and sell drug product to the applicable United States (U.S.) Federal Government agency, for distribution in the U.S. All manufacturing described herein will be compliant with Food and Drug Administration (FDA) current Good Manufacturing Oractices (cGMP), as 21 CFR 210 and 211.     </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Introduction</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The objective is to conduct the manufacturing production activities described in this proposal for prototypes consisting of novel, proprietary mAb therapeutics and prophylactics, to reduce pathology of COVID-19 disease and&#47;or prevent development of disease when administered prophylactically.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;Scope</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These manufacturing production activities will include manufacturing at-scale, filling and finishing, and storage and shipping of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (referred to herein as the &#8220;prototype&#8221;, the &#8220;prototype product&#8221;, the &#8220;product&#8221; or &#8220;drug product&#8221;) for treatment and&#47;or prophylaxis against COVID-19. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;Definition of the Prototype Project</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consistent with USG objectives, Regeneron will employ its proprietary manufacturing technology and processes, in a manner compliant with applicable laws and regulations, including 21 CFR 210 and 211 and the Drug Supply Chain Security Act, to manufacture the prototype product. This effort constitutes a prototype project because it will be used to evaluate the technical feasibility of manufacturing the prototype product during the ongoing COVID-19 pandemic.  In addition, this is a prototype project because Regeneron will demonstrate, and prove-out the at-scale, multi-lot proprietary manufacturing activities of Regeneron in order to assess the feasibility of these activities to support the necessary quantity of the prototype product to treat the U.S. population.  Successful completion of the prototype project will demonstrate Regeneron&#8217;s capability to (i) rapidly manufacture product, which can be further scaled-up to meet mutually agreed to surge requirements with little advance notification and (ii) facilitate the Government&#8217;s ability to stockpile and distribute large quantities of the drug product to respond when needed, including for use in clinical studies, under an Emergency Use Authorization (EUA), or pursuant to other clearance from the U.S. FDA. For clarity, any manufacturing and supply of drug product in excess of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">specific quantities set forth in Section 4.0 of this Statement of Work, shall be subject to a separate mutual agreement between Regeneron and the Government.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The scope of effort supported by this agreement is further clarified in Section 1.4.  It is important to note that nonclinical and clinical studies for the prototype are being conducted by Regeneron outside of this agreement. The results of those studies may be used to develop use case scenarios and, in turn, inform the USG&#8217;s deployment strategy as it relates to product manufactured under this agreement&#59; however, such results (including the degree to which the data are &#8220;positive&#8221; or &#8220;negative&#8221;) shall not be a factor in this prototype project. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;Objective</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Conduct its proprietary manufacturing production activities described in this proposal for prototypes consisting of novel, proprietary mAb therapeutics and prophylactics, to reduce pathology of COVID-19 disease and&#47;or prevent development of disease when administered prophylactically.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The prototypes will include one or more of the following, as mutually agreed between Offeror and the Government&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">the mAbs known as REGN10987 and REGN10933, as a cocktail&#59;</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">Other mAbs (as monotherapies or a cocktail) as agreed to by bilateral modification between Offeror and the Government.</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The deliverables will be the products listed above (i.e., REGN10987 and REGN10933), in the form of bulk formulated drug substance and&#47;or filled and finished product in vials, as mutually agreed between Offeror and the Government, packaged and labeled drug product, results, reports and records associated with generation of data demonstrating quality and control. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The products will be delivered in the form and quantity to be agreed between Offeror and the Government.  It is expected that the prototypes will be stored by Offeror until such time as (a) they can be used for pre-clinical or clinical development purposes under an Investigational New Drug application (IND), or (b) upon the FDA&#8217;s grant of an EUA under Section 564 of the Food, Drug and Cosmetic Act (FD&#38;C Act), or full marketing approval under a full Biologics License Application (BLA) under Section 351(a) of the Public Health Service Act (PHSA). </font></div><div style="padding-left:68pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5&#160;&#160;&#160;&#160;Follow-on Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accordance with 10.U.S.C. 2371b(f), and upon successful demonstration of the prototype, or at the accomplishment of particularly favorable or unexpected results achieved outside of this Agreement that would justify transitioning to production (e.g., EUA or BLA), additional at-scale manufacturing of &#91;* * *&#93;, supported by a mutually agreed upon follow-on production contract or Other Transaction Agreement, may be awarded to Regeneron, without further competition, to partially or completely meet the USG objective of supplying a safe and effective COVID-19 therapeutic or prophylactic treatment courses to ensure nationwide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">access. For clarity, any manufacturing and supply of drug product in excess of the specific quantities set forth in Section 4.0 of this Statement of Work shall be subject to a mutually-agreed upon separate agreement between Regeneron and the Government. For further clarity, neither party shall be obligated to negotiate or enter into such a separate agreement for follow-on production. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the performance of the prototype project, the Government and contractor may negotiate the scope and price of follow-on production.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.0&#160;&#160;&#160;&#160;APPLICABLE REFERENCES</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Current Good Manufacturing Practices, 21 CFR 210, 211</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.0&#160;&#160;&#160;&#160;DELIVERABLES</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Offeror assumed &#91;* * *&#93;.  Regeneron shall have the right to provide deliverables directly to the Government and not to the Consortium Management Firm (CMF). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Deliverable Table (June 2020 - June 2021)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:34.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deliverable</font></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Due Date</font></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Total Program Funds</font></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Rights</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Project Kick-Off&#59; Deliverable</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DS&#47;FDS Bulk GMP Lot &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DS&#47;FDS Bulk GMP Lot &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DS&#47;FDS Bulk GMP Lot &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fill Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fill Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fill Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Package&#47;Label Product</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Storage of Drug Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Storage of Drug Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Storage of Drug Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Storage of Drug Product &#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$450,262,000 (FFP)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*Upon payment, delivery and acceptance in accordance with the terms of this Project Agreement, the Government will have title to the product produced under this Statement of Work. The Government will have the rights described below in Section 7.3 to technical data disclosed under this Statement of Work. </font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">** Packaging and labeling of product will be performed following the determination of the use of the applicable drug product (e.g., for clinical trials or for distribution under an EUA or BLA).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.0 &#160;&#160;&#160;&#160;MILESTONE PAYMENT SCHEDULE&#59; TERMINATION COSTS </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:12.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone #</font></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Description</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Deliverable Reference)</font></div></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Due Date</font></td><td colspan="3" style="background-color:#d9cba7;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Total Program Funds</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.5</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.6</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.7</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.10</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.11</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Total (Include Payment Type&#59; FFP)&#58;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$450,262,000</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Period of Performance&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">June 2020 &#8211; June 2021</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The overall price is fixed price at $450,262,000.  Milestone payments will be made quarterly as set forth in the table above, corresponding to the deliverables and any 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> party commitments Regeneron needs to make. In the event the deliverables in a given quarter are less than or exceed the projected quantity, the milestone payment for such quarter will be equitably adjusted based on the shortfall or excess amount, as applicable, however the price will not exceed $450,262,000 Milestone payment terms will be net 30 days.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Total pricing is a firm fixed price per lot, &#91;* * *&#93;. Regeneron will deliver &#91;* * *&#93; of filled&#47;finished drug product.  Regeneron will be entitled to full payment for drug product upon delivery&#47;acceptance (as described herein) of filled&#47;finished drug product, prior to packaging and labeling. However, Regeneron shall be responsible for the packaging and labeling of product at no additional cost following the determination of the use of such drug product (e.g., for clinical trials or for distribution under an EUA or BLA).  Drug product will comply with the Drug Supply Chain Security Act serialization and tracking requirements. Drug product will not be co-formulated, except as otherwise mutually agreed by the parties. Unless and until otherwise mutually agreed, the drug product produced under this Statement of Work will be filled for therapeutic use. &#91;* * *&#93; Regeneron will provide the Government with the timeline for fill&#47;finish activities, including the dates by which the parties must determine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the allocation of fill&#47;finish activities. Notwithstanding the foregoing, as part of this Project Agreement, Regeneron will have the right to utilize material and capacity supported by this agreement to fill up to &#91;* * *&#93;, as well as any additional drug product mutually agreed upon by Regeneron and the Government (with respect to which use the Government will not unreasonably withhold consent.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event this Statement of Work is terminated prior to completion, termination costs recoverable by Regeneron under Section 2.04 of the MCDC Base Agreement, shall include the following&#58; the full contract price for any drug product manufactured and not yet paid for&#59; a pro-rated portion of the contract price for drug substance or drug product that is in process, based on the stage of production&#59; &#91;* * *&#93; and raw materials that Regeneron purchased (or is obligated to purchase) that cannot be allocated to other products.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.0 &#160;&#160;&#160;&#160;PATENT RIGHTS&#59; DATA RIGHTS&#59; PREP ACT AND TRANSPARENCY</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article X, (&#8220;PATENT RIGHTS&#8221;) and Article XI. (&#8220;DATA RIGHTS&#8221;) of Other Transaction Agreement number W15QKN-16-9-1002 shall not apply to this Project Agreement and are hereby replaced for the purpose of this Project Agreement, with this Section 7.0 (including Sections 7.1-7.4 and the Definitions Appendix).</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Definitions&#58; </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Capitalized terms used in this Section 7.0 (including Sections 7.1-7.4) shall have the meanings ascribed to such terms in the Definitions Appendix to this Project Agreement.  </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Project Agreement, all rights of the Government in and to Data or Subject Inventions are granted solely to The United States of America, as represented by the Department of Health &#38; Human Services, Office of the Assistant Secretary for Preparedness &#38; Response (&#8220;ASPR&#8221;), Office of Biomedical Advanced Research and Development (&#8220;BARDA&#8221;) (represented by Office of Acquisition Management, Contracts and Grants (AMCG)) and to no other agency of the United States of America (including JPEO) or representative of any such other agency (including the CMF). The parties acknowledge that Regeneron is permitted to communicate solely with BARDA regarding the matters described in this Section 7.0 (including Sections 7.1-7.4) and is not obligated to communicate with any other Government agency or representative regarding such matters.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;BACKGROUND INTELLECTUAL PROPERTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each party acknowledges that it has no rights to the other party&#8217;s inventions, discoveries, know-how, Data, technology or intellectual property generated, discovered, conceived or reduced to practice prior to or otherwise outside of this Statement of Work (also referred to herein as, this &#8220;Project Agreement&#8221; or this &#8220;Agreement&#8221;), and any improvements or modifications thereto, including, without limitation, the background intellectual property </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(and improvements&#47;modifications) for the Government and Regeneron described below, as follows&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Government Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. None.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Contractor Background Intellectual Property&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63&#47;004,312, filed April 2, 2020 &#8220;Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments&#8221;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63&#47;014,687, filed April 23, 2020 &#8220;Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments&#8221;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63&#47;025,949, filed May 15, 2020 &#8220;Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments&#8221;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63&#47;034,865, filed June 4, 2020 &#8220;Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments&#8221;</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No party relinquishes rights in any of its background intellectual property to any other party under this contract.  </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Either Party may update its disclosure of background intellectual property under this Section 7.1 upon written notice to the other Party.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PATENT RIGHTS</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Allocation of Principal Rights  </font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties agree that the Bayh-Dole statute does not apply to this Project Agreement. Ownership of inventions Made in the performance of this Project Agreement shall follow inventorship, and inventorship shall be determined in accordance with United States patent laws. With respect to any Subject Invention Made (in whole or in part) by or on behalf of Regeneron, unless Regeneron shall have notified the Government (in accordance with Subparagraph b. below) that Regeneron does not intend to properly disclose and elect title to a Subject Invention, Regeneron shall retain the entire right, title, and interest throughout the world to such Subject Invention, and the Government shall have a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the United States the Subject Invention throughout the world.  This license does not include the right to use or allow others to use the Subject Invention for commercial purposes. If Regeneron does not properly disclose and elect title to any such Subject Invention (in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accordance with Subparagraph b. below), then the Government may exercise its rights to seek ownership of such Subject Invention, pursuant to clause 7.2.c. below.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt">Invention Disclosure, Election of Title, and Filing of Patent Application</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.02pt">Regeneron shall disclose in writing each Subject Invention to the OTTR within 12 months after the inventor discloses it in writing to Regeneron personnel responsible for patent matters. The disclosure shall identify the inventor(s) and this Project Agreement under which the Subject Invention was made. It shall be sufficiently complete in technical detail to convey a clear understanding of the Subject Invention. The disclosure shall also identify any publication, on sale (i.e., sale or offer for sale), or public use of the Subject Invention, or whether a manuscript describing the Subject Invention has been submitted for publication and, if so, whether it has been accepted for publication. In addition, after disclosure to the Government funding agency (HHS&#47;BARDA), Regeneron shall promptly notify the OTTR of the acceptance of any manuscript describing the Subject Invention for publication and any on sale or public use. </font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:0.5pt">Regeneron shall elect in writing whether or not to retain ownership of any Subject Invention by notifying the OTTR within 2 years of disclosure to the Government funding agency. However, in any case where publication, on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, the period for election of title may be shortened by the agency to a date that is no more than 60 calendar days prior to the end of the statutory period.</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.1pt">Regeneron shall file either a provisional or a non-provisional patent application for an elected Subject Invention within 1 year after election of title. However, in any case where a publication, on sale, or public use has initiated the 1-year statutory period during which valid patent protection can be obtained in the United States, Regeneron shall file the application prior to the end of that statutory period. If Regeneron files an initial provisional application, it shall file a non-provisional application within 10 months of the filing of the initial provisional application.   Regeneron shall include a Government Support Clause (GSC) within the specification of any United States patent applications and any patent issuing thereon covering a subject invention.</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt">Regeneron may request extensions of time for disclosure, election, or filing under subparagraphs (b)(i), (b)(ii) and (b)(iii) of this clause. An extension of time for each deadline, may be granted at the discretion of the Government funding agency.  </font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.If Regeneron determines that it does not intend to elect to retain title to any such Subject Invention, Regeneron shall notify the Government, in writing, within two (2) years of disclosure to the Government.  However, in any case where publication, sale, or public use has initiated the one (1)-year statutory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">period wherein valid patent protection can still be obtained in the United States, the period for such notice may be shortened by the Government to a date that is no more than sixty (60) calendar days prior to the end of the statutory period.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.68pt">Conditions When the Government May Obtain Title</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon the Government&#8217;s written request, Regeneron shall convey title to any Subject Invention to the Government funding agency if Regeneron fails to disclose the Subject Invention or elects not to retain title to the Subject Invention within the times specified in Subparagraph b of Section 7.2.  The Government may request title after learning of the failure of Regeneron to disclose or elect within the specified times for an unlimited time.  The Government funding agency may request title upon Regeneron&#8217;s omission to timely file patent applications in any country.  The Government funding agency may request title in any country in which Regeneron decides to discontinue prosecution. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt">Rights to Regeneron and Protection of Regeneron&#8217;s Right to File </font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron shall retain a fully paid up, sub-licensable, nonexclusive, royalty-free license throughout the world in each Subject Invention to which the Government obtains title.  Regeneron license extends to Regeneron&#8217;s subsidiaries and other affiliates (outside this Agreement), if any, within the corporate structure of which Regeneron is a party and includes the right to grant licenses of the same scope to the extent that Regeneron was legally obligated or permitted to do so at the time the Project Agreement was executed.  The license is otherwise transferable only with the approval of the Government, except when transferred to an Affiliate or successor of that part of Regeneron&#8217;s business to which the Subject Invention pertains.&#160; The Government approval for license transfer shall be provided on a timely basis (and in no event later than 90 calendar days following Regeneron&#8217;s request) and shall not be unreasonably withheld.</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.02pt">The Regeneron license may be revoked or modified by the Government to the extent necessary to achieve expeditious Practical Application of the Subject Invention pursuant to an application for an exclusive or nonexclusive license submitted consistent with appropriate provisions at 37 CFR Part 404.  Regeneron&#8217;s license shall not be revoked in that field of use or the geographical areas in which Regeneron has achieved Practical Application of the Subject Invention and continues to make the benefits of the Subject Invention accessible to the public.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.34pt">Before revocation or modification of Regeneron&#8217;s license, the Government shall furnish Regeneron with a written notice of its intention to revoke or modify the license, which notice shall include a detailed explanation of the reasons for such revocation or modification, and Regeneron shall be allowed thirty (30) calendar days (or such other time as may be authorized for good cause shown) after the notice to show cause why the license should not be revoked or modified.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.68pt">Action to Protect the Government&#8217;s Interest</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron agrees to execute or to have executed and promptly deliver to the Government all instruments necessary to (i)&#160;establish or confirm the rights the Government has throughout the world in those Subject Inventions to which Regeneron elects to retain title, and (ii)&#160;convey title to the Government when requested under Subparagraph c of this Section 7.2 and to enable the Government to obtain patent protection throughout the world in that Subject Invention.</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.02pt">Regeneron agrees to require, by written agreement, its employees, other than clerical and non-technical employees, to disclose promptly in writing to personnel identified as responsible for the administration of patent matters and in a format suggested by Regeneron, each Subject Invention made under this Agreement so Regeneron can comply with the disclosure provisions of this Section 7.2.  Regeneron shall use reasonable efforts to instruct employees, through employee agreements or other suitable educational programs, on the importance of reporting inventions in sufficient time to permit the filing of patent applications prior to U.S. or foreign statutory bars.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.34pt">Regeneron shall notify the Government of any decisions not to continue the prosecution of a patent application for a Subject Invention, pay maintenance fees, or defend in a reexamination or opposition proceedings on a patent of a Subject Invention, in any country, not less than thirty (30) calendar days before the expiration of the response period required by the relevant patent office.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron shall include, within the specification of any United States patent application and any patent issuing thereon covering a Subject Invention, the following statement&#58;  &#8220;This invention was made with Government support under Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MCDC2020-504</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, awarded by the U.S. Department of Health and Human Services.  The Government has certain rights in the invention.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt">Lower Tier Agreements</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron shall ensure that its Affiliate agreements and Sub-Recipient Agreements regardless of tier, for experimental, developmental, or research work entered into after the Effective Date and submitted for reimbursement under this Agreement, contain invention reporting and assignment requirements sufficient to permit Regeneron to comply with this Section 7.2.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Reporting on Utilization of Subject Inventions</font></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.02pt">Regeneron agrees to submit, during the term of this Project Agreement, an annual report on the utilization of a Subject Invention or on efforts at obtaining such utilization that is being made by Regeneron or its licensees or assignees.  Such reports shall include information regarding the status of development, date of first commercial sale or use, and such other data and information as the agency may reasonably specify.  Regeneron also agrees to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:90.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide additional reports as may be requested by the Government in connection with any march-in proceedings undertaken by the Government in accordance with Subparagraph h of this Section 7.2.  Consistent with 35 U.S.C. &#167;&#160;202(c)(5), the Government agrees it shall not disclose such information to persons outside the Government without permission of Regeneron.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.34pt">All required reports shall be submitted to the e-room, OTAS, OTAO, and OTTR.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt">Compulsory Licensing Rights</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron agrees that, with respect to any Subject Invention in which it has retained title, the Government has the right to require Regeneron, an assignee, or exclusive licensee of a Subject Invention to grant a non-exclusive license to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, and if Regeneron, assignee, or exclusive licensee refuses such a request, the Government has the right to grant such a license within the Field itself </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">only</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if the Government determines that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.67pt">Action is necessary to alleviate the following health or safety needs that may affect the United States and Regeneron (itself or through its assignee, subcontractor or licensee) is unwilling or unable to manufacture or supply the Subject Invention to address such needs&#58;   </font></div><div style="margin-bottom:6pt;padding-left:162pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Declaration for Public Health Emergency by the Secretary of HHS&#59;</font></div><div style="margin-bottom:6pt;padding-left:162pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Determination that there is a significant potential for a public Health emergency that has a significant potential to affect a national or health security of U.S. citizens as determined by the Secretary of HHS&#59; or </font></div><div style="padding-left:162pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Declaration by WHO Director General of a public health emergency of international concern. </font></div><div style="padding-left:162pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;DATA RIGHTS</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Allocation of Principal Rights</font></div><div style="margin-bottom:6pt;padding-left:108.7pt;text-align:justify;text-indent:-9.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3.02pt">For Data produced under this SOW including Computer Software, to the extent developed with Government funds provided under this SOW, except as expressly provided elsewhere in this Project Agreement (including Section 7.3.b.), Regeneron grants to the Government a paid-up, nonexclusive, nontransferable, irrevocable, worldwide license in such Data (a) to exercise Government Purpose Rights for a period of ten (10) years following the production of such Data, (b) to exercise Unlimited Rights following the expiration of such ten (10)- year period.  For Data produced under this Project Agreement, excluding Computer Software, to the extent developed with private funds and for other Data designated by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:108.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron as &#8220;Limited Rights Data&#8221;, Regeneron grants to the Government a paid-up, nonexclusive, nontransferable, irrevocable, worldwide license in such Data to exercise Limited Rights.  The Government will not obtain any rights in Computer Software produced under this Project Agreement to the extent developed with private funds. For certificates of analysis and batch records pertaining to drug product purchased under this Project Agreement, the Government shall have Unlimited Rights.</font></div><div style="margin-bottom:6pt;padding-left:108.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.34pt">Regeneron agrees to retain and maintain in good condition all Data produced under this Project Agreement and necessary to achieve Practical Application of any Subject Invention in accordance with Regeneron&#8217;s established record retention practices.  In the event of an exercise of the Government&#8217;s compulsory licensing rights as set forth under Section 7.2.h., Regeneron agrees, upon written request from the Government, to deliver at no additional cost to the Government, all existing Data produced under this Project Agreement necessary to achieve Practical Application of the relevant Subject Invention within sixty (60) calendar days from the date of the written request. </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.01pt">Regeneron&#8217;s right to use Data is not restricted and includes the right under Regeneron&#8217;s established business policies to make public research Data (especially human research Data) by publication in the scientific literature, by making trial protocols, trial results summaries, and clinical studies reports publicly available, and by making trial patient-level data available for third-party analysis.   </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt">Proprietary Manufacturing Data</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Project Agreement, Regeneron retains all rights in and to Data relating to or comprising Regeneron&#8217;s proprietary manufacturing technology and processes, including any trade secrets, Chemistry, Manufacturing and Controls information (CMC Data), and Data concerning or arising from test method development, device or delivery system development, assay development, formulation, quality assurance&#47;quality control development, technology transfer, process development and scale-up and cell-line development, and the Government shall have no rights to use such Data independently from this Agreement or to disclose such Data to any third party.  Regeneron may designate certain Data concerning its manufacturing activities as Limited Rights Data, in which case the Government shall have Limited Rights in and to such Data. Regeneron will use reasonable efforts to mark any Limited Rights Data delivered under this Project Agreement with appropriate Limited Rights markings.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.68pt">Identification and Disposition of Data</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron shall keep copies of all Data relevant to this Project Agreement as required by the Food and Drug Administration (FDA) for the time specified by the FDA.  The Government reserves the right to review any other data determined by the Government to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relevant to this Agreement.  The Government further acknowledges that Regeneron holds the commercialization rights for all products developed under this Agreement in the U.S. and will be responsible for their registration with the FDA. This provision is subject to any applicable limitations on the Government&#8217;s rights under Article VIII.B.a-b of the BARDA OTA.</font></div><div style="padding-left:68pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;REGULATORY RIGHTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Contractor agrees to the following&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a. Regulatory Data. Regeneron shall provide to the OTTR and OTAS copies of formal FDA submissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pertaining to the scope of the project, no later than 10 business days before submission to the FDA. For clarity, CMC Data included in such submissions shall be subject to Section 7.3.b.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b. Rights of Reference.  Upon mutual agreement, Regeneron will grant to the Government a right of reference to any Regulatory Application submitted in support of this Project Agreement, solely for the purpose of the Government conducting a clinical trial with the drug product supplied under this Project Agreement under a protocol approved by Regeneron for performance by the Government. In such a case, Regeneron agrees to provide a letter of cross-reference to the Government and file such letter with the appropriate FDA office.  Nothing in this paragraph reduces the Government&#8217;s data rights as articulated in other provisions of this award.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c. Clause 7.4.b. will survive the acquisition or merger of the Contractor by or with a third party.   This clause will survive the expiration of this contract.</font></div><div style="text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5 PREP Act Coverage. It is the intent of the Parties that the drug product provided pursuant to this Agreement be covered by the March 10, 2020 declaration under the Public Readiness and Emergency Preparedness Act (PREP Act), 42 U.S.C. &#167; 247d-6d, 85 Fed Reg. 15,198 (March 17, 2020), or any amendments thereto that provides liability protection for such use.&#160; Based on an independent review by each of the Parties of the PREP Act Declaration issued by DHHS on March 10, 2020, pursuant to section 319F-3 of the Public Health Service Act (42 U.S.C. 247d-6d), and a related advisory opinion issued by the DHHS Office of General Counsel on April 14, 2020, the Parties believe that Regeneron is a covered person eligible for immunity under the PREP Act for activities related to medical countermeasures against COVID-19. To the extent DoD or BARDA is authorized to do so as an Authority Having Jurisdiction, the Government designates Regeneron as a covered person eligible for immunity under the PREP Act Declaration issued by DHHS on March 10, 2020, pursuant to section 319F-3 of the Public Health Service Act (42 U.S.C. 247d-6d), for activities related to medical countermeasures against COVID-19.&#160; The Government further warrants that the drug product provided pursuant to this Project Agreement will not be (a) sold to any entity nor will it be returned after acceptance under the terms of this contract or (b) distributed or used, or authorized for distribution or use, outside the United States or to the extent such activities are not protected from liability under an active PREP Act declaration.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6 Transparency. To the extent permitted under applicable laws, the Government will provide Regeneron in a timely manner copies of reports concerning this Project Agreement that are provided to other Government agencies or legislative or executive branches of the government.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.0&#160;&#160;&#160;&#160;SECURITY</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The security classification level for this effort is UNCLASSIFIED.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS REQUIREMENTS (SAFETY, ENVIRONMENTAL, ETC.)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N&#47;A</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.0&#160;&#160;&#160;&#160;GOVERNMENT FURNISHED PROPERTY&#47;MATERIAL&#47;INFORMATION</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.0&#160;&#160;&#160;&#160;AGREEMENTS OFFICER&#8217;S REPRESENTATIVE (AOR) AND ALTERNATE AOR CONTACT INFORMATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AOR</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NAME&#58;  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMAIL&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PHONE&#58;  &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGENCY NAME&#47;DIVISION&#47;SECTION&#58;  HHS&#47;ASPR&#47;BARDA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Alternate AOR</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NAME&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAILING ADDRESS&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMAIL&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PHONE&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGENCY NAME&#47;DIVISION&#47;SECTION&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Requiring Activity&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">US Department of Health &#38; Human Services (HHS), Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Definitions Appendix</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Computer Software&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To perform and further this Project Agreement&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Computer programs that comprise a series of instructions, rules, routines, or statements, regardless of the media in which recorded, that allow or cause a computer to perform a specific operation or series of operations&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recorded information comprising source code listings, design details, algorithms, processes, flow charts, formulas, and related material that would enable the computer program to be produced, created, or compiled.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Does not include computer databases or computer software documentation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Means recorded information, regardless of form or the media on which it may be recorded. The term includes technical data and Computer Software. The term does not include information incidental to contract administration, such as financial, administrative, cost or pricing, or management information. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The development of anti-pathogen assets to treat, diagnose or prevent emerging infectious diseases.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The United States of America, as represented by the Department of Health &#38; Human Services (&#8220;Government&#8221;), Office of the Assistant Secretary for Preparedness &#38; Response (&#8220;ASPR&#8221;), Office of Biomedical Advanced Research and Development (&#8220;BARDA&#8221;) (represented by Office of Acquisition Management, Contracts and Grants (AMCG)). </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Purpose&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Any activity in which the United States Government is a party, including cooperative agreements with international or multi-national defense organizations, or sales or transfers by the United States Government to foreign governments or international organizations.  Government purposes include competitive procurement, but do not include the rights to use, modify, reproduce, release, perform, display, or disclose technical data for commercial purposes or authorize others to do so.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Purpose Rights&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The rights by Government to&#8212;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;Use, modify, reproduce, release, perform, display, or disclose technical data within the Government without restriction&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Release or disclose technical data outside the Government and authorize persons to whom release or disclosure has been made to use, modify, reproduce, release, perform, display, or disclose that data for United States Government Purpose.   </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Invention&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Any invention or discovery that is or may be patentable or otherwise protectable under Title 35 of the United States Code.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limited Rights&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The rights to use, modify, reproduce, perform, display, or disclose Data, in whole or in part, within the Government solely for research purposes for the Field. Government will ensure that disclosed information is safeguarded in accordance with the restrictions of this Agreement.  The Government may not, without the prior written permission of Recipient, release or disclose the Data outside the Government, use the Data for competitive procurement or manufacture, release or disclose the data for commercial purposes, or authorize the Data to be used by another party. The Parties shall maintain the confidentiality of all Data subject to or designated as falling within Limited Rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limited Rights Data&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Data, other than Computer Software, that embody trade secrets or are commercial or financial and confidential or privileged, to the extent that such Data pertain to items, components, or processes developed at private expense, including minor modifications. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Made&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The conception or first actual reduction to practice of the invention as defined in this Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Option&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An option,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">entered into by bilateral agreement pursuant to a Statement of Work and budget, by which, for a specified time, the Government may elect to purchase additional supplies or services called for by the Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Transaction Agreement Officer (&#8220;OTAO&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Is the responsible Government official authorized to bind the Government by signing this Agreement and bilateral modifications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Transaction Agreement Specialist (&#8220;OTAS&#8221;)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Is a supporting official that assists and represents the OTAO. The OTAO is the only official who can bind the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Transaction Agreement Technical Representative (&#8220;OTTR&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Is the primary Government official for all technical matters on the Agreement. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Practical Application&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> With respect to a Subject Invention, to manufacture, in the case of a composition or product&#59; to practice, in the case of a process or method&#59; or to operate, in the case of a machine or system&#59; and, in each case, under such conditions as to establish that the Subject Invention is capable of being utilized and that its benefits are, to the extent permitted by law or Government regulations, available to the public for a regulatory approved product.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subject Invention&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Any Invention Made in the performance of work under this Agreement within the Field for which Recipient pursues a patent.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sub-Recipient&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Akin to a subcontractor. Any supplier, distributor, vendor, or firm that furnishes supplies or services to or for the Recipient, an Affiliate, or a Sub-Recipient.&#160;A Sub-Recipient differs from an Affiliate in that Sub-Recipients are not listed as an Affiliate in Attachment 3 and may be used to execute tasks under the SOW by Recipient or Affiliate. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sub-Recipient Agreement&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any contract entered into by a Sub-Recipient to furnish supplies or services for performance of this Agreement. This term describes an agreement with a 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-Tier Sub-Recipient, except as expressly noted in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report Requirements</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This page intentionally left blank. See separate document for Attachment B.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:3.95pt;padding-left:181.15pt;padding-right:181.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT REQUIREMENTS</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If classified information is required to be submitted under this Agreement, it must be submitted to the addresses specified in the SOW or DD254. No classified information should be submitted directly to ATI.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Any applicable Contract Data Requirements Lists (CDRLs), Data Item Descriptions (DIDs) or other report guidance for this Project may be included at the end of this attachment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ATI, in addition to the AOR, must receive a copy of the Quarterly Status Reports and the Final Status Report.  Quarterly Status Reports, Annual Status Reports, and Final Status Reports should be submitted to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">           </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  All other deliverables shall be submitted to the AOR only, but ATI must be notified that the deliverable has been submitted to the AOR. The AOR will provide ATI a completed Sign- off Memorandum as evidence the milestone deliverable was received and deemed acceptable.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:47.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If you would like a copy of the Report  Requirements  template  in  MS  Word,  please  email  </font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.34pt">QUARTERLY STATUS REPORT</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Recipient shall submit or otherwise provide a Quarterly Status Report in the format as shown in   this attachment on the last day of the month of the calendar quarter (i.e., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">March 31, June 30, and December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">).  A sample template is provided.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:42pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Recipient&#8217;s Technical Status Report will, at a minimum, address the following&#58; Comments on Technical&#47;Cost&#47;Schedule Performance, Project Quad Chart, Milestone Status, Non-Traditional Defense Contractor Participation and Plans for the Next Quarter.</font></div><div><font><br></font></div><div style="padding-left:42pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:25pt">PAYABLE MILESTONES&#47;DELIVERABLES</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6pt;padding-right:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Recipient shall submit to the Agreements Officer Representative and MCDC CMF Representative documentation describing the extent of accomplishment of Payable Milestones and Deliverables.</font></div><div style="padding-left:42pt;padding-right:5.65pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.34pt">Submission of Payable Milestones&#47;Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Recipient is required to submit all deliverables identified as Payable Milestones, as shown in the Payable Milestone Schedule, as well as any other deliverables&#47;reports listed in the Statement of Work.</font></div><div><font><br></font></div><div style="padding-left:42pt;padding-right:5.4pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:23.68pt">Sign-off  Memorandum.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The  Sign-off  Memorandum  as  shown  in  this    attachment  shall accompany all submissions indicated in section B.I. The Agreements Officer Representative shall provide written approval using the Sign-off Memorandum to the MCDC Consortium Management Firm.   The  Sign-off  Memorandum  will  be  used  to  verify  that  all  submissions are technically  acceptable.  It will also be used to substantiate invoice payment for firm fixed price agreements.</font></div><div style="margin-top:0.05pt;padding-left:41.65pt;text-align:justify;text-indent:-35.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:23.99pt">ANNUAL STATUS REPORTING</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:42pt;padding-right:5.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:28.34pt">The Project Agreement Holder shall submit an Annual Status Report on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">September 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> each year (same format as Quarterly Status Report for one year period) for all projects whose periods of performances are greater than</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.8pt;padding-left:5pt;padding-right:8.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">one year in accordance with the terms and conditions of the MCDC Base Agreement. The Annual Status Report must also include the following&#58;</font></div><div style="padding-left:59pt;padding-right:5.9pt;text-align:justify;text-indent:-15.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.07pt">A comparison of actual accomplishments with the goals and objectives of the project established for the period.</font></div><div style="padding-left:59pt;text-indent:-18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.04pt">Reasons why established goals and objectives were not met, if appropriate.</font></div><div style="padding-left:59pt;padding-right:5.85pt;text-align:justify;text-indent:-22.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.06pt">A cumulative chronological list of written publications in technical journals. Include those in press as well as manuscripts in preparation and planned for later submission. Indicate likely journals, authors and titles.</font></div><div style="padding-left:59pt;text-indent:-21.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.07pt">Papers presented at meetings, conferences, seminars, etc.</font></div><div style="padding-left:59pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">New discoveries, inventions or patent disclosures and specific applications stemming from the individual project provided that such disclosure shall not compromise the rights of the inventor.</font></div><div style="padding-left:59pt;padding-right:5.85pt;text-align:justify;text-indent:-21.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.07pt">Reporting on Utilization of Subject Inventions should be included in the Annual Status Report per Section 10.08 of the Base Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_22"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:2.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quarterly Status Report</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">for</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">&#60;Project Agreement Holder Name&#62;</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">Project No. MCDC-XX-XX-XXX</font></div><div style="margin-top:11.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Reporting Period&#58;  DATE - DATE</font></div><div><font><br></font></div><div style="margin-top:10.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;text-decoration:underline">Project Agreement Holder</font></div><div style="margin-top:5.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">&#60;Project Lead&#62;</font></div><div style="margin-top:5.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">&#60;Other Project Team Member(s)&#62;</font></div><div style="margin-top:10.95pt;padding-right:25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Project Team Technical POC</font></div><div style="margin-top:6pt;padding-left:175.8pt;padding-right:200.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name Company Street Address</font></div><div style="padding-left:162.85pt;padding-right:187.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">City, State Zip Code Phone Number Email address</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.05pt;padding-right:0.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">Submitted&#58;&#160;&#160;&#160;&#160;&#60;date&#62;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_25"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:140.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Comments on Technical&#47;Cost&#47;Schedule Performance</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:23pt;padding-right:5.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of this section is to bring project stakeholders up to speed on current project status. It is not intended to be a line-by-line account of the quarter&#8217;s activities&#59; details of that nature are reserved for the latter section of this report. Rather, this section should highlight technical, cost, and schedule performance for the quarter, and report overall progress towards successful technology transition and implementation &#8211; an executive summary-like synopsis. This section should also be used to cite project-related concerns.</font></div><div style="margin-top:7pt;padding-left:23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Properly crafted, this section is typically about one-half page in length.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Project Quad Chart</font></div><div style="padding-left:23pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Quad charts are used for many purposes, including high level briefings. Therefore, it is imperative that information be current and accurate, especially in regards to the lower quadrants. The text - where populated - in the quad chart below is for sample purposes only.</font></div><div style="margin-bottom:0.05pt;margin-top:0.15pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.271%"><tr><td style="width:1.0%"></td><td style="width:9.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#33339a;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">&#60; Project Agreement Title&#62;</font></td></tr><tr style="height:18pt"><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goals &#38; Objectives</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Information</font></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Briefly describe the goals of the project&#59; include the technical objectives and the implementation targets.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.85pt;padding-right:150.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:172%">Project Lead</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:172%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:172%">Team Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:172%">&#58;</font></div></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Period of Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#58;</font></div></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#58;</font></div></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cumulative Amt Invoiced&#58;</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Cost Share Reported&#58;</font></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestones &#38; Technical Achievements</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Implementation &#38; Payoff</font></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Apr 16&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kickoff Meeting</font></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#58; Target date for implementation.</font></div><div style="margin-top:3pt;padding-left:53.75pt;padding-right:11.35pt;text-indent:-48.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#58;&#160;&#160;&#160;&#160;Current status towards implementation event.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jun 16&#58;</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Design Analysis complete</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jul 16&#58;</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Materials&#47;Equipment Rec&#8217;d</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oct 16&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prototype construction complete</font></td><td colspan="3" rowspan="4" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Briefly describe what benefits will accrue from this project&#8217;s successful completion and implementation. Be quantitative to the greatest extent possible.</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">May 17&#58;</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Initial testing complete</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Oct 17&#58;</font></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Production units implemented in shipyard processes</font></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:157%;text-decoration:underline">Current Status&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:157%">Technical &#61; Green&#47;Yellow&#47;Red (delta)     Schedule &#61; Green&#47;Yellow&#47;Red (delta)     Cost &#61; Green&#47;Yellow&#47;Red (delta)</font></div></td></tr></table></div><div style="margin-top:8.95pt;padding-left:95pt;padding-right:78.65pt;text-align:center;text-indent:-90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:118%;text-decoration:underline">Current Status Legend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:118%;text-decoration:underline">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:118%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">Green &#61; Good&#47;On Budget&#160;&#160;&#160;&#160;Yellow &#61; Minor Weakness&#47;Known Risk&#160;&#160;&#160;&#160;Red &#61; Major Weakness&#47;Critical Delta&#58; </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#61681;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">&#61; upgrade from last assessment&#59; </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#61682;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">&#61; downgrade from last assessment&#59; </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:118%">&#61680;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:118%">&#61; no change</font></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_28"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:42pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Supplemental Information</font></div><div style="padding-left:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to improve the usefulness of the quad charts and provide sufficient project information, the Quarterly Status Report must be supplemented with data described below.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:60pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt">Milestone Status&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.953%"><tr><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Due Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Percent Complete This Period</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cumulative Percent Complete</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3pt">Non-Traditional Defense Contractor Participation</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.953%"><tr><td style="width:1.0%"></td><td style="width:43.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Name of Nontraditional*</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Planned Start Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Actual Start Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reason for Deviation from Plan</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:60pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:3pt">Plans for Next Quarter</font></div><div style="padding-left:87pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.5pt">Major achievements planned for the next quarter</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_31"></div><hr style="page-break-after:always"><div style="min-height:67.7pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:10.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MEMORANDUM&#58;  Agreements Officer Representative Sign-Off</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:231.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:160%">To&#58;&#160;&#160;&#160;&#160;Agreements Officer Representative (AOR) From&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:160%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="margin-top:4.2pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference&#58;&#160;&#160;&#160;&#160;(a) MCDC Base Agreement between ATI and </font></div><div style="margin-top:4.2pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________&#160;&#160;&#160;&#160;Agreement No. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="margin-top:4.5pt;padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) Project Agreement No.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="margin-top:4.5pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject&#58;&#160;&#160;&#160;&#160;Milestone Approval</font></div><div style="margin-top:7.45pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following deliverable(s) associated with the Milestone(s) listed below have been completed&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:53.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">MS#</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Deliverable</font></div><div style="margin-top:4.45pt;padding-left:56.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">XX&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:47.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is requested that verification of these accomplishments be provided to the MCDC Consortium Management Firm.</font></div><div style="margin-top:0.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_____________________________________________________________________________________</font></div><div style="margin-top:6.1pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To&#58;  MCDC Consortium Management Firm</font></div><div style="margin-top:10.5pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CERTIFICATION BY AGREEMENTS OFFICER REPRESENTATIVE&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Project Agreement Holder has made satisfactory progress and provided the required deliverables associated with this milestone. I certify the work performed is in accordance with the approved Statement of Work (SOW) included in the agreement.</font></div><div style="margin-top:10.7pt;padding-left:6pt"><font style="color:#ed1c24;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Other comments or concerns regarding this or future milestones&#58;</font></div><div style="margin-top:10.5pt;padding-left:6pt;padding-right:25.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Note&#58; For any non-satisfactory areas include a discussion of what was not acceptable, references to previous correspondence on the issue, and what corrective actions are needed to effect payment.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.25pt;padding-left:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________________________ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   ___________________</font></div><div style="padding-left:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Agreements Officer Representative&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Date&#58;</font></div><div style="height:13.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><div id="iaa383481d5794ed7bcdc614b8587edf4_34"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="padding-left:22.5pt;text-align:right"><font><br></font></div><div style="padding-left:22.5pt"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:36pt;padding-right:12.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment C</font></div><div style="padding-left:36pt;padding-right:12.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Technical Direction Letter (TDL) RPP-20-08 Regeneron</font></div><div style="padding-left:36pt;padding-right:12.95pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;padding-right:12.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This page intentionally left blank. See separate document for Attachment C.</font></div><div style="height:13.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="padding-left:22.5pt;text-align:right"><font><br></font></div><div style="padding-left:22.5pt"><font><br></font></div></div><div style="margin-top:0.3pt;padding-left:72pt"><img alt="image_21a.jpg" src="image_21a.jpg" style="height:108px;width:106px"></div><div style="margin-top:4.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:114%">DEPARTMENT OF THE ARMY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. ARMY CONTRACTING COMMAND &#8211; NEW JERSEY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PICATINNY ARSENAL, NEW JERSEY 07806-5000</font></div><div style="margin-top:9pt;padding-left:85.1pt;padding-right:344.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REPLY TO</font></div><div style="padding-left:85.1pt;padding-right:344.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ATTENTION OF</font></div><div style="padding-right:5.7pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">06 July 2020</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:28.8pt;padding-right:279.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Army Contracting Command &#8211; New Jersey</font></div><div style="padding-left:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ACC-NJ, Building 9</font></div><div style="padding-left:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Picatinny Arsenal, NJ 07806</font></div><div><font><br></font></div><div style="padding-left:28.75pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBJECT&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Technical Direction Letter for Medical CRBN Defense Consortium (MCDC), Request for Prototype Proposals (RPP) 20-08, Objective TRE-PRE-20-08 for &#8220;Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2&#8221; (Regeneron Pharmaceuticals, Inc.)</font></div><div style="margin-top:11.55pt;padding-left:28.8pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REF&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Request for Technical Direction Letter, RPP 20-08 under OTA W15QKN-16-9- 1002 for Objective TRE-PRE-20-08, dated 30 June 2020</font></div><div><font><br></font></div><div style="padding-left:28.75pt;padding-right:279.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advanced Technology International </font></div><div style="padding-left:28.75pt;padding-right:279.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ATTN&#58;           Sr. Contracts Manager </font></div><div style="padding-left:28.75pt;padding-right:279.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">315 Sigma Drive</font></div><div style="padding-left:28.75pt;padding-right:351pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Summerville, SC 29486 </font></div><div style="padding-left:28.75pt"><font><br></font></div><div style="padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear          ,</font></div><div><font><br></font></div><div style="padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Army Contracting Command &#8211; New Jersey (ACC-NJ), in supporting the Joint Project Manager &#8211; Medical Countermeasure Systems (JPM-MCS), issued MCDC RPP 20-08 on 17 May 2020. Members of the MCDC submitted proposals in accordance with this RPP. The Government received and evaluated all proposal(s) submitted and a Basis of Selection has been executed, selecting Regeneron as the awardee. The Government requests that a Firm-Fixed-Price Project Agreement be issued to Regeneron to award this proposal under Other Transaction Agreement W15QKN-16-9- 1002, to be performed in accordance with the attached Government Statement of Work (SOW).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:28.75pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Based upon the acceptable update of Regeneron&#8217;s proposal for &#8220;Large-Scale Manufacturing of Antibodies Directed to SARS-CoV-2&#8221; and 1) The Project Agreement Recipient&#8217;s concurrence with the requirements included in the Government SOW&#59; 2) An acceptable milestone schedule that meets SOW requirements, and&#59; 3) The cost proposal that has been analyzed and negotiated by the Government, you are hereby directed to issue a Project Agreement to Regeneron for the subject project. The total project value has been determined fair and reasonable and Regeneron&#8217;s proposal has been selected IAW the above referenced Basis of Selection.</font></div><div style="margin-top:4.5pt;padding-left:28.8pt"><font><br></font></div><div style="height:13.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="padding-left:22.5pt;text-align:right"><font><br></font></div><div style="padding-left:22.5pt"><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The total approved cost to the Government for this effort is not to exceed &#91;* * *&#93;. The break-out of the costs is as follows&#58; $450,262,000.00 to perform project efforts included in the SOW and &#91;* * *&#93; for the Consortium Management Firm (CMF) Administrative Cost. &#91; * * *&#93; The effort currently has</font></div><div style="padding-left:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93; of available funding, comprised of $450,262,000.00 for the Project Agreement and &#91;* * *&#93; for the CMF. PAH COVID-19 work shall be tracked separately using the funding obligated via modification P00074. &#91;* * *&#93;</font></div><div style="margin-top:4.5pt;padding-left:28.75pt;padding-right:5.6pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:28.75pt;padding-right:5.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The PAH is considered a small business, nontraditional defense contractor, or nonprofit research institution and determined to be providing a significant contribution. The affirmation of business status certifications submitted as part of the proposal are hereby incorporated into the agreement. The contractor shall notify the MCDC CMF of any deviation from the final proposed affirmation of business status certifications that would affect the contributions of the small business, nontraditional defense contractor, or nonprofit research institution as proposed.</font></div><div><font><br></font></div><div style="padding-left:28.75pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accordance with 10.U.S.C. 2371b(f), and upon a determination that the prototype project for this transaction has been successfully completed, this competitively awarded prototype OTA may result in the award of a follow-on production contract or transaction without the use of competitive procedures.</font></div><div><font><br></font></div><div style="padding-left:28.75pt;padding-right:5.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Government and Advanced Technology International (&#8220;ATI&#8221;) hereby agree and confirm that (a) ATI, in its capacity as the Consortium Management Firm under the Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement No. W15QKN-16-9-1002 (the MCDC Agreement), has the authorization to enter into the Medical CBRN Defense Consortium Base Agreement No. 2020-504 and the Statement of Work (collectively, the &#8220;Regeneron Agreement&#8221;) with Regeneron on behalf of the Government, (b) the Government is and shall be bound by its obligations set forth in the Regeneron Agreement, and the MCDC Agreement is hereby amended to incorporate these obligations in the MCDC Agreement, as that Agreement relates to Regeneron, and (c) Regeneron is an intended third-party beneficiary of such obligations that can enforce them directly against the Government, and (d) in the event of any conflict between the Regeneron Agreement, on the one hand, and the MCDC Agreement, on the other hand, the Regeneron Agreement shall control and take precedence.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:28.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Points of Contact&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreements Specialist&#58;</font></div><div style="padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:28.75pt;padding-right:305.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E-mail&#58;  </font></div><div style="padding-left:28.75pt;padding-right:305.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;  </font></div><div><font><br></font></div><div style="padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreements Officer&#58;</font></div><div style="padding-left:28.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:28.75pt;padding-right:305.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E-mail&#58; </font></div><div style="padding-left:28.75pt;padding-right:303.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phone&#58;  </font></div><div style="height:13.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="padding-left:22.5pt;text-align:right"><font><br></font></div><div style="padding-left:22.5pt"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:3.35pt;padding-left:288.45pt;padding-right:126.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:129%">Regards,</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:4.3pt;padding-left:52.3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:23pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="margin-top:3.35pt;padding-left:288.45pt;padding-right:126.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:129%">Agreements Officer</font></div><div style="padding-left:288.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:132%">Signed by&#58;  </font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attachments&#58;</font></div><div style="margin-top:0.05pt;padding-left:28.8pt;padding-right:240.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attachment 1&#58; MCDC2008-005 - Regeneron - 7-3-2020</font></div><div style="margin-top:0.05pt;padding-left:28.8pt;padding-right:240.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attachment 2&#58; OPSEC Language Addendum</font></div><div style="padding-left:36pt;padding-right:240.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:28.8pt"><font><br></font></div><div style="padding-left:28.8pt"><font><br></font></div><div style="padding-left:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">______________________________ </font></div><div style="padding-left:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:102%">ATI Signatory</font></div><div style="height:13.7pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:2pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>regn-ex103x09302020x10q.htm
<DESCRIPTION>LICENSE AGREEMENT AMONG THE REGISTRANT, F. HOFFMAN-LA ROCHE, AND GENENTECH
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic19c56d7c1f146aa8be2e44378c796e8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibit 10.3</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXECUTION VERSION</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement is entered into with effect as of August 18, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by and between</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Basel</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with an office and place of business at 1&#160;DNA&#160;Way, South&#160;San Francisco, California&#160;94080, United States (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; together with Roche Basel &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on the one hand</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with an office and place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, United States (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on the other hand.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Table of Contents </font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Definitions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accounting Standards</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Affiliate</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement Term</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Director</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Antibody</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Applicable Law</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Back-Up Compound</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BARDA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biosimilar Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Business Day</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calendar Quarter</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calendar Year</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chugai Asset Criteria</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chugai Asset Data Package Criteria</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical Study</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CMO</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Code</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Co-Funded Development Plan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Co-Funded Studies</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collaboration Timepoint</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Combination Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercially Reasonable Efforts</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Companion Diagnostic</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Competitive Infringement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compound</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidential Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Control</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cover</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COVID19</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CRO</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CTA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dollars</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Drug Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Drug Substance</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EMA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Emergency Use Authorization or EUA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EU</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Expert</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDCA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Field</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finished Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First Commercial Sale</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fully Burdened Manufacturing Costs</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAVI Eligible Countries</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Global Gross Profit</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gross Profit</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Handle</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hospitalized Patients</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnitees</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvency Event</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Invention</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Know-How</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Know-How</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Knowledge</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lead Compound</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lead Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manufacturing Collaboration Timepoint</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Major Country</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net Sales</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NGO</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-US Affiliate</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ongoing Regeneron Studies</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Out-Patients</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmaceutical Company</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase I Study</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase II Study</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase III Study</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PHSA</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PPQ</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Presentation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Know-How</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Patent Right</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proprietary Manufacturing Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Approval</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Authority</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Base Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Cell Media</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Controlled Infringement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron-DOD&#47;BARDA Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron Existing BARDA Commitment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Know-How</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Patent Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Respective Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Major Countries</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Group</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Independent IP</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Know-How</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Manufacturing Facilities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Production Contribution</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Shared Infringement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ROW</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sales Volume</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SARS-CoV-2</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sensitive Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standard Cost</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensee</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party IP License</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party IP Payments</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">US</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">US Affiliate</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">US Person</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Valid Claim</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional Definitions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant of License</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licenses granted by Regeneron</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche&#8217;s Right to Sublicense</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Right to Sublicense to its Affiliates and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Right to Sublicense to Other Third Parties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Basel Right to Subcontract</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licenses granted by Roche</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron&#8217;s Right to Sublicense</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Right to Subcontract</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Combination Products and Companion Diagnostics</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Back-Up Compounds</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Antibody Conjugates</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Research and Development</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibilities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Co-Funded Development Plan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exchange of Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Records</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PII&#47;Samples</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manufacturing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manufacturing Responsibility</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shared Responsibility during the Agreement Term</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Excess Capacity</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specifications</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standard Costs</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Cell Banks and Cell Media.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Cell Banks</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Cell Media</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ownership and Restrictions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">5.</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">&#160;&#160;&#160;&#160;</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:none">Supply</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Allocation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Supply Price</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Supply Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron&#8217;s Responsibilities.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche&#8217;s Responsibilities.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Diligence Obligation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacovigilance and Global Safety Database</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibility</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pricing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization Diligence Obligation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Distribution of Products</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Distribution Audit</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governance</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Steering Committee</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Formation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Members</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibilities of the JSC</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meetings</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minutes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decisions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decision Making Authority</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consensus&#59; Good Faith</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure to Reach Consensus, Escalation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Manufacturing Committee</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Formation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Members</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibilities of the JMC</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meetings</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minutes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decisions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decision Making Authority</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consensus&#59; Good Faith</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure to Reach Consensus</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Operations Committee</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Formation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Members</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Responsibilities of the JOC</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meetings</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minutes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decisions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Decision Making Authority</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consensus&#59; Good Faith</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Failure to Reach Consensus</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial Working Group</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Formation.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Operation of the FWG.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exclusivity</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Compete Obligation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Right of First Negotiation to Chugai Asset</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chugai Asset Data Package</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chugai Asset Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reimbursement &#91;* * *&#93; for Development Activities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Global Gross Profit Sharing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disclosure of Payments</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accounting and Reporting</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mechanics and Timing of Payments</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Late Payment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Method of Payment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Currency Conversion</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reimbursement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment Disputes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taxes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain Taxes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Withholding Taxes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDII Documentation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Auditing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Right to Audit</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Audit Reports</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Over-or Underpayment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Intellectual Property</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ownership of Intellectual Property</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inventions Made by Employees, Subcontractors and Services Providers</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Trademarks and Labeling</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use of Corporate Names.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prosecution of Product Patent Rights in the Regeneron Patent Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prosecution of Product Patent Rights in the Roche Territory and Joint Patent Rights in the Territory</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Handling of Other Patent Rights.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Coordination&#59; No Invention Overlap</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unified Patent Court (Europe)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CREATE Act</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Infringement of Product Patent Rights and Joint Patent Rights</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Invalidity or Unenforceability Defenses or Actions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Defense</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Interest Disclosures</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Biosimilars</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Term Extensions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interference, Opposition and Reissue of Third Party Patents</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party IP Licenses</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Representations and Warranties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regeneron Representations and Warranties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Roche Representations and Warranties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mutual Representations and Warranties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Other Representations and Warranties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification by Roche</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification by Regeneron</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Fault Claims</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification Procedure</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Liability</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligation Not to Disclose Confidential Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Use and Non-Disclosure</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Permitted Disclosure</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proprietary Manufacturing Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Press Releases&#59; Use of Name</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Publications</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term and Termination</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commencement and Term</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination for Breach</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination for Roche Diligence Breach or Failure to Commercialize</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvency</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination by Roche for Technical Failure</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination by Roche due to &#91;* * *&#93; Third Party Product</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consequences of Expiration or Termination</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transfer of Products</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other Obligations</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations Related to Ongoing Activities</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations Related to Manufacturing</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ancillary Agreements</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Limitations on Grant-Backs&#59; Transfer Expenses</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment Obligations</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Return or Destruction of Confidential Information</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:78pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination with respect to a country.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Survival</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bankruptcy</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miscellaneous</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law&#59; Jurisdiction</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disputes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equitable Relief</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Expert Committee</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assignment</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Affiliates</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independent Contractor</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unenforceable Provisions and Severability</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Force Majeure</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waiver</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interpretation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Entire Understanding</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendments</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Invoices</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Counterparts</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party Beneficiaries</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further Assurances</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Regeneron is developing an antibody cocktail directed to the SARS-CoV-2 spike protein consisting of two antibodies known as REGN10933 and REGN10987&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche has expertise in the development, manufacture and commercialization of pharmaceutical products in the field of infectious diseases, including the ability to rapidly scale up commercial supply for pandemic stockpiling and discussions with governments&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche Basel and Regeneron intend to develop, manufacture and commercialize the antibody cocktail directed to the SARS-CoV-2 spike protein consisting of REGN10933 and REGN10987 globally as a treatment for COVID19&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche Basel and Regeneron have entered into a Technology Transfer Agreement as of July 22, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Technology Transfer Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Regeneron is willing to grant to Roche Basel rights to use certain of its intellectual property rights to make Compounds and Products in the Territory (as such terms are respectively defined below), develop Compounds and Products in the Territory, and use, offer for sale, sell and import Compounds and Products in the Roche Territory and export Compounds and Products to the Territory, in each case, for use in the Field (as such terms are respectively defined below), as contemplated herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche is willing to grant Regeneron rights to use certain of its intellectual property rights to make Compounds and Products in the Territory and to develop, use, offer for sale, sell and import and export Compounds and Products in the Territory for use in the Field, as contemplated herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche and Regeneron agree that Regeneron will continue to perform certain ongoing activities to develop the Compound&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Roche and Regeneron agree that Roche and Regeneron will perform certain activities to develop, manufacture and commercialize the Compound and Product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Accounting Standards</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Accounting Standards&#8221; shall mean the maintenance of records and books of accounts in accordance with IFRS (International Financial Reporting Standards) or GAAP (Generally Accepted Accounting Principles), which standards or principals (as applicable) are currently used at the applicable time by, and as consistently applied by the applicable Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Affiliate</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Affiliate&#8221; shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of &#8220;Affiliate,&#8221; the term &#8220;control&#8221; shall mean the direct or indirect ownership of more than fifty percent (&#62;50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, none of Chugai Pharmaceutical Co., Ltd, a Japanese corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and its subsidiaries (if any) shall be deemed to be Affiliates of Roche unless mutually agreed by the Parties. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Agreement&#8221; shall mean this document including any and all appendices and amendments to it as may be agreed by the Parties from time to time in accordance with the provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Agreement Term</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Agreement Term&#8221; shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided in Article&#160;20, ending seven (7) years after the First Commercial Sale of the first Product in the EU and any extension thereto mutual agreed by the Parties in writing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Alliance Director</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Alliance Director&#8221; shall mean one person of each Party appointed to be its point of contact with responsibility for facilitating communication and collaboration between the Parties who shall facilitate resolution of potential and pending issues and potential disputes to avert escalation of such issues or potential disputes.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Antibody</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Antibody&#8221; shall mean a protein or polypeptide sequence that includes a complementarity-determining region (CDR) of an antibody (e.g. mAb, Fab, scFv, other fragments of an antibody), whether polyclonal or monoclonal, fully human, humanized, chimeric, multiple or single chain, recombinant or naturally occurring.  For clarity, Antibodies shall not include other modalities such as nucleic acid, viral or cellular therapy modalities, or antibodies conjugated to a toxin or other active agent where the primary intended function of the antibodies is not to neutralize a target, but to direct such toxin or other active agent to such target (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Antibody Conjugate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Applicable Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Applicable Law&#8221; shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same is applicable to the Compounds, Products, or performance by the Parties of their respective obligations under this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Back-Up Compound</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Back-Up Compound&#8221; shall mean &#91;* * *&#93;. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:19.33pt">BARDA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;BARDA&#8221; shall mean the US Biomedical Advanced Research and Development Authority.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Biosimilar Product</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Biosimilar Product&#8221; shall mean, with respect to a Product and a country, </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any product that is claimed to be biosimilar to or interchangeable with such Product in such country (including a product that is the subject of a biologics license application submitted under Section 351(k) of the PHSA citing such Product as the reference product or any corresponding foreign application in the Territory, including, with respect to the European Union, an MAA for a similar biological medicinal product pursuant to Article 10(4) of Directive 2001&#47;83&#47;EC) or for which the biologics license application otherwise references or relies on such Product in such country.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Business Day</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Business Day&#8221; shall mean 9&#58;00 am to 5&#58;00 pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday in Switzerland (with regard to Roche) or New York, New York or elsewhere in the US (with regard to Regeneron).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Calendar Quarter</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Calendar Quarter&#8221; shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30, or December 31.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Calendar Year</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Calendar Year&#8221; shall mean the period of time beginning on January 1 and ending December 31, except for the first Calendar Year, which shall begin on the Effective Date and end on December 31.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Chugai Asset Criteria</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Chugai Asset Criteria&#8221; shall mean &#91;* * *&#93;.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Chugai Asset Data Package Criteria</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The term &#8220;Chugai Asset Data Package Criteria&#8221; shall mean data, reports, documentation and other information in the Chugai Asset Data Package that are reasonably sufficient to determine whether or not the Chugai Asset satisfies the Chugai Asset Criteria. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Clinical Study</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Clinical Study&#8221; shall mean any human clinical trial, including a Phase I Study, Phase II Study, or Phase III Study.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">CMO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;CMO&#8221; shall mean a Third Party contract manufacturing organization.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Code</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Code&#8221; shall mean the US Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Co-Funded Development Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Co-Funded Development Plan&#8221; shall mean the development plan for the Co-Funded Studies agreed and approved by the JSC.  The Co-Funded Development Plan shall initially include the Additional Regeneron Studies and shall be updated by the JSC to include any Clinical Studies described on Appendix 1.20(b) and may further be updated from time to time by the JSC to include additional Co-Funded Studies. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Co-Funded Studies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Co-Funded Studies&#8221; shall mean (a) the Clinical Studies as set forth on Appendix 1.20(a) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Regeneron Studies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (b) any additional Clinical Studies for which the Parties, through the JSC, agree to share the out-of-pocket costs, including the Clinical Studies described Appendix 1.20(b).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.21</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Collaboration Timepoint</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Collaboration Timepoint&#8221; shall mean &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Combination Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Combination Product&#8221; shall mean any product containing both the Compound and one or more other pharmaceutically active agents, regardless of their finished forms or formulations or dosages. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.23</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Commercially Reasonable Efforts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Commercially Reasonable Efforts&#8221; shall mean, with respect to a Party and any objective or decision pertaining to a Compound or Product under this Agreement, the level of efforts and resources &#91;* * *&#93;, taking into account, without limitation, the public health need for therapeutics due to the SARS-CoV-2 pandemic, epidemiology of SARS-CoV-2, commercial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">opportunity &#91;* * *&#93;, the available production supply of Compound and Product, legal factors, regulatory factors (including requirements of Regulatory Authorities), target product profiles, product liability, market exclusivity, cost of goods, pricing and access considerations, relative safety and efficacy, competitive market conditions, and its proprietary position&#59; provided that &#91;* * *&#93; shall not be considered as a factor to mitigate its obligation to use Commercially Reasonable Efforts under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Companion Diagnostic</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Companion Diagnostic&#8221; shall mean any product that is used for predicting or monitoring the response of a human being to treatment with a Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.25</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Competitive Infringement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Competitive Infringement&#8221; shall mean any (i) known infringement or suspected infringement by a Third Party of any Joint Patent Rights by the exploitation of a Competing Product, or (ii) known or suspected unauthorized use or misappropriation by a Third Party of any Joint Know-How by the exploitation of a Competing Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.26</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Compound</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Compound&#8221; shall mean the Lead Compound and each Back-Up Compound.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.29</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Confidential Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Confidential Information&#8221; shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by or on behalf of one Party or its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the other Party or its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in connection with this Agreement (including pursuant to the Technology Transfer Agreement), whether prior to, on, or after the Effective Date, including information relating to the terms of this Agreement, the Compound, the Products, any development, manufacture or commercialization of the Products, any Know-How with respect thereto developed by or on behalf of the Disclosing Party or its Affiliates, or the scientific, regulatory or business affairs or other activities of either Party.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Notwithstanding the foregoing, (a) Joint Inventions, Joint Know-How and the terms of this Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the Receiving Party and the Disclosing Party with respect thereto, and (b) Arising Regeneron Know-How shall be deemed the Confidential Information of Regeneron, and Regeneron shall be deemed to be the Disclosing Party, and Roche shall be deemed to be the Receiving Party, with respect thereto. For clarity, all Proprietary Manufacturing Information shall be Regeneron&#8217;s Confidential Information. Confidential Information shall not include any information, data or know-how of the Disclosing Party that the Receiving Party can demonstrate&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">was generally available to the public at the time of disclosure, or becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party&#59; provided that this exception shall not apply with respect to Arising Regeneron Know-How or Arising Regeneron Inventions,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.36pt">is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.74pt">is developed independently by the Receiving Party or its Affiliates other than through knowledge of Confidential Information&#59; provided that this exception shall not apply with respect to Arising Regeneron Know-How or Arising Regeneron Inventions, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">is approved in writing by the Disclosing Party for release by the Receiving Party. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the references to Arising Regeneron Know-How or Arising Regeneron Inventions in clauses (ii) and (iv) above, do not apply to any component or step of Arising Regeneron Know-How or Arising Regeneron Inventions that is not itself Arising Regeneron Know-How or Arising Regeneron Inventions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Specific elements of Confidential Information shall not be deemed to be generally available to the public or in the possession of the Receiving Party merely because such elements are encompassed by more general information that falls within the foregoing exclusions.  Furthermore, any combination of individual elements of Confidential Information shall constitute Confidential Information and shall not be deemed to fall within the foregoing exclusions merely because one or more individual elements of such combination fall within the foregoing exclusions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.30</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Continuation Election Notice</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Continuation Election Notice&#8221; shall mean the notice Regeneron provides to Roche under Section 19.3.1 describing (i)&#160;Regeneron&#8217;s </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> intentions to continue ongoing development and commercialization of Product(s) and (ii)&#160;Regeneron&#8217;s request for Roche&#8217;s continuation of activities or transfer of the data, material and information relating to the Product(s) in accordance with Section&#160;19.3.1.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.31</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Control</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Control&#8221; with respect to a Party shall mean (as an adjective or as a verb including conjugations and variations such as &#8220;Controls&#8221; &#8220;Controlled&#8221; or &#8220;Controlling&#8221;) (a)&#160;with respect to patent rights, inventions or know-how, the possession by such Party of the ability to assign or grant a license or sublicense of such patent rights, inventions or know-how without violating the terms of any agreement or arrangement between such Party and any Third Party and (b)&#160;with respect to proprietary materials, the possession by such Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any Third Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.32</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Cover</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Cover&#8221; shall mean (as an adjective or as a verb including conjugations and variations such as &#8220;Covered,&#8221; &#8220;Coverage&#8221; or &#8220;Covering&#8221;) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a Valid Claim in the absence of a license under or ownership in the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a country-by-country basis.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.33</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">COVID19</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;COVID19&#8221; shall mean the disease caused by the causative agent SARS-CoV-2.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.34</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">CRO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;CRO&#8221; shall mean a Third Party contract research organization.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.35</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">CTA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;CTA&#8221; shall mean clinical trial approval granted by national Regulatory Authorities in the EU.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.36</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Dollars</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Dollars&#8221; shall mean US dollars.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.37</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.38</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Drug Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Drug Product&#8221; shall mean a Product formulated and filled that meets the specifications determined pursuant to Section 4.1.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.39</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Drug Substance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Drug Substance&#8221; shall mean drug substance of Product in formulated bulk form that meets the specifications determined pursuant to Section 4.1.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.40</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">EMA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;EMA&#8221; shall mean the European Medicines Agency or any successor agency with responsibilities comparable to those of the European Medicines Agency.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.41</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Emergency Use Authorization or EUA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Emergency Use Authorization&#8221; or &#8220;EUA&#8221; shall mean an emergency use authorization issued by the FDA pursuant to Section 564 of the FDCA.&#160;&#160;The duration of an EUA depends in part on the duration of the declaration of the U.S. Department of Health and Human Services </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HHS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that supports the EUA. The HHS declaration must be current for an EUA to remain in effect. The HHS declaration terminates upon the earlier of (a) HHS determining that the circumstances justifying the EUA&#8217;s issuance no longer exist or (b) a change in the approval status of the product such that an EUA would no longer be needed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.42</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">EU</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;EU&#8221; or &#8220;European Union&#8221; shall mean the European Union and all its member countries as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.43</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Expert</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Expert&#8221; shall mean a person with no less than ten&#160;(10) years of pharmaceutical or biotechnology industry experience and expertise having occupied at least one senior position within a large pharmaceutical company relating to product development or licensing but excluding (a) any current or former employee or consultant of either Party (or its Affiliates), and (b) any person who has known personal financial interest in or who would benefit from the outcome or resolution of the applicable dispute. Such person shall be fluent in the English language.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.44</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">FDA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;FDA&#8221; shall mean the Food and Drug Administration of the United States of America or any successor agency thereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.45</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">FDCA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;FDCA&#8221; shall mean the United States Federal Food, Drug and Cosmetic Act, as may be amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.46</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Field</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Field&#8221; shall mean all prophylactic, therapeutic and diagnostic uses in all indications.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.47</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Finished Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Finished Product&#8221; shall mean the final Product including packaging and its final container(s) ready for delivery to the market that meets the specifications therefor determined pursuant to Section 4.1.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.48</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">First Commercial Sale</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;First Commercial Sale&#8221; shall mean, on a country-by-country basis, the first invoiced sale or distribution &#91;* * *&#93; of a Product to a Third Party by either Party or any of its Affiliates or Sublicensees following the receipt of any Regulatory Approval required for the sale of such Product, or if no such Regulatory Approval is required, the date of the first invoiced sale or distribution &#91;* * *&#93; of a Product to a Third Party by either Party or any of its Affiliates in such country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, compassionate use sales will not be considered in determining the First Commercial Sale.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.49</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.50</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.51</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.52</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.53</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Fully Burdened Manufacturing Costs</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Fully Burdened Manufacturing Costs&#8221; shall mean with respect to a Product, each Party&#8217;s consolidated fully-burdened cost incurred by such Party or any of its Affiliates in manufacturing such Product (including all commercial manufacturing activities related to CMC, formulation, quality control, packaging and labeling, failed batches, and including all activities related to the supply of plasmids, raw materials, and where applicable, Drug Substance, Drug Product and Finished Product) in accordance with this Agreement and each Party&#8217;s Accounting Standards, in bulk, vialed or finished product form as the case may be, including&#58; &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.54</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">GAVI Eligible Countries</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;GAVI Eligible Countries&#8221; shall mean the countries listed by the Global Alliance for Vaccines and Immunization (</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.gavi.org&#47;types-support&#47;sustainability&#47;eligibility</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the Effective Date, and such other low income countries (as determined by the World Bank) as may otherwise be agreed by the Parties in writing. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.55</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Global Gross Profit</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Global Gross Profit&#8221; shall mean, with respect to each Presentation of Product in a given Calendar Quarter, the sum of the Parties&#8217; respective Gross Profit for such Presentation of Product for such Calendar Quarter.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.56</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Gross Profit</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Gross Profit&#8221; shall mean, with respect to each Party and each Presentation in a given Calendar Quarter, the result of the following, for each such Presentation, (a) the Net Sales of such Presentation by such Party or any of its Affiliates or Sublicensees in its Respective Territory during such Calendar Quarter minus (b) &#91;* * *&#93;.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.57</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Handle</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Handle&#8221; (as an adjective or as a verb including conjugations and variations such as &#8220;Handling&#8221;) shall mean one or more of preparing, filing, prosecuting (including interferences, reissue, re-examination, post-grant reviews, inter-partes reviews, nullity actions, derivation proceedings and opposition proceedings) and maintaining any Patent Rights. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.58</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Hospitalized Patients</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Hospitalized Patients&#8221; shall mean COVID19 patients that are treated in hospital institutions providing acute, in-patient medical and surgical treatment and nursing care.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.59</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Indemnitees</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Indemnitees&#8221; shall mean the Regeneron Indemnitees or the Roche Indemnitees, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.60</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Insolvency Event</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Insolvency Event&#8221; shall mean circumstances under which a Party or any entity that controls such Party (i)&#160;has a receiver or similar officer appointed over all or a material part of its assets or undertaking&#59; (ii)&#160;passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction)&#59; (iii)&#160;enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring) or assignment for the benefit of creditors&#59; (iv)&#160;ceases to carry on business&#59; (v)&#160;is unable to pay its debts as they become due in the ordinary course of business&#59; (vi) files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the person or of its assets&#59; or (vii) is the subject of an involuntary petition in any bankruptcy or insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.61</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Invention</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Invention&#8221; shall mean an invention that is conceived or first reduced to practice in connection with any activity carried out pursuant to this Agreement. Under this definition, an Invention may be made by or on behalf of Regeneron or any of its Affiliates or Sublicensees solely or jointly with a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by or on behalf of the Roche Group solely or jointly with a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or jointly by or on behalf of Regeneron or any of its Affiliates, on the one hand, and by or on behalf of the Roche Group, on the other hand, with or without a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided any Invention that is specifically related to any Compound or Product (including the composition of, formulations containing, any methods of using, or the manufacture of, a Compound or Product) (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arising</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be a Regeneron Invention.  For clarity, Roche Invention shall not include Roche Independent IP, and Arising Regeneron Invention shall not include Roche Independent IP, or any Invention that is generally but not specifically related to a Product.  For example, an Invention relating to the purification of antibodies generally but not specific to purification of a Compound or Product shall not be considered an Arising Regeneron Invention.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.62</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Joint Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Joint Know-How&#8221; shall mean Know-How that is made jointly by or on behalf of Regeneron or any of its Affiliates or Sublicensees, on the one hand, and by or on behalf of the Roche Group, on the other hand, with or without a Third Party in connection with any activity carried out pursuant to this Agreement, excluding any Arising Regeneron Know-How.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.63</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Joint Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Joint Patent Rights&#8221; shall mean all Patent Rights Covering a Joint Invention.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.64</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Know-How&#8221; shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical and clinical data, assays, platforms, formulations, specifications, quality control testing data, that are confidential and necessary or useful for the discovery, manufacture, development or commercialization of Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.65</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Knowledge</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Knowledge&#8221; shall mean &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.66</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Lead Compound</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Lead Compound&#8221; shall mean Regeneron&#8217;s proprietary Antibody cocktail consisting of the Antibodies REGN10933 and REGN10987 which as of the Effective Date is under development by Regeneron.  The sequences of REGN10933 and REGN10987 are specified in Appendix 1.66.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.67</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Lead Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Lead Product&#8221; shall mean any product containing the Lead Compound as its sole pharmaceutically active agent, regardless of the finished form or formulation or dosage.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.68</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Manufacturing Collaboration Timepoint</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Manufacturing Collaboration Timepoint&#8221; shall mean &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.69</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Major Country </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Major Country&#8221; shall mean any of the following countries&#58; any country in the EU, Australia, Canada, the United Kingdom, Japan and China.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.70</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Net Sales</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Net Sales&#8221; shall mean, with respect to each Party and Presentation of Product in a particular period, (a) the sum of (i) Sales of such Party and its Affiliates and Sublicensees and (ii) Sublicensee Compensation for such Party, less (b) the Additional Deductions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Party, its Affiliates and, unless otherwise agreed by Regeneron pursuant to Section 2.2.2 or by Roche pursuant to Section 2.5, as applicable, Sublicensees, the amount of net sales of such Presentation of Product for such period (excluding sales among such Party, any of its Affiliates and Sublicensees) as calculated in accordance with such Party&#8217;s Accounting Standards. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sublicensee Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; for a Party shall mean the compensation received by such Party and its respective Affiliates from &#91;* * *&#93; any other Sublicensees to the extent agreed by Regeneron pursuant to Section 2.2.2 or by Roche pursuant to Section 2.5, as applicable, in each case in accordance with the sublicensee contractual terms and their then-currently used Accounting Standards. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Deductions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">A lump sum deduction of &#91;* * *&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">&#91;* * *&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">government mandated fees and taxes and other government charges accrued during such period not already taken as a gross-to-net deduction in accordance with the then currently used Accounting Standards in the calculation of Net Sales of such Presentation of Product for such period, including, for example, any fees, taxes or other charges that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other action of a government or regulatory body. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, any compensation received from &#91;* * *&#93; will not be considered party of Net Sales and will be addressed as provided in Section 7.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net Sales in currency other than Dollars shall be converted into Dollars according to the provisions of Section 11.4.  For purposes of determining Net Sales, (i) the Product shall be deemed to be sold in accordance with the applicable Party&#8217;s (or its applicable Affiliate&#8217;s or Sublicensee&#8217;s) Accounting Standards consistently applied&#59; (ii) and a &#8220;sale&#8221; shall not include transfers or dispositions of the Product among a Party, its Affiliates, and unless otherwise agreed by the Parties in writing, its or their Sublicensees.  Any of the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but that are separately charged to, and paid by, Third Parties shall not be deducted from the invoice price in the calculation of Net Sales.  In the case of any sale of the Product for consideration other than cash, such as barter or countertrade, or Sublicensee Compensation received in consideration other than cash, Net Sales shall be calculated on the fair market value of such consideration received as agreed by the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.71</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">NGO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;NGO&#8221; shall mean a not-for-profit, non-governmental organization providing or facilitating the provision of health care in low income countries (e.g., GAVI Eligible Countries), such as the World Health Organization, UNICEF and Red Cross International.  For the avoidance of doubt, the term NGO is limited to organizations that operate independently of government and does not include governmental or quasi-governmental organizations such as the EU or its institutions, bodies or agencies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 12 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.72</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Non-US Affiliate</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Non-US Affiliate&#8221; shall mean any Affiliate that is not a US Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.73</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Ongoing Regeneron Studies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Ongoing Regeneron Studies&#8221; shall mean the Clinical Studies that are being conducted by Regeneron as of the Effective Date to support the initial Regulatory Approval for treatment of Hospitalized Patients or Out-Patients that are listed on Appendix 1.73. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.74</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Out-Patients</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Out-Patients&#8221; shall mean COVID19 patients that are not treated in hospital institutions providing acute, in-patient medical and surgical treatment and nursing care.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.75</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Party</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Party&#8221; shall mean Regeneron or Roche, as the case may be, and &#8220;Parties&#8221; shall mean Regeneron and Roche collectively.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.76</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Patent Rights&#8221; shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application or claiming priority to any such patent or patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, divisional, continuation or continuation-in-part of any of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.77</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Pharmaceutical Company</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Pharmaceutical Company&#8221; shall mean any company whose primary business is the research, development, marketing and distribution of pharmaceutical or biopharmaceutical products, limited to the top 20 in global sales.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.78</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Phase I Study</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Phase I Study&#8221; shall mean a human clinical trial in any country that would meet the description in 21 C.F.R. &#167; 312.21(a), as amended from time to time, and the foreign equivalent thereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.79</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Phase II Study</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Phase II Study&#8221; shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. &#167; 312.21(b), as amended from time to time, and the foreign equivalent thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 13 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.80</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Phase III Study</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Phase III Study&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a human clinical trial that is prospectively designed to demonstrate with statistical significance whether a product is safe and effective for use in humans in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. &#167; 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.81</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">PHSA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;PHSA&#8221; shall mean the Public Health Service Act as set forth at 42 U.S.C. Chapter 6A, as may be amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.82</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">PPQ</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;PPQ&#8221; shall mean process performance qualification that is a component of process validation. The PPQ combines the actual facility, utilities, equipment (each now qualified), and the trained personnel with the commercial manufacturing process, control procedures, and components to produce commercial batches (i.e. commercial scale Drug Substance batches executed for the purpose of process validation which are commercially eligible upon license approval). PPQ batches do not include preceding engineering&#47;technical batches.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.83</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Presentation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Presentation&#8221; shall mean, (a) with respect to a Drug Product, such Drug Product filled in one or more distinct quantities of Drug Substance, and (b) with respect to a Finished Product, such Finished Product filled, packaged and labeled in one or more distinct quantities of Drug Substance.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.84</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Product&#8221; shall mean any product containing a Compound as its sole pharmaceutically active agent, regardless of its finished form or formulation or dosage. One Product may be distinguished from another Product by the Compound being a distinctive active pharmaceutical ingredient. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.85</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Product Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Product Know-How&#8221; shall mean any Regeneron Know-How that is specifically related to any Product that, without a license from Regeneron or its applicable Affiliate, would be infringed or misappropriated by the exploitation (other than manufacturing) of any Product by a Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.86</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Product Patent Right </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Product Patent Right&#8221; shall mean any Regeneron Patent Rights that includes at least one claim specifically related to a Product that, without a license from Regeneron or its applicable Affiliate, would be infringed (or, in the case of a patent application would be infringed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 14 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if it were to issue in a patent) by the exploitation (other than manufacturing) of any Product by a Third Party. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.87</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Proprietary Manufacturing Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Proprietary Manufacturing Information&#8221; shall mean all Regeneron Know-How that is used, or intended to be used, to manufacture the Products (or any component or intermediate thereof).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.88</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regulatory Approval</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regulatory Approval&#8221; shall mean</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any approvals (excluding pricing and reimbursement approvals), licenses, registrations or authorizations by a Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a regulatory jurisdiction in the Territory, including an Emergency Use Authorization, Biologics License Application submitted to FDA under Section 351 of the PHSA (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BLA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and, with respect to the EU, an application for marketing authorization approval (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) filed with the EMA pursuant to the centralized approval procedure, or with the applicable national Regulatory Authority of a country in the European Union with respect to the mutual recognition procedure, decentralized procedure or any other national approval. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.89</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regulatory Authority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regulatory Authority&#8221; shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of regulatory approval for the development, manufacture or sale of a Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Base Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Base Patent Rights&#8221; shall mean Product Patent Rights in the Territory that are Controlled by Regeneron or any of its Affiliates at the Effective Date, said Patent Rights being exhaustively listed in Appendix&#160;1.90 of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.91</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Cell Media </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Cell Media&#8221; shall mean any cell culture media that is proprietary to Regeneron and used by Regeneron or any of its Affiliates to manufacture any Drug Substance. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.92</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Controlled Infringement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Controlled Infringement&#8221; shall mean (a) any Infringement of a Product Patent Right or Product Know-How, in either case, in the Regeneron Territory or (b) any Competitive Infringement of a Joint Patent Right or Joint Know-How, in either case, in the Regeneron Territory (including any Competitive Infringement of a Joint Patent Right or Joint Know-How, in each case, in both the Regeneron Territory and the Roche Territory).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 15 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.93</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron-DOD&#47;BARDA Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron-DOD&#47;BARDA Agreement&#8221; shall mean that certain agreement between Regeneron and Advanced Technology International for the sale of Products entitled &#8220;Project Agreement NO. 1, MCDC BASE AGREEMENT NO. 2020-504, Project Title&#58; MCDC2008-005&#59; Large Scale Manufacturing of Antibodies Directed to SARS-CoV-2&#8221;, including any amendment thereto.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.94</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Existing BARDA Commitment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Existing BARDA Commitment&#8221; shall mean Regeneron&#8217;s commitment as of the Effective Date to manufacture a total of twenty eight (28) lots of the Antibodies included in the Lead Product for supply under the Regeneron-DOD&#47;BARDA Agreement.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.95</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Know-How&#8221; shall mean the Know-How that Regeneron or any of its Affiliates Controls at the Effective Date or during the Agreement Term, including any Arising Regeneron Know-How, For clarity, Regeneron Know-How shall not include any Roche Independent IP or Roche Know-How.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.96</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Patent Rights&#8221; shall mean the Patent Rights that Regeneron or any of its Affiliates Controls, relating to or arising from the discovery, manufacture, development or commercialization of or Covering a Compound, Product or Regeneron Invention. The term Regeneron Patent Rights shall include Regeneron Base Patent Rights, but excludes any Joint Patent Rights.  For clarity, Regeneron Patent Rights shall not include any Roche Independent IP or Roche Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.97</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Patent Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Patent Territory&#8221; shall mean the Regeneron Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.98</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Regeneron Territory&#8221; shall mean the US.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.99</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Respective Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Respective Territory&#8221; shall mean, with respect to Regeneron, the Regeneron Territory and with respect to Roche, the Roche Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.100</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Major Countries</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Major Countries&#8221; shall mean each of the following countries&#58;  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.101</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Group</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Group&#8221; shall mean collectively Roche, its Affiliates and its Sublicensees.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 16 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.102</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Independent IP</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Independent IP&#8221; shall mean inventions, patents, trade secrets, know-how or other intellectual property that Roche or any of its Affiliates Controls at the Effective Date, or made or lawfully obtained by Roche or any of its Affiliates independent of the activities carried out pursuant to this Agreement, and without referring to or using any Confidential Information of Regeneron.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.103</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Know-How&#8221; shall mean the Know-How arising from activities carried out pursuant to this Agreement and that Roche or any of its Affiliates Controls during the Agreement Term.  For clarity, the Roche Know-How does not include the Arising Regeneron Know-How or Roche Independent IP.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.104</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Manufacturing Facilities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Manufacturing Facilities&#8221; shall mean the facilities listed in Appendix 1.104.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.105</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Patent Rights&#8221; shall mean the Patent Rights that Roche or any of its Affiliates Controls, relating to or arising from the discovery, manufacture, development or commercialization of or Covering a Compound, Product or Roche Invention, but excluding any Roche Independent IP, Regeneron Patent Rights or Joint Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.106</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Production Contribution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Production Contribution&#8221; shall mean a fraction, (a) the numerator of which is equal to the sum of &#91;* * *&#93;, for which the Drug Substance was manufactured by the Roche Group, and (b) the denominator of which is the equal to the sum of &#91;* * *&#93;&#59; provided that beginning with the Calendar Quarter, if any, in which Regeneron first supplies Drug Substance to Roche for commercial use by Roche in the Roche Territory, Roche may elect to determine in accordance with Appendix 1.106 &#91;* * *&#93; for such Calendar Quarter for which the Drug Substance was manufactured by the Roche Group.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.107</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Shared Infringement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Shared Infringement&#8221; shall mean (a) any Infringement of a Product Patent Right or Product Know-How, in either case, in the Roche Territory or (b) any Competitive Infringement of a Joint Patent Right or Joint Know-How, in either case, in the Roche Territory that is unrelated to any Competitive Infringement of a Joint Patent Right or Joint Know-How in the Regeneron Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.108</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Roche Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Roche Territory&#8221; shall mean all countries other than the US, excluding any Terminated Country from and after the effective date of termination for such Terminated Country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 17 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.109</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">ROW</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;ROW&#8221; shall mean all countries in the Roche Territory other than the Roche Major Countries.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.110</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Sales Volume</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Sales Volume&#8221; shall mean, with respect to each Presentation of Product and a Party for the period measured, the number of units of such Presentation of Product that are sold in such Party&#8217;s Respective Territory (i.e., that constitute Net Sales for such Party) during such period (for the avoidance of doubt, excluding any such units distributed as &#91;* * *&#93; by or on behalf of such Party or any of its Affiliates or Sublicensees during such period).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.111</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">SARS-CoV-2</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;SARS-CoV-2&#8221; shall mean the virus known as the severe acute respiratory syndrome coronavirus 2.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.112</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Sensitive Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Sensitive Information&#8221; shall mean any Proprietary Manufacturing Information or information relating to Regeneron&#8217;s cell lines for any Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.113</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Standard Cost</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Standard Cost&#8221; shall mean, with respect to a Party for a given Calendar Year, (a) with respect to Product in its respective form (Drug Substance, Drug Product, Finished Product), such Party&#8217;s reasonable best estimate of its Fully Burdened Manufacturing Costs for such Product for such Calendar Year (without markup) based on such Party&#8217;s Fully Burdened Manufacturing Costs for the prior Calendar Year for such Product and any anticipated changes in Fully Burdened Manufacturing Costs for such Calendar Year (e.g., manufacturing efficiencies, changes in cost of raw materials) calculated on a per unit basis (i.e. kilogram for Drug Substance, and unit for Drug Product and Finished Product) and, for Finished Product, on a per Presentation basis, for such Party and with respect to Drug Product and Finished Product, each Party may have a different Standard Cost for each Permutation of each applicable Presentation of such Product, in each case determined pursuant to Section 4.2 and (b) with respect any manufacturing-related services (e.g., filling, finishing, packaging and labelling) that one Party performs for the other Party, the cost for such services determined by the Parties based on the Fully Burdened Manufacturing Costs of performing such services (without mark-up), in each case ((a) and (b)), in accordance with such Party&#8217;s Accounting Standards.  For clarity, if Finished Product distributed by a Party contains Drug Substance supplied by the other Party or the other Party performed any manufacturing services (e.g., filling, finishing, packaging and labelling) with respect to such Finished Product, then such Party would pay the other Party such other Party&#8217;s Standard Costs for such Drug Substance or such services and such Standard Costs shall be included in the Standard Cost for such Finished Product for such first Party.  A Party may have a different Standard Costs for Drug Product or Finished Product that is manufactured entirely by or on behalf of such Party as well as Drug Product or Finished Product that is filled, finished, packaged or labelled, or incorporates Drug Substance or Drug Product supplied by or on behalf of the other Party (each such permutation of Drug Product or Finished Product that is manufactured using a different combination of materials and services provided by or on behalf </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 18 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Parties, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permutation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding the foregoing, a Party may calculate and use a blended Standard Cost for use with all Permutations of a Presentation of Drug Product or Finished Product as provided in Section 4.2, in its own discretion.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.114</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Sublicensee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Sublicensee&#8221; shall mean a Third Party to which either Party has (sub)licensed rights (through one or multiple tiers) licensed to it under this Agreement, other than any Affiliate &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.115</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Territory&#8221; shall mean all countries of the world.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.116</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Third Party</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Third Party&#8221; shall mean a person or entity other than (i)&#160;Regeneron or any of its Affiliates or (ii) Roche or any of its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.117</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Third Party IP License</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Third Party IP License&#8221; shall mean any license or other agreement with a Third Party entered into by a Party pursuant to Section 14.18. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.118</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Third Party IP Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Third Party IP Payments&#8221; shall mean any amounts paid by a Party or any of its Affiliates under any Third Party IP License that are reasonably allocable to the Products.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.119</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">US</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;US&#8221; shall mean the United States of America and its territories and possessions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.120</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">US Affiliate</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;US Affiliate&#8221; shall mean any Affiliate that is a US Person. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.121</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">US Person</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;US Person&#8221; shall mean a &#8220;United States person&#8221;, as such term is defined in Section&#160;7701(a)(30) of the Code. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.122</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Valid Claim</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term &#8220;Valid Claim&#8221; shall mean a claim in any unexpired and issued Patent Right that has not been disclaimed, revoked or held invalid by a final non-appealable decision of a court of competent jurisdiction or government agency.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.123</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Additional Definitions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each of the following definitions is set forth in the Section of this Agreement indicated below&#58;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 19 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.070%"><tr><td style="width:1.0%"></td><td style="width:65.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Definition</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional Deductions</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.69</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional Regeneron Studies</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.20</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alternative Product Trademark</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alternative Third Party Product</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alternative Supply Allocation</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.3(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Antibody Conjugate</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.6</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arising Regeneron Invention</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.61</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arising Regeneron Know-How</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arising Roche Manufacturing IP</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.8</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bankruptcy Code</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BLA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.88</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Breaching Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CCDS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Agreement</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Amendment</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Data Package</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Option</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Positive Determination</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset Territory</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Claims</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Co-Funded Device Development Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competing Product</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Debarred</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.3(d)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Defending Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.12</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Defense Decision Period</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.12</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Defense Suit Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.12</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Device Development Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Device Development Plan</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disclosing Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.29</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective Date</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cover page</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 20 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.070%"><tr><td style="width:1.0%"></td><td style="width:65.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Enforcement Decision Period</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Enforcement Suit Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Officers</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercise Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercise Period</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expert Committee</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">First Approval Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">First EU Approval</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">First UK Approval</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FWG</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Genentech</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Cover page</a></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Global Gross Profit Final Report</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Global Trademarks</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gross Profit Interim Report</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HHS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.41</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indemnification Claim Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indemnified Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indemnifying Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.4</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Infringement</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Initiating Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ISS Strategy</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JMC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JOC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Joint Infringement Action</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.13</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Joint Invention</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.61</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JSC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Losses</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MAA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.88</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Material Additional Study Change</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.3(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Members</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Minimum Committed Regeneron Capacity</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Minimum Committed Roche Capacity</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No Fault Claim</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Breaching Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other Chugai Asset Activities</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 21 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.070%"><tr><td style="width:1.0%"></td><td style="width:65.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Owed Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Owing Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patent Term Extensions</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.16</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payment Currency</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Peremptory Notice Period</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Permitted Chugai Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Permutation</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.113</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PII&#47;Samples</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.5</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Product Distribution Audit</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Production Forecast</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proposing Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Publishing Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.5(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Publishing Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.5(c)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Receiving Party</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.29</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reconciliation Final Report</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reconciliation Interim Report</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Cover page</a></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron Indemnitees</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron Invention</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.61</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron Regulatory Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron Regulatory Responsibilities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Register</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.9</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right of First Negotiation</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Cover page</a></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a href="#ic19c56d7c1f146aa8be2e44378c796e8_1" style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none">Cover page</a></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Chugai Option</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Global Gross Profit</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Indemnitees</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Invention</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.61</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Publishing Notice</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.5(b)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Regulatory Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Regulatory Responsibilities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.2</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche-Shared Defense Patents</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.12</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Transfer Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Safety Data Exchange Agreement</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sales</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.70</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Settlement</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.11</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublicensee Compensation</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.70</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supply Agreement</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Technology Transfer Agreement</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Whereas clauses</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 22 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:69.070%"><tr><td style="width:1.0%"></td><td style="width:65.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Terminated Country</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.3</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third Party Infringement Action</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.13</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unilateral Device Development Activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unilateral Study</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unilateral Study Costs Report</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Working Cell Bank</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.1</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Grant of License</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Licenses granted by Regeneron</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron hereby grants to Roche Basel under the Regeneron Patent Rights and Regeneron Know-How and Regeneron&#8217;s interest in the Joint Patent Rights and Joint Know-How (and in the case of clause (v) below, under Regeneron&#8217;s rights in the Global Trademarks)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">a non-exclusive right and license to make, have made, import, have imported, export and have exported Compounds and Products in the Territory as contemplated by this Agreement, including the right to sublicense pursuant to Section 2.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">a non-exclusive right and license to research, have researched, develop, have developed, Compounds and Products in the Territory as contemplated by this Agreement, including the right to sublicense pursuant to Section 2.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.36pt">a co-exclusive right and license (together with Regeneron) to seek and maintain Regulatory Approval for, and have Regulatory Approval sought and maintained for, Compounds and Products in the Roche Territory as contemplated by this Agreement including the right to sublicense pursuant to Section 2.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.74pt">an exclusive (even as to Regeneron) right and license to market, have marketed, commercially distribute, have commercially distributed, sell and have sold Products in the Field in the Roche Territory and to use, have used, import and have imported Products in the Field in the Roche Territory in connection with such marketing, commercial distribution and sale, including the right to sublicense pursuant to Section 2.2&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">subject to Section 14.3, a non-exclusive, royalty-free, fully paid-up, license to use the Global Trademarks owned by Regeneron in the Regeneron Territory to (a) conduct activities with respect to the Products in the Field in the Regeneron Territory solely to support the marketing, commercial distribution and sale of the Products in the Field in the Roche Territory, if applicable and (b) supply Products to Regeneron pursuant to this Agreement or the Supply Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Roche&#8217;s Right to Sublicense</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Right to Sublicense to its Affiliates and &#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel shall have the right to grant (a) written sublicenses to its Affiliates (through multiple tiers)  and (b) &#91;* * *&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 23 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, if Chugai is not added as an Affiliate hereunder, Chugai shall be considered a Third Party hereunder, provided that Roche Basel may still sublicense rights granted under Section 2.1 to Chugai in Japan without the prior written approval of Regeneron pursuant to this Section.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel shall inform Regeneron promptly after having granted a sublicense pursuant to this Section 2.2.1 other than to an Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each permitted sublicense shall be in writing and consistent in all material respects with the terms and conditions of this Agreement and Roche Basel shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable Affiliate or &#91;* * *&#93; to the same extent as they apply to Roche Basel for all purposes&#59; provided that a separate written sublicense shall not be required for Affiliates or distributors who have existing agreements with Roche or its Affiliates that are consistent with the terms and conditions of this Agreement. Roche Basel assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Affiliate or &#91;* * *&#93;, as applicable, and shall itself account to Regeneron for all payments due under this Agreement by reason of such sublicense.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Right to Sublicense to Other Third Parties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel and its Affiliates shall have the right to grant written sublicenses to Third Parties (other than &#91;* * *&#93;, which are addressed in Section 2.2.1), through multiple tiers, under its rights granted under Section&#160;2.1(i) only upon prior written approval of Regeneron.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel and its Affiliates shall have the right to grant written sublicenses to Third Parties (other than &#91;* * *&#93;, which are addressed in Section 2.2.1), through multiple tiers, under its rights granted under Section 2.1(ii) - 2.1(v)&#160; (a) upon the prior written approval of Regeneron (i) in Regeneron&#8217;s sole discretion if the Third Party is a Pharmaceutical Company, (ii) not to be unreasonably withheld, conditioned or delayed, if such sublicense is granted with respect to a Roche Major Country, and (iii) in Regeneron&#8217;s sole discretion, if such proposed Sublicensee would have access to any Proprietary Manufacturing Information, including in connection with regulatory filings with applicable Regulatory Authorities in such country, and (b) otherwise without the prior approval of Regeneron.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each permitted sublicense shall be in writing and consistent in all material respects with the terms and conditions of this Agreement and Roche Basel shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable Sublicensee to the same extent as they apply to Roche Basel for all purposes&#59; provided that a separate written sublicense shall not be required for distributors who have existing agreements with Roche or its Affiliates that are consistent with the terms and conditions of this Agreement. Roche Basel assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Sublicensee and shall itself account to Regeneron for all payments due under this Agreement by reason of such sublicense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 24 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Roche Basel Right to Subcontract</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel, at its own cost and discretion, shall have the right to subcontract the work performed under Section 2.1(i) through Section 2.1(iv) to Affiliates without the prior approval of Regeneron.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel, at its own cost and discretion, shall have the right to subcontract the work performed under Section 2.1(i) to CMOs or other Third Parties in the Territory only with the prior approval of Regeneron&#59; provide that Roche Basel may subcontract the work performed under Section 2.1(i) to CMOs with respect to Finished Product or the conversion of Drug Substance to Drug Product or Finished Product or Drug Product to Finished Product (but not with respect to the manufacture of Drug Substance) without the prior approval of Regeneron&#59; provided further that Roche shall notify Regeneron in writing of such subcontracting in sufficient time for Regeneron to update its applicable regulatory filings for the applicable Product and shall use diligent efforts to ensure that there is no interruption for supply of such Product in the Regeneron Territory as a result of such subcontracting.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel, at its own cost and discretion, shall have the right to subcontract the work performed under Section 2.1(ii) through Section 2.1(iv) to Third Parties in the Territory without the prior approval of Regeneron.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each permitted subcontract shall be consistent in all material respects with the terms and conditions of this Agreement and Roche Basel shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable subcontractor to the same extent as they apply to Roche Basel for all purposes. Roche Basel assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such subcontractor and shall itself account to Regeneron for all payments due under this Agreement by reason of such subcontract.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Licenses granted by Roche</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche hereby grants to Regeneron under the Roche Patent Rights and Roche Know-How and Roche Independent IP and Roche&#8217;s interest in the Joint Patent Rights and Joint Know-How (and in the case of clause (v) below, under Roche&#8217;s rights in the Global Trademarks)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">a non-exclusive right and license to make, have made, import, have imported, export and have exported Compounds and Products in the Territory as contemplated by this Agreement, including the right to sublicense pursuant to Section 2.5&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">a non-exclusive right and license to research, have researched, develop, have developed, seek and maintain Regulatory Approval for, and have Regulatory Approval sought and maintained for, Compounds and Products in the Territory as contemplated by this Agreement, including the right to sublicense pursuant to Section 2.5&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.36pt">an exclusive (even as to Roche) right and license to seek and maintain Regulatory Approval for, and have Regulatory Approval sought and maintained for, Compounds and Products in the Regeneron Territory as contemplated by this Agreement, including the right to sublicense pursuant to Section 2.5&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 25 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.74pt">an exclusive (even as to Roche) right and license to market, have marketed, commercially distribute, have commercially distributed, sell and have sold Products in the Field in the Regeneron Territory and to use, have used, import and have imported Products in the Regeneron Territory in connection with such marketing, commercial distribution and sale, including the right to sublicense pursuant to Section 2.5&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">subject to Section 14.3, a non-exclusive, royalty-free, fully paid-up, license to use the Global Trademarks owned by Roche in the Roche Territory to (i) conduct activities with respect to the Products in the Field in the Roche Territory solely to support the marketing, commercial distribution and sale of the Products in the Field in the Regeneron Territory, if applicable and (ii) supply Products to Roche pursuant to this Agreement or the Supply Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Regeneron&#8217;s Right to Sublicense</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the right to grant written sublicenses to its Affiliates (through multiple tiers) and Third Parties under its rights granted under Section 2.4 without prior approval of Roche&#59; provided that, (a) with respect to any rights granted under Sections 2.4(i), Regeneron and its Affiliates shall not grant a sublicense (other than to a &#91;* * *&#93;) to a CMO or another Third Party to manufacture Drug Substance without Roche&#8217;s prior written consent (other than sublicensing manufacture of Drug Substance to CMOs in the Territory up to the Minimum Committed Regeneron Capacity, which may be without the prior approval of Roche)&#59; and (b) Regeneron and its Affiliates shall not grant a sublicense (other than to a &#91;* * *&#93;) under Section 2.4(ii) with respect to Roche Independent IP to a Third Party without Roche&#8217;s prior written consent, not to be unreasonably withheld, conditioned, or delayed. Regeneron must provide Roche reasonable notice before granting any &#91;* * *&#93;, and upon Roche&#8217;s request the Parties shall discuss in good faith options to avoid the grant of any &#91;* * *&#93; and Regeneron shall use diligent efforts to avoid having to grant any &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron licenses a Third Party in the Regeneron Territory under the rights granted to Roche under Section 2.1(iv) in the Roche Territory (whether or not Regeneron sublicenses the rights granted to Regeneron by Roche under Section 2.4(iv) to such Third Party), then, unless otherwise agreed by Roche in writing in its sole discretion, such Third Party will be considered a Sublicensee of Regeneron.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each permitted sublicense shall be consistent in all material respects with the terms and conditions of this Agreement and Regeneron shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable Affiliate or Sublicensee to the same extent as they apply to Regeneron for all purposes&#59; provided that a separate written sublicense shall not be required for Affiliates or distributors who have existing agreements with Regeneron or its Affiliates that are consistent with the terms and conditions of this Agreement. Regeneron assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such Affiliate or Sublicensee, as applicable, and shall itself account to Roche for all payments due under this Agreement by reason of such sublicense. Regeneron shall inform Roche promptly after having granted a sublicense pursuant to this Section 2.5.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 26 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Regeneron Right to Subcontract</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron, at its own cost and discretion, shall have the right to subcontract any work performed under this Agreement to Third Parties in the Territory without the prior approval of Roche, except that Regeneron shall not have the right to subcontract manufacture of Drug Substance to CMOs or other Third Parties in the Territory without the prior approval of Roche&#59; provided that Regeneron may subcontract manufacture of Drug Substance to CMOs in the Territory up to the Minimum Committed Regeneron Capacity without the prior approval of Roche.  Unless otherwise agreed by the Parties, any grant of rights by Regeneron to a CMO or Third Party under the rights granted to Roche Basel pursuant to Section 2.1(i) shall be considered a &#8220;subcontract&#8221; for purposes of restrictions under this Section 2.6, regardless of the structure of such arrangement with the CMO or Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each permitted subcontract shall be consistent in all material respects with the terms and conditions of this Agreement and Regeneron shall ensure that all of the applicable terms and conditions of this Agreement shall apply to the applicable subcontractor to the same extent as they apply to Regeneron for all purposes. Regeneron assumes full responsibility for the performance of all obligations and observance of all terms so imposed on such subcontractor and shall itself account to Roche for all payments due under this Agreement by reason of such subcontract.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Combination Products and Companion Diagnostics</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall not, and shall cause its Affiliates not to develop, have developed, seek and maintain Regulatory Approval for, and have Regulatory Approval sought and maintained for, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, commercially distribute, have commercially distributed, sell or have sold any Combination Product or Companion Diagnostic, unless and until the Parties have agreed in writing on the terms and conditions with respect thereto.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Back-Up Compounds</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Antibody Conjugates </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the Agreement Term, Regeneron will not, and will cause its Affiliates not to, clinically develop or commercialize an Antibody Conjugate that contains the Lead Compound or any Antibody in the Lead Compound, or grant a license to a Third Party to do so.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Research and Development</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Responsibilities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall, at its own cost and expense, use Commercially Reasonable Efforts to conduct the Ongoing Regeneron Studies and shall have the right to pursue Third Party funding for the Ongoing Regeneron Studies.  Regeneron shall provide Roche Basel periodic updates at interim analysis points regarding the progress and status of the Ongoing Regeneron Studies, including a high-level summary of any available data from the Ongoing Regeneron Studies.   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 27 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC will discuss and align on a strategy for investigator-sponsored studies with respect to the Compounds and the Products in the Territory (for example key clinical questions of interest, areas that the Parties do not wish to address, and any potential supply constraint) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ISS Strategy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Regeneron shall have the right, but not the obligation, to provide support for any investigator-sponsored studies with respect to the Compounds and the Products in the Regeneron Territory, consistent with the ISS Strategy, and will consult with Roche Basel regarding such studies and consider Roche Basel&#8217;s comments in good faith. Roche shall have the right, but not the obligation, to provide support for any investigator-sponsored studies with respect to the Compounds and the Products in the Roche Territory, consistent with the ISS Strategy, and will consult with Regeneron regarding such studies and consider Regeneron&#8217;s comments in good faith.  Unless otherwise agreed by the Parties, each Party will provide support for any investigator-sponsored studies for the Compounds and the Products &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to initiating a new Clinical Study that is not an Ongoing Regeneron Study and is not included in the then-current Co-Funded Development Plan and is not an ongoing Unilateral Study, the Party that desires to conduct such Clinical Study (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proposing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall propose such Clinical Study to the JOC, which proposal shall include a synopsis of the protocol for such Clinical Study and an estimated budget for such Clinical Study.  The JOC shall review and submit such Clinical Study to the JSC for approval.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JSC agrees that the Parties shall share the &#91;* * *&#93; with respect to such Clinical Study, then the Parties shall amend the Co-Funded Development Plan to include such Clinical Study and such Clinical Study shall be a Co-Funded Study.  With respect to each Co-Funded Study, the Party conducting such Co-Funded Study shall provide the other Party periodic updates at least once a Calendar Quarter regarding the progress and status of such Co-Funded Study, including a high-level summary of any available data from such Co-Funded Study. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JSC does not agree &#91;* * *&#93; with respect to such Clinical Study, then the Proposing Party shall have the right, but not the obligation, to conduct such Clinical Study &#91;* * *&#93; (each such Clinical Study, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unilateral Study</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall use Commercially Reasonable Efforts to perform the development activities with respect to the Co-Funded Studies that are assigned to such Party in the Co-Funded Development Plan and shall do so in accordance with the Co-Funded Development Plan.  The Parties acknowledge and agree that Regeneron is responsible for conducting the Additional Regeneron Studies, and Regeneron shall provide Roche Basel periodic updates at interim analysis points regarding the progress and status of the Additional Regeneron Studies, including a high-level summary of any available data from the Additional Regeneron Studies.  Each Party will be responsible for its own internal costs associated with development activities for the Co-Funded Studies.  &#91;* * *&#93; by or on behalf of either Party or any of its Affiliates in connection with the Co-Funded Studies (including, for clarity, such &#91;* * *&#93; incurred by or on behalf of Regeneron or any of its Affiliates with respect to the Additional Regeneron Studies prior to the Effective Date) that are not reimbursed by a Third Party shall be &#91;* * *&#93;.  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall &#91;* * *&#93; be responsible for all development activities with respect to each Unilateral Study conducted by such Party.  For clarity, neither Party shall have the obligation to conduct or, except as may be required by Applicable Law or ethical requirements, complete any Unilateral Study. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 28 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to initiating any development activities with respect to any delivery device for the Products (e.g., pre-filled syringe) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Device Development Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Party that desires to conduct such Device Development Activities shall provide a proposed development plan for such delivery device to the JOC (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Device Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which Device Development Plan will include an estimated budget for such Device Development Activities. The JOC shall review and submit such Device Development Plan to the JSC for approval.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JSC agrees &#91;* * *&#93; with respect to such Device Development Activities, then the Parties will agree to a final Device Development Plan and such Device Development Activities shall be &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Co-Funded Device Development Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.  With respect to Co-Funded Device Development Activities, the Party conducting such Co-Funded Device Development Activities shall provide the other Party periodic updates regarding the progress and status of such Co-Funded Device-Development Activities.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the other Party does not agree &#91;* * *&#93; with respect to proposed Device Development Activities, then the Party proposing such Device Development Activities shall have the right, but not the obligation, to conduct such Device Development Activities &#91;* * *&#93; (such Device Development Activities, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unilateral Device Development Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall use Commercially Reasonable Efforts to perform the Device Development Activities with respect to Co-Funded Device Development Activities that are assigned to such Party in the final agreed Device Development Plan for such Co-Funded Device Development Activities and shall do so in accordance with such final agreed Device Development Plan.  Each Party will be responsible for its own internal costs associated with the Co-Funded Device Development Activities and the &#91;* * *&#93; incurred by or on behalf of either Party or any of its Affiliates in connection with the Device Development Activities under the Device Development Plan shall be &#91;* * *&#93;.  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall, &#91;* * *&#93;, be responsible for all Unilateral Device Development Activities conducted by such Party.  For clarity, neither Party shall have the obligation to conduct or, except as may be required by Applicable Law or ethical requirements, complete any Unilateral Device Development Activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the foregoing, unless otherwise agreed by the Parties, Regeneron shall have the sole right, but not the obligation, to conduct any clinical assay that is designed to measure &#91;* * *&#93;. Regeneron shall use Commercially Reasonable Efforts to perform or have performed any &#91;* * *&#93; on biological samples collected in connection with any Clinical Study with respect to the Product conducted by or on behalf of Roche or its Affiliates or Sublicensees. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall conduct its development activities with respect to the Compounds and Products in accordance with Applicable Law and the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Co-Funded Development Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties shall conduct the Co-Funded Studies in accordance with the Co-Funded Development Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 29 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any proposed modifications to the Co-Funded Development Plan to include any additional Co-Funded Studies or to modify any existing Co-Funded Studies shall be made pursuant to Article 8.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Exchange of Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall disclose and make available to the other Party all data and information necessary for such other Party to conduct the development activities under this Agreement. Each Party shall answer any questions reasonably posed by the other Party with respect to the development activities under this Agreement and provide any information reasonably requested by the other Party with respect thereto that is in the possession of such first Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting reporting obligations under Section 3.1, each Party shall provide to the other Party (a) headline data on each Clinical Study with respect to a Product conducted by such Party as soon as possible after such data or results become available and before the final report(s) are written and (b) final reports of each Clinical Study with respect to a Product conducted by such Party promptly after such reports become available. The data exchanged between the Parties under this Section 3.3 shall be delivered in an electronic format that is appropriate for purposes of submission to Regulatory Authorities in support of Regulatory Approval. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Development Records</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall maintain records of its development activities under this Agreement (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of the development.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">PII&#47;Samples</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with Clinical Studies or other activities associated with the development and commercialization of Products, the Parties may collect (i)&#160;personally identifiable information about individual human subjects or (ii)&#160;human biological samples (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PII&#47;Samples</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Each Party shall collect the PII&#47;Samples in compliance with Applicable Law and Roche shall use Commercially Reasonable Efforts to obtain all consents necessary for such PII&#47;Samples to be transferred to Regeneron upon expiration or termination of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Manufacturing</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Manufacturing Responsibility</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Shared Responsibility during the Agreement Term</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall use diligent efforts to promptly complete those activities assigned to it pursuant to the Transfer Plan (as defined in the Technology Transfer Agreement) pursuant to the Technology Transfer Agreement.  Notwithstanding Section 7 of the Technology Transfer Agreement, the Parties agree (a) they shall not terminate the Technology Transfer Agreement separate from this Agreement and (b) if either Party breaches the Technology Transfer Agreement, such breach shall be deemed to be a breach by such Party under this Agreement.  Upon the Manufacturing Collaboration Timepoint, Roche shall, at its own cost, (i) dedicate and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 30 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">utilize the equivalent of at least 100,000 liters of annualized bioreactor capacity on a full-time campaign basis &#91;* * *&#93; for the manufacture of Drug Substance at the Roche Manufacturing Facilities or at CMOs (subject to Section 2.3) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Minimum Committed Roche Capacity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless the JMC decides a Minimum Committed Capacity Reduction pursuant to Section 8.2.3(g) and (ii) reserve sufficient capacity to fill, finish, pack and label, at its discretion, at Roche facilities or CMOs (subject to Section 2.3) the Drug Substance it manufactures.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise agreed by the Parties in writing, any Product supplied by Roche to Regeneron under this Agreement or the Supply Agreement shall be Finished Product.  Prior to beginning to manufacture Drug Substance at a Roche Manufacturing Facility other than the Roche Manufacturing Facility in Vacaville, California, Roche will notify the JMC for review and discussion of the Roche Manufacturing Facility pursuant to Section 8.2.3(i)&#59; provided that the JMC shall not have an approval right over use of such Roche Manufacturing Facility and Roche may determine to use such Roche Manufacturing Facility in its discretion.    </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the Manufacturing Collaboration Timepoint, Regeneron shall at its own cost, dedicate and utilize the equivalent of at least 40,000 liters of annualized bioreactor capacity on a full-time campaign basis &#91;* * *&#93; for the manufacture of Drug Substance at Regeneron&#8217;s facilities or at CMOs (subject to Section 2.6) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Minimum Committed Regeneron Capacity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless the JMC decides a Minimum Committed Capacity Reduction pursuant to Section 8.2.3(g). Unless otherwise agreed by the Parties in writing, any Products supplied by Regeneron to Roche Basel under this Agreement or the Supply Agreement shall be Drug Substance.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JMC decides to reduce the Minimum Committed Roche Capacity and Minimum Committed Regeneron Capacity because the demand in the Territory drops below 140,000 liters of bioreactor capacity on an annualized basis for commercial manufacture of the Drug Substance for the Lead Product, then, unless the JSC decides by mutual consent on a different proportion, the Minimum Committed Roche Capacity shall be reduced at the same proportion as the Minimum Committed Regeneron Capacity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Excess Capacity</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to its responsibilities set forth in Section 4.1.1 each Party shall have the right to make available bioreactor capacity for Drug Substance at its own facilities consistent with the terms of this Agreement, in excess of, respectively, the Minimum Committed Roche Capacity and the Minimum Committed Regeneron Capacity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel shall consider in good faith any request by Regeneron to convert Drug Substance which Regeneron manufactures to Drug Product or Finished Product.  For the avoidance of doubt, if Roche Basel determines that it does not or will not have sufficient excess capacity to accommodate Regeneron&#8217;s request, that shall be a sufficient good faith reason for denying such request.  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Specifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall be solely responsible for establishing the specifications for each Drug Substance and Drug Product. Prior to Regeneron finalizing any specifications, Regeneron will provide Roche with the proposed specifications and provide Roche with a reasonable opportunity to provide comments thereto, which Regeneron will consider in good faith. Each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 31 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Party shall be solely responsible for establishing the specifications for packaging and labeling of the Finished Product in its respective territory. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Standard Costs </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The Parties, through the JMC (in consultation with the FWG), shall determine each Party&#8217;s Standard Cost for each Drug Substance, Drug Product (which shall be on a Presentation-by-Presentation and Permutation-by-Permutation basis) and Finished Product (which shall be on a Presentation-by-Presentation and Permutation-by-Permutation basis), and any manufacturing services (i.e., filing, finishing, packaging and labelling) to be performed by or on behalf of such Party for the other Party, in each case prior to the &#91;* * *&#93; and prior to each October 31 thereafter&#59; provided that, with respect to each Presentation of Drug Product or Finished Product, the manufacturing Party may use a blended Standard Cost based on the weighted average of the Fully Burdened Manufacturing Costs for all applicable Permutations of such Presentation.  Prior to each such date, each Party shall provide to the JMC, with such supporting cost breakout information as determined by the JMC, (i) the Fully Burdened Manufacturing Costs for each Drug Substance, Drug Product or Finished Product, for each applicable Presentation, manufactured by or on behalf of such Party or its Affiliates in the prior Calendar Year and any manufacturing services (i.e., filling, finishing, packaging and labelling) performed by or on behalf of such Party or any of its Affiliates for the other Party in the prior Calendar Year, (ii) its reasonable best estimate of its Fully Burdened Manufacturing Costs for each Drug Substance, Drug Product or Finished Product, including for each applicable Presentation, to be manufactured by or on behalf of such Party or its Affiliates in such Calendar Year and any manufacturing services (i.e., filling, finishing, packaging and labelling) to be performed by or on behalf of such Party or any of its Affiliates for the other Party in such Calendar Year, in each case, taking into account any anticipated changes in Fully Burdened Manufacturing Costs for such Calendar Year (e.g., manufacturing efficiencies, changes in cost of raw materials), and (iii) for any Presentation of Drug Product or Finished Product for which the manufacturing Party elects to use one blended Standard Cost, the information used by such Party to determine the weighted average of the Fully Burdened Manufacturing Costs for the various Permutations of such Presentation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The Parties shall discuss and agree on, through the JMC (in consultation with the FWG), the Standard Costs for each Party with respect to each Drug Substance, Drug Product or Finished Product, including for each applicable Presentation to be manufactured by or on behalf of such Party or its Affiliates for the coming Calendar Year and for any manufacturing services (i.e., filling, finishing, packaging and labelling) to be performed by or on behalf of a Party or any of its Affiliates for the other Party, in each case, based on the information provided by each Party in accordance with Section 4.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Within &#91;* * *&#93; after the end of each of Calendar Year, with respect to each Presentation for which the manufacturing Party used one blended Standard Cost for all Permutations of such Presentation, such manufacturing Party shall report to the JMC such manufacturing Party&#8217;s actual Fully Burdened Manufacturing Costs for each Permutation and the quantity of each such Permutation that was manufactured during such Calendar Year.  &#91;* * *&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 32 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Regeneron Cell Banks and Cell Media.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Regeneron Cell Banks</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the technology transfer under the Technology Transfer Agreement and for the sole purposes of enabling Roche or its Affiliates to manufacture the Product(s) pursuant to this Agreement, Regeneron will, upon Roche&#8217;s request, supply to Roche &#91;* * *&#93; of vials of the working cell bank for the manufacture of Drug Substance (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Working Cell Bank</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions herein and in the Technology Transfer Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall pay &#91;* * *&#93; in connection with the supply of any quantity of Working Cell Bank requested by Roche after completion of the technology transfer pursuant to the Technology Transfer Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall not, and shall cause its Affiliates not to, (i) use or duplicate any Working Cell Bank (or any component thereof) for any purpose other than to manufacture the Drug Substance for purposes of manufacturing the Product(s), or (ii) transfer any Working Cell Bank (or any component thereof) to any Third Party, other than a CMO approved by Regeneron. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Regeneron Cell Media</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Roche Group shall only purchase Regeneron Cell Media from Regeneron or its Affiliates, or from any Third Party that Regeneron has authorized to manufacture Regeneron Cell Media, in each case, solely to enable Roche to manufacture the Product(s) pursuant to this Agreement, and upon Roche&#8217;s reasonable request, Regeneron shall provide a letter of authorization to any such Third Party in order to permit such Third Party to supply Regeneron Cell Media to Roche.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall not be required to disclose to Roche the composition, formula, properties or method of making any Regeneron Cell Media. Roche shall not, and shall cause its Affiliates not to, (a) use Regeneron Cell Media for any purpose other than to manufacture the Product(s) pursuant to this Agreement or (b) transfer Regeneron Cell Media to any Third Party other than a CMO approved by Regeneron.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing in this Section 4.3.2 shall be deemed or construed to limit Roche or any of its Affiliates with respect to any cell culture media that Roche can demonstrate was in the possession of Roche or any of its Affiliates as of the Effective Date other than under this Agreement or the Technology Transfer Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Ownership and Restrictions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Regeneron shall own exclusively the Working Cell Bank.  Regeneron hereby grants to Roche Basel a non-exclusive, royalty-free, fully paid-up, non-sublicensable (other than to any of its Affiliates or CMO approved by Regeneron), non-transferable (except as permitted in Section 21.5) license to use the Working Cell Bank and Regeneron Cell Media solely for the purposes of manufacturing the Product(s) pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche Basel shall not, and shall ensure that its Affiliates, and its and their permitted Sublicensees do not, reverse engineer any cell lines, media or feeds or any other proprietary materials in the Working Cell Bank or Regeneron Cell Media.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 33 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Roche Basel shall destroy any quantities of Working Cell Bank and Regeneron Cell Media remaining upon expiration or termination of this Agreement within &#91;* * *&#93; following such expiration or termination. Roche shall provide written certification of such destruction to Regeneron. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Supply</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Allocation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the &#91;* * *&#93;, Regeneron, may sell Product manufactured by Regeneron in the Regeneron Territory or transfer such Product to Roche Basel for sale in the Roche Territory by Roche Basel, its Non-US Affiliates or Sublicensees in accordance with this Section 5.1 and Section 10.2 (a) &#8211; (c). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the &#91;* * *&#93;, Roche may sell Product manufactured by Roche in the Roche Territory or transfer such Product to Regeneron for sale in the Regeneron Territory by Regeneron, its Affiliates or Sublicensees in accordance with this Section 5.1 and Section 10.2 (a) - (c). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Starting &#91;* * *&#93;, the Parties shall manufacture Drug Substance for the Lead Product at the Minimum Committed Roche Capacity and the Minimum Committed Regeneron Capacity, respectively. For clarity, each Party may, at its discretion, prior to &#91;* * *&#93; manufacture Drug Substance for the Lead Product that counts towards the Minimum Committed Roche Capacity or the Minimum Committed Regeneron Capacity, as the case may be, for the year 2021. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, the actual amount of Product provided from one Party to the other Party pursuant to this Section 5.1 will be determined in accordance with the forecasting and ordering process set forth in the Supply Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, Regeneron shall not be required to sell any Product to any US Affiliate of Roche. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Supply Price</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If one Party supplies to the other Party Drug Substance, Drug Product or Finished Product, as the case may be, such supply shall be &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Supply Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise agreed by the Parties, no later than &#91;* * *&#93; following the Effective Date, the Parties will negotiate in good faith and enter into a supply agreement on reasonable and customary terms for the process of ordering and supply of Products among the Parties, with a related quality agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The principles set forth in Sections 5.1 and 5.2 shall be further detailed in the Supply Agreement. The Supply Agreement shall also encompass precise descriptions of Drug Product manufacturing and labeling and packaging.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 34 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Regulatory</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Responsibility</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Regeneron&#8217;s Responsibilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall be solely responsible &#91;* * *&#93; for all regulatory affairs specifically with respect to any Product in the Regeneron Territory, including pursuing, compiling and submitting all regulatory filing documentation, and for interacting with Regulatory Authorities including the preparation and filing of applications for any or all Regulatory Approvals, as well as any or all governmental approvals required to develop, have developed, make, have made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold Products in the Regeneron Territory.  Regeneron or its Affiliates shall own, maintain and file in their discretion all regulatory filings and Regulatory Approvals for all Products throughout the Regeneron Territory. Roche shall, upon Regeneron&#8217;s reasonable request and &#91;* * *&#93;, provide assistance with respect to any such regulatory activities conducted by Regeneron, including that Roche shall prepare the portions of any regulatory filing documentation in the Regeneron Territory to the extent relating to Roche&#8217;s manufacture of Drug Substance, Drug Product or Finished Product, as applicable.  Notwithstanding the foregoing, Roche shall be responsible for the Roche Regulatory Activities (including any such activities in the Regeneron Territory), and to the extent permitted by Applicable Law, Roche and its Affiliates shall own, maintain and file all regulatory filings and Regulatory Approvals with respect to the Roche Regulatory Activities in the Regeneron Territory.  To the extent permitted by Applicable Law, Regeneron shall (a) provide Roche reasonable advance notice of any meeting with any Regulatory Authority in the Regeneron Territory related to the preparation or filing of such applications, and Roche may appoint up to &#91;* * *&#93; Roche employees to attend any such meeting with Regulatory Authorities in the Regeneron Territory&#59; and (b) upon Roche&#8217;s request, Regeneron shall provide Roche with copies of all material filings and submissions prepared and exchanged with Regulatory Authorities in support of obtaining or maintaining Regulatory Approval for the Products in the Regeneron Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall also be solely responsible &#91;* * *&#93; for all regulatory affairs related to (a) (i) the conduct of the Ongoing Regeneron Studies and (ii) any Co-Funded Study or Unilateral Study, in either case, conducted by or on behalf of Regeneron and (b) Regeneron&#8217;s manufacture of the Products, in each case ((a) or (b)), anywhere in the Territory (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Regulatory Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), including pursuing, compiling and submitting all regulatory filing documentation, and for interacting with Regulatory Authorities including the preparation and filing of applications for any or all Regulatory Approvals, as well as any or all governmental approvals with respect to the Regeneron Regulatory Responsibilities (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Regulatory Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the Parties shall &#91;* * *&#93; Regeneron&#8217;s &#91;* * *&#93; for all regulatory affairs related to any Co-Funded Study. Regeneron and its Affiliates shall own, maintain and file all regulatory filings and Regulatory Approvals with respect to the Regeneron Regulatory Activities in the Territory (but not, for clarity, any Regulatory Approval for commercialization of any Product in the Roche Territory except as provided in the next paragraph). Regeneron shall (A) provide reasonable advance notice of any meeting with any Regulatory Authority in the Roche Territory related to any Regeneron Regulatory Responsibilities, and, to the extent permitted by Applicable Law, Roche may appoint up to &#91;* * *&#93; Roche employees to attend any such meeting with Regulatory Authorities in the Roche Territory&#59; and (B) consider in good faith any input from Roche in preparing such regulatory materials and interactions. Roche shall, upon Regeneron&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 35 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reasonable request, provide assistance with respect to any such regulatory activities conducted by Regeneron, subject to the following paragraph with respect to the First Approval Activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall, in coordination with Roche, be responsible, &#91;* * *&#93;, for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with Regulatory Authorities (including the preparation and filing of applications) for the first MAA for the Lead Product in the EU (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First EU Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the first Regulatory Approval for the Lead Product in the United Kingdom (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First UK Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in each case, as determined by the JOC, either (A) in the name of Regeneron, or (B) in the name of Roche (in which case, Regeneron shall act as an agent of Roche) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Approval Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  If Regeneron acts as an agent of Roche and file the application for the First EU Approval or for the First UK Approval, as applicable, in the name of Roche, then upon Regeneron&#8217;s reasonable request, Roche shall execute any documentation necessary to enable Regeneron to act as Roche&#8217;s agent with respect to the applicable First Approval Activities.  Roche shall, upon Regeneron&#8217;s reasonable request and &#91;* * *&#93;, provide assistance with respect to the First Approval Activities, including that Roche shall prepare the portions of the application for the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">First EU Approval or the First UK Approval, as applicable, to the extent relating to Roche&#8217;s manufacture of Drug Substance, Drug Product or Finished Product, as applicable.  To the extent permitted by Applicable Law, (i) Regeneron shall provide Roche reasonable advance notice of any meeting with any Regulatory Authority in the EU or the United Kingdom, as applicable, related to the preparation or filing of such application, and Roche may appoint &#91;* * *&#93; Roche employees to attend any such meeting with Regulatory Authorities in the EU or the United Kingdom, as applicable&#59; and (ii) Regeneron shall seek input from Roche in preparing such regulatory materials and interactions, and Roche at its own discretion shall have the right to review and approve all documentation prepared and exchanged with Regulatory Authorities in support of filing for such First EU Approval or First UK Approval, as applicable, related to manufacturing sites and manufacturing specifications, label wording and claims (summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), primary&#47;secondary packaging text) and negotiation of pediatric investigational plans or post-approval commitments.  If Regeneron files the application for the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">First EU Approval or for the First UK Approval, as applicable, in the name of Regeneron, then, as soon as practicable after obtaining the First EU Approval or the First UK Approval, as applicable, Regeneron shall undertake all actions necessary to transfer to Roche such First EU Approval or First UK Approval, as applicable, and any regulatory filings in Regeneron&#8217;s possession with respect thereto (but excluding, for clarity, any CTA for the Lead Product) and, Regeneron shall, at Roche&#8217;s reasonable request, cooperate as necessary for such First EU Approval or First UK Approval, as applicable, to be transferred to Roche. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly after the Effective Date, Regeneron shall coordinate and cooperate with Roche to share with Roche, upon Roche&#8217;s reasonable request, (i) relevant historical clinical safety data, copies of all material correspondence with the Regulatory Authorities of the Roche Territory, (ii) electronic Clinical Study data (including Clinical Study reports, datasets, summaries, overviews and other relevant documentation) in an appropriate format and (iii) regulatory dossiers containing information necessary or useful to Roche in connection with its regulatory filings for any Products in the Roche Territory, including clinical trial dossiers, material regulatory correspondence, and study reports from completed non-clinical studies, in each case, ((i) - (iii)) to the extent in the possession of Regeneron or any of its Affiliates.  Regeneron shall, upon Roche&#8217;s request and at Roche&#8217;s cost, assist Roche in conducting any required GCP audit related to the above-mentioned documentation.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 36 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall maintain the company core data sheet for each Product (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CCDS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for purposes of enabling commercialization of such Product throughout the Territory.  Either Party may propose modifications to the CCDS and the Parties shall then discuss whether to modify the CCDS, with each Party considering the other Party&#8217;s comments with respect thereto in good faith&#59; provided, however, that Regeneron shall have the final decision-making authority with respect to any update to the CCDS.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Roche&#8217;s Responsibilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From and after the Effective Date, subject to the remainder of this paragraph and Regeneron&#8217;s obligations in Section 6.1.1, Roche shall be solely responsible &#91;* * *&#93; for all regulatory affairs specifically with respect to any Product in the Roche Territory, including the preparation and filing of applications for Regulatory Approval, as well as any or all governmental approvals required to develop, have developed, make, have made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold Products in the Roche Territory.  Roche shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for all Products throughout the Roche Territory.  To the extent permitted by Applicable Law, (i) Roche shall provide Regeneron reasonable advance notice of any meeting with any Regulatory Authority in a Major Country related to the preparation or filing of such applications, and Regeneron may appoint &#91;* * *&#93; Regeneron employees to attend any such meeting with Regulatory Authorities in such Major Country&#59; and (ii) Roche shall seek input from Regeneron in preparing such regulatory materials and interactions, and Regeneron shall have the right to review and comment on all material filings and submissions prepared and exchanged with Regulatory Authorities in support of obtaining or maintaining Regulatory Approval for the Products in each Major Country, and Roche shall consider such comments in good faith.  Without limiting the foregoing, in preparing regulatory filings with Regulatory Authorities with respect to the Products in the Roche Territory, Roche shall not disclose any Sensitive Information to any Regulatory Authority without Regeneron&#8217;s prior written approval, &#91;* * *&#93;.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall not submit to a Regulatory Authority, or otherwise agree to any Product labeling (or any modification thereto) that is not consistent with the CCDS, without the prior written consent of Regeneron. During the Agreement Term, Roche or its Affiliates shall own, maintain and file in their discretion all regulatory filings and Regulatory Approvals for all Products throughout the Roche Territory.  Notwithstanding the foregoing, Regeneron shall be responsible for the First Approval Activities and the Regeneron Regulatory Responsibilities, in each case, as described in Section 6.1.1 and Regeneron and its Affiliates shall own, maintain and file all regulatory filings and Regulatory Approvals with respect to the Regeneron Regulatory Activities in the Roche Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall also be solely responsible &#91;* * *&#93; for all regulatory affairs related to  (a) the conduct of any Co-Funded Study or Unilateral Study conducted by or on behalf of Roche and (b) Roche&#8217;s manufacture of the Products anywhere in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Regulatory Responsibilities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), including pursuing, compiling and submitting all regulatory filing documentation, and for interacting with Regulatory Authorities including the preparation and filing of applications for any or all Regulatory Approvals, as well as any or all governmental approvals with respect to the Roche Regulatory Responsibilities (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Regulatory Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that the Parties shall &#91;* * *&#93; Roche&#8217;s &#91;* * *&#93; for all regulatory affairs related to any Co-Funded Study. Roche and its Affiliates shall own, maintain and file all regulatory filings and Regulatory Approvals with respect to the Roche Regulatory Activities in the Territory (but not, for clarity, any BLA for a Product in the Regeneron Territory).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 37 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event Roche cannot conduct regulatory activities independent of Regeneron which would be needed to pursue Roche Regulatory Responsibilities, including for Regulatory Approval of a Product in the Roche Territory, Regeneron shall use Commercially Reasonable Efforts to assist Roche &#91;* * *&#93;, subject to Section 16.1(c).  In addition, Regeneron shall prepare the portions of any regulatory filing documentation in the Roche Territory to the extent relating to Regeneron&#8217;s manufacture of Drug Substance, Drug Product or Finished Product, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Regulatory Diligence Obligation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall use Commercially Reasonable Efforts to obtain (subject to Roche&#8217;s responsibilities pursuant to Section 6.1) and maintain Regulatory Approval for the Product in the Regeneron Territory&#59; and to obtain the First EU Approval and First UK Approval, as applicable&#59; provided, however, that Regeneron shall not be obligated to conduct any Clinical Studies other than the Ongoing Regeneron Studies and Additional Regeneron Studies to obtain such Regulatory Approval in the EU and the United Kingdom, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the case of multiple Products, then the Parties&#8217; diligence obligations under this Section 6.2 shall be with respect to all such Products, taken as a whole.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Pharmacovigilance and Global Safety Database</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties mutually agree to execute a separate safety data exchange agreement as deemed applicable but no later than the initiation of the first Clinical Study for a Product by Roche or the first Regulatory Approval in the Roche Territory (whichever comes first) (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Safety Data Exchange Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Such Safety Data Exchange Agreement shall set forth the responsibilities and obligations of the Parties with respect to the procedures and timeframes for compliance with the Applicable Law pertaining to safety reporting of the Product(s) and their related activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall be responsible for the establishment, holding and maintenance of the global safety database with respect to any Product at its expense.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Commercialization</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Responsibility</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron, &#91;* * *&#93;, shall have sole responsibility and decision-making authority for all activities associated with marketing, promotion, sale, medical affairs and distribution of Products in the Regeneron Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel, &#91;* * *&#93;, shall have sole responsibility and decision-making authority for all activities associated with marketing, promotion, sale, medical affairs and distribution of Products in the Roche Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in no event shall either Party or any of its Affiliates (a) if such Party or its Affiliates sell a Product in the Field in their Respective Territory to a customer who also purchases other products or services from any such entity, such Party shall not, and shall cause its Affiliates not to, bundle or include any Product as part of any multiple product offering </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 38 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or discount or price the Products in a manner that is reasonably likely to disadvantage a Product in order to benefit sales or prices of other products offered for sale by such Party or its Affiliates to such customer or (b) accept funding from a Third Party for any other products of services for such Party or any of its Affiliates that is reasonably likely to disadvantage the pricing of a Product.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Pricing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All decisions for each Product related to any pricing matter, including list price, targeted net pricing, sales-weighted average discounts and rebates, pricing strategy (including the approach to pricing with different types of accounts and plans, including types of discounts and rebates), and modifications to any of the foregoing, will be solely made by (a) Regeneron for the Regeneron Territory and (b) Roche Basel for the Roche Territory&#59; &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Commercialization Diligence Obligation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following receipt of Regulatory Approval in the US, Regeneron shall use Commercially Reasonable Efforts to commercialize the Product in the US.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Roche Major Country, following receipt of Regulatory Approval in such Roche Major Country, Roche Basel shall use Commercially Reasonable Efforts to commercialize the Product in such Roche Major Country. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel shall use Commercially Reasonable Efforts to commercialize the Product in the ROW.  Roche (and its Affiliates) shall &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the case of multiple Products, then the Parties&#8217; diligence obligations under this Section 7.3 shall be with respect to all such Products, taken as a whole.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Distribution of Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall manage its Finished Product inventory in the ordinary course of business consistent with its regular practices without regard to the calculation of the Global Gross Profit sharing.  &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Distribution Audit</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If, for a given period (but in no event shorter than &#91;* * *&#93;), one Party has a reasonable inquiry about the other Party&#8217;s distribution of any Product (including both sales of the Product and distribution of the Product as &#91;* * *&#93;) in such other Party&#8217;s Respective Territory &#91;* * *&#93;, then, upon request by the first Party, the Parties shall discuss such inquiry in good faith through the JMC.  Without limiting a Party&#8217;s right to conduct financial audit pursuant to Section 13.1, each Party shall have the right to audit the applicable books and records of the other Party (or, where applicable, its Affiliates and Sublicensees) relating to distribution of the Product by such other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 39 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Party, its Affiliates and Sublicensees, or its or their Third Party logistics service providers, including, to the extent permitted under the applicable agreements between such other Party (or, where applicable, its Affiliates and Sublicensees) and its or their Third Party logistics service providers, the distribution records furnished by such Third Party logistics service providers, for the sole purposes of confirming such other Party&#8217;s compliance with Section 7.5 (each such audit, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Distribution Audit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The terms and conditions set forth in Section 13.1 with respect to the confidentiality obligations, and the auditing process, limitations, and expenses shall apply, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to a Product Distribution Audit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Regeneron shall not have the right under this Section 7.6 to conduct a Product Distribution Audit with respect to any period for which Roche elects to determine in accordance with Appendix 1.106 the total number of units of all applicable Presentations of the Product that constituted Net Sales &#91;* * *&#93; for each applicable Calendar Quarter &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Governance  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Joint Steering Committee</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Formation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly after the Effective Date, the Parties shall establish a joint steering committee (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to oversee the development, manufacturing and commercialization activities under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Members</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JSC shall be composed of six (6) persons (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Members</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Roche and Regeneron each shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement upon written notice to the other Party&#59; provided, that a Party that replaces a Member shall notify the other Party at least &#91;* * *&#93; prior to the next scheduled meeting of the JSC. Each Party may invite a reasonable number of additional experts or advisors to attend part or the whole JSC meeting with prior notification to the JSC&#59; provided that any such expert or advisor who is not an employee of the applicable Party must be approved in advance by the other Party and bound by obligations of confidentiality and non-disclosure at least as protective of the other Party as those set forth in Article 18. The JSC shall be co-chaired by a Member from Regeneron and a Member from Roche.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Responsibilities of the JSC</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JSC shall have the responsibility and authority to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">review and discuss the development, commercialization and manufacturing activities of both Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">approve the Co-Funded Development Plan (including any Clinical Study for which the Parties will share &#91;* * *&#93; as a Co-Funded Study) and any material amendment to the Co-Funded Development Plan submitted by the JOC, including provisions regarding the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 40 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">responsibility for the performance of the respective development activities with respect to any additional Co-Funded Studies, provided that, (i) with respect to an Additional Regeneron Study any portion of the initial Co-Funded Development Plan with respect to such Additional Regeneron Study that is consistent with the protocol existing as of the Effective Date for such Additional Regeneron Study shall be deemed to have been approved by the JSC&#59; and (ii) with respect to any amendment to the Co-Funded Development Plan for an Additional Regeneron Study, only such amendment that involves &#91;* * *&#93; (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Material Additional Study Change</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be subject to the JSC&#8217;s approval&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">discuss the progress and status of each Unilateral Study&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">approve the initial Device Development Plan submitted by the JMC and any material amendment thereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">&#91;* * *&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">review all commercialization activities for the Products in the Territory&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">facilitate the exchange of information between the Parties with respect to the development, seeking and obtain Regulatory Approval and commercialization of the Compounds and Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">establish and delegate specifically defined duties to the JMC and JOC&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">establish additional subcommittees or operational teams as deemed appropriate and delegate specifically defined duties to them&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">attempt to resolve any matters escalated to the JSC by the JMC or JOC&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">perform such other tasks as set forth in this Agreement or as otherwise agreed by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JSC shall have no responsibility and authority other than that expressly set forth in this Section 8.1.3.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Meetings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Alliance Directors will be responsible for sending invitations and agendas for all JSC meetings to all Members at least &#91;* * *&#93; before the next scheduled meeting of the JSC, provided that the Alliance Director from either Party may request a JSC meeting under exigent circumstances by providing &#91;* * *&#93; prior notice. The JSC shall hold meetings no less than twice each Calendar Year during the Agreement Term, either in person or by tele-&#47;video-conference, and in any case as frequently as the Members of the JSC agree is necessary. The Alliance Director of each Party may attend the JSC meetings as a permanent participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Minutes</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 41 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Alliance Directors shall be responsible for recording, preparing and, within a reasonable time, issuing minutes of the JSC meetings, and shall circulate draft minutes of JSC meetings to all members of the JSC for comment and review within &#91;* * *&#93; after the relevant meeting. The Members of the JSC shall have &#91;* * *&#93; to provide comments. The Alliance Directors shall incorporate timely received comments and distribute finalized minutes to all Members of the JSC within &#91;* * *&#93; of the relevant meeting. Both co-chairpersons of the JSC must approve the final version of the minutes before its distribution.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Decisions</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Decision Making Authority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JSC shall decide matters within its responsibilities set forth in Section&#160;8.1.3.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Consensus&#59; Good Faith</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Members of the JSC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JSC. The Parties shall endeavor to make decisions by consensus with the Members of the JSC from each Party collectively having one (1) vote on behalf of such Party&#59; provided that no such vote taken at a meeting shall be valid unless a Member from each Party is present and participating in the vote. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1.6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Failure to Reach Consensus, Escalation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JSC is unable to decide a matter by consensus, then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.7pt">Roche shall have final decision authority on any matter relating to (i) the commercialization of Product in the Roche Territory, subject to Regeneron&#8217;s performance of the First Approval Activities pursuant to Section 6.1.1,&#59; and (ii) selection of Alternative Product Trademarks&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Regeneron shall have final decision authority on any matter relating to (i) the commercialization of Product in the Regeneron Territory&#59; (ii) &#91;* * *&#93;&#59; (iii) any Material Additional Study Change&#59; and (iv) the Global Trademarks&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the JSC is unable to resolve any other matters not addressed in the foregoing clauses (a) - (b), including any matter escalated to the JSC by the JMC or the JOC, then such matter shall be referred to the CEO of Regeneron and the CEO of Roche Pharmaceuticals for resolution, who shall use reasonable and good faith efforts to reach a decision by consensus within &#91;* * *&#93; after the date such matter is referred to them. If the CEOs of both Parties are unable to reach a decision within such &#91;* * *&#93; period, then unless otherwise agreed by the Parties, &#91;* * *&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Joint Manufacturing Committee</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Formation</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 42 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly after the Effective Date, the Parties shall establish a joint manufacturing committee (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">JMC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which will be a subcommittee of the JSC, to oversee the manufacturing activities under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Members</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JMC shall be composed of four (4) Members. Roche and Regeneron each shall be entitled to appoint two (2) Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement upon written notice to the other Party&#59; provided, that a Party that replaces a Member shall notify the other Party at least &#91;* * *&#93; prior to the next scheduled meeting of the JMC. Each Party may invite a reasonable number of additional experts or advisors to attend part or the whole JMC meeting with prior notification to the JMC&#59; provided that any such expert or advisor who is not an employee of the applicable Party must be approved in advance by the other Party and bound by obligations of confidentiality and non-disclosure at least as protective of the other Party as those set forth in Article 18. The JMC shall be co-chaired by a Member from Regeneron and a Member from Roche. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Responsibilities of the JMC</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JMC shall have the responsibility and authority to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Discuss, review and approve a rolling, 12-month production forecast for Drug Substance of each Product for each Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Production Forecast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and an Alternative Supply Allocation plan (as the case may be pursuant to Section 8.2.3(b)) to be used under the Supply Agreement.  &#91;* * *&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">decide on changing the allocation of the total Drug Substance of Product produced between the Regeneron Territory and the Roche Territory as foreseen in Section 5.1, including in accordance with demand for the Product in each Respective Territory (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alternative Supply Allocation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">determine each Party&#8217;s Standard Cost for Drug Substance, Drug Product or Finished Product, including for each applicable Presentation or Permutation, in accordance with Section 4.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">oversee all aspects of the manufacture of Products under the Supply Agreement, including product specifications and quality&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">discuss and approve any transfer of Drug Substance, Drug Product or Finished Product between Parties not included in the Supply Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">discuss and approve any request for one Party to convert the other Party&#8217;s Drug Substance or Drug Product to Drug Product or Finished Product respectively&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">decide on appropriate reductions to the Minimum Committed Roche Capacity or Minimum Committed Regeneron Capacity, including, in light of a decrease in demand such that there is no longer a demand for the equivalent of at least 140,000 liters of bioreactor capacity on an annualized basis for the manufacture of Drug Substance in the Territory&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 43 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">discuss any disproportional distribution by either Party of Product containing Drug Substance manufactured and supplied by the other Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">discuss and review use by Roche of an additional Roche Manufacturing Facility, as provided in Section 4.1.1&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">report on a regular basis to the JSC&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">escalate to the JSC as required.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JMC shall have no responsibility and authority other than that expressly set forth in this Section 8.2.3, except if the JSC decides to delegate specifically defined duties to the JMC pursuant to Section 8.1.3(h).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Meetings </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The co-chairpersons of the JMC will be responsible for sending invitations and agendas for all JMC meetings to all Members at least &#91;* * *&#93; before the next scheduled meeting of the JMC. The JMC shall hold meetings either in person or by tele-&#47;video-conference, and in any case as frequently as the Members of the JMC agree is necessary. The Alliance Director of each Party may attend the JMC meetings as a permanent participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Minutes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The co-chairpersons of the JMC will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of JMC meetings to all members of the JMC for comment and review within &#91;* * *&#93; after the relevant meeting. The Members of the JMC shall have &#91;* * *&#93; to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JMC within &#91;* * *&#93; of the relevant meeting. Both co-chairpersons of the JMC must approve the final version of the minutes before its distribution.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Decisions</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Decision Making Authority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JMC shall decide matters within its responsibilities set forth in Section 8.2.3.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Consensus&#59; Good Faith</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Members of the JMC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JMC. The Parties shall endeavor to make decisions by consensus with the Members of the JMC from each Party collectively having one (1) vote on behalf of such Party&#59; provided that no such vote taken at a meeting shall be valid unless a Member from each Party is present and participating in the vote.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2.6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Failure to Reach Consensus</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JMC is unable to decide a matter by consensus, then such matter shall be referred to the JSC for resolution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 44 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Joint Operations Committee</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Formation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly after the Effective Date, the Parties shall establish a joint operations committee (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JOC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which will be a subcommittee of the JSC, to oversee the development and commercialization activities under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Members</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC shall be composed of six (6) Members.  Roche and Regeneron each shall be entitled to appoint three (3) Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement upon written notice to the other Party&#59; provided, that a Party that replaces a Member shall notify the other Party at least &#91;* * *&#93; prior to the next scheduled meeting of the JOC. Each Party may invite a reasonable number of additional experts or advisors to attend part or the whole JOC meeting with prior notification to the JOC&#59; provided that any such expert or advisor who is not an employee of the applicable Party must be approved in advance by the other Party and bound by obligations of confidentiality and non-disclosure at least as protective of the other Party as those set forth in Article 18. The JOC shall be co-chaired by a Member from Regeneron and a Member from Roche.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Responsibilities of the JOC</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC shall have the responsibility and authority to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">submit to the JSC the Co-Funded Development Plan and any material amendment to the Co-Funded Development Plan, including any proposal to add any Clinical Study for which the Parties will share &#91;* * *&#93; as a Co-Funded Study, and any proposal regarding the responsibility for the performance of the respective development activities with respect to any additional Co-Funded Studies&#59; provided that, (i) with respect to any amendment to the Co-Funded Development Plan for an Additional Regeneron Study, only a Material Additional Study Change requires the JSC&#8217;s approval, and (ii) Regeneron may submit any Material Additional Study Change directly to the JSC without first submitting to the JOC&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">determine the ISS Strategy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">submit to the JSC the initial Device Development Plan and any material amendment thereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">review and monitor the development activities for the Products, including regulatory activities undertaken pursuant to this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">submit to the JSC for approval proposals to pursue Third Party funding for either Party for Co-Funded Studies &#91;* * *&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">discuss and review all commercialization activities for the Products in the Territory&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 45 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">discuss and approve &#91;* * *&#93; in the Roche Territory and the Regeneron Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">align on global guidelines and strategy for pricing for the Products&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">align on global contracting and communications strategy&#59; including strategies for interactions with governments, media, international institutions and stakeholders&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">&#91;* * *&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">select the Global Trademarks and, if applicable, Alternative Product Trademarks, and establish any applicable rules regarding the use of Global Trademarks or Alternative Product Trademarks&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">&#91;* * *&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:19.52pt">discuss and determine whether the regulatory filing for the First EU Approval or the First UK Approval will be made in Regeneron&#8217;s name or in Roche&#8217;s name with Regeneron acting as agent (provided that notwithstanding anything to the contrary in this Agreement, Regeneron will have the final decision making authority with respect to either filing being made in Regeneron&#8217;s name)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">discuss each Party&#8217;s plan for publication&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">discuss and approve the Other Chugai Asset Activities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">report on a regular basis to the JSC&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">oversee the operation and activities of the FWG and approve any matter submitted by the FWG&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">discuss updates provided by Regeneron pursuant to Section 2.8 and discuss any progress made on Additional Compounds, if any&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">escalate to the JSC as required.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC shall have no responsibility and authority other than that expressly set forth in this Section 8.3.3, except if the JSC decides to delegate specifically defined duties to the JOC pursuant to Section 8.1.3(h).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Meetings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The co-chairpersons of the JOC will be responsible for sending invitations and agendas for all JOC meetings to all Members at least &#91;* * *&#93; before the next scheduled meeting of the JOC. The JOC shall hold meetings either in person or by tele-&#47;video-conference and in any case as frequently as the Members of the JOC agree is necessary. The Alliance Director of each Party may attend the JOC meetings as a permanent participant. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Minutes</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 46 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The co-chairpersons of the JOC will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of JOC meetings to all members of the JOC for comment and review within &#91;* * *&#93; after the relevant meeting. The Members of the JOC shall have &#91;* * *&#93; to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute finalized minutes to all Members of the JOC within &#91;* * *&#93; of the relevant meeting. Both co-chairpersons of the JOC must approve the final version of the minutes before its distribution.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Decisions</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Decision Making Authority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC shall decide matters within its responsibilities set forth in Section 8.3.3.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Consensus&#59; Good Faith</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Members of the JOC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JOC. The Parties shall endeavor to make decisions by consensus with the Members of the JOC from each Party collectively having one (1) vote on behalf of such Party&#59; provided that no such vote taken at a meeting shall be valid unless a Member from each Party is present and participating in the vote.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3.6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:38.41pt">Failure to Reach Consensus</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the JOC is unable to decide a matter by consensus, such matter shall be referred to the JSC.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Financial Working Group</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Formation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly after the Effective Date, the Parties will establish a financial working group (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FWG</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to oversee the accounting, financial (including planning, reporting and controls) and funds flow matters related to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Operation of the FWG.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly following the Effective Date, each Party shall designate its respective initial representatives to the FWG to allow such FWG to begin operating under the direction of the JOC.  The FWG shall have no decision-making authority and shall report to the JOC.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27pt">Exclusivity</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Non-Compete Obligation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche and its Affiliates shall not, directly or indirectly, whether alone or with or through any Third Party, (a) prior to the first approval of the first MAA for a Product in the EU, clinically develop or (b) at any time during the Agreement Term, manufacture (other than for purposes of research and development activities of Roche and its Affiliates permitted hereunder), have manufactured (other than for purposes of research and development activities of Roche and its Affiliates permitted hereunder), sell, distribute or otherwise commercialize, in each case ((a) and (b)), any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 47 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">product containing Antibody(ies) &#91;* * *&#93; other than the Products (each, a  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Competing Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or directly or indirectly assist any Third Party to do so.  &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For clarity, prior to the first approval of the first MAA for a Product in the EU, Roche and its Affiliates may conduct pre-clinical or non-clinical research and development activities&#160;(including technology transfer activities and preclinical evaluation of Third Party assets) on any Competing Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:20.73pt">Regeneron Right of First Negotiation to Chugai Asset</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the Effective Date, Chugai has &#91;* * *&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Roche may enter into an agreement with Chugai for an option for an exclusive right and license under any Patent Rights and know-how owned or controlled by Chugai to develop, register, use, sell, market and import the Chugai Asset in &#91;* * *&#93; (such countries of the world, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;&#59; and such option, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Chugai Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Prior to Roche&#8217;s exercise of the Roche Chugai Option, Roche shall have the right to &#91;* * *&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permitted Chugai Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Regeneron acknowledges and agrees that is it not a breach of Section 9.1 by Roche for Chugai to &#91;* * *&#93; conduct the Permitted Chugai Activities.  Roche shall have the right to &#91;* * *&#93; Roche shall not &#91;* * *&#93; without the agreement of the Parties through the JOC (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Chugai Asset Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (disputes with respect to which, for clarity, shall be subject to Section 8.1.6.3(c)).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche hereby grants Regeneron an exclusive option to obtain the right and sublicense under any Patent Rights and know-how owned or controlled by Chugai that Roche obtains through the exercise of the Roche Chugai Option to &#91;* * *&#93; and a financial interest in the commercialization of the Chugai Asset in the entire Territory, in each case, in accordance with this Section 9.2 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall provide Regeneron periodic updates regarding the development and characteristics of the Chugai Asset at each JOC meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without Regeneron&#8217;s consent in its discretion, Roche will not enter into any agreement with a Third Party (including, for clarity, Chugai) that would conflict with the rights that Regeneron would have with respect to the Chugai Asset if Regeneron exercises the Chugai Asset Option.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Chugai Asset Data Package</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Roche desires to exercise the Roche Chugai Option, then after &#91;* * *&#93; Roche shall provide, or cause Chugai to provide, Regeneron a complete data package with respect to the Chugai Asset, including all data, reports, documentation and other information relating to the Chugai Asset, necessary or reasonably useful for the Parties to determine whether the Chugai Asset has satisfied the Chugai Asset Criteria, including the results of such Clinical Study and any other clinical or non-clinical data, all information regarding the manufacturing process (including yields), route or frequency of administration, and the proprietary position of the Chugai Asset (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Data Package</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within &#91;* * *&#93; after Regeneron receives the Chugai Asset Data Package, the Parties shall discuss in good faith and endeavor to mutually agree (a) whether or not the Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria and (b) if the Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria, then whether or not the Chugai Asset satisfies the Chugai Asset Criteria.  If the Parties cannot agree within &#91;* * *&#93; following Regeneron&#8217;s receipt </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 48 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Chugai Asset Data Package (x) whether or not the Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria, or (y) whether or not the Chugai Asset satisfies the Chugai Asset Criteria, then, in either case ((x) or (y)), such dispute shall be determined in accordance with Section 21.2, and if still not resolved, then decided by an Expert Committee pursuant to Section 21.4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If both Parties agree, or the Executive Officers or Expert Committee, as applicable, determines that the Chugai Asset Data Package does not satisfy the Chugai Asset Data Package Criteria or that the Chugai Asset has not satisfied the Chugai Asset Criteria, then, in either case, Roche shall not exercise the Roche Chugai Option and the Chugai Asset shall remain a Competing Product for purposes of this Agreement, and the obligations set forth in Section 9.1 shall continue to apply to Roche with respect to the Chugai Asset.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter, if Roche receives any additional data or information with respect to the Chugai Asset and desires to exercise the Roche Chugai Option, Roche shall deliver to Regeneron an updated Chugai Asset Data Package, and the process set forth in this Section 9.2.1 shall apply to determine whether the updated Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria, and whether the Chugai Asset satisfies the Chugai Asset Criteria. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.57pt">Chugai Asset Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If both Parties agree, or the Executive Officers or Expert Committee determines that the Chugai Asset satisfies the Chugai Asset Criteria (such agreement or determination, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Positive Determination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then Regeneron shall have the right, within &#91;* * *&#93; following the date on which the Chugai Asset Positive Determination is made (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exercise Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to exercise the Chugai Asset Option by providing written notice to Roche (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exercise Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall not exercise the Roche Chugai Option until the Chugai Asset Positive Determination has been made, and either (a) Regeneron exercises the Chugai Asset Option by providing the Exercise Notice, or (b) Regeneron notifies Roche in writing that Regeneron will not exercise the Chugai Asset Option or fails to provide the Exercise Notice during the Exercise Period.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron exercises the Chugai Asset Option by providing the Exercise Notice within the Exercise Period, then Regeneron and Roche shall, and Roche shall cause Chugai to, promptly negotiate and execute a separate license agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or an amendment to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Chugai Asset Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is consistent with the terms and conditions set forth on Appendix 9.2 and on other terms mutually acceptable to Regeneron, Roche and Chugai, which the Parties anticipate will be substantially similar to the terms of this Agreement except as set forth on Appendix 9.2. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If (A) Regeneron notifies Roche in writing that Regeneron will not exercise the Chugai Asset Option or (B) Regeneron fails to provide the Exercise Notice during the Exercise Period, then the Chugai Asset Option shall expire.  If thereafter Roche exercises the Roche Chugai Option or otherwise obtains any right to develop or commercialize the Chugai Asset, then (X) Roche shall promptly notify Regeneron of such exercise or receipt of such other right, and (Y) Regeneron shall have the right to terminate this Agreement upon &#91;* * *&#93; prior written notice to Roche, which right must be exercised within &#91;* * *&#93; after notice from Roche of the first commercial sale of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 49 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chugai Asset, and such termination by Regeneron shall be deemed to be a termination by Roche pursuant to Section 19.2.5 for purposes of post-termination effect and obligations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, if the Chugai Asset receives Regulatory Approval in Japan, and the Parties have not entered into the Chugai Asset Agreement or Chugai Asset Amendment, as applicable, then upon Regeneron&#8217;s request, Roche shall immediately terminate Chugai&#8217;s sublicense with respect to the Products in Japan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the Agreement Term, neither Party shall have the right to develop or commercialize the Chugai Asset until the Chugai Asset Agreement or Chugai Asset Amendment is executed by the Parties and Chugai, except that (i) Roche shall have the right to conduct the Permitted Chugai Activities and Other Chugai Asset Activities approved by the JOC&#59; (ii) if (A) Regeneron notifies Roche in writing that Regeneron will not exercise the Chugai Asset Option or (B) Regeneron fails to provide the Exercise Notice during the Exercise Period, then Roche shall thereafter have the right to develop and commercialize the Chugai Asset, and (iii) if Regeneron exercises the Chugai Asset Option by providing the Exercise Notice within the Exercise Period, then, for clarity, the last sentence of the first paragraph of Section 9.2 shall remain in effect while the Parties and Chugai are negotiating the Chugai Asset Agreement or Chugai Asset Amendment, &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Payment</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Reimbursement &#91;* * *&#93; for Development Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Co-Funded Study, the Party not performing such Co-Funded Study shall reimburse the Party performing such Co-Funded Study for &#91;* * *&#93; incurred by or on behalf of such performing Party or any of its Affiliates in connection with performing such Co-Funded Study (including, for clarity, such &#91;* * *&#93; incurred by or on behalf of Regeneron or any of its Affiliates with respect to the Additional Regeneron Studies prior to the Effective Date) to the extent such &#91;* * *&#93; are not funded by a Third Party. For clarity, each Party shall bear its internal costs with respect to performing any Co-Funded Study.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to Co-Funded Device Development Activities, the Party not performing such Co-Funded Device Development Activities shall reimburse the Party performing such Co-Funded Device Development Activities for &#91;* * *&#93; incurred by or on behalf of such performing Party or any of its Affiliates in connection with performing such Device Development Activities to the extent such &#91;* * *&#93; are not funded by a Third Party.  &#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Unilateral Study, if the Party not performing such Unilateral Study uses any data or results from such Unilateral Study to obtain, maintain or expand any Regulatory Approval or any pricing or reimbursement for, otherwise includes such data or results in the label for, or uses such data and results to commercialize, a Product in its Respective Territory, then such non-performing Party shall reimburse the Party that performed such Unilateral Study for &#91;* * *&#93; incurred by or on behalf of such performing Party or any of its Affiliates in connection with such Unilateral Study to the extent such &#91;* * *&#93; are not funded by a Third Party.  For clarity, the submission of data and results from a Unilateral Study to a Regulatory Authority only for safety reporting purposes in connection with periodic safety reporting or as a courtesy copy shall not result in a reimbursement obligation under this paragraph.  The Party not performing the applicable Unilateral Study shall promptly notify the performing Party of any use of the data or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 50 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">results of such Unilateral Study that would result in a reimbursement obligation under this paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to Unilateral Device Development Activities, if the Party not performing such Unilateral Device Development Activities wishes to use the delivery device or other results of such Unilateral Device Development Activities for a Product in its Respective Territory, then such non-performing Party shall reimburse the Party that performed such Unilateral Device Development Activities for &#91;* * *&#93; incurred by or on behalf of such performing Party or any of its Affiliates in connection with such Unilateral Device Development Activities to the extent such &#91;* * *&#93; are not funded by a Third Party, and the performing Party shall provide the results of the Unilateral Device Development Activities to the non-performing Party and such other information and assistance as is required for the non-performing Party to manufacture and use the delivery device resulting from such Unilateral Device Development Activities.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Global Gross Profit Sharing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Beginning with the Calendar Quarter in which the Collaboration Timepoint occurs, with respect to each Presentation of Product, Roche Basel shall be entitled to the product of (i) &#91;* * *&#93; of the Global Gross Profit for such Presentation in such Calendar Quarter, multiplied by the Roche Production Contribution for such Presentation in such Calendar Quarter (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Global Gross Profit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (ii) Regeneron will be entitled to the remainder of the Global Gross Profit&#59; provided, that for the Calendar Quarter in which the Collaboration Timepoint occurs, for purposes of this Section 10.2 the amount of the Global Gross Profit for such Calendar Quarter shall be prorated based on the ratio of the number of days in such Calendar Quarter from and after the Collaboration Timepoint and the total number of days in such Calendar Quarter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Example&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) if prior to the &#91;* * *&#93;, Roche Basel has received all Regulatory Approvals necessary to manufacture Finished Product for commercial use in the EU but not the Regeneron Territory, Roche Basel may sell Product in the Roche Territory and, in the case of such sales, may retain &#91;* * *&#93; of the Global Gross Profit for the Roche Territory prior to the &#91;* * *&#93; (and shall provide &#91;* * *&#93; of such Global Gross Profits to Regeneron), &#91;* * *&#93;.  For clarity, Roche Basel shall not be entitled to share any of the Global Gross Profit in the Regeneron Territory until Roche Basel has received all Regulatory Approvals necessary to manufacture Finished Product for commercial use in the Regeneron Territory&#59; or  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b) if prior to the &#91;* * *&#93;, Roche Basel has received all Regulatory Approvals necessary to manufacture Finished Product for commercial use in the Regeneron Territory, but not the EU, &#91;* * *&#93;, then (i) Roche shall transfer such Product to Regeneron for sale in the Regeneron Territory by Regeneron in accordance with the allocation provided in Section 5.1 following the &#91;* * *&#93;, and Roche may, upon mutual agreement of the Parties, transfer additional Product to Regeneron for sale in the Regeneron Territory by Regeneron&#59; and (ii) the Parties shall share the Global Gross Profits for the Regeneron Territory as provided in the first paragraph of this Section 10.2&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 51 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) if prior to the &#91;* * *&#93;, Roche Basel has received all Regulatory Approvals necessary to manufacture Finished Product for commercial use (X) in the EU and the Regeneron Territory, or (Y) in the Regeneron Territory but not the EU, and in either case ((X) or (Y)), &#91;* * *&#93;, then Roche shall transfer such Product to Regeneron for sale in the Regeneron Territory by Regeneron in accordance with the allocation provided in Section 5.1 following the &#91;* * *&#93;, and in the case of clause (Y), Roche may, upon mutual agreement of the Parties, transfer additional Product to Regeneron for sale in the Regeneron Territory by Regeneron&#59; provided that, in either case ((X) or (Y)), &#91;* * *&#93;, (A) Regeneron may retain &#91;* * *&#93; of the Global Gross Profit for the sales of Products supplied by Roche in the Regeneron Territory &#91;* * *&#93; and (B) &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">10.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Disclosure of Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party acknowledges that the other Party may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as required under Applicable Law&#59; provided, however, that any such disclosure shall be subject to the provisions of Section 18.2. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Accounting and Reporting</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Mechanics and Timing of Payments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For Global Gross Profit payments, on a Presentation-by-Presentation basis, commencing with the first Calendar Quarter after the Collaboration Timepoint or any Interim Collaboration Timepoint in which a Party incurs Net Sales (a) within &#91;* * *&#93; after the end of each Calendar Quarter, such Party shall share with the other Party a good faith estimate of (i) such Party&#8217;s Net Sales of such Presentation, (ii) the units of such Presentation sold by or on behalf of such Party, its Affiliates and Sublicensees in such Calendar Quarter, (iii) the units of such Presentation sold by or on behalf of such Party, its Affiliates and Sublicensees in such Calendar Quarter for which the Drug Substance was manufactured by the Roche Group (which may be determined in accordance with Appendix 1.106, if applicable), (iv) &#91;* * *&#93;, and (v) the units of such Presentation distributed as &#91;* * *&#93;, in each case, by or on behalf of such Party, its Affiliates and Sublicensees in such Calendar Quarter&#59; and (b) as soon as practicable after the end of each such Calendar Quarter, but in any event no later than &#91;* * *&#93; after the end of each such Calendar Quarter, such Party shall share with the other Party the actual Net Sales in accordance with the foregoing subclause (i) and units dispersed in accordance with the foregoing subclauses (ii) - (v) of such Presentation, together with a calculation of such Party&#8217;s Gross Profit for such Presentation for such Calendar Quarter (each report described in this clause (b), a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gross Profit Interim Report</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Each Party shall have &#91;* * *&#93; after the delivery of the other Party&#8217;s Gross Profit Interim Report to review and ask questions. Within &#91;* * *&#93; following the end of such Calendar Quarter, each Party shall update its Gross Profit Interim Report to reflect the final amounts and the Parties shall coordinate to aggregate the final reports to calculate the total Global Gross Profit and Roche Global Gross Profit (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Global Gross Profit Final Report&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  The Party that owes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 52 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">payment to the other Party pursuant to the Global Gross Profit Final Report shall pay such amount within &#91;* * *&#93; after receipt of an invoice from the Party that is due payment.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For Co-Funded Study reimbursement and Co-Funded Device Development Activities reimbursement, respectively, the Parties shall share a good faith estimate of the applicable costs incurred, within &#91;* * *&#93; after the end of each Calendar Quarter in which such costs are incurred. As soon as practicable after the end of each such Calendar Quarter, but in any event no later than &#91;* * *&#93; after the end of each such Calendar Quarter, each Party shall share with the other Party &#91;* * *&#93; incurred by such Party (each, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Reconciliation Interim Report&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), together with reasonable supporting documentation for such &#91;* * *&#93;. Each Party shall have &#91;* * *&#93; after the delivery of the other Party&#8217;s Reconciliation Interim Report to review and ask questions. Within &#91;* * *&#93; following the end of such Calendar Quarter, each Party shall update its Reconciliation Interim Report to reflect the final amounts and the Parties shall coordinate to aggregate the reports to calculate the total amount to be reimbursed under this Agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Reconciliation Final Report&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  The Party that owes payment to the other Party pursuant to the Reconciliation Final Report shall pay such amount within &#91;* * *&#93; after receipt of an invoice from the Party that is due payment.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Unilateral Study for which reimbursement becomes due, within &#91;* * *&#93; after the Party that performed such Unilateral Study becomes aware that such reimbursement is due, such performing Party shall share with the other Party the &#91;* * *&#93; incurred by such conducting Party for such Unilateral Study (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unilateral Study Costs Report</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), together with reasonable supporting documentation for such &#91;* * *&#93;.  The non-performing Party shall have &#91;* * *&#93; after the delivery of the Unilateral Study Costs Report to review and ask questions. If the non-performing Party raises any questions to be addressed, the performing Party shall update its Unilateral Study Costs Report to reflect the final amounts within &#91;* * *&#93; after the delivery of the initial Unilateral Study Costs Report.  The non-performing Party shall pay the performing Party the applicable amount within &#91;* * *&#93; after receipt of an invoice from the performing Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any payments of Standard Costs for Product supplied by one Party to the other Party or for manufacturing services performed by one Party to the other Party under this Agreement shall be paid in accordance with Section 11.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any payment required to be made to Regeneron by Roche pursuant to this Section 11.1 or Section 11.5 shall be made by Roche Basel.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Late Payment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at a rate equal to &#91;* * *&#93; points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is overdue, unless such payment amount is reasonably disputed in good faith, in which case the amount payable after such dispute is resolved shall start to earn interest hereunder on the date such dispute is resolved. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 53 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Method of Payment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All amounts payable by one Party hereunder shall be paid by the other Party in Dollars (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment Currency</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by bank wire transfer in immediately available funds to account(s) designated by the other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Currency Conversion</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In those cases where the amount due in Dollars is calculated based upon one or more currencies other than Dollars, the Party converting such amounts to Dollars shall use their respective then-current internal foreign currency translation method actually used on a consistent basis in preparing its audited financial statements.  As of the Effective Date, the internal foreign currency translation method (a) for Roche, is to convert currencies other than Dollars or Swiss Francs to Swiss Francs and then to Dollars at the year-to-date average rate as reported by Reuters (or any successor thereto), and (b) for Regeneron, is to convert currencies other than Dollars to Dollars using the average of the daily spot rates (the Mid Price Close) found on Bloomberg (or any successor thereto).  Each Party shall promptly notify the other Party if there is any change to its then-current internal foreign currency translation method.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Reimbursement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For all amounts for which a Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Owing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is obligated to reimburse or pay the other Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Owed Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to this Agreement or the Technology Transfer Agreement, for which no specific provision is provided hereunder or thereunder regarding how such payment shall be made, or any payments under Section 4.2(c), the Owed Party shall send to the Owing Party an invoice for such amount within &#91;* * *&#93; after the Owed Party&#8217;s determination that such amount is payable by the Owing Party, which invoice shall include a reference to the section of this Agreement under which the Owed Party is requesting reimbursement or payment and be accompanied by reasonable documentation of the incurrence or accrual of the costs to be reimbursed.  Payment with respect to each such invoice shall be due within &#91;* * *&#93; after receipt by the Owing Party thereof and shall be made in accordance with Section 11.3 and Section 11.4. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">11.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Payment Disputes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any payment obligations under this Agreement, if the Owing Party in good faith disputes any portion of any such payment, it shall pay the undisputed portion and shall provide the Owed Party with written notice of the disputed portion and its reasons therefor, and the Owing Party shall not be obligated to pay such disputed portion unless and until such dispute is resolved in favor of the Owed Party.  The Parties shall use good faith efforts to resolve any such disputes promptly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Taxes </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Certain Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments accruing or made to Regeneron under this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 54 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments accruing or made to Roche under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Withholding Taxes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If provision is made in law or regulation of any country for withholding or deduction of taxes of any type, levies or other charges with respect to any amounts payable under this Agreement to Regeneron or Roche, then Roche or Regeneron (as applicable) shall be entitled to withhold or deduct the amount of such taxes, levies, or other charges from such amount payable and shall promptly pay such tax, levy or charge for and on behalf of Regeneron or Roche (as applicable) to the proper governmental authority, and shall promptly furnish Regeneron or Roche (as applicable) with receipt of payment. Roche or Regeneron (as applicable) shall be entitled to deduct any such tax, levy or charge actually paid from payment due Regeneron or Roche (as applicable) or be promptly reimbursed by Regeneron or Roche (as applicable) if no further payments are due to Regeneron or Roche (as applicable). Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted. Any amounts deducted and withheld from any payment to a Party pursuant to this Section 12.2 shall be treated as having been paid to such Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">FDII Documentation </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent applicable and reasonably requested by Regeneron, Roche shall use commercially reasonable efforts to provide Regeneron with any documentation or other certifications required pursuant to Section&#160;250(b) of the Code, and any regulations or other guidance promulgated thereunder necessary for any payments made to Regeneron pursuant to this Agreement to qualify as &#8220;foreign-derived deduction eligible income&#8221; within the meaning of Section&#160;250(b)(4) of the Code. Regeneron shall reimburse Roche for all reasonable out-of-pocket costs incurred by Roche in connection with providing such documentation or other certification to Regeneron. The Parties intend that Regeneron shall be entitled to any deduction under Section 250(b) of the Code for which Regeneron is eligible with respect to the remainder of the Global Gross Profit under Section 10.2, and this Agreement shall be interpreted accordingly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Auditing</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Right to Audit</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall keep, and shall require its Affiliates and its and their Sublicensees, if any, to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all payments payable under this Agreement (e.g. the Parties&#8217; calculation of Standard Costs). Such books of accounts shall be kept at such Party&#8217;s, Affiliate&#8217;s or Sublicensee&#8217;s, as applicable, principal place of business. At the expense of the auditing Party, the auditing Party shall have the right, in accordance with the remainder of this Section 13.1, Section 13.2 and Section 13.3, to engage an internationally recognized independent public accountant reasonably acceptable to the audited Party to perform, on behalf of the auditing Party, an audit of such books and records of the audited Party and its Affiliates and its and their Sublicensees that are deemed necessary by the independent public accountant to report on the correctness of any financial report or payments made under this Agreement for the period or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 55 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">periods requested by the auditing Party.  The Parties shall cause such accountant to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such accountant to retain all such financial information in confidence pursuant to terms no less stringent than those set forth in Article 18.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon timely request and at least &#91;* * *&#93; prior written notice from the auditing Party, such audit shall be conducted for those countries the auditing Party has specifically requested, during regular business hours in such a manner as to not unnecessarily interfere with the audited Party&#8217;s normal business activities. Such audit shall be limited to books and records with respect to the &#91;* * *&#93; Calendar Years prior to audit notification, and if the auditing Party requests an audit for a country for a given Calendar Year, no additional audits may be conducted for such country for such Calendar Year unless a material discrepancy is found in such audit. If auditing Party does not request an audit for a given Calendar Year on or before the &#91;* * *&#93; anniversary of the end of such Calendar Year, then the auditing Party shall no longer have the right to conduct an audit for such Calendar Year under this Section 13.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such audit for a country shall not be performed more frequently than once per Calendar Year nor more frequently than once with respect to records covering any specific country for any specific period of time unless a material discrepancy is found in such audit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All books of accounts herein referred and any information contained therein shall be (a) used by the auditing Party only for the purpose of verifying payments and reports hereunder and (b) treated as the audited Party&#8217;s Confidential Information subject to the obligations of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Audit Reports</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The auditors shall only state factual findings in the audit reports and shall not interpret this Agreement. The auditors shall share all draft audit findings with the audited Party before sharing such findings with the auditing Party and before the final audit report is issued and shall remove any information reasonably identified by the audited Party as being confidential or competitively sensitive or proprietary information.  The final audit report shall be shared with the audited Party at the same time it is shared with the auditing Party.  The auditors shall not reveal to the auditing Party the details of its review, except for the findings of such review and such information as is required to be disclosed under this Agreement.  The results of any such audit shall be final and binding upon the Parties, unless disputed by a Party within &#91;* * *&#93; of delivery.  Notwithstanding any other provision of this Agreement to the contrary, the obligation to pay any amount based on a disputed audit shall not be deemed to have been triggered until such dispute is resolved hereunder&#59; provided that all amounts that are not in dispute shall be paid in accordance with the provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Over-or Underpayment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the audit reveals an overpayment, the overpaid Party shall reimburse the other Party for the amount of the overpayment within &#91;* * *&#93; (and, if such overpayment was made due to an error in an invoice or report provided by such overpaid Party, with interest thereon as provided in Section 11.2). If the audit reveals an underpayment, the underpaying Party shall reimburse the other Party for the amount of the underpayment within &#91;* * *&#93; (and, if such additional amounts are owed due to an error in an invoice or report provided by such underpaying Party, with interest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 56 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereon as provided in Section 11.2). The audited Party shall reimburse the auditing Party for the audit costs if the cumulative discrepancy of amounts reported or paid during the applicable audited period exceeds &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Intellectual Property</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Ownership of Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing in this Agreement shall affect the ownership of any Patent Rights, know-how or other intellectual property, in each case, developed prior to the Effective Date or independent of this Agreement, including, for clarity, Roche Independent IP.  Regeneron shall own all Regeneron Inventions and all Patent Rights and other intellectual property rights that Cover the Regeneron Inventions.  Roche shall own all Roche Inventions and all Patent Rights and other intellectual property rights that Cover the Roche Inventions. Regeneron and Roche shall jointly own all Joint Inventions and Joint Patent Rights.  Regeneron and Roche each shall require, and shall cause its respective Affiliates to require (a) all of its (or its Affiliates&#8217;) employees and consultants to assign all inventions related to Compounds or Products made by them to Roche or Regeneron (or such Affiliate), as the case may be and (b) all other persons or entities who perform any activities for or on behalf of such Party to assign (or, if such Party is unable to cause such person or entity to agree to such assignment obligation despite such Party&#8217;s using Commercially Reasonable Efforts to negotiate such assignment obligation, provide an exclusive license under) their rights in any such Inventions or Patent Rights to such Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall promptly disclose to the other Party in writing, the discovery, development or creation of any Invention made solely or jointly by or on behalf of such Party, any of its Affiliates, or, if applicable, Sublicensees in connection with the performance of obligations under this Agreement. Each Party shall promptly disclose to the other and shall cause its Affiliates and Sublicensees to disclose any Know-How made solely or jointly by or on behalf of such Party or any of its Affiliates or Sublicensees in connection with the performance of obligations under this Agreement that constitutes an improvement to the process of manufacturing the Compounds or Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The determination of inventorship for Inventions shall be in accordance with US inventorship laws as if such Inventions were made in the US.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the licenses granted under this Agreement and Roche&#8217;s obligation under Article 9, Regeneron and Roche will each have an equal undivided share in the Joint Patent Rights, without obligation to account to the other for exploitation thereof, or to seek consent of the other Party for the grant of any license thereunder. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as specifically set forth herein, this Agreement shall not be construed as (i)&#160;giving either of the Parties any license, right, title, interest in or ownership to the Confidential Information of the other Party&#59; (ii)&#160;granting any license or right under any intellectual property rights&#59; or (iii)&#160;representing any commitment by either Party to enter into any additional agreement, by implication or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to Know-How (other than Inventions) generated pursuant to this Agreement, (a) Regeneron shall own such Know-How (i) generated by or on behalf of Regeneron or any of its Affiliates or Sublicensees solely or jointly with a Third Party or (ii) generated by or on behalf of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 57 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Roche Group solely or jointly with Regeneron or any of its Affiliates or a Third Party that is specifically related to any Product (including the composition of, formulations containing, any methods of using, or the manufacture of, a Product) ((i) and (ii) together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arising Regeneron Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (b) Roche shall own such Know-How generated by or on behalf of the Roche Group solely or jointly with a Third Party, excluding any Arising Regeneron Know-How, and (c) the Parties shall jointly own any Joint Know-How.  For clarity, Arising Regeneron Know-How shall not include any Roche Independent IP or any Know-How of general applicability to antibody products and not specific to the Product.  For example, Know-How that can be applied to purification of antibodies generally but not specific to manufacturing of a Compound or Product shall not be considered Arising Regeneron Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall, and does hereby, assign, and shall cause its Affiliates and its and their Sublicensees, as applicable, to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Inventions, Know-How, Patent Rights or other intellectual property rights as is necessary to fully effect, as applicable, the sole or joint ownership provided for in this Section 14.1.  Pursuant to Section 21.18, each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such applications, approvals, assignments, agreements, documents, and instruments, and shall provide any additional consents, as may be necessary or as the other Party may reasonably request for a Party to perfect or exercise its rights provided for in this Section 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche here grants Regeneron a non-exclusive, worldwide, royalty-free, perpetual, irrevocable, transferable, sublicensable (through multiple tiers) license under any Arising Roche Manufacturing IP for any and all purposes.  &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arising Roche Manufacturing IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Inventions, Know-How, Patent Rights and other intellectual property rights arising under this Agreement generated by or on behalf of the Roche Group solely or jointly with Regeneron or any of its Affiliates or a Third Party that is related to Regeneron&#8217;s manufacturing process for a Product and that does not constitute Arising Regeneron Invention, Arising Regeneron Know-How or a Patent Right that Covers any Arising Regeneron Invention or Arising Regeneron Know-How (which Patent Rights, for clarity, shall be owned by Regeneron). For clarity, Roche shall own any Arising Roche Manufacturing IP.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Inventions Made by Employees, Subcontractors and Services Providers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with any Applicable Law regarding employee&#8217;s inventions, each Party agrees to claim the ownership or exclusive and unlimited use of any Invention conceived, reduced to practice, developed, made or created in the performance of, or as a result of, any activities under or in connection with this Agreement by employees of such Party or its applicable Affiliates. For the avoidance of doubt, each Party, or its Affiliates (as applicable) is responsible for fulfilling the obligations towards its or their respective employees under any Applicable Law providing for compensation to employees for inventions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall, and shall cause its Affiliates and Sublicensees to, obtain an assignment from subcontractors or service providers to such Party or its applicable Affiliates or Sublicensees of all Inventions related to a Product made by such individuals during the course of and as a result of their performance under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 58 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Trademarks and Labeling</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the right and responsibility to create, select and obtain the International Non-proprietary Name (INN) from the World Health Organization and the US Adopted Name (USAN) from the US Adopted Names Council (USANC) as the generic name(s) for the Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The JOC shall select one or more global trademark(s) for use on the Product in the Territory, including any accompanying logos, slogans, trade names, domain names, trade dress or other indicia of origin, excluding the corporate names and logos of either Party  (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Global Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  If, under Applicable Law, none of the Global Trademarks for a Product can be used for the commercialization of such Product in a country in the Roche Territory, the JOC shall discuss and select one (1) or more alternative trademarks, including any accompanying logos, slogans, trade names, domain names, trade dress or other indicia of origin, for the commercialization of such Product in such country (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alternative Product Trademark</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that if the Parties are unable to agree on such Alternative Product Trademarks, the JOC shall have the right to select such Alternative Product Trademarks.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall own all Global Trademarks in the Regeneron Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of all Global Trademarks in the Regeneron Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall own all Global Trademarks and, if applicable, Alternative Product Trademarks, in the Roche Territory, and shall, at its sole cost, be responsible for procurement, maintenance, enforcement and defense of Global Trademarks and if applicable, Alternative Product Trademarks, in the Roche Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall keep the other Party reasonably informed regarding any material, substantive issue or any opposition, cancellation, invalidity or other proceeding that may be raised or asserted against any application or registration for a Global Trademark, or, with respect to Roche if applicable, Alternative Product Trademark in its Respective Territory. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party and its Affiliates and its and their Sublicensees shall not license (or, as applicable, sublicense) rights to use, or otherwise transfer ownership of the Global Trademark(s) or, if applicable with respect to Roche, Alternative Product Trademarks, without the prior written consent of the other Party except with respect to any manufacturing or development activities permitted hereunder.  Each Party and its Affiliates and its and their Sublicensees shall only utilize the Global Trademark(s) or, if applicable with respect to Roche, Alternative Product Trademarks, on materials related to the Products in its Respective Territory (including package inserts, packaging, trade packaging, internet pages, social media, advertising and promotional materials used or distributed in connection with the Products).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party agrees that at no time during the Agreement Term will it or any of its Affiliates attempt to use or register in its Respective Territory any trademarks, trade dress, service marks, trade names or domain names confusingly similar to any Global Trademark or, if applicable with respect to Roche, any Alternative Product Trademark, in relation to a product that is not a Product, or take any other action that damages or dilutes the rights to, or goodwill associated with, any Global Trademark or, if applicable with respect to Roche, any Alternative Product Trademark. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 59 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All use of the Global Trademarks and Alternative Product Trademarks, as applicable, by a Party or its Affiliates or Sublicensees, or, where applicable, its or their distributors, shall be in accordance with (a) rules established by the JOC, if any, and (b) quality standards established by the respective trademark owner, in each case ((a) or (b)), that are reasonably necessary in order to preserve the validity and enforceability of the Global Trademarks and Alternative Product Trademarks, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Use of Corporate Names. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall not, and shall cause its Affiliates and Sublicensees not to, include Regeneron&#8217;s name on materials related to the Products in the Roche Territory (including package inserts, packaging, trade packaging, internet pages, social media, advertising and promotional materials used or distributed in connection with the Products), unless (a) with respect to packaging for the Products (including package inserts, packaging and trade packaging for the Products) requested by Regeneron in writing (unless it is commercially unreasonable to do so, or prohibited by Applicable Law) or required under Applicable Law, or (b) with respect to other materials related to the Products (including internet pages, social media, advertising and promotional materials used or distributed in connection with the Products) upon mutual agreement by the Parties or required under Applicable Law, in which case ((a) or (b)), Regeneron&#8217;s name shall have equal prominence with Roche&#8217;s name on such materials.  Regeneron hereby grants to Roche Basel the right (which right may be sublicensed to Roche Basel&#8217;s Affiliates and Sublicensees), free of charge, to use Regeneron&#8217;s name and logo on package inserts, packaging, trade packaging, internet pages, social media and all promotional materials used or distributed in connection with the Products in the Roche Territory during the Agreement Term, in each case, only to the extent pursuant to subclause (a) or (b) in this paragraph.  During the Agreement Term, Roche shall submit samples of each such package inserts, packaging, trade packaging, internet pages, social media and all promotional materials using Regeneron&#8217;s name or logo to Regeneron for approval in accordance with the review and approval process established below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall not, and shall cause its Affiliates and Sublicensees not to, include Roche&#8217;s name on materials related to the Products in the Regeneron Territory (including package inserts, packaging, trade packaging, internet pages, social media, advertising and promotional materials used or distributed in connection with the Products), unless (i) with respect to packaging for the Products (including package inserts, packaging and trade packaging for the Products) requested by Roche in writing (unless it is commercially unreasonable to do so, or prohibited by Applicable Law) or required under Applicable Law, or (ii) with respect to other materials related to the Products (including internet pages, social media, advertising and promotional materials used or distributed in connection with the Products) upon mutual agreement by the Parties or required under Applicable Law, in which case ((i) or (ii)), Roche&#8217;s name shall have equal prominence with Regeneron&#8217;s name on such materials.  Roche hereby grants to Regeneron the right (which right may be sublicensed to Regeneron&#8217;s Affiliates and Sublicensees), free of charge, to use Roche&#8217;s name and logo on package inserts, packaging, trade packaging, internet pages, social media and all promotional materials used or distributed in connection with the Products in the Regeneron Territory during the Agreement Term, in each case, only to the extent pursuant to subclause (i) or (ii) in this paragraph.  During the Agreement Term, Regeneron shall submit samples of each such package inserts, packaging and trade packaging, internet pages, social media and all promotional materials using Roche&#8217;s name or logo to Roche for approval in accordance with the review and approval process established below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 60 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promptly following the Effective Date, the Parties shall discuss in good faith and establish guidelines and an expedited review and approval process regarding the use of each Party&#8217;s name on material related to the Products. During the Agreement Term, if a Party&#8217;s name is included on materials related to the Product in the other Party&#8217;s Respective Territory in accordance with the terms hereunder, the other Party shall comply with the applicable use guideline with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as expressly provided herein, no right, express or implied, is granted by this Agreement to use in any manner the name of the other Party or its Affiliates or any other trade name, symbol, logo or trademark of the other Party or its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Prosecution of Product Patent Rights in the Regeneron Patent Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the sole right, but not the obligation, to Handle all Product Patent Rights in the Regeneron Patent Territory.  The Parties shall share &#91;* * *&#93; all of Regeneron&#8217;s &#91;* * *&#93; incurred with respect to Handling the Product Patent Rights in the Regeneron Patent Territory.  Regeneron shall use good faith efforts to notify Roche Basel of filing of any provisional or utility application for any Product Patent Right in the Regeneron Patent Territory, if practicable, and shall notify Roche Basel of filing of any application under the Patent Cooperation Treaty for any Product Patent Right.  At Regeneron&#8217;s reasonable request, Roche Basel shall cooperate, in all reasonable ways with the Handling of all Product Patent Rights in the Regeneron Patent Territory.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Prosecution of Product Patent Rights in the Roche Territory and Joint Patent Rights in the Territory</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the first right, but not the obligation, to Handle all Product Patent Rights in the Roche Territory and all Joint Patent Rights in the Territory.  Regeneron shall promptly inform Roche Basel of all material steps with regard to the Handling of such Patent Rights, including by providing Roche Basel with a copy of material communications to and from the applicable patent authorities regarding such Patent Rights.  Regeneron shall provide Roche Basel drafts of any material filings or responses to be made to such patent authorities sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for Roche Basel to review and comment thereon, and Regeneron shall consider in good faith the requests and suggestions of Roche Basel with respect to such drafts and with respect to strategies for filing and prosecuting such Patent Rights.  At Regeneron&#8217;s reasonable request, Roche Basel shall cooperate, in all reasonable ways with the Handling of all Product Patent Rights in the Regeneron Patent Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron determines to abandon any Product Patent Right in the Roche Territory or Joint Patent Right in the Territory then, prior to such abandonment, Regeneron shall offer such Patent Right to Roche Basel to Handle, subject to the following&#58; Roche Basel&#8217;s Handling of such Patent Right must be consistent with Regeneron&#8217;s global patent strategy for the Products.  Roche Basel shall promptly inform Regeneron of all material steps with regard to the Handling of such Patent Rights, including by providing Regeneron with a copy of material communications to and from the applicable patent authorities regarding such Patent Right.  Roche Basel shall provide Regeneron drafts of any material filings or responses to be made to such patent authorities sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for Regeneron to review and comment thereon, and Roche Basel shall consider in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 61 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">good faith the requests and suggestions of Regeneron with respect to such drafts and with respect to strategies for filing and prosecuting any such Patent Right&#59; provided that if Regeneron determines that any proposed actions by Roche Basel with respect to any such Patent Right would reasonably be expected to have a negative impact on the global patent portfolio for the Products, then Roche Basel must implement Regeneron&#8217;s comments with respect to any such actions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties shall share &#91;* * *&#93; all of the Handling Party&#8217;s &#91;* * *&#93; incurred with respect to Handling the Product Patent Rights in the Roche Territory and the Joint Patent Rights in the Territory&#59; provided that, with respect to each Joint Patent Right, the non-Handling Party for such Joint Patent Right may elect, upon written notice to the Handling Party for such Joint Patent Right to no longer share the Handling Party&#8217;s &#91;* * *&#93; and expenses incurred for such Joint Patent Right, in which case the non-Handling Party shall assign all of its right, title and interest in and to such Joint Patent Right to the Handling Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Handling of Other Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche Basel shall, at its own expense and discretion, have the sole right, but not the obligation, to Handle (including abandon) all Roche Patent Rights and Regeneron, shall, at its own expense and discretion, have the sole right, but not the obligation, to Handle (including abandon) all Regeneron Patent Rights that are not Product Patent Rights, in each case, without any coordination with, or notice to, the other Party.  At the Handling Party&#8217;s reasonable request, the other Party shall cooperate, in all reasonable ways, with the Handling of the Patent Rights described in this Section 14.7. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Coordination&#59; No Invention Overlap</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Parties need to consult with each other on the Handling of Patent Rights, the Parties may establish a patent coordination team by mutual agreement and shall adopt procedures for interacting on patent matters. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Party Handling the Regeneron Patent Rights shall ensure that, unless otherwise agreed by the Parties in writing, no Patent Right that Covers a Regeneron Invention also Covers a Roche Invention or a Joint Invention.  The Party Handling the Roche Patent Patents shall ensure that, unless otherwise agreed by the Parties in writing, no Patent Right that Covers a Roche Invention also Covers a Regeneron Invention or a Joint Invention.  The Party Handling the Joint Patent Rights shall ensure that, unless otherwise agreed by the Parties in writing, no Patent Right that Covers a Joint Invention also Covers a Regeneron Invention or a Roche Invention.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Unified Patent Court (Europe)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At any time prior to the end of the &#8220;transitional period&#8221; as such term is used in Article&#160;83 of the Agreement on a Unified Patent Court between the participating Member States of the European Union, Regeneron shall have the sole right to make decisions regarding whether, for a given relevant Product Patent Right or Joint Patent Right in the European Union, to (i)&#160;opt out from the exclusive competence of the Unified Patent Court or (ii)&#160;if applicable, withdraw a previously-registered opt-out, and Regeneron shall so notify the Registry of the Unified Patent Court in the manner specified by Rule 5 of the Rules of Procedure of the Unified Patent Court, pay any such registry fee and take such other action as may be necessary to effect the opt-out or opt-out </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 62 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">withdrawal (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Register</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The costs to Register shall be shared in the same manner as the Handling costs are shared for the applicable Patent Right. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">CREATE Act </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that either Party to this Agreement intends to overcome a rejection of a claimed Invention pursuant to the provisions of 35&#160;USC&#160;&#167;&#167;&#160;102(a)-(d), such Party shall first obtain the prior written consent of the other Party.&#160; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Infringement of Product Patent Rights and Joint Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (i)&#160;known infringement or suspected infringement by a Third Party of any Product Patent Right or Joint Patent Rights, or (ii)&#160;known or suspected unauthorized use or misappropriation by a Third Party of any Product Know-How or Joint Know-How ((i) and (ii) collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and shall provide the other Party with all information in its possession supporting such Infringement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the sole right, but not the obligation, to initiate a suit or action regarding any Regeneron Controlled Infringement, including to settle any such suit or action.  Regeneron shall use good faith efforts to notify Roche Basel of any material progress in connection with any such suit or action.  At Regeneron&#8217;s written request, Roche Basel shall offer reasonable assistance to Regeneron in connection any such suit or action at no charge to Regeneron except for reimbursement &#91;* * *&#93; incurred by Roche in rendering such assistance (&#91;* * *&#93;). The Parties will &#91;* * *&#93; of Regeneron&#8217;s &#91;* * *&#93; in connection with any suit or action with respect to any Regeneron Controlled Infringement as follows&#58; &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the first right, but not the obligation, to initiate a suit or action regarding any Roche Shared Infringement.  Within&#91;* * *&#93; after Regeneron provides or receives written notice of any Roche Shared Infringement (such &#91;* * *&#93; period, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enforcement Decision Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Regeneron, in its sole discretion, shall decide whether or not to initiate a suit or action regarding such Roche Shared Infringement and shall notify Roche of its decision in writing (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enforcement Suit Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  If Regeneron decides to bring a suit or take action with respect to any Roche Shared Infringement, once Regeneron provides the applicable Enforcement Suit Notice, Regeneron may immediately commence such suit or take such action. In the event that Regeneron (i)&#160;does not in writing advise Roche Basel within the Enforcement Decision Period that Regeneron will commence suit or take action with respect to a Roche Shared Infringement, or (ii)&#160;fails to commence suit or take action within a reasonable time after providing the applicable Enforcement Suit Notice, Roche shall thereafter have the right (subject to Regeneron&#8217;s written consent, not to be unreasonably conditioned, withheld or delayed) to commence suit or take action with respect to such Roche Shared Infringement and shall provide written notice to Regeneron of any such suit commenced or action taken by Roche. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Party bringing suit or taking action with respect to any Roche Shared Infringement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Initiating Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall keep the other Party reasonably informed of the progress of such suit or action and shall provide the other Party with advance copies, to the extent the Initiating Party is lawfully permitted to do so, of all material documents or communications to be filed or positions to be taken in such suit or action and will consider the other Party&#8217;s comments with respect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 63 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereto in good faith. The Initiating Party shall have the sole and exclusive right to select counsel for any such suit or action.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron is the Initiating Party with respect to any suit or action with respect to any Roche Shared Infringement, the Parties will &#91;* * *&#93; of Regeneron&#8217;s &#91;* * *&#93; in connection with such suit or action &#91;* * *&#93;.  If Roche Basel is the Initiating Party with respect to any suit or action with respect to any Roche Shared Infringement, the Parties will &#91;* * *&#93; of Roche Basel&#8217;s &#91;* * *&#93; in connection with such suit or action as follows&#58; &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise agreed by the Parties, all monies recovered upon the final judgment or settlement of any action with respect to any Regeneron Controlled Infringement or Roche Shared Infringement shall be used as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">First, (i) with respect any Regeneron Controlled Infringement, to reimburse each Party for its share of Regeneron&#8217;s &#91;* * *&#93; associated with such action and (ii) with respect to any Roche Shared Infringement, to reimburse each Party for its share of the Initiating Party&#8217;s &#91;* * *&#93; associated with such action&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Second, any remaining amount shall be retained by or paid to (i) with respect any Regeneron Controlled Infringement, Regeneron and (ii) with respect to any Roche Shared Infringement, the Initiating Party&#59; provided, however, any such amount shall constitute Global Gross Profit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Initiating Party believes it is reasonably necessary or desirable to obtain an effective remedy for the other Party to be joined as a party to the applicable suit or action, upon written request the other Party agrees to be joined as a party to such suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At the Initiating Party&#8217;s written request, the other Party shall offer reasonable assistance to the Initiating Party in connection therewith at no charge to the Initiating Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance (which shall then be subject to same reimbursement provisions as the out-of-pocket costs of the Initiating Party). The other Party shall have the right to participate and be represented in any such suit or action by its own counsel at its own expense.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Initiating Party may settle, consent to a judgment or otherwise voluntarily dispose of any Roche Shared Infringement suit or action (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Settlement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) without the written consent of the other Party&#59; provided, that, Roche, as the Initiating Party, shall not admit non-infringement or grant a license or other right, including any covenant not to sue, with respect to any Product Patent Right, Product Know-How, Joint Patent Rights or Joint Know-How or otherwise settle in a manner that would reasonably be expected to have a negative impact on a Product or the global patent portfolio for the Products, or on the employees of Regeneron or on Regeneron&#8217;s reputation, in each case, without Regeneron&#8217;s consent.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall, at its own cost and expense, have the sole right, but not the obligation, to decide whether or not to initiate (or settle) any suit or action in the Territory with respect to any (i) known infringement or suspected infringement by a Third Party of any Roche Patent Right, or (ii)&#160;known or suspected unauthorized use or misappropriation by a Third Party of any Roche Know-How in each case, without any coordination with, or notice to, Regeneron.  Regeneron, shall, at its own </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 64 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">costs and expense, have the sole right, to decide whether or not to initiate (or settle) any suit or action in the Territory with respect to any&#160;(iii) known infringement or suspected infringement by a Third Party of any Regeneron Patent Rights that are not Product Patent Rights, or (iv)&#160;known or suspected unauthorized use or misappropriation by a Third Party of any Regeneron Know-How that is not Product Know-How, in each case, without any coordination with, or notice to, Roche.  Each Party, shall, at its own costs and expense, have the sole right, to decide whether or not to initiate (or settle) any suit or action in the Territory with respect to any&#160;(v) known infringement or suspected infringement by a Third Party of any Joint Patent Rights, or (vi)&#160;known or suspected unauthorized use or misappropriation by a Third Party of any Joint Know-How, in each case ((v) and (vi)), that is not Competitive Infringement, without any coordination with, or notice to, the other Party. The Party initiating any suit or action pursuant to this paragraph shall retain all monies recovered upon the final judgment or settlement of any action.  With respect to any suit or action initiated pursuant to this paragraph, at the acting Party&#8217;s written request, the other Party shall offer reasonable assistance to the acting Party in connection therewith at no charge to the acting Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt"> Invalidity or Unenforceability Defenses or Actions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any of the Product Patent Rights or Joint Patents Rights by a Third Party of which such Party becomes aware. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the sole right, but not the obligation, to defend and control the defense of the validity and enforceability of the Product Patent Rights in the Regeneron Patent Territory.  The Parties shall share &#91;* * *&#93; all of Regeneron&#8217;s &#91;* * *&#93; incurred with respect to defending the Product Patent Rights in the Regeneron Patent Territory.  Regeneron shall use good faith efforts to notify Roche of any material steps taken in connection with defending the Product Patent Rights in the Regeneron Patent Territory. At Regeneron&#8217;s written request, Roche shall offer reasonable assistance to Regeneron in connection with defending the Product Patent Rights in the Regeneron Patent Territory at no charge to Regeneron except for reimbursement of reasonable out-of-pocket expenses incurred by Roche in rendering such assistance (which shall then be subject to same reimbursement provisions as the out-of-pocket costs of Regeneron).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the first right, but not the obligation, to defend and control the defense of the validity and enforceability of the Product Patent Rights in the Roche Territory and the Joint Patent Rights in the Territory (such Patent Rights, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche-Shared Defense Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Within &#91;* * *&#93; after Regeneron provides or receives written notice of any alleged or threatened assertion of invalidity or unenforceability of any of the Roche-Shared Defense Patents (such &#91;* * *&#93; period, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Defense Decision Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Regeneron, in its sole discretion, shall decide whether or not to defend and control the defense of the validity and enforceability of such Roche-Shared Defense Patents and shall notify Roche of its decision in writing (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Defense Suit Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  If Regeneron decides to defend and control the defense of the validity and enforceability of such Roche- Shared Defense Patents, once Regeneron provides the applicable Defense Suit Notice, Regeneron may immediately commence such defense. In the event that Regeneron (i) does not in writing advise Roche within the Defense Decision Period that Regeneron will defend and control the defense of an Roche-Shared Defense Patent, or (ii) fails to commence the defense of such Roche-Shared Defense Patent within a reasonable time after providing the applicable Defense Suit Notice, Roche shall thereafter have the right (subject to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 65 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron&#8217;s written consent, not to be unreasonably conditioned, withheld or delayed) to defend and control the defense of such Roche-Shared Defense Patent and shall provide written notice to Regeneron of any such defense taken by Roche. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Party defending and controlling the defense with respect to any Roche-Shared Defense Patent (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Defending Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall keep the other Party reasonably informed of the progress of such suit or action and shall provide the other Party with advance copies, to the extent the Defending Party is lawfully permitted to do so, of all material documents or communications to be filed or positions to be taken in such suit or action and will consider the other Party&#8217;s comments with respect thereto in good faith&#59; provided, that, with respect to Roche as the Defending Party, if Regeneron determines that any proposed actions by Roche with respect to such defense would reasonably be expected to have a negative impact on the global patent portfolio for the Products, then Roche must implement Regeneron&#8217;s comments with respect to any such actions. The Defending Party shall have the sole and exclusive right to select counsel for any such suit or action.  At the Defending Party&#8217;s written request, the other Party shall offer reasonable assistance to the Defending Party in connection with defending the Roche-Shared Defense Patents at no charge to the Defending Party except for reimbursement of reasonable out-of-pocket expenses incurred by the other Party in rendering such assistance (which shall then be subject to same reimbursement provisions as the out-of-pocket costs of the Defending Party).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron is the Defending Party with respect to any Roche-Shared Defense Patent, the Parties will share all of Regeneron&#8217;s &#91;* * *&#93; in connection with such defense &#91;* * *&#93;.  If Roche is the Defending Party with respect to any Roche-Shared Defense Patent, the Parties will share all of Roche&#8217;s &#91;* * *&#93; in connection with such suit or action as follows&#58; &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Defense</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If an action for infringement is commenced against either Party, its Affiliates or its licensees or its sublicensees (including Sublicensees) related to the discovery, development (including the conduct of the Co-Funded Development Plan), manufacture, use or sale of a Product (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Party Infringement Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then, subject to Article 16, the following shall apply&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt"> The Party (or its Affiliate, licensee or sublicensee, as applicable) who is named as the defendant shall have the right (but not the obligation) to defend such Third Party Infringement Action at its own expense&#59; provided, however,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that if a Third Party Infringement Action is commenced against both Regeneron (or any of its Affiliates, licensees or sublicensees), on the one hand, and Roche (or any of its Affiliates, licensees or Sublicensees), on the other hand (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Joint Infringement Action</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then Regeneron shall have the first right, but not the obligation, to conduct and control the defense of such Third Party Infringement Action, using counsel of its own choice.  Roche shall assist and cooperate with Regeneron, at Regeneron&#8217;s expense, to the extent necessary in the defense of such suit.  If Regeneron elects not to defend or control the defense of, or otherwise fails to initiate and maintain the defense of, any such Joint Infringement Action, Regeneron shall notify Roche of such election within such time periods so Roche is not prejudiced by any delays, and Roche shall have the right (but not the obligation), to conduct and control the defense of such Joint Infringement Action using counsel of its own choice.  The Parties will share the &#91;* * *&#93; of the controlling Party in defense of a Joint Infringement Action as follows&#58; &#91;* * *&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 66 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The Party entitled to defend any Third Party Infringement Action shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion&#59; provided, that Roche shall not enter into any settlement of any Third Party Infringement Action that &#91;* * *&#93; in each case ((i) - (iii)), without Regeneron&#8217;s prior written consent in its sole discretion, and provided, that Regeneron shall not enter into any settlement of any Third Party Infringement Action that &#91;* * *&#93; in each case ((iv) and (v)), without Roche&#8217;s prior written consent in its sole discretion.  Unless otherwise agreed by the Parties, with respect any settlement of a Third Party Infringement Action, the Parties shall share responsibility for the payment of any award for damages, or any amount due pursuant to such settlement as follows&#58; to the extent that such settlement is with respect to the Regeneron Territory, &#91;* * *&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each Party will provide the other Party with prompt written notice of the commencement of any proceedings under this Section 14.13 and such Party will keep the other Party reasonably informed of all material developments in connection with any such Third Party Infringement Action, including by promptly furnish the other Party with a copy of all documents or communications filed in such action.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Common Interest Disclosures</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the Co-Funded Development Plan or Compounds or Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of the Co-Funded Development Plan or Compounds or Products. Accordingly, any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property or technology owned by Third Parties will be used solely for purposes of the Parties&#8217; common legal interests with respect to the conduct of this Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#8217;s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party. Notwithstanding the foregoing, neither Party&#8217;s attorney represents the other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Biosimilars</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything herein to the contrary, if either Party receives notice or a copy of an application submitted to a Regulatory Authority in the Territory for a Biosimilar Product or similar notice or communication pursuant to which a product is claimed to be interchangeable with a Product, whether or not such notice or copy is provided under any Applicable Law, or otherwise becomes aware that such an application, notice or communication has been submitted to a Regulatory Authority in the Territory for approval, such Party shall notify and provide the other Party copies of such application, notice, communication and any other relevant information to the extent permitted by Applicable Law.  The Parties shall cooperate in good faith with one another with respect to the foregoing, including with respect to proceedings related thereto, in a manner consistent with the rights and obligations of the Parties set forth in Section 14.11, Section 14.12 or Section 14.13, as applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 67 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Patent Term Extensions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Patent Term Extensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all available patent term extensions, adjustments or restorations, or supplementary protection certificates. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall have the sole right, but not the obligation, to file for Patent Term Extensions with respect to the Products in the Regeneron Patent Territory.  The Parties will share all of Regeneron&#8217;s &#91;* * *&#93; for such Patent Term Extensions &#91;* * *&#93;.  Roche shall have the sole right, but not the obligation, to file for Patent Term Extensions, including Supplementary Protection Certifications, with respect to the Products in the Roche Territory&#59; provided, that if filing for any such Patent Term Extension would reasonably be expected to have a negative impact on the Product in the US then Regeneron&#8217;s prior approval, in its sole discretion, shall be required for such Patent Term Extension.  The Parties will share all of Roche&#8217;s &#91;* * *&#93; for such Patent Term Extensions &#91;* * *&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to Patent Term Extensions with respect to the Products in the Roche Territory, subject to Roche obtaining Regeneron&#8217;s approval if necessary, Regeneron shall (a) grant Roche the right to file for such Patent Term Extension and (b) execute such authorizations and other documents and take such other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions. Each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such Patent Term Extensions. The Parties shall cooperate with each other in gaining Patent Term Extensions with respect to the Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any filings made to Regulatory Authorities with respect to any Compounds or Products, including, as required or allowed in the US, the FDA&#8217;s Purple Book, if applicable, or outside the US, other international equivalents, Regeneron will have the sole right to make any such decision whether to list Regeneron Patent Rights, but in all events will comply with Applicable Law, provided that Regeneron will consider in good faith any timely comments received from on behalf of Roche with respect to such filings in the Roche Territory prior to submission. Upon Regeneron&#8217;s request, Roche will reasonably cooperate in the implementation of Regeneron&#8217;s decision made under this Section 14.16.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Interference, Opposition and Reissue of Third Party Patents</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If either Party or one of its Affiliates or its or their Sublicensees desires to initiate any interference, opposition, post-grant review, reissue or reexamination proceeding relating to a Patent Right of a Third Party in furtherance of a Product in the Territory, then such Party shall notify the other Party in writing of such desire.  As soon as reasonably practicable after the receipt of such notice, the Parties shall meet and discuss the appropriate course of action with respect to such proposed interference, opposition, post-grant review, reissue or reexamination proceeding&#59; provided, that after such discussion either Party may initiate any interference, opposition, post-grant review, reissue or reexamination proceeding relating to a Patent Right of a Third Party in furtherance of a Product in the Territory, except that Roche may not initiation any such interference, opposition, post-grant review, reissue or reexamination proceeding in the US without Regeneron&#8217;s prior written consent in its sole discretion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 68 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Third Party IP Licenses </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any Patent Right or other intellectual property right of a Third Party that is necessary or reasonably useful for the development, manufacture or commercialization of the Products, (a) Regeneron shall have the exclusive right to negotiate and enter into any such license or other agreement with a Third Party to obtain rights to any such Patent Right or other intellectual property right solely in the Regeneron Patent Territory, (b) Roche Basel shall have the exclusive right to negotiate and enter into any such license or other agreement with a Third Party to obtain rights to any such Patent Right or other intellectual property right solely in the Roche Territory and (c) the Parties must mutually agree on the terms and conditions of any license or other agreement with a Third Party to obtain rights to any such Patent Right or other intellectual property right in both (i) some or all of the Regeneron Patent Territory and (ii) some or all of the Roche Territory.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Representations and Warranties</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Regeneron Representations and Warranties </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron represents and warrants to Roche, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Product Data</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The data, results, reports, and other documentation disclosed by Regeneron to Roche, either via the electronic data room or direct communication in writing between the business representatives of the Parties, in each case, to the extent related to any Compound or Product, are true and accurate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Ownership of Patent Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron owns all of the Regeneron Base Patent Rights. Appendix&#160;1.90 contains a complete and accurate list of all patents and patent applications included in the Regeneron Base Patent Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Inventors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The inventors of the inventions disclosed or claimed in the Regeneron Base Patent Rights have transferred full ownership of such inventions to Regeneron, or are under an obligation to transfer the full ownership of such inventions to Regeneron.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Grants</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To Regeneron&#8217;s Knowledge, Regeneron has the lawful right to grant Roche the rights and licenses described in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Validity of Patent Rights&#59; Inventorship Disputes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To Regeneron&#8217;s Knowledge, the claims in the Regeneron Base Patent Rights are valid and enforceable.  Regeneron has no Knowledge of any inventorship disputes concerning any Regeneron Base Patent Rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 69 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">Ownership and Validity of Know-How</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To Regeneron&#8217;s Knowledge, Regeneron&#8217;s Know-How has not been misappropriated from any Third Party. Regeneron has taken reasonable measures to protect the confidentiality of its Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">No Limitations on Manufacturing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting Regeneron&#8217;s representation and warranty in Section 15.3(a), neither &#91;* * *&#93; nor any other indenture, mortgage, deed of trust, lease, agreement, or other instrument to which Regeneron is a party or by which Regeneron or any of its property is bound, contains a term that would restrict Roche from using any of the Roche Manufacturing Facilities to supply Regeneron with Products for the Regeneron Territory or to otherwise fulfill any of Roche&#8217;s manufacturing and supply obligations under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Regeneron and its Affiliates have not clinically developed or commercialized or granted a license to a Third Party to clinically develop or commercialize an Antibody Conjugate that contains any Antibody in the Lead Compound.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Roche Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche represents and warrants to Regeneron that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All written information disclosed by Roche to Regeneron regarding Roche&#8217;s and its Affiliates&#8217; manufacturing or organization manufacturing capabilities and compliance history is true and accurate. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Mutual Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party represents and warrants to the other Party as of the Effective Date, and covenants, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Authorization </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The execution, delivery and performance of this Agreement by such Party and all instruments and documents to be delivered by such Party hereunder&#58; (i)&#160;are within the corporate power of such Party&#59; (ii)&#160;have been duly authorized by all necessary or proper corporate action&#59; (iii)&#160;are not in contravention of any provision of the organization documents of such Party&#59; (iv)&#160;to the Knowledge of such Party, will not violate any law or regulation or any order or decree of any court of governmental instrumentality&#59; (v)&#160;will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party or by which such Party or any of its property is bound, which violation would have an adverse effect on the financial condition of such Party or on the ability of such Party to perform its obligations hereunder&#59; and (vi)&#160;do not require any filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than Regulatory Approvals required for the sale of Products and filings with Regulatory Authorities required in connection with Products).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting the foregoing, (A) such Party is duly organized and validly existing under the Applicable Laws of its jurisdiction of incorporation&#59; (B) such Party has full corporate power and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 70 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">authority and the legal right to own and operate property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement&#59; (C) this Agreement is its legal, valid and binding obligation, enforceable in accordance with the terms and conditions hereof (subject to Applicable Laws of bankruptcy and moratorium)&#59; and (D) the individuals executing this Agreement for such Party have been duly authorized to execute and deliver this Agreement on behalf of such Party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">No Claims</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no claims or investigations pending or, to such Party&#8217;s Knowledge, threatened against such Party or any of its Affiliates, at law or in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially impair, prevent or delay such Party&#8217;s ability to perform its obligations hereunder. During the Agreement Term, each Party shall promptly notify the other Party in writing upon learning of any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Insurance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the Agreement Term and for a minimum period of &#91;* * *&#93; thereafter and for an otherwise longer period as may be required by Applicable Law, each of Regeneron and Roche will procure and maintain insurance consistent with industry practice or required by Applicable Law, which may be through self-insurance.  Such insurance shall insure against liability arising from this Agreement on the part of Regeneron or Roche, respectively, or any of their respective Affiliates, due to injury, disability or death of any person or persons, or property damage arising from activities performed by such Party or its Affiliates in connection with this Agreement.  Any insurance proceeds received by a Party in connection with any indemnified claim shall be retained by such Party and shall not reduce any obligation of the other Party under Article 16 with respect to such claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Debarment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party covenants that it and its Affiliates and, to the best of such Party&#8217;s knowledge, its and their respective employees who are involved in the development or commercialization of the Compounds or the Products will not be debarred under 21 U.S.C. &#167;335a, disqualified under 21 C.F.R. &#167;312.70 or &#167;812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C &#167;1320 a-7b(f)), including the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar federal or state agency or program in the United States or any other country (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Debarred</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In the event a Party receives notice of, or becomes aware that any of its Affiliates or any employee of such Party or any of its Affiliates receives notice of, in either case, debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes or any other similar federal or state agency or program in the United States or any other country, such Party shall promptly notify the other Party in writing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party has adopted and implemented compliance policies that conform to industry standards.  Each Party will use commercially reasonable efforts to ensure that no employees of such Party or its Affiliates who are involved in the development or commercialization of the Compounds or the Products are Debarred. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">No Force Majeure Event</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 71 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party represents and warrants that as of the Effective Date it is not currently under the effects of a force majeure event as contemplated by Section 21.9 such as would prevent or materially hinder or delay its performance hereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">No Other Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS.  EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Indemnification</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Indemnification by Roche</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall indemnify, hold harmless and defend Regeneron, Regeneron&#8217;s Affiliates and its and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from and against any and all losses, expenses, cost of defense (including reasonable attorneys&#8217; fees, witness fees, damages, taxes, judgments, fines and amounts paid in settlement) (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) arising from or occurring as a result of (a) the breach of this Agreement or the Supply Agreement by Roche or any of its Affiliates, if applicable, (b) the negligence or willful misconduct of any Roche Indemnitee or a Sublicensee of Roche in performing its or their obligations under this Agreement, (c) any regulatory activities conducted by Regeneron or its Affiliates to assist Roche to obtain Regulatory Approval for a Product (other than the First Approval Activities) in the Roche Territory pursuant to Section 6.1.2, or (d) any employee of Roche or its Affiliates who is involved in the development or commercialization of the Compounds or the Products being Debarred,  except, in the case of (a) and (b), to the extent Regeneron has an obligation to indemnify Roche for Losses pursuant to Section 16.2, as to which Losses each Party shall indemnify the other Party to the extent of their respective liability for such Losses.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Indemnification by Regeneron</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regeneron shall indemnify, hold harmless and defend Roche, Roche&#8217;s Affiliates and its and their respective directors, officers, employees and agents (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from and against any and all Losses in connection with any and all Claims arising from or occurring as a result of (a) the breach of this Agreement or the Supply Agreement by Regeneron or any of its Affiliates, if applicable, (b) the negligence or willful misconduct of any Regeneron Indemnitee or a Sublicensee of Regeneron in performing its or their obligations under this Agreement, or (c) any employee of Regeneron or its Affiliates who is involved in the development or commercialization of the Compounds or the Products being Debarred, except, in each case ((a) and (b)), to the extent Roche has an obligation to indemnify Regeneron for Losses pursuant to Section 16.1, as to which Losses each Party shall indemnify the other to the extent of their respective liability for such Losses.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 72 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">No Fault Claims</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any Claim arising out of or related to the research, development, seeking and obtaining Regulatory Approval for, making, using, importing or exporting of the Compounds or Products under this Agreement that is not subject to indemnification under Section 16.1 or Section 16.2 and is not subject to Section 14.13 (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Fault Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (a) the provisions of Section 16.4 shall not apply with respect to the defense of such No Fault Claim and the Parties shall cooperate in good faith to establish a mutually agreeable strategy with respect to defending such No Fault Claim, including whether to settle any such No Fault Claim and (b) &#91;* * *&#93;.  For clarity, neither Party shall settle any No Fault Claim without the other Party&#8217;s consent, not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">16.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Indemnification Procedure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All indemnification claims in respect of a Regeneron Indemnitee or a Roche Indemnitee shall be made solely by Regeneron or Roche, as applicable (each of Regeneron or Roche in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Indemnified Party shall promptly notify the other Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in writing of the Claim, and any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 16.1 or Section 16.2 (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification Claim Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Claim, the obligations of the Indemnifying Party shall be governed by and contingent upon the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">At its option, the Indemnifying Party may assume the defense of any Claim by notifying the Indemnified Party in writing within &#91;* * *&#93; after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice.  The assumption of the defense of a Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify the Indemnified Party or its Indemnitees, in respect of such Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s or its Indemnitees&#8217; claim for indemnification. Upon assuming the defense of a Claim, the Indemnifying Party may appoint the lead counsel in the defense of such Claim.  If the Indemnifying Party assumes the defense of a Claim, the Indemnified Party shall promptly deliver to the Indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party or any of its Indemnitees in connection with the Claim.  If the Indemnifying Party assumes the defense of a Claim, except as provided in subsection (b) below, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by the Indemnified Party or any of its Indemnitees in connection with the analysis, defense or settlement of such Claim unless specifically requested in writing by the Indemnifying Party.  If it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party or its Indemnitees from and against the Claim, the Indemnified Party shall reimburse the Indemnifying Party for any Losses incurred by the Indemnifying Party in its defense of the Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The Indemnified Party shall be entitled to participate in, but not control, the defense of a Claim and to employ counsel of its choice for such purpose&#59; provided, however, that such employment shall be at the Indemnified Party&#8217;s sole cost and expense unless (i)&#160;the employment thereof, and the assumption by the Indemnifying Party of such cost and expense, have been specifically requested in writing by the Indemnifying Party, (ii) the Indemnifying Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 73 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">has failed to assume the defense and employ counsel in accordance with Section 16.4(a) (in which case the Indemnified Party shall control the defense) or (iii)&#160;the interests of the applicable Indemnitees and the Indemnifying Party with respect to such Claim are sufficiently adverse to prohibit the representation by the same counsel of both entities under Applicable Law, ethical rules or equitable principles (in which case the Indemnified Party shall control its defense). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">With respect to any Losses relating solely to the payment of money damages in connection with a Claim and that shall not result in the applicable Indemnitee becoming subject to injunctive or other relief or otherwise adversely affecting the business of the applicable Indemnitee in any manner and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate.  With respect to all other Losses in connection with any Claim, if the Indemnifying Party has assumed the defense of the Claim in accordance with Section 16.3, the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss&#59; provided it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed).  If the Indemnifying Party controls the defense of a Claim as provided above, the Indemnified Party shall not settle such Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party shall, and shall cause each Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.  Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party and Indemnitees of, records and information that are reasonably relevant to such Claim and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder and the Indemnifying Party shall reimburse the Indemnified Party for all its out-of-pocket expenses in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Except as provided above, the Losses incurred by the Indemnified Party in connection with any Claim shall be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party&#8217;s right to contest the Indemnified Party&#8217;s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party or its Indemnitees.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Liability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EXCEPT FOR INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER ARTICLE&#160;16, BREACHES OF CONFIDENTIALITY IN ARTICLE 18, BREACHES OF ARTICLE 9, GRANT BY EITHER PARTY OF A LICENSE IN BREACH OF THE Exclusive license granted BY IT under Section 2.1(IV) or Section 2.4(IV), GROSS NEGLIGENCE, WILLFUL MISCONDUCT, AND ANY OTHER LIABILITY TO THE EXTENT SUCH LIABILITY CANNOT BE LIMITED UNDER APPLICABLE LAW, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 74 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, DAMAGES FOR LOSS OF PROFIT, LOSS OF REVENUE, OR LOST OPPORTUNITY IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER REGARDLESS OF ANY PRIOR NOTICE OF SUCH DAMAGES.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Obligation Not to Disclose Confidential Information</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Non-Use and Non-Disclosure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the Agreement Term and for &#91;* * *&#93; thereafter, a Receiving Party shall (a)&#160;treat Confidential Information of the Disclosing Party as strictly confidential and with similar care as it would treat its own information of a similar nature, and (b)&#160;not use such Confidential Information other than for fulfilling its obligations or exercising its rights under this Agreement&#59; provided that with respect to any Confidential Information that is specifically identified as a trade secret, or that the other Party has reason to know is a trade secret under Applicable Law, such obligations shall survive until such Confidential Information is no longer a trade secret under Applicable Law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Receiving Party covenants that neither it nor any of its respective Affiliates shall disclose any Confidential Information of the other Party (or its Affiliates) to any Third Party except (i) to its employees, agents, consultants or any other person under its authorization&#59; provided that such employees, agents, consultants or persons are subject in writing to substantially the same confidentiality obligations as the Parties, (ii) as approved by both Parties hereunder, (iii) Third Parties to the extent reasonably necessary to market the Product in the Territory&#59; provided that such Third Parties are subject in writing to substantially the same confidentiality obligations as the Parties under this Agreement, (iv) to permitted potential and actual Sublicensees or subcontractors&#59; provided that such permitted potential and actual Sublicensees or subcontractors are subject in writing to substantially the same confidentiality obligations as the Parties under this Agreement, or (v) as set forth elsewhere in this Agreement&#59; provided that the exceptions in clauses (iii), (iv) and (v) shall not apply with respect to Proprietary Manufacturing Information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Permitted Disclosure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the obligation of confidentiality, non-use and non-disclosure set forth in Section&#160;18.1 but subject to Section 18.3, the Parties recognize the need for certain exceptions to this obligation, and each Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such disclosure is&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial or local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the Receiving Party&#8217;s legal counsel, such disclosure is otherwise required by Applicable Law, including by reason of filing with securities regulators&#59; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment&#59; provided, further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Confidential Information disclosed in response to such order or as required by Applicable Law shall be limited to that information that is legally required to be disclosed in response to such order or by such Applicable Law&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 75 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">made by or on behalf of the Receiving Party to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval pursuant to the terms of this Agreement&#59; provided, however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">made to a US government agency or contractor in connection with performance of a US government agreement or sub-agreement (provided that appropriate markings to protect Confidential Information pursuant to US government regulations are applied to Confidential Information to the extent applicable)&#59; provided, however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">with respect to Joint Know-How, made by either Party or its Affiliates as may be necessary or useful in connection with the exploitation of any product that is not a Competing Product in the Territory. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Proprietary Manufacturing Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limitation of any of the foregoing, Roche shall adopt and implement reasonable firewall procedures to prevent the disclosure of and use of Proprietary Manufacturing Information beyond the persons who are required to receive such information in order to manufacture the Products or to prepare, submit, obtain or maintain Regulatory Approvals for the Products in the Field in the Roche Territory in accordance with this Agreement (and who are bound by confidentiality obligations no less stringent than those provided in this Agreement), including by establishing reasonable physical and electronic safeguards, segregating all Proprietary Manufacturing Information from its own information or materials or that of others (including Affiliates) in order to prevent commingling&#59; not copying or otherwise duplicating any embodiments of the Proprietary Manufacturing Information, except as necessary to manufacture the Products or to prepare, submit, obtain or maintain Regulatory Approvals for the Products in the Field in the Roche Territory in accordance with this Agreement (provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that any such copies or duplications of such Proprietary Manufacturing Information shall be marked &#8220;confidential,&#8221; &#8220;proprietary&#8221;, or the like)&#59; and notifying Regeneron immediately, and cooperating with Regeneron as Regeneron may reasonably request, upon any discovery of any loss or compromise of Proprietary Manufacturing Information.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything else in this Agreement to the contrary, if Roche or any of its Affiliates receives a request for any Proprietary Manufacturing Information from any governmental authority under any freedom of information law, including the United States Freedom of Information Act or the State Council Regulations on Open Government Information, then Roche shall (i) notify Regeneron of such request within &#91;* * *&#93;, (ii) permit Regeneron or any of its Affiliates to oppose such request or to seek other limitations on such request, in each case, to the extent consistent with the Applicable Law and (iii) provide Regeneron with reasonable assistance in opposing such request or seeking such limitations.  Roche shall not, and shall cause its Affiliates not to, disclose any Proprietary Manufacturing Information to any governmental authority in response to a request under any freedom of information law without Regeneron&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 76 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided that Regeneron acknowledges and agrees that it would be unreasonable for it to not consent to any disclosure if such lack of disclosure would cause Roche or any of its Affiliates to violate Applicable Law.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any Regeneron Confidential Information (as the term is defined in the Technology Transfer Agreement) that constitutes Proprietary Manufacturing Information shall be governed by the applicable terms under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Press Releases&#59; Use of Name</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties shall mutually agree on the content of any press releases, and shall coordinate on the initial press release promptly after the Effective Date. Except as otherwise expressly provided herein or for any such disclosure that is, in the opinion of the issuing Party&#8217;s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the issuing Party (or any parent entity thereof) are listed, neither Party shall issue any other public announcement or press release or make any other public disclosure regarding this Agreement, its terms or its subject matter without the other Party&#8217;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. Notwithstanding the foregoing, Regeneron shall be responsible for, and shall have the final decision-making authority on any press releases for any Ongoing Regeneron Studies. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The restrictions imposed by this Section 18.4 shall not prohibit either Party from making any disclosure if, in the opinion of the counsel of the Party making such disclosure, such disclosure is required by Applicable Law or the rules of a stock exchange on which the securities of the first Party, provided, that such Party shall submit the proposed disclosure to the other Party in advance (and in no event less than &#91;* * *&#93; prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon, and shall consider the other Party&#8217;s comments in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as expressly provided herein or required by Applicable Law, neither Party shall use the name, logo or trademark of the other Party or any of its Affiliates or any of its or their Sublicensees (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or other form of publicity without the prior written approval of such other Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Publications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Compounds or Products in any publication or presentation&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">With respect to publications or presentations relating to Co-Funded Studies where Roche is involved in operationalizing the Co-Funded Study and for other joint publications or presentations, the Parties will work together in good faith to co-author such publication or presentation, and will mutually agree in good faith on all aspects of such publication or presentation, including without limitation the content of the publication or presentation and the timing and manner of its publication or presentation. If the Parties cannot reach agreement, then the Party that sponsors, or is primarily responsible for operationalizing, the Co-Funded Study will make the final determination on all aspects of such publication or presentation except with respect to disclosure of an invention, solely or jointly conceived or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 77 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reduced to practice by the other Party, or the Confidential Information of the other Party (other than the results of the Co-Funded Study). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">With respect to publications or presentations relating to Co-Funded Studies where Roche is not involved in operationalizing the Co-Funded Study (including, for clarity, the Additional Regeneron Studies), Regeneron shall provide Roche with a copy of such proposed publication or presentation at least &#91;* * *&#93; (or at least &#91;* * *&#93; in the case of oral presentations) prior to submission for publication so as to provide Roche with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by Roche to Regeneron in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused&#59; and if Roche notifies (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Publishing Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) Regeneron in writing, within &#91;* * *&#93; after receipt of the copy of the proposed publication or presentation (or at least &#91;* * *&#93; in the case of oral presentations), that such publication or presentation in its reasonable judgment (i) contains an invention, solely or jointly conceived or reduced to practice by Roche, for which Roche reasonably desires to obtain patent protection, in which case Regeneron shall delay such publication for a mutually agreeable period of time not to exceed &#91;* * *&#93; from the date of the Roche Publishing Notice&#59; or (ii) contains Confidential Information of Roche (other than the results of any Co-Funded Study), in which case, Regeneron shall, upon Roche&#8217;s request, remove from the publication such information. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">With respect to publications or presentations related to Unilateral Studies or other unilateral publications or presentations by a Party relating to the Compounds or Products, subject to Section 18.5(d), the Party proposing such publication or presentation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Publishing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall provide the other Party with a copy of such proposed publication or presentation at least &#91;* * *&#93; (or at least &#91;* * *&#93; in the case of oral presentations) prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused&#59; and if such other Party notifies (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Publishing Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;) the Publishing Party in writing, within &#91;* * *&#93; after receipt of the copy of the proposed publication or presentation (or at least &#91;* * *&#93; in the case of oral presentations), that such publication or presentation in its reasonable judgment&#59; (i) contains an invention, solely or jointly conceived or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection, in which case the Publishing Party shall delay such publication for a mutually agreeable period of time not to exceed &#91;* * *&#93; from the date of the Publishing Notice&#59; or (ii) contains Confidential Information of such other Party (other than the results of any Clinical Study conducted under this Agreement, if applicable), in which case, the Publishing Party shall, upon the other Party&#8217;s request, remove from the publication such information.  In the case of publications or presentations by Roche relating to a Roche Unilateral Study, Roche agrees to include authors from Regeneron in such publication or presentation.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">The obligations under Section 18.5(c) shall not apply to any publications or presentations by Regeneron or any of its Affiliates related to activities conducted with respect to the Compounds or Products prior to the Effective Date, and Regeneron shall provide Roche an advance copy of any such publications or presentations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 78 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Term and Termination</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">19.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Commencement and Term</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall commence upon the Effective Date and continue for the Agreement Term (which, for clarity, includes any extension agreed by the Parties).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">19.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Termination</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Termination for Breach</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-Breaching Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall have the right to terminate this Agreement in its entirety in the event the other Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Breaching Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is in breach of any of its material obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify in reasonable detail the facts underlying or constituting the alleged breach. The Breaching Party shall have a period of &#91;* * *&#93; after such written notice is provided (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Peremptory Notice Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to cure such breach. If the Breaching Party has a bona fide dispute as to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such bona fide dispute is resolved pursuant to Section&#160;21.2. Upon a determination of breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party&#8217;s request for termination, this Agreement shall terminate in its entirety effective as of the expiration of the Peremptory Notice Period.  A Party&#8217;s failure to meet the Minimum Committed Regeneron Capacity or the Minimum Committed Roche Capacity, as the case may be, shall be considered a breach of a material obligation by such Party. Notwithstanding the foregoing, Regeneron&#8217;s rights with respect to Roche&#8217;s breach of its diligence obligations set forth in Section 6.2 or Section 7.3 shall be subject to Section 19.2.2(a) and Section 19.2.2(b).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Termination for Roche Diligence Breach or Failure to Commercialize</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary set forth in this Agreement, </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche&#8217;s breach of its regulatory diligence obligation set forth in Section 6.2 or its commercialization diligence obligations set forth in Section 7.3 with respect to a Roche Major Country will not give Regeneron the right to terminate this Agreement in its entirety and will give Regeneron the right to terminate this Agreement solely with respect to such Roche Major Country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche&#8217;s breach of its regulatory diligence obligation set forth in Section 6.2 or its commercialization diligence obligations set forth in Section 7.3 with respect to the ROW, taken as a whole, will not give Regeneron the right to terminate this Agreement in its entirety and will give Regeneron the right to terminate this Agreement solely with respect to the ROW.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">If, after &#91;* * *&#93; following the First Commercial Sale of the Lead Product in any country in the EU or the United Kingdom, Roche is not commercializing any Product in a country in the Roche Territory, and upon Regeneron&#8217;s written inquiry to the Roche Chair of the JOC, confirms in writing that it has no plans to commercialize any Product in such country, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 79 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">does not provide Regeneron within &#91;* * *&#93; after receiving such inquiry from Regeneron with a reasonable written plan to commercialize a Product in such country during the Agreement Term, and Regeneron in good faith plans to commercialize the Product in such country, then Regeneron shall have the right to terminate this Agreement solely with respect to such country immediately upon written notice to Roche.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notice requirement and opportunity to dispute and cure a breach as set forth in the second through fifth sentences of Section 19.2.1 above shall apply to any termination pursuant to clauses (a) or (b) of this Section 19.2.2, provided that Regeneron&#8217;s right to terminate will be limited as set forth in this Section.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Insolvency</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency Event&#59; provided, however, in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within &#91;* * *&#93; after the filing thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Termination by Roche for Technical Failure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If (i) both of the first two Ongoing Regeneron Studies listed in Appendix 1.73 are placed on clinical hold by the FDA or EMA that continues for thirty (30) days, unless Regeneron is undertaking reasonable actions to have either such clinical hold removed, in which case if such hold continues for ninety (90) days, (ii) the Lead Product has not received an Emergency Use Authorization prior to May 31, 2021, (iii) Regeneron has not filed for full Regulatory Approval of the Lead Product in the US prior to May 31, 2021, or (iv) Regeneron terminates further development of the Lead Product, then Roche shall have the right to terminate this Agreement in its entirety upon thirty (30) days&#8217; prior written notice, provided in each case, such notice of termination is delivered by Roche within thirty (30) days after the occurrence of the condition giving rise to the right of termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Termination by Roche due to &#91;* * *&#93; Third Party Product</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a Third Party Antibody product targeting SARS-CoV-2 in form of a single Antibody or a cocktail of at least two Antibodies is &#91;* * *&#93; the safety and efficacy profile of such Third Party Antibody product confers a substantial public health benefit over the Lead Product &#91;* * *&#93; (an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alternative Third Party Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then Roche shall have the right to terminate this Agreement in its entirety upon (a) sixty (60) days prior written notice at any time if such notice is given prior the First Commercial Sale of the Lead Product in the Territory&#59; or (b) six (6) months prior written notice at any time if such notice is given after First Commercial Sale of the Lead Product in the Territory&#59; provided, that, with respect to the Chugai Asset as the Alternative Product, Roche shall not have the right to terminate this Agreement pursuant to this Section 19.2.5 unless Regeneron has notified Roche in writing that Regeneron will not exercise the Chugai Asset Option or Regeneron does not provide the Exercise Notice during the Exercise Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Parties cannot agree on whether the safety and efficacy profile of an Alternative Third Party Product confers a substantial public health benefit over the Lead Product in either treatment or prophylactic use, such matter shall be determined in accordance with Section 21.2, and if still not resolved, then decided by an Expert Committee pursuant to Section 21.4, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 80 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roche shall not have the right to terminate this Agreement pursuant to this Section 19.2.5 unless and until such Expert Committee determines that the safety and efficacy profile of such Alternative Third Party Product confers a substantial public health benefit over the Lead Product in either treatment or prophylactic use.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">19.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Consequences of Expiration or Termination </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Transfer of Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the expiration or earlier termination for any reason of this Agreement, the rights and licenses granted by each Party to the other under this Agreement shall terminate in their entirety, on the effective date of expiration or termination, as applicable, subject to Regeneron&#8217;s rights in Section 19.3.1(c).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon any termination or expiration of this Agreement, if Regeneron desires to continue development or commercialization of Product(s), Regeneron shall give a Continuation Election Notice to Roche within &#91;* * *&#93; of Regeneron&#8217;s notice of termination (in the event of termination by Regeneron) or receipt of Roche&#8217;s notice of termination (in the event of termination by Roche). If Roche receives such a timely Continuation Election Notice, and to the extent requested by Regeneron and consistent with ensuring a smooth and orderly transition to Regeneron or its designee, Roche shall perform the following activities (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Transfer Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche shall assign and transfer to Regeneron or its designee all regulatory filings and approvals, regulatory communications, all final pre-clinical and Clinical Study reports and Clinical Study protocols, Product Trademarks and all data, including clinical data, in Roche&#8217;s possession or control related to all Product(s). All data shall be transferred in the form and format in which it is maintained by Roche or otherwise reasonably requested by Regeneron. Original paper copies shall also be transferred. Roche shall not be required to prepare or finalize any new data, reports or information solely for purposes of transfer to Regeneron.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche shall assign to Regeneron or its designee agreements between Roche or any of its Affiliates on the one hand, and any Third Party on the other hand (including such agreements with CROs, CMOs or distributors) to the extent relating to the Product(s), provided that, with respect to any such Third Party agreement entered into by Roche or any of its Affiliates prior to the Effective Date, to the extent that the assignment by Roche requires any notice to or consent of the relevant Third Party counterparty to such agreement, or requires the separation of such agreement into an agreement that is retained by Roche or any of its Affiliates and an agreement that is assignable to (or entered into by) Regeneron, as applicable, (i) Roche shall use reasonable efforts to give such notice, or (ii) the Parties will reasonably cooperate to (A) obtain such consent or (B) at the request and with the reasonable assistance of Roche, negotiate such separation, in each case ((i) and (ii)), as soon as practicable, provided that neither Roche nor any of its Affiliates shall agree to any material undertakings in connection therewith, and until such assignment is executed, the Parties will reasonably cooperate to provide Regeneron the benefits under such agreement to the extent applicable to the rights to be assigned to Regeneron, provided further that Regeneron will be responsible for all payments under such agreement to the extent applicable to the benefits provided to Regeneron with respect to the Product(s), and any payments required by such Third Party as pursuant to any such agreement to secure such consent. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 81 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Roche shall grant and hereby grants (effective as of expiration or termination of this Agreement) to Regeneron a non-exclusive, worldwide, sublicenseable (through multiple tiers) license under the Roche Independent IP, Roche Patent Rights, Roche Know-How, and Roche&#8217;s interest in the Joint Patent Rights and Joint Know-How, to the extent necessary or reasonably useful to allow Regeneron, its Affiliates or licensees to develop, manufacture, have manufactured, use, offer to sell, sell, promote, export and import the applicable Product(s) in the Territory, provided that, if Roche identifies in writing to Regeneron that any Roche Independent IP, Roche Patent Rights or Roche Know-How granted to Regeneron under this Section 19.3.1(c) is under a Third Party agreement between Roche or any of its Affiliates on the one hand, and any Third Party on the other hand, and if such Third Party agreement is not assigned to Regeneron pursuant to Section 19.3.1(b), then Regeneron shall be responsible for the payment obligations under such Third Party agreement to the extent related to any Product(s) sold on or after the expiration or termination of this Agreement&#59; provided, that the Parties shall negotiate in good faith the financials terms for any such license under the Roche Independent IP, taking into account the value of such Roche Independent IP.  If the Parties are unable to agree on such financial terms, such dispute shall be submitted for resolution by a Third Party expert jointly selected by the Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche shall, and shall cause its Affiliates and subcontractors to conduct such other actions as are reasonably necessary to ensure a smooth and orderly transition without interruption.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Other Obligations</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Obligations Related to Ongoing Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Regeneron does not provide a timely Continuation Election Notice to Roche then Roche (a)&#160;shall have the right to cancel such ongoing obligations, and (b)&#160;shall complete all non-cancellable obligations at its own expense.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the foregoing, from the date of notice of termination until the effective date of termination, Roche shall continue activities, including preparatory activities, ongoing as of the date of notice of termination, but shall not be obliged to initiate any new activities not ongoing at the date of notice of termination.  With respect to any Clinical Study or other development activities with respect to the Product that Regeneron does not elect to assume, unless the continued conduct of such Clinical Study or other development activity is required by the applicable Regulatory Authority or Applicable Law or the termination of such Clinical Study or other development activity would be inconsistent with standards of ethical conduct of human clinical trials, Roche shall wind-down such activities in a smooth, orderly and efficient manner in compliance with Applicable Law and with due regard for patient safety and the rights of any subjects that are participants in any such Clinical Studies, and take any actions that is reasonably necessary or appropriate to avoid any human health or safety problems or that is otherwise required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">After the end of the effective date of termination, Roche shall have no obligation to perform or complete any activities or to make any payments for performing or completing any activities under this Agreement, except for the Roche Transfer Activities or as otherwise expressly stated herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 82 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Obligations Related to Manufacturing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a Product is marketed in any country in the Territory on the date either Party provides a notice of termination of this Agreement (other than a termination pursuant to Section 19.2.4), then upon the request of Regeneron, Roche shall manufacture and supply such Product to Regeneron at the then-current Minimum Committed Roche Capacity prior to expiration or termination for a period that shall not exceed &#91;* * *&#93; from the end of the Agreement Term at &#91;* * *&#93;, then &#91;* * *&#93;&#59; (b) if this Agreement is terminated by Roche pursuant to Section 19.2.1, then Roche shall not be obligated to supply Product to Regeneron under this Section 19.3.2.2. Without limiting Roche&#8217;s obligation under Section 19.3.1, Regeneron shall use Commercially Reasonable Efforts to take over the manufacturing as soon as practicable after termination of this Agreement&#59; and (c) if this Agreement is terminated by Roche for an Alternative Third Party Product pursuant to Section 19.2.5, and, during the &#91;* * *&#93; post-termination supply period, Roche enters into an agreement with the applicable Third Party with respect to such Alternative Third Party Product and, as a result, will have insufficient capacity to manufacture such Alternative Third Party Product and the Product at the Roche Manufacturing Facilities, then Roche may reduce its supply of the Product to Regeneron as needed to manufacture such Alternative Third Party Product upon &#91;* * *&#93; prior written notice (which notice may be delivered at any time concurrently with or after Roche executing the agreement with the applicable Third Party with respect to such Alternative Third Party Product).  During the post-termination supply period, Roche shall cooperate with Regeneron to facilitate a smooth and orderly transition of manufacturing of the Product to Regeneron or its designee.  Upon expiration of the post-termination supply period, Roche shall, upon Regeneron&#8217;s request, sell to Regeneron all or any requested portion of its inventory, if any, of Drug Substance, Drug Product and Finished Product remaining after fulfillment of Regeneron&#8217;s orders during the post-termination supply period at Roche&#8217;s Fully Burdened Manufacturing Cost.   </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Ancillary Agreements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise provided in this Agreement (including pursuant to Section 19.3.2.2), the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, if any.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Limitations on Grant-Backs&#59; Transfer Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of clarity, irrespective of anything to the contrary in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">Roche shall transfer to Regeneron all PII&#47;Samples promptly following expiration or termination of this Agreement subject to compliance with applicable contractual restrictions, patient consents and Applicable Law. Roche shall not be obligated to transfer an PII&#47;Samples that Roche in good faith believes would be prohibited or would subject Roche to potential liability by reason of Applicable Law, contractual restrictions or insufficient patient consent.  Upon completion of such transfers, Regeneron shall use the transferred PII&#47;Samples for the sole purpose of developing, manufacturing and commercializing the Product(s), and Regeneron shall be responsible for the correct use of the PII&#47;Samples in line with the informed consent forms (including but not limited to potential re-consenting of the patients at Regeneron&#8217;s costs).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 83 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">The costs and expenses incurred in connection with the Roche Transfer Activities shall be shared by the Parties as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if this Agreement is terminated by Regeneron pursuant to Section 19.2.1, Section 19.2.3 (or, with respect to a Terminated Country, pursuant to Section 19.2.2(a) or Section 19.2.2(b)), Roche shall be responsible for its own costs and expenses incurred for the Roche Transfer Activities, and shall reimburse Regeneron for all reasonable out-of-pocket costs and expenses incurred by or on behalf of Regeneron for the Roche Transfer Activities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if this Agreement is terminated by Roche pursuant to Section 19.2.1 or Section 19.2.3, Regeneron shall be responsible for its own costs and expenses incurred for the Roche Transfer Activities, and shall reimburse Roche for all reasonable out-of-pocket and internal costs and expenses incurred by or on behalf of Roche for the Roche Transfer Activities&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if this Agreement is terminated pursuant to Section 19.2.4 or Section 19.2.5 (or, with respect to a Terminated Country, pursuant to Section 19.2.2(c)), Regeneron shall be responsible for its own costs and expenses incurred for the Roche Transfer Activities and shall reimburse Roche for all reasonable out-of-pocket costs and expenses incurred by or on behalf of Roche for the Roche Transfer Activities&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided further that transfer activities corresponding to the return of material remains, data, reports, records, documents, regulatory filings and Regulatory Approvals originally provided by Regeneron to Roche no less than three (3) years from the effective date of termination or expiration shall be returned to Regeneron free of charge. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Unless otherwise agreed to by the Parties, transfer of physical materials that are required under Roche Transfer Activities shall be delivered, at Roche&#8217;s option, FCA international courier near location where materials stored at time of transfer (Incoterms 2010) or CPT Regeneron or Regeneron&#8217;s designee (Incoterms 2010).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Payment Obligations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Termination of this Agreement by a Party, for any reason, shall not release either Party from any obligation to make any payments that are payable prior to the effective date of termination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.2.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.3pt">Return or Destruction of Confidential Information</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as expressly permitted under this Agreement, including, with respect to Regeneron, for purposes of continuing development, manufacture and commercialization of the Product(s), following expiration or earlier termination of this Agreement and upon the written request from either Party, each Party shall promptly return to the other Party (or destroy) all Confidential Information of the other Party, including any copies thereof (except one (1) copy of such Confidential Information, which may be retained for archival purposes, solely to ensure compliance with the terms of this Agreement).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.46pt">Termination with respect to a country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 84 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If this Agreement is terminated by Regeneron with respect to a particular country, but not in its entirety, pursuant to Section 19.2.2 (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Terminated Country</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then (a) the Terminated Country shall be excluded from the Roche Territory for purposes of this Agreement from and after the effective date of such termination, and Regeneron shall have the sole right, but not the obligation, to import, export, sell, offer to sell or otherwise commercialize or explore any Compound or Product in the Terminated Country, at its sole cost and expense, and any and all profits for any Compound or Product sold in the Terminated Country shall be retained by Regeneron and shall not be subject to the Global Gross Profits sharing under this Agreement&#59; (b) the licenses granted by Regeneron to Roche under Section 2.1(iii) and Section 2.1(iv) shall terminate with respect to the Terminated Country&#59; and (c) Section 19.3.1 and Section 19.3.2 (other than Section 19.3.2.2) shall apply </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to such Terminated Country&#59; provided that, (i) unless otherwise agreed by the Parties, removal of a Terminated Country from the Roche Territory shall not reduce the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Minimum Committed Roche Capacity or increase the Minimum Committed Regeneron Capacity, (ii) Regeneron, any of its Affiliates or Sublicensees, shall have the right to sell in a Terminated Country any Product supplied by Roche, and, (iii) notwithstanding Section 19.3.1(c), with respect to any Product sold by Regeneron, any of its Affiliates or Sublicensees in a Terminated Country for which the Drug Substance is manufactured by Roche, Regeneron shall pay to Roche</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">plus a five percent (5%) royalty on the Net Sales of such Product.    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">19.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Survival</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Article 1 (Definitions, to the extent necessary to interpret this Agreement), Section 4.3.1 3rd paragraph (Regeneron Cell Bank), Section 4.3.2 (Regeneron Cell Media) (second and third paragraphs), Section 4.3.3 other than the second sentence of subsection (a) thereof (Ownership and Restrictions), Section 15.4 (No Other Representations and Warranties), Section 19.3 (Consequences of Termination), Section 19.4 (Survival), Articles&#160;10, 11 and 13 (Payment, Accounting and Reporting, and Auditing, each to the extent payment obligations exist at the time of termination), Article&#160;12 (Taxes, to the extent such were incurred at the time of termination), Section&#160;14.1 (Ownership of Intellectual Property)&#59; Article&#160;16 (Indemnification), Article 17 (Liability), Article&#160;18 other than Section 18.5 (Obligation Not to Disclose Confidential Information)&#59; Article 20 (Bankruptcy) and Article 21&#160;other than Section 21.4 (Miscellaneous) shall survive any expiration or termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Bankruptcy</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties intend to take advantage of the protections of Section 365(n) (or any successor provision) of the U.S. Bankruptcy Code (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Bankruptcy Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the maximum extent permitted by Applicable Law.  All rights and licenses granted under or pursuant to this Agreement, but only to the extent they constitute licenses of a right to &#8220;intellectual property&#8221; as defined in Section 101 of the Bankruptcy Code shall be deemed to be &#8220;intellectual property&#8221; for the purposes of Section 365(n).  The Parties shall retain and may fully exercise all of their rights and elections under the Bankruptcy Code, including the right to obtain the intellectual property from another entity.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 85 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:21pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Governing Law&#59; Jurisdiction</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States, without reference to its conflict of law principles that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party (a) irrevocably submits to the exclusive jurisdiction of (i) the state courts of the State of New York in Manhattan, New York, and (ii) the United States District Court for the Southern District of New York, for the purposes of any suit, action, or other proceeding arising out of or relating to this Agreement or out of any transaction contemplated hereby, (b) waives any objections to such jurisdiction and venue and (c) agrees not to commence any suit, action or other proceeding arising out of or relating to this Agreement except in such courts. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, issues regarding the scope, construction, validity or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions that issued the Patent Rights in question.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Disputes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or their designees, for good faith negotiations attempting to resolve the dispute for a period of &#91;* * *&#93;. Such Executive Officers are as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For Regeneron&#58;&#160;&#160;&#160;&#160;&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For Roche&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Equitable Relief</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Parties hereby acknowledge and agree that the restrictions on the Parties under Article 9 and Article 18 are special, unique and of extraordinary character, that the Parties would not have entered into this Agreement absent the restrictions set forth in Article 9 and Article 18, and that if any Party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of Article 9 or Article 18, such refusal or failure may result in irreparable injury to the other Party, the exact amount of which would be difficult to ascertain or estimate and the remedies at law for which would not be reasonable or adequate compensation.  Accordingly, if either Party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of Article 9 or Article 18, then, in addition to any other remedy that may be available to the other Party at law or in equity, such other Party will be entitled to seek specific performance and injunctive relief.  Nothing in this Section 21.3 or elsewhere in this Agreement is intended or should be construed to limit either Party&#8217;s right to equitable relief or any other remedy for a breach of any other provision of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 86 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Expert Committee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If, after escalation to the Executive Officers in accordance with Section 21.2, the Parties are unable to agree on whether (a) the safety and efficacy profile of an Alternative Third Party Product confers a substantial public health benefit over the Lead Product in either treatment or prophylactic use settings, (b) whether or not the Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria, (c) if the Chugai Asset Data Package satisfies the Chugai Asset Data Package Criteria, then whether or not the Chugai Asset satisfies the Chugai Asset Criteria, (d) whether or not an Additional Compound Data Package satisfies the Additional Compound Data Package Criteria, or (e) whether or not an Additional Compound or a Back-Up Compound, as applicable, satisfies the Additional Compound Criteria (each of (a) - (e), an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expert Matter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then any such Expert Matter shall be decided by the following procedure. Roche will select one&#160;(1) individual who would qualify as an Expert, Regeneron will select&#160;(1) individual who would qualify as an Expert, and those two&#160;(2) individuals shall select one&#160;(1) individual who would qualify as an Expert and who shall be chairperson of a committee of the three Experts (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expert Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), each Expert with a single deciding vote.  The Parties shall use good faith efforts to form the Expert Committee within &#91;* * *&#93; after expiration of the Executive Officers&#8217; negotiation period.  The Expert Committee will promptly (but no more than &#91;* * *&#93; after the appointment of the third (3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Expert) hold a meeting to review the issue under review and will provide the Parties with at least &#91;* * *&#93; notice of such meeting.  At such meeting, the Expert Committee will consider memoranda submitted by each Party at least &#91;* * *&#93; before the meeting, as well as reasonable presentations that each Party may present at the meeting. The Expert Committee may order the Parties to produce any additional documents or information that are relevant to the Expert Committee decision. The agreement of two (2) of the three (3) Experts on the Expert Committee shall be sufficient to render a decision.  The Parties shall use diligent efforts to cause the completion of any such dispute resolution within &#91;* * *&#93; following expiration of the Executive Officers&#8217; negotiation period.  The determination of the Expert Committee as to the issue under review will be binding on both Parties. The Parties will share equally in the costs of the Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide any issues other than the applicable Expert Matter.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Assignment</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as otherwise expressly provided herein, neither Party shall have the right to assign this Agreement or any part hereof or any of the rights or obligations hereunder without the prior written approval of the other Party except (a) in whole or in part to an Affiliate of the assigning Party, or (b) in whole to any Third Party who acquires all or substantially all of the business of the assigning Party by merger, sale of assets or otherwise&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the assigning Party shall remain primarily liable hereunder with respect to any assignment under this clause (b) with respect to obligations and liabilities relating to the period prior to such assignment, and in each case ((a) and (b)), so long as such Affiliate or Third Party agrees in writing to be bound by the terms of this Agreement. Notwithstanding the foregoing, Roche Basel shall not assign its rights under this Agreement or any part thereof to any US Person without the prior written consent of Regeneron. Any attempted assignment in violation hereof shall be void. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 87 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Affiliates</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party may perform its obligations under this Agreement through one or more of its Affiliates.  Each Party absolutely, unconditionally and irrevocably guarantees to the other Party the prompt and timely performance of the responsibilities, liabilities, covenants, warranties, agreements and undertakings of its Affiliates pursuant to this Agreement.  Without limiting the foregoing, no Party shall cause or permit any of its Affiliates to commit any act (including any act or omission) which such Party is prohibited hereunder from committing directly.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Independent Contractor</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other liability on the other Party without said Party&#8217;s prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the Parties&#8217; legal relationship under this Agreement shall be that of independent contractors, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties or any of their respective Affiliates. Nothing contained in this Agreement shall be deemed or construed by the Parties, any of their Affiliates, or any third party to treat the relationship between the Parties contemplated by this Agreement as a partnership, joint venture or other business entity under US federal, state, local, or non-US tax law, and the Parties shall not take any position, on a tax return or otherwise, inconsistent therewith.  Each Party shall bear its own costs and expenses incurred in the performance of its obligations hereunder without charge or expense to the other Party except as expressly provided for in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Unenforceable Provisions and Severability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If any of the provisions of this Agreement are held to be invalid, illegal or unenforceable at law or in equity, then such invalid, illegal or unenforceable provisions shall be enforced to the maximum extent permitted under Applicable Law, and the Parties shall consult and use all reasonable efforts to agree upon, and hereby agree and consent to, replacement legal, valid and enforceable provisions that will achieve as far as possible the intentions of the Parties (including the economic benefits and rights contemplated herein) while avoiding any unjust enrichment of either Party. However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.62pt">Force Majeure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except for payment obligations, each Party shall be excused from any failure or delay in performance required hereunder (and any liability or responsibility for such failure or delay) to the extent such failure or delay is caused by or results from any catastrophes or other major events beyond its reasonable control, including, embargoes, acts of terrorism, civil commotions, acts of God, disease, pandemics, lockouts or other labor disturbances, war, riot, and insurrection&#59; laws, proclamations, edicts, ordinances, or regulations&#59; strikes, lockouts, or other serious labor disputes&#59; and floods, fires, explosions, or other natural disasters. When such events have abated, such Party&#8217;s obligations hereunder will resume.  The affected Party will notify the other Party of such force majeure circumstances as soon as reasonably practical and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 88 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will use commercially reasonable efforts to mitigate the effects of such force majeure circumstances.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Waiver</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The failure by either Party to require strict performance or observance of any obligation, term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. No delay or omission by a Party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such Party. No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting the waiver.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except where the context expressly requires otherwise&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa),</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein),</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">any reference herein to any Party or Third Party or person shall be construed to include the Party&#8217;s or Third Party&#8217;s or person&#8217;s permitted successors and assigns,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">any reference herein to a number of &#8220;days&#8221; shall be construed to refer to calendar days,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.57pt">all references herein to Articles, Sections or Appendices shall be construed to refer to Articles, Sections or Appendices of this Agreement, and references to this Agreement include all Appendices hereto,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 89 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:26.24pt">the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;and&#47;or&#8221;, and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">references to a decision that must be agreed by the Parties, such agreement must be evidenced in writing between the Parties, irrespective of whether the applicable provisions provides for such agreement to be in writing throughout this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Entire Understanding</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement (including all Appendices attached hereto), together with the Supply Agreement, and the Safety Data Exchange Agreement, constitute the entire understanding between the Parties with respect to the subject matter hereof and supersedes any and all prior agreements, understandings and arrangements, whether written or oral, other than the Technology Transfer Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Amendments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No amendments of the terms and conditions of this Agreement shall be binding upon either Party unless in writing and signed by both Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Invoices</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All invoices that are required or permitted hereunder shall be in writing and sent by the invoicing Party to the other Party at the following address or such other address as such other Party may later provide&#59; provided that, with respect to Regeneron, all invoices to be submitted hereunder shall only be submitted in PDF format via email to the invoice email addresses indicated below and Roche may similarly request that invoices be submitted in PDF format via email and provide an email address for such submissions&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Notice</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as set forth below.  Any such notice shall be deemed to have been delivered (a) upon receipt if delivered by hand, (b) upon confirmation of transmission if transmitted by facsimile, (c) one (1) Business Day after it is sent via a nationally recognized overnight courier service or (d) upon receipt of proof of delivery if sent by registered or certified mail, postage prepaid, return receipt requested.  Either Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 90 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may change its address by giving notice to the other Party in the manner provided above.  This Section 21.15 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:28.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if to Regeneron, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if to Roche, to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Counterparts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  This Agreement may be executed by exchange between the Parties of electronically transmitted signatures (via facsimile, PDF format via e-mail or other electronic means) and such signatures shall be deemed to bind each Party as if they were original signatures.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Third Party Beneficiaries</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as provided below in this Section 21.17, none of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either Party. No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party. Notwithstanding the foregoing, Article 16 is intended to benefit, in addition to the Parties, the other Regeneron Indemnitees and Roche Indemnitees as if they were parties hereto, but this Agreement is only enforceable by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">21.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:8.51pt">Further Assurances</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure such other Party its rights and remedies under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 91 -</font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:50.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Pharmaceuticals, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_&#47;s&#47; Nouhad Husseini____________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Nouhad Husseini</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; SVP, Business Development</font></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">__&#47;s&#47; James Sabry__________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; James Sabry</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; SVP, Head of Partnering</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">__&#47;s&#47; F. B&#228;chler_______________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Dr. Franziska B&#228;chler</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Attorney-at-Law</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:50.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">__&#47;s&#47; Edward Harrington__________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Edward Harrington</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; CFO Genentech</font></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">SIGNATURE PAGE TO THE LICENSE AGREEMENT</font></div><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix  1.20(a)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Regeneron Studies</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.20(b)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Agreed Co-Funded Studies</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.66</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lead Compound</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.883%"><tr><td style="width:1.0%"></td><td style="width:13.857%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="11" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.73</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ongoing Regeneron Studies</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.106 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Contribution Alternative Principles</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Roche Quarterly Distribution&#8221; shall mean, with respect to a Presentation and a &#91;* * *&#93;.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to each Presentation, the number of units of the Roche Quarterly Distribution for which the Drug Substance was manufactured by the Roche Group for inclusion in the numerator of the Roche Production Contribution shall be determined based on the following principles&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) With respect to the portion of the Roche Quarterly Distribution for a Presentation for a Calendar Quarter that is less than or equal to Roche&#8217;s &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#91;* * *&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) &#91;* * *&#93;.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An example of the application of such principles is attached as Exhibit A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.90</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regeneron Base Patent Rights</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic19c56d7c1f146aa8be2e44378c796e8_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 1.104</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Roche Manufacturing Facilities</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appendix 9.2</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>regn-ex311x09302020x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i36ecd8d68f0d421bb496b6a6947f1365_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Certification of Principal Executive Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Leonard S. Schleifer, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>regn-ex312x09302020x10q.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ibf65c9a1f724466ea558c276865bab9b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Certification of Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Robert E. Landry, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-right:2.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>regn-ex32x09302020x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7cbd215a57554771a2c4ee52fcf71a11_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Exhibit 32</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the Quarterly Report of Regeneron Pharmaceuticals, Inc. (the &#34;Company&#34;) on Form 10-Q for the quarterly period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:12pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:32.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>regn-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:regn="http://www.regeneron.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.regeneron.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.regeneron.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatements" roleURI="http://www.regeneron.com/role/InterimFinancialStatements">
        <link:definition>2101101 - Disclosure - Interim Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsPolicies" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies">
        <link:definition>2202201 - Disclosure - Interim Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsTables" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsTables">
        <link:definition>2303301 - Disclosure - Interim Financial Statements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsScheduleofBalanceSheetDataDetails" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails">
        <link:definition>2404401 - Disclosure - Interim Financial Statements - Schedule of Balance Sheet Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails">
        <link:definition>2405402 - Disclosure - Interim Financial Statements - Schedule of Statements of Operations Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsScheduleofCashFlowsDataDetails" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails">
        <link:definition>2406403 - Disclosure - Interim Financial Statements - Schedule of Cash Flows Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.regeneron.com/role/ProductSales">
        <link:definition>2107102 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.regeneron.com/role/ProductSalesTables">
        <link:definition>2308302 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofNetProductSalesDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails">
        <link:definition>2409404 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
        <link:definition>2410405 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreements" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements">
        <link:definition>2111103 - Disclosure - Collaboration, License, and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTables" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables">
        <link:definition>2312303 - Disclosure - Collaboration, License, and Other Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
        <link:definition>2413406 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
        <link:definition>2414407 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
        <link:definition>2415408 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails">
        <link:definition>2416409 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
        <link:definition>2417410 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
        <link:definition>2418411 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
        <link:definition>2419412 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
        <link:definition>2420413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
        <link:definition>2421414 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
        <link:definition>2422415 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
        <link:definition>2423416 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
        <link:definition>2424417 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails">
        <link:definition>2425418 - Disclosure - Collaboration, License, and Other Agreements - BARDA Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.regeneron.com/role/NetIncomePerShare">
        <link:definition>2126104 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.regeneron.com/role/NetIncomePerShareTables">
        <link:definition>2327304 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2428419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
        <link:definition>2429420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.regeneron.com/role/MarketableSecurities">
        <link:definition>2130105 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables">
        <link:definition>2331305 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
        <link:definition>2432421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails">
        <link:definition>2433422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
        <link:definition>2434423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>2435424 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.regeneron.com/role/FairValueMeasurements">
        <link:definition>2136106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables">
        <link:definition>2337306 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2438425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2439426 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.regeneron.com/role/Inventories">
        <link:definition>2140107 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.regeneron.com/role/InventoriesTables">
        <link:definition>2341307 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2442427 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.regeneron.com/role/Debt">
        <link:definition>2143108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.regeneron.com/role/DebtNarrativeDetails">
        <link:definition>2444428 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.regeneron.com/role/IncomeTaxes">
        <link:definition>2145109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesDetails">
        <link:definition>2446429 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.regeneron.com/role/StockholdersEquity">
        <link:definition>2147110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.regeneron.com/role/StockholdersEquityTables">
        <link:definition>2348308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2449430 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRepurchasedSharesDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails">
        <link:definition>2450431 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySanofiFundingDetails" roleURI="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails">
        <link:definition>2451432 - Disclosure - Stockholders' Equity - Sanofi Funding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlows" roleURI="http://www.regeneron.com/role/StatementofCashFlows">
        <link:definition>2152111 - Disclosure - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsTables" roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables">
        <link:definition>2353309 - Disclosure - Statement of Cash Flows (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2454433 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails">
        <link:definition>2455434 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.regeneron.com/role/LegalMatters">
        <link:definition>2156112 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMattersDetails" roleURI="http://www.regeneron.com/role/LegalMattersDetails">
        <link:definition>2457435 - Disclosure - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" abstract="false" name="DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_EyleaNetProductSalesMember" abstract="true" name="EyleaNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_GainContingencyInterPartesReviewFiledNumber" abstract="false" name="GainContingencyInterPartesReviewFiledNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_CommonStockHeldBySanofiMember" abstract="true" name="CommonStockHeldBySanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpense" abstract="false" name="ReimbursementOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_A165PatentMember" abstract="true" name="A165PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_PraluentCrossLicenseAndCommercializationAgreementMember" abstract="true" name="PraluentCrossLicenseAndCommercializationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_LossContingencyPercentageOfDamagesResponsibleFor" abstract="false" name="LossContingencyPercentageOfDamagesResponsibleFor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" abstract="false" name="PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_RestrictedMember" abstract="true" name="RestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" abstract="true" name="AmountsRecognizedInConnectionWithUpFrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_A487PatentMember" abstract="true" name="A487PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" abstract="false" name="RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_ProductSalesandConcentrationRiskTextBlock" abstract="false" name="ProductSalesandConcentrationRiskTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="regn_IntelliaMember" abstract="true" name="IntelliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ArcalystNetProductSalesMember" abstract="true" name="ArcalystNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_Maximumsharesthecollaboratorcouldsell" abstract="false" name="Maximumsharesthecollaboratorcouldsell" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="regn_UnsatisfiedObligation" abstract="false" name="UnsatisfiedObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_BesseMedicalMember" abstract="true" name="BesseMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_NetProfitInConnectionWithCommercializationMember" abstract="true" name="NetProfitInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsTable" abstract="true" name="ResearchCollaborationAndLicensingArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" abstract="false" name="ReimbursementOfSellingGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_CollaborativeArrangementUpfrontPaymentMade" abstract="false" name="CollaborativeArrangementUpfrontPaymentMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_BARDAOtherTransactionAgreementMember" abstract="true" name="BARDAOtherTransactionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" abstract="false" name="MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PercentageOfTrialCostsBorneByCollaboratingParty" abstract="false" name="PercentageOfTrialCostsBorneByCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_GrossSalesRevenueMember" abstract="true" name="GrossSalesRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_BridgeFacilityMember" abstract="true" name="BridgeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2050Member" abstract="true" name="SeniorUnsecuredNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ShareOfProfitLossesInConnectionWithCommercializationMember" abstract="true" name="ShareOfProfitLossesInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_LibtayoDevelopmentMember" abstract="true" name="LibtayoDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SanofisShareofLibtayoU.S.GrossProfitsMember" abstract="true" name="SanofisShareofLibtayoU.S.GrossProfitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_LossContingencyClaimsInvalidNumber" abstract="false" name="LossContingencyClaimsInvalidNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" abstract="false" name="Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementOfOtherExpenses" abstract="false" name="ReimbursementOfOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_LIBTAYONetProductSalesMember" abstract="true" name="LIBTAYONetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_A631PatentMember" abstract="true" name="A631PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" abstract="false" name="PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_GainContingencyClaimsInvalidatedNumber" abstract="false" name="GainContingencyClaimsInvalidatedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_RevenuebasedonpercentageofannualsalesinJapan" abstract="false" name="RevenuebasedonpercentageofannualsalesinJapan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsLineItems" abstract="true" name="ResearchCollaborationAndLicensingArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="regn_CollaborationandContractManufacturingMember" abstract="true" name="CollaborationandContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_OtherRevenueMember" abstract="true" name="OtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" abstract="false" name="ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2030Member" abstract="true" name="SeniorUnsecuredNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_OtherCollaborationAgreementsMember" abstract="true" name="OtherCollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_TevaPharmaceuticalsCollaborationAgreementMember" abstract="true" name="TevaPharmaceuticalsCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementAntibodyMember" abstract="true" name="SanofiCollaborationAgreementAntibodyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" abstract="true" name="RegeneronsShareOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_DupilumabREGN3500EligibleInvestmentsMember" abstract="true" name="DupilumabREGN3500EligibleInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ReimbursementOfCommercializationRelatedExpensesMember" abstract="true" name="ReimbursementOfCommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_PercentageOfTrialCostsBorneByEntity" abstract="false" name="PercentageOfTrialCostsBorneByEntity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_PercentageOfRoyaltyPaymentThatCanBeOffset" abstract="false" name="PercentageOfRoyaltyPaymentThatCanBeOffset" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementImmunooncologyMember" abstract="true" name="SanofiCollaborationAgreementImmunooncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_A741PatentMember" abstract="true" name="A741PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_REGNCOV2Member" abstract="true" name="REGNCOV2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_Amgenv.s.RegeneronMember" abstract="true" name="Amgenv.s.RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentAxis" abstract="true" name="ClassificationOfInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_LossContingencyDamagesSoughtPerUnitProduced" abstract="false" name="LossContingencyDamagesSoughtPerUnitProduced" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_BayerCollaborationAgreementMember" abstract="true" name="BayerCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_MaximumTransactionAgreementPayments" abstract="false" name="MaximumTransactionAgreementPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentDomain" abstract="true" name="ClassificationOfInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_PraluentNetProductSalesMember" abstract="true" name="PraluentNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_UnrestrictedMember" abstract="true" name="UnrestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementMember" abstract="true" name="SanofiCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="regn_ReimbursementForManufacturingOfCommercialSuppliesMember" abstract="true" name="ReimbursementForManufacturingOfCommercialSuppliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>regn-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20200930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e9dd0bc2-eb7b-4830-8cb4-30b1eda35c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_PreferredStockValue_e9dd0bc2-eb7b-4830-8cb4-30b1eda35c44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bf366dc1-7e4e-4039-8ab2-cfda9ab131dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_CommonStockValue_bf366dc1-7e4e-4039-8ab2-cfda9ab131dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0e7f404a-2e62-4831-9ea0-f3da886fbc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0e7f404a-2e62-4831-9ea0-f3da886fbc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea7dac58-c3b5-4aa1-9866-350e3439e919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea7dac58-c3b5-4aa1-9866-350e3439e919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_205c0e92-d25e-4e8c-9e6d-d3fc4a7f696b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_205c0e92-d25e-4e8c-9e6d-d3fc4a7f696b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f12f97dc-cf38-4a71-95aa-9c4eeab239a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580af7be-b627-4700-8477-af75bff6811b" xlink:to="loc_us-gaap_TreasuryStockValue_f12f97dc-cf38-4a71-95aa-9c4eeab239a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c0f41ff-a11f-4739-9178-4025617adecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c0f41ff-a11f-4739-9178-4025617adecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_98750919-be84-4f03-bc00-64c064389fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_98750919-be84-4f03-bc00-64c064389fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4f9eb899-7f57-4fd0-b432-31f20f4c68fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4f9eb899-7f57-4fd0-b432-31f20f4c68fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c9d40920-a226-4588-8576-645b146d7515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c9d40920-a226-4588-8576-645b146d7515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_878213f6-6951-4bd4-8f8d-1c057c949939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15bfb726-d87b-4646-93fe-88764c9be867" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_878213f6-6951-4bd4-8f8d-1c057c949939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_41423b6c-9d3f-4993-bdd7-7c2b9843e236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1a72499f-0d31-4d14-b376-45166157e0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41423b6c-9d3f-4993-bdd7-7c2b9843e236" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_1a72499f-0d31-4d14-b376-45166157e0ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1e2a7078-5f15-4202-b7e0-cbe000cd47de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41423b6c-9d3f-4993-bdd7-7c2b9843e236" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1e2a7078-5f15-4202-b7e0-cbe000cd47de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_65e4603c-4707-4953-9e35-e9080b5b205e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41423b6c-9d3f-4993-bdd7-7c2b9843e236" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_65e4603c-4707-4953-9e35-e9080b5b205e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e4dcc80-0f13-4b12-b7fc-76b944b5d765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_41423b6c-9d3f-4993-bdd7-7c2b9843e236" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3e4dcc80-0f13-4b12-b7fc-76b944b5d765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2fe3a070-3ec6-4e04-8ebc-da1f0f6532d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cfbff4c1-d894-4728-8cff-c0966157253b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2fe3a070-3ec6-4e04-8ebc-da1f0f6532d3" xlink:to="loc_us-gaap_Liabilities_cfbff4c1-d894-4728-8cff-c0966157253b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_403e7b86-2520-46b9-ad4e-e0200f42dba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2fe3a070-3ec6-4e04-8ebc-da1f0f6532d3" xlink:to="loc_us-gaap_StockholdersEquity_403e7b86-2520-46b9-ad4e-e0200f42dba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ff18d98d-abbf-492b-850b-038a1408a570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:to="loc_us-gaap_AssetsCurrent_ff18d98d-abbf-492b-850b-038a1408a570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8bd4673e-a6a2-4089-9716-9bc0de01ea56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8bd4673e-a6a2-4089-9716-9bc0de01ea56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_04c0b754-04f1-4ae9-9a2e-4d2cf7d5e030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_04c0b754-04f1-4ae9-9a2e-4d2cf7d5e030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba33a11a-bd2e-449b-90cb-a7ec2dff6afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba33a11a-bd2e-449b-90cb-a7ec2dff6afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_3ddaadb8-0221-4dd6-ae2f-0f5a117a6fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c6c2b83-1908-4855-9a1c-dde251aaeb29" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_3ddaadb8-0221-4dd6-ae2f-0f5a117a6fd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbd31595-7dd8-4f45-8eb7-44a96370fdb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bbd31595-7dd8-4f45-8eb7-44a96370fdb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_074f9b85-5990-453d-bdff-a06ed141871d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_074f9b85-5990-453d-bdff-a06ed141871d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_c2c00d85-9a29-46d4-97dc-a0998b2e2673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_c2c00d85-9a29-46d4-97dc-a0998b2e2673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d1c5552b-4f44-4f51-bee0-fb40fbb9108b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d1c5552b-4f44-4f51-bee0-fb40fbb9108b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a67ed649-08d4-4d50-a025-b88c615b62c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a67ed649-08d4-4d50-a025-b88c615b62c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_04857fa2-7442-4409-be01-be0ec1ed31a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_InventoryNet_04857fa2-7442-4409-be01-be0ec1ed31a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_c6f3a3f2-c7ff-4ddf-a613-8b017e7f7fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_04ae6831-9e0c-4044-8458-94dd0448836e" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_c6f3a3f2-c7ff-4ddf-a613-8b017e7f7fbc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_68fb33ff-3363-49a4-91e7-30ef199029eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_38106bdd-07dc-4bdc-9fc8-6821d1b20029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_68fb33ff-3363-49a4-91e7-30ef199029eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_38106bdd-07dc-4bdc-9fc8-6821d1b20029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb512fa0-8c85-4aca-9368-594fbcfcf63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_68fb33ff-3363-49a4-91e7-30ef199029eb" xlink:to="loc_us-gaap_NetIncomeLoss_eb512fa0-8c85-4aca-9368-594fbcfcf63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_08e52b4f-8097-48e4-a942-8b2c0416c80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_68fb33ff-3363-49a4-91e7-30ef199029eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_08e52b4f-8097-48e4-a942-8b2c0416c80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_70109856-e87b-4280-a015-04c5aff013b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fb0ef564-8339-47d1-90fe-477b9410383f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70109856-e87b-4280-a015-04c5aff013b5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fb0ef564-8339-47d1-90fe-477b9410383f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_871f188c-c6dc-4926-8f45-078f363cb710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70109856-e87b-4280-a015-04c5aff013b5" xlink:to="loc_us-gaap_InterestExpense_871f188c-c6dc-4926-8f45-078f363cb710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a9664d7-217e-4abd-ac0f-e42362a670f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a8ca985b-e6e8-49f2-90bc-d25a92eda8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9a9664d7-217e-4abd-ac0f-e42362a670f0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a8ca985b-e6e8-49f2-90bc-d25a92eda8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_183b0ccb-a325-4d53-a7cd-7eeaa16a4d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9a9664d7-217e-4abd-ac0f-e42362a670f0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_183b0ccb-a325-4d53-a7cd-7eeaa16a4d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_81f72eb1-1975-412b-a5dd-ea3daa9cfc38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e6acf1a9-17dd-4a7b-8700-7244bfab6d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_81f72eb1-1975-412b-a5dd-ea3daa9cfc38" xlink:to="loc_us-gaap_OperatingIncomeLoss_e6acf1a9-17dd-4a7b-8700-7244bfab6d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3ec8e5d6-420b-413f-b90f-fc299427ff62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_81f72eb1-1975-412b-a5dd-ea3daa9cfc38" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3ec8e5d6-420b-413f-b90f-fc299427ff62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_223ab051-5562-4203-a746-0aa1ca181dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a92edf7-e17f-4fb0-8971-61b757fc94a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_223ab051-5562-4203-a746-0aa1ca181dfb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a92edf7-e17f-4fb0-8971-61b757fc94a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7525d3d9-004b-4544-89a5-6c257547d58e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_223ab051-5562-4203-a746-0aa1ca181dfb" xlink:to="loc_us-gaap_CostsAndExpenses_7525d3d9-004b-4544-89a5-6c257547d58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d0529946-8a19-44a1-ba12-e0ca6f1ac39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3aa130b-e715-4d0f-b9b1-c8dd312a81f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d0529946-8a19-44a1-ba12-e0ca6f1ac39a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3aa130b-e715-4d0f-b9b1-c8dd312a81f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2e574482-c0b2-4454-a733-fdf5c39a7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d0529946-8a19-44a1-ba12-e0ca6f1ac39a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2e574482-c0b2-4454-a733-fdf5c39a7ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_6bb82484-7964-4be5-8621-5170cb79edfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d0529946-8a19-44a1-ba12-e0ca6f1ac39a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_6bb82484-7964-4be5-8621-5170cb79edfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5def94b9-c211-4cf3-a63a-88cffe6dc01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_d0529946-8a19-44a1-ba12-e0ca6f1ac39a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5def94b9-c211-4cf3-a63a-88cffe6dc01b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_84e3ea27-9860-4d40-9dc6-efecff4f8e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_84e3ea27-9860-4d40-9dc6-efecff4f8e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_da966c0c-7bdf-4d87-a643-61989ae74357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_ShareBasedCompensation_da966c0c-7bdf-4d87-a643-61989ae74357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_51bd5e5b-64ad-424b-a824-0030ca91daed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_51bd5e5b-64ad-424b-a824-0030ca91daed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b889f8e5-24f4-422f-8acc-72d5bd46befc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b889f8e5-24f4-422f-8acc-72d5bd46befc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ca48f9ef-c4f7-4357-b972-8a5397c0c621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ca48f9ef-c4f7-4357-b972-8a5397c0c621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c2d9c682-6677-437a-8afe-5a1de92a56e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c2d9c682-6677-437a-8afe-5a1de92a56e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1212b04d-fba2-494b-8a4a-60e991d6ff3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1212b04d-fba2-494b-8a4a-60e991d6ff3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_64fbaed1-6ca9-4210-b818-c68a26c0b232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_64fbaed1-6ca9-4210-b818-c68a26c0b232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fed380cc-0eec-4a40-ab65-aa40d467f613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f4deb89d-07dd-42b1-956a-cbc43016e440" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_fed380cc-0eec-4a40-ab65-aa40d467f613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d1a295-824d-45d1-87fa-e32baeea4442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0b4bc476-4568-4f23-b4fd-819ab2ce680f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d1a295-824d-45d1-87fa-e32baeea4442" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0b4bc476-4568-4f23-b4fd-819ab2ce680f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_24229782-ebb1-4de8-845e-0e639c41dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d1a295-824d-45d1-87fa-e32baeea4442" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_24229782-ebb1-4de8-845e-0e639c41dcfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_e3a494f0-a66c-4c29-a979-d38562daba39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d1a295-824d-45d1-87fa-e32baeea4442" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_e3a494f0-a66c-4c29-a979-d38562daba39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20c3b8bd-b268-4d72-b001-30dc0aa284c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_20c3b8bd-b268-4d72-b001-30dc0aa284c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10ea7fc0-e31d-4551-9046-ef9d33fa2500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10ea7fc0-e31d-4551-9046-ef9d33fa2500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acf154d8-5b89-413e-8f17-ef189876ffec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acf154d8-5b89-413e-8f17-ef189876ffec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_81447557-20cd-4060-8115-32fe13926528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_81447557-20cd-4060-8115-32fe13926528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_90864351-0e36-4003-b683-14d744250ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_90864351-0e36-4003-b683-14d744250ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_d4d7206d-6407-41b5-9347-bd6701b40436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8643d3-dd28-4c8c-829d-619485ce5f4d" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_d4d7206d-6407-41b5-9347-bd6701b40436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1180249-cfca-4063-aa72-57aaea6b21fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e58a32e9-a522-4f2e-821c-52e8e394b1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1180249-cfca-4063-aa72-57aaea6b21fb" xlink:to="loc_us-gaap_NetIncomeLoss_e58a32e9-a522-4f2e-821c-52e8e394b1c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_7cd51413-6ae9-420e-84bb-9c85d1242454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1180249-cfca-4063-aa72-57aaea6b21fb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_7cd51413-6ae9-420e-84bb-9c85d1242454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c14a545f-5a6e-4909-9fa5-8585cdce42be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32a0225b-8c75-443c-b3ec-f136709b8c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c14a545f-5a6e-4909-9fa5-8585cdce42be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32a0225b-8c75-443c-b3ec-f136709b8c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_459021fa-afe1-4fa7-8785-d001bdaee8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c14a545f-5a6e-4909-9fa5-8585cdce42be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_459021fa-afe1-4fa7-8785-d001bdaee8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb07eb74-ee28-48ea-9b01-f9cb10d96fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c14a545f-5a6e-4909-9fa5-8585cdce42be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb07eb74-ee28-48ea-9b01-f9cb10d96fa2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatements"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsPolicies"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofBalanceSheetDataDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofCashFlowsDataDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSales"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShare"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b32d55d-31f5-4e50-afcd-d626fc3445b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0615c7d8-3844-4d6d-8692-ec64a0c302c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b32d55d-31f5-4e50-afcd-d626fc3445b8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0615c7d8-3844-4d6d-8692-ec64a0c302c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_270713f9-8122-4f8b-aaac-b74a6e4b9d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b32d55d-31f5-4e50-afcd-d626fc3445b8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_270713f9-8122-4f8b-aaac-b74a6e4b9d5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2722addf-458f-4416-9424-fc3c3b975803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce72ca32-9ec5-46bc-851f-1cdb0090e1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2722addf-458f-4416-9424-fc3c3b975803" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ce72ca32-9ec5-46bc-851f-1cdb0090e1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_691f0b9e-14e5-46d6-bac8-e2ebb91eed51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2722addf-458f-4416-9424-fc3c3b975803" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_691f0b9e-14e5-46d6-bac8-e2ebb91eed51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87ca42c2-7217-4967-833d-c53839f568d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2722addf-458f-4416-9424-fc3c3b975803" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87ca42c2-7217-4967-833d-c53839f568d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_297e2285-1e65-4a4d-bd9e-2f07be35571b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5357db00-2074-4bb6-bf69-45c5f5eb1136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_297e2285-1e65-4a4d-bd9e-2f07be35571b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5357db00-2074-4bb6-bf69-45c5f5eb1136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bef3c8f3-c526-4c26-b1f2-46632cfcb0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_297e2285-1e65-4a4d-bd9e-2f07be35571b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bef3c8f3-c526-4c26-b1f2-46632cfcb0ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_43b41519-4f0e-463c-b224-8ed734cdc16e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b35bc211-d0d1-4ca3-bee7-ff54a8dbd7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_43b41519-4f0e-463c-b224-8ed734cdc16e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b35bc211-d0d1-4ca3-bee7-ff54a8dbd7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ce6ce21-60d8-4ac9-bbed-97e2788f3c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_43b41519-4f0e-463c-b224-8ed734cdc16e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ce6ce21-60d8-4ac9-bbed-97e2788f3c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0701c69b-54a8-4b83-b269-3d38c10e6040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b6fdb364-c2d4-47fd-8c41-047a2d6d704d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0701c69b-54a8-4b83-b269-3d38c10e6040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_b6fdb364-c2d4-47fd-8c41-047a2d6d704d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0b402c27-79ab-4c74-b744-32d637e2a33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0701c69b-54a8-4b83-b269-3d38c10e6040" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0b402c27-79ab-4c74-b744-32d637e2a33c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_b4f5aae9-02a3-4faf-b093-c490d666b922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fac9742-30e4-42df-9951-f9bedb6067c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_b4f5aae9-02a3-4faf-b093-c490d666b922" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0fac9742-30e4-42df-9951-f9bedb6067c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_abd4add6-6cb3-4c9d-bd06-7e879886f22a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_b4f5aae9-02a3-4faf-b093-c490d666b922" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_abd4add6-6cb3-4c9d-bd06-7e879886f22a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20200930.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fc52c994-29bb-4ad0-a125-b102e59aaf23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0be23a30-329e-4ce3-a3c1-8124a7e43424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc52c994-29bb-4ad0-a125-b102e59aaf23" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0be23a30-329e-4ce3-a3c1-8124a7e43424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_96b48c8b-09c7-4dc4-8f15-cafab9984f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc52c994-29bb-4ad0-a125-b102e59aaf23" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_96b48c8b-09c7-4dc4-8f15-cafab9984f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_847f8b9e-d6f1-4841-832d-39cee9b5c8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc52c994-29bb-4ad0-a125-b102e59aaf23" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_847f8b9e-d6f1-4841-832d-39cee9b5c8d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_15d81f78-b1cd-4261-9ae9-46e09edda189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_fc52c994-29bb-4ad0-a125-b102e59aaf23" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_15d81f78-b1cd-4261-9ae9-46e09edda189" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Debt" xlink:type="simple" xlink:href="regn-20200930.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquitySanofiFundingDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsTables"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd95dea5-b7de-403b-8264-575160681582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8103a45d-c6fc-49b0-a64a-8a1ee84b0370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd95dea5-b7de-403b-8264-575160681582" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8103a45d-c6fc-49b0-a64a-8a1ee84b0370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_6311c705-7681-4d33-aeb6-d2bcbfe8bd4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd95dea5-b7de-403b-8264-575160681582" xlink:to="loc_us-gaap_RestrictedCash_6311c705-7681-4d33-aeb6-d2bcbfe8bd4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMatters"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMattersDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>regn-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20200930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended" id="ic657ba69f12b4f61a3d5ac34b0773faa_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9d4354ea-f0a6-4eed-beb4-02f4068df27f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentType_9d4354ea-f0a6-4eed-beb4-02f4068df27f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_25f03fbe-3de6-41d7-ae0f-022ff89422f4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentQuarterlyReport_25f03fbe-3de6-41d7-ae0f-022ff89422f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7487abbe-f02a-4db3-9f14-c764df7abac2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentPeriodEndDate_7487abbe-f02a-4db3-9f14-c764df7abac2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2c07fec1-847b-45cb-b4da-30929c7bacf3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentTransitionReport_2c07fec1-847b-45cb-b4da-30929c7bacf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_45d80c6f-1e87-4601-bc33-083b2026ef3b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityFileNumber_45d80c6f-1e87-4601-bc33-083b2026ef3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c907c67-87da-46a5-a330-f7d10dd89e3a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityRegistrantName_1c907c67-87da-46a5-a330-f7d10dd89e3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8e49def8-12fa-4ef6-b8f3-194fe791ac0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8e49def8-12fa-4ef6-b8f3-194fe791ac0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6707fbb2-ee9d-49cb-937a-938a03f6047e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityTaxIdentificationNumber_6707fbb2-ee9d-49cb-937a-938a03f6047e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b573aeba-7429-4fe8-86dc-2945d2ab65a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressAddressLine1_b573aeba-7429-4fe8-86dc-2945d2ab65a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_448daedc-397f-4102-b2b6-5c7aeb6ceab7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressCityOrTown_448daedc-397f-4102-b2b6-5c7aeb6ceab7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_68069eaf-b8b4-46a8-a5e2-ffe4aa8d28af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressStateOrProvince_68069eaf-b8b4-46a8-a5e2-ffe4aa8d28af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5cb32ee3-ba24-4211-832f-0473ad4ac087" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressPostalZipCode_5cb32ee3-ba24-4211-832f-0473ad4ac087" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a5e22019-7b16-4cb2-a78a-2cb28c623dbc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_CityAreaCode_a5e22019-7b16-4cb2-a78a-2cb28c623dbc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d224f9b7-8123-45ba-a4ad-8a2cbc9a8ce2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_LocalPhoneNumber_d224f9b7-8123-45ba-a4ad-8a2cbc9a8ce2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2bb346ee-661e-4542-978f-41300a7ed5b5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_Security12bTitle_2bb346ee-661e-4542-978f-41300a7ed5b5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac7169e7-8d51-4aa1-9b35-e02d3c668da0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_TradingSymbol_ac7169e7-8d51-4aa1-9b35-e02d3c668da0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af3eccb8-6012-4e1f-ba31-df8086433689" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_SecurityExchangeName_af3eccb8-6012-4e1f-ba31-df8086433689" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2501990b-f13d-4713-9166-89686870d4f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCurrentReportingStatus_2501990b-f13d-4713-9166-89686870d4f7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a101ee0b-7c01-4c59-8bce-3dc752187ca7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityInteractiveDataCurrent_a101ee0b-7c01-4c59-8bce-3dc752187ca7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_27d329b0-fb91-4e5c-bf55-ca9d6c1fcf4b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityFilerCategory_27d329b0-fb91-4e5c-bf55-ca9d6c1fcf4b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ec5ca084-d47d-46b5-9f67-32274b221d55" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntitySmallBusiness_ec5ca084-d47d-46b5-9f67-32274b221d55" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3c0a0c00-d835-4a93-8709-f3ac1dba8bfb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityEmergingGrowthCompany_3c0a0c00-d835-4a93-8709-f3ac1dba8bfb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1cf276ba-c327-4071-847f-4db77ec6821d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityShellCompany_1cf276ba-c327-4071-847f-4db77ec6821d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b7d13289-2b09-4e83-a1da-2e92da472ce1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b7d13289-2b09-4e83-a1da-2e92da472ce1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd8d5017-5e0c-4fde-812e-d121a417fd7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCentralIndexKey_fd8d5017-5e0c-4fde-812e-d121a417fd7e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_936f208e-718b-4b39-b5a9-f8255dbcf860" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_CurrentFiscalYearEndDate_936f208e-718b-4b39-b5a9-f8255dbcf860" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2b7b6fd-8e0b-43b5-abd6-1b489b68ad59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentFiscalYearFocus_b2b7b6fd-8e0b-43b5-abd6-1b489b68ad59" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d1ce5401-a4da-4ae7-ac1e-fc46465cf9e1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d1ce5401-a4da-4ae7-ac1e-fc46465cf9e1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_02b89bd3-5bb4-4682-8c1e-fce6401f9065" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_AmendmentFlag_02b89bd3-5bb4-4682-8c1e-fce6401f9065" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3400aa3-70c0-4239-a430-0223e5865512_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:to="loc_us-gaap_ClassOfStockDomain_d3400aa3-70c0-4239-a430-0223e5865512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:to="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5a64e73c-2437-445b-b7fc-8fc8600d2efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:to="loc_us-gaap_CommonClassAMember_5a64e73c-2437-445b-b7fc-8fc8600d2efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9589d625-507f-432e-b0b2-ac864107d25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:to="loc_us-gaap_CommonStockMember_9589d625-507f-432e-b0b2-ac864107d25d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended" id="i55d4a076f98d46fc992fb13f9e55a759_CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a59801-1377-4d88-a1ae-2732ef3aa43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a59801-1377-4d88-a1ae-2732ef3aa43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_05800f82-5358-4b75-a801-f4a4d6ec75a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_05800f82-5358-4b75-a801-f4a4d6ec75a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_abb39355-985b-4ea7-b6e9-6834b2a49375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_abb39355-985b-4ea7-b6e9-6834b2a49375" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_684225fa-f77b-4a3f-9212-11dcca9fb350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_684225fa-f77b-4a3f-9212-11dcca9fb350" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_11316a60-047b-472c-a8d2-739f3c875bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_11316a60-047b-472c-a8d2-739f3c875bcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_86999386-7162-49b9-a038-425c230addf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_InventoryNet_86999386-7162-49b9-a038-425c230addf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135ff17e-d036-4c65-86a4-fc40444d589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135ff17e-d036-4c65-86a4-fc40444d589a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_738b3ca1-bcec-4a77-ba98-94368aa0258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AssetsCurrent_738b3ca1-bcec-4a77-ba98-94368aa0258a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_3a40523d-4a85-4f09-bde6-595970bd1197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_3a40523d-4a85-4f09-bde6-595970bd1197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_457cd7cc-b530-42f3-8c88-31470e86dfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_457cd7cc-b530-42f3-8c88-31470e86dfa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e4478fe-8970-4780-ad2c-3eeb41f90362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e4478fe-8970-4780-ad2c-3eeb41f90362" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e080791c-1752-4c2b-bad7-2fed777c5757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e080791c-1752-4c2b-bad7-2fed777c5757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1d4ea45c-b2c2-4003-8898-e7c50fb30c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_Assets_1d4ea45c-b2c2-4003-8898-e7c50fb30c0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_bf48417f-864b-41eb-9e15-55ccd6bdbd50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_bf48417f-864b-41eb-9e15-55ccd6bdbd50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_be676258-b809-4079-a3cb-796683bace37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_be676258-b809-4079-a3cb-796683bace37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73740080-f039-42da-84ca-8e99746c4e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73740080-f039-42da-84ca-8e99746c4e95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a5cee0ed-594a-4952-8824-489f823dbcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a5cee0ed-594a-4952-8824-489f823dbcf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f024bdd2-2f7d-4058-ae30-cb0bf2db7ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_LiabilitiesCurrent_f024bdd2-2f7d-4058-ae30-cb0bf2db7ff0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1a3843bf-7caa-4c78-b96f-a3d79458fcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1a3843bf-7caa-4c78-b96f-a3d79458fcac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b26ee7d0-23ac-416a-bed1-0dacfd4a0f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b26ee7d0-23ac-416a-bed1-0dacfd4a0f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1e6d832f-5149-40b2-8b81-87e2d4509259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1e6d832f-5149-40b2-8b81-87e2d4509259" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a716e9a3-3a27-481a-9fa8-1d6e7964a673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a716e9a3-3a27-481a-9fa8-1d6e7964a673" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b7ce0a1-57b7-4a0c-b07b-64310ba18f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_Liabilities_6b7ce0a1-57b7-4a0c-b07b-64310ba18f89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_16f7525e-743e-4bd0-a0f5-e368aed85b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_PreferredStockValue_16f7525e-743e-4bd0-a0f5-e368aed85b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ce57737-0873-4cad-a0f3-64e172d8ce9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_CommonStockValue_3ce57737-0873-4cad-a0f3-64e172d8ce9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fc9a1b58-315b-4200-a32f-783614f798d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fc9a1b58-315b-4200-a32f-783614f798d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c624737-94df-42ea-925d-ac56298ac4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c624737-94df-42ea-925d-ac56298ac4da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03857899-0987-47e1-ac05-f9972ee0d976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03857899-0987-47e1-ac05-f9972ee0d976" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_db62bc9a-1c58-448d-bed3-b536f34c23b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_TreasuryStockValue_db62bc9a-1c58-448d-bed3-b536f34c23b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a98a163-6110-48c5-b942-9c3581b8e8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_StockholdersEquity_4a98a163-6110-48c5-b942-9c3581b8e8d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af91f50-a165-449e-b26a-a891b1e78484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af91f50-a165-449e-b26a-a891b1e78484" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_01bbf873-14ed-461e-87c3-494658bd2fc7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:to="loc_us-gaap_ProjectMember_01bbf873-14ed-461e-87c3-494658bd2fc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:to="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_320fb462-b775-489f-9e93-01a262301864" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:to="loc_regn_SanofiCollaborationAgreementMember_320fb462-b775-489f-9e93-01a262301864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_f1810c5f-fcec-4e76-9334-5bffa62c7faf" xlink:href="regn-20200930.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:to="loc_regn_OtherCollaborationAgreementsMember_f1810c5f-fcec-4e76-9334-5bffa62c7faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:to="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_250c1f27-3853-4f3e-ac89-2a77a6724b79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:to="loc_us-gaap_ClassOfStockDomain_250c1f27-3853-4f3e-ac89-2a77a6724b79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:to="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_abf1ca36-e87e-4671-9f4f-1cebf2a04541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:to="loc_us-gaap_CommonClassAMember_abf1ca36-e87e-4671-9f4f-1cebf2a04541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e6179f6-3c8b-4f74-9693-6b17f4551a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:to="loc_us-gaap_CommonStockMember_8e6179f6-3c8b-4f74-9693-6b17f4551a4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended" id="ib9cdaf9288664a579e6a528d658d2956_CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:to="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f8b2be1-638d-4337-b4a9-4a9a4adf0192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f8b2be1-638d-4337-b4a9-4a9a4adf0192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08f5b5ca-b2c3-4307-a352-c839e0528d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08f5b5ca-b2c3-4307-a352-c839e0528d32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6224885c-c67f-4845-8a80-a32f1bc59089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6224885c-c67f-4845-8a80-a32f1bc59089" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_afa58d98-0efa-47a7-8382-4ee21d3d8262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_afa58d98-0efa-47a7-8382-4ee21d3d8262" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_72d03f8e-94b1-4114-9ac0-54bfc65acea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_72d03f8e-94b1-4114-9ac0-54bfc65acea2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_732191e1-bad3-4dbe-9788-12266e298b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_732191e1-bad3-4dbe-9788-12266e298b42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1d2ae5f0-7ad9-4137-8180-982e158e3fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesIssued_1d2ae5f0-7ad9-4137-8180-982e158e3fd8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43430c9e-79ba-4ad1-bad5-9e3b6f005641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43430c9e-79ba-4ad1-bad5-9e3b6f005641" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a0d63cf2-afd5-473e-921e-0f38fe9dbe51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_TreasuryStockShares_a0d63cf2-afd5-473e-921e-0f38fe9dbe51" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:to="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:to="loc_us-gaap_ClassOfStockDomain_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:to="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_660b257f-afaa-412d-ac2a-02a1d3c7ccb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:to="loc_us-gaap_CommonClassAMember_660b257f-afaa-412d-ac2a-02a1d3c7ccb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89216f56-d6c2-438e-8f16-c5f372760d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:to="loc_us-gaap_CommonStockMember_89216f56-d6c2-438e-8f16-c5f372760d2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended" id="ib80199cfee574f6bb49b248b31ccb551_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:to="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da11dc42-620a-44ab-88c5-50af5d636a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da11dc42-620a-44ab-88c5-50af5d636a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_719728ac-61cd-4675-8619-9b0b6fd524bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_719728ac-61cd-4675-8619-9b0b6fd524bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a61514f-634f-4bd9-8b3e-579277c74849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a61514f-634f-4bd9-8b3e-579277c74849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3b45e5d-4da2-4ebb-b808-427e4f255965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3b45e5d-4da2-4ebb-b808-427e4f255965" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c14d8b9-ffe7-42ec-9e2e-785b97aeac8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c14d8b9-ffe7-42ec-9e2e-785b97aeac8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2c351653-c6d5-4270-a76e-f95f5a07a34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_CostsAndExpenses_2c351653-c6d5-4270-a76e-f95f5a07a34b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c64e3330-4fd4-4429-bf8b-3ccf2c44bf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_OperatingIncomeLoss_c64e3330-4fd4-4429-bf8b-3ccf2c44bf7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e352c21d-c637-4bba-8aea-ef18a68f5bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e352c21d-c637-4bba-8aea-ef18a68f5bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_edca1104-4351-4c3e-9dfd-925538ac37d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_InterestExpense_edca1104-4351-4c3e-9dfd-925538ac37d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3ffb5be8-d7a8-45a7-8c54-adbb55b17cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3ffb5be8-d7a8-45a7-8c54-adbb55b17cdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_edfc0a88-2d02-452d-885d-903cdd844027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_edfc0a88-2d02-452d-885d-903cdd844027" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e5a48a3d-2226-4296-8293-6753f1383c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e5a48a3d-2226-4296-8293-6753f1383c88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52591481-47ca-45a0-9071-d2c423262e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_NetIncomeLoss_52591481-47ca-45a0-9071-d2c423262e36" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9193a227-09e6-4f06-b08d-cf220719a74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_9193a227-09e6-4f06-b08d-cf220719a74f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9213fa34-c1fd-4dd6-888d-cf652c275961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9213fa34-c1fd-4dd6-888d-cf652c275961" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6d458db6-2d25-4862-9c8c-35b6d205dcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6d458db6-2d25-4862-9c8c-35b6d205dcff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5f77f60-5236-4add-b6f8-2e3e09c078e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5f77f60-5236-4add-b6f8-2e3e09c078e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d9f296d-1951-42e5-8dd3-d37037167a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f03b9657-ee01-4889-86d9-5f9e85b4eeec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f03b9657-ee01-4889-86d9-5f9e85b4eeec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f5f72642-640b-4704-9766-a50ee55cd1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f5f72642-640b-4704-9766-a50ee55cd1fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbee1c19-e2cc-4f05-9517-53bff8670a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbee1c19-e2cc-4f05-9517-53bff8670a70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:to="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8fbc76fa-1beb-4eac-889a-9a59721c990b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:to="loc_us-gaap_ProjectMember_8fbc76fa-1beb-4eac-889a-9a59721c990b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:to="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_ffda342b-26d4-4d67-9c33-e0646954344f" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_SanofiCollaborationAgreementMember_ffda342b-26d4-4d67-9c33-e0646954344f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_dd47c375-0d04-4bd0-96bb-9bf2507376d5" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_BayerCollaborationAgreementMember_dd47c375-0d04-4bd0-96bb-9bf2507376d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherRevenueMember_6894cdf5-cf77-4753-a339-d066031d535f" xlink:href="regn-20200930.xsd#regn_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_OtherRevenueMember_6894cdf5-cf77-4753-a339-d066031d535f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:to="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea01ce13-6f85-4efd-9226-b7e553fed76f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:to="loc_srt_ProductsAndServicesDomain_ea01ce13-6f85-4efd-9226-b7e553fed76f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:to="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_310b49cf-c20a-4de4-b6d8-6ebd3501e5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_us-gaap_ProductMember_310b49cf-c20a-4de4-b6d8-6ebd3501e5b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b5160a26-9adb-451e-ac46-713090d9841a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b5160a26-9adb-451e-ac46-713090d9841a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_c65399af-d1ab-4b68-b579-ef50f7668f82" xlink:href="regn-20200930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_regn_CollaborationandContractManufacturingMember_c65399af-d1ab-4b68-b579-ef50f7668f82" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="i89792d183e1b4451a8c37b8fee9337ee_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f0be1588-14ca-431c-a8fb-22373babe09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_SharesOutstanding_f0be1588-14ca-431c-a8fb-22373babe09e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23eb70c3-b564-482a-a188-8149a7302ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockholdersEquity_23eb70c3-b564-482a-a188-8149a7302ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1a93d185-7d42-48ed-845b-9c0accefbe10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1a93d185-7d42-48ed-845b-9c0accefbe10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5486017-cd05-4a4b-b53d-949261e44b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5486017-cd05-4a4b-b53d-949261e44b34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fce7648c-958f-4a9c-b5d9-fac0203efdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fce7648c-958f-4a9c-b5d9-fac0203efdad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7459f22f-30d0-4939-9908-f9b46dd944e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7459f22f-30d0-4939-9908-f9b46dd944e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_77d8ad3c-4a8e-4587-bff3-10da0ec12ac2" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_77d8ad3c-4a8e-4587-bff3-10da0ec12ac2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_f5442194-40d7-45c4-b6c8-b619eac7849c" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_f5442194-40d7-45c4-b6c8-b619eac7849c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_66f87c3e-0a24-4c63-89d3-c88e7d08906f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_66f87c3e-0a24-4c63-89d3-c88e7d08906f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aec3908a-053d-4a9b-9e7c-a8c089b566b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aec3908a-053d-4a9b-9e7c-a8c089b566b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4bf23561-3772-4c70-8a7f-14711993339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4bf23561-3772-4c70-8a7f-14711993339a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_440b124b-37be-478e-a551-a2753a51c348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_NetIncomeLoss_440b124b-37be-478e-a551-a2753a51c348" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a557fd1-13f1-4b81-ab3c-2998639b923b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a557fd1-13f1-4b81-ab3c-2998639b923b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_87b3f010-b090-4633-8c66-d1f071e1c130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_87b3f010-b090-4633-8c66-d1f071e1c130" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_e218b602-ecb9-460b-8f86-2cdf29665e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_e218b602-ecb9-460b-8f86-2cdf29665e06" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd0e8aae-cf13-4640-9f63-82489578432c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c91bded9-129e-4ac7-85c1-ce3f73b03cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:to="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15a4e8ec-19be-4c82-b612-12f840c742a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:to="loc_us-gaap_ClassOfStockDomain_15a4e8ec-19be-4c82-b612-12f840c742a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:to="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_310234c4-cbb2-4d94-aaec-fdb55f9d446f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:to="loc_us-gaap_CommonClassAMember_310234c4-cbb2-4d94-aaec-fdb55f9d446f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdf27f87-9978-4a0d-bcce-cd87c1107950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:to="loc_us-gaap_CommonStockMember_bdf27f87-9978-4a0d-bcce-cd87c1107950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bbfd3230-f458-4038-b2d5-e217d1307077_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:to="loc_us-gaap_EquityComponentDomain_bbfd3230-f458-4038-b2d5-e217d1307077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:to="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_78ff709b-b963-4a64-921b-6a9efa7b2a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_78ff709b-b963-4a64-921b-6a9efa7b2a1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6a992e69-e994-4f5c-921a-b04817ba7636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_RetainedEarningsMember_6a992e69-e994-4f5c-921a-b04817ba7636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_670fe4c0-e203-4415-9b91-8ffc787d2af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_670fe4c0-e203-4415-9b91-8ffc787d2af6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e6398000-67b5-4314-8744-6686b22ffaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_TreasuryStockMember_e6398000-67b5-4314-8744-6686b22ffaad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b78ca5c8-e304-456d-bd0d-88f3cc52f56f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b78ca5c8-e304-456d-bd0d-88f3cc52f56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e18c2d5-f0d5-4fce-b926-75349068ca9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e18c2d5-f0d5-4fce-b926-75349068ca9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended" id="i9126b2b7810c40fd8e265ad39eb265fc_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatements"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="extended" id="i262ae65efa5247e99ad2399b2b0d98ff_InterimFinancialStatements"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsPolicies"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="extended" id="i79e91eb5a7dc40f7a32748e3a4463ca2_InterimFinancialStatementsPolicies"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="extended" id="iab8560ff544e49cda47f68c0997c92dc_InterimFinancialStatementsTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofBalanceSheetDataDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="extended" id="ib778bb0ecfc74d82a179c0f3335f2008_InterimFinancialStatementsScheduleofBalanceSheetDataDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b837e624-71c0-4145-9ec1-fe7629e27fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b837e624-71c0-4145-9ec1-fe7629e27fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_596802cf-4880-4e2f-a822-f6b4864306d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_596802cf-4880-4e2f-a822-f6b4864306d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c530aaf5-10cd-4815-8f0e-1c0886dd8943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c530aaf5-10cd-4815-8f0e-1c0886dd8943" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3c31c225-857d-4628-b3f3-6606f306aa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3c31c225-857d-4628-b3f3-6606f306aa04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a87b9db8-904e-4c33-b477-134dfded4f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a87b9db8-904e-4c33-b477-134dfded4f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:to="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_9c6f988f-0739-4d2b-9add-04f1fe77e168_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:to="loc_srt_RestatementDomain_9c6f988f-0739-4d2b-9add-04f1fe77e168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:to="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_72664528-f73c-4a8a-9c02-a6136f0b8394" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_72664528-f73c-4a8a-9c02-a6136f0b8394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_3106b813-a751-4f3f-8307-fa87c69e21fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:to="loc_srt_RestatementAdjustmentMember_3106b813-a751-4f3f-8307-fa87c69e21fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e98a4baf-d981-49af-a577-b046e9d9e96a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:to="loc_us-gaap_ProjectMember_e98a4baf-d981-49af-a577-b046e9d9e96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:to="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_4ee47a7f-5897-44f8-bb65-ad98fabe79ec" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:to="loc_regn_SanofiCollaborationAgreementMember_4ee47a7f-5897-44f8-bb65-ad98fabe79ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_c2d039c2-4ed3-4c88-ae10-e0650a43d61d" xlink:href="regn-20200930.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:to="loc_regn_OtherCollaborationAgreementsMember_c2d039c2-4ed3-4c88-ae10-e0650a43d61d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="extended" id="i87f62b5f46d44889b452f56c879dfbaa_InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6079037-4b0d-4abf-947a-52cca9158e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6079037-4b0d-4abf-947a-52cca9158e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_508932f1-5a98-46ed-8df3-166bed5e3ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_508932f1-5a98-46ed-8df3-166bed5e3ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c76db9e3-49c7-488a-90d8-734c98b2de95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c76db9e3-49c7-488a-90d8-734c98b2de95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9ddc168c-3039-49f3-b807-37c4a5f6664e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9ddc168c-3039-49f3-b807-37c4a5f6664e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_6634bc1c-8366-4e17-a959-c112666d4e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_6634bc1c-8366-4e17-a959-c112666d4e96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_061ff121-e68d-4b53-98e2-962a9ff0385e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_CostsAndExpenses_061ff121-e68d-4b53-98e2-962a9ff0385e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_892befd9-8356-4321-9166-a46f9ea80540_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:to="loc_srt_RestatementDomain_892befd9-8356-4321-9166-a46f9ea80540_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:to="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_df9e8e00-af03-4628-95bd-1104322d42d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_df9e8e00-af03-4628-95bd-1104322d42d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_9b54c143-1af1-4b93-9746-633178e93f93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:to="loc_srt_RestatementAdjustmentMember_9b54c143-1af1-4b93-9746-633178e93f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_2099988a-649d-4829-acbe-d73ffa2b1a9b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:to="loc_us-gaap_ProjectMember_2099988a-649d-4829-acbe-d73ffa2b1a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:to="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_6b070941-2818-4ff5-87e0-46148a457a47" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_SanofiCollaborationAgreementMember_6b070941-2818-4ff5-87e0-46148a457a47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_306285b8-0690-4331-99c7-cfbf33d7092a" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_BayerCollaborationAgreementMember_306285b8-0690-4331-99c7-cfbf33d7092a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherRevenueMember_6a56abf0-a3ee-4ea3-a608-1b61c81b3be5" xlink:href="regn-20200930.xsd#regn_OtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_OtherRevenueMember_6a56abf0-a3ee-4ea3-a608-1b61c81b3be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89411d19-275f-4559-acee-c0455c570efd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:to="loc_srt_ProductsAndServicesDomain_89411d19-275f-4559-acee-c0455c570efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:to="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_487a4e1f-b424-411c-bbb7-01aed76cdcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_487a4e1f-b424-411c-bbb7-01aed76cdcf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_5a07dcb9-f942-4d93-b060-18fa36974823" xlink:href="regn-20200930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:to="loc_regn_CollaborationandContractManufacturingMember_5a07dcb9-f942-4d93-b060-18fa36974823" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofCashFlowsDataDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="extended" id="i44573742ec4a40b781c0bc592eb36c2d_InterimFinancialStatementsScheduleofCashFlowsDataDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_26bc9674-b64e-484f-a8e3-90a5b19ad035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_26bc9674-b64e-484f-a8e3-90a5b19ad035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5156d347-4f2b-4817-a654-a7bcf80ea5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5156d347-4f2b-4817-a654-a7bcf80ea5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:to="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_05ff9f6e-238d-4dd4-a243-d1914356fae5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:to="loc_srt_RestatementDomain_05ff9f6e-238d-4dd4-a243-d1914356fae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:to="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_dd4485f6-82e9-45b4-8619-9ac0a53e708c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_dd4485f6-82e9-45b4-8619-9ac0a53e708c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_996473be-2ba6-482f-8dd7-110c7667ed0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:to="loc_srt_RestatementAdjustmentMember_996473be-2ba6-482f-8dd7-110c7667ed0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSales"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended" id="i5d91cfcaec8442c18863c339b857db98_ProductSales"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended" id="iec7f65581d7444a8bba5abf8c52430b3_ProductSalesTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended" id="i28e7ec7bf2d34a0b977d9dc66f5285bb_ProductSalesScheduleofNetProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ceb9661-f7b8-470f-9931-f96b716d42d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ceb9661-f7b8-470f-9931-f96b716d42d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:to="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:to="loc_srt_SegmentGeographicalDomain_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:to="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4623afab-3bbd-4ec8-b866-535c46d2fd42" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:to="loc_country_US_4623afab-3bbd-4ec8-b866-535c46d2fd42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:to="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d2b27c3-efc7-4696-90c8-855137f6577b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:to="loc_srt_ProductsAndServicesDomain_0d2b27c3-efc7-4696-90c8-855137f6577b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:to="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:to="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_2f6bfe08-5b1c-47f6-afe1-fec094a09bb2" xlink:href="regn-20200930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_EyleaNetProductSalesMember_2f6bfe08-5b1c-47f6-afe1-fec094a09bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_a8f42376-aff4-43e5-aecc-116151e0219d" xlink:href="regn-20200930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_LIBTAYONetProductSalesMember_a8f42376-aff4-43e5-aecc-116151e0219d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_1ab96f10-264a-460c-b0a7-bf77b0c3e5b4" xlink:href="regn-20200930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_PraluentNetProductSalesMember_1ab96f10-264a-460c-b0a7-bf77b0c3e5b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGNCOV2Member_ed437b04-c618-4dd2-93bc-4d081023bc1e" xlink:href="regn-20200930.xsd#regn_REGNCOV2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_REGNCOV2Member_ed437b04-c618-4dd2-93bc-4d081023bc1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_4c1e7c12-6408-43ec-8573-52bc63225850" xlink:href="regn-20200930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_ArcalystNetProductSalesMember_4c1e7c12-6408-43ec-8573-52bc63225850" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended" id="ic8f4ff2bc69a4c00948842c102a4861a_ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2b4533b2-4a3d-43cb-84bc-d6c32e565b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2b4533b2-4a3d-43cb-84bc-d6c32e565b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:to="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossSalesRevenueMember_b430491f-e91c-4b98-8d9b-95570d4f6c72" xlink:href="regn-20200930.xsd#regn_GrossSalesRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:to="loc_regn_GrossSalesRevenueMember_b430491f-e91c-4b98-8d9b-95570d4f6c72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26b174b5-5154-498f-8ea6-d149b4bf9397_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26b174b5-5154-498f-8ea6-d149b4bf9397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3dc64466-4ba9-4b14-965e-76b60484340f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3dc64466-4ba9-4b14-965e-76b60484340f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6e7ea336-5541-4448-8fd2-57fc9c82a921_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:to="loc_srt_NameOfMajorCustomerDomain_6e7ea336-5541-4448-8fd2-57fc9c82a921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:to="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_fe1adac3-cd44-46b2-a3ac-890f5bbfb383" xlink:href="regn-20200930.xsd#regn_BesseMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:to="loc_regn_BesseMedicalMember_fe1adac3-cd44-46b2-a3ac-890f5bbfb383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_96172d6f-3559-468f-8bcc-b501d3e822f8" xlink:href="regn-20200930.xsd#regn_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:to="loc_regn_McKessonCorporationMember_96172d6f-3559-468f-8bcc-b501d3e822f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended" id="ib6b86b98fb6a4a3c9dba33def619bd6b_CollaborationLicenseandOtherAgreements"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended" id="i4fe1773403314857bab61a5f11a57e0e_CollaborationLicenseandOtherAgreementsTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended" id="i1444f78f1ef84c3ba69947daa73ee47e_CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty_125335bb-5dbe-4ae7-92b0-c95fe5b07131" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty_125335bb-5dbe-4ae7-92b0-c95fe5b07131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByEntity_0ab89c14-9751-4477-8e06-431dd9077a45" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfTrialCostsBorneByEntity_0ab89c14-9751-4477-8e06-431dd9077a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc2f6f22-8c4a-4631-9eb6-91c11f5cd18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc2f6f22-8c4a-4631-9eb6-91c11f5cd18c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_5c2b0024-dd27-4b37-a7d9-5a4f76e45da4" xlink:href="regn-20200930.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_5c2b0024-dd27-4b37-a7d9-5a4f76e45da4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_fef1df88-95cb-478d-a7cb-c8e2b32b2508" xlink:href="regn-20200930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_fef1df88-95cb-478d-a7cb-c8e2b32b2508" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_4f604f81-101c-479a-900a-53fddfc7a1fd" xlink:href="regn-20200930.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_4f604f81-101c-479a-900a-53fddfc7a1fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_fad36b8c-0f57-44d2-a92c-a3bd348f142e" xlink:href="regn-20200930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_fad36b8c-0f57-44d2-a92c-a3bd348f142e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_6225e322-bf4d-47e5-97ef-f61b1ed84a2b" xlink:href="regn-20200930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_6225e322-bf4d-47e5-97ef-f61b1ed84a2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_440f4719-3fd8-48fd-9a93-ad362b496b0a" xlink:href="regn-20200930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_440f4719-3fd8-48fd-9a93-ad362b496b0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9e651e0b-55ab-4872-ba24-53157e5aabcd_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:to="loc_dei_EntityDomain_9e651e0b-55ab-4872-ba24-53157e5aabcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:to="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_f920003d-c660-4a20-91ef-5fbd215a8261" xlink:href="regn-20200930.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:to="loc_regn_SanofiMember_f920003d-c660-4a20-91ef-5fbd215a8261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fc29626d-d0ec-4768-bad7-d142b4332ee2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:to="loc_us-gaap_ProjectMember_fc29626d-d0ec-4768-bad7-d142b4332ee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:to="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1fb9c581-1dfe-4e2d-b725-789326ce0e80" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1fb9c581-1dfe-4e2d-b725-789326ce0e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c2922fea-ee65-4ac4-9e56-9332fd85eb5b" xlink:href="regn-20200930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c2922fea-ee65-4ac4-9e56-9332fd85eb5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b33bbdb1-3a27-412d-bb0d-52adae113249_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:to="loc_srt_ProductsAndServicesDomain_b33bbdb1-3a27-412d-bb0d-52adae113249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:to="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneMember_1aa3fd39-4ce9-4b53-97e1-0ce5fdad39bb" xlink:href="regn-20200930.xsd#regn_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:to="loc_regn_SalesBasedMilestoneMember_1aa3fd39-4ce9-4b53-97e1-0ce5fdad39bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended" id="i8ee32b727f984f59b2527dd3f852f374_CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f735de32-77bc-424c-ad92-88c83d607309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f735de32-77bc-424c-ad92-88c83d607309" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_d86c8a56-a0c9-4969-97a1-7912e8649775" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_d86c8a56-a0c9-4969-97a1-7912e8649775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_940c9c82-2d91-4079-8295-8fe0622ea006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_940c9c82-2d91-4079-8295-8fe0622ea006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_a54c7eb6-9cdb-482c-95e0-16f05e46b4cb" xlink:href="regn-20200930.xsd#regn_ReimbursementOfSellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_a54c7eb6-9cdb-482c-95e0-16f05e46b4cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2457d7d0-4134-4736-bb7d-aacc5870e1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2457d7d0-4134-4736-bb7d-aacc5870e1b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_dd0eeb66-4a40-4e4e-b334-08ee88ad92bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_OtherOperatingIncome_dd0eeb66-4a40-4e4e-b334-08ee88ad92bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0e96d07b-c6e7-433d-8053-9997130649c8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:to="loc_srt_SegmentGeographicalDomain_0e96d07b-c6e7-433d-8053-9997130649c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:to="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_95940f93-8c0d-4ab4-85d3-e8f7154e0c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:to="loc_us-gaap_NonUsMember_95940f93-8c0d-4ab4-85d3-e8f7154e0c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4819e380-f7b5-412c-b31a-20ea413650e7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:to="loc_srt_ProductsAndServicesDomain_4819e380-f7b5-412c-b31a-20ea413650e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:to="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_03ac1b39-5e44-4168-a3aa-3277f15ca754" xlink:href="regn-20200930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_03ac1b39-5e44-4168-a3aa-3277f15ca754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneMember_d4492b58-ea92-46b9-ada4-0d0f165e612d" xlink:href="regn-20200930.xsd#regn_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_SalesBasedMilestoneMember_d4492b58-ea92-46b9-ada4-0d0f165e612d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_c306c48d-1539-4ba5-a663-921807117a3d" xlink:href="regn-20200930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_c306c48d-1539-4ba5-a663-921807117a3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0196420a-9cb1-43e0-b2e7-5f7231bb7d7a" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0196420a-9cb1-43e0-b2e7-5f7231bb7d7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_dec46ee7-8f63-4e51-ba96-4b701a76ecb2" xlink:href="regn-20200930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_dec46ee7-8f63-4e51-ba96-4b701a76ecb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_9d159566-3263-4ab4-85ee-7c4629b2f036" xlink:href="regn-20200930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_9d159566-3263-4ab4-85ee-7c4629b2f036" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_b7b46e33-7c91-4ab8-a808-d6b06943e00f" xlink:href="regn-20200930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_b7b46e33-7c91-4ab8-a808-d6b06943e00f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_158aafaa-6e16-4165-b9d8-dcbc0df39a4a" xlink:href="regn-20200930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_158aafaa-6e16-4165-b9d8-dcbc0df39a4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e356332f-be49-4a64-880f-ea8bb7206efb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:to="loc_us-gaap_ProjectMember_e356332f-be49-4a64-880f-ea8bb7206efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:to="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_0897bc26-dffd-4a25-a142-a259200bfa7e" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_0897bc26-dffd-4a25-a142-a259200bfa7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_5b2322b3-1343-4d6c-8162-fb50294fc262" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_5b2322b3-1343-4d6c-8162-fb50294fc262" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended" id="ib106eddbbf604733a8f69365dc39fa85_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2eb2fcc4-2795-468b-a889-f1221879c35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2eb2fcc4-2795-468b-a889-f1221879c35b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a92cd228-04ec-4767-8c0c-551f97d3c85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a92cd228-04ec-4767-8c0c-551f97d3c85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:to="loc_us-gaap_ProjectMember_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:to="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_445c1606-dbeb-46a3-ac38-a19df5721074" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_445c1606-dbeb-46a3-ac38-a19df5721074" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="extended" id="i9ea8f31730cf48e58dc7efb148faabaf_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4a9aef4f-b71b-420f-9147-b9dbb0291b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4a9aef4f-b71b-420f-9147-b9dbb0291b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fa401286-f479-442f-a10e-f47c37c72c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fa401286-f479-442f-a10e-f47c37c72c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_abd203a4-7779-4cc9-982e-d852783ddd88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_OtherLiabilities_abd203a4-7779-4cc9-982e-d852783ddd88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f0000d06-331d-45b5-a94f-591123a34054_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:to="loc_us-gaap_ProjectMember_f0000d06-331d-45b5-a94f-591123a34054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:to="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_820a036f-6470-4406-b5f5-ff8f1323e37e" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_820a036f-6470-4406-b5f5-ff8f1323e37e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended" id="i79d81cb284484aa0b09d9d3c0df2fc34_CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnsatisfiedObligation_a34b64c4-fde9-460f-8992-1fcc464ea5c4" xlink:href="regn-20200930.xsd#regn_UnsatisfiedObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:to="loc_regn_UnsatisfiedObligation_a34b64c4-fde9-460f-8992-1fcc464ea5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_9271137e-22bb-474c-bdb1-348003a1b2f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:to="loc_us-gaap_ProjectMember_9271137e-22bb-474c-bdb1-348003a1b2f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:to="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a0f16d1c-b915-4766-84c1-2f520bff3492" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a0f16d1c-b915-4766-84c1-2f520bff3492" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended" id="iea87e0e61a1a4a31ab7692522a6dbbac_CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a15ad2a-67e0-443f-ab65-bc21c90f45a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a15ad2a-67e0-443f-ab65-bc21c90f45a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_2ea0ee7a-c35f-4d47-8c9d-836d84f1a749" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_2ea0ee7a-c35f-4d47-8c9d-836d84f1a749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3219b0c-9d7c-463e-bf16-385fdb221c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3219b0c-9d7c-463e-bf16-385fdb221c53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfOtherExpenses_3d3a5798-4897-48e0-8d73-c309972cc54f" xlink:href="regn-20200930.xsd#regn_ReimbursementOfOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_regn_ReimbursementOfOtherExpenses_3d3a5798-4897-48e0-8d73-c309972cc54f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a41abbd1-47ca-47aa-9eff-2b173546a791_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:to="loc_srt_SegmentGeographicalDomain_a41abbd1-47ca-47aa-9eff-2b173546a791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:to="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_18c0ceba-4abd-4469-ad31-b462da100ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:to="loc_us-gaap_NonUsMember_18c0ceba-4abd-4469-ad31-b462da100ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3f311743-b6ff-4852-921b-4fa6f78696f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:to="loc_us-gaap_ProjectMember_3f311743-b6ff-4852-921b-4fa6f78696f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:to="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_e9c749c4-979e-43b1-9c13-6ac1c1f7220e" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:to="loc_regn_BayerCollaborationAgreementMember_e9c749c4-979e-43b1-9c13-6ac1c1f7220e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42ead78f-89c7-4923-a477-b1382e8c4e42_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:to="loc_srt_ProductsAndServicesDomain_42ead78f-89c7-4923-a477-b1382e8c4e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:to="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_d8714cd5-3568-4286-ada4-6c57ed2c1a0b" xlink:href="regn-20200930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_d8714cd5-3568-4286-ada4-6c57ed2c1a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_a2d3334b-8683-45e0-b495-61e054dec87a" xlink:href="regn-20200930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_a2d3334b-8683-45e0-b495-61e054dec87a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0bc8ddc1-39ef-473e-8c54-d1f945fcebf3" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0bc8ddc1-39ef-473e-8c54-d1f945fcebf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_00c2d32e-9186-429a-aaeb-959313752cb0" xlink:href="regn-20200930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_00c2d32e-9186-429a-aaeb-959313752cb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherMember_63228793-b316-4b2e-9981-3daa38474f23" xlink:href="regn-20200930.xsd#regn_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_OtherMember_63228793-b316-4b2e-9981-3daa38474f23" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended" id="i026dec5ac5114bbc8fc4620659dd865d_CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenuebasedonpercentageofannualsalesinJapan_0bb03c01-244c-446c-86d8-572c3b378d8b" xlink:href="regn-20200930.xsd#regn_RevenuebasedonpercentageofannualsalesinJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:to="loc_regn_RevenuebasedonpercentageofannualsalesinJapan_0bb03c01-244c-446c-86d8-572c3b378d8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:to="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_505cbcb2-19ac-410a-a6bb-f14a63a83ec7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:to="loc_srt_RangeMember_505cbcb2-19ac-410a-a6bb-f14a63a83ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:to="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51f67b77-46fa-4381-b6b1-d4d208558619" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:to="loc_srt_MinimumMember_51f67b77-46fa-4381-b6b1-d4d208558619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a763154-b574-4086-be94-32dca5d25631" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:to="loc_srt_MaximumMember_5a763154-b574-4086-be94-32dca5d25631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7b220c67-79d0-40c3-8245-c5a76eab0ba5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:to="loc_us-gaap_ProjectMember_7b220c67-79d0-40c3-8245-c5a76eab0ba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:to="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_5a957aae-4e71-4e97-b328-9d9b07af0ce9" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:to="loc_regn_BayerCollaborationAgreementMember_5a957aae-4e71-4e97-b328-9d9b07af0ce9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended" id="i9495866dea974cffb9ac232756de497a_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_9e56385f-5251-40e7-86f1-bafe6d23ccea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_9e56385f-5251-40e7-86f1-bafe6d23ccea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_034c565f-b61e-45f6-9086-2f565ff3c82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:to="loc_us-gaap_ContractWithCustomerLiability_034c565f-b61e-45f6-9086-2f565ff3c82a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_4857cb6e-b206-45a4-818d-a822082f01a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:to="loc_us-gaap_ProjectMember_4857cb6e-b206-45a4-818d-a822082f01a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:to="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_77bf8b84-6a0a-42ff-9610-a8e78597adc2" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:to="loc_regn_BayerCollaborationAgreementMember_77bf8b84-6a0a-42ff-9610-a8e78597adc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended" id="i80142d8ec55a4742bd0ba2cda10c6b00_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_cbcb494b-c640-4993-9b83-12f26ea13580" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_cbcb494b-c640-4993-9b83-12f26ea13580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_e08f69ef-1ec0-47b3-b396-7ae3910f9a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:to="loc_us-gaap_OtherOperatingIncome_e08f69ef-1ec0-47b3-b396-7ae3910f9a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e130d6a2-3a75-4336-a589-ebe181de9137_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:to="loc_us-gaap_ProjectMember_e130d6a2-3a75-4336-a589-ebe181de9137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:to="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_8bec6b23-ccb6-4044-9a50-6b017ceb0704" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_8bec6b23-ccb6-4044-9a50-6b017ceb0704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:to="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7703e1a-c0ab-4859-87c9-407827cca5b7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:to="loc_srt_ProductsAndServicesDomain_e7703e1a-c0ab-4859-87c9-407827cca5b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:to="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c07a1ba3-4b5f-4f32-8147-f885a668ce7c" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c07a1ba3-4b5f-4f32-8147-f885a668ce7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_8ae85fbf-c8c1-4c71-95f5-f18ba65c44aa" xlink:href="regn-20200930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_8ae85fbf-c8c1-4c71-95f5-f18ba65c44aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended" id="i0635a99b46824896a45101edaecd6784_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_5b5c9595-1ea9-4fc1-95c8-81b61419b4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_5b5c9595-1ea9-4fc1-95c8-81b61419b4fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_4d7c2b13-9fcf-4a81-8ead-c441b330bf36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:to="loc_us-gaap_OtherLiabilities_4d7c2b13-9fcf-4a81-8ead-c441b330bf36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_04ec3c61-0d56-47d1-8042-191decdd376a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:to="loc_us-gaap_ProjectMember_04ec3c61-0d56-47d1-8042-191decdd376a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:to="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_a704de19-9041-429f-962d-94e7e2e565aa" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_a704de19-9041-429f-962d-94e7e2e565aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended" id="i864e58b6625a4d5895bf3352b4aee01a_CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnsatisfiedObligation_4fddb75e-04be-4244-9107-d34764630903" xlink:href="regn-20200930.xsd#regn_UnsatisfiedObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:to="loc_regn_UnsatisfiedObligation_4fddb75e-04be-4244-9107-d34764630903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_2316f796-9819-424a-bd3a-324ece8f3075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:to="loc_us-gaap_ProjectMember_2316f796-9819-424a-bd3a-324ece8f3075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:to="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_0c8124b6-1b03-42c1-a09f-60cad2935480" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_0c8124b6-1b03-42c1-a09f-60cad2935480" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended" id="i88241379bc6d4654a8b63c6961647695_CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_5a772623-c61b-41e9-b6a6-b2f0ec7ee194" xlink:href="regn-20200930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_5a772623-c61b-41e9-b6a6-b2f0ec7ee194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_b969a099-439e-4e1d-b739-f6b0955f401f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_b969a099-439e-4e1d-b739-f6b0955f401f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_49c694a7-68d9-4133-ad04-1ca6ce261f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_49c694a7-68d9-4133-ad04-1ca6ce261f87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_38eaa9f3-f8cd-45a2-831c-b4812244cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_38eaa9f3-f8cd-45a2-831c-b4812244cb4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_62df762d-7483-4abb-9c1b-98cd6c6a7176_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:to="loc_us-gaap_ProjectMember_62df762d-7483-4abb-9c1b-98cd6c6a7176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:to="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember_31b826f9-7449-4465-afb9-a803958109a5" xlink:href="regn-20200930.xsd#regn_IntelliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:to="loc_regn_IntelliaMember_31b826f9-7449-4465-afb9-a803958109a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:to="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1f488c71-9010-41f7-810f-b09bf449203a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1f488c71-9010-41f7-810f-b09bf449203a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_727382a9-0f7e-49a3-aefd-bce27c56d0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:to="loc_us-gaap_CommonStockMember_727382a9-0f7e-49a3-aefd-bce27c56d0e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="extended" id="i2661cc4107544ca6a735159ecd7b1b49_CollaborationLicenseandOtherAgreementsBARDANarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_7d5d1937-c2ae-4ca0-9f01-aae87eab053f" xlink:href="regn-20200930.xsd#regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:to="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_7d5d1937-c2ae-4ca0-9f01-aae87eab053f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_a8879543-839c-48f0-98f7-dd18bfd204d5" xlink:href="regn-20200930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:to="loc_regn_MaximumTransactionAgreementPayments_a8879543-839c-48f0-98f7-dd18bfd204d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_174e52fd-d2e0-4642-aa4b-9353bfb9a259_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:to="loc_us-gaap_ProjectMember_174e52fd-d2e0-4642-aa4b-9353bfb9a259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:to="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_8cb091fd-66ea-45a8-ab8e-014aa540c97b" xlink:href="regn-20200930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_8cb091fd-66ea-45a8-ab8e-014aa540c97b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff200a6f-868f-4459-9e16-a0409159dfbe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:to="loc_srt_ProductsAndServicesDomain_ff200a6f-868f-4459-9e16-a0409159dfbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:to="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGNCOV2Member_87bd95a1-aefc-4958-b779-31baa0b3069d" xlink:href="regn-20200930.xsd#regn_REGNCOV2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:to="loc_regn_REGNCOV2Member_87bd95a1-aefc-4958-b779-31baa0b3069d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_82b996f9-9e2b-48d9-8ec1-9ef351230d74_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:to="loc_srt_SegmentGeographicalDomain_82b996f9-9e2b-48d9-8ec1-9ef351230d74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:to="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_50507891-63c5-45d6-9e29-4245010251b1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:to="loc_country_US_50507891-63c5-45d6-9e29-4245010251b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShare"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended" id="if71bb49012494d199fc35ecbcb75aad2_NetIncomePerShare"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended" id="if5d2ec6c73c14943a1afd1993326628b_NetIncomePerShareTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="i2ce67eedac9646a791d32a72df9900ea_NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8f958fc-dc08-4cc8-94bf-5f78eb01f7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_NetIncomeLoss_c8f958fc-dc08-4cc8-94bf-5f78eb01f7b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a499b6c3-3d66-4ca7-93ff-8202094305ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a499b6c3-3d66-4ca7-93ff-8202094305ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_089411e2-ee02-45a4-a025-ed9b75e3cda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_089411e2-ee02-45a4-a025-ed9b75e3cda1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d59429d6-491d-49d4-910b-a2d826293259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d59429d6-491d-49d4-910b-a2d826293259" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9b3e6ca-5699-4430-b263-d678ae1bd07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9b3e6ca-5699-4430-b263-d678ae1bd07f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f306dbcd-5c9a-48ff-b9dd-cd6f03ff1bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f306dbcd-5c9a-48ff-b9dd-cd6f03ff1bb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:to="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee8c5300-4aa4-406d-bb42-40dc9593ff3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee8c5300-4aa4-406d-bb42-40dc9593ff3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb8028c1-f046-4c9a-98ac-d5579c9ba99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb8028c1-f046-4c9a-98ac-d5579c9ba99b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9f7c17fe-2754-4716-bbe5-cd241fe3ed08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:to="loc_us-gaap_RestrictedStockMember_9f7c17fe-2754-4716-bbe5-cd241fe3ed08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended" id="i7e0adec807134e22982a4ad75772fcad_NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1808c1f-bbee-4694-8e71-6beb41286b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1808c1f-bbee-4694-8e71-6beb41286b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_25c03aec-ef32-4ca5-bc95-fbd89f2a8029_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_25c03aec-ef32-4ca5-bc95-fbd89f2a8029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ddf59610-8d9d-4774-a346-2e0f7def3bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ddf59610-8d9d-4774-a346-2e0f7def3bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1fb3d3d0-7752-45e6-9444-9788614693b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:to="loc_us-gaap_RestrictedStockMember_1fb3d3d0-7752-45e6-9444-9788614693b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended" id="i45e3b230e7dd40cba2580010eca21501_MarketableSecurities"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended" id="iff430d1c1e6d41ba9dae6b0bfa711439_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" id="i0003d4747f764a20a8ae43e94b5cee2e_MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe8df96-3adf-452f-a838-92312d56b620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe8df96-3adf-452f-a838-92312d56b620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a478cd50-698e-4349-97b8-bda7f35ad582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a478cd50-698e-4349-97b8-bda7f35ad582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58ac4e21-0121-436a-bd06-f9469307b3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58ac4e21-0121-436a-bd06-f9469307b3bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a13fa0c-2732-4d36-9def-57f252363696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a13fa0c-2732-4d36-9def-57f252363696" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d6be916-2021-442c-b8ee-fcd8eebd07fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d6be916-2021-442c-b8ee-fcd8eebd07fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5119ec16-e18c-4695-8070-0db1582aa374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5119ec16-e18c-4695-8070-0db1582aa374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_06f7267b-d6d6-4fc5-bebf-2f0a9beda769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_06f7267b-d6d6-4fc5-bebf-2f0a9beda769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ffa3d507-4065-4613-98ac-c6b863dbadb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ffa3d507-4065-4613-98ac-c6b863dbadb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_94e078a4-ece4-437e-b7ed-04d427cb33b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CommercialPaperMember_94e078a4-ece4-437e-b7ed-04d427cb33b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b23e6d5f-c9df-4a04-948f-c7da9e0f40c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b23e6d5f-c9df-4a04-948f-c7da9e0f40c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:to="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_4a81d2b7-fc4a-4360-9fbd-38d4c229404c_default" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:to="loc_regn_ClassificationOfInvestmentDomain_4a81d2b7-fc4a-4360-9fbd-38d4c229404c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:to="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_7eafb088-4f5c-49e1-beda-7c4807fb1ab4" xlink:href="regn-20200930.xsd#regn_UnrestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:to="loc_regn_UnrestrictedMember_7eafb088-4f5c-49e1-beda-7c4807fb1ab4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended" id="iea86b3eeae704c338a7ec95e8f10c963_MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended" id="i660a9d4d2255472ca8c0742e193f547a_MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7a5eb14b-fe90-4997-a59c-e34c84f34cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7a5eb14b-fe90-4997-a59c-e34c84f34cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9e80a80d-4bd5-4745-9ae8-b69e79d366cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9e80a80d-4bd5-4745-9ae8-b69e79d366cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3441621e-441d-415d-9cb8-85e54bb90e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3441621e-441d-415d-9cb8-85e54bb90e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3a7097b8-ea68-4f30-8a50-619d11b30a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3a7097b8-ea68-4f30-8a50-619d11b30a9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_46334687-3e07-4dd6-927e-ee85bf3e7826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_46334687-3e07-4dd6-927e-ee85bf3e7826" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7913d9cd-44d5-4399-8dc7-be5a267625b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7913d9cd-44d5-4399-8dc7-be5a267625b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:to="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_886f24f6-0866-4122-9de3-a669419ffa64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_886f24f6-0866-4122-9de3-a669419ffa64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0b3139f7-8d77-452a-8145-87639ebde50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0b3139f7-8d77-452a-8145-87639ebde50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b23cb947-94a0-4831-a223-c6eedbc0f897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b23cb947-94a0-4831-a223-c6eedbc0f897" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended" id="i2c477e25870e435f8acbf98452795f04_MarketableSecuritiesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended" id="idf95a401a1dc4d48a43cc2e72c476162_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i9328f87375534cd79047e61f8c5836bf_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i63026b49428f4a41bf4688c9444b2524_FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4aa9088d-328a-401c-9372-3c0547018c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4aa9088d-328a-401c-9372-3c0547018c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_323f1945-f9a7-4c30-a79b-900a7e47ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_323f1945-f9a7-4c30-a79b-900a7e47ae7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8b7d49f3-7347-432c-b088-a3b007b6421d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_MarketableSecurities_8b7d49f3-7347-432c-b088-a3b007b6421d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6cf56be-b44e-4fdb-b73f-92d3ac12c609_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6cf56be-b44e-4fdb-b73f-92d3ac12c609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_36d86d29-8449-4577-bcc7-6a989f2aa1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_36d86d29-8449-4577-bcc7-6a989f2aa1cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1c34387c-46be-4104-91db-ef0a8bab20d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1c34387c-46be-4104-91db-ef0a8bab20d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_6eff0085-3a30-4477-8a7b-02cd4f3ea87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_6eff0085-3a30-4477-8a7b-02cd4f3ea87f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_dadbbf2a-ea5a-4fc9-bd66-8a6f9127ebe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CommercialPaperMember_dadbbf2a-ea5a-4fc9-bd66-8a6f9127ebe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_43e403c7-a01e-4037-bf38-26436084c995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_43e403c7-a01e-4037-bf38-26436084c995" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e56c3312-57bc-4a49-9b67-c1b5ec23381b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e56c3312-57bc-4a49-9b67-c1b5ec23381b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_095c52bd-9429-4d69-96a7-7e80f5196ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_095c52bd-9429-4d69-96a7-7e80f5196ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e2ad2e57-9cd2-45e1-aad6-8ddbbe5d6559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e2ad2e57-9cd2-45e1-aad6-8ddbbe5d6559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_98f11ac3-5a01-4c0d-a440-40bafe19cfff_default" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:to="loc_regn_ClassificationOfInvestmentDomain_98f11ac3-5a01-4c0d-a440-40bafe19cfff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:to="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_1a0a114d-c3bd-4732-8bdc-43fd3aa9801d" xlink:href="regn-20200930.xsd#regn_UnrestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:to="loc_regn_UnrestrictedMember_1a0a114d-c3bd-4732-8bdc-43fd3aa9801d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_183886a8-2666-4e57-9410-223e7c058617" xlink:href="regn-20200930.xsd#regn_RestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:to="loc_regn_RestrictedMember_183886a8-2666-4e57-9410-223e7c058617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75698696-5caf-4428-9de4-124773674745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75698696-5caf-4428-9de4-124773674745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b723a73-f614-4df9-b97b-884074e9e05b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8b723a73-f614-4df9-b97b-884074e9e05b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dd14e15b-79c0-45d9-ac78-36479c3efb47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dd14e15b-79c0-45d9-ac78-36479c3efb47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0490416-4cc3-4cf7-8c92-d41e8cc0def6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0490416-4cc3-4cf7-8c92-d41e8cc0def6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i9219951b2b9a44b48d5b755efaa4b831_FairValueMeasurementsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20200930.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended" id="ifabbb902d3d946ec986b6dd84660bb1c_Inventories"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended" id="i4d1e02a2c1574a848edc30175d2d0003_InventoriesTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="ic5b27bc1977048bebad666d9258097b2_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Debt" xlink:type="simple" xlink:href="regn-20200930.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Debt" xlink:type="extended" id="if44cc0ead12a4f859ab1a6a8ce953b60_Debt"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended" id="if62c1a87a8b146fa9010ee41e35d8c44_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_745cde48-7e67-4032-a835-17bace011ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_745cde48-7e67-4032-a835-17bace011ded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a433822-c819-4a00-91a0-74fe45c0202e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a433822-c819-4a00-91a0-74fe45c0202e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9b29b460-822e-4834-ba67-f7b522ce0334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9b29b460-822e-4834-ba67-f7b522ce0334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_4844cfb5-a425-42a9-9e1b-c3fc332f0fb5" xlink:href="regn-20200930.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_4844cfb5-a425-42a9-9e1b-c3fc332f0fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_98330881-f333-4641-8a63-f6669e283aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_InterestExpenseDebt_98330881-f333-4641-8a63-f6669e283aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a8a4e36-69f8-4398-90c7-86cbac18e199_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a8a4e36-69f8-4398-90c7-86cbac18e199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember_a0dcaa75-338e-4b67-8077-35e226918590" xlink:href="regn-20200930.xsd#regn_BridgeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_BridgeFacilityMember_a0dcaa75-338e-4b67-8077-35e226918590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_3e7b8323-abe4-46b8-b910-1b7a66451072" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_3e7b8323-abe4-46b8-b910-1b7a66451072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_ad59a322-84e5-4a83-b4c0-03e5f0d0f2ca" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_ad59a322-84e5-4a83-b4c0-03e5f0d0f2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c35142b9-77ee-4fcd-b583-4d4ecc948be5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c35142b9-77ee-4fcd-b583-4d4ecc948be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CommonStockHeldBySanofiMember_2ebd20a0-5dfa-4848-b4aa-b4920421bba4" xlink:href="regn-20200930.xsd#regn_CommonStockHeldBySanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:to="loc_regn_CommonStockHeldBySanofiMember_2ebd20a0-5dfa-4848-b4aa-b4920421bba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b1ae6e97-86e5-40b3-afbc-407c46debaf6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b1ae6e97-86e5-40b3-afbc-407c46debaf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_f21b3497-bd5b-4a1a-9469-ae0a46fa46d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:to="loc_us-gaap_BridgeLoanMember_f21b3497-bd5b-4a1a-9469-ae0a46fa46d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e7feef19-4327-4420-b99e-2ad3d4f3ac12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e7feef19-4327-4420-b99e-2ad3d4f3ac12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_da28d03b-8ecb-4d12-a9fc-1562de421c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:to="loc_us-gaap_SeniorNotesMember_da28d03b-8ecb-4d12-a9fc-1562de421c57" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended" id="i99cfb3af96f94a918baf3bb02bc168a4_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="extended" id="ie3b119588d1b4ed5a1f40fa6b34a6f71_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended" id="i9892443ba6ea4e9cbd0ed6ccf1d4b6be_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended" id="i4e97d67e0be8475fb616827054245ff0_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i20943abafd7542599ac9c3021f3808a5_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_74b5b004-a3d8-4536-b269-39b795a3cd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_74b5b004-a3d8-4536-b269-39b795a3cd74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f0ae6a2-c140-4823-8566-8a9aa983f0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f0ae6a2-c140-4823-8566-8a9aa983f0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Maximumsharesthecollaboratorcouldsell_f98219ed-4d4c-4828-963d-d99fc8c3ade5" xlink:href="regn-20200930.xsd#regn_Maximumsharesthecollaboratorcouldsell"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_regn_Maximumsharesthecollaboratorcouldsell_f98219ed-4d4c-4828-963d-d99fc8c3ade5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_df41a6d0-ca9f-4f5b-a652-22e8295c4289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_df41a6d0-ca9f-4f5b-a652-22e8295c4289" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a92b9f8d-75b7-432d-a7e9-a9846101c07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a92b9f8d-75b7-432d-a7e9-a9846101c07e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_96fc338f-ebf1-4e49-9f77-7a2614311fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_96fc338f-ebf1-4e49-9f77-7a2614311fb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_112deb4d-ec5c-4dce-8c1d-b7d6016add7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_112deb4d-ec5c-4dce-8c1d-b7d6016add7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramMember_5798a14f-00d4-4a34-a2eb-8b8bd15a7628" xlink:href="regn-20200930.xsd#regn_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:to="loc_regn_ShareRepurchaseProgramMember_5798a14f-00d4-4a34-a2eb-8b8bd15a7628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_02be97a6-9729-4356-8e60-02bb2f0aea95_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:to="loc_dei_EntityDomain_02be97a6-9729-4356-8e60-02bb2f0aea95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:to="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_26a162fe-2e09-44fe-ab47-4e2f1525a996" xlink:href="regn-20200930.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:to="loc_regn_SanofiMember_26a162fe-2e09-44fe-ab47-4e2f1525a996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:to="loc_us-gaap_ProjectMember_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:to="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a5435074-ec1f-480a-a2f7-80c69b9dde54" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a5435074-ec1f-480a-a2f7-80c69b9dde54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended" id="i0825d114c76e4c2f9d51c850f3de4389_StockholdersEquityScheduleofRepurchasedSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_356dbb5d-ed14-4942-9a67-406b40607803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_356dbb5d-ed14-4942-9a67-406b40607803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f9fb3dee-0a1f-415a-82a8-44c305dea379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f9fb3dee-0a1f-415a-82a8-44c305dea379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a95bf97a-98cd-45bb-8f3b-256121d62f14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a95bf97a-98cd-45bb-8f3b-256121d62f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramMember_b7384376-7414-4c16-8b06-5bd7e6bffd9e" xlink:href="regn-20200930.xsd#regn_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:to="loc_regn_ShareRepurchaseProgramMember_b7384376-7414-4c16-8b06-5bd7e6bffd9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquitySanofiFundingDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="extended" id="i19b0c7ed944148db8689d9b1d945db22_StockholdersEquitySanofiFundingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_48eea8e9-a7b6-4a88-a33c-3e53f81d36c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_48eea8e9-a7b6-4a88-a33c-3e53f81d36c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_68841f30-4ded-4022-a60a-c5544a43bcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_68841f30-4ded-4022-a60a-c5544a43bcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_90b62b87-ce6d-44f8-884f-a4e8aca29c16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:to="loc_us-gaap_ProjectMember_90b62b87-ce6d-44f8-884f-a4e8aca29c16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:to="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember_09900b76-6748-41c2-ac4b-9a4f507b731b" xlink:href="regn-20200930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:to="loc_regn_LibtayoDevelopmentMember_09900b76-6748-41c2-ac4b-9a4f507b731b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_4c2bb713-9cf4-49e1-95fd-6cb35c6563a5" xlink:href="regn-20200930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:to="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_4c2bb713-9cf4-49e1-95fd-6cb35c6563a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlows"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="extended" id="i2f3d4387c39d4cbb85c8db8f896a23f3_StatementofCashFlows"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsTables"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="extended" id="ic42cef0305cf4e9ab6cff778066dc0e0_StatementofCashFlowsTables"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="ib572f1742b634e46b1d757cae58d3d15_StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended" id="ia8a998f43bbd472baf3df2a2191e0331_StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMatters"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended" id="i568512fbaf5b42f0b17566b428106a35_LegalMatters"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMattersDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended" id="ie4240dd76a934d39bd20c0316ccacc7f_LegalMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f6846fe9-ca7d-4509-955b-9312e58ad354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f6846fe9-ca7d-4509-955b-9312e58ad354" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_fadf8b90-3017-4023-b2ac-af8327e5fbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_fadf8b90-3017-4023-b2ac-af8327e5fbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber_b2e68e09-c049-427b-a800-a4c999eb6a72" xlink:href="regn-20200930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_LossContingencyClaimsInvalidNumber_b2e68e09-c049-427b-a800-a4c999eb6a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyDamagesSoughtPerUnitProduced_317fae4c-7cec-45e5-b4b5-7e92fddfb9b0" xlink:href="regn-20200930.xsd#regn_LossContingencyDamagesSoughtPerUnitProduced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_LossContingencyDamagesSoughtPerUnitProduced_317fae4c-7cec-45e5-b4b5-7e92fddfb9b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_b1747cf5-78f3-428b-bad8-34a4c88cde8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_b1747cf5-78f3-428b-bad8-34a4c88cde8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber_c911e222-bda1-4a48-9211-6c0a7d732d36" xlink:href="regn-20200930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_GainContingencyInterPartesReviewFiledNumber_c911e222-bda1-4a48-9211-6c0a7d732d36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber_9d21d2b3-00c6-4d4b-9228-c03ae4ff6002" xlink:href="regn-20200930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_GainContingencyClaimsInvalidatedNumber_9d21d2b3-00c6-4d4b-9228-c03ae4ff6002" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_430e1c11-12cd-41bd-85ef-e8bf002e86b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:to="loc_us-gaap_LossContingencyNatureDomain_430e1c11-12cd-41bd-85ef-e8bf002e86b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:to="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember_15136705-f942-40c7-9411-9989c11ad61e" xlink:href="regn-20200930.xsd#regn_A165PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A165PatentMember_15136705-f942-40c7-9411-9989c11ad61e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember_1bee2878-1153-4ee2-b3f1-ef1df4a93027" xlink:href="regn-20200930.xsd#regn_A741PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A741PatentMember_1bee2878-1153-4ee2-b3f1-ef1df4a93027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember_461fcd2c-0af3-443d-a967-777f1e626de1" xlink:href="regn-20200930.xsd#regn_A487PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A487PatentMember_461fcd2c-0af3-443d-a967-777f1e626de1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_f35ee380-8d53-4769-adbf-bc00c189c14e" xlink:href="regn-20200930.xsd#regn_A631PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A631PatentMember_f35ee380-8d53-4769-adbf-bc00c189c14e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_de4936ad-6be2-47a2-93ad-999453114262_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:to="loc_srt_LitigationCaseTypeDomain_de4936ad-6be2-47a2-93ad-999453114262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:to="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember_81b24fd9-74ff-47f6-9059-955dcaf1aef1" xlink:href="regn-20200930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:to="loc_regn_Amgenv.s.RegeneronMember_81b24fd9-74ff-47f6-9059-955dcaf1aef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4b11b643-2f00-44a0-852e-52d6fd8863d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:to="loc_us-gaap_LitigationStatusDomain_4b11b643-2f00-44a0-852e-52d6fd8863d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:to="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e15f090d-0514-40c6-82ea-8ee3bc702463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:to="loc_us-gaap_PendingLitigationMember_e15f090d-0514-40c6-82ea-8ee3bc702463" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>regn-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RestatementAxis_3ac3a9bf-5c73-4869-942a-c846d53d23d3_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d18e3695-1f62-414f-a263-7507c5ac7e7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_1396b018-f085-4a38-85fb-c53fe043b6d6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_798f0446-7c2a-461b-8a1a-3d78bedd1a4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Class A Stock to Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dcbc95e8-f6f0-4633-95d9-0fcb6d36aea5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_9764e397-3ab0-4d30-8d03-49dca7e48965_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_8a2fa54f-90e2-445d-8662-22e1c112141e_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9ae4beb5-1669-4294-9e04-68b65972f1a4_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_0ccf7ddc-f389-4b2c-b545-df906130fc9d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchase price</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7c7f435e-b4e2-4da3-a0f8-f8ab1e7ba138_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales or maturities of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_27004769-8672-4587-ae0a-9870f17389ca_terseLabel_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be received on net product sales outside of the United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_label_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_documentation_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:href="regn-20200930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:to="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eda39eb8-bc82-4349-a0b4-7cce64a5d8cf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_647a6cae-6820-411c-992f-bbdab08f74c5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_403ceeaf-c9e2-45d3-a587-22d85ca90137_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fe632ab3-4b0c-47ed-86e2-4f765dc682f6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f10e945-f9ab-4c85-9051-4a2e5a12e80a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_ce4ff3df-4a9a-4e7e-abfe-4af7ed565247_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_10a19472-3800-4861-9eb5-454583d97c80_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_06a62ae6-5be3-46f5-a167-3d0060592acc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_33b577d8-2d9a-4cdc-b693-1bb764b3027a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_0db6b581-58e0-4483-b943-2a1e2828f03f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Class A Stock to Common Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8a10cdef-ee53-418b-ae91-0cc1c075792d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A487PatentMember_fcb81f0c-f282-413d-bb2f-58ccb1df340c_terseLabel_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent</link:label>
    <link:label id="lab_regn_A487PatentMember_label_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent [Member]</link:label>
    <link:label id="lab_regn_A487PatentMember_documentation_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember" xlink:href="regn-20200930.xsd#regn_A487PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A487PatentMember" xlink:to="lab_regn_A487PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8d6e41ff-43bd-4b9c-a543-df5bf27cc477_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_b02068ca-a906-4877-ae17-b122122dadf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e707f197-7abe-4b09-a4a7-41b9a79a420c_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2c1f76dc-9da3-46a0-8b07-c4a3c751ab42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_88d48fcf-bf39-4f77-8178-6523d2fccc76_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e49c812f-0e7f-4743-adeb-4347dc3de6ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a9532e57-a8aa-4076-a89e-4cc1eacd18e7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6cfdc4b2-bbad-46bb-88fb-8aa052e7e872_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e8ef3792-b4c1-4f7d-aa25-aad9b517b0ca_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f053b09e-f418-4649-a56c-7d0ffc515e53_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8805c859-418c-4a0f-865b-cf9c1b67261f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_05d6c78a-723f-459b-8c50-8546e8e17f1f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_31b93e45-12cc-4a11-8c11-98b6201db60f_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_McKessonCorporationMember_b562161e-b346-41a1-a2de-11efaf7e73d5_terseLabel_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_label_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_documentation_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember" xlink:href="regn-20200930.xsd#regn_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_McKessonCorporationMember" xlink:to="lab_regn_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_3cbff951-0f91-4dc3-9ccd-0f5fd734ecae_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_22fcd7b3-d5c9-4017-a0f5-68f83f781b14_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_92798847-4af8-4d71-aec0-1d65341a9ee2_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneMember_4c65b920-c91a-4572-8c61-d7f976ae6455_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone earned</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneMember" xlink:href="regn-20200930.xsd#regn_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneMember" xlink:to="lab_regn_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_21b638e9-5805-4a28-b699-906934e23d3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a21995e8-557d-43c9-be60-20e8db2777d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fdd3de73-01bc-4f01-9114-4dcfae87cc90_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_6c25d6fd-3d72-4ab0-97a2-e3016739e2cd_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_afa4b42d-7e4d-4aac-93f0-2ea94f1ee1bb_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_c066cc46-1da2-4fea-8bf9-b0a6e06b9484_netLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_131c2629-4eca-4e85-91c0-fd2f7c0b7d5e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5e6586ce-578e-4b5b-b50b-f7ac51563d70_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_2c0ca320-b209-4fbb-800f-66018775c84e_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff1933c-d749-46a6-bb41-133163700b54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bfe4cbf9-429f-41ed-a2fa-cbafd561bf50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1a2d8e48-c5bd-4628-8d0e-a0d69f4736fc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_b365e7e5-7d84-40d7-a743-57045db64294_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_f83af07d-524c-439a-937f-26122d7c1072_terseLabel_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_label_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_documentation_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember" xlink:href="regn-20200930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LIBTAYONetProductSalesMember" xlink:to="lab_regn_LIBTAYONetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_17c43471-d209-4528-a46d-5c51edb8c8c6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f8b427d0-5476-4c0e-a024-60057c64840a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation charges</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_274c0336-0646-4e67-90e9-e33a7c906f08_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2fde9345-0d62-4197-bb96-be08d120f0b5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7f65fe06-2460-4560-bf69-18da27c3abb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5d82a0bf-d950-4347-ae22-fa2fb3339df5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_3db31a65-2182-4f08-9843-f378a26657a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_label_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryNetOfReserves" xlink:to="lab_us-gaap_OtherInventoryNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EyleaNetProductSalesMember_1152ae05-682b-4397-96c4-8226f4d58e15_terseLabel_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_label_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember" xlink:href="regn-20200930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EyleaNetProductSalesMember" xlink:to="lab_regn_EyleaNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_b923c210-b122-4360-a0ba-fbd9ca8a2c80_terseLabel_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:href="regn-20200930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:to="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_5c86503a-15b0-4171-9f66-523ac824e54d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0c67a758-d092-472e-8186-45c129c8612b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_0d36dc08-081a-4296-ab50-d79ffe030da5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c896c111-c546-4d65-b1cb-68d9a455d7b2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e82f172f-c84d-466e-9a35-115bb76fc1c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_80d573ae-ad83-4910-a3b9-d2a0c135bc29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OtherMember_23a95b3e-d692-4f83-921e-e5bb598632d5_verboseLabel_en-US" xlink:label="lab_regn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of other expenses</link:label>
    <link:label id="lab_regn_OtherMember_label_en-US" xlink:label="lab_regn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_regn_OtherMember_documentation_en-US" xlink:label="lab_regn_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherMember" xlink:href="regn-20200930.xsd#regn_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OtherMember" xlink:to="lab_regn_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_751c889d-65be-48bb-a4ff-1667e57db819_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_fa0fadf7-59df-440e-b188-8eda17288e18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4ebbbfe5-06a6-4316-8b2d-49bbb0f56020_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_621c6669-19a7-488c-bcd9-5ad5f433a464_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_622674d8-c6be-4b76-a495-c0b6508b2159_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6ca8af1f-1545-4f7d-b476-f16be0536217_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_795e99c5-15bd-4341-93ea-a72ac1bce748_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_a62fad55-ff4e-4fa4-b27e-cf67096de14d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b55adc13-d34c-4bcb-9707-038fb82e93ff_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_44208df5-7fee-42da-8426-be1b45a60f77_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f4d7cdf1-771c-4e10-b3ea-d4f2df29ff8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10e830a3-47ef-476a-872f-977e8527b28e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_f314eb76-4e76-4785-b48f-f9dd981a432a_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_73cd2b68-8cc6-4fb3-9a21-de0ecfaef634_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_64da839b-32cf-4495-91ed-cfcfed896b76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_00ffaa85-93c0-4497-bba5-945d8f7421f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bd8c5b11-fdba-4bf1-b665-67e3297cb98d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_00db07f8-ed28-4222-a1be-d664e7b3820e_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentAxis" xlink:to="lab_regn_ClassificationOfInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_d48dcade-73ad-4123-b6d8-76db72bfde6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Repurchased</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b312a470-1bc1-460e-b1a7-d656097617c5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyDamagesSoughtPerUnitProduced_4906415a-4edd-4652-9b80-4f1cecd38fec_terseLabel_en-US" xlink:label="lab_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought, per unit produced</link:label>
    <link:label id="lab_regn_LossContingencyDamagesSoughtPerUnitProduced_label_en-US" xlink:label="lab_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Per Unit Produced</link:label>
    <link:label id="lab_regn_LossContingencyDamagesSoughtPerUnitProduced_documentation_en-US" xlink:label="lab_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Per Unit Produced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:href="regn-20200930.xsd#regn_LossContingencyDamagesSoughtPerUnitProduced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:to="lab_regn_LossContingencyDamagesSoughtPerUnitProduced" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BesseMedicalMember_2c7a36f5-a04b-4aa0-8483-1cb2e47abbf1_terseLabel_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical, a subsidiary of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_regn_BesseMedicalMember_label_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:label id="lab_regn_BesseMedicalMember_documentation_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember" xlink:href="regn-20200930.xsd#regn_BesseMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BesseMedicalMember" xlink:to="lab_regn_BesseMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_7a50ab17-b2cb-4766-a0b3-777cb5b17d58_terseLabel_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_label_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Agreements [Member]</link:label>
    <link:label id="lab_regn_OtherCollaborationAgreementsMember_documentation_en-US" xlink:label="lab_regn_OtherCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember" xlink:href="regn-20200930.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OtherCollaborationAgreementsMember" xlink:to="lab_regn_OtherCollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_48330321-cc09-4878-a3a2-88be15a5cda5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c2081001-4edd-4acc-975d-cb9ad395e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_OtherRevenueMember_2e7ba6bb-d8c2-4a1e-b342-66876e9807d2_terseLabel_en-US" xlink:label="lab_regn_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_regn_OtherRevenueMember_label_en-US" xlink:label="lab_regn_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:label id="lab_regn_OtherRevenueMember_documentation_en-US" xlink:label="lab_regn_OtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherRevenueMember" xlink:href="regn-20200930.xsd#regn_OtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_OtherRevenueMember" xlink:to="lab_regn_OtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ee09f825-805b-48f0-b927-7be9d31a3603_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramMember_44f62cbe-d1cc-4b94-b984-caa8561aac6c_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramMember" xlink:href="regn-20200930.xsd#regn_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramMember" xlink:to="lab_regn_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_51bf7bcc-027b-4b50-9bf8-98ab8f80cac9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_72084fd4-2f4c-4aaa-aea6-2cd25e62aaab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bridge loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A165PatentMember_09c04703-af13-48c9-b08b-ddba31d67aaa_terseLabel_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent</link:label>
    <link:label id="lab_regn_A165PatentMember_label_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent [Member]</link:label>
    <link:label id="lab_regn_A165PatentMember_documentation_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember" xlink:href="regn-20200930.xsd#regn_A165PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A165PatentMember" xlink:to="lab_regn_A165PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_42248250-566f-4cb0-90af-c670c6857f06_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_eb4b7897-ce15-4dc3-b7f4-e5619b6bb2df_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8b906317-7b75-41e8-9d4c-f33851354207_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c19394ff-46ad-4ff9-95e7-18e32b1ff65e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ProductSalesandConcentrationRiskTextBlock_3f634d98-fb31-4645-8743-1a6c04a0575d_terseLabel_en-US" xlink:label="lab_regn_ProductSalesandConcentrationRiskTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_regn_ProductSalesandConcentrationRiskTextBlock_label_en-US" xlink:label="lab_regn_ProductSalesandConcentrationRiskTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales and Concentration Risk [Text Block]</link:label>
    <link:label id="lab_regn_ProductSalesandConcentrationRiskTextBlock_documentation_en-US" xlink:label="lab_regn_ProductSalesandConcentrationRiskTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales and Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ProductSalesandConcentrationRiskTextBlock" xlink:href="regn-20200930.xsd#regn_ProductSalesandConcentrationRiskTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ProductSalesandConcentrationRiskTextBlock" xlink:to="lab_regn_ProductSalesandConcentrationRiskTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1a06883f-8042-430c-b8dd-4d070889effc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_db52c449-3c55-411c-adfc-a96dc1469023_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7510973f-1c2f-4b50-9297-a59100a3746c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_3188ade7-7f15-40bc-9512-2c2a36147c6f_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Selling, general, and administrative expense</link:label>
    <link:label id="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Selling, General And Administrative Expense</link:label>
    <link:label id="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Selling, General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:href="regn-20200930.xsd#regn_ReimbursementOfSellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:to="lab_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_4ca889d9-e549-473d-af9e-f89f863282a0_terseLabel_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invalid claims</link:label>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_label_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalid, Number</link:label>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_documentation_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalid, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber" xlink:href="regn-20200930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyClaimsInvalidNumber" xlink:to="lab_regn_LossContingencyClaimsInvalidNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_64ec215e-122e-4dee-8d60-a1562a7322ba_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f215e501-d13a-427d-bbff-d1eb925ef458_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiMember_46a7396b-0e26-4a89-893b-a8ed8f3aa934_terseLabel_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_regn_SanofiMember_label_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_regn_SanofiMember_documentation_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember" xlink:href="regn-20200930.xsd#regn_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiMember" xlink:to="lab_regn_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_46f5597b-9fe4-453f-9853-1ea35cb4ef6f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_08fb08a1-7776-40d4-8168-52510d77d285_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_a18c9390-4933-4b3c-9342-fcbc482f5c92_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e5353357-dac3-453a-890f-51d169d55432_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_85d1f420-9423-41b3-a9f8-b59fca3983d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_b84ba8e0-50f0-4f89-bebd-9090bd0aa82e_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_98a407c0-1395-428d-8c1a-8b85f5361641_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_100272f0-34b9-450a-ace8-8a4e85e0f7eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_c1ec63eb-2c70-4c3a-96b4-759f9b890604_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_207b203e-fbd2-4bdc-b2c2-717289d6274a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b6d0c1a6-265b-4d70-8f39-2d554842c5a3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_67fa9687-635a-4432-b52c-986aebda7266_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a16e177f-67d1-4523-b112-fc51fcef155a_terseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_4982e56b-eefa-4ea8-8a9f-2f290b0d9fb3_verboseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front and development milestone payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_label_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_documentation_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:href="regn-20200930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:to="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_51fcb6f8-5468-4a75-807f-281fed226057_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6798d288-e092-4b74-9259-9368b7876523_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1f50d3c-2822-406d-9658-e0b434d5a7bb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d6b87072-0f62-4120-b44c-195def25ec70_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_b5bbd61b-06ce-4137-8e69-83688ecf9808_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">As Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0012ee9b-dfb2-45f9-8c96-9e5d727f7110_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f1b498e6-0d71-44c5-a2b3-3a0f7871f6c1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fd9f9f20-1549-4a4a-87bd-29e158677294_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_d7704129-acd4-4769-aafa-4dbf89d18b76_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of research and development expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_810ac8b3-9cfa-4cd2-b7ee-529660d3419b_verboseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of development expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b5034c11-06ef-49c2-a6b9-c1e0d11e5577_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_aa8d3f76-1b3c-4202-bb64-3d37a3428ae1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6bef5ab9-c327-440b-b233-e65f5d3e1b57_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e6cfee46-1306-4368-a80e-716f593af884_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_313640a0-b62b-49a8-bc49-198655a78951_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_e56adbaf-073a-4fdb-a93a-c0f9319800f8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_7ed45696-828a-4d7a-b848-97f3ef4a6ead_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of commercialization-related expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:href="regn-20200930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:to="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_2bc319ca-b8af-411c-9cd4-80ef4e5db22d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_de5f3e65-8821-49c9-a477-61e517efe74b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08c74ca5-6cd9-4b6f-b17e-68b8d5e69684_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a8668300-1b9d-426a-a5e9-579f6c7190df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b5979593-4503-4d49-9709-4e858756e9e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7108c3d7-54e8-422c-a1e2-b683e553f353_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cc6fb4f0-28eb-497c-9441-4558fc1e0d79_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_3aa519bd-0f17-47e0-84c5-d61799aab7da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_8ce97e05-b42b-400d-9e72-62cf240ae9d6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_d963ab94-85c9-4066-9b4d-192d93ddfefd_terseLabel_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:to="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_a6a00983-b4a7-4f6e-8a43-daee018fd72d_terseLabel_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_label_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_documentation_en-US" xlink:label="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount of twelve month sales upon which sales milestone would be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:href="regn-20200930.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:to="lab_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GrossSalesRevenueMember_b9415d04-218b-4c4b-b509-c3de0d93f55d_terseLabel_en-US" xlink:label="lab_regn_GrossSalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Sales Revenue</link:label>
    <link:label id="lab_regn_GrossSalesRevenueMember_label_en-US" xlink:label="lab_regn_GrossSalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Sales Revenue [Member]</link:label>
    <link:label id="lab_regn_GrossSalesRevenueMember_documentation_en-US" xlink:label="lab_regn_GrossSalesRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Sales Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossSalesRevenueMember" xlink:href="regn-20200930.xsd#regn_GrossSalesRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GrossSalesRevenueMember" xlink:to="lab_regn_GrossSalesRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_67a583f1-7dee-4f06-89c7-0588f89d194b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_75ae2b84-ea9d-46fa-ad9d-e65694c082f3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b7f571c8-ca60-46ff-969c-193e30d399aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_8d7dd5cc-6a49-4dd4-8580-0827de276835_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_204757d5-fb4c-4ad8-8ea7-95ece0e3f941_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_0ff919e9-4d34-4c92-aec0-ab484d1907e3_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_87c55bb3-f7f7-44af-bf1e-edd0fef95cec_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of treasury stock received</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6d13f003-a23f-4835-b302-a4c54da24029_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of shares received</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ec668443-4273-42dd-aa2d-7ff221d20350_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a5a181ed-99de-474f-9662-41b11e548dc7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4bed630c-627c-4e4f-ba14-ea93c56105b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5907edd3-3e21-4e6d-bc96-335be3b844ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a9bf6bd8-1dfc-4e1c-9f86-42f861a89d0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_45eddbff-f95c-452d-9fa4-1955873051a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_432214ea-8c65-4931-bb40-e59a88d5fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_55b8cd58-7e94-46e0-a1c9-73f250ec3a87_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1081c609-6e1a-40f1-aa20-ef7d02ec766e_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0ed0424d-8e4c-4121-b03d-4829cc379bce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d1218236-f076-4c77-8683-f9b44d354100_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f22a0a25-9196-472a-bcde-4f8c087d04f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8f223c39-872c-4d96-b82c-6e54b1915ee5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BridgeFacilityMember_8fb0731a-490d-4fe5-8036-294ecba2dbfb_terseLabel_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:label id="lab_regn_BridgeFacilityMember_label_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility [Member]</link:label>
    <link:label id="lab_regn_BridgeFacilityMember_documentation_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember" xlink:href="regn-20200930.xsd#regn_BridgeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BridgeFacilityMember" xlink:to="lab_regn_BridgeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fc7eda1c-90b2-49d7-bdc2-a70bd0aa69fa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c8b54dc-356a-4573-b22b-ce146a964126_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2f261f13-5c79-4b43-aaaf-5d1ec28d5524_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_615d836f-1542-4802-a0fe-07e61e4f6ea4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_23516248-070f-4cdc-b1c8-ce8c6cd60550_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Based on Contractual Maturity Dates</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75fce5fb-a0fd-4406-a459-e9461c630daf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8b3115d7-c24c-4899-85b4-18778e6f9416_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_68053215-ef57-4780-aa21-0b6f169d8d88_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_0258a10f-552c-4f75-b453-a15fd66db890_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:to="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_88a66e07-0af6-4f97-9b8a-68ba1634b190_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RevenuebasedonpercentageofannualsalesinJapan_3dde003c-b184-40ba-afee-9a1dace37a88_terseLabel_en-US" xlink:label="lab_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based on percentage of annual sales in Japan</link:label>
    <link:label id="lab_regn_RevenuebasedonpercentageofannualsalesinJapan_label_en-US" xlink:label="lab_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based on percentage of annual sales in Japan</link:label>
    <link:label id="lab_regn_RevenuebasedonpercentageofannualsalesinJapan_documentation_en-US" xlink:label="lab_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:href="regn-20200930.xsd#regn_RevenuebasedonpercentageofannualsalesinJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:to="lab_regn_RevenuebasedonpercentageofannualsalesinJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnsatisfiedObligation_160b3d20-414d-43db-b265-16458646a19e_terseLabel_en-US" xlink:label="lab_regn_UnsatisfiedObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsatisfied obligation</link:label>
    <link:label id="lab_regn_UnsatisfiedObligation_label_en-US" xlink:label="lab_regn_UnsatisfiedObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsatisfied Obligation</link:label>
    <link:label id="lab_regn_UnsatisfiedObligation_documentation_en-US" xlink:label="lab_regn_UnsatisfiedObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsatisfied Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnsatisfiedObligation" xlink:href="regn-20200930.xsd#regn_UnsatisfiedObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnsatisfiedObligation" xlink:to="lab_regn_UnsatisfiedObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_959a5e8a-911b-4b04-805d-abd7f0b87b7c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_Maximumsharesthecollaboratorcouldsell_48cd4fe5-f224-4a7d-9e7b-af58da43323d_terseLabel_en-US" xlink:label="lab_regn_Maximumsharesthecollaboratorcouldsell" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares the collaborator could sell (in shares)</link:label>
    <link:label id="lab_regn_Maximumsharesthecollaboratorcouldsell_label_en-US" xlink:label="lab_regn_Maximumsharesthecollaboratorcouldsell" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares the collaborator could sell</link:label>
    <link:label id="lab_regn_Maximumsharesthecollaboratorcouldsell_documentation_en-US" xlink:label="lab_regn_Maximumsharesthecollaboratorcouldsell" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares the collaborator could sell through September 30, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Maximumsharesthecollaboratorcouldsell" xlink:href="regn-20200930.xsd#regn_Maximumsharesthecollaboratorcouldsell"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_Maximumsharesthecollaboratorcouldsell" xlink:to="lab_regn_Maximumsharesthecollaboratorcouldsell" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7a54a106-0dfd-4ff4-a64f-ad9ea5253a47_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_c1132880-2cd2-4894-a7a1-a64f7896fa7b_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d400cae4-0510-4264-bcc7-3b4cbe99d861_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ae32d233-b148-43f0-8ca5-60fe70250ec7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_cd65cd8f-d490-414b-9e4f-ef5e40254fcc_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made for collaboration agreement</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_label_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment Made</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made under a collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:href="regn-20200930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:to="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfOtherExpenses_be6281a1-8f5e-4401-ba52-7b244fa50870_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaboration and contract manufacturing</link:label>
    <link:label id="lab_regn_ReimbursementOfOtherExpenses_label_en-US" xlink:label="lab_regn_ReimbursementOfOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Other Expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfOtherExpenses_documentation_en-US" xlink:label="lab_regn_ReimbursementOfOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfOtherExpenses" xlink:href="regn-20200930.xsd#regn_ReimbursementOfOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfOtherExpenses" xlink:to="lab_regn_ReimbursementOfOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_699363eb-49f0-40e9-9cd5-f0304ab46889_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_11546e47-7eb0-4c6f-944f-4cae64bbbb4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_60903d24-9972-4aff-b755-4ce6cf784c62_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable - Sanofi</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_49132d8b-9148-4665-a42c-6cae9c5c1e84_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_ee2c93e4-626e-48f0-9a32-8d11b9531ab6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_892f7e4d-4139-4b78-b90b-7cdfc6af3e9a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of product sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_99a921d9-8905-415c-9a1f-ce838f4bf3ba_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a0244fd4-ecf4-45ea-b999-65353a15cd1d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_e74717a9-3203-4f8f-9a9d-bd490177e7a9_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5f2ae0eb-8a26-4dc5-b611-e0c97e3b03cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d063a2ff-5003-4cbe-b859-34586cbd08c0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1c349f86-4d7e-432a-b62d-c8593ac21a34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_03ee2ffb-112a-46af-b704-3dc017bd0643_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bfb07165-7910-4a42-bbf3-b36e3d1d2574_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_29dbd5e3-d51a-4761-9818-e616da65a564_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_d2a5301e-ab67-47bf-a0b2-e11751abe6ef_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_c40f5175-caf6-49f2-821c-e7901fd5edde_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByEntity_652c74d9-f33d-4d2f-8389-c905550736a8_terseLabel_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs borne by entity</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByEntity_label_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs borne by entity</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByEntity_documentation_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByEntity" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfTrialCostsBorneByEntity" xlink:to="lab_regn_PercentageOfTrialCostsBorneByEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_59908a30-723c-4b7a-a6e0-973c6793e67a_terseLabel_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron</link:label>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_label_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron [Member]</link:label>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_documentation_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember" xlink:href="regn-20200930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_Amgenv.s.RegeneronMember" xlink:to="lab_regn_Amgenv.s.RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_99d67683-b54c-4f61-8d19-c1bba5c65adf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments in connection with Common Stock tendered for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty_53c67468-267a-4374-b911-048589098286_terseLabel_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs borne by collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty_label_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs borne by collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty_documentation_en-US" xlink:label="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:to="lab_regn_PercentageOfTrialCostsBorneByCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_04996f65-6d20-4d2d-a140-db1f4e4aaca6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_73801b35-62b4-46c2-ae1b-cf666145487f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8a3a16a4-9a96-41a0-85ad-ec73ca88a354_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d2fdaca2-1a4d-4f5b-b01f-39293bbe1650_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnrestrictedMember_d70e4202-4b25-496b-8c86-61dbcc36ad1a_terseLabel_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted</link:label>
    <link:label id="lab_regn_UnrestrictedMember_label_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted [Member]</link:label>
    <link:label id="lab_regn_UnrestrictedMember_documentation_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember" xlink:href="regn-20200930.xsd#regn_UnrestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnrestrictedMember" xlink:to="lab_regn_UnrestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_b2c256b0-d8f6-44ac-8af5-24e75e0880b1_terseLabel_en-US" xlink:label="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of research and development costs to be paid by counterparty</link:label>
    <link:label id="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_label_en-US" xlink:label="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Research And Developments Costs To Be Paid By Counterparty</link:label>
    <link:label id="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_documentation_en-US" xlink:label="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Research And Developments Costs To Be Paid By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:href="regn-20200930.xsd#regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:to="lab_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d9bceea8-eb9b-4c20-a47f-2154050c6f0f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_92fc3db1-c214-4c40-a310-8bfe199e6476_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_88fc4c21-0c39-40ea-9471-3cd4a0c57196_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_18e40d83-e473-4981-8901-6b18103843da_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaboration and contract manufacturing</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_471ad0cd-27b2-46ef-a5f5-858ea8404726_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b92c3182-ef91-401d-b599-12d478d7b832_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a89613b-76df-4921-940d-f146198221d7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0aced268-3363-4624-8890-217a0216debd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8c50fcbc-d371-4b0e-a146-dfea513dba01_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ef27d9ae-4154-4344-8e10-1dc52cfe8ac1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_03f22294-9995-4dfc-a1bb-bf466de3f0e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bbaef33b-c69f-4cc9-afc3-534bbd3ca875_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_3c4f760f-7217-491b-945e-7ab2083a088f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_9e1ec23a-af59-48d4-ac97-0ebc0e98bd81_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_8b81d80e-8dfb-4a82-85e4-0655a6e9a791_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_03a45c4b-682b-461d-a962-fdfdf8eb8448_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4253e1dd-287e-48e7-b071-d14fc6c1e25c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0bf2bc66-58a3-4666-b086-73eb35cc4b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_2e247734-d9f5-4fd6-b047-afcc098c7bf3_terseLabel_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits in connection with commercialization of antibodies</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:href="regn-20200930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:to="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_6cd48287-a572-431e-b23a-46fcb4ff59ff_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_8dd88fb5-6358-4531-9849-aff208e4072b_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_2a0edd03-964d-42f7-9bd2-e5df96a1872a_netLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8bee1f54-d213-4e37-b7a3-8537b7094bac_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_5f04897f-d84b-4c51-8afa-378e4fb9d8a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f25e9d45-e7d4-47d8-9fae-7ab7df2a248e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_9fc8de14-550f-4102-8789-76fa7d4ad56d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c18e8391-7f5f-44ae-b286-20638b0f5afb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0c104cc1-ee1a-4357-beb0-093778969dae_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dd709424-1df3-4c16-91c1-0a7694e93f02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2bcaa2d7-8631-4e0c-9ba7-960a98cdfe82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value and Unrealized Losses of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_5e059d88-14f4-4fa5-a887-9a49db355da9_terseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi research and development expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_a37ab06d-d121-4028-b5dc-e247eee52431_verboseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Bayer research and development expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20200930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestrictedMember_3f882cf9-c9f6-42d0-8bba-85aa4050b473_terseLabel_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted</link:label>
    <link:label id="lab_regn_RestrictedMember_label_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:label id="lab_regn_RestrictedMember_documentation_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember" xlink:href="regn-20200930.xsd#regn_RestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestrictedMember" xlink:to="lab_regn_RestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_dffc0623-2f62-4196-9094-f5a33be5771b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b0a61112-38b7-4e8b-b67a-498ef9693974_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_a7a2dc3b-5171-479e-9ec7-28c1e123439b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_76b586f3-7a3f-4939-b5d4-f22baefaa552_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5fa2c926-324f-488c-a73e-d84387f313b8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementMember_cf5ba57f-f485-4af8-81ac-ba0fde0b9a11_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementMember" xlink:to="lab_regn_SanofiCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A741PatentMember_f505e56f-0ce6-4d33-8163-b9f70cd0da1d_terseLabel_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent</link:label>
    <link:label id="lab_regn_A741PatentMember_label_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent [Member]</link:label>
    <link:label id="lab_regn_A741PatentMember_documentation_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember" xlink:href="regn-20200930.xsd#regn_A741PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A741PatentMember" xlink:to="lab_regn_A741PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_edc475a2-826d-4598-a716-8257d9263ba3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable - trade, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_3b5dfe53-36f1-4c16-8f91-3c99c41efa57_terseLabel_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum agreement payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_label_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_documentation_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments" xlink:href="regn-20200930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumTransactionAgreementPayments" xlink:to="lab_regn_MaximumTransactionAgreementPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_967a9709-acce-4eaa-a632-03fb8e3f5a16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cf14b1e-dbb9-440d-ac7d-d85b157cb9a9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_28615089-b8ff-4023-ac60-9aac8ab19767_terseLabel_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and contract manufacturing</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_label_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_documentation_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember" xlink:href="regn-20200930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationandContractManufacturingMember" xlink:to="lab_regn_CollaborationandContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndNotesReceivableNet_f9e65d06-e494-4416-821b-700d5f89bbd8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndNotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable - other</link:label>
    <link:label id="lab_us-gaap_AccountsAndNotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsAndNotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndNotesReceivableNet" xlink:to="lab_us-gaap_AccountsAndNotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ed08c7fe-2920-4dd2-a0d0-7052c0869b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1ce34b9e-fd30-4b21-b719-967a20f2c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_833f1719-43bf-4df3-ba4e-828f32bea79d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4e856ce3-b90d-464c-8bd6-9b72ecf2caa5_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_e68efc17-6d3f-48cf-ba3f-f5a7a02b4aec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_83f55c64-d260-424b-a247-d37ddfad29fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_dd78ff3b-61bd-477e-bd6b-bd36b2c3e651_terseLabel_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARCALYST</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_label_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcalyst Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember" xlink:href="regn-20200930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ArcalystNetProductSalesMember" xlink:to="lab_regn_ArcalystNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_706fa241-505d-4288-ad83-98fc097f87f7_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_740f1b2d-d7b1-4917-b659-de20c1143330_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_245cf7bc-cb24-43b5-a9be-fcfe7fa165da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_efee82a8-ab3f-4156-a27a-033de5bd47ee_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_afbc6399-85cb-4255-92ef-8cb23ea4046d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_99565227-ff17-4a57-89c9-b80d8f186dbb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_2c199a2c-1183-4334-8f4d-c35f5f1e89fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reclassifications</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_9adeb34c-9b2e-4b81-b8ee-7663fc2476eb_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_6d91b940-45da-4da6-bea6-b2c7af4539ee_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_d90db3ad-8e5e-4e8d-a6b8-84f718da16bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of bridge loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_76414fd7-678d-4270-a91f-c28baae6b419_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1639c5e3-361c-4d1e-ab98-9f0b91556464_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_dd6356c4-0959-42e6-8565-13d165bf77de_terseLabel_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims invalidated</link:label>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_label_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Claims Invalidated, Number</link:label>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_documentation_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Claims Invalidated, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber" xlink:href="regn-20200930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GainContingencyClaimsInvalidatedNumber" xlink:to="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_05f37108-08d4-4263-8024-51cb5575ad10_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_94c2299d-c637-4aeb-94e8-889df9728f4e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_febde402-a253-4e96-a607-7775c160d5f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_8d9d87f0-8761-43be-8d02-1a9201086cc9_terseLabel_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of damages company is responsible for</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_label_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_documentation_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:href="regn-20200930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:to="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89329c88-9ba3-44a2-8790-22aa837e9c31_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_cade1c6c-01ba-4c16-8fae-01f52dbb49c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_62504626-e5f2-4c34-812d-26dc0fcc5130_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_ecdd46f2-24e1-418b-a928-eb7683246858_terseLabel_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Agreement</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_label_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License And Commercialization Agreement [Member]</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_documentation_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License And Commercialization Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:href="regn-20200930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:to="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_9a651971-a4b2-40d8-8aa2-8cdf1ae4bf7a_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c837a9db-9670-45b6-875a-732091f23d9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_d69f59e6-4502-4c75-8d44-a920c045e477_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_dd986fca-b1ba-4e25-96cd-9f88320adb79_terseLabel_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for achieving sales target for milestone payment, rolling basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_label_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_documentation_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:href="regn-20200930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:to="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18aee8af-a22b-4fbb-b34b-736736fee6a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_ffb55d9f-b978-4418-85e2-bf127c95eb4f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2136a4e1-df1c-4ac6-92f3-8745c4a96dfa_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Other Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ef827f7-ae59-4c5e-8931-0d3f0d8b0e4f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d0e9b56c-1e9b-4a1f-a37f-147962ecf229_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5df1613-74d1-43e4-b062-38e36afb5c3b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12bba77e-7b22-445c-aedb-2978d2f4b869_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_c0125ce8-89df-4c01-9982-c6224eca2f6f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_163453c8-9b4c-4e76-a9c6-4decd1c25758_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9367418e-9a09-4dc9-a07e-08d16add1a05_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_4358b3a3-5ecf-42b4-82f6-6d4cacb1580f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_890168a8-e799-45e9-92d8-083bf4f29b54_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Sanofi, trade, and other accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_0539e70c-04c4-42aa-bc6a-9d9bb6538fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_0e67b28f-a22b-4e77-bb60-4b347f35f72e_terseLabel_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty payment that can be used to offset litigation proceedings</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_label_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Payment That Can Be Offset</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_documentation_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Payment That Can Be Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:href="regn-20200930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:to="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4d7bd345-6a74-47d8-a3b2-b96ca4715578_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_47f0a620-c299-4a26-816e-51fa6650cb46_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0df73e40-8cc3-4533-b632-1882dab7048d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ea851384-2954-470a-8e81-6aa21753eee5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock_6eb10597-5ff4-419d-a692-b63493c1d120_terseLabel_en-US" xlink:label="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contract balances</link:label>
    <link:label id="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer and Collaborator Asset And Liability [Table Text Block]</link:label>
    <link:label id="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer and Collaborator Asset And Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:href="regn-20200930.xsd#regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:to="lab_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_701217af-cddf-4924-b8f9-6ed90911d093_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A631PatentMember_01bf7702-aa23-4bf5-901a-d687f47afb34_terseLabel_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:label id="lab_regn_A631PatentMember_label_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent [Member]</link:label>
    <link:label id="lab_regn_A631PatentMember_documentation_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember" xlink:href="regn-20200930.xsd#regn_A631PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A631PatentMember" xlink:to="lab_regn_A631PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_476d5558-b8ee-4b56-a301-2dfbfe0eadd7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d1d7d0e5-4aa7-417f-80cf-b583f86dc41f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fd6595a3-08e5-44bf-9b97-87a43d60f665_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fda4ca2c-1da8-49f4-8bb5-527ec4faebca_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_e6b2d5b4-a4eb-47a6-ac0f-5f8fdf2f9b81_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_969a6435-1066-4dba-bf10-c56e2015f25d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb7b08e2-5a62-40fa-93d5-5247060473ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_eb81c017-d39d-433d-b944-4e7290da71e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_7408eb71-7d11-4483-a0f0-d8617b74a17a_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2050 Notes</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a9626f34-4830-497c-8f9f-f0f22c422dd6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive weighted average number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_b02637c0-2368-4241-b0d0-4e8f43b29214_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_70ead89c-f917-4302-9ef6-9e80306e7dc0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fe88beb3-cd99-4abf-86dc-a9d101ff0ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_57dfda3f-e292-4dd0-ac1f-00623ce2d63d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_910d86cc-10e0-4bf1-832f-c1425e441263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b0df431a-e84e-4557-9438-6c108c87e40b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2be9ac6a-e88c-4237-b762-d017e0082f65_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_11c822c5-5f42-486d-ae7b-79bdfb3e7c70_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c4bd8dbd-47c0-416d-acce-c0edf69a6746_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_277f7cf6-df61-4b8c-973e-fb66997b4a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ee589736-16af-45aa-9a31-7a2d8e433528_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_0dfd7ed5-c784-46f2-9da3-875c7313661a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_99c87e11-5b45-4234-bb8f-21f4c3b6623f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_fc712b72-8810-43d2-8e5b-810db3bd40ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities - Sanofi</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_db5edd7a-0b6c-4d2d-9b58-94c54f79663d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9aad4f1-0ca2-4a45-902d-1cba13c9f332_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3f8e0128-bdb3-446e-a5a1-f89ea62b03f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f35cc70c-1171-4005-9950-485710e58877_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d6bcea9b-b427-42a0-af55-819ba87e8366_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_89df6667-e33e-4910-b09b-91767256e892_terseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_label_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:href="regn-20200930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:to="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8477318d-a712-432b-b8b9-0ec434172562_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_IntelliaMember_93039be8-0490-4c5c-96b1-b0352b4476fd_terseLabel_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia</link:label>
    <link:label id="lab_regn_IntelliaMember_label_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia [Member]</link:label>
    <link:label id="lab_regn_IntelliaMember_documentation_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember" xlink:href="regn-20200930.xsd#regn_IntelliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_IntelliaMember" xlink:to="lab_regn_IntelliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9ca19399-b80e-4b5b-b3cf-63565a71b4d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5adba249-a86f-4183-b4b2-071c1cb4cd05_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2cccf39e-d2c8-4b98-bb20-e09fcef5fb01_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ffd45181-cdf0-4a7c-bc59-d7b0ea277d96_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_36cda2f7-97d6-4d3b-8ff9-2802b895ff5f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_cff96827-0fae-47fa-b60d-85ed26471e22_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_604e0f1d-871c-4f05-878c-3a5afc061ef9_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2030 Notes</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_c1016c91-7a89-4e91-99ac-336f1a46673d_terseLabel_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Transaction Agreement</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_label_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement [Member]</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_documentation_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember" xlink:href="regn-20200930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BARDAOtherTransactionAgreementMember" xlink:to="lab_regn_BARDAOtherTransactionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_aec696a3-9dff-40dc-87a7-507fb3c96c73_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ef502765-be4b-414e-87aa-60c0af1ea74c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_fa79870e-1416-45a3-9776-4f5b290c0a37_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provides general categories of investments for which information is required or determined to be disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentDomain" xlink:to="lab_regn_ClassificationOfInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentNetProductSalesMember_5ce57fda-f80f-4ddf-b869-defbcfdba8ed_terseLabel_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_label_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember" xlink:href="regn-20200930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentNetProductSalesMember" xlink:to="lab_regn_PraluentNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_f99248d7-3135-4ffa-86e4-27e66501afae_terseLabel_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of sales milestone payments if total sales achieve specific levels</link:label>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_label_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of sales milestone payments if total sales achieve specific levels</link:label>
    <link:label id="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_documentation_en-US" xlink:label="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:href="regn-20200930.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:to="lab_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_10eb0f31-e9cd-45f2-ad25-03cd9eb67144_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f865352c-a206-4041-b548-59383fccb136_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_59e1762c-21c8-42d0-b374-481b9162a2e3_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_7eabd483-48c0-479f-bf32-0ce6abefcd46_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_15f6fd94-fe69-41e6-bc15-e5926f7a6405_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LibtayoDevelopmentMember_c17f68d8-c70d-46a7-93f6-d45b22f8d97d_terseLabel_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo development</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentMember_label_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development [Member]</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentMember_documentation_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember" xlink:href="regn-20200930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LibtayoDevelopmentMember" xlink:to="lab_regn_LibtayoDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c6101252-b2f0-408b-9344-d6ed87e8309b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of collaboration revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_5e84bb9e-a02b-42eb-9640-fe18e642c795_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_e1f49353-54f4-4522-8954-c2287bf148fd_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_ca7ca834-c9da-4e1d-9924-2c994890ec20_verboseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CommonStockHeldBySanofiMember_8cc9bc30-4369-49e7-af4f-fef996c06786_terseLabel_en-US" xlink:label="lab_regn_CommonStockHeldBySanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held By Sanofi</link:label>
    <link:label id="lab_regn_CommonStockHeldBySanofiMember_label_en-US" xlink:label="lab_regn_CommonStockHeldBySanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held By Sanofi [Member]</link:label>
    <link:label id="lab_regn_CommonStockHeldBySanofiMember_documentation_en-US" xlink:label="lab_regn_CommonStockHeldBySanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Held By Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CommonStockHeldBySanofiMember" xlink:href="regn-20200930.xsd#regn_CommonStockHeldBySanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CommonStockHeldBySanofiMember" xlink:to="lab_regn_CommonStockHeldBySanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_37066efb-c7d1-4b38-ae0c-d73da4bb27da_terseLabel_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of IPR filed</link:label>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_label_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Inter Partes Review Filed, Number</link:label>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_documentation_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Inter Partes Review Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber" xlink:href="regn-20200930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GainContingencyInterPartesReviewFiledNumber" xlink:to="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_def51350-2696-4113-a581-ddff4b23bed0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_c2490f90-a2af-4a67-8dcb-e27b8521c19b_terseLabel_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BayerCollaborationAgreementMember" xlink:to="lab_regn_BayerCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_f347f933-b8f3-4d9e-834d-07ff5a30630f_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_28ad5735-076d-4997-8426-67d2f0647a08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_7d40ff8a-30cc-43c9-9e72-46f2607b7394_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_371ca3c5-bd7b-4ee0-97e5-0be3a82994ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_a9fe692f-6a6d-4799-97ca-614b1f4b14cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and service, other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4420dab-cbac-4fa2-a57e-7acecaf589fd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5b65727e-c97c-4653-9fd7-4e10cba888c3_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_a754b1fd-a693-4aa7-8456-0b18424d52cb_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_b5340d30-5161-405a-bcb8-ce87175ccf1b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7c453de9-665c-4878-aa6c-c6314e6676db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4da89687-2eae-4a70-943f-1ea25f68553f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_e70511a8-ffb6-422f-a09d-fbfc1a54f8e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f261ee5-7de3-4086-9b5b-077740cf7d81_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_133f270d-9b0d-4baa-b406-7e7d7147e9a9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_ce6e3ccd-c8af-46e1-a722-0f035b0285ce_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_dbb1adc8-36ce-4444-9cdc-5b2be7340ad4_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Research and development expense</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_fea9877e-f9fb-4ea4-895f-2d85cdcc6780_verboseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Research and development expense</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expense</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_f9337b21-0ba9-41fd-ad70-c2e2bc7329ec_terseLabel_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments</link:label>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_label_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments [Member]</link:label>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_documentation_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:href="regn-20200930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:to="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_a85e787c-4f02-4556-962d-9ecc8d8adfe9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9040b048-50f7-4a1f-965d-15170d18f014_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities owned not readily marketable</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5b2970c6-6b0c-4bc8-ac90-249c12626812_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Financial Statements</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6fee5f67-f870-4d6d-a588-ca5fd225eedf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_16b5b2d8-4ab9-4e44-9f62-d23ce242c303_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_124188ff-a2bd-4287-9946-40d40784e033_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cd0e9b15-6b1a-4300-a5e6-5926ba85edf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033c78f1-833a-4350-a028-3eea5be4069d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27967310-3b96-47d9-90e7-0d3851be8eb0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8fe288a-96d6-4842-961b-7de0bdb62cf0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_df5ed7f0-5f69-46bc-a261-6e9d43735219_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_6e230765-0bbe-403c-a586-dde9e676d401_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b11575be-8bcd-4741-80aa-376061076671_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3e7d9cfc-6614-45f4-b8bf-0b53d1ee71fa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_60079aa9-2491-404e-91a5-815826c2846f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_6b62fc9f-d319-4a59-90f7-92fe700eed7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a60f3d9a-86fd-4dc7-8277-d0df68a4e60b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_REGNCOV2Member_bc139bac-9950-4712-88f1-dd3232c32de8_terseLabel_en-US" xlink:label="lab_regn_REGNCOV2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGN-COV2</link:label>
    <link:label id="lab_regn_REGNCOV2Member_label_en-US" xlink:label="lab_regn_REGNCOV2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGN-COV2 [Member]</link:label>
    <link:label id="lab_regn_REGNCOV2Member_documentation_en-US" xlink:label="lab_regn_REGNCOV2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGN-COV2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGNCOV2Member" xlink:href="regn-20200930.xsd#regn_REGNCOV2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_REGNCOV2Member" xlink:to="lab_regn_REGNCOV2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2ff80675-3dca-49b6-b1c5-d7d9ec117d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2b47494f-fb54-469e-b2c4-cb2119490bd7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_92c7d510-61ba-41b8-b0cf-9be42c4849d6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_648eea12-b935-4474-8ed9-cafe8b156cb1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_91d761ec-7f89-46e3-9247-0e1817f5e9a9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5a8241bf-904d-499c-9fcb-8e0f1fb08ef4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_23f755a8-f166-495f-83fe-ddbcb87793f2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7c46e1e6-98b7-4975-b1d9-b1914b9d6a50_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_37847475-e0e1-4a4d-b77c-c646bff0b07f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_81dbc83b-1329-4945-b386-ec9b355c47c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_7eaa330e-b206-4e96-841e-649e5165a498_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c7860af5-ef53-4529-8420-608cd1401039_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e46de75-c8f2-446c-aa4e-51c321d90129_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_991afc68-1564-474d-aa7b-bf742c13dfa3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_7be437f1-947a-445f-901f-c84258e8ded5_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7e232e0-8c68-469f-bcf8-fe12d0b277cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_31cdceff-d7c4-441c-8f85-4e2537b9fce4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_96b5d86d-02a6-4ea1-bc91-5549a175ce89_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_7521faaa-f286-4943-b00a-f5e3cd22844f_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_7c1ae31c-421c-4f78-9501-eb30440801d2_netLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_b7567469-f2fc-499c-bf48-9ef96cfa7d25_verboseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:to="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_c36d8ff1-e04f-43a1-84a3-119e1a485f48_terseLabel_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_label_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_documentation_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:href="regn-20200930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:to="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_2fca6535-66c3-4fb9-bc81-4397d4aafdd1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_853e000b-114e-49ba-8175-0356bdd1fe57_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_9743c89c-98c6-4c53-8d8c-3af7243c1a69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at cost; 15,741,824 shares in 2020 and 4,860,123 shares in 2019</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_85c67d54-dd2a-43b5-bf90-ca2b41ff2f65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dceb98a-c505-4564-90b8-0a695b43b3da_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c07b39d2-4383-46dd-9814-5036a5280b90_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4f9b4776-66ec-4adf-8221-ee342931d30e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e5710cb6-7991-486c-b0dd-03eb4c781216_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0325345f-ee97-4ae3-a482-01a73d154f4c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e539c5ae-8cc7-4dec-bb69-411791987da9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_9139b5d4-e80d-4376-9ff1-8787c1a1f0ce_terseLabel_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price with change-in-control provision, percentage</link:label>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_label_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</link:label>
    <link:label id="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_documentation_en-US" xlink:label="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:href="regn-20200930.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:to="lab_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>regn-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:bffb07f0-b9de-47a6-8d8d-570b4833f09f,g:307c6806-1768-4c0c-9109-161bbe2fe6ee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20200930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fc42182c-b97a-43dc-a53e-c41b775ef982" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fc42182c-b97a-43dc-a53e-c41b775ef982" xlink:to="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3400aa3-70c0-4239-a430-0223e5865512" xlink:to="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5a64e73c-2437-445b-b7fc-8fc8600d2efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:to="loc_us-gaap_CommonClassAMember_5a64e73c-2437-445b-b7fc-8fc8600d2efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9589d625-507f-432e-b0b2-ac864107d25d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_33e00c83-f277-4eaf-a18f-07546586ddd3" xlink:to="loc_us-gaap_CommonStockMember_9589d625-507f-432e-b0b2-ac864107d25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_b2d55e57-ff41-4d6f-995b-e4308883dabd" xlink:to="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9d4354ea-f0a6-4eed-beb4-02f4068df27f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentType_9d4354ea-f0a6-4eed-beb4-02f4068df27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_25f03fbe-3de6-41d7-ae0f-022ff89422f4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentQuarterlyReport_25f03fbe-3de6-41d7-ae0f-022ff89422f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7487abbe-f02a-4db3-9f14-c764df7abac2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentPeriodEndDate_7487abbe-f02a-4db3-9f14-c764df7abac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2c07fec1-847b-45cb-b4da-30929c7bacf3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentTransitionReport_2c07fec1-847b-45cb-b4da-30929c7bacf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_45d80c6f-1e87-4601-bc33-083b2026ef3b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityFileNumber_45d80c6f-1e87-4601-bc33-083b2026ef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c907c67-87da-46a5-a330-f7d10dd89e3a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityRegistrantName_1c907c67-87da-46a5-a330-f7d10dd89e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8e49def8-12fa-4ef6-b8f3-194fe791ac0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8e49def8-12fa-4ef6-b8f3-194fe791ac0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6707fbb2-ee9d-49cb-937a-938a03f6047e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityTaxIdentificationNumber_6707fbb2-ee9d-49cb-937a-938a03f6047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b573aeba-7429-4fe8-86dc-2945d2ab65a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressAddressLine1_b573aeba-7429-4fe8-86dc-2945d2ab65a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_448daedc-397f-4102-b2b6-5c7aeb6ceab7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressCityOrTown_448daedc-397f-4102-b2b6-5c7aeb6ceab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_68069eaf-b8b4-46a8-a5e2-ffe4aa8d28af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressStateOrProvince_68069eaf-b8b4-46a8-a5e2-ffe4aa8d28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5cb32ee3-ba24-4211-832f-0473ad4ac087" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityAddressPostalZipCode_5cb32ee3-ba24-4211-832f-0473ad4ac087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a5e22019-7b16-4cb2-a78a-2cb28c623dbc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_CityAreaCode_a5e22019-7b16-4cb2-a78a-2cb28c623dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d224f9b7-8123-45ba-a4ad-8a2cbc9a8ce2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_LocalPhoneNumber_d224f9b7-8123-45ba-a4ad-8a2cbc9a8ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2bb346ee-661e-4542-978f-41300a7ed5b5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_Security12bTitle_2bb346ee-661e-4542-978f-41300a7ed5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac7169e7-8d51-4aa1-9b35-e02d3c668da0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_TradingSymbol_ac7169e7-8d51-4aa1-9b35-e02d3c668da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af3eccb8-6012-4e1f-ba31-df8086433689" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_SecurityExchangeName_af3eccb8-6012-4e1f-ba31-df8086433689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2501990b-f13d-4713-9166-89686870d4f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCurrentReportingStatus_2501990b-f13d-4713-9166-89686870d4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a101ee0b-7c01-4c59-8bce-3dc752187ca7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityInteractiveDataCurrent_a101ee0b-7c01-4c59-8bce-3dc752187ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_27d329b0-fb91-4e5c-bf55-ca9d6c1fcf4b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityFilerCategory_27d329b0-fb91-4e5c-bf55-ca9d6c1fcf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ec5ca084-d47d-46b5-9f67-32274b221d55" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntitySmallBusiness_ec5ca084-d47d-46b5-9f67-32274b221d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3c0a0c00-d835-4a93-8709-f3ac1dba8bfb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityEmergingGrowthCompany_3c0a0c00-d835-4a93-8709-f3ac1dba8bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1cf276ba-c327-4071-847f-4db77ec6821d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityShellCompany_1cf276ba-c327-4071-847f-4db77ec6821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b7d13289-2b09-4e83-a1da-2e92da472ce1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b7d13289-2b09-4e83-a1da-2e92da472ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd8d5017-5e0c-4fde-812e-d121a417fd7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_EntityCentralIndexKey_fd8d5017-5e0c-4fde-812e-d121a417fd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_936f208e-718b-4b39-b5a9-f8255dbcf860" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_CurrentFiscalYearEndDate_936f208e-718b-4b39-b5a9-f8255dbcf860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2b7b6fd-8e0b-43b5-abd6-1b489b68ad59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentFiscalYearFocus_b2b7b6fd-8e0b-43b5-abd6-1b489b68ad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d1ce5401-a4da-4ae7-ac1e-fc46465cf9e1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d1ce5401-a4da-4ae7-ac1e-fc46465cf9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_02b89bd3-5bb4-4682-8c1e-fce6401f9065" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e7c62bbc-76c5-4569-8d2c-cb0c5b44ef0c" xlink:to="loc_dei_AmendmentFlag_02b89bd3-5bb4-4682-8c1e-fce6401f9065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_06e2f91d-ffde-4533-846d-21aa43b6fd2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_06e2f91d-ffde-4533-846d-21aa43b6fd2d" xlink:to="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_01bbf873-14ed-461e-87c3-494658bd2fc7" xlink:to="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_320fb462-b775-489f-9e93-01a262301864" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:to="loc_regn_SanofiCollaborationAgreementMember_320fb462-b775-489f-9e93-01a262301864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_f1810c5f-fcec-4e76-9334-5bffa62c7faf" xlink:href="regn-20200930.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_8a589a07-cc0f-4e77-80cd-9ee1613cd675" xlink:to="loc_regn_OtherCollaborationAgreementsMember_f1810c5f-fcec-4e76-9334-5bffa62c7faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:to="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_250c1f27-3853-4f3e-ac89-2a77a6724b79" xlink:to="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_abf1ca36-e87e-4671-9f4f-1cebf2a04541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:to="loc_us-gaap_CommonClassAMember_abf1ca36-e87e-4671-9f4f-1cebf2a04541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e6179f6-3c8b-4f74-9693-6b17f4551a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_abf4ebab-db11-4039-be36-2327350d66c9" xlink:to="loc_us-gaap_CommonStockMember_8e6179f6-3c8b-4f74-9693-6b17f4551a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2cceef2d-d8ea-4cab-bdaa-a5abb8ab2320" xlink:to="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a59801-1377-4d88-a1ae-2732ef3aa43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66a59801-1377-4d88-a1ae-2732ef3aa43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_05800f82-5358-4b75-a801-f4a4d6ec75a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_05800f82-5358-4b75-a801-f4a4d6ec75a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_abb39355-985b-4ea7-b6e9-6834b2a49375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_abb39355-985b-4ea7-b6e9-6834b2a49375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_684225fa-f77b-4a3f-9212-11dcca9fb350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_684225fa-f77b-4a3f-9212-11dcca9fb350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_11316a60-047b-472c-a8d2-739f3c875bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_11316a60-047b-472c-a8d2-739f3c875bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_86999386-7162-49b9-a038-425c230addf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_InventoryNet_86999386-7162-49b9-a038-425c230addf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135ff17e-d036-4c65-86a4-fc40444d589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_135ff17e-d036-4c65-86a4-fc40444d589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_738b3ca1-bcec-4a77-ba98-94368aa0258a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b57a36ab-34ec-4034-964f-28d56fa43522" xlink:to="loc_us-gaap_AssetsCurrent_738b3ca1-bcec-4a77-ba98-94368aa0258a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_3a40523d-4a85-4f09-bde6-595970bd1197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_3a40523d-4a85-4f09-bde6-595970bd1197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_457cd7cc-b530-42f3-8c88-31470e86dfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_457cd7cc-b530-42f3-8c88-31470e86dfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e4478fe-8970-4780-ad2c-3eeb41f90362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7e4478fe-8970-4780-ad2c-3eeb41f90362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e080791c-1752-4c2b-bad7-2fed777c5757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e080791c-1752-4c2b-bad7-2fed777c5757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1d4ea45c-b2c2-4003-8898-e7c50fb30c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73608fa0-74bb-4d06-98f9-afaeb7f871cd" xlink:to="loc_us-gaap_Assets_1d4ea45c-b2c2-4003-8898-e7c50fb30c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_bf48417f-864b-41eb-9e15-55ccd6bdbd50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_bf48417f-864b-41eb-9e15-55ccd6bdbd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_be676258-b809-4079-a3cb-796683bace37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_be676258-b809-4079-a3cb-796683bace37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73740080-f039-42da-84ca-8e99746c4e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_73740080-f039-42da-84ca-8e99746c4e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a5cee0ed-594a-4952-8824-489f823dbcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a5cee0ed-594a-4952-8824-489f823dbcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f024bdd2-2f7d-4058-ae30-cb0bf2db7ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9001d881-4f9b-4973-a23c-5807aaa2739f" xlink:to="loc_us-gaap_LiabilitiesCurrent_f024bdd2-2f7d-4058-ae30-cb0bf2db7ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1a3843bf-7caa-4c78-b96f-a3d79458fcac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1a3843bf-7caa-4c78-b96f-a3d79458fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b26ee7d0-23ac-416a-bed1-0dacfd4a0f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b26ee7d0-23ac-416a-bed1-0dacfd4a0f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1e6d832f-5149-40b2-8b81-87e2d4509259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1e6d832f-5149-40b2-8b81-87e2d4509259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a716e9a3-3a27-481a-9fa8-1d6e7964a673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a716e9a3-3a27-481a-9fa8-1d6e7964a673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6b7ce0a1-57b7-4a0c-b07b-64310ba18f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_Liabilities_6b7ce0a1-57b7-4a0c-b07b-64310ba18f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e0055e05-fe8d-40df-888d-a8b3c15219d7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_16f7525e-743e-4bd0-a0f5-e368aed85b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_PreferredStockValue_16f7525e-743e-4bd0-a0f5-e368aed85b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ce57737-0873-4cad-a0f3-64e172d8ce9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_CommonStockValue_3ce57737-0873-4cad-a0f3-64e172d8ce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fc9a1b58-315b-4200-a32f-783614f798d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fc9a1b58-315b-4200-a32f-783614f798d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c624737-94df-42ea-925d-ac56298ac4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2c624737-94df-42ea-925d-ac56298ac4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03857899-0987-47e1-ac05-f9972ee0d976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03857899-0987-47e1-ac05-f9972ee0d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_db62bc9a-1c58-448d-bed3-b536f34c23b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ff8375e-1f14-4298-bd09-6d6b5d9bab8c" xlink:to="loc_us-gaap_TreasuryStockValue_db62bc9a-1c58-448d-bed3-b536f34c23b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a98a163-6110-48c5-b942-9c3581b8e8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_StockholdersEquity_4a98a163-6110-48c5-b942-9c3581b8e8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af91f50-a165-449e-b26a-a891b1e78484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cade524d-2488-4d6e-a8b3-4404cf0de0df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af91f50-a165-449e-b26a-a891b1e78484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7ef09949-b387-4be2-a1a4-456d67ba310e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7ef09949-b387-4be2-a1a4-456d67ba310e" xlink:to="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b9f83cb-e676-43ca-b7e6-61aeb2927d3a" xlink:to="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_660b257f-afaa-412d-ac2a-02a1d3c7ccb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:to="loc_us-gaap_CommonClassAMember_660b257f-afaa-412d-ac2a-02a1d3c7ccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89216f56-d6c2-438e-8f16-c5f372760d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_808f823c-7aeb-4f9b-bc60-06d306c6065f" xlink:to="loc_us-gaap_CommonStockMember_89216f56-d6c2-438e-8f16-c5f372760d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7b3a6ca2-b7f5-43d6-a22a-9b7057143cbc" xlink:to="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fab72bd6-7726-475f-9c76-638d8fc4f6f0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4637e77-d6f5-4ec4-9417-ac98639de096" xlink:to="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f8b2be1-638d-4337-b4a9-4a9a4adf0192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f8b2be1-638d-4337-b4a9-4a9a4adf0192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08f5b5ca-b2c3-4307-a352-c839e0528d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08f5b5ca-b2c3-4307-a352-c839e0528d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6224885c-c67f-4845-8a80-a32f1bc59089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6224885c-c67f-4845-8a80-a32f1bc59089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_afa58d98-0efa-47a7-8382-4ee21d3d8262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_afa58d98-0efa-47a7-8382-4ee21d3d8262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_72d03f8e-94b1-4114-9ac0-54bfc65acea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_72d03f8e-94b1-4114-9ac0-54bfc65acea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_732191e1-bad3-4dbe-9788-12266e298b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_732191e1-bad3-4dbe-9788-12266e298b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1d2ae5f0-7ad9-4137-8180-982e158e3fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesIssued_1d2ae5f0-7ad9-4137-8180-982e158e3fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_43430c9e-79ba-4ad1-bad5-9e3b6f005641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_43430c9e-79ba-4ad1-bad5-9e3b6f005641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a0d63cf2-afd5-473e-921e-0f38fe9dbe51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adaafa59-63f2-451d-9443-343c922a342d" xlink:to="loc_us-gaap_TreasuryStockShares_a0d63cf2-afd5-473e-921e-0f38fe9dbe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8419fa3d-91b6-4ca4-9bda-1836231fd938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8419fa3d-91b6-4ca4-9bda-1836231fd938" xlink:to="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_8fbc76fa-1beb-4eac-889a-9a59721c990b" xlink:to="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_ffda342b-26d4-4d67-9c33-e0646954344f" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_SanofiCollaborationAgreementMember_ffda342b-26d4-4d67-9c33-e0646954344f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_dd47c375-0d04-4bd0-96bb-9bf2507376d5" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_BayerCollaborationAgreementMember_dd47c375-0d04-4bd0-96bb-9bf2507376d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherRevenueMember_6894cdf5-cf77-4753-a339-d066031d535f" xlink:href="regn-20200930.xsd#regn_OtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_be064406-f856-4ce4-898d-e04a01a5bb26" xlink:to="loc_regn_OtherRevenueMember_6894cdf5-cf77-4753-a339-d066031d535f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:to="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea01ce13-6f85-4efd-9226-b7e553fed76f" xlink:to="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_310b49cf-c20a-4de4-b6d8-6ebd3501e5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_us-gaap_ProductMember_310b49cf-c20a-4de4-b6d8-6ebd3501e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b5160a26-9adb-451e-ac46-713090d9841a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b5160a26-9adb-451e-ac46-713090d9841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_c65399af-d1ab-4b68-b579-ef50f7668f82" xlink:href="regn-20200930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06f0541a-1030-4087-8a82-2595164c1860" xlink:to="loc_regn_CollaborationandContractManufacturingMember_c65399af-d1ab-4b68-b579-ef50f7668f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7790a3e-b195-4596-b1e5-78133a0979b2" xlink:to="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:to="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da11dc42-620a-44ab-88c5-50af5d636a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c732c4cb-7706-4375-9dec-12f127719604" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da11dc42-620a-44ab-88c5-50af5d636a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_719728ac-61cd-4675-8619-9b0b6fd524bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_719728ac-61cd-4675-8619-9b0b6fd524bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a61514f-634f-4bd9-8b3e-579277c74849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6a61514f-634f-4bd9-8b3e-579277c74849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3b45e5d-4da2-4ebb-b808-427e4f255965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3b45e5d-4da2-4ebb-b808-427e4f255965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c14d8b9-ffe7-42ec-9e2e-785b97aeac8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8c14d8b9-ffe7-42ec-9e2e-785b97aeac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2c351653-c6d5-4270-a76e-f95f5a07a34b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1be22a63-9195-4fff-b805-77b02cb605b3" xlink:to="loc_us-gaap_CostsAndExpenses_2c351653-c6d5-4270-a76e-f95f5a07a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c64e3330-4fd4-4429-bf8b-3ccf2c44bf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_OperatingIncomeLoss_c64e3330-4fd4-4429-bf8b-3ccf2c44bf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e352c21d-c637-4bba-8aea-ef18a68f5bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e352c21d-c637-4bba-8aea-ef18a68f5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_edca1104-4351-4c3e-9dfd-925538ac37d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_InterestExpense_edca1104-4351-4c3e-9dfd-925538ac37d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3ffb5be8-d7a8-45a7-8c54-adbb55b17cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1bb9c73f-89a6-4958-8041-ab872b2d98f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3ffb5be8-d7a8-45a7-8c54-adbb55b17cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_edfc0a88-2d02-452d-885d-903cdd844027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_edfc0a88-2d02-452d-885d-903cdd844027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e5a48a3d-2226-4296-8293-6753f1383c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e5a48a3d-2226-4296-8293-6753f1383c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52591481-47ca-45a0-9071-d2c423262e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_NetIncomeLoss_52591481-47ca-45a0-9071-d2c423262e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9193a227-09e6-4f06-b08d-cf220719a74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_9193a227-09e6-4f06-b08d-cf220719a74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9213fa34-c1fd-4dd6-888d-cf652c275961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9213fa34-c1fd-4dd6-888d-cf652c275961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6d458db6-2d25-4862-9c8c-35b6d205dcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6d458db6-2d25-4862-9c8c-35b6d205dcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5f77f60-5236-4add-b6f8-2e3e09c078e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b0af7835-ad9e-4f9a-91cf-513f0a5081aa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5f77f60-5236-4add-b6f8-2e3e09c078e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f6fbcc83-9cad-4702-ba4b-40f17dff6f46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d9f296d-1951-42e5-8dd3-d37037167a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:to="loc_us-gaap_NetIncomeLoss_8d9f296d-1951-42e5-8dd3-d37037167a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f03b9657-ee01-4889-86d9-5f9e85b4eeec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f03b9657-ee01-4889-86d9-5f9e85b4eeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f5f72642-640b-4704-9766-a50ee55cd1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dbb1489a-e623-404f-b198-f7e201b3f26b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f5f72642-640b-4704-9766-a50ee55cd1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbee1c19-e2cc-4f05-9517-53bff8670a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c747808e-5f31-4736-85c8-a3c9771cdfb0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbee1c19-e2cc-4f05-9517-53bff8670a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_29fa27b6-e2ba-4391-a3c3-40d5f2b519a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_29fa27b6-e2ba-4391-a3c3-40d5f2b519a5" xlink:to="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15a4e8ec-19be-4c82-b612-12f840c742a6" xlink:to="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_310234c4-cbb2-4d94-aaec-fdb55f9d446f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:to="loc_us-gaap_CommonClassAMember_310234c4-cbb2-4d94-aaec-fdb55f9d446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdf27f87-9978-4a0d-bcce-cd87c1107950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_36fd307d-96c2-4a4d-acad-4d1527bd3386" xlink:to="loc_us-gaap_CommonStockMember_bdf27f87-9978-4a0d-bcce-cd87c1107950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bbfd3230-f458-4038-b2d5-e217d1307077" xlink:to="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_78ff709b-b963-4a64-921b-6a9efa7b2a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_78ff709b-b963-4a64-921b-6a9efa7b2a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6a992e69-e994-4f5c-921a-b04817ba7636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_RetainedEarningsMember_6a992e69-e994-4f5c-921a-b04817ba7636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_670fe4c0-e203-4415-9b91-8ffc787d2af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_670fe4c0-e203-4415-9b91-8ffc787d2af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e6398000-67b5-4314-8744-6686b22ffaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8b7f5ac-7fa1-4074-91de-ebfaf965982a" xlink:to="loc_us-gaap_TreasuryStockMember_e6398000-67b5-4314-8744-6686b22ffaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b78ca5c8-e304-456d-bd0d-88f3cc52f56f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e18c2d5-f0d5-4fce-b926-75349068ca9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6fa640ce-fce6-432c-a743-06373f2b8b12" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e18c2d5-f0d5-4fce-b926-75349068ca9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22096735-9de0-4a22-a634-cb0bbfb6214f" xlink:to="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13229fc0-dade-4751-8049-94d76ccf4534" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f0be1588-14ca-431c-a8fb-22373babe09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_SharesOutstanding_f0be1588-14ca-431c-a8fb-22373babe09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23eb70c3-b564-482a-a188-8149a7302ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockholdersEquity_23eb70c3-b564-482a-a188-8149a7302ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1a93d185-7d42-48ed-845b-9c0accefbe10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1a93d185-7d42-48ed-845b-9c0accefbe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5486017-cd05-4a4b-b53d-949261e44b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b5486017-cd05-4a4b-b53d-949261e44b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fce7648c-958f-4a9c-b5d9-fac0203efdad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_fce7648c-958f-4a9c-b5d9-fac0203efdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7459f22f-30d0-4939-9908-f9b46dd944e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7459f22f-30d0-4939-9908-f9b46dd944e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_77d8ad3c-4a8e-4587-bff3-10da0ec12ac2" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_77d8ad3c-4a8e-4587-bff3-10da0ec12ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_f5442194-40d7-45c4-b6c8-b619eac7849c" xlink:href="regn-20200930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_f5442194-40d7-45c4-b6c8-b619eac7849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_66f87c3e-0a24-4c63-89d3-c88e7d08906f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_66f87c3e-0a24-4c63-89d3-c88e7d08906f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aec3908a-053d-4a9b-9e7c-a8c089b566b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aec3908a-053d-4a9b-9e7c-a8c089b566b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4bf23561-3772-4c70-8a7f-14711993339a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4bf23561-3772-4c70-8a7f-14711993339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_440b124b-37be-478e-a551-a2753a51c348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_NetIncomeLoss_440b124b-37be-478e-a551-a2753a51c348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a557fd1-13f1-4b81-ab3c-2998639b923b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a557fd1-13f1-4b81-ab3c-2998639b923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_87b3f010-b090-4633-8c66-d1f071e1c130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_87b3f010-b090-4633-8c66-d1f071e1c130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_e218b602-ecb9-460b-8f86-2cdf29665e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_e218b602-ecb9-460b-8f86-2cdf29665e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd0e8aae-cf13-4640-9f63-82489578432c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_SharesOutstanding_cd0e8aae-cf13-4640-9f63-82489578432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c91bded9-129e-4ac7-85c1-ce3f73b03cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a90aca97-4680-4adb-a354-10301ec2a50b" xlink:to="loc_us-gaap_StockholdersEquity_c91bded9-129e-4ac7-85c1-ce3f73b03cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2357c4b7-760d-4bf9-bb4e-db07d1f588b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2357c4b7-760d-4bf9-bb4e-db07d1f588b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b146955-1b18-439a-8c48-8479a8f86e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2357c4b7-760d-4bf9-bb4e-db07d1f588b5" xlink:to="loc_us-gaap_NetIncomeLoss_8b146955-1b18-439a-8c48-8479a8f86e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2357c4b7-760d-4bf9-bb4e-db07d1f588b5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6e229982-dc90-4fa0-a087-5eb12380a821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6e229982-dc90-4fa0-a087-5eb12380a821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_63e38220-faa3-455f-8435-026b05dbca79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_ShareBasedCompensation_63e38220-faa3-455f-8435-026b05dbca79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_35d27c37-af1d-416c-ae23-4350ceb2296f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_35d27c37-af1d-416c-ae23-4350ceb2296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f9e858ee-2df7-4003-b277-d6ed91d9e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f9e858ee-2df7-4003-b277-d6ed91d9e7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2da226ba-8ea0-4e1d-b3ff-0a0988defbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2da226ba-8ea0-4e1d-b3ff-0a0988defbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_65357395-a604-4d34-9d7a-1bc985c2b9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_65357395-a604-4d34-9d7a-1bc985c2b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e98c2bca-b21f-4008-8cc0-231f0abd124f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e98c2bca-b21f-4008-8cc0-231f0abd124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c212f361-cc9f-4833-a960-82fb2195ee56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c212f361-cc9f-4833-a960-82fb2195ee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01c0939e-9bb5-419e-8c5e-ea039622ad25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_051c34a9-5077-41a5-8333-69e16ada95b8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01c0939e-9bb5-419e-8c5e-ea039622ad25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_27da9528-e7ea-472a-9776-38325761ea46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1c55bd4c-49fc-4660-9163-af474b5204f5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_27da9528-e7ea-472a-9776-38325761ea46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58a83890-e4cf-4e5a-889e-dd7852a61c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2357c4b7-760d-4bf9-bb4e-db07d1f588b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58a83890-e4cf-4e5a-889e-dd7852a61c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6fcbdf4c-9830-47a7-8691-ddefe250a43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6fcbdf4c-9830-47a7-8691-ddefe250a43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_44a2c30a-b9f6-468b-b8ff-cf19f055c007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_44a2c30a-b9f6-468b-b8ff-cf19f055c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d90fbe35-3ebf-4b1d-b384-ce9ff17949d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d90fbe35-3ebf-4b1d-b384-ce9ff17949d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce99535f-bbdd-4617-8029-3d71b906e4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_255718d1-b7ab-4e2a-a647-85fefbdd4fe7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce99535f-bbdd-4617-8029-3d71b906e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_54440457-8921-488a-b60e-9a39f1686aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_54440457-8921-488a-b60e-9a39f1686aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_122a6ba3-a6f7-494f-b719-fbfda04800a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_122a6ba3-a6f7-494f-b719-fbfda04800a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_7318316e-ccb0-4481-b905-ab4cd14e31b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_7318316e-ccb0-4481-b905-ab4cd14e31b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bb3caf0-70c8-4660-8955-706d1c0b7f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bb3caf0-70c8-4660-8955-706d1c0b7f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_567762ca-ad13-42e1-aade-662877b6ea99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_567762ca-ad13-42e1-aade-662877b6ea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_89dbb6ad-aed1-41c6-ac2f-3f54814753c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_89dbb6ad-aed1-41c6-ac2f-3f54814753c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3efec174-c94b-41df-80f8-c05723e6d744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2a6fa7ea-f7d1-4302-ad35-23d6be4fda76" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3efec174-c94b-41df-80f8-c05723e6d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a810ea22-b343-4a88-94c6-615797a78d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a810ea22-b343-4a88-94c6-615797a78d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62087f92-006d-4a86-b87d-f043bb05257c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62087f92-006d-4a86-b87d-f043bb05257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93890072-f662-4eeb-8213-2fb35da2c136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7241980e-5149-4582-9be7-5a5cabc44523" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93890072-f662-4eeb-8213-2fb35da2c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d58b9ba-dbdc-4d93-b3a0-77296157e4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_04dde850-3f3b-4fb4-bff4-02729afcdb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d58b9ba-dbdc-4d93-b3a0-77296157e4f2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_04dde850-3f3b-4fb4-bff4-02729afcdb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2d0e88ca-e43a-47bf-b59b-0aafab0e88a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2d0e88ca-e43a-47bf-b59b-0aafab0e88a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_cb4fa077-6f7a-445f-95f3-366f794f5d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:to="loc_us-gaap_UseOfEstimates_cb4fa077-6f7a-445f-95f3-366f794f5d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0db85fa-3605-4d9d-bec2-9d75c708914b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0db85fa-3605-4d9d-bec2-9d75c708914b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_654f59ac-7177-419f-96b2-23a0a13a1c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_654f59ac-7177-419f-96b2-23a0a13a1c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_baecfefa-a12e-461b-bd9c-d83fe06f7c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494e7ebc-a20f-482e-8cfd-d00a98e5844c" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_baecfefa-a12e-461b-bd9c-d83fe06f7c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f7e25bf-d986-488d-aa23-2e701e841f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_749e0ec5-3cec-4ee0-8216-f8e93aba89a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f7e25bf-d986-488d-aa23-2e701e841f30" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_749e0ec5-3cec-4ee0-8216-f8e93aba89a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofBalanceSheetDataDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71d79e54-6031-4941-958d-9730f595f9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_71d79e54-6031-4941-958d-9730f595f9bb" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:to="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_9c6f988f-0739-4d2b-9add-04f1fe77e168" xlink:to="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_72664528-f73c-4a8a-9c02-a6136f0b8394" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_72664528-f73c-4a8a-9c02-a6136f0b8394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_3106b813-a751-4f3f-8307-fa87c69e21fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_19af7d47-2d64-48a3-b784-5a3eb3d2dbbd" xlink:to="loc_srt_RestatementAdjustmentMember_3106b813-a751-4f3f-8307-fa87c69e21fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e98a4baf-d981-49af-a577-b046e9d9e96a" xlink:to="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_4ee47a7f-5897-44f8-bb65-ad98fabe79ec" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:to="loc_regn_SanofiCollaborationAgreementMember_4ee47a7f-5897-44f8-bb65-ad98fabe79ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherCollaborationAgreementsMember_c2d039c2-4ed3-4c88-ae10-e0650a43d61d" xlink:href="regn-20200930.xsd#regn_OtherCollaborationAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_e1046e30-b93c-4261-a66b-d7e563eabd38" xlink:to="loc_regn_OtherCollaborationAgreementsMember_c2d039c2-4ed3-4c88-ae10-e0650a43d61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_63db3d17-a95d-4579-99e4-9a42009c584f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b837e624-71c0-4145-9ec1-fe7629e27fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_b837e624-71c0-4145-9ec1-fe7629e27fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_596802cf-4880-4e2f-a822-f6b4864306d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_596802cf-4880-4e2f-a822-f6b4864306d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c530aaf5-10cd-4815-8f0e-1c0886dd8943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c530aaf5-10cd-4815-8f0e-1c0886dd8943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3c31c225-857d-4628-b3f3-6606f306aa04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3c31c225-857d-4628-b3f3-6606f306aa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a87b9db8-904e-4c33-b477-134dfded4f38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_861d54de-8914-43bf-9d5b-6e43642dd385" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a87b9db8-904e-4c33-b477-134dfded4f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_319de8d1-035e-4044-bdbd-ed23c2644aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_319de8d1-035e-4044-bdbd-ed23c2644aab" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_892befd9-8356-4321-9166-a46f9ea80540" xlink:to="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_df9e8e00-af03-4628-95bd-1104322d42d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_df9e8e00-af03-4628-95bd-1104322d42d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_9b54c143-1af1-4b93-9746-633178e93f93" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5337a678-1a98-4191-8e9e-c9a82177d9c8" xlink:to="loc_srt_RestatementAdjustmentMember_9b54c143-1af1-4b93-9746-633178e93f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2099988a-649d-4829-acbe-d73ffa2b1a9b" xlink:to="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementMember_6b070941-2818-4ff5-87e0-46148a457a47" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_SanofiCollaborationAgreementMember_6b070941-2818-4ff5-87e0-46148a457a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_306285b8-0690-4331-99c7-cfbf33d7092a" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_BayerCollaborationAgreementMember_306285b8-0690-4331-99c7-cfbf33d7092a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherRevenueMember_6a56abf0-a3ee-4ea3-a608-1b61c81b3be5" xlink:href="regn-20200930.xsd#regn_OtherRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_02471d95-20a4-4042-8dda-017bf5fd4168" xlink:to="loc_regn_OtherRevenueMember_6a56abf0-a3ee-4ea3-a608-1b61c81b3be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_89411d19-275f-4559-acee-c0455c570efd" xlink:to="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_487a4e1f-b424-411c-bbb7-01aed76cdcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_487a4e1f-b424-411c-bbb7-01aed76cdcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_5a07dcb9-f942-4d93-b060-18fa36974823" xlink:href="regn-20200930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_070e75fb-b2a1-4e00-a140-3b009212f78f" xlink:to="loc_regn_CollaborationandContractManufacturingMember_5a07dcb9-f942-4d93-b060-18fa36974823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3e2a2a14-a3a9-4deb-bf4d-444d83a3a92e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6079037-4b0d-4abf-947a-52cca9158e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c6079037-4b0d-4abf-947a-52cca9158e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_508932f1-5a98-46ed-8df3-166bed5e3ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_508932f1-5a98-46ed-8df3-166bed5e3ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c76db9e3-49c7-488a-90d8-734c98b2de95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c76db9e3-49c7-488a-90d8-734c98b2de95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9ddc168c-3039-49f3-b807-37c4a5f6664e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9ddc168c-3039-49f3-b807-37c4a5f6664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_6634bc1c-8366-4e17-a959-c112666d4e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_6634bc1c-8366-4e17-a959-c112666d4e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_061ff121-e68d-4b53-98e2-962a9ff0385e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_49931504-27e2-4adb-a10e-5bfa9a4bc798" xlink:to="loc_us-gaap_CostsAndExpenses_061ff121-e68d-4b53-98e2-962a9ff0385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InterimFinancialStatementsScheduleofCashFlowsDataDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2012ea56-6058-4130-9a64-3fc34ee58d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2012ea56-6058-4130-9a64-3fc34ee58d23" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:to="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_05ff9f6e-238d-4dd4-a243-d1914356fae5" xlink:to="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_dd4485f6-82e9-45b4-8619-9ac0a53e708c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_dd4485f6-82e9-45b4-8619-9ac0a53e708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_996473be-2ba6-482f-8dd7-110c7667ed0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d8b814f3-4d27-4400-ad89-eaab86a47fd5" xlink:to="loc_srt_RestatementAdjustmentMember_996473be-2ba6-482f-8dd7-110c7667ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_21cff71b-009c-40e4-b435-bf96c8a3a59c" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_26bc9674-b64e-484f-a8e3-90a5b19ad035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_26bc9674-b64e-484f-a8e3-90a5b19ad035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5156d347-4f2b-4817-a654-a7bcf80ea5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_76f21fe6-f25e-42e0-86e1-83217b702bb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5156d347-4f2b-4817-a654-a7bcf80ea5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d2d3bc11-defb-42d1-b1d6-ecb0b8bc7971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ProductSalesandConcentrationRiskTextBlock_289b3f71-5c17-41b4-8e03-03f82298db34" xlink:href="regn-20200930.xsd#regn_ProductSalesandConcentrationRiskTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d2d3bc11-defb-42d1-b1d6-ecb0b8bc7971" xlink:to="loc_regn_ProductSalesandConcentrationRiskTextBlock_289b3f71-5c17-41b4-8e03-03f82298db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5ca147f0-b445-4bb1-a0a3-49e69ea0c786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1c83604e-6d19-48ae-8309-3d1ed5baef24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ca147f0-b445-4bb1-a0a3-49e69ea0c786" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1c83604e-6d19-48ae-8309-3d1ed5baef24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a93ac409-1ee3-40f9-8bf2-efae1f1f1e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5ca147f0-b445-4bb1-a0a3-49e69ea0c786" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_a93ac409-1ee3-40f9-8bf2-efae1f1f1e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_79e169c5-e328-43bc-bf84-bfa9f0a96baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_79e169c5-e328-43bc-bf84-bfa9f0a96baa" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:to="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f4b8a1c8-af3b-4b05-895e-68fd7c3c8987" xlink:to="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4623afab-3bbd-4ec8-b866-535c46d2fd42" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a095484d-9818-4675-bfd8-fd9dfa502ca5" xlink:to="loc_country_US_4623afab-3bbd-4ec8-b866-535c46d2fd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:to="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0d2b27c3-efc7-4696-90c8-855137f6577b" xlink:to="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4dd69e5c-e2f7-415c-900b-35a0554231a9" xlink:to="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_2f6bfe08-5b1c-47f6-afe1-fec094a09bb2" xlink:href="regn-20200930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_EyleaNetProductSalesMember_2f6bfe08-5b1c-47f6-afe1-fec094a09bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_a8f42376-aff4-43e5-aecc-116151e0219d" xlink:href="regn-20200930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_LIBTAYONetProductSalesMember_a8f42376-aff4-43e5-aecc-116151e0219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_1ab96f10-264a-460c-b0a7-bf77b0c3e5b4" xlink:href="regn-20200930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_PraluentNetProductSalesMember_1ab96f10-264a-460c-b0a7-bf77b0c3e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGNCOV2Member_ed437b04-c618-4dd2-93bc-4d081023bc1e" xlink:href="regn-20200930.xsd#regn_REGNCOV2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_REGNCOV2Member_ed437b04-c618-4dd2-93bc-4d081023bc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_4c1e7c12-6408-43ec-8573-52bc63225850" xlink:href="regn-20200930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_d5e319d1-224b-4ef7-95a3-a04e72b2956d" xlink:to="loc_regn_ArcalystNetProductSalesMember_4c1e7c12-6408-43ec-8573-52bc63225850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1d9ae97f-5f03-42e9-b391-30ee1c7b4d91" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ceb9661-f7b8-470f-9931-f96b716d42d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7e9c8bd7-cc3a-4694-88f0-5db6bce2a14d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ceb9661-f7b8-470f-9931-f96b716d42d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_791a9d47-f9bc-4a54-b874-fa8870dcbc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_791a9d47-f9bc-4a54-b874-fa8870dcbc7e" xlink:to="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a06a9c44-bf16-49e6-ba87-9ec0616ec6ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossSalesRevenueMember_b430491f-e91c-4b98-8d9b-95570d4f6c72" xlink:href="regn-20200930.xsd#regn_GrossSalesRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1037ee3f-d429-4445-adfd-369a28968ef1" xlink:to="loc_regn_GrossSalesRevenueMember_b430491f-e91c-4b98-8d9b-95570d4f6c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_26b174b5-5154-498f-8ea6-d149b4bf9397" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3dc64466-4ba9-4b14-965e-76b60484340f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7ac287ee-961d-41bc-ae03-a55c3317f384" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3dc64466-4ba9-4b14-965e-76b60484340f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6e7ea336-5541-4448-8fd2-57fc9c82a921" xlink:to="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_fe1adac3-cd44-46b2-a3ac-890f5bbfb383" xlink:href="regn-20200930.xsd#regn_BesseMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:to="loc_regn_BesseMedicalMember_fe1adac3-cd44-46b2-a3ac-890f5bbfb383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_96172d6f-3559-468f-8bcc-b501d3e822f8" xlink:href="regn-20200930.xsd#regn_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6b054fbe-3d29-4845-a036-e1ddc3a243fc" xlink:to="loc_regn_McKessonCorporationMember_96172d6f-3559-468f-8bcc-b501d3e822f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_618877c9-a277-4226-b6fa-9c766c2e96f5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2b4533b2-4a3d-43cb-84bc-d6c32e565b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2374ee99-f20f-4241-8495-792a2cd77297" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2b4533b2-4a3d-43cb-84bc-d6c32e565b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fee3870-1f66-4d94-8c65-b993f5a9a2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d900d24e-a9c4-46b5-9159-e72615b0e697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6fee3870-1f66-4d94-8c65-b993f5a9a2f2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_d900d24e-a9c4-46b5-9159-e72615b0e697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f45deead-d037-4a01-ac3a-fd176e2b057a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3bf93ac5-f85b-4fd1-a1cc-089ff4b87e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f45deead-d037-4a01-ac3a-fd176e2b057a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3bf93ac5-f85b-4fd1-a1cc-089ff4b87e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock_4cf87a73-c7c9-4778-9632-c153f7988e60" xlink:href="regn-20200930.xsd#regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f45deead-d037-4a01-ac3a-fd176e2b057a" xlink:to="loc_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock_4cf87a73-c7c9-4778-9632-c153f7988e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6211faa0-ffe0-4ea7-b733-6afc19c0e773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6211faa0-ffe0-4ea7-b733-6afc19c0e773" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9e651e0b-55ab-4872-ba24-53157e5aabcd" xlink:to="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_f920003d-c660-4a20-91ef-5fbd215a8261" xlink:href="regn-20200930.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2f0aaebb-0efa-41b1-9658-cf44592d91fe" xlink:to="loc_regn_SanofiMember_f920003d-c660-4a20-91ef-5fbd215a8261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_fc29626d-d0ec-4768-bad7-d142b4332ee2" xlink:to="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1fb9c581-1dfe-4e2d-b725-789326ce0e80" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1fb9c581-1dfe-4e2d-b725-789326ce0e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c2922fea-ee65-4ac4-9e56-9332fd85eb5b" xlink:href="regn-20200930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_aa90dfe3-8df3-4265-9065-93c82618b046" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_c2922fea-ee65-4ac4-9e56-9332fd85eb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b33bbdb1-3a27-412d-bb0d-52adae113249" xlink:to="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneMember_1aa3fd39-4ce9-4b53-97e1-0ce5fdad39bb" xlink:href="regn-20200930.xsd#regn_SalesBasedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e5a8c05-8ab0-4fbb-906d-a9b247fa512d" xlink:to="loc_regn_SalesBasedMilestoneMember_1aa3fd39-4ce9-4b53-97e1-0ce5fdad39bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_698938bf-4a2f-49fa-b6b5-bb94bb2697d1" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty_125335bb-5dbe-4ae7-92b0-c95fe5b07131" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfTrialCostsBorneByCollaboratingParty_125335bb-5dbe-4ae7-92b0-c95fe5b07131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsBorneByEntity_0ab89c14-9751-4477-8e06-431dd9077a45" xlink:href="regn-20200930.xsd#regn_PercentageOfTrialCostsBorneByEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfTrialCostsBorneByEntity_0ab89c14-9751-4477-8e06-431dd9077a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc2f6f22-8c4a-4631-9eb6-91c11f5cd18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc2f6f22-8c4a-4631-9eb6-91c11f5cd18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_5c2b0024-dd27-4b37-a7d9-5a4f76e45da4" xlink:href="regn-20200930.xsd#regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived_5c2b0024-dd27-4b37-a7d9-5a4f76e45da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_fef1df88-95cb-478d-a7cb-c8e2b32b2508" xlink:href="regn-20200930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_fef1df88-95cb-478d-a7cb-c8e2b32b2508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_4f604f81-101c-479a-900a-53fddfc7a1fd" xlink:href="regn-20200930.xsd#regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_4f604f81-101c-479a-900a-53fddfc7a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_fad36b8c-0f57-44d2-a92c-a3bd348f142e" xlink:href="regn-20200930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_fad36b8c-0f57-44d2-a92c-a3bd348f142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_6225e322-bf4d-47e5-97ef-f61b1ed84a2b" xlink:href="regn-20200930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_6225e322-bf4d-47e5-97ef-f61b1ed84a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_440f4719-3fd8-48fd-9a93-ad362b496b0a" xlink:href="regn-20200930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2e56f741-d03d-4390-8056-ae553ec7e0bf" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_440f4719-3fd8-48fd-9a93-ad362b496b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a05c79ab-3052-4dd6-845b-976186655e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a05c79ab-3052-4dd6-845b-976186655e01" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0e96d07b-c6e7-433d-8053-9997130649c8" xlink:to="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_95940f93-8c0d-4ab4-85d3-e8f7154e0c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fca4160d-21a8-4deb-8d26-6c9e83d1f45e" xlink:to="loc_us-gaap_NonUsMember_95940f93-8c0d-4ab4-85d3-e8f7154e0c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4819e380-f7b5-412c-b31a-20ea413650e7" xlink:to="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4b34244-2056-41e9-b997-e1f9f7264185" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_03ac1b39-5e44-4168-a3aa-3277f15ca754" xlink:href="regn-20200930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_03ac1b39-5e44-4168-a3aa-3277f15ca754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneMember_d4492b58-ea92-46b9-ada4-0d0f165e612d" xlink:href="regn-20200930.xsd#regn_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_SalesBasedMilestoneMember_d4492b58-ea92-46b9-ada4-0d0f165e612d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_c306c48d-1539-4ba5-a663-921807117a3d" xlink:href="regn-20200930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_c306c48d-1539-4ba5-a663-921807117a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0196420a-9cb1-43e0-b2e7-5f7231bb7d7a" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0196420a-9cb1-43e0-b2e7-5f7231bb7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_dec46ee7-8f63-4e51-ba96-4b701a76ecb2" xlink:href="regn-20200930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_dec46ee7-8f63-4e51-ba96-4b701a76ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_9d159566-3263-4ab4-85ee-7c4629b2f036" xlink:href="regn-20200930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_9d159566-3263-4ab4-85ee-7c4629b2f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_b7b46e33-7c91-4ab8-a808-d6b06943e00f" xlink:href="regn-20200930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_b7b46e33-7c91-4ab8-a808-d6b06943e00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_158aafaa-6e16-4165-b9d8-dcbc0df39a4a" xlink:href="regn-20200930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_2cf4c0bc-aaf7-4a30-a3d6-8a1274b230c7" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_158aafaa-6e16-4165-b9d8-dcbc0df39a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e356332f-be49-4a64-880f-ea8bb7206efb" xlink:to="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_0897bc26-dffd-4a25-a142-a259200bfa7e" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_0897bc26-dffd-4a25-a142-a259200bfa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_5b2322b3-1343-4d6c-8162-fb50294fc262" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_60e5d308-aed0-42b6-939f-822b130db1a9" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_5b2322b3-1343-4d6c-8162-fb50294fc262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6ae399dc-1a46-4d80-9cd6-ab76b828e20a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f735de32-77bc-424c-ad92-88c83d607309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f735de32-77bc-424c-ad92-88c83d607309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_d86c8a56-a0c9-4969-97a1-7912e8649775" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_d86c8a56-a0c9-4969-97a1-7912e8649775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_940c9c82-2d91-4079-8295-8fe0622ea006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_940c9c82-2d91-4079-8295-8fe0622ea006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_a54c7eb6-9cdb-482c-95e0-16f05e46b4cb" xlink:href="regn-20200930.xsd#regn_ReimbursementOfSellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense_a54c7eb6-9cdb-482c-95e0-16f05e46b4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2457d7d0-4134-4736-bb7d-aacc5870e1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2457d7d0-4134-4736-bb7d-aacc5870e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_dd0eeb66-4a40-4e4e-b334-08ee88ad92bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3529cce3-7a59-4db6-beb3-4bfa949eb4fb" xlink:to="loc_us-gaap_OtherOperatingIncome_dd0eeb66-4a40-4e4e-b334-08ee88ad92bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c968003d-a24d-47d2-8eae-88ee4a578d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c968003d-a24d-47d2-8eae-88ee4a578d01" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_899d3bc3-e6d0-4888-b24d-bf0bf7eaad8a" xlink:to="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_445c1606-dbeb-46a3-ac38-a19df5721074" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_c81fa05e-8a98-4609-9cd3-3fb1df6a13d4" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_445c1606-dbeb-46a3-ac38-a19df5721074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_00b14c03-bdf5-41e7-b2c2-a20538a7ec19" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2eb2fcc4-2795-468b-a889-f1221879c35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2eb2fcc4-2795-468b-a889-f1221879c35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a92cd228-04ec-4767-8c0c-551f97d3c85c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_350927e9-c7f8-47d0-8d50-1f48590d4786" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a92cd228-04ec-4767-8c0c-551f97d3c85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d0e18c3e-6539-43e1-b567-787109fe660f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d0e18c3e-6539-43e1-b567-787109fe660f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f0000d06-331d-45b5-a94f-591123a34054" xlink:to="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_820a036f-6470-4406-b5f5-ff8f1323e37e" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_3cafcfa1-d49b-46dd-8796-1e19d63723c1" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_820a036f-6470-4406-b5f5-ff8f1323e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1c9b0eec-0ee1-4287-be2e-d462aa949a6f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4a9aef4f-b71b-420f-9147-b9dbb0291b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_4a9aef4f-b71b-420f-9147-b9dbb0291b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fa401286-f479-442f-a10e-f47c37c72c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fa401286-f479-442f-a10e-f47c37c72c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_abd203a4-7779-4cc9-982e-d852783ddd88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_987f8c70-5610-4536-ac7a-cec9535ca191" xlink:to="loc_us-gaap_OtherLiabilities_abd203a4-7779-4cc9-982e-d852783ddd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba977484-d713-4363-ae46-53c5ce751d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba977484-d713-4363-ae46-53c5ce751d65" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_9271137e-22bb-474c-bdb1-348003a1b2f9" xlink:to="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a0f16d1c-b915-4766-84c1-2f520bff3492" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_bc86c22e-adc9-432f-b737-ef850363fef2" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a0f16d1c-b915-4766-84c1-2f520bff3492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cc48c6d5-7957-4393-a38b-6d279d0ef47c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnsatisfiedObligation_a34b64c4-fde9-460f-8992-1fcc464ea5c4" xlink:href="regn-20200930.xsd#regn_UnsatisfiedObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3874758-9b27-442d-9b9c-7cedf3fbf35d" xlink:to="loc_regn_UnsatisfiedObligation_a34b64c4-fde9-460f-8992-1fcc464ea5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1901252-09ac-467d-a295-41ab973645cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c1901252-09ac-467d-a295-41ab973645cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a41abbd1-47ca-47aa-9eff-2b173546a791" xlink:to="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_18c0ceba-4abd-4469-ad31-b462da100ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_11eee552-22bb-4a75-8b5c-9c4555289fbb" xlink:to="loc_us-gaap_NonUsMember_18c0ceba-4abd-4469-ad31-b462da100ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_3f311743-b6ff-4852-921b-4fa6f78696f7" xlink:to="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_e9c749c4-979e-43b1-9c13-6ac1c1f7220e" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_59611048-e158-4a24-a7c5-481da0eb5cf9" xlink:to="loc_regn_BayerCollaborationAgreementMember_e9c749c4-979e-43b1-9c13-6ac1c1f7220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_42ead78f-89c7-4923-a477-b1382e8c4e42" xlink:to="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c544b6e3-40cb-4372-933d-2905318415b9" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_d8714cd5-3568-4286-ada4-6c57ed2c1a0b" xlink:href="regn-20200930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_d8714cd5-3568-4286-ada4-6c57ed2c1a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_a2d3334b-8683-45e0-b495-61e054dec87a" xlink:href="regn-20200930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_a2d3334b-8683-45e0-b495-61e054dec87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0bc8ddc1-39ef-473e-8c54-d1f945fcebf3" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_0bc8ddc1-39ef-473e-8c54-d1f945fcebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_00c2d32e-9186-429a-aaeb-959313752cb0" xlink:href="regn-20200930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_00c2d32e-9186-429a-aaeb-959313752cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_OtherMember_63228793-b316-4b2e-9981-3daa38474f23" xlink:href="regn-20200930.xsd#regn_OtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_5af8f3f9-adff-4b90-a9f1-2ffbb46b0a93" xlink:to="loc_regn_OtherMember_63228793-b316-4b2e-9981-3daa38474f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6434ff94-e9a3-44af-bfc4-de8593b34709" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a15ad2a-67e0-443f-ab65-bc21c90f45a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6a15ad2a-67e0-443f-ab65-bc21c90f45a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_2ea0ee7a-c35f-4d47-8c9d-836d84f1a749" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_2ea0ee7a-c35f-4d47-8c9d-836d84f1a749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d3219b0c-9d7c-463e-bf16-385fdb221c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d3219b0c-9d7c-463e-bf16-385fdb221c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfOtherExpenses_3d3a5798-4897-48e0-8d73-c309972cc54f" xlink:href="regn-20200930.xsd#regn_ReimbursementOfOtherExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c1406a41-9067-4a1d-bf29-83e339d7ca7c" xlink:to="loc_regn_ReimbursementOfOtherExpenses_3d3a5798-4897-48e0-8d73-c309972cc54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25ddbbfa-14c1-4661-b150-2ca5274c2938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25ddbbfa-14c1-4661-b150-2ca5274c2938" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:to="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_505cbcb2-19ac-410a-a6bb-f14a63a83ec7" xlink:to="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51f67b77-46fa-4381-b6b1-d4d208558619" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:to="loc_srt_MinimumMember_51f67b77-46fa-4381-b6b1-d4d208558619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5a763154-b574-4086-be94-32dca5d25631" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1050d351-f5d6-48c4-848a-bf5d3c0acc8d" xlink:to="loc_srt_MaximumMember_5a763154-b574-4086-be94-32dca5d25631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7b220c67-79d0-40c3-8245-c5a76eab0ba5" xlink:to="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_5a957aae-4e71-4e97-b328-9d9b07af0ce9" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_80491a65-e168-4cf8-ab87-2f8d8732f0b6" xlink:to="loc_regn_BayerCollaborationAgreementMember_5a957aae-4e71-4e97-b328-9d9b07af0ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5b769c2c-5072-4394-a3ee-1d2f461d64d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenuebasedonpercentageofannualsalesinJapan_0bb03c01-244c-446c-86d8-572c3b378d8b" xlink:href="regn-20200930.xsd#regn_RevenuebasedonpercentageofannualsalesinJapan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_db7f2d34-1460-47d5-9b04-062cffb8b3ee" xlink:to="loc_regn_RevenuebasedonpercentageofannualsalesinJapan_0bb03c01-244c-446c-86d8-572c3b378d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3a5e1d84-76ff-47bb-a9bc-edb5abe1406e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3a5e1d84-76ff-47bb-a9bc-edb5abe1406e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_4857cb6e-b206-45a4-818d-a822082f01a9" xlink:to="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_77bf8b84-6a0a-42ff-9610-a8e78597adc2" xlink:href="regn-20200930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_42aee9f3-2e1e-4ef6-a5fb-77adc7918f4a" xlink:to="loc_regn_BayerCollaborationAgreementMember_77bf8b84-6a0a-42ff-9610-a8e78597adc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6339f5f-e350-4d01-aa6e-35db8f2245a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_9e56385f-5251-40e7-86f1-bafe6d23ccea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_9e56385f-5251-40e7-86f1-bafe6d23ccea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_034c565f-b61e-45f6-9086-2f565ff3c82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_275b98a1-34fd-4ca5-8daf-6f5cafc14009" xlink:to="loc_us-gaap_ContractWithCustomerLiability_034c565f-b61e-45f6-9086-2f565ff3c82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa101eac-4885-4014-8f42-e3cad565d03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa101eac-4885-4014-8f42-e3cad565d03a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e130d6a2-3a75-4336-a589-ebe181de9137" xlink:to="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_8bec6b23-ccb6-4044-9a50-6b017ceb0704" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_384f1be4-e0de-49ae-b49e-88c23e6a3acf" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_8bec6b23-ccb6-4044-9a50-6b017ceb0704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:to="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e7703e1a-c0ab-4859-87c9-407827cca5b7" xlink:to="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c07a1ba3-4b5f-4f32-8147-f885a668ce7c" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c07a1ba3-4b5f-4f32-8147-f885a668ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_8ae85fbf-c8c1-4c71-95f5-f18ba65c44aa" xlink:href="regn-20200930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06e569bf-d9e7-47c5-9076-a9de48875fdf" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_8ae85fbf-c8c1-4c71-95f5-f18ba65c44aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e2007627-8b53-4b54-a159-b8998a365d7c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_cbcb494b-c640-4993-9b83-12f26ea13580" xlink:href="regn-20200930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_cbcb494b-c640-4993-9b83-12f26ea13580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_e08f69ef-1ec0-47b3-b396-7ae3910f9a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a9ebb9b-bf1b-464c-8c64-66497208dbe9" xlink:to="loc_us-gaap_OtherOperatingIncome_e08f69ef-1ec0-47b3-b396-7ae3910f9a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2f8e650-4e89-4453-8431-246e8b830d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2f8e650-4e89-4453-8431-246e8b830d9c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_04ec3c61-0d56-47d1-8042-191decdd376a" xlink:to="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_a704de19-9041-429f-962d-94e7e2e565aa" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_235bd72e-54e7-426a-b993-5cc8d4e38ae1" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_a704de19-9041-429f-962d-94e7e2e565aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2db2e6ef-41af-459a-b04e-425daa582649" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndNotesReceivableNet_5b5c9595-1ea9-4fc1-95c8-81b61419b4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndNotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:to="loc_us-gaap_AccountsAndNotesReceivableNet_5b5c9595-1ea9-4fc1-95c8-81b61419b4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_4d7c2b13-9fcf-4a81-8ead-c441b330bf36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_741c07ba-1927-46fd-b167-9aceb86ffe13" xlink:to="loc_us-gaap_OtherLiabilities_4d7c2b13-9fcf-4a81-8ead-c441b330bf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_067eb8bc-0261-4e7d-9609-d46f020a6dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_067eb8bc-0261-4e7d-9609-d46f020a6dd1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2316f796-9819-424a-bd3a-324ece8f3075" xlink:to="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_0c8124b6-1b03-42c1-a09f-60cad2935480" xlink:href="regn-20200930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_83190d18-c9cc-463c-b33b-3e6f9a8cc182" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_0c8124b6-1b03-42c1-a09f-60cad2935480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_de8f3bd6-d430-4501-8892-dcb711ca29c2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnsatisfiedObligation_4fddb75e-04be-4244-9107-d34764630903" xlink:href="regn-20200930.xsd#regn_UnsatisfiedObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d5cba392-da76-408a-b7e4-640ca19559a4" xlink:to="loc_regn_UnsatisfiedObligation_4fddb75e-04be-4244-9107-d34764630903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3c1985f2-0073-4968-b546-018e4a9d5590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3c1985f2-0073-4968-b546-018e4a9d5590" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_62df762d-7483-4abb-9c1b-98cd6c6a7176" xlink:to="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember_31b826f9-7449-4465-afb9-a803958109a5" xlink:href="regn-20200930.xsd#regn_IntelliaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_abd0a7d3-93e4-49bc-991b-b220b32bf517" xlink:to="loc_regn_IntelliaMember_31b826f9-7449-4465-afb9-a803958109a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:to="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1f488c71-9010-41f7-810f-b09bf449203a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_727382a9-0f7e-49a3-aefd-bce27c56d0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c4be2ef4-03c7-46ab-8d2c-959aaffc5643" xlink:to="loc_us-gaap_CommonStockMember_727382a9-0f7e-49a3-aefd-bce27c56d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:href="regn-20200930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_60be3675-817a-407b-8a73-99c90725d5eb" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_5a772623-c61b-41e9-b6a6-b2f0ec7ee194" xlink:href="regn-20200930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_5a772623-c61b-41e9-b6a6-b2f0ec7ee194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_b969a099-439e-4e1d-b739-f6b0955f401f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_b969a099-439e-4e1d-b739-f6b0955f401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_49c694a7-68d9-4133-ad04-1ca6ce261f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_49c694a7-68d9-4133-ad04-1ca6ce261f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_38eaa9f3-f8cd-45a2-831c-b4812244cb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_aecaa7cc-8abf-45d7-8b76-03bf749f1c34" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_38eaa9f3-f8cd-45a2-831c-b4812244cb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f635774-3a83-46ce-b855-c34eda6dce06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f635774-3a83-46ce-b855-c34eda6dce06" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_174e52fd-d2e0-4642-aa4b-9353bfb9a259" xlink:to="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_8cb091fd-66ea-45a8-ab8e-014aa540c97b" xlink:href="regn-20200930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_e726e0c0-f10b-49c9-ae11-142153aac92b" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_8cb091fd-66ea-45a8-ab8e-014aa540c97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ff200a6f-868f-4459-9e16-a0409159dfbe" xlink:to="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGNCOV2Member_87bd95a1-aefc-4958-b779-31baa0b3069d" xlink:href="regn-20200930.xsd#regn_REGNCOV2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cbe96b5c-d20e-4c8c-94f6-cbb9f6216174" xlink:to="loc_regn_REGNCOV2Member_87bd95a1-aefc-4958-b779-31baa0b3069d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_82b996f9-9e2b-48d9-8ec1-9ef351230d74" xlink:to="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_50507891-63c5-45d6-9e29-4245010251b1" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2c323b57-081d-4f17-9319-c0d5f230f819" xlink:to="loc_country_US_50507891-63c5-45d6-9e29-4245010251b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26786c51-b765-4052-9b8c-d53ff3390b7f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_7d5d1937-c2ae-4ca0-9f01-aae87eab053f" xlink:href="regn-20200930.xsd#regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:to="loc_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty_7d5d1937-c2ae-4ca0-9f01-aae87eab053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_a8879543-839c-48f0-98f7-dd18bfd204d5" xlink:href="regn-20200930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a9755d6d-556e-465f-8fd0-759f5c081f34" xlink:to="loc_regn_MaximumTransactionAgreementPayments_a8879543-839c-48f0-98f7-dd18bfd204d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_33fb7ab4-379d-4ff1-827a-d48f6074a56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_17026ec2-7ef2-4e64-84eb-db14f8a84d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_33fb7ab4-379d-4ff1-827a-d48f6074a56b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_17026ec2-7ef2-4e64-84eb-db14f8a84d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_62c5c7ac-33d0-45c5-84bc-a26696128091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2f72fa87-e882-4321-9d97-10054bb6093f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62c5c7ac-33d0-45c5-84bc-a26696128091" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2f72fa87-e882-4321-9d97-10054bb6093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_62700fd0-acd9-4d86-b1ff-32535b72ce6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62c5c7ac-33d0-45c5-84bc-a26696128091" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_62700fd0-acd9-4d86-b1ff-32535b72ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_13e25e8b-29ff-4af6-b6a9-d50c1bb7bcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_13e25e8b-29ff-4af6-b6a9-d50c1bb7bcb7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:to="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ee8c5300-4aa4-406d-bb42-40dc9593ff3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb8028c1-f046-4c9a-98ac-d5579c9ba99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb8028c1-f046-4c9a-98ac-d5579c9ba99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9f7c17fe-2754-4716-bbe5-cd241fe3ed08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72bab961-5f53-4119-b986-1e1daaef227a" xlink:to="loc_us-gaap_RestrictedStockMember_9f7c17fe-2754-4716-bbe5-cd241fe3ed08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_8e53dddc-9b82-4bd7-8282-08b8e1ab2e42" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8f958fc-dc08-4cc8-94bf-5f78eb01f7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_NetIncomeLoss_c8f958fc-dc08-4cc8-94bf-5f78eb01f7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a499b6c3-3d66-4ca7-93ff-8202094305ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a499b6c3-3d66-4ca7-93ff-8202094305ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_089411e2-ee02-45a4-a025-ed9b75e3cda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_089411e2-ee02-45a4-a025-ed9b75e3cda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d59429d6-491d-49d4-910b-a2d826293259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d59429d6-491d-49d4-910b-a2d826293259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9b3e6ca-5699-4430-b263-d678ae1bd07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9b3e6ca-5699-4430-b263-d678ae1bd07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f306dbcd-5c9a-48ff-b9dd-cd6f03ff1bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_217e204b-98f6-4289-97e8-2ab275b72c09" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f306dbcd-5c9a-48ff-b9dd-cd6f03ff1bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c8963067-e163-44d1-baee-3fce0bcf2bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c8963067-e163-44d1-baee-3fce0bcf2bad" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_25c03aec-ef32-4ca5-bc95-fbd89f2a8029" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ddf59610-8d9d-4774-a346-2e0f7def3bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ddf59610-8d9d-4774-a346-2e0f7def3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1fb3d3d0-7752-45e6-9444-9788614693b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5249999-6438-4198-ad8f-8fb67632eac8" xlink:to="loc_us-gaap_RestrictedStockMember_1fb3d3d0-7752-45e6-9444-9788614693b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_14863f22-eec6-487f-a998-da42ea085d6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1808c1f-bbee-4694-8e71-6beb41286b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9c42d879-850d-47b2-a548-bd01c278863e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1808c1f-bbee-4694-8e71-6beb41286b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9e28dbac-94a0-48b7-8a88-0f6bad5a8f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e77f5802-8704-4839-a4f1-8c726016e077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9e28dbac-94a0-48b7-8a88-0f6bad5a8f20" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e77f5802-8704-4839-a4f1-8c726016e077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32296d88-b9cd-453b-9859-0082e3211d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7e368e1c-576b-4596-90ab-462127a781e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32296d88-b9cd-453b-9859-0082e3211d08" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7e368e1c-576b-4596-90ab-462127a781e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_70c8870b-e76d-4e26-9cb2-721679fa699e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32296d88-b9cd-453b-9859-0082e3211d08" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_70c8870b-e76d-4e26-9cb2-721679fa699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_32e1b40f-67f0-40b0-8d36-48dc237969d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32296d88-b9cd-453b-9859-0082e3211d08" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_32e1b40f-67f0-40b0-8d36-48dc237969d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8300c112-0f0e-4a8e-90bb-b1f9e965c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8300c112-0f0e-4a8e-90bb-b1f9e965c106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8d6be916-2021-442c-b8ee-fcd8eebd07fe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5119ec16-e18c-4695-8070-0db1582aa374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5119ec16-e18c-4695-8070-0db1582aa374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_06f7267b-d6d6-4fc5-bebf-2f0a9beda769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_06f7267b-d6d6-4fc5-bebf-2f0a9beda769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_ffa3d507-4065-4613-98ac-c6b863dbadb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_ffa3d507-4065-4613-98ac-c6b863dbadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_94e078a4-ece4-437e-b7ed-04d427cb33b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CommercialPaperMember_94e078a4-ece4-437e-b7ed-04d427cb33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b23e6d5f-c9df-4a04-948f-c7da9e0f40c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_169319a4-7818-4308-a11d-307a14f46ab4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b23e6d5f-c9df-4a04-948f-c7da9e0f40c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:to="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentAxis_4a81d2b7-fc4a-4360-9fbd-38d4c229404c" xlink:to="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_7eafb088-4f5c-49e1-beda-7c4807fb1ab4" xlink:href="regn-20200930.xsd#regn_UnrestrictedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_c4b85df4-df0e-4684-b8cc-84497bb6fca0" xlink:to="loc_regn_UnrestrictedMember_7eafb088-4f5c-49e1-beda-7c4807fb1ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7fc7da6a-2ae6-43a2-a1dd-bf831999ee14" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe8df96-3adf-452f-a838-92312d56b620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1fe8df96-3adf-452f-a838-92312d56b620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a478cd50-698e-4349-97b8-bda7f35ad582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a478cd50-698e-4349-97b8-bda7f35ad582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58ac4e21-0121-436a-bd06-f9469307b3bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58ac4e21-0121-436a-bd06-f9469307b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a13fa0c-2732-4d36-9def-57f252363696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1097c9fd-1c1a-4447-9d48-07f75e8d455c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3a13fa0c-2732-4d36-9def-57f252363696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1a3647c-ae3c-4748-814a-27fdf88355af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90749baf-a44b-454f-843e-fb6fdfa4634a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1a3647c-ae3c-4748-814a-27fdf88355af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_90749baf-a44b-454f-843e-fb6fdfa4634a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fab5e595-795b-4dfe-ac60-bba2eadd298d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1a3647c-ae3c-4748-814a-27fdf88355af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fab5e595-795b-4dfe-ac60-bba2eadd298d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55de948b-9def-46c0-9575-ac6d2d902b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a1a3647c-ae3c-4748-814a-27fdf88355af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55de948b-9def-46c0-9575-ac6d2d902b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d11dca-6e8d-41ee-b97f-da252a0adcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75d11dca-6e8d-41ee-b97f-da252a0adcbe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:to="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_886f24f6-0866-4122-9de3-a669419ffa64" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0b3139f7-8d77-452a-8145-87639ebde50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0b3139f7-8d77-452a-8145-87639ebde50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b23cb947-94a0-4831-a223-c6eedbc0f897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebfdfeae-11f4-4538-be68-f27fe25b46e6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b23cb947-94a0-4831-a223-c6eedbc0f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3a6d5a61-a1fc-4f07-98c9-b0f65aac4944" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7a5eb14b-fe90-4997-a59c-e34c84f34cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7a5eb14b-fe90-4997-a59c-e34c84f34cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9e80a80d-4bd5-4745-9ae8-b69e79d366cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9e80a80d-4bd5-4745-9ae8-b69e79d366cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3441621e-441d-415d-9cb8-85e54bb90e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3441621e-441d-415d-9cb8-85e54bb90e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3a7097b8-ea68-4f30-8a50-619d11b30a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3a7097b8-ea68-4f30-8a50-619d11b30a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_46334687-3e07-4dd6-927e-ee85bf3e7826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_46334687-3e07-4dd6-927e-ee85bf3e7826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7913d9cd-44d5-4399-8dc7-be5a267625b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5afcce1c-3a25-4b5c-90ab-0aa3b4d537b0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7913d9cd-44d5-4399-8dc7-be5a267625b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_421c71bd-2bfc-47e0-8d25-ac540942b3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_41275082-60fe-4a5b-8e89-dc816e512837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_421c71bd-2bfc-47e0-8d25-ac540942b3cb" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_41275082-60fe-4a5b-8e89-dc816e512837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7a97fb9b-e7f1-4815-bf4e-88f6aac2a0c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5a894e1f-1d5a-4101-bce3-ec0a6117d7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7a97fb9b-e7f1-4815-bf4e-88f6aac2a0c4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5a894e1f-1d5a-4101-bce3-ec0a6117d7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0953cfbd-b6f6-4df8-af6b-4182953d2a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5f1421a0-962b-4ad7-b091-b438189c7ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0953cfbd-b6f6-4df8-af6b-4182953d2a0a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5f1421a0-962b-4ad7-b091-b438189c7ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4013570d-d0ea-4957-a767-1524c81fc6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4013570d-d0ea-4957-a767-1524c81fc6e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6cf56be-b44e-4fdb-b73f-92d3ac12c609" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_36d86d29-8449-4577-bcc7-6a989f2aa1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_36d86d29-8449-4577-bcc7-6a989f2aa1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1c34387c-46be-4104-91db-ef0a8bab20d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1c34387c-46be-4104-91db-ef0a8bab20d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_6eff0085-3a30-4477-8a7b-02cd4f3ea87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_6eff0085-3a30-4477-8a7b-02cd4f3ea87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_dadbbf2a-ea5a-4fc9-bd66-8a6f9127ebe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CommercialPaperMember_dadbbf2a-ea5a-4fc9-bd66-8a6f9127ebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_43e403c7-a01e-4037-bf38-26436084c995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9eb4cada-b582-4d69-86a9-7bc07794277c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_43e403c7-a01e-4037-bf38-26436084c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e56c3312-57bc-4a49-9b67-c1b5ec23381b" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_095c52bd-9429-4d69-96a7-7e80f5196ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_095c52bd-9429-4d69-96a7-7e80f5196ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e2ad2e57-9cd2-45e1-aad6-8ddbbe5d6559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b6df9b91-8437-47b8-81ad-86a28b7ae1e5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e2ad2e57-9cd2-45e1-aad6-8ddbbe5d6559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:href="regn-20200930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentAxis_98f11ac3-5a01-4c0d-a440-40bafe19cfff" xlink:to="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_1a0a114d-c3bd-4732-8bdc-43fd3aa9801d" xlink:href="regn-20200930.xsd#regn_UnrestrictedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:to="loc_regn_UnrestrictedMember_1a0a114d-c3bd-4732-8bdc-43fd3aa9801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_183886a8-2666-4e57-9410-223e7c058617" xlink:href="regn-20200930.xsd#regn_RestrictedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_ad1b7a04-77d1-4910-9841-183a51762e9f" xlink:to="loc_regn_RestrictedMember_183886a8-2666-4e57-9410-223e7c058617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_22d49486-ef9e-4c0d-bf07-6acc3a10aa8f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_75698696-5caf-4428-9de4-124773674745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_984e3075-32a2-415e-bcca-f9541794feb7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_75698696-5caf-4428-9de4-124773674745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8b723a73-f614-4df9-b97b-884074e9e05b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dd14e15b-79c0-45d9-ac78-36479c3efb47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dd14e15b-79c0-45d9-ac78-36479c3efb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e0490416-4cc3-4cf7-8c92-d41e8cc0def6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91f5a776-162f-471d-9a45-8a2af6f39377" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e0490416-4cc3-4cf7-8c92-d41e8cc0def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e215301-5370-4415-b242-9aef3ae2ad55" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4aa9088d-328a-401c-9372-3c0547018c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4aa9088d-328a-401c-9372-3c0547018c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_323f1945-f9a7-4c30-a79b-900a7e47ae7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_323f1945-f9a7-4c30-a79b-900a7e47ae7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8b7d49f3-7347-432c-b088-a3b007b6421d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6bc5284-52c4-49e7-b17f-984257c3aecb" xlink:to="loc_us-gaap_MarketableSecurities_8b7d49f3-7347-432c-b088-a3b007b6421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d44fd85-041f-434a-bb4f-8ee02c9a126b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d50dbfee-7792-44fc-95be-33c95af017e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d44fd85-041f-434a-bb4f-8ee02c9a126b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d50dbfee-7792-44fc-95be-33c95af017e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b6ebb116-7a03-4789-a3cd-2874bd2d50ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d44fd85-041f-434a-bb4f-8ee02c9a126b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b6ebb116-7a03-4789-a3cd-2874bd2d50ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_b8a9365d-3ff5-45c6-8650-d8390ff23ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d44fd85-041f-434a-bb4f-8ee02c9a126b" xlink:to="loc_us-gaap_LongTermDebtFairValue_b8a9365d-3ff5-45c6-8650-d8390ff23ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20200930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_269819c7-05c9-4828-88e4-21491a95de85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1b41ea15-4470-4c61-bfc1-bbbba27a5daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_269819c7-05c9-4828-88e4-21491a95de85" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1b41ea15-4470-4c61-bfc1-bbbba27a5daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e1dde152-86ff-45be-8eb1-89d0c436d1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bb906ac7-0258-4850-aad7-f7276acd1d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e1dde152-86ff-45be-8eb1-89d0c436d1d6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bb906ac7-0258-4850-aad7-f7276acd1d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_38c76abf-6ffa-4709-bd8b-8c3fef6dafb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_38c76abf-6ffa-4709-bd8b-8c3fef6dafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_87a04f88-e6e1-47e6-9515-69b5117f7956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_87a04f88-e6e1-47e6-9515-69b5117f7956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d05e001-1175-4990-a48b-6f50cfa4d609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0d05e001-1175-4990-a48b-6f50cfa4d609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_fda6c88c-25b5-4cfa-87e5-855108457ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_fda6c88c-25b5-4cfa-87e5-855108457ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e298f1a4-f2ed-4609-a53a-d60866382b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bf0861bb-8db5-4d88-85a3-93e9e342aeec" xlink:to="loc_us-gaap_InventoryNet_e298f1a4-f2ed-4609-a53a-d60866382b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Debt" xlink:type="simple" xlink:href="regn-20200930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5366bbe0-c9c5-4858-bf4a-b23f9f37559f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_53a908b5-4220-422b-be82-0a7f8031cbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5366bbe0-c9c5-4858-bf4a-b23f9f37559f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_53a908b5-4220-422b-be82-0a7f8031cbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b63e1f83-e455-4a27-bef7-af109b26fced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b63e1f83-e455-4a27-bef7-af109b26fced" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a8a4e36-69f8-4398-90c7-86cbac18e199" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember_a0dcaa75-338e-4b67-8077-35e226918590" xlink:href="regn-20200930.xsd#regn_BridgeFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_BridgeFacilityMember_a0dcaa75-338e-4b67-8077-35e226918590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_3e7b8323-abe4-46b8-b910-1b7a66451072" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_3e7b8323-abe4-46b8-b910-1b7a66451072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_ad59a322-84e5-4a83-b4c0-03e5f0d0f2ca" xlink:href="regn-20200930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d9ce8f82-bff7-48ef-b531-aab9d8c315ed" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_ad59a322-84e5-4a83-b4c0-03e5f0d0f2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_c35142b9-77ee-4fcd-b583-4d4ecc948be5" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CommonStockHeldBySanofiMember_2ebd20a0-5dfa-4848-b4aa-b4920421bba4" xlink:href="regn-20200930.xsd#regn_CommonStockHeldBySanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b69d6d85-a15a-490b-8b3c-d3475289111f" xlink:to="loc_regn_CommonStockHeldBySanofiMember_2ebd20a0-5dfa-4848-b4aa-b4920421bba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b1ae6e97-86e5-40b3-afbc-407c46debaf6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_f21b3497-bd5b-4a1a-9469-ae0a46fa46d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b81235e5-a0f3-4fc3-9c63-b5e1b5291478" xlink:to="loc_us-gaap_BridgeLoanMember_f21b3497-bd5b-4a1a-9469-ae0a46fa46d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e7feef19-4327-4420-b99e-2ad3d4f3ac12" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_da28d03b-8ecb-4d12-a9fc-1562de421c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0988e95c-0b51-47e9-acf5-3a0bc25dc53b" xlink:to="loc_us-gaap_SeniorNotesMember_da28d03b-8ecb-4d12-a9fc-1562de421c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_d7bc1a79-9953-4b9b-824a-b1906fe89be6" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_745cde48-7e67-4032-a835-17bace011ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_745cde48-7e67-4032-a835-17bace011ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a433822-c819-4a00-91a0-74fe45c0202e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a433822-c819-4a00-91a0-74fe45c0202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9b29b460-822e-4834-ba67-f7b522ce0334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9b29b460-822e-4834-ba67-f7b522ce0334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_4844cfb5-a425-42a9-9e1b-c3fc332f0fb5" xlink:href="regn-20200930.xsd#regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage_4844cfb5-a425-42a9-9e1b-c3fc332f0fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_98330881-f333-4641-8a63-f6669e283aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_07f33912-2e58-4766-9e69-b2852780cd54" xlink:to="loc_us-gaap_InterestExpenseDebt_98330881-f333-4641-8a63-f6669e283aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0c03054d-b873-4949-932f-87b7580281d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9c811b14-44e6-4d55-b806-7a455e49d18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c03054d-b873-4949-932f-87b7580281d2" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9c811b14-44e6-4d55-b806-7a455e49d18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82b793a7-db58-48c5-8c90-a6725ba5126d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f2332391-b3d8-4328-b832-355057598748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82b793a7-db58-48c5-8c90-a6725ba5126d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f2332391-b3d8-4328-b832-355057598748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10cd71f0-4fdf-4ec7-9b22-a0a7a8943ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d1269f98-1e07-48fc-bced-e7f63f84c2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10cd71f0-4fdf-4ec7-9b22-a0a7a8943ef7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d1269f98-1e07-48fc-bced-e7f63f84c2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6df11fca-d388-402e-a716-a356d00e6a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_c3811de1-aa41-4ebb-b114-0554a39f71ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6df11fca-d388-402e-a716-a356d00e6a99" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_c3811de1-aa41-4ebb-b114-0554a39f71ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e43af3bc-848e-446c-9403-b15e2d1dadd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e43af3bc-848e-446c-9403-b15e2d1dadd4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_cc728ee6-3e67-4aac-9f3f-d1181bcaf7aa" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramMember_5798a14f-00d4-4a34-a2eb-8b8bd15a7628" xlink:href="regn-20200930.xsd#regn_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_88e3f80f-0ac8-403f-9e6f-30e04201db03" xlink:to="loc_regn_ShareRepurchaseProgramMember_5798a14f-00d4-4a34-a2eb-8b8bd15a7628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_02be97a6-9729-4356-8e60-02bb2f0aea95" xlink:to="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_26a162fe-2e09-44fe-ab47-4e2f1525a996" xlink:href="regn-20200930.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_34a009db-b991-4009-91c8-add966a65687" xlink:to="loc_regn_SanofiMember_26a162fe-2e09-44fe-ab47-4e2f1525a996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_388d3d4f-4ecd-42d6-a91d-7ed4234b27f8" xlink:to="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a5435074-ec1f-480a-a2f7-80c69b9dde54" xlink:href="regn-20200930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_d1b58c16-f543-4ac1-902c-04e58e1344ac" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_a5435074-ec1f-480a-a2f7-80c69b9dde54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_db980b9d-1449-4e29-a5f5-c258d79915a3" xlink:to="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_74b5b004-a3d8-4536-b269-39b795a3cd74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_74b5b004-a3d8-4536-b269-39b795a3cd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f0ae6a2-c140-4823-8566-8a9aa983f0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9f0ae6a2-c140-4823-8566-8a9aa983f0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Maximumsharesthecollaboratorcouldsell_f98219ed-4d4c-4828-963d-d99fc8c3ade5" xlink:href="regn-20200930.xsd#regn_Maximumsharesthecollaboratorcouldsell"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_regn_Maximumsharesthecollaboratorcouldsell_f98219ed-4d4c-4828-963d-d99fc8c3ade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_df41a6d0-ca9f-4f5b-a652-22e8295c4289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_df41a6d0-ca9f-4f5b-a652-22e8295c4289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a92b9f8d-75b7-432d-a7e9-a9846101c07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a92b9f8d-75b7-432d-a7e9-a9846101c07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_96fc338f-ebf1-4e49-9f77-7a2614311fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_96fc338f-ebf1-4e49-9f77-7a2614311fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_112deb4d-ec5c-4dce-8c1d-b7d6016add7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_af45b141-3d68-4944-a73f-c786d35d1492" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_112deb4d-ec5c-4dce-8c1d-b7d6016add7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27ec9c11-04e7-4b3f-95fc-d034e2e81d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27ec9c11-04e7-4b3f-95fc-d034e2e81d57" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a95bf97a-98cd-45bb-8f3b-256121d62f14" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramMember_b7384376-7414-4c16-8b06-5bd7e6bffd9e" xlink:href="regn-20200930.xsd#regn_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_d7fdcf0c-2a3f-4adc-b00b-01eaca838d6f" xlink:to="loc_regn_ShareRepurchaseProgramMember_b7384376-7414-4c16-8b06-5bd7e6bffd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_e6502dba-045f-4096-bd13-4edd2b456205" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_356dbb5d-ed14-4942-9a67-406b40607803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_356dbb5d-ed14-4942-9a67-406b40607803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f9fb3dee-0a1f-415a-82a8-44c305dea379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_5353bfcb-2c8f-441c-8916-a8bed8fad455" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f9fb3dee-0a1f-415a-82a8-44c305dea379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StockholdersEquitySanofiFundingDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e3a3653e-f555-4ed0-a98f-7f3ca6321a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e3a3653e-f555-4ed0-a98f-7f3ca6321a64" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_90b62b87-ce6d-44f8-884f-a4e8aca29c16" xlink:to="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember_09900b76-6748-41c2-ac4b-9a4f507b731b" xlink:href="regn-20200930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:to="loc_regn_LibtayoDevelopmentMember_09900b76-6748-41c2-ac4b-9a4f507b731b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_4c2bb713-9cf4-49e1-95fd-6cb35c6563a5" xlink:href="regn-20200930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_ed0be603-7dfd-4efd-b68a-9c12bcc8540d" xlink:to="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_4c2bb713-9cf4-49e1-95fd-6cb35c6563a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_0994c464-ec36-476d-93f3-922ee0104e90" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_48eea8e9-a7b6-4a88-a33c-3e53f81d36c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_48eea8e9-a7b6-4a88-a33c-3e53f81d36c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_68841f30-4ded-4022-a60a-c5544a43bcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e2dc0569-2fd0-4724-b2ee-71b9409f1600" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_68841f30-4ded-4022-a60a-c5544a43bcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_06e8ceb1-65e8-451a-a969-ddb5a1433fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_e29166e4-f83d-46fc-803d-058c4172c35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_06e8ceb1-65e8-451a-a969-ddb5a1433fc8" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_e29166e4-f83d-46fc-803d-058c4172c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_cefc84af-1235-43ca-ac1f-c06e23e8d33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7db2a28d-ad92-46fc-9a24-30fde25db12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cefc84af-1235-43ca-ac1f-c06e23e8d33e" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7db2a28d-ad92-46fc-9a24-30fde25db12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ebb13560-5d94-4bcd-b782-b9113164e514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cefc84af-1235-43ca-ac1f-c06e23e8d33e" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ebb13560-5d94-4bcd-b782-b9113164e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_846e6af2-2105-410c-9739-89b583e3fb7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cefc84af-1235-43ca-ac1f-c06e23e8d33e" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_846e6af2-2105-410c-9739-89b583e3fb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7fb2a56a-7048-4765-8da6-ad9896fcbca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7f32ed3-a7e5-4636-a2a5-cb8911aa8e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7fb2a56a-7048-4765-8da6-ad9896fcbca5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7f32ed3-a7e5-4636-a2a5-cb8911aa8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_02932e0f-93b0-4ce9-848e-c69fdfe5c994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7fb2a56a-7048-4765-8da6-ad9896fcbca5" xlink:to="loc_us-gaap_RestrictedCash_02932e0f-93b0-4ce9-848e-c69fdfe5c994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8991308-2d47-44f3-bb40-aa8fed3710a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7fb2a56a-7048-4765-8da6-ad9896fcbca5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8991308-2d47-44f3-bb40-aa8fed3710a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_60169c34-a15d-464d-bb36-2674b6430a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_700742c2-9bd6-40fd-aa86-a19ad6fde356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_60169c34-a15d-464d-bb36-2674b6430a2e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_700742c2-9bd6-40fd-aa86-a19ad6fde356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80082ac8-e2a4-4cea-a33c-f42d89fa9127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_99102459-3a13-4d5f-b20c-d7244dce71e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80082ac8-e2a4-4cea-a33c-f42d89fa9127" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_99102459-3a13-4d5f-b20c-d7244dce71e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20200930.xsd#LegalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f20fed9d-3d78-4dd4-88c1-b896a611dd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f20fed9d-3d78-4dd4-88c1-b896a611dd37" xlink:to="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_430e1c11-12cd-41bd-85ef-e8bf002e86b7" xlink:to="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember_15136705-f942-40c7-9411-9989c11ad61e" xlink:href="regn-20200930.xsd#regn_A165PatentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A165PatentMember_15136705-f942-40c7-9411-9989c11ad61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember_1bee2878-1153-4ee2-b3f1-ef1df4a93027" xlink:href="regn-20200930.xsd#regn_A741PatentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A741PatentMember_1bee2878-1153-4ee2-b3f1-ef1df4a93027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember_461fcd2c-0af3-443d-a967-777f1e626de1" xlink:href="regn-20200930.xsd#regn_A487PatentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A487PatentMember_461fcd2c-0af3-443d-a967-777f1e626de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_f35ee380-8d53-4769-adbf-bc00c189c14e" xlink:href="regn-20200930.xsd#regn_A631PatentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_95214d97-bf9a-42f5-bbad-091e72356f5a" xlink:to="loc_regn_A631PatentMember_f35ee380-8d53-4769-adbf-bc00c189c14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_de4936ad-6be2-47a2-93ad-999453114262" xlink:to="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember_81b24fd9-74ff-47f6-9059-955dcaf1aef1" xlink:href="regn-20200930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_08d202e4-dbbc-416d-ab30-711cbf77fecc" xlink:to="loc_regn_Amgenv.s.RegeneronMember_81b24fd9-74ff-47f6-9059-955dcaf1aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4b11b643-2f00-44a0-852e-52d6fd8863d8" xlink:to="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e15f090d-0514-40c6-82ea-8ee3bc702463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6acf835b-85b9-457a-8f7f-0d4d5a53cb62" xlink:to="loc_us-gaap_PendingLitigationMember_e15f090d-0514-40c6-82ea-8ee3bc702463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e4a7452b-9da3-497c-8f19-c8b1bb662096" xlink:to="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f6846fe9-ca7d-4509-955b-9312e58ad354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f6846fe9-ca7d-4509-955b-9312e58ad354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_fadf8b90-3017-4023-b2ac-af8327e5fbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_fadf8b90-3017-4023-b2ac-af8327e5fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber_b2e68e09-c049-427b-a800-a4c999eb6a72" xlink:href="regn-20200930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_LossContingencyClaimsInvalidNumber_b2e68e09-c049-427b-a800-a4c999eb6a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyDamagesSoughtPerUnitProduced_317fae4c-7cec-45e5-b4b5-7e92fddfb9b0" xlink:href="regn-20200930.xsd#regn_LossContingencyDamagesSoughtPerUnitProduced"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_LossContingencyDamagesSoughtPerUnitProduced_317fae4c-7cec-45e5-b4b5-7e92fddfb9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_b1747cf5-78f3-428b-bad8-34a4c88cde8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_b1747cf5-78f3-428b-bad8-34a4c88cde8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber_c911e222-bda1-4a48-9211-6c0a7d732d36" xlink:href="regn-20200930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_GainContingencyInterPartesReviewFiledNumber_c911e222-bda1-4a48-9211-6c0a7d732d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber_9d21d2b3-00c6-4d4b-9228-c03ae4ff6002" xlink:href="regn-20200930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6c036a21-b05a-4f63-86b1-cb94b877d500" xlink:to="loc_regn_GainContingencyClaimsInvalidatedNumber_9d21d2b3-00c6-4d4b-9228-c03ae4ff6002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
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M- 0@FYEP24>^X^/C75UI"\K$1%14%)P"X B5#PST!P3X ^WU]?5I-,4>'A[
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M W"C (+A:%\?#=^.CG*YO+^O#\8,7'09O<-=+2XN!LR%\0GL@FN'GO?R_>X
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M C#-PG<>P/>-&S<8^'9UC;T;.S--^;P!H#GXQE,-)E"1;U<4^0;X9OF8,77
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M6%@ + Y<OB%\HW0B9FOK='9V)B8F4N9U1)XT7P)\PR\%]$I"634HT(<K@O%
M4E*RDY-S=DX.2D.>FIH*UP@ #<.#]/1T9R?G3/I<. 25P"$@>/@X,S,#G8=V
MJ=0>+BZW_&_!3\D\O4IQ;EX>[(%Z1D='81BC4BG]_'SA&EV<G6_>O%E:6@JW
MEUK),BZ.2AJ#V)5^A]L+8PFS5(-:K18&"2XNKF@4X>_O#_#=W-P4%A;J1DD
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MV.!V=F+PK50J#QTZ=/WZ==B?D9'YYIO[H"'85FLT;[[YYC/_[YF(<*I:@4
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MEP7&;A8<(0T^.NP(SK^-G:V&N;DX7JVI>LJ*P\[.SH</JV*BI31_C62#TW1
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M Y[:F^NF0BF_50K%R\F80$! 0$#P?.'N[O[!!Q\@!HQGN$0^W^@XHV\." @
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ML8=/>40]E[$0$! 0#!Z4EY6.&$%1<!3K[4-V,NK;44%!9Q#Y!B)K:FK*D.^
MHT?'C![]X,$#V%YM;^_0)_G^Y9=?,C+2@<Z^@>'--]\T,C(&\JT$\CU^/"-W
M[J8U&'#5L6/'8-O/SV_]A@T)B91^LM?(=U)BXD\S9GC1D>^M6[>^P<7;;[_]
M5/*-<.'"A2^^^,+"PB(E)9F*?(\?W\_(-UIM.6;,&!@+7AL0;N1V\N&''XX=
M.Q8F'G*Y?,V:-2$A(5! 3[YUD6^XX3"Z[[X;*Y?+XN/CIDZ=@F0G0+XM+05P
M%:JVJ:GIV+& $2-&X'%Z@J=B,)+O>V%)]M..6YBX<K4??'D))I7&U@YRP]6X
MU 37?"/O%(S']TQCR8F(\Y0A0([GC?0,#U*V:)XH(TY1%.)A;PO&QH35G&"=
M-]*]+%#8>PJM]C;0V[NEN?4ZI?;VUGD:8NLL>Q&W&/%D)ZZKS8]%7(Q_YM_>
M$Z'5:O/S\U%J3"&6AU*O-J$."3']B4@D5"H4<,FS-ZUI;KUY3B4P<ELV\? ?
MB27/7B$! 0'!H )PUI$C1R(U=D_RO6+ERD(J\JW3?&MZBWP'! 0 W=21[]XB
MWR4E'/*=GDZ1[WW[]C$-,0#R#7TX=>H4?G#5JE7;MFVMK*R FG\]^"M:=O_$
MR#=&OA<L6#!@5<;%BQ?-S,S.G#D#HYL\>7(_-=\P/?CHHX_\_?V?5" F)L;.
MSL[;VSLT-/2==][A30\^^. #=W?W\^?/#S4UO7GS)KHD/CY^ZM2I<^?.I60G
M]O8,^09<OWY]Y(@1T81\&X)!1[Z54=EK?SJN(\>]V6#K@]-.K.T@UZ@$4XDX
M\6@Z'H'F^!(:XRR<N83A]/@:39T/R9+Q?I'7TSIZY,M$T#1I0WPEMF.\V; W
MMBI4'W=G!N4T&XO!4][>FZX7&Q[VSDHI^]7ABL#$C3>7P.\&HU_G*G-<X"JG
M=:&5+U+M#;-VF)'KI=Y,5IQ(7:[*2"9=/)LW1R02)24EM='F)\^(ND?JO<LN
MSA_EY[;Y&K$=)" @(# (%144^09.C,CWOMXUWWKRK:'(MU0B&3IT*![Y'HU%
MOON6G>RG&YH_?[Z-C4UZ1@:O,TAVPB/?0$8='-8<.N2]<>-&IM$G:K[ULA-G
M9V=S<W,\ FT0&/*M4"B@'L9GL \$!0<-&SZ\#^;=3<M.YLV;QXAA$-1(\TU;
M#:K5:N]#AZ9,F8)L!P%P]V#@0+YA#@,W<]HT,^0S" -W=G+Z_OOOB>S;( PN
M\IV95+)E7I"5J1M/9(*OF\3Y-$\*0F?/<:,RZ5#O],O(E3[H+M ?1QEV4#&@
MN3JQM1'&Z7DA=DQSPO!CN';MK$"5,.=) TE1%NY9PH2]^6H9"YR.\^3@1B[+
M)_M'7$HPE"!28>_@V/ECO6F3$VY*(&3OC3E\\W;ADM7FQR,NOD"U-\Q1ZNH?
MRV0Q8I&(DQ:>49Y$Z84HZ"S-R$5"H5*I;&IZ>@[1IZ*MM5T1F64]S&/)CT=$
MOZ=W=G;6UM:6EI;"%W%]?3VAXP0$! 0X4I*3@58F)NK,K[9LWF+TG__$Q<5U
MT]%B(R,CI-ZVL[/[G__W/SSRC60G?/*-1[Y[DYV4%%/_EF0BWT"^T8++0]Z'
M@&MV4YKO(%\?7V;!)8]\Y^7FK%B^?.;,F7OV[$E*TN7'X)-OG=5@ D.^T8)+
M!P<'>!QTTU(9-U<WA9P:VN[=N[_]=E1$1 3>BI^O[^9-FXJ+*9/OC/0,H,B+
M%BXLHE7IQXX=^]>__N7FYH9*9F5F>GIXX#[?W700&F8@!PX<Z./.1T3<@1OU
M\\\_\XZK&UGR#;LW;MPP-35U=75%9V_?NF5J8H+67(:&AG[VV6<HQ8],)@/F
MS:C)"?J)042^RPMK]RR_ /3(PLB9([S&C0*Y8@G$E0641Y[;\LD!88'RQ)B\
M)%E^4DQ>,KS+\A-CF/>")/1.GTU5%08?$@+-I:@JU[L07Y')E[LPF6B,77<M
M.I<66]3K0#1-K2&^8FK5HQ%;%3X0=C6GD1/O!36[;PH?0-@[.[7\X)HPY.W-
MT\^PLF_\WPB,<R(T:N)"A;U+7F#8FQ9\UT9'2ZFEEHAJ"WDF)_HUE]QEE[&Q
ML>AK]]G14-?LM?.&W7<^QSW"Y3(9/!CD,BI#CT0B5JF4560Q"@$! 0$&QNT$
M21W@VY@Y-7[\>'3<U]<7^.Z&#1N ?*>GI8X:-3(H6!?YYFN^ P*8R+=];Y'O
MGN2[6V]X@MH"IIN6GM[]!-D)8/>>W7_[V]\.'CR(-"?=O42^UY>7<\@W(!FS
M&L0M1X!\P_0#R"O>1'U]W:9-CHP"9-&BA45%A<S9RY>O?/GED#=HW?:G/3)<
MEI>7PXW2"]C?0/)NX-GW[MV32B4P(G3DZZ^_1JM%>: TWUZ>YN;3F 67NM66
M]%6,VTDWK?,^ZN^/VGGGG7?[YOH$O6*PD.^ZZD;W+>&VWWI;L.[43KP(-,^?
MA&&T<(GMZ$,WS\:J'QO@27<I(&;QN,.4@SA'UH)+P/&5EYP5G\!Q71ROY67V
M3M=2E)3:&WF3XV8L%JPJ'5_EB2^X=%TVB0I[=SY!S?(DM#2WW@A1+?C.6]\H
M8]7"7:C*_B?!B?$=%QBYVD\[=OM%AKT1X-L0OC&IA/!ZS0F^P=M%#H0BH3 ^
M+NYY)33N:._(RRP]?_)F3(P4G@HHOAY)K_*42L1RN3PS*\M =QD" @("@M<0
M4JD4I@1X^G>"085!0;Y;-&W'?KNW\#M??7X9;M06CQ/CT6)$+HV<K4S=@[RB
M:JH,L,4 FNZ]\Z;U<'>F1;W;MVX1)%<*PB[<1'36TL3-?_^=7D/%+9K6LU38
MVUMG]L>8I1CA<6Z.V1\6:'=U<[Q6F&UP0IGLU/+?UERQ9#+8,Y,'[%[AP7M\
M D.'O:]4%+]P#SZ8BZ>EI<9$1U,+*UFODRC&^831G*! N$@DA,+/4:;6UM:6
MDYT5$RUAF].WA?J@4BES<D@B3 (" H+!CMV[=V_9L@69?Q,,0KS^Y+NSL^M2
M0,S2\4=H!0C?VF\V5SO!73=);5L:N_GNNFDH=\S/K-J[[ )FC<+4S\J[F6BQ
M!19%1DXI0%A#?(0-=;UHD9':VQ*9)/*G"JP'(IY7$FT(C%V73QJ0VEO3=B,D
M;L'W/NB?!IR!X)8OO2G.H=&7$_;NIA-;EI66((=OQ'=1B%N( MUZJ3=#BT4B
M47Q\W/.R)NWL[*RNKI9*)"):]Z);W(GK7NC\/G*YO*;&X,1&! 0$! 0$!*\-
M7G_R?>=*XJJI 18]@MR\X#=W^:".60+S/F!_>0"AXIB[?VRT/*V3N."J#%Q6
MCLO-L329 B,7FU%>-X)56DT;K]J6EO:S?A+;L8<P@4</[Q2]L@5?_HC(M_NF
M\*+L@:F]0P7&;A9&_#HYIBX\ 0QB_"942LN*%ZGVQM'<W)R>ED8%OVF2K?,Y
MP1=9ZM=? O.6RV09&7\\KY60;6UMN;DYLI@8/*V/7N6BZX9(*(R)B<GHL;*>
M@(" @(" 8/#@-2??BL@LA^G'V.SKC+JC1P)(#I<U0MH/]TUS@]+B2PU- PD(
M/2%;.N&(!9.XGG$3Q]8^6N FW%@X'%CRT@F'Q91C!K_=5%41"GMS)@R\(+=.
MIZX/I>M$Y"[+)QVY?3&AO=W0L'?K]6#5@K$ZE8L%_S\#3DQ^4/PX&@O,(NS-
MCMV^\ *]O7F .U9;5Y>0$"^+B18*A9CA221N^PW,&UAR<G(R6C+_7*#5:N/C
MXZ02,9O'1_]BY2YT/!Z:UCPGE3D! 0$! 0'!GPZO,_G.2"S9-.>T)>5+S6'8
M-(/4997G2% X^@W7%5,"Y/<S6[4&FT"K&[5^>R)L1ARR-':G70CAW4.W;>1&
M[9IX6)EXZ T**:="*V-VU\K$<Z/%Z5A1+J]:;7/K.5_I@K%^J*2^<C=]$U0K
M5M0[7:<)=81I!5IT<PPOR*HR="Q9R>6_.H1!E^CZD9$B6RT:CLYU47_$4M<9
M:E!.:T/+BUYJQO7.KJ[ZAH:DI"0I0"(1"86,\ ,HL%@DBI9*%7)Y6FJJ1F/
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MW9_V#JBSLJ*RC<;5JU<M+2T3$Q/;.SK1#:RNKBDL*%#3+<+4"&KOHNYA%Q2
M%^Q"9\K*RE!OX52+MA7ZP]R*@H+"#1LV;M^^ ^J#(S"T6IKT0^N/'S\N+"R
M=]2WCJXN&$*SI@7&WM2DN^$PEHKR<I@,H)OVJ+IZU^[=:]:LZ?D7"+_TY.1D
MN4R&Z[T1_Q:+A"J5ZDG!!KBPN5G309+/$Q 0$! \/^3FYBQ?OJQGM(C@U>+U
M(=^9226.5J<L3=WTB=PYIMVSC7I$OEF3$RJ9SL(?_*)NI&J:*<8,9&ZUPVHW
M-[>Y<^<Z.3D!;86#28F)5E960[[\TMC(Z,,//SSB?\1QTZ8C1XX@ 4-H:.C>
MO7O=W=W-S,R^^NJK+[[XPM[>_H\__E H%##+-#<W-S4U_?333[R\/&GN6[5[
M]^[APX=_^>67 H&E7"Z/B(@0" 3#A@T=.7*DKZ\/T-/4U-1%BQ9!/=]\\\TG
MGWSBX>'.<$$&T.B2)4MNW;K534UG<[=MW3IJU"@3$Y,5*U8 70;:#=T;/7HT
M3"&@5\>/']^R9<N8,6/'C1_WSW_^<\&"!4 3H7MKUZXUFS;-=.A0:.O@P8/U
M]?6%A84_[_S9R,@(FK9;L"!6I4I*2MSHN!'(-U#DPX?]1HP8\?777T^?/ATU
M'1<7!]/HSS__W-3$9-+D2:ZN+CX^WOM_^473W SL-B+BSJ9-FU+34IENPU3A
MT*%#BQ<MJJNMA3Y !V;,F#%L^+#/O_A\UZY="0D)4-M?__I7Z,!J>_N$^'@?
M'Q^X5U!@]JQ94JD4+EFU:A5<!01]^XX=KBXN4Z9,A9G2QQ]_;#W7&CJ?E95E
M8S,/AO/O?_\;!G[__OVPT-!WWWWW_???GS1YLI.SLYN;*]R-QL:&D.!@(QK?
M?_]]*#V'.7KTZ,2)$^$JJ&W"A EI:6F5E97PM?79O_X%M<'M#0L+0Y%OZ$"O
M?X?:UK:,C'2I5"*7Q4@E$K%8#.^4UTJT%'Y'/<O#A*VHJ# W)[L 9G5Y><4E
MSRW>3T! 0$#P,A$9&3E[]NQ3IT^AW1,G3L#C$M[1;GAX.#S=;&UM;6QL+EZ\
MB ["TQ">^^?.G4.[L %GUZQQ@/>@H"!T,.#HT9$C1IPZI:L6GE;S;.9=O7:5
MU_J9,V?^\7__]R:-=>O6P9&;-V_"D^L-/6;-FA4=';U]^_8G1;Z#@X.9PC"0
M1S2]*2HJ@D>>A87%QHT;X;BUM34<#+MZ]8TWWV0*?_KII\>.'7M^-_+UQVM"
MOLN+:G]>?,YZF(>%D8L^X(U)36@B+N FE<32Q+C A5=/RAOJ=>Y^Z6EI0(4C
MHX2!)T\M7+@0R.7CQPVPL7'C!B!VZ>GILV;.# D)\?'U7;IT66QL;%M;FZ.C
MHY.S4W)24DE)L4;3#&6 &IX]>Q:8'Y"YG3MWYN;F^?KZSK.Q$8G%SL[.<ZSG
MP*>THJ)")!(!GUNQ? 7\T;>TM  +7[Y\^84+%QP=-]JO6@44/",C YIV]W!O
M5/-5+O )7+IT*3!@M5H-O'G'CAU /4M+2X'L.CL[P2>!ZL.Y<P\?/@+J%W'[
MMH/#ZIDS9XHE$J%(O,#.#D@MM Z?Q@T;UF=E94)Y^%*X?3O"S^\P?.QA7% ;
MC L^;]#G+5NV C$-#;TR9X[5M?#PVKI:5U=7.SL[Z#!\DH'N%Q47JV)C8:9Q
M\+??+EZX %5!#<!<G9V<H#\:+)T-<%QO;V]$OI5*)70 +L_,S+QTZ1)L__[[
M[Z%A83_]]!-P5K@_(2'!P*0S,_^ 20MT&,8+=';<N'$PGX$O,B"U&]:OGSQI
M$LP09#(9C->#UN? M ?F'G#YOGW[8 Z3GY^_>K4## 0F#]#0A@T;G%U<XN(3
M?OCAARN7+T/Y,Z=/PS9T!N9:QL;&0J$0:K"=/Q^F*_!+@>VZNMK'CQ_#;W#*
ME"G5U=6[GQ#Y1H I!PP-?G$JI1)Z"/<A.SL;_H1ZED3,NZ*\'/Y.KE^_$1D9
M50PH*GH>GPD" @("@I<*>-8 -UV_?GUY61GLPA,$B"D0@/KZ>MB%9S0\&8%V
M Y&%4W 0'DGKUJV%,@<.'.BF'XX;'1V7+%D"S^NYUM;KUJZ%1PD4V[IU*ZH'
MRCRNK]])UU-04( W#<S;P<$!.@#;-V[<,#,S0_^LYLE.X*&\??LVX.Z/JCGD
M6]W8Z.GA,6S8,!13 PX#- ">R \?/@3R#0_-M]YZ"\:%"@.#M[2T0I.*>_?N
MC1DS)B @X,7>V=<.KP/YKJ]1.V^\.F^D%Y7.W0@S\,:"W!;<U99,XDDD. ET
M>5!=Q5);H*' JI.3D]/34F?,F %_QW*Y'#XM=^[>I84*]8L6+012F)24-'?N
MW*O7PE-24H ?PQ2SM;55(A;OV[MWOJWMD"%#CA\_#G_'\$&"O\YN>DX,W#$X
M* C>_?Q\U7HR??KT:?@3AX_EL8#_W]Z5?U=59.O^"^1'ES^IR^=Z+KN%IR"-
M* 04GY(%*/.H( 020A $(81Y""CS% B1,)][&+JADR *A-C,2>"),BOD9B3<
M1.Q R(!!(.\[ITY5[3KW@M+=*TJO_7D]G%.U:]?>NZ:O3BHWJ;-FSP:MQ*YW
MX,"!(*.-SB&-:V"-],RW@GKSC7$R>/!@%$E)25FQ<@68/:J D4E)DRHJ0D(8
M<T'BQ(E@S#_]]%-Y>?E$]_PW.-^H4:/ _H5YN,<N'&0Z>6ZR.#>":0+,&&,,
MYBU<N # 3 &3D 7B'BLA-O$8Y$F3)LU-3L9V)2XN#EP9A!@D%7L):K9X\PU.
M?/UZ%0(+OBZ*@_L.'39L\Y8M>_?NQ;X<E+>DN"1Q8F*G-SJEKDY=L6(%S,/F
M 6$9-&A@9F9&HW.>I! ^3ILV#??8*D X:5(2+,<>"=L55-&V[:N]>O<N*BZ>
M,&'"E"F319$Q'XZ9.7,&MD9=NW81YU) CC%C@EO#L*%#AR(%#'O>)_.@ 2U>
M=J5\^?(5L*UCQXZOOOIJ26GIU*E3'T"^*1[PUU&14W_K5L'E K3(KIV[T+Y9
M6;M+2TO%[,E@,!B,1P[)R<F#!@TZ<>)$83 X*C[^F6>>P<J%Y0PK%-9HK$0@
MTY,G3\8:=_[\^3-G3F/!A4S,L&&E)25GSY[MU:O7].G3H6?.G#D]>O00+^ F
M)R4]^^RS* XE4#5@0'_H>8 -7W_]-1:OF3-G-D8FWQ'>?*-JB&%+H%+ ?%Y[
M[37P$Y=\CP874G^A MRC=>O61X\>Q?VE2Y=@C*B+\>OQR)/O6_6W5\W\<E#;
M93V<+Q;47^DMV?8\_R'O%R@%G]NCQ8*%'V?0O\+X\^W;H(-//OEDBQ8M6K9L
MV:Q9LVE3I^[8L0/D[.#!@XW.+UQ>!]7>L'Y=;4T-^MR\>?,P2+ Q!06?/W]^
M^_;MDY*2-F_>'!T=O7;M9[MW[P8M%N0;;'78L)BTM#48%>GIZ>K+25)25F&3
MFI"0@$$[>_;LU:M35ZY<B2IV[=J%W!^O71OSX8<+[T.^Q9MOC/.^??KV[-$3
MELR>,^?3^?,#@0#H+\9#=;5WFAGDVR7<(-\-5Z]>!9F>]\DG,"Q>DN^OOOH*
MNUNP<PR_Q8L7BU*P(79$[,H5*['G!AD%*1\W;IPX?2Z.K/3MVP?APBAM='^3
M [Z+LRM@L=@8+%NV=&3\2-^O3KKDVWOS#?(=,WRX8.?Y^?G#8X8C="[Y[H,I
M!@H1E@Y147/GSD5D<-V^;1LV#/T'],_:G=7H,FD8!BJ,^Y+BXJE3IB0F3CIZ
MY,@K;=I\,&3(QHT;X28:+EA8B.EF,B'?F-VPH\ T)_88J @!1_R7+%Z,D#:Z
M!]/1FN\/'OS]I8)V[=IA$L2N*3EY+N[A#NC^_8Z=_'K<NW>ONKJZ[$K9K5NW
M-JQ?'["LK5NWW;USI^!RA-,I# :#P?C]PSD3TK<OEDXLJ9,2)TV9,G72I"0L
M6^ /(T:,V+Y]>Z/[EKI___Y??OEE5E96DHO)DY/ 9??L^3P^?B1H V2PB/?K
MUP\"$,,R!_Z-*Y1@U0:3%O3 AZ5+EZIS((\]]MB,&3,:(Y'OQ$CD&Q9B050'
M70#P"BR+H 186T%"4$1E'3ERI&=/X\TWGSEY6#S:Y/ONW7O6RD.#VZ>HKS<A
M?\9RKGKG[='Q%^C)$T<2S#MIL%5PL>(>>3UYYO3I+EVZI*Q<"7+YS3??@+\.
M&#!@_?IUW;IU \4$5ZNJ^L? @0/6I:>#@XHC7-@"KENW#EM2['=7K4H!H[I^
MO0K=?>W:M;MW9YGD>]BV;5LQ N?-FZO^T@K&& @?_>JZDR=/0M6F39ONWKU[
M[=H/HT=_N&C1(O4+EPJ*?&-TQ8\<N6S9,D7HZ^IJ9TR?/FI40C#H_63JRI4R
MD&_GS7=#0^CJU4F)B;XWWS!@5$)"RJH4D%2@KJ[N[KU[F"-B8F(LRP)YQ<!>
MMGSY\.$QI>ZY9,P(V*Q#,C8V5OQX"QOTL6/&S$U.QOW^??L[O?%&5%1[6.4S
MVSUVL@1A$6^^8V(T^49=+OG^LG?O7MB(EY>7)\^9,S(NKJ%!?ZLCVD5,28TF
M^<;N'#?8/WSV65J/[CU@/[8KF$IZ]^E36%P"^\7/[% $,K-FS]JU:V>G-SM=
M<W_T!LNCHSNO6Y>^>-$B1;X7S)^/IL_(R,#N'UL@Q/:++[X ^49%_R[RC68*
M!ITWW]NW[R@K+=FV;?O-FIK"8,&_J)G!8# 8OPF"P6"?/GT6+UX,;HHE":O&
MZ(0$W(,DQ,>/RLO+@\SITZ>'#1V*=7/)DB43)DS8LV=/XL1$K+,K5C@K[)DS
MSJ](G3MW#FLK]$!LS)@QT(.5&4K2TM*&#!D"<N*K%PMT\^;-=^SX2^,OOOF>
M,"$B^>[=NS=8ATH!^882< 9Q[,1'OE_\GQ<%RW_\\<?%F1G&0^'1)M^?V_\W
M[/75\H_I@&'/%<=.Y%^/U\>^N_M(N<N\$[JN/9U;?,?\H^O+ER_';N_;;[\5
MCQ@DT9VCT]/3T0O!O]&_X^/CGWKZZ;0U:VIK:BHK*MYYYYT77WSQT*%#H% @
MN]@.IJ6M^?CCC__KV6=3UZP!,P;+W+MW;Z-+OC%F,,PP?CIV[(AAN7[]^FG3
MIX-#8VQT[=H5XQ,5C1LW#IP>U[???GO!@@5CQXY][KGG,  >0+ZQ)4A-=7Y3
M<-HTYR7]I*0DC,_MV[9U[=(%HQ?#:>:L61C X\>/_W3^?(=\AZXF3A)OOO?#
M'>_-=\Y7N,>^?.O6K9T[=YXW;QXV#W!YSIPYV Q\]-%'JU:O!D'OWKT[)H*M
M6VT0T]C8$1<O7EBP8/Z?7GCAW>[=X=3SSS\/4QM=CCMR9%Q4AZB\O%QJ,Z)T
M[-@QL&<P6H3EF'OLQ+:=8R<N^1Z^:?-F;.[?>NLMQ! "X.5145%@NCMW[L1N
M 4';\_GG P<.%.\&_.1[RA1,9'_[VZZ77GH)<]:2Q8O;_/G/(.)70Q4H^TJ;
M-MNV;LW,R/APS!@\7KQX$6YB(X04V(!8%146PO@AY,TW>L+1HT?_^,<_(@B(
M1OOV46W:M"DN+GGPF>]?CSMW[A047*ZL_.'0P8.U=?6YN7F84HN+BOYUS0P&
M@\'X38#E,B$A <O<Y,F3;]RX@54)W!?+5F+BQ!LWG,/?557_&#4J'NL.>,7L
MV;.KJJI&CQX]%/C@ _&ZVI&Y7@4:  &(0<_UZ]>A9^#  7%Q<1,G3O356%Y>
M#GX,/B"^O=<DW\:WG=SOV$EN;B[(#)9=E9*9F0D2DI6555)20LEW;6WMJE4I
MR*J4IU 8_P0>8?)]=-_%$?^[IGOS^3V:?XI/]^:?OOO")]U;?/IN<^?375Z=
M3PM</WF7I/1H/G]PAY5']E[XZ9;_#^6 L^[.RL)@$(^@JNLW;,C).7#A_/G$
MQ$1TN-FS9H$3@U.*U\R@;CNV;T>';G2/#H\?-RXZ.GIN<O+B18OR\_+.GSMG
M;=ERX<(%Y!9<OARPK//GSS<T-&1E[?Y@R <@W L7+@1K+"LKPP[X71>X00J(
M( 8AV"%&'5(._OU@^-_0 5$+!*#P7*/[97_@HQA[J!WD& 2WX><[QX[G8@KH
MTJ4+Z&GN\>/P*_O  3#UZNIJC*@#!W*^^_Y[,'BQT[ATZ1*(^ZE3IS"TP%\Q
MTF >*#N&Z)4K5\!]#Q\^C++8\F(N #F>,7.F^/J.ZNH;V#2GK$S!I@*3#CQ"
M8D5%!>@[+*DCOVH)W*B^L7/7SMBXN%$)":FIJ=CB@^YCIFATV3-X/W;;4.C^
M9J=S] V1 2D?&1>'4,3$Q&"G4514M&GCQG-GSS:Z%!F.8#_3Z$YGR,4C#%ZY
M8L6;;[X)?KP1V+2IH>%V44GIQ^YV?_/FS9A3]N_;=_OGG[_Y]EOX DG,./ %
MVYOL_?O%:W@$X4!VMF5MN7GSIF59D,'&"=N8E)045/K%GCU_V;'CW]*-;_]\
MY_*E[X/!8'GY%5P++A<\X)@X@\%@,'[GP*K:IT^?EJU:IJ]+Q^/:M6NQ8K9J
MU2HM+4W)8&E"(AB%6'&6+EWZ\LLOXW'+EBU*!EEO.7A[PX8-C<YOHZ6V:M42
MS^GIZ4)@T:)%3SWU%-2"XF.5C^[<^=377X.(CQT[MEFS9H)\7[UZ=?SX<6#M
MXL>\@GSWZ]OWV@\_.%]%$!O;H4.'$_GY$7_A<L"  8WND4[?FV\X^ >"IY]^
M.I6/G3PD'F'R772QXG1>T9G\XO,G2\^=+#E[0G[RBYS'D\Z-=W^BV+D_62+2
MSYTH/I-75'*ILB&,>3,>%K<;&K!/P.X")'7G7_^*S;TXBW;HT.&8F.%;Y-<G
M,1X ]_Q)W?7KU^ODE[XS& P&XQ'%J5.GHJ.C7WGEE>SL[$;W-5G7KET[=^XL
MSIP('#YT^/6.SM?:'CMVK-$]R/%&IS=Z]7+.6RH99$'@]==?AW"C^YT$4-*M
M6S?UDWE%OAO==W_OO_^^8,-MV[95;[X!\&GQA8/]^_<_>_;,Q D3^O7K"RXN
MR'=45)0PK*;F)A0J2HW57!0/)]^P-G9$K/B%R[K:VK0U:Z!_YT[_5Q\R'H!'
MF'PS?@^HKZ_'IORYY_[[B2>>:-VZ=6IJ*E)NW:K?LF7SZ-$)17R"@L%@,!B,
M_Q24EI:,'3NV9\^>*D5\I3*3[X<"DV\&@\%@,!@,QB^CM+3TH[%C.T1%773/
MTY:5E8T?/ZY=NW87SI__K4U[E,#DF\%@,!@,!H/QJ_#==]^]]]Y[ZH *,^]_
M DR^&0P&@\%@,!B,)@*3;P:#P6 P& P&HXG Y)O!8# 8# :#P6@B,/EF,!@,
M!H/!8#":"$R^&0P&@\%@,!B,)@*3;P:#P6 P& P&HXG Y)O!8# 8# :#P6@B
M,/EF,!@,!H/!8#":"'\H*RO+S3V.#Y"7FRONQ:-[X]SB_[Q<D9N;EY<K[]U<
M5]0L#H%<<9\G,HY[DIYF3UBH)>G'O>KR<I6\JT<:X&3E"0&AW#-25N?52\SS
M5.5I;:HL59ZK:B>YQ_.\9&V\\E2H\F)UW),DON2J=%JC\L7P+M>GTW/!*9*G
MBU#S5,3R_"E:IPHF+D>/'OG[5SD'!+*SQ;\Y,D$EN@DY-#''%!!W$/'2S7\\
MC=D'J)(<><TQE,@:<[0=.3Z35-D<7S7N38XT!A]EIY#TS"!UJ1II8HZ6S)&Y
MII%$CTKTJ84&E,I1'LJKZ6F.*T;2<TC (YFG@D/31461X*1G9XO0'Q 1\]DI
ME(3%WV<"T1B60FTCJB(U:PXUYO[J?<TDXR/+"LTRKB1ZV;('1@H(4G)(:HY.
M#//"B[#9)6AWHMZ%Q?.^;1?N:;@&55CI">MF$89>=O:^??MV[_X\TX>,#'%U
MD*ENO63QJ/(](7WGY @=[L<KJK1*_4)A1B1MJKA.T!^=Y=QE969F$9.(J=0H
M+RM+94LKA&B6ML'Y9!DF9690G=(JXJ//2.FI7UX91VVC\<Z@UF5))9D9Q%\2
M)JTMTPN+:4^F9V)FAC^1V.D5R=3RICL9*JZ>@4;3J.:0349;P>Q'_FY%'FFG
M$SE92I*(^SJ "F>6+JX*T>[D^4;;2#6#H9XTAQ%)TAE<[4H%Z8HTJBH:AC;J
MA:XHB\AYVF77(37JP&:H)I?9RH9=NW9MW[8M8%EV(!"P LXUX%XM2WX"$K;*
MLK6,F^-=+:'!RS)4N;>6D:5!4]Q*O6='7I0PRECN?UXIR]3@%K=566*8%@NK
MWZW -=&V34N(<)C94EC]8[LRMFN K:(AE ,0L$1(M27>HVWX:-L^(STQ6XA8
MEG1?:3/E;7&Q=$OEY^?] OD^>_:L#)EE>4&TC8"Z<=<QU;;:]#DLQ+8*KALB
M6WFN_+55**68<LE2QMBV]-S2741',Z!UTL;V"LI618HM#=81=+PV##"NHE;3
M:6FGI7JAK)^TEI8DS6E;U$Z9;(M18QE5JUYE$U7A/5@H)&U@M)KM^4M<]D&6
ME1'00U2/5=)-Z7CP^4M;Q[ V$%:O)9O6UWW]PR/@UR,EI6UFG(U>1,RFPUH,
M4=D0_DKEQY@!I21M:3TZA#FJATL1FSZ20>1)VG;8")?BJG9Q[PX9.7<$3-BN
M4;8.EQ&Z0&2_:&"I28&P(6 &QU(SFG39)C%1-NLY3JNWU#S@ZZBZ9<)K)(D6
M?:1M2F<#:D;DGD,BX(,L8O:3@#FYR7'D,SC"#!;0)JG%4EH7,(VE+I.Q;A0W
MPQZ@:Y41!ZF3FNW)!LSH&4YY\=4=+-*($,+^@K[0:.5VV$2C?0FHCB2J]-$"
M:J$Q!K6URF5;C"/WH^8?8VD(L\'?NTA!;SDSNQF1UQID..1B+Y=P+XY:@VV,
M(.VF4Y$D6V%3@;ZQC7YH>&2K(%OA90V7#6?]C6M$AHA[W@7HY$:(@4OFZ+0J
ME80M@K::*[Q)P##.%EQ.K4%D$0F$#Q"S#]M*PHBAV;Z6^4C]M:7)D0-%],M%
M1X\^M0H9=9%P1%@-2:5Z9E.]W2)3I\S5_5P%P;!6#U[#?5G$F!GDU?8+!PSN
M8<N544;#:#%OGO2[[V]5XH+IB!K[_OY,%@(UW=F!!\=05V33MK/#[9$!(3.O
MGVY9>C(Q.:39,M)4FYJAVC+@=7?"P6P[/S__%\CWF3.G_4WE:TX=+.V[G'WT
M=._?OGC_&EU*]P#?I*/C:(XZ:8"WWJBN3QLO@GEJ8V#[]!AE=1!)>\CF,9FH
MER-C8UM&B.C0HHTA]01(NY+9..)\1-U2'<)8_,VBU'W+"NC!X1NZJJP:YL19
MLY7#0&=5RQ]M6T92L0$]1=ET[3=G@?#J?-.WBK4B-_0Q$ B8*[?M8[]2I=>U
M:!RD%_X-L1EA:7ZD!=*8&KQ9P H0G<0J0IUM*>)%R+;)W$&9M]E+O2F/##>3
M2>M.3B9T@[CXMGS&+$^'K5>U[*=J]*E*I4YC#E4C5,]<>B!H.FB1N)$&LE07
MLO4674W9EEF+XEN&P<H&:7RD)E./QG3D8^]&E,C,XYI"2@4$'8W,Y_W3)BWG
M>TU@0BP\!N^GU@;TV#$:VG#3,LJ2J2:R@-%/I/N61XO][R\BS6#J2@W38\&P
MD$Q;XL4'X?3Z]9*/]X3OJV4DE87AP:3O>E2:UN";$MV>0S;J=-4P-/@$3'IB
MUJ_HFAJALG8YFFSM7<#K:;;J5'373?JV&<R([NC)V9C?++USH)U!#W/="VS:
M%N: M0/AB21%\!@YX2I>;<L]H$5;7/4D-?7)L68Z94[:RE357#)J-#XTRS>!
MJU:@B70\VOYT?VS]7E/AL$V[,=FJ@NJ%%QV ]R6RQ%H[PGP=MH*3CF')5R>^
M81C1J;#NH28!SP9)JNALK!D_C8"L-*RSA7LG;ZRP8 ;4& DS4FZ5*2TR%E_?
M_DJ_>(W CFAW-?BT'KRRB70,2$^S_44"8B"<^$7R7555%0P6% :#\AH,NO\4
M%JI;)]W+$NF%7JX6D,*%JKB;+I/D#<T2"85:<]!+UUG!@LNZHD+#$EFPH%":
M&BR4I5Q[=+K23,TNU!^97N#="^&"R\*8PD(2"FF#=+E N24>I0O22",W&*3&
M%VHE.J50"QA52R.5U\1979>RS;N1VHJ*BLK+RRLK'+C7D'/CP$NI1$HH%'+3
M/9F0*U-16>D5<5)$V4J1ZA20\JXJ6<H1\QYE+M$9DLDAH4+(2^6>9F6JJCW\
M7HE)M<1X88#GGZ$V)*XAPPQ75JL-55 [*[PH56KE,C=$;F1@0QX\!YUPZ3B'
M*G264Z$79"]<H5!(1=Z+9"5QQZA=ATA4(5.D/6YKTN(ZX"$J*0Q2*2$OSJY"
MV925M.?HOJ&C2]JK4E^5>;11A%,Z>JZ;(:_>D.I([M5Y"'DRI&5IC])*S"HJ
MO!Y%:HS06*J31.YU(1(0U2YZX(14[4I;19@&SQ<:?[.Z"M*O*M6(4ZIDNPLE
M/_YXK;JZNK:VSOG4N9_:VAKWXZ4X6;4T762Y5_?>S:KU)8KB4HF7XFF3*;)@
MC<JJJU<UTKI4$24I;FJ,>O6CHZ=6655K6E6K]"L+B7G:4QD-H8TJ,=RIH:I4
M6:J0!D%Z07Q1;JK$>L/R.L-:735I+&DGJ<[GN(S5S1J=2P+H<T$K-V-K= 9M
M@V@U8B<1KM,5^;M!K:]VVM:T+]%NX L=55ZK80;*WR)FKZZK\ZM2]=*HFF$A
MG4=5K6VFP:>/OOZL[=3Q\;4I"0N-N3E:A7Q]??V=.W<>[H PXS\._ N7# :#
MP6 P& Q&$X')-X/!8# 8# :#T41@\LU@,!@,!H/!8#01F'PS& P&@\%@,!A-
M!";?# :#P6 P& Q&$X')-X/!8# 8# :#T43X?Q=-H4,D?'9M     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_11a.jpg
<TEXT>
begin 644 image_11a.jpg
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MEWP;91B&81B&84:8:I6@0R7%2V6TC[N,&.ZLJ]8BX%..&7G8/!IE2KWL^7;
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M*ESZ+H00UEFSLO8_QMSTAS_\(8=CET'.L W;<T0@E#;5Y2NC1& #"6FO4)T
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MD5@D'F5EVWA<BM4#1:J]*G6MT9F+K\(3NA\<2E>//O!5P[5^>!GH'[%YM-_
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ME.2_+2O(NW/S:E@P,SXFXLKY4R=2#D(F4$>H%-R."?3>$Q5\X_+)0_NB*?A
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M1W,C_"R>9SY>N'"AE9552DH*_  ='1T7+%@0%Q=WZ]8M[1]A4![]?PB#\LB
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M,'02%AR(QR3C03!O=Y>=KML0NSRI>%T,BTK0.Z@=GTV+".%$"R 3;F@PA<N
M;S$@ A$3Z+S9?O'\V3M=G=YFO_@X,M+9TI)^]1HF,,C<;+GIXD7V-FOMK"UM
MUII#,G>GS60<] [">9/]%GM;J"%BO/M $A(FR-_+ XJX>.[$X0,)"7%127MC
MDA/W[$O8DYP8EY9Z)"*4[^'J8KW&TF[]>@:%\N)IEF9(_>FO8NQ_'TTR_KS]
MCW6A<<O1P[JM==HQY:"J6]S7W-0NJJX75HC*RZI+2RJ+"RO*2BMK1'4U-77"
MBJI*875=70,XD:BNK:VSO;VKOKY)5%V;GU]85%32WMXY/*R5RZ4JE52K'1S6
MR+1:A48S,#(B__1)/3JJ5*L'AH?UX<&1$85NB=*P?'14_=F"N'XWF?YIUYNU
MUAT2._[^4'\RG?YT5?V)&,/#ZH:&^NKJ:J&P\L7SEZ6EY20B=8.MP]$C:76U
M36J5MJ.]K[:FM:E1ISEJ:FH"O[V]O6\</3T]"H7B3WYHO[)Z;H !!AA@@ '_
M?M"O0QE?C:LS./WYI X8^&[>O.GN[H['X]^_?]_6UG;X\&%[>WNSI28'DQ/%
M':W2ONX!2<^YTR>LUUC,^6':9H>-IXZG!K/HJU<MATL3HP4+Y\[RWNG^_NWK
M$96RHZ4IZ_%#/V_/!7-F^>STR'[VE,]AK5]KN=)LZ2ZOG9X>;HE[]_3UB'7[
MSH8UTG[)G5NW_';M6F9J&AL=U=W5V=?3S6;2%\Z?.WWJ]V@DXM7+YU7"LHZV
MYM[NSAO7+J^U7.WBM,UYZ^9)WWTS[?M)?CY>3Q[>ETIZ%3)I3U?'D%)165'&
MH)*7FAC-G?6#H_U&:VMK9V=G'Q^?@(  3T]//I\/8SU46:\STD//@G3[E#3:
MW,*R*[?O1^Q-<G1Q2TXY7E7?U-'3I]:.R@85"J52,SS<)>XJ+,S/RWOSY'&&
MC]>.*9,F3)[P[=3)$\D$W*L7SW*S7Y06%2CE R#,XXS[*(3_O-DSMVYR='-Q
M6C!WMHGQ8F#9N;FYT,)'CAQ9OWZ]FYL;G4[W]?5=L6(%M#^T^<:-&RTM+8.#
M@TM+2^4#TJ>/,C8[.BPW74HG$Y/BXP[MW^?EX39UTH39/TQ?O'#^&O.5^Q/C
M6YL;/XX;_93T]I24E"0D),R9,V?6K%GSY\___OOO9\Z<.7?N7&]O[\+"0J@I
MT)LS9\XL6K1HXL2).SW<<UX\ZQ5WJ(<4T,NBRO*LQQE<)FW)XH7KUEBL,%L"
M#C[H9$)Y<4%'2V-G:U-W9UM.]K/#!_8YV-G.F#H%W+3O)\^:,1W<E$F3OOCM
M;TQ-%A\^D'SYPCE3$Z/%"^>1\+B*LI)QJP[*]M;&GZY=W"W@)<5'S9PQ8<&\
M:6LM3?U\7;>[;GS[^G%YV>N6YNJBHJ*4E!20[<LOOYPV;=K4J5.__?;;!0L6
M[-FS!WH*A->3/:52.0A0*OOEBH>93\W7K'78O"4T(K)O0#:HUJA&M$JU9O33
MIY&QCT/#(^"@Y]1:;=[[=^8K3;_\W7]-GO#U_#DSO_S=;[_]ZJOI4Z8B_ /J
MJD4#DGX@A5<O70P*V#5U\K=3)GUM;V<='AYN;FYN;&P,+0G-N&/'#OB! "&$
M=K:QL8%X.SL[% H%70D"+UJXP-%V/06/!1+:V]&6<B!YY5(3'P^W5:9+?MQ@
ML\YBU>QI4YQ^=%#)I,.#<GE?SYV;-VQM;1T<'(X>/;IY\V8C(Z/ITZ=#3T$1
MGV=V?_+[_2?]<_S;X/_TOOQ?%@;ED0%_%_[2ST#_G_+Y)9+^#9)NJC\Z+.L3
MCPS)B_)>Y[_.#N4P<$A_*@%-P@:!(^-0X'3Z(QR2C$=1B1@J$4_"8/$H%!&-
MH1&)+"J52293\7@*#D<E$.@D$H-,9M-H?!8[E,/E,5F1H1PZ":D[P92 0OG[
M['1UQB.1904%K?7UW6UM_>*NOLZV^^G7V33"QO46CAO6>+D[(?V]*00TFT9D
M4/!0+AX=2, @((9&Q(P[+#B0!&+(XU(QR'@Z&8=#!2!\/5$!/@1T(!&# +$I
M(# !S2#CN$P*GT,'GTDA4 D870R#' R75 )D2"=A65 6&8]'!:(#?2&?7ZJ,
M#8)L.70RCT4-X=#!9U$(="*62<'#O1P:B4TE0B2?38-X$B:(BD=#,@&?+>"Q
M0]CTR%!N># +4D)9X3R6/C*,RX06YC&I7#H97#"#$LZC1PO8? Z)2D30B$AP
M 3X>5A;+W)VW/+Q[:T@^, (#GJ3_X9V['LZNZU>O==NV-=!GI[>[BYO3IIVZ
M%57;\,@ <! )S8M%^ 5X[X P$8W0K\.")J*2,"PZ,8S/WBW@AX+$)"P:X4_&
M8RA$/,+?UVZ]]19'QW.G3HO;.\:&=08F_QSPV !Q'!@8 /($C\WG)VU4=_"$
MZH^F 4?T=OVDTH&VMO:ZNH;*2E%%>559665Y696PHJ:ZJEY4W2BL@,C*ZNH:
MD:BNOKZIH:&YJJJFO+SRPX>BI,1D+T\?5Q>W-9965FNM P*"PD(%%R^<']4.
M:M0#6NVX>DBG)%* _^F3>FA((I.)AX=E$-!H9) , H.#4KE<WM/3T]+2TM34
MU-G9V=_?#S$@.="&WMY>N!P:/_9/OY!X?(\=T&)@>;*VMM8+%RYX>7F9FBXS
M-[<T6@2TS73;5K?,)R_K:]OZ>A3=70/M;>*NKB[]XJ.&<8A$HIJ:&BCQUR.W
M07ED@ $&&&# OSM@7(.A$[BB?E#3'S.OT6@*"PNW;]\.4W0T&@T35Q@6T]/3
MMVW;MLG1_MRI-'%GFZ2GJ[JBE$DEF1HOLERUW-_'<Y>G!S+0SV;=FF^^_/V<
M'V8L7C!OXK??I!U+U=O].7_V])+%1M]]_8?]20FW?_XIC!_L8&<[Z=NOO_W#
M[W=Y[CB8G)3UY)%,*E$I![-?/#^>FN+MZ6EI87[J1)JDM_O.K9_M[6R-%LZW
MMEH3%QN=_>)9K:BJOE;TTXVK(,_4R1.G3)HP\;NOC1;,F_W#]&5+C<-#>,*R
M$JU&I1CH?_<Z![B0TY9-:U>;?_WE[W_[F]_ E'[RY,DP_U^S9@W,_+.RLA0*
MQ> ?#][]O$M=KSSJ'5#D5XC2,S(#L*1EENO"8N*$M?6:T;$AG5Y)U='5"42G
MID:4D+C7PV.[GZ^WC?7:.;-^F#)YTK3O)[LZ.\5&14)-GS]]TB/NR,E^'ATI
M<'=U<MQH:VF^\H=I4Z9/^7[&M&G 22Y?OEQ149&=G1T?'T^E M<F^/O[6UE9
MS9PY\[OOOILW;]Z*%2NLK:TO7;K4W]=[_W8ZM-@&:ZN=;JXH1  .%;1P[NPU
MYBM=MVU98[%J_IQ96WYT2$L]6B>JZFQK^? ^#W);LF3)W+ES(;=ITZ8M7+AP
MPX8-#@X.LV?/AJ^*BHJ ->7FYN+Q^(D3)]JLMSYU/*6WJUW>WUM7+=P7O\=Z
MC<6\63-6F)K,GST3FAKJM<1HX68'NZL7SSW.N/?\Z>/.MN:[MVX&^/K86J\U
M7K1@[JP?S)88+YH_%\*.&^TVVMIN<G1X^>SIO3L_8Y !T$.S9DSG<SG0-?V]
MW0\?W%FWUGSNK*E3)\.#\%_KK):3B('SYDRV6&5T(BU9(FDN+W^?F9GYXX\_
M@K1+ERYU<G*"BDR8,&'1HD5L-CLG)P>HFOZ$7/#URJ/F]HXK-W[:XNRRWFYC
M1%3T\-C'X;&Q0;5&I^<;^PB!@4&E:OQL8X5*_?.M6U]]^3L0P,9ZS2;'C2#M
M9D='.QM;/!H;$[E;-:C\.#;:VM00LSO<TGS9_+DSEIN96%I:\G@\,S,S1T='
M$Q,3Z!<BD=C6U@:2I*2DS)HUR\7%!9XN^/F D%NW;)D_:U;*@62-4O'D_MWU
MEA8D#&J+O9W-FM7;'.T=;*Q-C182T<B#B?'"DB*9I/?9XX?GSIU#H5!)24D)
M"0G09<;&QLN7+T].3C8HC_XV&)1'!ACP%W\&GU<SZI-]-BS7W=XFZ^V^>/KD
MX[MW*#B,O[<GE8##HY$D/(9*(E!(>#(11R)BR20<E49B,*D<%I=%Y](I+ 85
M0OQ0G@ <CQM*Q%$P2#P.32!@R?!M,)L?S EAT-AD I;%(/*X#!PJD$8B8((0
M%BM6NKML?_,J5]XO'=%HM!IUYJ,'<3$1;";\9_IAT8%X' J'08(CXC%T&CF$
MQ]D=&28(#PGE<X.Y+#:3QJ!3Z%02@T:& !/D8%)I5"(!RL:A:502DT&AD@DT
M"I%*(4 .X"AD HM)XW%9D!67S8![240< 8\!'Y+!O9 2AT4A@_S!X;!((@&+
MQ^ID@+K3*20FE<QF4*':'":-1:/0(6<2GDVG!K,9ND@&C4XF0C5I9(*N:9AT
M2$#"8> N2,"'-N*RPOC<\)!@\ 4A//#Y'!;<#G=1B#@B#LFBD_0Z'3P:02:@
M\>@@R.'Q@WM]XLZ!OI[! 6E!7EZ40(!#H<@P>J-16!0"'12 0O@##T/X[2+B
MT) /&8\%V:"%]0["(#/(2=15$\MFTP3A_ @H/I@%340F$;@<-HU"]?+TA*'K
MP/[]'6WMPYIAK<Z*Y<B?;[SZ,Y-&'S_K(L</8]7J2)16(U?(>GJZ6UM;1")1
M65E%46%I<5%Y<5%%<9&PI+BJK%0DK*BK**\I*146%9<7%)66E@DKA*+*JMJ6
MULX7+W-3CYWD\<--S5;.F;MPK97-BI6K)TR<LM+(&+-M*][%.=C?+S4\+"4L
M-//\N>>7+_U\Y/#+*Y>[2XH;7N?VU]5J>KI5;:V?Y#*U5-K3T]?<W%I5):JJ
MJFYJ;!:+NWM[)>WMG>7EPK=O\TI+RUN:6SL[NL O*2E[\N3ID:,I6[9N^^;;
M"7_XZIMY\Q=9K%Z[V'CI*O,U(, Z:[N0T-U'4TZ6E%8U-7=453<4%94+A<*R
MLK+2TM**<927ES<W-^OI]6=.^>MV^\?_"1A@@ $&&&# WX_Q<R1TYT<-#<K5
M0\JQ42V,:?7U]0*!8,F2)5.F30L31#2WMFG'/HIJZXADJI'18AP6 V/_J'9$
M.ZQYGO74;;OK8J-%RY>9K;-:NV+Y,A*10"81K=:N,3%>;+W.:MO6+;?2TU7*
MH>JJ*EYPL/G*5;-^F.GAY@[\)"YV#_BKS2V,C19O<OR11"#>O7-'+I,!:4 '
M(2=/G&BQROSZU6O]?7V=[6UW;Z=O<K2W6+7\9%JJN+-U5*O.R+ACM7:UN[L[
M!H-)2TO+R,B ^386B_7R\MJ\>7-B8F)O;Z]8++YY\R:%0EFU:M7.G3OW[MT;
M$QN[-R$^8G<DC\_'XG%KK*Q"0D-[>GM'M%K-R+ 6ZC\V.C*JU>IVYX^-V_W6
M2@<'\TM*#Q\[[A>$=';W.'W^@D0F5ZA44KEL<$C9WM'Q.#.3R6:MLUX7%;7[
MR9/'3Y\^A8+H='ID9"3X=^_>K:RL;&UMO7+E"LB 1"*]O;W)9')(2(B)B<EB
M8V,G%]=7N:^[>_OV)B1:6*[9Z@2%[-AH[S!_P<*0L/ ;/]U$HC%SYLTW6FR<
MD+BOKZ^_L* 0$1!HMM1TP?SY<V;/YK#928F)(3S^T2-'G)V<(,<],;'#:HUJ
M:*C@PP<*A3IU^HQY"Q8Z;MH,77GYZK739\^]_U# 9'.^_N8[%U<W*+J^L4G2
M+SU^XN3,67-66ZR^?O5*?U^OI*_W]JUTZ,JPT!!@EG0:E<UB!@;X.VW;:KYJ
M)73T!IOU1P\?JJFI%G=WG#I]<MTZ*VOK=<>.'7_PX.&)M-,/,YZ@4%@VBQL5
M%2T45DHD?9F9CS?8K3<U,W9VV93U[-&G3R.MK0V7+I]ALDAHC/_Y"VG1,:'9
MKYX<.[Z?SL1M=]_DY>,2'1/R\:,&^O'&C1M<+C<^/CX\/!PZ]/[]^Q"&Y@6V
M]G%\OJ.WT@6SGGZIM$O<?>_^ P:3Q0WFO<K-[1\8T(QH]<?T#JG4T@'9H'((
M+J4# QF/'J>DIMZYFW[MVN7R\K)+ERY*I0/-S6T9&4\<[#<O7&#,X?#E\D&-
M1O/NW5L$(L!B]<H=.]US<]\ (09:2*<SC8R,UUO;Q,7%R^4*G9V0P:&FIN:4
ME%0N)SB8RP.J.*P9T2V#UZC+2XI9=)A-D D8S)!"H7NM.3;:T]5Y_LSIJ A!
M1&AH_KNW8\/#-=55/KZ[5IJOHM"H+[)?IM^^U=S:(I'VC^IL=OZB/1K].'[^
MRR^'POR;*4'^\3 HCPSX)^!?[;'[2_)\7FWT><W1^)X=-0R%.<^?[=L3N\W1
M/L#;$QL42"%@L4@$"8^A4XAT*HE.(]/'U30L-IT;S KEAX4$AP>S0X+9?!XG
ME,\-Y;!X#!H[T ^YR\LOP#<(AR:P&5Q!:&1X:"27Q<=AD"0"TL?3#1R9@/-P
M=?'U\GIPYVZ?N&=X2"7M[1U2R!E4DN-&FQUN3EB4'YF(P:*# OUW!?CY8% (
M!IT<%LJ+VBW8'1D6(0@1A//ADA_,YK(9;"8-'(M!A304,H& 0Y,(6!"52:=0
M2'@"'JU39>'1.@T1E<0<5S.-*YLH- H1CT5A=8)A]<HC,A''H)$A*Z@OE4R
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MY-MO+&9,MYXW=]6TJ4N^^V[9]Y.W+E^VPVKM^0/[VR&SK,R>TN+J]WGY^1_
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M,$$A@"404,J)RF)!@9E<+B2#,(/#8?%X"/_%9B-<$I,%\6@D&L]@<Q#FR)4
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M[6V1=$%\>TO/8+]:/J!I:Y96EM;6E0O[NV2#?0J]U@2MH3.9C':;;7C(.NQ
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ML* 8+G>Y/-NV;E_PU/SA#SW4[\[?S9C\IV?2DV,6SK_Q/_YCW(CA>W;M8*$
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MX_:180G=#L^"]#D> _ '*/;&5@M?$5*'7^P=$9%_ HF 1S^S_%I75M=LP(_
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M3K>'9EF*8>$GJ"Y>9.S$BK LYQ%&(2*H*(BQ) FA,PPR (*K!$G&P4! Y<#
M!UJK!WL39&($1*0I5A(1:"(@O84<$@A 0$B.,.(@$+>@'BW[*O ([@]M%N6@
M&$"160EN)06"4 >:Y3Q^"GTX0YYW,B\%L%^;3',2(\A>6N;E,.*.%!$"QTE!
M'R/[F0 OA2#!3RD89H00G(#4CV (&N_WT5 +CA-Y3D0$C!@$@<?"0$DL3],,
M D2@CT347%;@L5D24EM(T&4_0[N\'H1VP".0H1JL $\6TP#!S4%A@U9"A_+8
MI4L4))X3L/.4A$&G'CR(ICF:9GO@)!2##OED05=!!\)301_?0*$4)8_'1U$T
M=&ES2_OA8R=2,Y]^=,*4P7\<=O<]]__FOV[YS]_<])\WW'SO_8->>V.]C^(H
MEH<!0[&BV\=(V)@(UQ$T3)X8^Y!!2,Q\>@$CXBG6:_@3Q @FV2&$!C1-]YHF
MP7V(]1ST)+0%=13&C(@I$+XA:@ZR0A(DOY^"?&BISTOA!K*DK- 5LR8"8!%X
MD=BI07U"&//"H!(\(P&Z)83*PBZ'<@ ZAT,]@_J0@3ZDV" N%Z->R#:*87CL
MDB9[O7Y9#F*02(0GCK"A0 B!7#3\,4AA;+5$P*P0IB2+F!U%)!0!CR+R [G6
M"O#JET4O]BQC[!K6][+ P<M)Y-B6RTW'CQW=MV>WV:A?MB1*D1BO4B:J50JC
M04<@("MV23-:#,3:R&(S6Y.3[#CLFBW92G EY->FU\ )%IL%&>^@8%X6#!L1
MVB/BOV8P)5F248RS-%NR'07V0H1'&F.246-0IV:D)*>E+(V)R5R^XMBQ[^"-
M#._$BQ>;7G_UC=$C1S\V=IPJ,<&69$Y-3K*8383JR&1"6!!!;2!'K]?K=#IL
MV:.#GX0_.ST]W6JW&: F5UD2$=C(CJ$?Q)F=F8&JA,UP2!0V1 .$ ZZ9DY*(
MJYH1.;+I()FP%U@/NH0MF*R8##LM+2T#"Y0(V\S,3-@A#-F$#LEJM9(:ZK#Y
M%8FYIE"IXA(2$I4*Q  %^28C%*%0*:&JJ&?,IIBXV#E///'::Z\U-C8ZG<[.
MSL[\_'QHVI0I4Q8M6@2-)?964 JQ;TK"GG=&BUF#L">52J.&6R&R)]Q>:&8Z
M5"PSD] >$1#-9$E2J+312V.?G#?_D5%C)DZ>NF=?%J$/(''68/8$Q:.CJ_O<
M^0NEY14EITM+3I6>/%ERJOAT555-8^-EC]L' PI''NT)RDLF=3)9NESN]>LW
M#AHT^):;;YTY<_877WP%.3#5,DS/M[(?)/R!128FQ/7U]1LV;% H%&^\\<;Y
M\^>);3#,TP3@Z$4ZB.J&F0[1563 AZ[ZZA+J#9HK@WXF@_;A8;BF]L[:"PW5
MY\Z7U=2>JJBJJJNOJ*TK*BTOJ:R&'#@$/]__=//C,V?<<-/_61P]OZJZC**]
MH&I*(E)+X*Z@>W(LA_ R":EH5[[\A*\EO\C[(2(1B4A$?L42 <'__\C?\1&B
M=Y5.0!;R@4@.A@49)5@URZ%P8W/[AG<_&/O8I.AE"=DY!13+^V!-3B/K&U9
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M;C]-L2@6R=GZ<RN?63E^XO@%BQ:\]_ZFNK.UZ$:B%)+DD!P@<2["6.?KX5/
M?W<_EF!D,1.1B$0D(C^W_ T5*"(_HUSG"OE_P2.BA?[O)(CG3)@Q>4&F&4%
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MPT8P B<H @Y"/0SV P*@4.+B*,_PS0>LQ3F$![WY 6NFNKJVJ<G@\P9"H4C
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MT*\9_=TW_</((/#@Z?5Z+;AW<W-75Q>0W^ (:*O5ZOKZ>J52*9?+52H5>#:
M+H5%* /_^\ OLA!">+CQH*+V0?%GC^]106C^0_@A'K;O]1]]_8<0#S0T3,'
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M)LQ'L.SO&QP*16(Q%'/4=K+SX/.'GSMPZ'>_>Z.SLZ.[N\OK[>[I\?I\_8$
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MAPO#ESU*5=[6WO+PRN4K5BS3:%0FDR$O+S<]/6W^0W-5JGRU6NGQN!!>8S;
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MS2]M>WWK2R\\]_9;;S8WUH/2P)H-#X;@WX<'PW24BH0QQ%7"<BV-31^\M_/
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MSP;S@T=<-L$!WY:7GI=F9RR8.VO:';??<N,?KOFO,=/NNF/'CAU@RX$^"8*
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M<,0CCD6.BT:PCW=]^.#L66-OO'[<S3>-O_E/CZY96>1Q7GGY91,F3'CGG7?
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M!P[B GUCXCM@UMF>SW]6/XJ/T#PESTC6]EWD"/J"Z$D+AD4H%(H( J:&2!\
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MZ9*2X*MYZ6E9"Q>"6H1B,:*+4LCG1$?%S(W??^!(@]%69:BW@-G!2;/9!O[
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MG>;GY]>J5:L9,V=NV+CIX%>'C68+= 5Z!42C:&97TQ.C[F;JE#R%D"B7!YP
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MJ<EDH6DW>-$PN^L0$!@0$#ABQ,C<6[GLDUE45/355U]U[=IU^O3I24E); 5
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M,_?2CY<IBMZW[XNPL/"HJ)CWW]]\^?*5JBH#[-/8:-JZ=?N8,>.7+EM96]=
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M1[.B76AC&"S$)(F%PP1)H>?.GUZY\LVTM)0Y<^:DIJ:*Q6*Y7 X\D<ED H&
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M,BO*RO?MW:O7Z6#,O/+2RT:]0:O1='CHH2?Z/3YKQLS"_ (Z&%XDRCC9#-&
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M\VY56FMP+-3D]+[[SMK'^CXQ:=*4HT>/,3&=0SYOH+;&_M57^U>O7GOTZ'&
M7@B" 8BZ<3UO_?J-LV?/[=RY4Z=.'>YC:-Z\N0</[B\N*08 4UI:"IAYS.@Q
MJ]Y=?>W:-1PG6*5O G =&?*C1$%Q^=9//Y\^<^ZPX:,U!LMK;ZVD;=9B<3H:
M'4%5V&I,F3GM.CZ<SA=?S2OTHV2CV__.F@T3ITY[[>V5)[X[7^=P'3WYG<9H
M@0LV;=FZZZL#1"0."2-"[B;7AG7KV[=M!ZE7CYZC1X[BIG,^WKKUX/X#.(J%
M2.J+SS_OW+%3V_]J,V;TZ*_V[?-X/ "]4!1%$,3G\P6!:RCJ=#HK*BI6KES9
MNW?O/GWZ=.W:]4F&UFU\SX6$G7Z<BL<1*NP-$J%HO+2L2JLUM6_;H7O7'MTZ
M=GFD0Z=V]]W?N4W;D8,&KWKK;;AM[!=G0% 15 %(=.?.G; 7Z]NW+]R\8\>.
M;=NV[=RY,\O&^^^[K\>CW34J];%OC^[X;'OOGKW:M6W;[9%''GS@@8>[=.G5
ML^>$\>,+\O/A6?Q>'PI=3$5"3"P@9K_#&*]%X@"&LS(7<])YY\[]0! AUI\#
M] L@Y'=6KAH^;.0S0X=-GS9S[-AQB8G3IDQ)>.VUUZ.T+X40=+K'[86U *[<
MN/&]M]Y< 1N*]>O73YHT*3,S<\>.'? XM'H41?UO,< ]HC]ZBK<23:W"HV:F
MNYT&H7\3&]T6'OWW*0)GK ]A-(A$PY& ST\1)!((%A?=,NCT\)9Y/C&1DY9N
MU!OT6IV6T=51*U6T#V7:,;:8=8S-.J76:-1WM%2T&ATDC4:O4>LT:CJPF<Y@
M,9BS15(51R!9L"AM<L*,XZ?.?GWHV^OYMS[^[(OS%RZOV_A^87'Y!Q]]6E)N
M^^2S+R_?*+]XO?QF2=V+;ZP]]U/!!Y_M.WWQ^H'CYXZ>O<25:0Z?//O%UX?W
M'S\ITN@7\@2SDE.5*FBMP:BS"/E2C4HO%2MT&I->:X8C)*W:"(4JA58A4\LD
M2OA5)I-HU(HE.5G+EN:L6?UN=E:&D,]3*17IJ:GSY\U+7I2<DIP"SWOPP(%S
M9\XV.ISP J53A'F-WM8NN=TIL">/1,(>C^NCK5L$0M[X"<]-39B4EIZLTZL-
M!LWBG$R56J[1*F6T<RB16JV /!P5"BDDR.L-&JU.I5!*9'*A7"Z2*X"KM.H/
ME\=)3DU9E)*:N^P%4T;6RE5K3Y^[L&/GOAN%Q0@1)LC_H';T&W(!:#F!AU$D
M%(85B7;I1UN)P[-\<_CHQ F)LV<M% KDJ2E\J40MEVG%(B6<BD5RJ40I$2M$
M0ADDR*M4>IW6;-!G&/06K<8()1R.,#F9LR@I/3D]5:*62#4T=^':=+Z +Y2.
M'3=YP<*T,V<O!@($$J1-NG",_G;!N!AOGG%^-_>YK1-$4=!9_MK:AJJJNMJ:
MAH;ZID:'V]% NSIJ:G*[75XX-C0TUM3455716DC%Q:5%1<6%A;< ,Y66T.*D
MDI*R.V(F*($+ &8YG2YF@0S?:^$15( 1!$:1Y;:JS1]MX0CY0T<,&SWNN=34
MU(,'#P* <+O=<#$\3'5U=2 0\#$$P 7'<=:$[;=9?;?M;"YJ:>UI:=1<4Z.E
MT9_UN9J+FHL/]YJ?OW;_?_> WEPU-B^UCK=6:LD$(S%"6PC<3G0 C4@T%(DZ
MG$W6*MNAP]]D92_6&TV6C,RUZ];_<.%B8Y,K&J>C;= !-R 3CI955*U\=TU.
M[@N+ERSC<(7SYB_:_/Y'#J<[$$0Q@L1P$L-PGR]06EH.\ 9%L8 ?H7WI,+C7
MYPW<N)YWY>=KC*0@$@J%493PN*&PX.*%R]>OY55:JP%;UE37[=JY[]C1$W6U
M#1ZWCR!HLS6H'O[KRR]V[]W[%6 DP)]0$8*@+I<+$!2&$>%P%.[O\_HI*D02
ME-U>_\7G.]5JK<EDR<S(SLG)+2^K"(=HGSZ 9U@5'H_'[7(UL7[#8[$(11$8
M@9&1J#> >H.0D,H:>V5U76E%E=/M!<R+49$@3N%4!/(-SJ;O+UXN+"XCP[ G
MBL.QH<ES^-OC>[\^"'F4(/]^ZLQGG^^$6_F"&)00H3""P]]X0T/3K5M6J[7Z
MU*F+QX^?W[CQXY,G+^S=>\3C0<+AN,/A/WCP!(^G2$R<]^VW9_Q^XHZ7 %;7
M,LJX* )@AJ)H8V-C7EZ>P^&PV^VUM;7EY>6Q>!PJ\OA1/R UD@XIX_.CP/R"
M_&)@Z84??MRX;M-WI\YNWO#^N=/G=VS;$0U%62='%$6Q;U?V-0LX]9-//BDK
M*]N]>_<//_R0FYN[=>M6V&]\]?77+RQ??O#0H4/?'$9QX#I>;JW8?_# I<N7
M/_CPPRM7KZY;O[ZFKI;=(?[#&R[=;%IA'Y M09 ,@,>0(-R ?;I?E-F9($+P
MG]#C#H?SAQ\N>CR>"Q<NN=W>LK(*'"-IZ1Y!P>@*PDXS2D>I9G7?"8*HJJJ"
MIL)3L"R"_=1OKO_WD/[@&=Y*#+4*CYJ9[G8:_(;P*!+[AQX*[<4--I0D[2V;
MP'$TB)PZ<=)65241B5.34]0J%8_#%8M$<"H6BG0:;58&'5Y+K]4QX;_DC-ML
MF4PFD4A$+$FE4@4=^$RCT^IU6H-6:X"C7F?D":5"J5(D526G\Q>E\HZ=.'/\
MY%E;K</C9]_.,92 UWHL &]NYK31%W*CL08OY?!%?&0<C\6#X3@.BU"0M'O0
M<KO31Y"- >2377LGSYHS8?I,/E]BT-&BHMR<Y29#9E9&#BLSTFF,6K5!JS)H
M5 :U4J^2L_(C%9_'E<O%!OA%*5O^PE(N)VWTJ!'3$A/24E)4"F5::BJ/RTU-
M27GEY9?S;N3!JD9[^&-E\+\X7696T!#C+1M6CM"/ER]MV_8Q\&3FK&ESYL[4
MZS4Y.5G+7UQJ-.IT>K54)J)%2!JET:2S9!CAJ-8HE+3<3:G5J2#/"H]DC/"(
M=D,N%0F$@C0.1RB6I*1SE!KMR3/G;74./P*+8-R/4G00BW\*RLYF?D-X1)*1
M$$6+C<+ :H0*^HF '_=Z4+-I\<P9\[D<D52BTFK,4HE:(=>9C=EF8Y9>;]%J
M34JECI4?P5$AUZA5!JW&I-.:M!HCY)4*'1322:/BB-+Y$CYP6JI2SEFP<,3H
MY^;.3SYT^#A!A&GP$HLC00Q#<1AXL#S 4M$LX_QNY@L3ARX6I[^D>0(UU?76
MBFHX-M0W-=2[:@!J5,+ K[;9:JIMM9!8V5"EU59>;BTKK8 CZU&[L;')T>"D
M)4U.-_Q*2Y1*RZNK:YEU$;W7#K/)<(@(41A)!C 4($FIU;I]YY=BN?2^^^]K
MUZY=1D8&X)+Z^OJ2DA*OU^OS^4I+2RLK*Z$$3F&LLIQGW2O>+4OO-;6T]K0T
M:JZIT=+HS_I<S47-Q8=[S<]?NS_[D:/ERX]:QULKM62*,%%<[\B/(!-FY$<P
M0%$,#R(H%0K[ _ 7!7#O\P=\ 5HHY/$% 3,&$,+M#2 83E#A)I?/5FVOJ6VP
MU=A='A] ,Q0G@PB!P@X?IY/'XW.Y/!B&HRCF]?H# 03'697J&.S\ W2 +,3M
M]I* U"-QUIPN&$#M=8VTL(GQ)DD288J,>CU!2!A&X1B!!%&_/P@7DP2M<X0@
M&$%0@)=(,@30*!0*TZ97H3#< :J&>G\16\3\OH#7XX5I"/_N\_D!;#L<#@ V
M &;\?E]]?5T@ 'F$"A%D"$ 1[O%#6["&)C>"4R@9]B,X9.A8;#@%>6\ #6!$
M$"><;A]] 1&JKFNHJJD#*(7@!+2+"$5\0<Q#7T:RHB4<GH@*D^$(K8A#Q0'-
MNMUX(!#&L#AP&L-HT9#7&ZRN=I:45.ETV8,&C<S,7'[TZ&E&OH;B#+'*1X"^
MV.<"  :/ (4$04 &.A=^<D$/H= _4>@O,A2!G@VB!((0P%[@#!*D@RM#]X>)
M2(2"CH_%0O3V#?XQQM@30 9XPMZ-=8'$ZB6QIU C- /!4%8P%**9'29#%*VZ
M%@D3<),X'9.9@89A%+H0=CLQ.O1O](Z6&[W?H>W.V(V/EY;TA6&TP$B (_2C
M!S(TP S1K8]$,)2 (51=74/W8R3*7@.UTM[6&2_L<)G?[[\3_IC91H4!IK9J
M'OT/IU;A43/3W4Z#,.,>^U_%1K_(%YA7/NTDFX[@#B\,@H1I##]]__WWUZ]?
M7[)DB40B24E),1@,BQ<OAAVI0J$0B40*AOA\?GIZND0J5"BE*B;FFE@B$@KY
M8O$=R9':H*?]1.MU1M;GD4RF3$KFI*0)>O5^8N#@86?.7:JHK$-Q B,B+@\2
M1$(>+U95W>#S$X$@!0DG8YY@U!.,$9$X%:-3DP]O]&)>-.0*X*X@AD>BUPN+
MOCGQ]X6<U"1.VH+T%(% H%(H<Q?G0'IQV0N99DN&V6(VFHPZ/223P6@QFB#=
M,5TSFS0OO[3DI1=SEN28<Q9;5 IQTH(Y0CY'I]$L69P#*=.2D67).K3_L+VF
M 4=( B=9W\,L ]F7-;R.82&%0M;O'9?+34A( /X  W.7YN0N6YR1;;)D&94:
MF4:O5.OHI(%$YX%-4DCL*5S F,W)90JI5":1R65R)1V[#HYPHM$9)DY)>//M
ME=:J6H^/7EY@P86W_C^_[Z+_9AWPK^,A3,L>8$5 $8(BP]#[5WZ^9M";Y\Y9
MD);*%?#%"Q8DIR1S(&,Q9T&Y5JLW6RP&DU&CU2J42JE,)I7+9 K:>DVA4M$*
M9EJMSF"@#=@R+)",F2:-22M3*Z0J9<*,&5V[]TR</OO@X6.-3A\.<,$7;')Z
M 3?\\G6"^*.$1\Q7E!BLVHV-;EM57:6U!HZ02DNM!05%>3<+;ES/NW$C#_*E
M)>76BJKR,FOQK5+6, U.6>D2I'J[H[[> 1FKM:JZNA80#^ >8&R([I?_%V9K
M"('[D& H'OON^W-+EK_PQMMOKUNWH:"@T.&@@\%A&%%375MIK:JKM5? 9*NK
M;W*ZW"Z/V^T!!(:A.*S7=\O2>TTMK3TMC9IK:K0T^K,^5W-1<_'A7O/SU^[/
M^N-H^?*CUO'62BV9PM%X"%(L'H84IX^0AQ*<B@0QP%81@(:-;I_'CR!$B!5\
MT)*F>)P*1P T_B_VOCP\CNK:\\_9WIL-F.$EA)" C<$VV,:[;%FK+:G5VEJ]
M[WNW=LLV!F,(27C)O&22F;R$?"1D>9EO\LV7E[Q B"$L"2$.O/!AO-O:U=WJ
M7;UW5==>73WG5DE"7F2[P<:VTN<[+E]5UW*W.O?<WSWW'*Z(EO!(FJ$8%IBD
M69R@D,$11:<R.=#&/W)E7YJ#A"@*E%Z$=[ ,QS"LN/<J3R)-&)0WT*-X'",R
MZ1PP0= <,E"2O&HB'4]ZCF1)A+ AFA.#V$80$L$7Q;BT/#P<%!5Q(1:YUY$6
MMJ0CAFQ;0,/FL1R5S>#I5(Z$C-(,09 ,"A4#>2 +!%8J\313(,@<*)4T0\*K
M( <TR^5Q>##4 ?(-FL,)F#' >6!>K#><I+)Y#'YEH);$:J%8#JX'W8V@64H$
M3N!*@F:R>1Q.HKN*(E17A(>70-%+(\=$<$$1(_@L!A6(1V=3SW[UF__A;^^Z
MZ^[[!H</!2-IJ"1)@"S4*D@_4'W3Z70T&I72V6Q6BI(FFMOP'$L+Z,U0(2S\
M*D .D8-.AD?UPU$D#T>DP?(EEA4(@D-XD(A)20Y,X5VL2)+C@@5S)RD-DI=D
M&8IC,9) 3M<% 1+)3 9:+I7+SJ:3R#:(94&1A9_@,APNFQ?=Q>)B4Z2Y9THK
MD1(6!O-'L=] &8L(,2-HZ!OB;(D7FQB=A#D4W(B:E6+%!7A>LH6'"I&<+<!D
MJN+SJ$(5\.@Z4[F?05G@$4A=$,AOOOGFZZ^_OFW;MA4K5K2UM4D;T"PBB3ZP
MD8,>.&JU6CBCT:AT.K7)I#>:]#J]5J?3F,UFE\OE=KM[>GKZ^P?[^@9<+J_1
M:%&IM(HN97-+QZ/KMZS;L/6EW_P.Q(BX$@)"GR^0? ZC*1K&E%(Z4T#8--I=
M7&2*0HX0,G@I1Z#]QHDL46!XG!'(HI#$B#S%Q#+9__W"]W_]VF^'GCB@L1@U
M6HW%9/8X70.]?1Z7VR5B1GW>'FG#'9SI]7C[>GKG$"6GRV8U[!WR>#U6C]O2
MU2G3Z[H-.I7=9A[HZ]NW=_CPH:>>.?QT0VW#WW_E:V,C$X4\6< +4C0K29A*
M0#X(NU0JE<_G3YPXH5*I&AH:=#J=T^DT& Q6N\7;YQ[8VXOPHSZWTV.WVDTZ
M@[I;U:E4=VGT2IU1;;+J[2ZKTVVS.<QFJU%OU*FU*J6Z6ZW5&$Q&J]WF<#F]
MO7U[FF5:O?GHN^\S:/6#P@D6I+$(4A07=X\K@T<P"#$TBKO),I NSL;3OWWE
MM1YO?W5U7:NL'5YH-MD,>K/=YO)Z^OK[]_;T]MN19W$'9 /MLD-F9B8#:F^#
M5H\,T71ZO<EBA@NDRQQ>E]:LUUM-*H-N\_;M:KWQM3?^,.T/9[+Y= ;+YPMB
MU :T3"8M-2PEJ:^7N+_LM9+]+;P<ZB&7+01GHN/COM'1J;'1:9]O)A@,CX]/
MGCY]]L3Q4W"4]J8%_,&9F5 X#,-]/!2*^/TSDH'2U)0/+IZ8F()?DPF$'*&5
M%E#?;O"V-1:^5XXC&0:GT H?)AY'IR?/CXV)V_&RD*7)B:ED,@UZ7CR>F)R<
MAIS'8[.1<-0O9AM*D<]A%?#HMJ/K]6G<:K1<RW6]Z'K5PXVNSZ6>S\U3!3RJ
M4(4^-BT%'C&\ $>,(#'0"Q$.PI,,7Z#8+ 83=AKT$8)B)%0%*Q"B\9$$'J&3
MK+CQ30*8&#&N%HO,2:A\'A<1"5[4EWC);$1:.67@=O%.:9T,9A(X3F 8#N=!
M_Q&O03'=T2T4"RH+@C]$]]BBH0J5S>0E> @2N2Q&(RL507P1CYY 4-(*',^A
MF+P\VC>!( EX2RZ'IU,9$6\B$')4@'N)/)8A*5!FB*( )46%A:S!_$*"D# H
M/^@YI1*4.C:+%IWASAR&(V,KBDKG\C17)!F.@/O$S6L4RZ&Z%01X0BJ;9\3*
M@8= O<'TA*3Y=);*%Y"]4BH+U0A5#7?!42#H8B*=^\6OCG0J], G3X]R(FP'
M0H^<IX7H)4413I+2DB=*"7\IX#@"Q HXJ.D,<BI1%"N=@SJD*0X!6M#6-)?)
M$@PCJK*B\]KB/#8$SY?<<DLOE1(P9Y$$+\H O(YC<P4<)H8DR^0('"8$#,\3
M#.HVD,!IDBGR"&#BV0(-)X4%J(CG)>\FB.!UI-@A)+A'<J**2D@@S CR*5F3
MP=V0R&1R(LY8%/TEB1 2A?9,X"B4&YH%2$ORB40"QW')8$IZXTVAF_N!5TBB
M"GAT%5JJ^TJ?HK H(@E_H6MD05B\0K#D9\:+@3WG8C-(6UA%DN(NL31=Y/A"
M'H-C.I'D&(1;S\S,?/G+7SYPX$!]?7U?7Y_)9#(:C7:1)#?8#H?#Y7(A6Y/>
M7J_7[?6Z>GL]_0.]0WL'AX>'@ 9$@D1?;__^?0>L5D=[>Y>\M:.]K>OAU8^N
M7+GFI9=>_?%/_J_/%\9$P(CE2GSQ\CP?EA2FRT4>ILLTDE@P.Z=)G"(PEL;C
MT9D?_?![:U:O4"O;70Z34B5O:JEU><S>7IO#932:E$-[O7OW]0P,N8?W]0X-
M>_<=Z-O_>/_C3PQ:;%J;7>]RF^&" X\/:G7=6IU2IU-9+":GT^YPV,62.NOK
M&QUV][%C)V/19#J5+Q2(!;DI81\@/24+&I!W;[SQQC///".3R50JE=/IM%JM
MP_OWNKQ.J\-B<UFM3HO%859JE2:;2:U70Z)3V0%IG5&K-^G@C-%J,-LM=K?3
M8#$I5,H6N=QLM2F4ZO9.Q;KU&[4ZXQ_>/EI 2RZ\&!"O)&)]2T[^EQ"+?('(
M85@&PS,, V4ACQY]^\E#C_</]#B0QR6]5J?J'_ >?&+__@-[^_NA=6U6IT%K
M[%;I.C5&A4+3IK>H]&:5R::%\U+"XM [O&97K]7N,1EM1H/-XAGHMWL\\B[%
MRH?7MG6JWOO+,6ABZ%P<)[IZG.NZ: 7H9JPN"/,^_Y#C*H;FL3R9F,T&_)'S
MYR9&SD^@4&OSV]:0,Z.Q"00DG3AU]LSYB?$IOV\F'DND4]E8=#8<BH9"D6 P
M' G'9N-)&"!A4!1;1) 4G27XDXH(?M[A/5/D:(2 %:DBAU%DEL!G4ZFI*1_D
M>6K*'PB$Q%SEL7PAE<P@+TZSJ60B#3F';">3:1Q'H_]B42/,NUW\%*(@+=D\
M%:K0#:";U=\J_?S6I/(&C5L/I+M9M%S+=;L0+Z%%U\Q<F<QRHE?C>>Q& H:D
MO6,25'017V&'_F69%RW?$7/%C_R'7ODN_A*>\S0*4R$.\B4R(S(M[N%;<D+Q
MR1F]3UR2OXB9(@)E"(;&:;+ 4!0*RXQ0KW)U7*$(6C(M,C/O;H2?^T7T5"U:
M/\TQ*^:GK.?#LRZ;?V1D($VV+N3R=71A*=6WW/74,M][W43TC:9/]/W_U5 %
M/+H*+=6]%B-$@KB758J4=!%^=/7GB/#+'(2T"#SB&!;'<! D-(DL5D%"T 7R
M]/&3)XX?_\YWOC,X.&@VF_?MVR?%"/-ZO3J=3J_72]'9@9Q.)YSL[^\?&NH?
M%'D(\<# 0)_'XX$+X/:]>_?NWW_@R2</.>RNKBYEU?;JZIVU&S9L^?T?CC(L
M%PK'4VF,I'@,IT'87P$\0C:FR#\P,K?@T=XZY*Z-A7P36)&G:1(;'NKK:&_6
M:[M4W7*;7>_V6(QF%1PA/;RO]^"30U]Y[JG#SQP8W.L9VNL=&'0?.KSOJ</[
M>_OL=J>AM]_9V^<T6W0FLU:G5SF=4$";3J\Q&/100+/9<O#@DS_^\3^]].M7
M8M&X(-I82H@^AF&2E2FDH5W@SV/'CKWTTDM0!6ZW6PJCMG__?I?'V=/O[1WL
M,=M-.I,6TE:'16O46AP6C4&M-^NZE)WPD\&BMT"=V<T.C\MH,9NLEFZUJDNI
M:FF5-\ODF[9L._S,LW_\T[N^0 @O0'4A@U481<1-[^5)0)HA68[BBPQ-%S*9
MA#\PY>UQ&4VZOCZ/5J=R."W0>FZWW6(Q&(P:.*JU76:[SNXV=6O:-(8NG4FI
MTG78W4:376NT:?1F%9PQ6C6N'JO-982$UJ35F8UVC]O9T[.CMJZZKO%?7CZ"
M%5B2*K*W$G@D:3 ,@[;OI5/Y6#3I]X5'SD^<.7U^='3<[T?V1P@5BL1BL=EH
M)(X0I>G Z=-GCQY]]YUWCIXX?BH4BL"OB40J'(Y*ER63Z5P.A;-E&1ZI##<2
M/(*O@>$Y2C0_)CFT?!1)S/I"P6 D$H\G$<<2P1G(61PY_TYE( $<"D;"H>C,
M3#@0"*62XM9T!'LR"_C17 55P*,*+3NZ6?VMTL]O32ICQ/A8[;5<VWVYENMV
MH1L.'B&K(@YT&&X^P);DJA)9BTN@SX6\X "T#/ (N<X1P2-^&8%' D_Q"#PJ
MT"B,"=H5(/!<!3RJ@$>?.)]_G50!CZY"U]*]))LCBJ)(DI3<W%Y+I.V%!UW4
M527((36;X%AN9MI'4[3 <C1.Q&9"_O%)L\7<+&OIZE9XO%Z3V6RUV23O-@:3
MR>9P]/;W]0\.N+T>F\-N=SK<*%H[LCSJZ?7T]??T]R-3))?+9;5:^_O[GWON
M.8^G9VAH^+O??7YP<*]6:ZBO:_P?7__&0/_0V.AX-!)#/MY$-VREI<6**#U%
M2<K3)8XJL83 %'@*!\;2\7PR/G;VY O?_5^J3KE>V=7KLO4/NIU>\\ ^K]FA
M._C4L+O7UCOH&MK?N_^)@?Z];E>/=6#8Z_1:I*/=8[(ZK%J#?FAX>'C_?G>/
MMU.AT)O,%KNC?W#8[O0\]?2S32UREZ?WS+DQ7R <C:?0;)NE2*H S+(TM$Q1
MP@E*I3-GSK2TR-:N?73GSEUJE5:CUMFL4&/] \-#%H?MP*$GG#T>D\VJ,QGA
M3X?7W3LT8',YG5ZWQJ"W..TVM]/=US.P;__@_H,FN]-HM1LL=KW9UMZEVG_P
MD$IC>/J9+X^-33%,D219'",IDA7'I3)')H$CR"S#X"Q'G!\]]:UO?]WCM5FL
M.I?;8G,8]0:E3M_M=)F]/7:GVV*VZO1FM5+78;1I+"Z#P::!!*HTET%C4EA<
M>K-3KS%UP[%OK]LSX'#UV9R]+D>/5VLR[ZIOU.C-+[WRNU2FP(IH%\LA"UMQ
MJ)!</2)%!3E__+1) H^0SR.&X:$F4ZE</)8*SL0FQOVG3IT[<_J<;SJ S(ZF
M \A)4"(%/!,(C8R,34Q,O?_^!^^]]Y>I*5\X%(7SP6 X&HW'HK.S\60JE9'
M(X;F>'$/_>7Y$XL(T?)H?D=J2:!X+I7/30<#9\=&SHV.34[Z X%P.!3W^X+A
M4"R5S&)Y,AI-3$[XQD8GX0@\/34S&T]!V0LX21#$0IR.N0JJ@$<56G9TL_I;
MI9_?FG3-X\7';*_EVN[+M5RW"Q6+\SZSKXVY"]U67)V+\\C.)69!$M9S*9?W
M(?'%A9C%UX0<7<Q"\6*EEY]#D>;X!JN4 BBSU&691;Z2<(K!: Z'-">(YX7R
M'#^+-<( (SQJSND(_]&/J$T7(UDHW%ZY)9 4R$M9FBU>PL5%=7LMS"^E^E;
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MT'D4,$8@6!HC"7$^(M!P#M4D5"X/$SB8$?"B.RA6C#=$%UD&;2Z!C*+]"9S
M43Q:I&=1HR#O40@ME69]\WRC^V&%;@6J@$?7F<K-/\Q688;.H0DY2Q%D$<VS
M.03FL]3DQ.COW_J=U:)7=K=WM#?)90VRYKK'#PZY/;9#3QVP6/4JM<)HTK6U
MM3J==KO=:K-9;/#/8M'I=$JELDNDCM9=30T;E8K=G1T-G=WRMJ[6ZH;Z'?7U
M7WSXD3OO^4+=GK9?O?+Z3W_V_WR!*!)B8G2 Q> 1B#&FB/X$,9G(Y&;368)A
M8XDD <*U5,)(BH/_+P*/1 :Y#A(2*Q1S&)_#BAA1*M E@BFE,"J9)W,D5V %
M@BMA=#&-T[,Y(H73%%_,4UPB1Q L#[\&X^E(,A>)YPF:(YE2+(%G,;9 E5)9
M"B-XT:"$B\YF,3$K)%V2?/<4"K0HAP620/&V6!:F[DP!)],H#AJ33*9#H0A)
M@@C& OX@,(J:'HVD,ID\#E=1!9I)Y?%$#L^2;([B4P2;P)E9G$T4^!0II&D8
MF4H8 =F D:.4P^E4ELSA3#I'9G$J3S D(WJ!X@6**[*BUV[V8FQM'CQ:A!PM
M!H_R)%1%/I'/94DB1U$)* /#X) KO)!#(49Y:( <Q6%,$8YYBA<A)'3$&2Y'
MP@4LBB0AAB$%AI\@#>?A@DR! 4YC!$'3,-"1- /EI5F.1:LD H6L<UB*H9.9
M5 Z'=H !%-E0066R,%80+#2T!!LA+$G"B1@42PS2/%Q*SYU'^",G2'9,# NC
M+XSY/$&RT$CE@D><<'DF&2&'\YD\DR_ " 9_E@H4]! .VBZ1R<22B5P!ZH#/
M8+E4/DTB1!2%V8!^@I$TB8*U<B3++?72JX)'%^%'<(0A/)%(X#@."3@N_KJE
M\1MTA4PF \/\S,S,]+1?#+(V<N[LV.1$8"80#<[$) Z'9N$(YT=')OT^A"*-
MC_G.G#X_-C8&3P8E@Q)) J1HFKY>(NC3%(\5JM"M1I7OY<JT4.J+?#A>"A[=
MS%Q6J$++B\J52Y^"R"KW^=<EGS1-@B[,\Z#Y4*!3,RP%>AS#<1A!@F*,UEE+
M)8(7\FP1XXJDZ'X5Z=5LD:98GI.LL] LJP0:*H$Q6$Y@&5%4(50(+L$*-*BI
M>(&F4#P5- /BT(2"(TBDLX+B2HEI$5KB\QB1QPH$119((O__V?L.^"BJ+6ZQ
M("((J("T1P^]ARX@(B&!]-XKA"+*XZ&(2),B)%*57@PE5%$@= B$ *%#0D]/
M-G4W6Z?WW>_<N4E>?*#?Q_M ?;KG=WZ3V=G)S+UW9L\Y]W]/H4C80DO4%*&*
M((();^-%T4P0K%KX!B8B'/R5)##>\&HB1G.L5<@1PS"42F ?5EN/T%^S62>(
M-$$8X (,2]"T6:<KE62P !FC47_V[)FM6[<8# :KNI0(__ODZ%4/*8:KX,IX
M=1.V%H( FQ^GXX0M)XD4#]W@\0"(5IF3D<L\'.'4TC\RJJ4MT3)+<"0ET+S"
MBVJL@H3&@T>%K1&+-F!%PORBWT,[_1G(#AX]9WK6]DN"!))0Y$05H%8H@N1H
MFC"9=.6E=VY=]W!S<1TWQL?;-2HR)"C0>_Z\67'QBP[^M'?8\,&1D2'CQT?Z
M^'I\.NUC'Q^O\/#0\1-B)DR8$!T='1(2XNOKZ^'AX>KJ&A3D.6;,D-%.P\(C
M OR"_5R]W,9Z>?8;,K19F_:SYBV\=@OFIGDZG5$$:0 2DX*YM@R3?^1S(BEX
M;@Q"$P0G0=$LQ\-P4PP-,A&D)R<($LK;#X+36A-WQKZIHF#E.1!;(DGQ%"VR
MG,(+(%AAJH^J9<(<_M\LR(Q:/Q.V)"L8"9I#,LE*<R"_U 4$Q492' R,B+)A
MVPB0823/L!)(=IH1&)1*&!ILQ9@%:K:$@K^@==BW2 7=>0P>P?N")** U@G@
M( EJ@&%9E@,M0%,,'&?@7Z EP- P28$M)<@$+U,B4DL\RK!G XG+,(BA=Q0E
ML)P,?00%@\9-DD49Y]!35P>L5:GNK+9_<W6)5G4-1509+:94^MNB\:- .0F<
M9+."$ =13K"TSF0T4S3)\A::I3@0[E8\: 3-$PS/J$F6,$J%T2C8YV5%D*TD
MP\$)9HJ%L87_PDFHX=G1'/*70HH!% ;"?Y#G$8R-A4*)FN#YPNFB(E&@5%F^
MTC..$U G92M'<W 0=57-D(ZR0\.(JA]E=?QAG)_F$?,T_K\A-?_!>'4(8S<8
MQX&AX]&#0PL^R!K@>8(DT98B25#&Z%\4M!*$UZ'P$I/:ZJ=>WUI]TI-<G06@
MTI=;C7%3K!@>@B_!%"!)$G_$OV[8QZ /' =EK]/IM-J*TI(*-<^15EMN4.NI
M(><C. A'RLOT.=D%!?FP9RQ0R[%9+#0,7?4U,1J%=_XH7V([V>FO1/;?RV]3
M=9?_H_I'M;2Q_A)7LI.=[/3_3\\JEWX'D?6LUW\N[41>.VH""D%@51\=011Y
M;(6!X0DFJZCZRZBS$!LG@?7.HYP+ IJ;B+P@@*7.,2)ED1A29"C68K+)DL"C
M&0%%,Y*"/.5Q9):*K8!A#Y,@J=IA!SDH(4,.S"U%;0PRO7 !$WP"QH/@'#@(
M%B 6@_C?X9SJ(W "F'!&HQ$.$@3,\$PXF<F3OIS009BF\ +"E$C*J!:/!G,5
MYA8\39,G3AQKTZ9-CQX]5JY<"58E7-_Z-'P??ZQV=,)-Q=DSP6[E10%G^>;1
MTJI:'Z>&>5R3*X/RT,1%J5E#24$/@E?4B -%A+D #UOXB+P&9#MX]+<@.WCT
MG.E9VR^"\..06P<.7F- GE%D3E96\IE3/;IW"0KT]?/QB)T0&1T5$A$>Z./M
M.FO6O[Y>.&?RE F^?IYAX<'A$2'!P0&3ITR,B8E2"ZM%X;"UT%!45<W?W]_+
MRSD@8*R[A]/P$0,_<OEHV(?#G3T\!G\P<OH77UVYE4$P LG O%0R&0F&9"@S
M*0@8/$(Q2SCL",DM439;"(X7LG-S*9HNUVE9GD/(D15Y<"*QK3+&G2M#?9'S
M$8A A>.M?&4E+Q74MU9Z,W&2%9B75:0#!1,AP,A@)ED!Q<>Q*#H*I0P2)"M!
M<&8SPW(R+UAI6F08T!Y6AI5(BF=9V62F.1"! MS+BNN[DR2MT^EAJ]<;-9IB
MLYG@D!LKBF*#'9;ARTJU#(UDNL5"P#G 967EJ!JZ)%,TRW H+D^-09-H4:$1
M?J10<$=%]8]5/:J "9*W$"S<G1<D8%958BPOPA7@HYKV&D2^.L6OPHD05R-'
M,BH+!RRH6['J*QJ%#W(4SQ@(,\'0@B*;"()D&0M-6VA0:S+%"0POP5AQHL((
M"LTCQ V.T[R(83A>DO%X8CP.GA/L8YP.!AR:"PH'](F@QN^!WF5X#BV>J(@2
MKSK7L@('S8 MQ2'% TTD3.CU@/>395AHE\ ):L ::C=Z 63LVHM8 CW/\@P,
M(\VJWKMH"##.\O1 :\7V"V2M!O]"656'J&,T$]X6068Y@:(1BHF0(U[@!1$Z
MPL S5I> 6(XS&(TD1:,$3J!X!5&L@NK@?!K>IZ?>]#? (^N_P:/*(AKP%) 7
M&X'=CA ,R7'56))2%;_&\Z#U:3 7=#I=>;FNK!2!1T6:,DUA65ZN)O-Q[N-'
M*%0-CJBXDE936 HG%!:4P/&,]'MFL[D:/((+HKQ>:C7#9Q4U_RLBU$YVJDDO
M^KVU_UY^F_ZCRTH5;(3QZR>__7U;9R<[_37IO]?HO[NH?%Y=^+7+6*U@78-=
MS>"5:C#B!)@$R)*::4%4*Z@I*/>" E:N1#(<A1:546@_@D^0GY&,/6*L(H_2
MM"HR_!/#J,O?-AL8C33-P.P [%6&84F2 CL.&ZXHA,&* \\4^ JL/)2K0\6/
M<+B9@+ I!K<<@TK6*I =K_/A:#6PV>!,? +^B-$<C.Q@08KS&\#53":CKJ*D
MJ#AOYZYM"=LW@\TKBJQ>KRW7EA07:[[]-NZ55U[IV;/G@0,'<#!:]5+E?XP\
MW!H[',$^W(@D87(GH):((IJ[V1!@1-(4#",(<8Y'G@%@K[-@7JI9.Q%R!.,)
M5Q=XL.AE%,$&C00S&PQ[%@4:J Y'*'N%"A[)=O#H;T9V\.@YT[.V7_5VL,'<
MEZ554$2Q<@R=^>CAWMV[%B]<,,[%:5)LC+/3AY$1(8$!WI].G1@>$;QXR0)O
M'[>IGTP,"O:+C@D/"0F<-&E"1$08KJ06&AH:%A86'AZ.,Q^%1(9Z^GNY>KF/
M'#-JE(NSXY AS5JWC5_]W8X]^Q/W_:C3&5"T$LM;)<52H8=I+O(A 4&-CO*H
M6#I\!$$K\' $.K=^_;HEBQ<5%VE$4;"832"N)36U,F:,CU0O2&(#$ZZ XJ)L
MN*;HK^;*LZJ"6!76E>:I507.L0,/'B5)A5OP$3B#YSAH'4U2T%Y1$#B&16X>
MJ!R[@FU:H]'$,ASRFE%!>9#[ HIOKH3G591(PHB B)QL%)*@! Z)5[U>CT4M
M7FY FL<JB2K+:M)EU1,'[5 D;3*8;ER_<?+$R?MW[YE-1IHB.99!<=K0UAIC
M"*.*6/UHK1K52JYQW*8ZP,)@<!S%\S3HH,N74T^?/IF=DVVQ6$ ?X/4-$.F@
M-50E)V']A&$+U5NV<B5$J;+RL=,L? 7_B" 4-6TTZ E0:"I@A#S(D+<1*#9%
M@:W98D$+-G G>"_ALJ#J8!#0)3CH@IK@!X9+K.J.#(H4&@]ZSV(T\BR#O7(E
M=+*( C#AL?)\U?@]P6JOG\*XT-I36%97=%27++3NP5<G/X2!("T$O \R K!8
MGD6/7D1/G4=6!#P,#H8,9?9"ML"OW]KV1(+'7S &1R4),_H)2%)A8>&Y<^<*
M"@KP2XOQ'?P(L)T!RMM@,!07%Y>6EIF,A$%OUE<@+B_3JR@2*JR6DYU?I"DM
M*]6EW[F7EG:]2%-B,)CV[3NP:=,FG L>3 '\-''.H^<E@GX7N6@G._V7]*+?
M6_OOY;>I9I>5&C5 JL&CZA/^GN-C)SN]"'I6N?0[B*QGO?YS:6>5S<.KN7H0
M&L0+8,A1/$<+' V&IU7F18YB2)/(4VH2)-7G"%FF5F3^<:PB\ K/*3P+C.Q4
M@N!5AR"07@S-DQ8*/BHB7 ,M1ZM^.S*V3N$@'"%,)FP PVFRNHX',S7": *F
M+:3 <'CR Y,49'FJ<1;0'&"PY>%,RD)@\ C;;&!68TL>IAA*E;]2S;[#66#F
M'SM^J'6;%AT=VBY>\K4@L HR;WF2)#9L6/_**Z\T:=)DSIPYR.87)(9A:SJ!
M6FO@^W!?@B P;H7A*K@IW%#U* *[F"$)$T,3,)(T98$A%07XD@23';;X*V!D
M8*NA'#),$%@80Q[:AVQ@U?W(JLX%U&F.J*;N5F-%7O![:*<_ ]G!H^=,S]I^
M%3>WPB0=YKH@$A5)3KMT<=>.[9]\/,7'RV/:)U.\/=VB(D)<QHP*"O!V=W,.
M#P^<-#DF*CHT.,1O\N0)$R?&A(8%^P?X1D2&142&AX6%A8:&8N0H,C(2H4<Q
M$>$QX<[N8YW=QWD'!;;JT'[FG+G'SY[[;L.FHM(RU4M#-ND-*^.7KXG_]LZU
M:RQ%2@@\ OG(J]" B+$DZ)E!7^'A[O;Y9S/2+E]"SBLL@V;.R)7#6NW3@3QH
M)+D:2J_$1'")!01+\:(ZV<;8D+5&=F'LX8F3N8"P@WDRGG)+:AP=J N.81D*
M5(4$ IA&3D=(@J,% 1J: 0U$)\ 1D\EB,9,WKM]:LF1I4%!(8N*>XJ)2@J",
M1K/%0AX_=G+&OS[W\?;S]PN<-'$*S,P7+5@\(2HV-F9B9%AD;$QLTN&C)I,9
MS\]1S!&ZO:3Z;8)01!@[?.88@44J!U27R#&<7J=/V)80%1&Y?NVZDN)B&!,U
M(!IT&X.P>47".(NH G 8)[)BA([G4%@QBJ-#QS&<H2B@5(R@?,QFO=Z@+2TK
M^G3:QR,^&/;##]LT&@T,"(Z-@O%1-VCA D:L>AT8-[N:X",H)S@?>\?@$5:=
M4:T,Q[$H^1'"\Z";%#Q0Y+LC4C0-#Z"TO&SSUBW+5ZZ(CX];M6+Y_;L9+$T!
M2VJX.$40-$6J$!**4@.="KTHS,\[<^KD[1LWH'UP#@R5HCZL2G\PI,G%)UD-
M,GPZ5Q6R^ ^65(\N#L%&JL,;NC]-L@R-4GZCEPG!:?"J: H*CQPZO&'=NM0+
M*11)R&IR)^2KJUX9OYE/N:DL50-#O\:5+8=')B HS6@T)B0D3)HTZ<2)$UAG
M8ZA.J?(<QI"?R60J*BK*S,RZ?^_1W8P'#^X_SLK,S<[*RWR<\_A1=D%^46Y.
MP=6K-]/3[V=GYY>6: L+2[9NW1X:&I&8F(BA3+RNA>/@[."1G?XF]&OAF<_K
M^O;?R_\[*57@$5;9-?$C^_C8R4[/D9Y5+OT.(NM9K_]<VED]00"I0X.EQ](*
M3B@*K(B2 -:?25!A(TED:,+ 4&#L@9D$AC1,(M#ZI6JP\0KR.4)+@V SBF@E
M%0QCF,4(I(4L+RX6& ;9D2836-ZPY<#6!>N<H26PNR@*S%3":-25EHH<PE58
MBL;A S:K#0Q.EJ1$-3)"9'F)%RHS;*-P [2"S*F19=A'"4PXL]F,$U?#$:4J
MLX%534V L1X2IA:,Y?J-M"%#!PP=.O#HT<.\P)C,!I*R\#R7E949%Q>W<.'"
MJU>OHOF1),.<H%H45Q/^"->$"^*E9;RNK(:Y@>G*2B(KBASL<BQ5B1"I47KP
M$?DD23!;87F.-ADK8+ 0S,;QT =<>DUB60'!;0*:) IHYF*K6NNMS-7Q@M]#
M._T9R X>/6=ZUO;S+"NJWHHP<;68C/FY.5.G3/)P<^W5H]LG'T]V&^<R*7;\
MK)DSID^;&AX6'!H<X._G%1,3_L_I4X%]?#W"PH.\O#UBQD?%QHZ/B8F*B$#X
M$5!(2$A@8*"?GY^SI[=;0%!@]/B/W#SJ-WKGB[GSM^S8=3+YO(D@!=5-J*2H
M:-P8IX9OUGVC5JV$C>M)<X4B,#)/RP)M%5FKQ"EJPF2&-.NUI=$187'?+-:5
MEPDP62<LLNHIRD$O5!9 ]J@^-B+\E5$N-D5BK3)KDQF;1%L%0F)-DD K(F^5
MA,KD:K)H16F6.7P$ME89_AL^\HIZ4.)I@2%8R@1:06 )J\+;%$'B*)ZVB!R(
M;)(RZSG:0A-&CC)#LQDD3Z7BHI*%7R\."XVXDG8-Y)Z@%E^#^792TM'(R.B.
M'3LU?K=IO7IOO?IJ[5=JO5KGE3<&.PX&03UJ^,AEB[ZY<^.666] X6T,11%&
M8($CH!=6A96A%Q+<EF5)4#-FD*ZJRXMUYP_;APX<..NS&87Y>2BC'TN)'"WQ
M#(P>2BLM(;T%'T&-R#P+_;))@B+ <Z?1:1P-PPL?K4A&@^)!2(XL,<"*S)&$
M8=K4R1\,'[)FU?*[=VY9#'K0E1R-&%0:=)>C0),1LH!*M*&A$^%&K,@SL*.H
M<<@"2V.6X?I6F>=97JV:!N^<6JT"Z0+L.HN\L9"7*D]8R'U[]X\8,?*MMQK6
M?JUV_7IU_SGMX\*"')M-8FB+7E<&S]Z*U#:+'C'H3.B%P%Z_>GGVEY_'+5EX
M^VH:H=<Q9B-'F*W0<9:6&,K*LS90WD\RM HYNSZ%8=R>QM U0A(PDP)K(4VZ
MBO+B+1O7>;F[1H:&KHB+OY]^EV?8D\=.C',:V[=7KUF?37]\/X,T&Z"1:/&(
M,%,6>%N(I]\7VO/4=M9@Z MFA6/TY64)"0F.CHX.#@[;MFUC4#IROB:R@U4X
M5MMZO5ZC*<K)R<_,S(%M45%I69FNI+A,HRE!N=OS-46P4UC\$.7(SM;K#?#2
M4B0-ZK]F'B6\CJ14+2[9<Q[9Z:]-=O#H3T*X^Q@YPJL43X)'S_&YV,E.?V=Z
M5KGT.XBL9[W^\VHG]F;!<5@L"W:4[M;UJ^DWKY&F"HFQ,&:=0)LHB^Y:ZIG-
M:^)W;ML(UI7 "PQ%@W%.$61!;FYQ86%Y<7%A7M[C!P])LP6%+% 4.L%F@SG7
MP3V)]V_?%%D:34# 4A5YD6,,925EA?FTV0C6.QBT.0_O9S^X!^8O0JN,9L)D
MR;A^\U;:M;Q'F>6:8I%F.0M)&RVDP:3)SLU_G"718!\**.^&7.F-3I(D3=.P
M#Q9=5E96;F[NE2M7,E5;L*"@H*2D! M/G4Y[YLR)Q,0=WMX>DR9-F/'9](L7
M4S9NVO#HT2.SV9R?7[!IT^:[&?<8AH5YC=E$*+)2O=J-420LGW4ZW5F5DI*2
MEBU;%A<7=^3(D3MW[IA-1IBAP+R#9TB6(3)N7S][ZMB#N[=3DD_OV[T3#.GS
M9T_"2-FLDLF@^VG_GO7?K3JX8_?AW?M/'THZ\=/AQ*T)>Q-VW+UY&T4KT(R
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M=48:DT$;&AQP=W59L7SY0;D#EZ,NW;AV_>R9,VZNKELV;_;V\JRIKDJX$W]
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M>6/D_?OW(B(BLK*RR<G)! (_,/;'CQ\D)25W[-@1&QL[3Q?)5"H5%%-9475
M[K"<[*'+EZ[/9X1CXW'\5X:"#,L$ F%B8J*ZNAK88FO7KM73TVMH:  G!5O)
M $L$)N'J5:M4E)0KRRLFD.-3J,F$.W>!)65J<J2UN87%CX/!X+#8DQ.HDR=.
M #JMK*04?2.:0J1PV=R9R9G8Z%@I2>FDI.29F5DN?\73?)H9#M]ZX ?<YO(/
M%I?WO<;G_S3^W>O_K?CS7EMT'OV&A1KN?W3]US?_@B^"E$G S.OI:F]KJ7>
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MWG57_X<>&KIF];I1HUXH5*CPRZ/_2R< >A'=\18O7W5KKSLQJ&_\?1M&^O1
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M\B2/+Y<[)VR?;1.3!8.Z:$X,U4B1!/93,VV5K:U#+5"&0#@3*\L!VK3RR*,
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M;+Y.%6UD6/RLG ?BRACGX8Z#[!6A?A[8968D=006V,NBC<PIG[RB0,3)8?L
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M?'4#+ZN!6\=-WFA'BY>P)"^/#T@Y VZNHJ#6SP O-\N"^!0QC[,I[WYC!5^
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M4?Q-]9>\7HLJ#=PN1.'8_%27K_)$ M=+=AOV*N(M!G?#^ARO<L2O.$P$NXV
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ME\!JDW$/S,2-\#N+>9^>2$B*%?1(DMC=U0FAIUA%)M!'EL2QD==6LXGF5Y
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MR"Z1AH#5B QP0\0NX#F27C;=K?(1X?WEN!NZCP@;C%I:6L(%B/C!6Z0WR+7
M 5P#GB!O <?P%5$IZ$?" YZ@!5?.S,S@+-B./48!P>NK5Z_ 2<2L:,$!KL1X
MX8D0:W0<>[3CH5:;"<DY.(GAMECV$0&,C0\-#?<C.0'!R!A5%>F6Y'(I2$[
MSXF),<Y#D 'UF)J:PN- .8@!&<@'( EX],K*"H8>"H-3$!6>MH$8,!G$HX^X
M $3BY[@5B,<>C2#,8C$@J<:88B@QRDA.D!8B45E974#6"G%U>Y"04_+.$V\J
MOE!4I+"J()EV]S5%]>KNONZ7=5752$H505R:F[<:36M+R\WU#8_O/>CM>8F'
M0A*@ZB"OO[^?DP0Z(0EH24U-;6AH*"XN1L0/V1X?FQ@;G5A>7JVMK:^IJ4M)
M2<O-S<?QV!@Z,[6XL-S>UCDT]+J_?V!V=GYOS["UM8$1GYP:P1X,A%0L+,Z
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M+ SW!)$(;'[WN]\AH@"1R\O+"(-!P]FS9TFL^*RHH[T7R*.NM@D8$2 ): .
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MSIP%Z@^'2]*L)J)!$ ,=9)BW<0>'(H%G\V36C*!1FUDF4:\G_@YV2:,QPX"
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M1FR&)GN3F>Y51W+N, [XBAF]P^W;R*@+Q #4BN"QF4HOT2,KDU@;1)0CIN.
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MX0!)K,#J&9-IPL["@C?VU5'.R$B-OI%:) +N6:Q+YDB1])!@.E097 1S)%/
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MZ =\S=LTF))HRI=Q-P\[R *714+++HPC$RYC9!8<K9MD%.%'L]25D=23-N)
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5/U_F7J]PJ-('     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_21a.jpg
<TEXT>
begin 644 image_21a.jpg
MB5!.1PT*&@H    -24A$4@   2X   $Q 0,   #X#MU.    !E!,5$4   #_
M__^EV9_=     6)+1T0 B 4=2     EP2%ES   .Q   #L0!E2L.&P  %S])
M1$%4:(&%FD^,&\EUAU^K!96<C-DR'"!CF&*/+_$Q(PC(4A:7+<.'7 SDFD,
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MC8>7!(LWC" [XC.)W4SE-.5>CKEAF4>_> M?#_."4[2&7F/'G0 +;NO2*W9
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>96S6(= [^UGV_[PP?P_F$@LG     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>regn-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:regn="http://www.regeneron.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="regn-20200930.xsd" xlink:type="simple"/>
    <context id="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92bcdb9b7b864199b967467d316c3c36_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i0883093cd35746e1a9961ef2b396311a_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i00959df13c4a47889ab1b2afc9be2d60_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i734f13176346421b8ee85411fad81c78_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i093941038ceb4a2e8821227dedd1ed05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i35263a3519634adea7dcab66a8b1e11c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id1dd19a4363b42258975d1bb4365b864_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3235f9163fb4412faece41710cd7e880_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c115ff83ee44b0aa8d8f69f486f45c4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i482f52a211724b65982994e352203f86_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i81303cd78a934bbda788e5640aace50b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if06871b3ff554800abeeb70d0b62897f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iad3352f230c1452e890cc614c8897783_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f16611576d448be82f57639682001f2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d509e43524b46db858b6d36d8865013_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i035f917b860a4f768fe2549dd9543867_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic91b3ef18aaa4ad4a4bf04dc6109978e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifecf127247f14d498c30b360496d431a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i63e9d4d4034b4d7f982d34bd64567768_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic722d7b117f44dfea29c3cd481f51536_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i577c609c14224e14bab80ff04411fadc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd60199c2fea4aa6b05d646072ecd355_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icb0ffcf9d201484c9266a9e0eb9c3699_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1496d62f31ce472a895a9f7ee128dcde_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i675c01e82a4f4e03aae9d3f62c0f88a1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5209c4293dba429294a909ce19bcd10f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id2a442e00aba438eaf835e73a520b7c9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if63987c408794f65bf06da42ebd33fdb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2e316c4afa634ebfae1c7f8337aa165f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78089fb22ef5491881366c4ba92689ec_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9579d06815ca4b268c93324679499313_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4525169eade14ddd931acd9ebfcd8ca6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia498f71e843b46caa332f9386b2a8a77_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i406ac9ba980e4136af01f1c5b4139a6f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i133407deeda04cfcaaca9a0f8b8ce3a7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i07264113e8534e54adbff64a62edf458_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i92b811303f2b4ac48bf302278623bcec_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9a8e33e4c564462baa741028cfca1b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86e212993795477f8b66d1a401e7449b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i35565fb3ae5b4966af577b02b5b1a8a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4784f44bf1f04a1592918d8d7ba96743_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i926e5a0e99ba4804814d49ee066a7499_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5ce1551350fe413883e19b37029324a2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20a21886017f4e2184b5ab2de327322b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1bd8de61d5594cc0a90ae1aa4ec131cd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i68fbf82feee845b8bd4480b59aa72864_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5381a9cd688d4fc8a51b1cdde15f6dbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if30a2465e1c142e4b97306dd631b2630_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id1dbcf1c58b04386b0b8628caf87d9d6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie449572134e244aeb3c0162e874670f7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2525fcd8b64f424981d34550a4882b28_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad3302f7141c4de7a1b4ad4a9e1248f3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a59ed42376b439fa09f3f52339203c4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i06ba7e0bbf404b678cc2a4e9a17e6a98_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i69e52cf5b7084ff6bdac52905e07508d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i81df8d94688a4785b4fcdee55b999ff5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i50e9062cb41a4ef582967a70ea3d968a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7663889c931a45829c5bd7a59fc6c036_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib28eccdf14bd4f3db6fe4948f581213b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i31fbe348fcbf489c8e3bce16aba7c016_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ida39a32e51e34d42b313e6250995a791_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if627925a7144416dad03494b413c8c61_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0d32369eb9904de592697e700da19318_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id5854d26eafb49958a08f5eb2ce7d9a0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic6aecf582e764d5c8603bb9cedda4ca8_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4e5e669d94774805aabf0020dadd0d57_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i377c1ec369d2482fa9a2758786c551a2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0559295694514aa8be74a966d65f6235_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i687d1a3db056417a8c3ae24d7fd80e51_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1e5368714b52465da523e0607775d0ec_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i08d3f5064b5a48e29625e4a30f388481_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia6b26cf777144ecea7d36c98690e9db2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie2c759feb874484d9c65a0976149d579_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a79bd68191745689351c05a41d63699_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8204fd099a854ea1a40d19bf4c7433b9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i940f4ab7445647329c8c94c4fc6ca764_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idedb24cf92424d13afb7f8971ec77486_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if8409743b587499c9431d97cf882be4a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="icb1f38aa9fd24905a4230a517daef524_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i84e068d5db5e440bb019a77918a1f513_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i24c0d06309ba48f3842f3304738d7c4e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i208259b9728c4fb78df67ba613da6db2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93ab20c00413412fb90e7a9897470fa0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if260882197374baea06d232c9dbdae20_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13a06a306ebb4c579cddd781e1b375c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fe190863af84a0296aa289188b4b233_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee18f385dd8849668c5be259e457682c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic00f8b9e2a0b49449c6f19540f28b731_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i936c971cd6804e7ab94e27735c0fdef9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia007c7f6d5ed4efca99a88aa3102d6a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib420108285b94badbb732b426062abd7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief4a936fac9948ef8229a2a83ad922ea_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id60df2d7f3b5418e8a6614f237c06dd7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i341faabd353947de903f5e3eff280493_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i24811c1ea905459f8e11c86cf166e750_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d26b43c17754b828848943ea0e32972_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2384b7830806480cbeaa6244e94a5866_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1cd7679bb2cb437b89a2c91b4e76a30b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i51906d645bca4b2ca7899fcbd47e0874_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5f0ba82258c54e758ead2a40321a3329_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iedbfb2b1ebb640c1b73cd3e30e74c02f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4f6d86539ab6438a81f9d17a87d8108d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a52597c51f5412492f6c132bf465821_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifdc6f6996a634c0e9b097ac2f58e752b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i59fc78e9a3304a3bac95b0cf117279a6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c30004e4fe94ba4875ced4b468677a8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7289e9b303ae482ab10a155371fd403e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2e2d6a85606748b6ae2be54b2683aae9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae4274b29daf4675ab09b5e77fa76d58_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf0ca2aae29d4d96bd94dc0a09fb6e08_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icbbdbae70a344ee9bc01b9143fdf9a7e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b7e691f7dab4bb58c1c0765d7ddc72a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfabd1b7b627426f9a33e66492f38481_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b02c0994812409f96b2fbccef842513_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5aac854b44a486b905645bbb8b852d8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1323fcbcb772436a8c497dcb0925c29a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGNCOV2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8fab8149afc476fbcd010d6fac8dfc3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i72da8bc596c7486cb41228ce22a460c6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c4ff746cc404cf9a2e0326b7e30ecb8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i913cae035ec5417db5bb2235faaa5b0c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf58700054b74965a4154a14e0348fc2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id287f840c8b942fb96eb5ac0f597ff16_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i259fa8cda2034a8485dd4d98ae1d54b9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i210976468f6d4beea437d37b4aa63663_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0e0f96f1723947e68a27075b552c4719_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i30e9eead3dd34158b0429a505019d3f1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i93c5788ee66d4e5e89464da41cc6269a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63d16524c09f42f9bc5b0d1c70c5817e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i793d1c60fb2e41319710da444819bf38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66079e1a96d94e1eab04aea3ea86a08b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i89ae37db927b4fae8c60dc4bbeea1188_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77597e8bfdd64fe2bae163eb8fec1490_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossSalesRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7440ca289f91448e86b7140c31a5c495_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a3b75b9f9ab41f6b1c862dcdff343eb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i629b8945a2b244738e800fb84f2b891d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7992d88a42314fd9959ab26fd254bdc4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a403650d89b4cdbacb41612bdcdc2fa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia7bc77d612f847c88293dde238e89d6f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i858f26c124514e65930d2a7c4d3ae840_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f34054df8504a19a5ad1c41cc47fff2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieccb4e85845442c5b68026da6ae50775_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7812846c7af642bf8c717b3128434e3f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50af2d0e293b46ddb00a3419f1912ad6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f305f8e6ace47fd86b9631dd499da4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50af2638268242f6b59b88d1b6a5770b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib39afe508e4c415cbb06cf308ee47ccb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i23e99f703b684f02a5aa414ea753d8aa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0e216705cab94a00b9676a165f2bcefa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4d68f82974548b4bee81aecd0a90d14_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3e8d4c3b1834a21843449aa8b585d68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i975f4a743b164615bd2ef7edf00f00b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i32c2a84796d544b182e6e74ceb73a585_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i155a77df03774a34b4015dc1801c5b18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if30550b7dd2b49b4b69c045354a6a07f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e159ae1bc03421c808cd526f3c49fb0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i91ae24fdf2ba43769cc7901206518a12_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e4206c910554d81af805977f3002947_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib09a1e9f85cf481ab3cc770922ba3391_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f74bf2738be48258c23b0dcbdaa12ea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f86c58c4b574796881d49e37d000bae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice9e38a9d51f4fbaa964316765d51ca0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i424392c0a0484adfafb25cbcffa01a84_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife607ecedd0549008b720df4da98fba3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i524b4d40e946437f9cc3badd5234eca4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i249d2b86432a4c65bd64b122b30b44a1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icd85c66a10c44e869a10593d3b0aae6e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i903692403a774f48bb520b2c3aaa8879_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i11c8625c815b4033956a9b3202d3f56e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1288473dda949c38b342de4f098cc6d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i125e5e85d95a405e8280fe383b98b6c0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3725af6673294f5aa8ee78886c09a9af_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9269fb1edbc04cd1ac5f2238658e8872_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i789f27d056fe4015b571c9fc45b1bdc3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4bfa0b97e54d49f7a24ff6f66c316d8b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89320920064f41bf969faeb62c0e0007_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7075e6f52bc44235a553c88375786049_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f314f4872f04da6b2b01389f0883f09_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2cd6be8d9b3e4d459a816ed46de88b98_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if734d160735a4b25bcf2df8175aebb38_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i647137868b2d4017a026a60b257f74d9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i82b9876c37a342a39a55d03fb7cd497c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i768f3f67a5ad413cb73fbc810de0d72b_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="ie52e1228322949d0906b14737878fbb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18ea0893a48f488d8f88308c3e9ee61b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie2ac5fc163d3459aa29a0f7e270b195c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic62eefa1863e47f7a276818d52328f65_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a032ed700df48e8b4754328ea168c43_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaa95e30f69814af0a60388d1bb9f88a6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbd823974b604b1390f3616a69d17bd6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibc38fd53dce24fa3abe9de323809035c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33902f27fb464f2788858727dc0f48f4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd88b5df537c46f0a7f3172ab2b40960_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2e78e3764fb346d9abe7fb4037bb0528_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5aef510b4bff453f8d176f79acb15431_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba52ce52c05f40beba9639ea3d78c7d3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia7e6521a7a684a99872680a1548d3d37_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01db19eff4ba44168b83edd0617cc0bb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f67f970eb284b439ef2084a5ddf0c4e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc03aab082174d41aa16b8adf809207e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i042578dd0f7942d0837b6e77eecbd085_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia17ddd9842744aaea31d03825f513ff8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4e0d66d038e84724bc6951ccc43d25a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b24fd379cb345f092d697825567373e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i796be097beaf45008b0b52db759c841c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idab077eab2b448d4bc8e7af35fdefa59_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5351df69b749490991f52fb2919ecaa6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if1febd6b0737446ebac35bb01d092f15_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7058246a9659451f88d94beb0d3ec13e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0ae545194ff24904a88dd0e9092398b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe3f67d977694fb89ca3de52695ce285_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf58477014064d2aa4d6dc03bb6963ed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic85be8c3176d432ca84c44b9cab50dde_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i64bf72d6126149e4abf801ce66065da4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic184b458c91d499fa1a5711477b97f68_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i478c123cbdf04a5693d39fe47d38ee54_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i36638689867843109daff532397d136a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i6e8b16b9d02f4c5db91ce70d178e3e91_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iffa227b8deba441693b33a2fbafddb8e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ab2a78eec84461897d6a611b6915df8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9825a846e164e5ea7cfe55e771e11b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic7f5db47717d49e1844b3f7b3174f1dd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife0ade14d07348fea114a6a08fedda5a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f33ed3e59d44118a5a40e3435d58ef8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iff9d9e2ee1494f5f9a4f9463de7838e6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66510b4d5ffc47b6a9f4b37c4c429ca3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib54c03b4823b4871926f13634d87caab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9207f4bbca3f4cf89c0781ee2963e848_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icafbbe3c8ece417ea95836d71b2b8d9c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia323b61d6ca54592b8470bc4a3c536af_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i78f643a7609c4ebfbb43b0e1032cdde6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60c6215466c64dd8a803be94b251edda_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id810e98c23264dd7862faff8c51896f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if92d56f793334c729cbf51da9cc2bb80_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic6371d5d148549828b6707ade5b5f0ea_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id99617e0fbe44be4ba82c4083676868b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i911314304b514431af13b55d5a2dc5ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d63c24f0218414e9990379ad00300cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c8ceb313d6d4253941c222abbdda87d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idad0c140dee94620bf61713792c263c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20d30029d14449749b125424cd027e65_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if71c780a8fb44eb3a2cfd3e811018adf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae6ef393ea1f41409b5056fb005e2f77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57ac96ed0be24de7b4d78a4154650332_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib3a8bbfcd7a24b5b824f96ad7338a054_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i713f9254ad4e48be9e5d986625994aa4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i13644cdf2ce34c7c8c816531c17bffac_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4cbc42470c77425ba7013c4d8b733291_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ife4de3948dc24c89953087647ee69972_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if88b69bb3d8246e492ef775636b3be4e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i40e7fa786500484f9ecd6a1394da0446_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id9dbf1de37814cc591de5f5dfd7367a5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9d60d80740cb4c3d8c3264e5a536bb75_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i45c4643a0fbe4860b2b92747ba930b68_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifdbc67414a3f4b75a4caa66eca345086_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibb5b3e8bce4a477b86a941cc7530a23e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie06ce8aa5e2b4cc09ea1c19bd54664cc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i73ca96a034d34a608df2c5923fa76c90_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i40d96bb16db141e2a860d5637be2962e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2506ac5a2034c828fe5038d9beb37ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i541eacb289b24268a93f9d97ac19b713_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id6e6ac37be9848dda98174ec211537bb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia9c906750bd44ebfa1472014377a3aa1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i358f15a0dd6d48b29acf4a71f823027f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4c52905678f44008a79f2f04de098ce4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i52447f425dcf49d6b1e10676a99f4280_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i28b2946c537042c89d7783ab07d85448_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0579df393aca4a968868c9bb40a1ab0e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68f420c9c13e4e23a601c1b506fa4a4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19e0aead3d7445da8371fd938402c091_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e14cefc3db84553880f64ccb1fa43bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86accf19d5314b94b2f97f98ad733968_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e0b94218008446f83e54c839d26d417_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8d5e6f8e04c640e9a3a58b970d0b5099_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i322b98f3dc874456add467767aaa4162_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i278d21029b334fdfa0462d06cf1f3130_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e8ef1954ceb4ec99864b1fe9544ceef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7feff46efcfb423cb246abcc1bb4d36a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18805c870e4245d592672c40510db7b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8876032e074445d89ddad2131dd29fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45fd969b6c884737a5442b5de99684a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8593ca7502ee42d499fd89567506b6c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib31d2a9dd29b41c98f55f6c5305d8e3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8532b49a5daa42f2a3875d2512dbd140_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3c2c6d2774a4997916504acf5a44d4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbb07d4899f3445b83edd542e47de881_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i490a6a8ff60443ed968309024d4e02ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9093b35e7b624c38a7f019c21a2e9a5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc12bd1bc93d4447ae534aa38c459530_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0e42d73bc9440fcb7dfe671ce0e5ccd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i771b1c5b394f47639c3f9bdf6695758d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8d06b9c5853e400a9847d748ae198625_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:BridgeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:CommonStockHeldBySanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ie7c14da02ab04b15a697c1f976f6c63b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ied42ff47bb2e4f48ad72135de84e2827_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ie7b56bd9207547a3a35c46fed3f56b79_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ie00da91153ab4285948986d4a8528f33_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c5a33a1ef064741af1b75d4df1e7b8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib14491178e814761b044424a9d90cc57_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i136244d2dc724edcbda67477d4375855_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i7fb343771e004b36a23994024299f080_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="id7a7a7f0ec7b41ccb9e296ec34a49d62_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ic76fb63f2f534fd586e297b9d26b3169_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75a462a19f724c93b0ad3e5e3df53fa2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib4162e2d3ffa40cab347875d0e8141e1_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A165PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="i76ec0cbb09134d05af796df3d6121770_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A741PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-26</startDate>
            <endDate>2016-09-26</endDate>
        </period>
    </context>
    <context id="i00e0c80c71e941b48916ad1f5287ba31_D20170728-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-28</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="i841077884f1e4957adca717303635407_I20190214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-14</instant>
        </period>
    </context>
    <context id="i4b28b11bf97045e493c30eaae17baf6a_D20200716-20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-16</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="claim">
        <measure>regn:claim</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml80LTEtMS0xLTA_72f9f22f-0c1c-4a84-96ff-ba4ac61d6b55">0000872589</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml81LTEtMS0xLTA_f822bcf2-b253-480e-91ce-cb59ad43922a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml85LTEtMS0xLTA_a325aded-0187-4155-995a-a005fb60923f">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml8xMC0xLTEtMS0w_f9fab79e-8ea1-4261-8dad-1852c0535ed2">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80L2ZyYWc6YWQzNDkzMTJmZDRhNGNkNWJhMmNmYzM2NmUwNDMyNjMvdGFibGU6NjI0NDQ0OWQ4N2NlNDM1ZDkzYzMzZTY1YTI2ZGU3NjIvdGFibGVyYW5nZTo2MjQ0NDQ5ZDg3Y2U0MzVkOTNjMzNlNjVhMjZkZTc2Ml8xMS0xLTEtMS0w_54756975-9833-4ec3-8c18-906b32cc1e0b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80Mjk_58f0a0bf-34d5-4bf0-9602-3e559fba7c2d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF8xLTAtMS0xLTA_c5335e6e-77a9-4d79-b5be-4b75108965e7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF8yLTEtMS0xLTAvdGV4dHJlZ2lvbjo5Y2NkNTUxNTJhZmU0ZWJjYTRmNTY1OTZmOWE5ZTFkNl8zNQ_d66f8683-eaa7-4ecd-9a7e-1bdd67ec5872">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YWM1MzU5NTRjZTYwNGMxYWE4ZTE4ZDc2OTY3ZDcyZjgvdGFibGVyYW5nZTphYzUzNTk1NGNlNjA0YzFhYThlMThkNzY5NjdkNzJmOF80LTAtMS0xLTA_d3b39f47-0c21-4128-ae19-9cc314338c0f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjVjNjY0YTMyZDYzNDIzMjhmNTdhM2UxMjAyYTZmODMvdGFibGVyYW5nZTpiNWM2NjRhMzJkNjM0MjMyOGY1N2EzZTEyMDJhNmY4M18wLTEtMS0xLTAvdGV4dHJlZ2lvbjpjYmVlMGNiMmZhN2Q0ZjFkOTY1MjVlYTkzMGIwYmZiNF8yOQ_e64552e6-c047-4acb-ac2f-6e5d170a020d">0-19034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzA_24c2e955-0270-42bb-8e49-f8933fa9371f">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YzZmMDkxOTU5MzkxNGEwNzg5OTQ1YTljNjEzZDJhMjkvdGFibGVyYW5nZTpjNmYwOTE5NTkzOTE0YTA3ODk5NDVhOWM2MTNkMmEyOV8wLTAtMS0xLTA_c784eb22-5944-4d5c-8497-bdd2bf6c1fc5">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YzZmMDkxOTU5MzkxNGEwNzg5OTQ1YTljNjEzZDJhMjkvdGFibGVyYW5nZTpjNmYwOTE5NTkzOTE0YTA3ODk5NDVhOWM2MTNkMmEyOV8wLTItMS0xLTA_82936c0f-3c92-4f76-97e0-a93ae7c82cbe">13-3444607</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV80_d221b722-52ac-4548-b07b-228997f4d670">777 Old Saw Mill River Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV85_327b173d-3a91-40cc-9943-ac19aa21ef61">Tarrytown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV8xNA_22e2d912-b9f4-41a3-8996-3e3841830428">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ZDhlMWJlN2JlNjM2NDcwMWFjMTJlNjFmZWNhZTIxNzcvdGFibGVyYW5nZTpkOGUxYmU3YmU2MzY0NzAxYWMxMmU2MWZlY2FlMjE3N18wLTAtMS0xLTAvdGV4dHJlZ2lvbjo0ZmM4YTI1YjQyMGE0NjRjYTNiY2E5NjJkZTNlNDA0ZV8xOA_7f678782-385f-4100-94f9-64c3748aaf93">10591-6707</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzE_63ecf41c-da74-4aa6-8c1e-65b819a228d5">914</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGV4dHJlZ2lvbjoyZThlZWY1ZTFmNDE0NDc5OGQ2YTE0MGExNzYzNzU0ZF80MzI_c49574ff-42b6-4839-a768-3b8d7f6a5a26">847-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTAtMS0xLTA_b407dadb-040d-464d-9159-a00fb3f8c6c6">Common Stock - par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTEtMS0xLTA_bd4c3c10-4003-4d1a-991d-e90dcc9f3342">REGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6MGYzNzgyNjAyNWM3NDFkOGExMzcyYmEwOGU5YWRiNjQvdGFibGVyYW5nZTowZjM3ODI2MDI1Yzc0MWQ4YTEzNzJiYTA4ZTlhZGI2NF8xLTItMS0xLTA_bb550cc1-caa3-4211-af77-81cb4e22aa3a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjZhZGU0NTZjMTEwNDY2YjgwODhhOTU2NjQwZDdlYTUvdGFibGVyYW5nZTpiNmFkZTQ1NmMxMTA0NjZiODA4OGE5NTY2NDBkN2VhNV8wLTEtMS0xLTA_17241d0c-97cf-4799-b82b-384792cc6c1e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6YjZhZGU0NTZjMTEwNDY2YjgwODhhOTU2NjQwZDdlYTUvdGFibGVyYW5nZTpiNmFkZTQ1NmMxMTA0NjZiODA4OGE5NTY2NDBkN2VhNV8yLTEtMS0xLTA_1ba8ca45-95d4-4953-bb36-9a80796fd415">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTAtMS0xLTA_590d193e-4173-4641-ac91-c00108cd2d12">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTEwLTEtMS0w_dd373a9a-ad21-4819-a8b4-afb03dc728f8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NDE2YTM4ZGIxYWI0NDc5OGE3ZTQ1MjJhMmNkNTQzMTAvdGFibGVyYW5nZTo0MTZhMzhkYjFhYjQ0Nzk4YTdlNDUyMmEyY2Q1NDMxMF8wLTEzLTEtMS0w_eea0c0b1-440a-4aa5-96e2-948357767dfa">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6ODRkNWEyODVmMDA4NDhlNWE4OGY3NzdmMTEzNjVmYWUvdGFibGVyYW5nZTo4NGQ1YTI4NWYwMDg0OGU1YTg4Zjc3N2YxMTM2NWZhZV8yLTItMS0xLTA_aaec1fd4-5f03-4320-bd2c-4ee8f2411618">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i92bcdb9b7b864199b967467d316c3c36_I20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NWU0MzZiYmMwNmNmNGEwNDhiMzIwMDYzYWEzOTQ0NzgvdGFibGVyYW5nZTo1ZTQzNmJiYzA2Y2Y0YTA0OGIzMjAwNjNhYTM5NDQ3OF8xLTItMS0xLTA_b6572723-9c09-4005-9e83-12fc0ef28d03"
      unitRef="shares">1848970</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0883093cd35746e1a9961ef2b396311a_I20201023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xL2ZyYWc6MmU4ZWVmNWUxZjQxNDQ3OThkNmExNDBhMTc2Mzc1NGQvdGFibGU6NWU0MzZiYmMwNmNmNGEwNDhiMzIwMDYzYWEzOTQ0NzgvdGFibGVyYW5nZTo1ZTQzNmJiYzA2Y2Y0YTA0OGIzMjAwNjNhYTM5NDQ3OF8yLTItMS0xLTA_5b9f4b5f-a9a2-4396-aff9-3f749a82c9db"
      unitRef="shares">104857294</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNC0xLTEtMS0w_d0f1dbd0-69ae-4555-839f-1cefa7a89d02"
      unitRef="usd">1573000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNC0zLTEtMS0w_12780a71-08c6-4a8c-9068-4d889d73cfda"
      unitRef="usd">1617800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNS0xLTEtMS0w_58cadfc7-7a91-40a1-ac03-63ba45ace6e3"
      unitRef="usd">1452900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNS0zLTEtMS0w_9afdbc36-8aa6-4d51-8b66-c75fd62cda8e"
      unitRef="usd">1596500000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNi0xLTEtMS0w_593e8c6d-5328-45c3-b4f5-3a4eed4a3d89"
      unitRef="usd">3092500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNi0zLTEtMS0w_91d61c17-eee6-466c-90d0-5e7725c2e189"
      unitRef="usd">2100000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNy0xLTEtMS0w_30c21a6d-1a6c-4f01-b4e9-b3a3622743f0"
      unitRef="usd">460800000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNy0zLTEtMS0w_d6f30eae-5a76-43b1-b1f6-46451118fb13"
      unitRef="usd">260600000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOC0xLTEtMS0w_6e0b07d1-1c8e-4529-99c9-f6f824d0674e"
      unitRef="usd">486200000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOC0zLTEtMS0w_cbf092cf-ad34-4788-b57a-5dafd3b86666"
      unitRef="usd">425000000.0</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:InventoryNet
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOS0xLTEtMS0w_91c4c2b2-155c-4e63-95c9-f101b26bbfdd"
      unitRef="usd">1801600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfOS0zLTEtMS0w_89a4e396-e040-4441-a7bf-22011c3df3a8"
      unitRef="usd">1415500000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTAtMS0xLTEtMA_058aa582-2ced-47c7-9086-d2983cca835b"
      unitRef="usd">230600000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTAtMy0xLTEtMA_1556f97f-a4ab-455a-8a5c-5825ee46187a"
      unitRef="usd">273700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTEtMS0xLTEtMA_a1297450-8fc6-49bb-8350-243af7af43b5"
      unitRef="usd">9097600000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTEtMy0xLTEtMA_c10d7cab-e006-4e6c-8c8e-cc3001da188d"
      unitRef="usd">7689100000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTMtMS0xLTEtMA_356eb508-8a83-475b-9ab6-22f3d5e36bee"
      unitRef="usd">2875100000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTMtMy0xLTEtMA_f75d6544-38de-40e1-8397-d2e523d206e3"
      unitRef="usd">3256800000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTQtMS0xLTEtMA_7e3769dd-7339-46a7-9f5f-528f617b5e19"
      unitRef="usd">3138300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTQtMy0xLTEtMA_44fb101d-36c6-4b26-aeda-5985c01b7909"
      unitRef="usd">2890400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTUtMS0xLTEtMA_de167732-9ad6-44f1-9a22-e51a0ed361e6"
      unitRef="usd">804200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTUtMy0xLTEtMA_ac1ff09d-2f8a-4299-9366-7220a7443a25"
      unitRef="usd">824200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTYtMS0xLTEtMA_dcbb75b8-d373-4368-a25b-a1f728724d46"
      unitRef="usd">168800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTYtMy0xLTEtMA_60ca65ce-c853-4fc6-9ec8-72648327789c"
      unitRef="usd">144700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTctMS0xLTEtMA_3c1812ae-9e0c-4172-bd8e-f0ee902f9a19"
      unitRef="usd">16084000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMTctMy0xLTEtMA_525c854d-91ca-4540-b336-c7d5b6b30e89"
      unitRef="usd">14805200000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjEtMS0xLTEtMA_166f6777-7c1e-4758-92fe-081f880e28ef"
      unitRef="usd">443100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjEtMy0xLTEtMA_7a612afa-eb91-4c60-a5fb-f72bd3e0b531"
      unitRef="usd">418100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjItMS0xLTEtMA_db6fd910-654b-4ddb-aa58-51c06fcdf835"
      unitRef="usd">1303000000.0</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjItMy0xLTEtMA_19394bb9-ee18-4be2-80e4-b583cf80c5b2"
      unitRef="usd">1211400000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjQtMS0xLTEtMA_0eb1315a-f6ad-453a-b896-0521e0def60f"
      unitRef="usd">409300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjQtMy0xLTEtMA_e6abb9be-1195-47c6-8427-2739df6490ff"
      unitRef="usd">310500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i734f13176346421b8ee85411fad81c78_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjUtMS0xLTEtMA_20574258-eb96-4cea-b452-0a9d82ebe67a"
      unitRef="usd">85500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjUtMy0xLTEtMA_af3f8842-1440-4fcd-8171-f8f8dcd37952"
      unitRef="usd">71600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjYtMS0xLTEtMA_076500ed-14b5-40a3-b051-fe727cc1d500"
      unitRef="usd">96900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjYtMy0xLTEtMA_da49c2c6-5046-4c4b-b9e3-87d124e2cd02"
      unitRef="usd">85000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjctMS0xLTEtMA_0735c538-abff-4cab-9c55-efda342ab62f"
      unitRef="usd">2337800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjctMy0xLTEtMA_1e47bf59-f84f-4080-8aba-ae2dd621f2f4"
      unitRef="usd">2096600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjgtMS0xLTEtNjg5_8232e958-75c6-4be8-a7b6-464076a17e5b"
      unitRef="usd">1978300000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjgtMy0xLTEtNjg5_306fb074-c9ca-4c79-bfec-0d9b07cafce3"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjktMS0xLTEtMA_8fa03f2c-4c31-4f5c-b194-4d07a27615e2"
      unitRef="usd">716500000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMjktMy0xLTEtMA_e6e0849f-e12c-46dc-974a-86c2304d4ea6"
      unitRef="usd">713900000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzAtMS0xLTEtMA_4ab74318-7d0a-449c-9cd8-171506407c35"
      unitRef="usd">37900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzAtMy0xLTEtMA_9d8bec7e-46f3-4515-87cf-6af2756bdc7a"
      unitRef="usd">27700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i734f13176346421b8ee85411fad81c78_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzEtMS0xLTEtMA_93a4e5dd-ff41-4036-b7dc-5adcabd313d9"
      unitRef="usd">67000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzEtMy0xLTEtMA_f9b2da60-3fea-4112-aedc-878cbfc3007e"
      unitRef="usd">77600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7a3826bcb56c446e85cb1d3861f5eb56_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzItMS0xLTEtMA_ef3eb7e4-6cc1-42f7-b1fd-f0ee73a994fb"
      unitRef="usd">367000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzItMy0xLTEtMA_5689a075-3af3-462a-a6f8-adb5389a2231"
      unitRef="usd">482000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzMtMS0xLTEtMA_9dbb0073-7cbe-4f91-b753-fa72cc800ea1"
      unitRef="usd">454000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzMtMy0xLTEtMA_72709fcb-c36e-479f-a73f-37998e038834"
      unitRef="usd">317700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzQtMS0xLTEtMA_ff69b1af-65eb-433d-8a39-1d07226884d1"
      unitRef="usd">5958500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzQtMy0xLTEtMA_48ce4a28-b66b-479c-89a9-194dce738e16"
      unitRef="usd">3715500000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzIy_1be8e282-4aa8-43b3-88e0-af48fb87ab00"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzIy_ea391c57-9adf-48b9-af31-a7276e864259"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzM2_b2b05b7c-92b6-434e-b626-4cf479b2c12a"
      unitRef="shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4XzM2_d08d20ac-6979-478d-bc89-476a455df8b6"
      unitRef="shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_1df1fa31-56da-44ef-99fa-1770f89105ef"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_2b1433f0-4c66-4e59-93d4-236189bcc98a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_3ca4765c-5fcd-45a5-897c-c9e2c120568a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmUyMzA2ZjQ3YWZlNTQwZTRhZjA3MzZhMmI0Mzc1MzI4Xzgz_42b5b262-fc60-4024-a732-65d0a3d32a6d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMS0xLTEtMA_faf99f04-6799-480c-8790-a9b22c479885"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzctMy0xLTEtMA_13f5aef5-ff11-42b2-bc31-52766ab0efd5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzMz_b4a0c588-0649-4253-9a75-cd1e1fdd95b3"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzMz_b629aedc-935c-40e1-8e13-1522d5040997"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzQ3_1bea6414-a168-4dd9-a05b-d5d19a8791ef"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzQ3_68ad7584-eaf3-4503-b0e0-5a792458562d"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_1d5eb95a-79c9-4b7a-a7f6-ead2f98e4674"
      unitRef="shares">1848970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_223d7a4d-541a-470a-b7c2-e31654ce8f3e"
      unitRef="shares">1848970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_6cbd5075-f26b-4eda-9f05-045bf27293f3"
      unitRef="shares">1848970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjk3NmI3YTU5OTM3NDQ3ZDQ5YWU3ZTc0ZDJhMzFiZWExXzEwMQ_7f739371-1e42-4e12-aa20-1651d766d31f"
      unitRef="shares">1848970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMS0xLTEtMA_54926f44-474c-41a7-9662-41e730d3e772"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzgtMy0xLTEtMA_f24a54db-bf37-4c7e-9d65-e9fe7b7e654a"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzE5_10b3cc76-40c9-4e3a-baf0-6c1edae44e84"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzE5_2fbce3b6-3b70-46dc-92eb-719ffb8a645e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzMz_5ef93481-ce85-4f21-88b1-b4bbade60ded"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0XzMz_c91cd6e9-4fb4-4248-b352-e39ddb672121"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0Xzcx_b39ba46d-363b-4a61-8053-8e44bcbdcd5d"
      unitRef="shares">120516837</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjUyODQ1N2Q0YzM2OTQxZDdiNDVhYWNiNWM3NWFmNzM0Xzg2_7d32c138-169d-4b65-a53b-1964f22c9cf4"
      unitRef="shares">113288103</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMS0xLTEtMA_2a31078e-feda-46e3-a900-c59ebc5389a0"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfMzktMy0xLTEtMA_d9603f74-9103-4f3a-8d71-3e66d598e850"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDAtMS0xLTEtMA_bd358afa-746a-4422-9dd0-ce30ffa0f936"
      unitRef="usd">6592800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDAtMy0xLTEtMA_e77159e9-bf91-4c38-8e65-eaebe12fe380"
      unitRef="usd">4428600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDEtMS0xLTEtMA_24967643-8d6c-4e40-9dd0-e326a33e9be2"
      unitRef="usd">9743800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDEtMy0xLTEtMA_abab785f-7ff5-49a6-b38b-690e8e4defdd"
      unitRef="usd">7379800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDItMS0xLTEtMA_6cdc903b-7a72-471d-83ba-c58bf6b9cf0b"
      unitRef="usd">30800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDItMy0xLTEtMA_d3b76e8d-559f-4d78-ae88-9f675bf8959b"
      unitRef="usd">21100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjAyZTg0MjkwNjc3ODQ3ZjI5ZTQ1Mzg5ZTVkMTEyMzBkXzI5_cc82cd51-1763-4fee-aeb6-742c6f77c5e7"
      unitRef="shares">15741824</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjAyZTg0MjkwNjc3ODQ3ZjI5ZTQ1Mzg5ZTVkMTEyMzBkXzUx_b2ec0c78-9546-4675-a34b-4b5c4e2da4af"
      unitRef="shares">4860123</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMS0xLTEtMA_994ea7c8-cefa-49be-95c4-e3a4eef37971"
      unitRef="usd">6242000000.0</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDMtMy0xLTEtMA_0b79cfb1-53c7-470a-afc1-63f9422db740"
      unitRef="usd">739900000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDQtMS0xLTEtMA_a53bd4e7-a137-44bc-9c5c-aa435f86450f"
      unitRef="usd">10125500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDQtMy0xLTEtMA_8e09cd73-59c4-45e8-a0a7-d03046eaf54e"
      unitRef="usd">11089700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDUtMS0xLTEtMA_f8253dde-cac2-475a-acc8-084276ef895c"
      unitRef="usd">16084000000.0</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xNi9mcmFnOmUwMDY3MDY0MDU1ZjQxZTZiNGE3ZTVhZDUzYWNjYjczL3RhYmxlOjA0ZWYzYWZjZWI5ZDQ2ZDc4OTMzZDY3MjIzYzg2NzMwL3RhYmxlcmFuZ2U6MDRlZjNhZmNlYjlkNDZkNzg5MzNkNjcyMjNjODY3MzBfNDUtMy0xLTEtMA_b224501b-17ee-4d50-b1aa-45958dae3155"
      unitRef="usd">14805200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC0yLTEtMS0w_c239af0e-67e9-4cf1-a29c-ef31d69282bc"
      unitRef="usd">1482200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC00LTEtMS0w_bd04e293-9e1a-4ba7-b4c6-2d811006f02a"
      unitRef="usd">1238300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC02LTEtMS0w_85a5efee-b1a8-4905-8425-d897c9f9023a"
      unitRef="usd">3945800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNC04LTEtMS0w_76bc5f45-48ad-4e86-a3bf-93d36ef5c709"
      unitRef="usd">3548000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1dd19a4363b42258975d1bb4365b864_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS0yLTEtMS0w_f893519b-83e2-4814-b649-4cc7944b182c"
      unitRef="usd">353300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS00LTEtMS0w_a41baa19-87f1-4ce1-887b-133ffd7c7235"
      unitRef="usd">175000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3235f9163fb4412faece41710cd7e880_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS02LTEtMS0w_de1d9330-e7c8-4150-9a63-4eeeed108112"
      unitRef="usd">869300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNS04LTEtMS0w_db545b8c-c874-4188-9eb4-849ef04efc19"
      unitRef="usd">232800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c115ff83ee44b0aa8d8f69f486f45c4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi0yLTEtMS0w_3da64126-1ba9-4ecb-975e-d54aebec446e"
      unitRef="usd">299900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i482f52a211724b65982994e352203f86_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi00LTEtMS0w_ebe16145-5127-491a-9cfc-cd5a58a207d2"
      unitRef="usd">293600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81303cd78a934bbda788e5640aace50b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi02LTEtMS0w_aa3921bd-1f4a-45cc-ac9a-8eead314071d"
      unitRef="usd">825500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNi04LTEtMS0w_c7ef803f-e96c-4323-8247-9135190f1a77"
      unitRef="usd">834800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06871b3ff554800abeeb70d0b62897f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy0yLTEtMS0w_9aac8d32-0343-41ca-ba80-4b74bcc57295"
      unitRef="usd">158600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy00LTEtMS0w_52183e32-9552-4418-ad77-9fbfac69483d"
      unitRef="usd">36800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad3352f230c1452e890cc614c8897783_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy02LTEtMS0w_cefaf36a-7fe3-461d-acfc-a20e944ef57b"
      unitRef="usd">433600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f16611576d448be82f57639682001f2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNy04LTEtMS0w_de41301e-80d0-45e3-a684-aec034202498"
      unitRef="usd">78500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC0yLTEtMS0w_26bbc1be-19c5-4167-acec-d412ab5f99a9"
      unitRef="usd">2294000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC00LTEtMS0w_3202c102-6afb-4975-b4e5-e17c3e3063c7"
      unitRef="usd">1743700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC02LTEtMS0w_9fe33893-3e6a-49ee-a1d5-57f93c306f23"
      unitRef="usd">6074200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfOC04LTEtMS0w_0ced2f3f-617e-4110-a628-144c6623ec05"
      unitRef="usd">4694100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtMi0xLTEtMA_b1779a7a-d588-4c1d-a55e-b3e0898b4586"
      unitRef="usd">684600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtNC0xLTEtMA_34f9d3be-132c-4605-ad16-3813aab8e5a5"
      unitRef="usd">526000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtNi0xLTEtMA_3a723b48-214f-4792-be5a-2abaaa52fcc7"
      unitRef="usd">1990500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTEtOC0xLTEtMA_35e74652-8fd0-42a6-adba-2828333c5586"
      unitRef="usd">1897600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItMi0xLTEtMA_05bf44d8-dc82-4222-b578-e27fd2500f74"
      unitRef="usd">326900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItNC0xLTEtMA_fa262ee9-b14b-4c17-ae3e-9d4ff8fdbaec"
      unitRef="usd">304400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItNi0xLTEtMA_bb1af597-4eb0-4ca6-b057-e211963c1ce2"
      unitRef="usd">1042500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTItOC0xLTEtMA_55969fb0-3e3d-4341-9f72-9c8772873ba6"
      unitRef="usd">890100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib00d67d3ca3d42fdab71b84b35b1f86f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtMi0xLTEtMA_3cd5011d-a6c0-4053-ad72-5f85fe955016"
      unitRef="usd">131000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic66b6615f2bf41348c56a3587daacb1c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtNC0xLTEtMA_a5705949-560c-4010-ad23-a921d0d2abd4"
      unitRef="usd">115900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie7bec991a5644f2d99981bce0d579a4a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtNi0xLTEtMA_00bdf20d-c27e-43f1-8f31-487903e633e3"
      unitRef="usd">312300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0422640c20d24c4085ccac41abf9190b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTMtOC0xLTEtMA_e7052d69-fffd-44d4-884d-55d387bb2d33"
      unitRef="usd">253800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i035f917b860a4f768fe2549dd9543867_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtMi0xLTEtMA_479ebbb1-8a0e-4c76-9285-9f91df9204f6"
      unitRef="usd">143000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtNC0xLTEtMA_e050a474-7442-4e0a-aef6-ac0486fcf28b"
      unitRef="usd">109600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic91b3ef18aaa4ad4a4bf04dc6109978e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtNi0xLTEtMA_15616b0c-3009-4919-abc1-485c0d7a9d3c"
      unitRef="usd">454500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTQtOC0xLTEtMA_ca4869e5-e294-4501-96f5-35076ee67837"
      unitRef="usd">289600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtMi0xLTEtMA_9d354ebf-565f-4e09-b522-8c5e4739f141"
      unitRef="usd">44600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtNC0xLTEtMA_90f8ec72-f2d6-4be4-a4d3-a3daded341db"
      unitRef="usd">50700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtNi0xLTEtMA_804679f2-1bfc-4f70-bbd3-48262f4b612f"
      unitRef="usd">135200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTUtOC0xLTEtMA_fed1e58f-31d5-4a9b-879a-b0a2aa2400a6"
      unitRef="usd">171100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtMi0xLTEtMA_06bda02b-880b-4f54-90c8-c84f9b5f2734"
      unitRef="usd">1240900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtNC0xLTEtMA_87c71931-0418-45da-99b8-3a13065bd767"
      unitRef="usd">1005200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtNi0xLTEtMA_ddce5579-808f-492c-91bc-88ef53831cc6"
      unitRef="usd">3664600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTYtOC0xLTEtMA_91d2d3cf-a20f-4e7e-9424-98761e90429f"
      unitRef="usd">3160000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtMi0xLTEtMA_f2e1df29-638a-4e46-87aa-28f928180e8e"
      unitRef="usd">1053100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtNC0xLTEtMA_e4023517-54da-4473-9db2-826e4b34dc84"
      unitRef="usd">738500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtNi0xLTEtMA_3b13b1fc-2055-41fa-9bcb-126d9fdf93b7"
      unitRef="usd">2409600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMTgtOC0xLTEtMA_ac5fdb20-754f-413f-bd83-d41714048131"
      unitRef="usd">1534100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtMi0xLTEtMA_42c5b1a7-a6e7-4d33-a53b-8b603de26a30"
      unitRef="usd">-28500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtNC0xLTEtMA_d66e3a5c-ada1-48f9-97e1-90c600ca2dcc"
      unitRef="usd">37800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtNi0xLTEtMA_c717d372-86d0-4d3b-8e18-bd00cfba82fd"
      unitRef="usd">218300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjEtOC0xLTEtMA_52cc3a5d-cabe-4f59-95d7-38ece97db440"
      unitRef="usd">28700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItMi0xLTEtMA_6da2213e-38e8-4bd0-b164-3d380c92b14d"
      unitRef="usd">26300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItNC0xLTEtMA_7b9fa7f4-f139-4a06-b71c-44357c901755"
      unitRef="usd">7800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItNi0xLTEtMA_808adc97-f53d-4c0b-af9e-75b2ce337ae3"
      unitRef="usd">42100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjItOC0xLTEtMA_a5176385-f5f7-40a5-aab6-a419cbb754df"
      unitRef="usd">23500000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtMi0xLTEtMA_c614e75c-dfab-4cfb-ad9e-ae798ebd472a"
      unitRef="usd">-54800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtNC0xLTEtMA_1c270f1b-f5f2-467b-80fc-2a9c25f61394"
      unitRef="usd">30000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtNi0xLTEtMA_d838d070-ff8b-44bb-b8f9-993899104d71"
      unitRef="usd">176200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjMtOC0xLTEtMA_e94e51cd-fb5b-4547-bf52-f413794d221b"
      unitRef="usd">5200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtMi0xLTEtMA_81303265-67a9-44dc-90aa-77bf8653d711"
      unitRef="usd">998300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtNC0xLTEtMA_49baa6ba-d31d-42ad-bf16-16aa2cb3d40d"
      unitRef="usd">768500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtNi0xLTEtMA_b2a2e04d-0589-456c-89be-e765ad7c7c82"
      unitRef="usd">2585800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjUtOC0xLTEtMA_7b265d94-874c-49a7-bb21-ce07573db81c"
      unitRef="usd">1539300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctMi0xLTEtMA_d60e2c7a-cff9-490d-b52c-05c64bcf1c00"
      unitRef="usd">156200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctNC0xLTEtMA_793e337d-e021-450e-8a6d-fd631fcf20e0"
      unitRef="usd">98900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctNi0xLTEtMA_b59a7a2f-5a93-49e0-9335-082e61572426"
      unitRef="usd">221800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjctOC0xLTEtMA_537ec8be-15a1-479d-8081-61d29bc1a740"
      unitRef="usd">215500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktMi0xLTEtMA_49a6e178-28a5-4ae3-8ae7-275589249cba"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktNC0xLTEtMA_3aa85e40-b4ad-48fd-b682-80cc2abb660f"
      unitRef="usd">669600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktNi0xLTEtMA_0ffc34b8-aed4-4766-b5b0-07994bbeb0d1"
      unitRef="usd">2364000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMjktOC0xLTEtMA_222b42bf-dc84-4d59-b75d-c399fcc64ba9"
      unitRef="usd">1323800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtMi0xLTEtMA_039aed97-1e89-4612-89c4-3d31733e9a70"
      unitRef="usdPerShare">7.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtNC0xLTEtMA_4e347043-02f3-4044-8728-9ef1ca4e2b55"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtNi0xLTEtMA_fd7eac92-a076-478e-bb83-28ea9c09acec"
      unitRef="usdPerShare">21.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzEtOC0xLTEtMA_71073d6b-39b5-4567-a87f-a66d99a424c4"
      unitRef="usdPerShare">12.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItMi0xLTEtMA_3b934267-5cae-4ed0-b2e3-2337c62a23fc"
      unitRef="usdPerShare">7.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItNC0xLTEtMA_6216e80b-d152-4750-9add-a84ac881f894"
      unitRef="usdPerShare">5.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItNi0xLTEtMA_1bff6f55-574a-4ac8-87c6-fc77e8b88593"
      unitRef="usdPerShare">20.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzItOC0xLTEtMA_8f0ce353-882c-4a68-a071-587329a72ba2"
      unitRef="usdPerShare">11.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtMi0xLTEtMA_f6981412-e0a5-4324-8e2b-e731118c2987"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtNC0xLTEtMA_57091313-a9da-4700-aa97-d3c84d99dd84"
      unitRef="shares">109400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtNi0xLTEtMA_459ab687-9f2c-41ee-a95f-a34080275346"
      unitRef="shares">108300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzQtOC0xLTEtMA_2534a12f-558c-4239-9802-4b039ed2a633"
      unitRef="shares">109200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtMi0xLTEtMA_af2ed847-03e8-4235-8013-ac4965a1af72"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtNC0xLTEtMA_8e67165f-9982-4993-8eb6-ea42d0a930ea"
      unitRef="shares">114200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtNi0xLTEtMA_ceedf006-d512-4b78-913b-69ff24246285"
      unitRef="shares">116100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzUtOC0xLTEtMA_48bdf911-3af8-4b9e-8a39-311861ca1bab"
      unitRef="shares">114700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtMi0xLTEtMA_5289126f-6fb8-4317-8a20-3b14e1c926d5"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtNC0xLTEtMA_b4bc9de7-47d5-4fc8-828d-ad64642d5f83"
      unitRef="usd">669600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtNi0xLTEtMA_3a73fac8-4509-43b2-b2c5-3b2d52e2b4e8"
      unitRef="usd">2364000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfMzgtOC0xLTEtMA_e7e94548-fb16-4105-80c4-a2068a401b72"
      unitRef="usd">1323800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtMi0xLTEtMA_e816b252-889f-471b-b55a-49655e44ee08"
      unitRef="usd">-4900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtNC0xLTEtMA_4003d20c-a08b-48cd-8c20-5b18c6fb842f"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtNi0xLTEtMA_93960eea-9a28-43e4-9fe4-9719bc86b1b1"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDAtOC0xLTEtMA_cf293fe8-111f-468a-912d-5f7b4dd72cdb"
      unitRef="usd">31500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtMi0xLTEtMA_4359e042-090c-4a32-9b03-0b05b58f5e37"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtNC0xLTEtMA_f08ebe7b-6ec9-498b-8a04-29298d140670"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtNi0xLTEtMA_be4b855b-7378-4611-83e8-263f5efd11e4"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDEtOC0xLTEtMA_4951d90f-a7c8-4e27-8861-744c62d539ef"
      unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItMi0xLTEtMA_7d591e5b-3de2-452c-acfc-7cca91b46d5a"
      unitRef="usd">837400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItNC0xLTEtMA_825f331c-5ca4-4046-965c-3a983cf4d421"
      unitRef="usd">670300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItNi0xLTEtMA_26405fe3-7d4b-40a1-b0b7-01e3d8087eea"
      unitRef="usd">2373700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8xOS9mcmFnOjYxMTE2YWJmY2Q0NDQzYzg5YWNjMTE4Y2Y3MTE5NTdkL3RhYmxlOjg4ODllZWY4ZjAyZDRmMjc5NGZhMTI1NzcyYmQ4ZWY5L3RhYmxlcmFuZ2U6ODg4OWVlZjhmMDJkNGYyNzk0ZmExMjU3NzJiZDhlZjlfNDItOC0xLTEtMA_c1462bb7-93ab-4816-adf5-6d9c9e883ebd"
      unitRef="usd">1352600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0yLTEtMS0w_e8e3e16a-ecfe-4042-a8f7-709377aa0ac1"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i226a2220e8914a74a7e8bf7ed82d5f71_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi00LTEtMS0w_243f5a8f-7921-41e4-b503-861b3d6a4b6a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi02LTEtMS0w_2387245a-c705-4924-be1e-5106aa76cb2d"
      unitRef="shares">113300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i35263a3519634adea7dcab66a8b1e11c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi04LTEtMS0w_bbeb83e7-bed4-4038-a1ee-fc6964af7bc3"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifecf127247f14d498c30b360496d431a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xMC0xLTEtMA_35258cd2-d622-404e-80c3-24e90e07e853"
      unitRef="usd">4428600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63e9d4d4034b4d7f982d34bd64567768_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xMi0xLTEtMA_83bccf6f-a191-4308-8578-b731f2e6ee2c"
      unitRef="usd">7379800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic722d7b117f44dfea29c3cd481f51536_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xNC0xLTEtMA_b77d0848-7c80-4c02-b022-05128d9697d7"
      unitRef="usd">21100000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xNi0xLTEtMA_d0345aba-d9f6-43a4-b435-605add861316"
      unitRef="shares">-4900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58c4842d8b024e37aaa83b53c7ea0c39_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0xOC0xLTEtMA_33ea1a2b-9308-4b44-9061-0f7face0f663"
      unitRef="usd">-739900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMi0yMC0xLTEtMA_e0e476a9-5868-493f-a93c-44496ef18020"
      unitRef="usd">11089700000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy02LTEtMS0w_2457f55f-a958-4e91-bb56-9a542868105a"
      unitRef="shares">3100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy0xMC0xLTEtMA_b283433f-6bf7-49eb-8306-a19d60ff8516"
      unitRef="usd">817400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMy0yMC0xLTEtMA_e684881c-411b-4e19-beed-909e89b662aa"
      unitRef="usd">817400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib7870e3d89104b5997896b1fff5540f5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC02LTEtMS0w_e859f055-1bea-4dc6-a9d1-d138eae6c734"
      unitRef="shares">400000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC0xMC0xLTEtMA_b912e933-37ca-4b30-906a-1fbbce002e63"
      unitRef="usd">155100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNC0yMC0xLTEtMA_79ad39d7-bd91-432f-973b-d3124e3fe90a"
      unitRef="usd">155100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xMC0xLTEtMA_c6ba00f1-6956-428b-8dd4-1df7f97ed99d"
      unitRef="usd">12500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xNi0xLTEtMA_672b6d17-3545-40e6-aedd-a123edeeb255"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0xOC0xLTEtMA_57bbbd09-002b-4481-b48b-d64f8ad77b61"
      unitRef="usd">2100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNS0yMC0xLTEtMA_2789379e-a701-4495-ab39-43bf0547e9e9"
      unitRef="usd">14600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0xNi0xLTEtMA_d9c64854-3342-4479-87fc-5f4993441eeb"
      unitRef="shares">800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0d0ab16bd06e40d793715b151421ccc7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0xOC0xLTEtMA_896e0bfa-a58a-4ba8-b1d9-3f94d7094927"
      unitRef="usd">336000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNi0yMC0xLTEtMA_c6c2b6cc-d2a1-43ad-8204-681671cd1f83"
      unitRef="usd">336000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i577c609c14224e14bab80ff04411fadc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNy0xMC0xLTEtMA_68379b91-fc80-4559-b525-284f38d1dbd7"
      unitRef="usd">108000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNy0yMC0xLTEtMA_a0157dfd-f1b9-47e7-83c5-d945221597db"
      unitRef="usd">108000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ibd60199c2fea4aa6b05d646072ecd355_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOC0xMi0xLTEtMA_30dc04ab-96c9-45a9-8e5a-0953b0e48eef"
      unitRef="usd">624600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOC0yMC0xLTEtMA_9d119506-b6ec-40f1-9a75-e3938303a41d"
      unitRef="usd">624600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icb0ffcf9d201484c9266a9e0eb9c3699_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOS0xNC0xLTEtMA_54f52d57-0cd7-4f7e-a376-820bc25fc477"
      unitRef="usd">-30200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6153bc62b7844bcba015e051cd0cd739_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfOS0yMC0xLTEtMA_b650aff9-7b15-42a3-8ac6-c54f906bab86"
      unitRef="usd">-30200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMi0xLTEtMA_1c2e5115-d256-4177-b513-06ae13866f30"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib7cf1e4cac394e3cbc5bab47d00d128a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtNC0xLTEtMA_3ca0af34-7448-4e12-a861-44a7b82f4c99"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i1496d62f31ce472a895a9f7ee128dcde_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtNi0xLTEtMA_1b4d4d92-0c26-4a84-8054-ece2687cb643"
      unitRef="shares">116000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1496d62f31ce472a895a9f7ee128dcde_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtOC0xLTEtMA_291f61dc-e532-4b25-9252-a37df2498e3e"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i675c01e82a4f4e03aae9d3f62c0f88a1_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTAtMS0xLTA_d6179d7c-a11c-4b87-b5fc-42d5001d8bbe"
      unitRef="usd">5211400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5209c4293dba429294a909ce19bcd10f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTItMS0xLTA_32f0a801-c5fc-405f-aa78-079528aba727"
      unitRef="usd">8004400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2a442e00aba438eaf835e73a520b7c9_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTQtMS0xLTA_c44eb738-6c60-477e-95ed-cdeff6354f02"
      unitRef="usd">-9100000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if63987c408794f65bf06da42ebd33fdb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTYtMS0xLTA_d046ee5e-d7df-4e9f-a868-e4c1e3a2631f"
      unitRef="shares">-5700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if63987c408794f65bf06da42ebd33fdb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMTgtMS0xLTA_ade170bd-a685-4ba8-9464-cd45a6bcbc77"
      unitRef="usd">-1073800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e316c4afa634ebfae1c7f8337aa165f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTAtMjAtMS0xLTA_4e22b8b1-c50a-4e39-bbcf-da3e42e726b8"
      unitRef="usd">12133000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtNi0xLTEtMA_f11e8639-d1d3-413b-966e-2e0d6f39c526"
      unitRef="shares">4400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtMTAtMS0xLTA_ac0e8d07-ec14-4aed-ba6b-7655b1d90b42"
      unitRef="usd">1355500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTEtMjAtMS0xLTA_910c19aa-d557-4a07-b7d6-ae4a4fd2532a"
      unitRef="usd">1355500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i5027668f091c4377b315cfcbf10bdabb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItNi0xLTEtMA_1bfefd88-e4ba-463f-8abb-d2c778c29e90"
      unitRef="shares">600000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItMTAtMS0xLTA_b17e5729-f961-4f3b-8bcd-b68f6a24d6af"
      unitRef="usd">416500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTItMjAtMS0xLTA_20e835ef-ac5f-4ad8-b75b-78f0830ef36f"
      unitRef="usd">416500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTAtMS0xLTA_220cd128-408c-4367-a37d-7cd6a0d5d576"
      unitRef="usd">7400000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTYtMS0xLTA_f230793d-c76e-4fea-97c9-07ca4971de97"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMTgtMS0xLTA_d3f7d2ac-79e8-43f5-a8fe-eaccadd75832"
      unitRef="usd">2700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTMtMjAtMS0xLTA_8c736f90-347d-4c2f-818d-cb3add7191e3"
      unitRef="usd">10100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMTYtMS0xLTA_2e75f7b1-8a23-4fda-a298-5eac0b48b416"
      unitRef="shares">9900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibcfcd415bb2c446782f64493530ad23c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMTgtMS0xLTA_c14976ae-5aa0-4d71-b9ba-ea26045a3538"
      unitRef="usd">5071800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTQtMjAtMS0xLTA_35c2bbbb-0799-450c-9006-4b815254dfdc"
      unitRef="usd">5071800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9413ea7b5d0843a88a9a682130b0304d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTUtMTAtMS0xLTA_78234bad-e369-4797-86f0-9429f842b65a"
      unitRef="usd">105200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTUtMjAtMS0xLTA_f1b83fae-cb31-424e-bc17-056103bd8b5c"
      unitRef="usd">105200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i78089fb22ef5491881366c4ba92689ec_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTYtMTItMS0xLTA_52c89546-f4af-41c5-b49b-283405a6b0e1"
      unitRef="usd">897300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTYtMjAtMS0xLTA_501ea93c-f1ba-441e-b1f8-3b5f2aedee9e"
      unitRef="usd">897300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9579d06815ca4b268c93324679499313_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTctMTQtMS0xLTA_f71419f8-4355-4d88-9edb-4a53d6c71355"
      unitRef="usd">44600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i054fd65de2504ca7b16deca9ef996431_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTctMjAtMS0xLTA_f1329863-2d00-4c5e-9206-34c9be6cda62"
      unitRef="usd">44600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i4525169eade14ddd931acd9ebfcd8ca6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMi0xLTEtMA_4ba83225-dd81-48da-8607-2143ae773089"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4525169eade14ddd931acd9ebfcd8ca6_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtNC0xLTEtMA_ee9cf9e2-33ee-4f47-9bd9-28778e3890c4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtNi0xLTEtMA_34913bc9-4cb2-4491-8d86-c893a387131f"
      unitRef="shares">119800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib9d29feeb21a4d3593cba6cf3bbb4ea4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtOC0xLTEtMA_59b70bd0-271e-41bc-8f35-1106ba687197"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia498f71e843b46caa332f9386b2a8a77_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTAtMS0xLTA_d6c5b17a-4560-46d1-9323-a853e52cea0d"
      unitRef="usd">6263000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i406ac9ba980e4136af01f1c5b4139a6f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTItMS0xLTA_05efc902-80ae-429d-a544-b4862972c0d0"
      unitRef="usd">8901700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i133407deeda04cfcaaca9a0f8b8ce3a7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTQtMS0xLTA_15ee1ed3-c871-43c8-a535-752df8b91f59"
      unitRef="usd">35500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i07264113e8534e54adbff64a62edf458_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTYtMS0xLTA_74cfe647-c088-4f08-9fc9-0e2f80a36cec"
      unitRef="shares">-15600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i07264113e8534e54adbff64a62edf458_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMTgtMS0xLTA_e842d5c6-5462-4506-af1d-2baca1463fa2"
      unitRef="usd">-6142900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92b811303f2b4ac48bf302278623bcec_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTgtMjAtMS0xLTA_2202c474-5aa8-4ae3-806f-d6e83f11e546"
      unitRef="usd">9057400000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktNi0xLTEtMTgz_8a269d7c-db5f-4bfc-96a5-921f0bf9634c"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktMTAtMS0xLTE4Mw_57c2145d-1c61-49b6-9233-ef73cef7fa6e"
      unitRef="usd">297500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMTktMjAtMS0xLTE4Mw_50ad8363-f83f-44d3-8c8e-f0e8c9544583"
      unitRef="usd">297500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if9f86fedc3bd4c1d927965e822c4c126_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtNi0xLTEtMTgz_f49deebf-1b76-4977-9a13-74be967640d7"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtMTAtMS0xLTE4Mw_8f47e52f-faa4-43d8-9f5c-6d4bf847d93d"
      unitRef="usd">80900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjAtMjAtMS0xLTE4Mw_c4ba8758-69dd-40cf-8fba-8a1819d7c6c0"
      unitRef="usd">80900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTAtMS0xLTE4Mw_008eebb3-2ebf-4bab-924b-060a7751cb74"
      unitRef="usd">8600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTYtMS0xLTE4Mw_5fe307ce-ccd5-4ff7-8daf-5d17f15b8a9d"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMTgtMS0xLTE4Mw_c9b9a631-633e-4472-bdb8-49385f4cc836"
      unitRef="usd">1300000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjEtMjAtMS0xLTE4Mw_6c212db3-af06-414a-bb19-6569bf5cc7fd"
      unitRef="usd">9900000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMTYtMS0xLTE4Mw_6eebe03d-468f-438e-ac64-c449e2668709"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i02dd5bb351d64ec79abb3ac704b41674_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMTgtMS0xLTE4Mw_6f246869-9421-440f-826e-3bd77aa42032"
      unitRef="usd">100400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjItMjAtMS0xLTE4Mw_0967e828-768d-4904-9938-f773c296b21f"
      unitRef="usd">100400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iccfc5f4f9c78478185f6db5c7ae861e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTAtMS0xLTE4Mw_40e6b3c1-82d5-4e80-b532-0a500a78f55f"
      unitRef="usd">104600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMjAtMS0xLTE4Mw_3031d30b-9515-4bb9-a08f-4feb1942745b"
      unitRef="usd">104600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie9a8e33e4c564462baa741028cfca1b5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMTItMS0xLTE4Mw_d7c65831-fb9f-4044-89c7-6f7696ba82f2"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMjAtMS0xLTE4Mw_b13136bc-b242-4f0d-a8d4-f6e2a54b2351"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i86e212993795477f8b66d1a401e7449b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMTQtMS0xLTE4Mw_32128392-6a6a-4469-ac33-b3241c794389"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMjAtMS0xLTE4Mw_7f1ad5ed-55d9-4c9a-85cd-14ceca3540d3"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMi0xLTEtMTg3_beafbfc8-4999-4a09-a9ad-a5bac507eed6"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9a6e0393261c4d128ba0a8fa3264de7a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtNC0xLTEtMTg3_1a705af3-98d0-4db6-b4b6-836c6b92efc4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtNi0xLTEtMTg3_1d0eb87b-6dcd-4628-889a-8258a340c4e9"
      unitRef="shares">120500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i093941038ceb4a2e8821227dedd1ed05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtOC0xLTEtMTg3_f33d2e73-b0f6-4be5-870f-9b694186ed12"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35565fb3ae5b4966af577b02b5b1a8a6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTAtMS0xLTE4Nw_e174faa0-0582-4b75-b256-5536994dfe8c"
      unitRef="usd">6592800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4784f44bf1f04a1592918d8d7ba96743_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTItMS0xLTE4Nw_c384a80e-f656-4a18-b3be-3145c4b2f78a"
      unitRef="usd">9743800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i926e5a0e99ba4804814d49ee066a7499_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTQtMS0xLTE4Nw_69706770-48bf-48be-bda6-fb6c50055e70"
      unitRef="usd">30800000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5ce1551350fe413883e19b37029324a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTYtMS0xLTE4Nw_d7c35db2-9355-45c5-b831-7f606efc7cd2"
      unitRef="shares">-15700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5ce1551350fe413883e19b37029324a2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTgtMS0xLTE4Nw_3746f862-cd76-4e0b-8b12-be1e50697ad3"
      unitRef="usd">-6242000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMjAtMS0xLTE4Nw_fc338b90-677f-447a-8305-bf58e09cd87c"
      unitRef="usd">10125500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i20a21886017f4e2184b5ab2de327322b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMi0xLTEtMA_85810b28-2136-4262-bda5-86d4c9fdc0f5"
      unitRef="shares">1900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i20a21886017f4e2184b5ab2de327322b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtNC0xLTEtMA_620a6add-1c4b-41b8-acba-ee925943704c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtNi0xLTEtMA_7b518509-ee16-473d-83a8-43e0a3682d01"
      unitRef="shares">111100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5c0a63f62626424f9a3c984dc6b1fa34_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtOC0xLTEtMA_6070c6e0-cf99-4949-91ed-2dd7278edf38"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bd8de61d5594cc0a90ae1aa4ec131cd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTAtMS0xLTA_dfdf2d71-9590-456e-a1c8-63292a06b2a7"
      unitRef="usd">3911600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i68fbf82feee845b8bd4480b59aa72864_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTItMS0xLTA_9aa6b131-a3d3-4dc3-85e6-0e49d0f66aec"
      unitRef="usd">5254300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5381a9cd688d4fc8a51b1cdde15f6dbc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTQtMS0xLTA_5bff65e0-1ea2-4c27-9f37-585cd2ed484e"
      unitRef="usd">-12300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTYtMS0xLTA_74747450-fe1d-48b2-9b6e-b42ebc97192f"
      unitRef="shares">-4000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMTgtMS0xLTA_dca25a98-bb16-4421-b073-67fcfd44663d"
      unitRef="usd">-396400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if30a2465e1c142e4b97306dd631b2630_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjMtMjAtMS0xLTA_2b5a521a-8d39-4cd5-86ac-609b07226548"
      unitRef="usd">8757300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id1dbcf1c58b04386b0b8628caf87d9d6_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtNi0xLTEtMA_15337737-04c4-4e7e-b28b-42a5cd8a6de7"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMTAtMS0xLTA_6783b697-66d1-4e3e-96b8-5da27814bc59"
      unitRef="usd">140900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjQtMjAtMS0xLTA_e0862901-3ebf-4e5a-a414-478b518e4fd3"
      unitRef="usd">140900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMTAtMS0xLTA_171ff380-ecc4-49df-9783-d625e5c2bd48"
      unitRef="usd">10700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjUtMjAtMS0xLTA_b036f360-c5af-466f-ae13-e342a2b3b243"
      unitRef="usd">10700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTAtMS0xLTA_ec0fdf19-c470-409e-95c4-4a98e663767a"
      unitRef="usd">4300000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTYtMS0xLTA_261d4f26-7352-48df-9a2f-6ef482dd93d2"
      unitRef="shares">100000</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMTgtMS0xLTA_5de97b75-45e9-4aad-835a-4b7633ce6d76"
      unitRef="usd">6200000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjYtMjAtMS0xLTA_d1b102e9-944c-469a-89a8-e4ce47705a2b"
      unitRef="usd">10500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMTYtMS0xLTA_5ee42d8a-0632-4b44-9ac2-df01ae85ba23"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0706213d96ae4353a4779f78b35ccd34_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMTgtMS0xLTA_6b532b1b-91d3-498b-be50-90ff0224c357"
      unitRef="usd">54000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjctMjAtMS0xLTA_47241791-c9b4-4137-a770-b637d88bd80e"
      unitRef="usd">54000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if063536fe9e74b93802ebaaa7a37330c_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjgtMTAtMS0xLTA_0512710d-40d3-498a-a3f6-aa2a5a1d18ac"
      unitRef="usd">114800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjgtMjAtMS0xLTA_32d49ce2-e405-4d62-a63a-a8ff88c03524"
      unitRef="usd">114800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i2525fcd8b64f424981d34550a4882b28_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjktMTItMS0xLTA_ed956283-4f32-40b9-95aa-a29b2a3a4eda"
      unitRef="usd">9700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad3302f7141c4de7a1b4ad4a9e1248f3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMjktMjAtMS0xLTA_9617cd2e-3f96-4fa9-aeda-106885512b2e"
      unitRef="usd">9700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0a59ed42376b439fa09f3f52339203c4_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzAtMTItMS0xLTA_a79d1264-f087-43b8-bca5-523f34965ccc"
      unitRef="usd">461100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzAtMjAtMS0xLTA_6a4a524d-9506-49b0-a456-8bc1ed1de4e0"
      unitRef="usd">461100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i06ba7e0bbf404b678cc2a4e9a17e6a98_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzEtMTQtMS0xLTA_28b49a1c-3e3f-4db9-9fd9-7e323513f31d"
      unitRef="usd">15100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie449572134e244aeb3c0162e874670f7_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzEtMjAtMS0xLTA_59ffaa73-bc9f-4c25-b4eb-539b492dbbe1"
      unitRef="usd">15100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i69e52cf5b7084ff6bdac52905e07508d_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMi0xLTEtMA_4f5a11b0-a8be-4538-81ee-7f2c59ad8d51"
      unitRef="shares">1900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i69e52cf5b7084ff6bdac52905e07508d_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItNC0xLTEtMA_a3620e75-f625-4221-bd9f-1de14e08a3c5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i81df8d94688a4785b4fcdee55b999ff5_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItNi0xLTEtMA_9dc05046-1084-49fc-982e-e166976087a0"
      unitRef="shares">111700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i81df8d94688a4785b4fcdee55b999ff5_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItOC0xLTEtMA_d4773826-94ef-41a2-91af-59003725db50"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50e9062cb41a4ef582967a70ea3d968a_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTAtMS0xLTA_08966f29-40b4-43b0-bb52-f43072e1184b"
      unitRef="usd">4160900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7663889c931a45829c5bd7a59fc6c036_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTItMS0xLTA_64e4d32d-a168-4ccc-a134-11acab72949d"
      unitRef="usd">5725100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib28eccdf14bd4f3db6fe4948f581213b_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTQtMS0xLTA_2227144d-f27a-4a3f-ad5a-2ecc66a84170"
      unitRef="usd">2800000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i31fbe348fcbf489c8e3bce16aba7c016_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTYtMS0xLTA_1a1004d3-ff3f-4173-aff1-45761fed403c"
      unitRef="shares">-4000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i31fbe348fcbf489c8e3bce16aba7c016_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMTgtMS0xLTA_6f3806c3-9bab-434f-bac0-0dc5760a2c79"
      unitRef="usd">-444200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida39a32e51e34d42b313e6250995a791_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzItMjAtMS0xLTA_d7c4c713-93e1-43a1-abb6-409c1286e3f7"
      unitRef="usd">9444700000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if627925a7144416dad03494b413c8c61_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtNi0xLTEtMA_4ac6bcbd-169d-43b1-b500-5346cfcddff6"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtMTAtMS0xLTA_62a7fe06-a363-4d46-aa21-9b367cd60d19"
      unitRef="usd">13900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzMtMjAtMS0xLTA_24f667ba-7d09-4f2f-b0f4-0a2fb67524eb"
      unitRef="usd">13900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="if627925a7144416dad03494b413c8c61_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtNi0xLTEtMA_77e62739-2793-418b-b023-20e3673a226a"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtMTAtMS0xLTA_19a1e491-e863-484b-8293-164c1a17f948"
      unitRef="usd">29700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzQtMjAtMS0xLTA_9d538802-3f9a-4c0d-99e3-e8d6f9e8eb49"
      unitRef="usd">29700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMTAtMS0xLTA_b32bcdcd-0bd6-4c3f-8822-12cb5b8f62d3"
      unitRef="usd">9300000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="id5854d26eafb49958a08f5eb2ce7d9a0_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMTgtMS0xLTA_03d4efb4-c02f-475c-9521-f51b4644dff8"
      unitRef="usd">2400000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzUtMjAtMS0xLTA_57fbf4a0-a246-4483-b73f-da6360825aaa"
      unitRef="usd">11700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie2e269b12cc94e3185a8ed24ea5952bd_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzYtMTAtMS0xLTA_4d4026de-ccf6-4dfc-a9f5-f76f74130f3d"
      unitRef="usd">109200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzYtMjAtMS0xLTA_0d82ecf5-fbcf-4478-abff-84267a02341a"
      unitRef="usd">109200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ic6aecf582e764d5c8603bb9cedda4ca8_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzctMTItMS0xLTA_436b2eae-8292-40ef-8481-daca6c0dfbc2"
      unitRef="usd">193100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzctMjAtMS0xLTA_1626b1dd-673c-4bde-a124-9af2f1bb6db8"
      unitRef="usd">193100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e5e669d94774805aabf0020dadd0d57_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzgtMTQtMS0xLTA_11f8329b-54b4-4238-b594-6fd53e155b9d"
      unitRef="usd">13000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0d32369eb9904de592697e700da19318_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzgtMjAtMS0xLTA_11f61342-a293-4a00-aee0-28d8b00ad245"
      unitRef="usd">13000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i377c1ec369d2482fa9a2758786c551a2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMi0xLTEtMA_89679985-f391-42b3-9c18-914951432bf4"
      unitRef="shares">1900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i377c1ec369d2482fa9a2758786c551a2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktNC0xLTEtMA_b4278fcf-a284-4b08-a633-9027e3cfb0fc"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0559295694514aa8be74a966d65f6235_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktNi0xLTEtMA_3aec0d5a-946b-4c28-add6-b87869f1d252"
      unitRef="shares">111900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0559295694514aa8be74a966d65f6235_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktOC0xLTEtMA_2f0810ce-acd8-4292-a012-607eb2b0c19d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i687d1a3db056417a8c3ae24d7fd80e51_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTAtMS0xLTA_aaead11f-2d62-4b61-baea-b07cce97b4c6"
      unitRef="usd">4263600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e5368714b52465da523e0607775d0ec_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTItMS0xLTA_b96c9387-bd86-46e8-8555-54ebb7bf6a93"
      unitRef="usd">5918200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08d3f5064b5a48e29625e4a30f388481_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTQtMS0xLTA_61706fa3-2a16-4465-81f7-0a94966002a1"
      unitRef="usd">15800000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTYtMS0xLTA_b22e73c7-b170-43f0-8940-e09ddb511926"
      unitRef="shares">-4000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifb0cbe5ffb5c41e689fb65118b6a3e53_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMTgtMS0xLTA_0d205916-8951-4eae-b269-f8f5bece59cc"
      unitRef="usd">-441800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6b26cf777144ecea7d36c98690e9db2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfMzktMjAtMS0xLTA_aa5bb63e-d48b-48d5-a154-f9e6261a40d2"
      unitRef="usd">9755900000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtNi0xLTEtMTk2_e62b0047-b014-4c79-9c52-e5dd1a863168"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtMTAtMS0xLTE5Ng_e777c010-2d4d-494b-a692-c9402597f1dd"
      unitRef="usd">8300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDgtMjAtMS0xLTE5Ng_4f4101b3-3a99-4858-992c-aa1427977ea6"
      unitRef="usd">8300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktNi0xLTEtMTk2_3c12bc7f-0b50-4d3b-a766-d9eb901f5fe3"
      unitRef="shares">0</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktMTAtMS0xLTE5Ng_14db3bc7-60a1-4b4a-bc4a-d0ca0af02362"
      unitRef="usd">100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNDktMjAtMS0xLTE5Ng_81f639bf-bd49-4f96-8518-e8f9dcee9a1f"
      unitRef="usd">100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMTAtMS0xLTE5Ng_d061d05a-6910-40b3-a3c2-a7f7b705478e"
      unitRef="usd">3900000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMTgtMS0xLTE5Ng_4884a963-290b-4275-8b2e-cfdd7bae4ab0"
      unitRef="usd">2100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTAtMjAtMS0xLTE5Ng_b3632944-e320-41d5-a1f4-193085927828"
      unitRef="usd">6000000.0</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMTYtMS0xLTE5Ng_9d2e5445-ef2e-4216-9b6a-f1a081a67594"
      unitRef="shares">200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie2c759feb874484d9c65a0976149d579_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMTgtMS0xLTE5Ng_61418293-39ce-409d-a8c1-6da30d22d7a2"
      unitRef="usd">48700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTEtMjAtMS0xLTE5Ng_ff9d60ca-3f46-4384-b060-b26d1779de4e"
      unitRef="usd">48700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="i3a79bd68191745689351c05a41d63699_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMi0xLTEtMjUx_dc3de400-e903-4d37-8d91-f46c9f0c4f7f"
      unitRef="shares">-100000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="ie17aa138cf014ac182d15c8a12b31f1c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItNi0xLTEtMjUx_301f4ed9-3d51-4236-8102-7584cdb4232c"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMjAtMS0xLTI1MQ_616c440d-c01f-4991-9a73-9428d7f15e4c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i30a5a1329f784d05b298d4df4c8c3b87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMTAtMS0xLTE5Ng_a414b0e7-087f-458f-8ae3-68fff290c5bb"
      unitRef="usd">112700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTItMjAtMS0xLTE5Ng_97141f2f-5b85-47e6-a7f0-b44b203b2766"
      unitRef="usd">112700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i8204fd099a854ea1a40d19bf4c7433b9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTQtMTItMS0xLTE5Ng_a91bc911-1552-449a-8840-043f3ec41a54"
      unitRef="usd">669600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTQtMjAtMS0xLTE5Ng_8a7d0ad3-5622-42e7-9b96-43f7671fc079"
      unitRef="usd">669600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i940f4ab7445647329c8c94c4fc6ca764_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTUtMTQtMS0xLTE5Ng_2023c794-cb40-41e2-a58c-556e60cdabdc"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTUtMjAtMS0xLTE5Ng_dd22382c-4b85-4978-a22c-8c0120f0b529"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idedb24cf92424d13afb7f8971ec77486_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMi0xLTEtMTk2_e2d9b042-212a-48f3-b93e-bb7e6766b08a"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idedb24cf92424d13afb7f8971ec77486_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtNC0xLTEtMTk2_6ea8684a-22d4-4a4c-b28e-76d7fde9eb4e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtNi0xLTEtMTk2_456fd602-2f63-4de5-aced-aedd279f1571"
      unitRef="shares">112100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib6e7fd172eb94800b3b10472e81c1f2b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtOC0xLTEtMTk2_2653df92-3239-4ae5-8f20-bd439ba7810f"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8409743b587499c9431d97cf882be4a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTAtMS0xLTE5Ng_767c8a55-9fd1-452d-bb6b-153ae0d5670b"
      unitRef="usd">4388400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb1f38aa9fd24905a4230a517daef524_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTItMS0xLTE5Ng_91895f70-1f70-44ba-b3bb-4fb7b1dc01e3"
      unitRef="usd">6587800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84e068d5db5e440bb019a77918a1f513_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTQtMS0xLTE5Ng_79144c4e-e477-4d69-b2e6-951a7fd810cd"
      unitRef="usd">16500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i24c0d06309ba48f3842f3304738d7c4e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTYtMS0xLTE5Ng_49f4e6c0-1d54-47f3-9cd3-b641405905fc"
      unitRef="shares">-4200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24c0d06309ba48f3842f3304738d7c4e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMTgtMS0xLTE5Ng_8dc7f6d3-0a58-476f-bce9-b0684094a5fc"
      unitRef="usd">-488400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yMi9mcmFnOjk1NTAxNzYzNjgyMDRlMjliMWFiOThjZGM0MDdiZGYxL3RhYmxlOmY4OTdlOGZhYTNmNTQxOGNhMTljZDc1OWFkMjFiMWYyL3RhYmxlcmFuZ2U6Zjg5N2U4ZmFhM2Y1NDE4Y2ExOWNkNzU5YWQyMWIxZjJfNTYtMjAtMS0xLTE5Ng_3bdcfd83-60a3-4d02-b0e0-622c93b87303"
      unitRef="usd">10504400000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMy0yLTEtMS0w_dfb9d71f-8181-4d00-bb92-885ca28ecb0e"
      unitRef="usd">2364000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMy00LTEtMS0w_3c083c20-1a75-49c5-9b16-e90ec410d96c"
      unitRef="usd">1323800000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNS0yLTEtMS0w_af9f821a-c85f-419d-a925-d44f0d10a834"
      unitRef="usd">174200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNS00LTEtMS0w_34099cbb-7fc8-4d30-a6ee-5e40c305ace3"
      unitRef="usd">156000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNi0yLTEtMS0w_ec611798-385c-48a9-af6a-28c1a4084c46"
      unitRef="usd">310500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNi00LTEtMS0w_6e0de783-d1d9-4d11-b49c-be4fb91ad16e"
      unitRef="usd">330800000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNy0yLTEtMS0w_d7639f07-53b2-4cc9-99cf-45a61c9d949e"
      unitRef="usd">111300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfNy00LTEtMS0w_01869839-7a7f-40f7-a38e-4535002604fd"
      unitRef="usd">-113200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfOC0yLTEtMS0w_85adc75c-d8e9-4575-9d73-14efceb02548"
      unitRef="usd">-117900000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfOC00LTEtMS0w_03122a7b-a281-4a3e-971d-6aacc6d31262"
      unitRef="usd">110000000.0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTAtMi0xLTEtMA_49fb3036-7ae7-463a-91df-44161fb14021"
      unitRef="usd">1275300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTAtNC0xLTEtMA_2f2c6fa8-a389-40f4-9cb8-8b2cb5eb099f"
      unitRef="usd">464500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTEtMi0xLTEtMA_c941c38c-9348-45d3-a617-05ddd57b0a1f"
      unitRef="usd">402400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTEtNC0xLTEtMA_33ebdc16-1669-490c-830b-7b22925a9f8b"
      unitRef="usd">227200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTItMi0xLTEtMA_13b6cc0b-7614-4c0a-836c-817384829dc1"
      unitRef="usd">-16400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTItNC0xLTEtMA_44fc92b3-a505-4da6-90f4-f7f4db02e953"
      unitRef="usd">-24800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTMtMi0xLTEtMA_413334af-97eb-4a35-b732-3738f0bd5123"
      unitRef="usd">112300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTMtNC0xLTEtMA_721dd523-f869-4da4-89ce-e3585ee9f4b6"
      unitRef="usd">166800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTQtMi0xLTEtMA_90abec40-7657-494e-bbf4-4e9b159a99c1"
      unitRef="usd">80800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTQtNC0xLTEtMA_ac14f253-1315-4969-ac9c-c1aa18fbd99e"
      unitRef="usd">328900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTUtMi0xLTEtMA_13786f1f-88a9-4d79-ac41-d0554421c896"
      unitRef="usd">-976900000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTUtNC0xLTEtMA_835e34bb-e612-4e7b-8893-9e0f87b3c900"
      unitRef="usd">318800000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTYtMi0xLTEtMA_b1f7ab23-2e80-44af-a8a8-6e21bd5a7c5f"
      unitRef="usd">1387100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTYtNC0xLTEtMA_ffdf97a9-8316-4b9f-bbb3-b28fa4076db6"
      unitRef="usd">1642600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTktMi0xLTEtMA_09f2dc39-86a3-4a5c-afa2-372b3b98c40f"
      unitRef="usd">2642700000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMTktNC0xLTEtMA_3f7d3d1f-5cc1-43c1-8192-a5e30cb28b04"
      unitRef="usd">2834900000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjAtMi0xLTEtMA_3a4ed476-f4f5-4fce-9aaa-9f1e2e38a241"
      unitRef="usd">3330300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjAtNC0xLTEtMA_f57ce5a3-0594-4509-8c44-75c4949fa8c7"
      unitRef="usd">1306400000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjEtMi0xLTEtMA_fd4c0c9e-0fd0-4b85-95a0-5ea67623cb4d"
      unitRef="usd">453200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjEtNC0xLTEtMA_ee75bc93-4091-49ea-b804-bd3e646828f9"
      unitRef="usd">290600000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjItMi0xLTEtMA_74aa7c19-675d-4b86-8ed9-bd0e9444fa2f"
      unitRef="usd">234400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjItNC0xLTEtMA_53d2fc05-69d4-46bd-9265-1b3d01f4056f"
      unitRef="usd">-1819100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtMi0xLTEtMTY3Mw_6681e119-b90b-4b30-bc58-e08ebb7c90d0"
      unitRef="usd">1981900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtNC0xLTEtMjcxNA_ebec76ad-0a07-4242-b4e6-bec8af050d05"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtMi0xLTEtMA_03e9489f-690d-461f-9328-7268d765f3f6"
      unitRef="usd">1500000000.0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjUtNC0xLTEtMA_50477354-2892-4b89-b3b3-d5d90304c93b"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtMi0xLTEtMTY1OQ_c5f99b1e-3d82-4cb7-b565-ad4c5600ca61"
      unitRef="usd">1500000000.0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtNC0xLTEtMTY2Mw_86c5b9a6-9bea-4c09-9024-ca97f542fe95"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtMi0xLTEtMA_0542ea34-d222-4088-8491-5485ce65f16c"
      unitRef="usd">2471100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjYtNC0xLTEtMA_58b8ee6b-8b19-4960-ad6f-271d49dceb7a"
      unitRef="usd">163500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjctMi0xLTEtMA_9edc6dbf-0435-4c04-aa47-e4e5e9ec912d"
      unitRef="usd">652500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjctNC0xLTEtMA_6631c457-8d67-4474-9bbc-af3e8c1cd538"
      unitRef="usd">40500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjgtMi0xLTEtMA_720de301-1fed-483e-b3f1-76e13e19ecca"
      unitRef="usd">5465700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjgtNC0xLTEtMA_66f2be34-3443-46d3-986e-87770e31c5a1"
      unitRef="usd">29400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjktMi0xLTEtMA_3fb13b0f-297a-4d3d-b725-1d8924e5b89f"
      unitRef="usd">-1665200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMjktNC0xLTEtMA_1cf83679-f590-4519-a076-a68fbbc7c4ab"
      unitRef="usd">93600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzEtMi0xLTEtMA_6b299691-3b5d-4737-a955-a069ea368817"
      unitRef="usd">-43700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzEtNC0xLTEtMA_0027a135-9d8e-48e6-a1e1-859630c721ab"
      unitRef="usd">-82900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzMtMi0xLTEtMA_bb1950fc-59cc-431b-b315-25653dd98b19"
      unitRef="usd">1630300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if30a2465e1c142e4b97306dd631b2630_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzMtNC0xLTEtMA_42eb7be2-849a-492d-948d-a8e55c4a8637"
      unitRef="usd">1480200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzUtMi0xLTEtMA_4dbd7b54-81ea-4abf-aa9a-5020ce877edf"
      unitRef="usd">1586600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8yNS9mcmFnOjU0M2U4MjYwZDExNjQ4ODlhY2Y0ZjVlYjljMzBhODMzL3RhYmxlOjgwZmRjM2FlYjRmMDQyNTZiMTNiNTUyYjVhYzk0ZjVhL3RhYmxlcmFuZ2U6ODBmZGMzYWViNGYwNDI1NmIxM2I1NTJiNWFjOTRmNWFfMzUtNC0xLTEtMA_6c01f66a-22c4-498c-8a1f-b03c6161e6c3"
      unitRef="usd">1397300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYxOQ_71f7fe77-63d4-4575-a067-639d7ea185a3">Interim Financial Statements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2019 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, we changed the presentation of cost reimbursements from collaborators who are not deemed to be our customers from collaboration revenue to a reduction of the corresponding operating expense (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, either Research and development or Selling, general, and administrative) incurred by us. We also changed the presentation of amounts recognized in connection with up-front and development milestone payments received from collaboration revenue to other operating income. We made these changes in presentation because we believe the new presentation is preferable, as it better reflects the nature of the Company&#x2019;s costs incurred and revenues earned pursuant to arrangements with collaborators and enhances the comparability of our financial statements with industry peers.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in presentation has been applied retrospectively. The tables below present the impact of the change on the Company&#x2019;s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company&#x2019;s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company&#x2019;s previously-filed Consolidated Statements of Stockholders&#x2019; Equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Balance Sheet Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - Sanofi (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - other (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities - Sanofi (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - Sanofi (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - other (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities - Sanofi (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Statement of Operations Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(766.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,048.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(999.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of collaboration and contract manufacturing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,159.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(999.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Cash Flows Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows from operating activities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in accounts payable, accrued expenses, and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted Accounting Standards Update 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyMw_5cdb53d8-7316-43bd-94f9-57e297a4eff7">Basis of PresentationThe interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2019 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyNg_210cdbf5-cae4-471b-b16c-a8bfd2e845ce">The tables below present the impact of the change on the Company&#x2019;s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company&#x2019;s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company&#x2019;s previously-filed Consolidated Statements of Stockholders&#x2019; Equity.  &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Balance Sheet Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - Sanofi (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - other (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities - Sanofi (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - Sanofi (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue - other (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities - Sanofi (noncurrent)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Statement of Operations Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(766.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,048.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(999.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(455.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of collaboration and contract manufacturing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating (income) expense, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,159.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(999.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.211%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Cash Flows Data:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As Revised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows from operating activities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in accounts payable, accrued expenses, and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi0yLTEtMS0w_b6cccf5a-2ef7-407d-8653-0020b62e94e4"
      unitRef="usd">1086800000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi00LTEtMS0w_50231bda-3586-4c97-b504-dfca7f31eb0d"
      unitRef="usd">124600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMi02LTEtMS0w_c0eedf4f-fa52-4768-9884-a1d45ae2228a"
      unitRef="usd">1211400000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy0yLTEtMS0w_396a67ea-cec1-4010-bacb-ad21622c4ec0"
      unitRef="usd">395500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if260882197374baea06d232c9dbdae20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy00LTEtMS0w_fa6a5833-1df7-4ac4-8a26-cf0e2d3e0128"
      unitRef="usd">-85000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfMy02LTEtMS0w_014a2dfb-0dfd-4150-a9dc-27924b99b854"
      unitRef="usd">310500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i13a06a306ebb4c579cddd781e1b375c6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC0yLTEtMS0w_a7046ae1-f416-45eb-82a5-3a1ca958f59b"
      unitRef="usd">196200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8fe190863af84a0296aa289188b4b233_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC00LTEtMS0w_36205649-63b4-4d82-9c25-19214bb31c55"
      unitRef="usd">-124600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNC02LTEtMS0w_2212a20c-f8fc-4b5d-9770-2911f05ed2d3"
      unitRef="usd">71600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS0yLTEtMS0w_e775f7b3-864b-44ea-9fab-5806740315e5"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS00LTEtMS0w_81a2b824-8b65-4254-802e-951c157dea2a"
      unitRef="usd">85000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNS02LTEtMS0w_7f3e2dda-862c-4a15-aded-3c10cc10713c"
      unitRef="usd">85000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi0yLTEtMS0w_76f93769-56f7-43f7-84e5-88ba1ab86404"
      unitRef="usd">509700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if260882197374baea06d232c9dbdae20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi00LTEtMS0w_203ca74c-7ff6-4bca-80ee-196f6f4745a3"
      unitRef="usd">-482000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNi02LTEtMS0w_a00cc79d-d22c-472d-842c-2952e697005c"
      unitRef="usd">27700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i13a06a306ebb4c579cddd781e1b375c6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy0yLTEtMS0w_e2796d9e-4f06-4a34-9a04-8168f6600f2a"
      unitRef="usd">109300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8fe190863af84a0296aa289188b4b233_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy00LTEtMS0w_9881e2f3-22f2-47b1-987c-8818dc40083b"
      unitRef="usd">-31700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3527c3431d2b4fb2877bd0fa88aa4194_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfNy02LTEtMS0w_f436a8ca-5870-40ec-9e7e-8ad9969f2c10"
      unitRef="usd">77600000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i93ab20c00413412fb90e7a9897470fa0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC0yLTEtMS0w_adb77fda-0a38-434c-a65d-0e362d4fbd0d"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if260882197374baea06d232c9dbdae20_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC00LTEtMS0w_c8792565-f57b-4d8b-abb6-61e0e8525d2a"
      unitRef="usd">482000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="icdef9ea245ea41c3a7db2e6a4b0a7c62_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOC02LTEtMS0w_0c8460c9-ad25-4004-895d-10f0c3d2130e"
      unitRef="usd">482000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS0yLTEtMS0w_5f2b24a8-a93b-46c3-bc71-2251dd767da4"
      unitRef="usd">286000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i208259b9728c4fb78df67ba613da6db2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS00LTEtMS0w_73433392-a444-4de6-b2e2-64933224ab48"
      unitRef="usd">31700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOmE5YjU2N2IzYTkxMDRiZDI5ZDEyNzY5MGRiMWQwMTBmL3RhYmxlcmFuZ2U6YTliNTY3YjNhOTEwNGJkMjlkMTI3NjkwZGIxZDAxMGZfOS02LTEtMS0w_e03c2c03-5f53-47dd-a120-be8ce60f5ae2"
      unitRef="usd">317700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee18f385dd8849668c5be259e457682c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0yLTEtMS0w_a99ef078-d84d-4631-9591-83a0ba1bf089"
      unitRef="usd">404200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic00f8b9e2a0b49449c6f19540f28b731_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi00LTEtMS0w_e1ce017a-cdb2-4f78-9694-ac5fb6a945f0"
      unitRef="usd">-229200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic71c4dc269a749d587d976b958a1f06f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi02LTEtMS0w_f0ba655e-2671-4185-a374-776ca833139b"
      unitRef="usd">175000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i936c971cd6804e7ab94e27735c0fdef9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi04LTEtMS0w_8f8a580b-7c43-40a1-9ad3-2642dc9e7938"
      unitRef="usd">999700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia007c7f6d5ed4efca99a88aa3102d6a6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0xMC0xLTEtMA_af57cc9d-a267-4a98-b906-b04879c29f66"
      unitRef="usd">-766900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74cdc4c59dbb4afba5d2b2a1a14366ed_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMi0xMi0xLTEtMA_dfcb25f1-7a47-48ad-96cc-6efc6790c697"
      unitRef="usd">232800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib420108285b94badbb732b426062abd7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0yLTEtMS0w_b4217b40-3f7e-4614-9820-3050b9d28c85"
      unitRef="usd">302800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief4a936fac9948ef8229a2a83ad922ea_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy00LTEtMS0w_2a092e41-8a95-4f8b-8100-b90de90f9277"
      unitRef="usd">-9200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i482f52a211724b65982994e352203f86_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy02LTEtMS0w_56380e75-c185-4969-af7d-4aaabdc25cdb"
      unitRef="usd">293600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id60df2d7f3b5418e8a6614f237c06dd7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy04LTEtMS0w_44918eae-6961-43cc-9db0-a9303d653122"
      unitRef="usd">868000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i341faabd353947de903f5e3eff280493_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0xMC0xLTEtMA_786a5c55-06f9-4a0d-9b99-412f6149d1ed"
      unitRef="usd">-33200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb8b82d49ea74db6b3983e621d938e10_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMy0xMi0xLTEtMA_0acf6829-3c1a-4554-bd10-8f4587163e83"
      unitRef="usd">834800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24811c1ea905459f8e11c86cf166e750_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0yLTEtMS0w_ab49b12b-6585-4855-a807-9d6792f5c446"
      unitRef="usd">103100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d26b43c17754b828848943ea0e32972_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC00LTEtMS0w_c2606ffd-92c4-4ba0-bcf5-17304dda1627"
      unitRef="usd">-66300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3a47e47b8345a5a379c3505207bb4f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC02LTEtMS0w_9b8f835f-0dfe-43e2-8e76-c487617d9b6b"
      unitRef="usd">36800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2384b7830806480cbeaa6244e94a5866_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC04LTEtMS0w_e98726fc-efc2-4500-95d7-218238d5a495"
      unitRef="usd">278200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cd7679bb2cb437b89a2c91b4e76a30b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0xMC0xLTEtMA_5199cdf0-d153-4927-8c8d-ff8049a48d9d"
      unitRef="usd">-199700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f16611576d448be82f57639682001f2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNC0xMi0xLTEtMA_071f82a9-e51d-40d6-8a94-2936a4755308"
      unitRef="usd">78500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0yLTEtMS0w_992b5a6b-7878-4fcb-8e65-fe8696b15d97"
      unitRef="usd">2048400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS00LTEtMS0w_623799c9-6525-407a-ae21-4500c1a2e919"
      unitRef="usd">-304700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS02LTEtMS0w_f2608b91-0289-4059-a193-571a33410955"
      unitRef="usd">1743700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS04LTEtMS0w_a0104f39-fe5d-42df-81ea-8a2b5983c55e"
      unitRef="usd">5693900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0xMC0xLTEtMA_3d20ce9d-f18f-4ce2-8519-c42251bc4a9e"
      unitRef="usd">-999800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNS0xMi0xLTEtMA_2042b809-0ca4-4e5c-8135-96773531b801"
      unitRef="usd">4694100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0yLTEtMS0w_17d1be19-656a-47e9-84c6-201ab575e595"
      unitRef="usd">663400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy00LTEtMS0w_267e6e58-78ec-4206-b30b-f95890722b2b"
      unitRef="usd">-137400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy02LTEtMS0w_c66e1e3b-87f8-47c9-a754-d88af638b689"
      unitRef="usd">526000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy04LTEtMS0w_ffe26c2e-f48e-4b38-9b67-837af91715c9"
      unitRef="usd">2353500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0xMC0xLTEtMA_483f82d9-033e-43a1-bacf-72126d8d7a53"
      unitRef="usd">-455900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfNy0xMi0xLTEtMA_d6290db7-6180-4756-961a-d98236feb91a"
      unitRef="usd">1897600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0yLTEtMS0w_d1656827-0c36-497c-bf82-a22b7be40c0d"
      unitRef="usd">419900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC00LTEtMS0w_ad05a51e-de80-41af-8706-8f3846b15e06"
      unitRef="usd">-115500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC02LTEtMS0w_cef040cd-8b9f-43a4-a07a-74519f37187a"
      unitRef="usd">304400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC04LTEtMS0w_cfa8fbd0-993b-45c9-ac42-c875417b70e4"
      unitRef="usd">1248000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0xMC0xLTEtMA_6d72f4d8-7c68-4aba-b785-1832b45a86b8"
      unitRef="usd">-357900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOC0xMi0xLTEtMA_5365a784-aa54-4a0d-9028-d2f2abae3419"
      unitRef="usd">890100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51906d645bca4b2ca7899fcbd47e0874_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0yLTEtMS0w_8875b4bc-d1e8-49d9-b133-5bef0bc77943"
      unitRef="usd">110700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5f0ba82258c54e758ead2a40321a3329_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS00LTEtMS0w_7d3a4f35-8ba3-47b2-9d76-857b51e3e357"
      unitRef="usd">-1100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i72f61e9c5ba04d63a753df679cb06ceb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS02LTEtMS0w_c61e7260-5c62-4c3e-8cf9-9073d91bed73"
      unitRef="usd">109600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iedbfb2b1ebb640c1b73cd3e30e74c02f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS04LTEtMS0w_51d3f690-56b3-4847-a6f3-2f27f6225774"
      unitRef="usd">304500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4f6d86539ab6438a81f9d17a87d8108d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0xMC0xLTEtMA_043c0646-8748-45f2-bfa5-f6a6c6450916"
      unitRef="usd">-14900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id3e8b3c12909499c9547c15588fbc143_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfOS0xMi0xLTEtMA_d9a92e9e-e287-48ad-bf98-e183d59c1f93"
      unitRef="usd">289600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMi0xLTEtMA_2f9c926a-7d45-4aed-bb14-da179dd6118c"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtNC0xLTEtMA_d22d8fe7-25ba-4871-82b5-3f34b1bcc1b4"
      unitRef="usd">50700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtNi0xLTEtMA_7e4c25d7-4150-4154-8958-290eab98433f"
      unitRef="usd">50700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtOC0xLTEtMA_30005e13-92f7-48ac-ac30-a873301905e0"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMTAtMS0xLTA_f493e873-3846-48e6-91ea-47cd408755db"
      unitRef="usd">171100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTAtMTItMS0xLTA_0ee20c27-7a1c-4ed4-abfe-7af9cb3d6d96"
      unitRef="usd">171100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMi0xLTEtMA_a12db32b-be2a-47ef-bbd4-e59f8ad67862"
      unitRef="usd">1309900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic6c29fc6c8dd481fbcc296866fa3375b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtNC0xLTEtMA_1e50bc46-5bc1-462b-aa49-b4ca380be6d6"
      unitRef="usd">-304700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtNi0xLTEtMA_ed089f25-dacf-45a8-8da1-afdf43132ba7"
      unitRef="usd">1005200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtOC0xLTEtMA_d1171a50-8eb1-4be1-b039-367fbf762319"
      unitRef="usd">4159800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMTAtMS0xLTA_3157a891-fabb-4fc8-9bbe-12666caa6240"
      unitRef="usd">-999800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjJmMDkzYTc1NTY0YzRkZTM5YmU3MzdiNTkxMWYyYzM5L3RhYmxlcmFuZ2U6MmYwOTNhNzU1NjRjNGRlMzliZTczN2I1OTExZjJjMzlfMTEtMTItMS0xLTA_264d0616-fee4-423a-8529-c6afa2fa896a"
      unitRef="usd">3160000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy0yLTEtMS0w_d33cdd5b-87af-48d4-9316-50b14c33e24e"
      unitRef="usd">375800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy00LTEtMS0w_350de7bd-263e-4850-9dc7-35b37336a870"
      unitRef="usd">-209000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfMy02LTEtMS0w_721dd523-f869-4da4-89ce-e3585ee9f4b6"
      unitRef="usd">166800000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC0yLTEtMS0w_878d291b-dd19-4c44-871b-c02fb476d31a"
      unitRef="usd">119900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id48a087203eb4f9783b6cb9463e4e374_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC00LTEtMS0w_9e897a55-5bce-4dab-aeb4-7d16d766088d"
      unitRef="usd">209000000.0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RhYmxlOjAwNGUwMDM1MzljMDQzMGU5MGExN2ZjYmRiZDBhODUyL3RhYmxlcmFuZ2U6MDA0ZTAwMzUzOWMwNDMwZTkwYTE3ZmNiZGJkMGE4NTJfNC02LTEtMS0w_ac14f253-1315-4969-ac9c-c1aa18fbd99e"
      unitRef="usd">328900000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:UseOfEstimates
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYzMQ_68de30cc-2d64-4982-a2ab-85e8f4bc1aa9">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zMS9mcmFnOjcwZjY3NjgyZDhmMzRlNTNhMmIxNTdjZjc2ODkwM2YwL3RleHRyZWdpb246NzBmNjc2ODJkOGYzNGU1M2EyYjE1N2NmNzY4OTAzZjBfNDYyMA_adef3e3f-ea8d-48c7-9665-823df3a7bd3f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted Accounting Standards Update 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <regn:ProductSalesandConcentrationRiskTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzQ0_e29045fa-c5a2-4d2f-90d7-eed52527e9cd">Product Sales&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.461%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Net Product Sales in the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,422.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGN-COV2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2020 and 2019. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:ProductSalesandConcentrationRiskTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzkw_d188e176-a73e-4f1f-8fea-e3ced16b6ce1">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.461%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.093%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Net Product Sales in the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,422.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGN-COV2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,548.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a52597c51f5412492f6c132bf465821_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi0yLTEtMS0w_de4845f7-7d53-46df-a5d6-290f5f546a39"
      unitRef="usd">1318300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdc6f6996a634c0e9b097ac2f58e752b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi00LTEtMS0w_019e14dd-6364-4547-b1d2-7379ac2edd2d"
      unitRef="usd">1187700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59fc78e9a3304a3bac95b0cf117279a6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi02LTEtMS0w_52291d83-e2b0-407e-8494-3c689fea19b5"
      unitRef="usd">3604000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c30004e4fe94ba4875ced4b468677a8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMi04LTEtMS0w_acbfe5ae-87bf-4f5d-81bd-9fe33448ce26"
      unitRef="usd">3422100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7289e9b303ae482ab10a155371fd403e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy0yLTEtMS0w_ab0e6607-58d4-481f-b3db-ee5601dc3384"
      unitRef="usd">71600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e2d6a85606748b6ae2be54b2683aae9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy00LTEtMS0w_a76197bc-237f-47c4-904e-1df4489be232"
      unitRef="usd">47600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae4274b29daf4675ab09b5e77fa76d58_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy02LTEtMS0w_431386e8-1764-473e-b5f1-f926b04aec3e"
      unitRef="usd">196600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf0ca2aae29d4d96bd94dc0a09fb6e08_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfMy04LTEtMS0w_bfedbd4d-5fe7-4c30-9021-3354579203db"
      unitRef="usd">115200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbbdbae70a344ee9bc01b9143fdf9a7e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNC0yLTEtMS0w_eeab2b3a-cdc4-4d32-807c-5b66f336b085"
      unitRef="usd">48500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7e691f7dab4bb58c1c0765d7ddc72a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNC02LTEtMS0w_2ada5c66-6d60-4834-8f1b-6030c198dc7d"
      unitRef="usd">95700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfabd1b7b627426f9a33e66492f38481_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS0yLTEtMS0xNzE4_4a99a258-22dc-4aa6-af0b-bcb3a344d09e"
      unitRef="usd">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b02c0994812409f96b2fbccef842513_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS00LTEtMS0xNzIx_b4b0b185-eda8-4a8f-b5f7-83be5e35e49d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5aac854b44a486b905645bbb8b852d8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS02LTEtMS0xNzI0_070e04ce-f3c5-4cad-8501-fc4714e87220"
      unitRef="usd">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1323fcbcb772436a8c497dcb0925c29a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS04LTEtMS0xNzI3_6185d894-53df-4857-a556-3f9528b60e18"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8fab8149afc476fbcd010d6fac8dfc3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS0yLTEtMS0w_efd6ac90-e520-4ba1-a9fb-ceec4f67a1c6"
      unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72da8bc596c7486cb41228ce22a460c6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS00LTEtMS0w_de67da9e-01ca-4694-a75b-ce6dfd2215eb"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c4ff746cc404cf9a2e0326b7e30ecb8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS02LTEtMS0w_cd470544-1236-48a1-a78b-205b7a2a9eff"
      unitRef="usd">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i913cae035ec5417db5bb2235faaa5b0c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNS04LTEtMS0w_3aad05ac-e2a6-40ec-932a-c1c8fce7ab09"
      unitRef="usd">10700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf58700054b74965a4154a14e0348fc2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi0yLTEtMS0w_fed5e3a0-27ba-41f2-96a8-2cbe0ab7af56"
      unitRef="usd">1482200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id287f840c8b942fb96eb5ac0f597ff16_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi00LTEtMS0w_beef9c7c-3d22-4d98-a4ee-d9fe4fed30e9"
      unitRef="usd">1238300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i259fa8cda2034a8485dd4d98ae1d54b9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi02LTEtMS0w_0ef48ace-f085-4b2d-9349-be83634a9128"
      unitRef="usd">3945800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i210976468f6d4beea437d37b4aa63663_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjc4NDYyNjA2NTczYjQ5MDViNjZlZDMzMzMzMjY4YTFiL3RhYmxlcmFuZ2U6Nzg0NjI2MDY1NzNiNDkwNWI2NmVkMzMzMzMyNjhhMWJfNi04LTEtMS0w_ed57d318-95ac-47c0-bedf-a0f1f71c041d"
      unitRef="usd">3548000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RleHRyZWdpb246OGJjMDFmMmE3Yjc5NDc0ZTgxYmIwNmE5MjI5ZjFmYWVfMzYy_3fc99624-787a-40bf-a09b-9d1592063d30">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e0f96f1723947e68a27075b552c4719_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi0yLTEtMS0w_e00c54ad-fd80-4a92-8689-a2934433bbe1"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30e9eead3dd34158b0429a505019d3f1_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi00LTEtMS0w_7ec4cf90-49f4-4626-b402-7ea241f66c46"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93c5788ee66d4e5e89464da41cc6269a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi02LTEtMS0w_f32ea93b-4be9-4e13-acab-78867a7b4293"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i63d16524c09f42f9bc5b0d1c70c5817e_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMi04LTEtMS0w_6db8f366-e919-4009-8f12-1bde8cf9885e"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i793d1c60fb2e41319710da444819bf38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy0yLTEtMS0w_44222c18-0f9b-4444-bd94-f8242e62edf6"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66079e1a96d94e1eab04aea3ea86a08b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy00LTEtMS0w_704a55ef-c4c9-40a6-a8e9-50d9b9a7270e"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i89ae37db927b4fae8c60dc4bbeea1188_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy02LTEtMS0w_74810e15-b7a3-40fb-a634-7db57c946fbc"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i77597e8bfdd64fe2bae163eb8fec1490_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNC9mcmFnOjhiYzAxZjJhN2I3OTQ3NGU4MWJiMDZhOTIyOWYxZmFlL3RhYmxlOjk3MTMwMjliNTFlMjQwZTRhMjAzMWU3ZGM0NjFjODMxL3RhYmxlcmFuZ2U6OTcxMzAyOWI1MWUyNDBlNGEyMDMxZTdkYzQ2MWM4MzFfMy04LTEtMS0w_cd644c1e-8cb0-4607-bb9c-b74fb0da427f"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDU_a9c8bacc-1130-4f96-9ffb-79356dda9a46">Collaboration, License, and Other Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize product candidates and utilize our technology platforms. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we are entitled to reimbursement of all or a portion of the research and development expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred. In connection with the commercialization phase of our collaborative arrangements, we may be obligated to perform commercialization-related activities on behalf of the collaboration. If we are reimbursed for all or a portion of costs incurred for the commercialization-related activities, we record those reimbursable amounts in the period in which such costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;are obligated to use commercially reasonable efforts to supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator; however, recognition of such cost reimbursements is deferred until the product is sold by our collaborator to third-party customers; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for such quarter. These estimates are reconciled to actual results in the subsequent fiscal quarter, and collaboration revenue is adjusted accordingly, as necessary.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. Sanofi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestone earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of losses in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 8 and Note 10 for information regarding Sanofi's sale of our Common Stock during the second quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antibody&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the companies' Antibody License and Collaboration Agreement (the "LCA"), following receipt of the first positive Phase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate ("Shared Phase 3 Trial Costs") are generally shared 80% by Sanofi and 20% by Regeneron. All other agreed-upon worldwide development expenses incurred by both companies are funded by Sanofi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Refer to the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" section below for further details regarding the Letter Agreement and Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi leads commercialization activities for products developed under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. See discussion below related to the development and commercialization of Praluent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effective April 1, 2020. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $200.0&#160;million in additional sales milestone payments from Sanofi.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 is the last quarter for which Sanofi and the Company will share profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp;amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#x2019;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#x2019;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration is governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company ("IO Development Activities") under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. If Sanofi exercises its option to license rights to a BCMAxCD3 Program antibody or MUC16xCD3 Program antibody thereunder, it will co-develop these drug candidates with the Company through product approval. Sanofi will fund development costs up front for a BCMAxCD3 Program antibody and we will reimburse half of the total development costs for such antibody from our share of future IO Collaboration profits to the extent they are sufficient for this purpose. In addition, we and Sanofi will share equally, on an ongoing basis, the development costs for a MUC16xCD3 Program antibody. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the IO License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab), an antibody targeting the receptor known as programmed cell death protein 1 (PD-1). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. Pursuant to the Letter Agreement, the Libtayo development budget was increased and the Company has agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to the Libtayo development and Dupilumab/Itepekimab Eligible Investments incurred in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;periods through September 30, 2020 by selling certain shares of our Common Stock directly or indirectly owned by Sanofi; if Sanofi desires to sell such shares, we may elect to purchase, in whole or in part, such shares from Sanofi. See Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States and the parties equally share profits and losses from worldwide sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $951.0&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. Bayer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's net profit in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of collaboration and contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. In addition, the Company and Bayer share the funding of agreed-upon EYLEA development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable - other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;c. Teva&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company and Teva entered into a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan. The Company is also responsible for the manufacture and supply of fasinumab globally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable - other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $130.3&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;d. Intellia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either we or Intellia select pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at our option or Intellia&#x2019;s option, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gene edited products. In connection with the agreement, we made a $70.0&#160;million up-front payment, which was recorded to Research and development expense in the second quarter of 2020, and purchased 925,218 shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, was also recorded to Research and development expense in the second quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;e. Biomedical Advanced Research Development Authority ("BARDA")&lt;/span&gt;&lt;/div&gt;In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement ("OTA") with BARDA, pursuant to which the U.S. Department of Health and Human Services ("HHS") is obligated to fund 80% of certain of our costs incurred for certain research and development activities related to COVID-19 treatments. In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished REGN-COV2 to the U.S. government. The agreement could result in payments to the Company of up to $450.2&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish and storage activities. See Note 2 for REGN-COV2 net product sales recognized in connection with this agreement during the three months ended September 30, 2020.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDY_8bb06e26-1528-4ee8-bcfc-3ec55e9db07b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize product candidates and utilize our technology platforms. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we are entitled to reimbursement of all or a portion of the research and development expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred. In connection with the commercialization phase of our collaborative arrangements, we may be obligated to perform commercialization-related activities on behalf of the collaboration. If we are reimbursed for all or a portion of costs incurred for the commercialization-related activities, we record those reimbursable amounts in the period in which such costs are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;are obligated to use commercially reasonable efforts to supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator; however, recognition of such cost reimbursements is deferred until the product is sold by our collaborator to third-party customers; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.&lt;/span&gt;&lt;/div&gt;Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for such quarter. These estimates are reconciled to actual results in the subsequent fiscal quarter, and collaboration revenue is adjusted accordingly, as necessary.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMDc_2c309fd4-ba73-45ea-9a37-e922e05c6527">In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits or losses in connection with commercialization of products &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties and/or sales-based milestones earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's research and development expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestone payments to collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of Regeneron's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction to Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of collaborator's commercialization-related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestone earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of losses in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's net profit in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bayer collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of collaboration and contract manufacturing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7440ca289f91448e86b7140c31a5c495_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy00LTEtMS0w_744df0ca-1423-4970-9547-c794dee5ca0a"
      unitRef="usd">212800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a3b75b9f9ab41f6b1c862dcdff343eb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy02LTEtMS0w_5a2451a6-6e60-441d-bb8d-66b88faca7b9"
      unitRef="usd">94200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i629b8945a2b244738e800fb84f2b891d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy04LTEtMS0w_00943ec6-9932-457f-adb3-45fbe918fc49"
      unitRef="usd">555600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7992d88a42314fd9959ab26fd254bdc4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMy0xMC0xLTEtMA_fa080ccf-5c7b-4c47-8f07-a561039ec3a1"
      unitRef="usd">105200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC00LTEtMS02OTY0_884b3748-f00e-4b4e-87f6-bff466ee9f7f"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a403650d89b4cdbacb41612bdcdc2fa_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC02LTEtMS02OTYx_b985136f-e419-4c5b-af7b-a043a0c54d98"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7bc77d612f847c88293dde238e89d6f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC04LTEtMS02OTY5_db8efe0c-f198-4c52-9875-515dee411337"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i858f26c124514e65930d2a7c4d3ae840_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC0xMC0xLTEtNjk1Ng_b142b4e1-cd6a-4e29-a5e1-36f0ee9a8672"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f34054df8504a19a5ad1c41cc47fff2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC00LTEtMS0w_9461da00-7fd8-485d-8afc-8be663e46c99"
      unitRef="usd">94300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieccb4e85845442c5b68026da6ae50775_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC02LTEtMS0w_b568d400-7282-4221-8fcb-884f541a25a8"
      unitRef="usd">85400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7812846c7af642bf8c717b3128434e3f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC04LTEtMS0w_cff26084-0691-4307-b446-0918c65c0894"
      unitRef="usd">275000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50af2d0e293b46ddb00a3419f1912ad6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNC0xMC0xLTEtMA_bda05ae7-061d-4378-87cc-cc77e9fcb322"
      unitRef="usd">143800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i8f305f8e6ace47fd86b9631dd499da4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS00LTEtMS0w_eea2f547-e475-48f6-ad7c-39a451c79065"
      unitRef="usd">45500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i50af2638268242f6b59b88d1b6a5770b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS02LTEtMS0w_7ea77717-f0fd-4414-8f2b-e87d315ee8e7"
      unitRef="usd">60200000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ib39afe508e4c415cbb06cf308ee47ccb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS04LTEtMS0w_7e820851-2cb5-4d26-8266-7a3e895361cc"
      unitRef="usd">174400000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i23e99f703b684f02a5aa414ea753d8aa_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNS0xMC0xLTEtMA_167f830e-fe95-425b-89cb-740cd4b98d5d"
      unitRef="usd">216500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0e216705cab94a00b9676a165f2bcefa_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi00LTEtMS0w_4eee9c29-d3f6-4366-b9c8-d1a51abf0fce"
      unitRef="usd">17500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id4d68f82974548b4bee81aecd0a90d14_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi02LTEtMS0w_e39b8c56-8870-4119-8c83-d87625169ccf"
      unitRef="usd">10200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie3e8d4c3b1834a21843449aa8b585d68_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi04LTEtMS0w_ede3123e-7f92-4856-9903-e76339a24c62"
      unitRef="usd">59100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i975f4a743b164615bd2ef7edf00f00b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNi0xMC0xLTEtMA_daef76fd-19bd-4058-a479-422d5eae014b"
      unitRef="usd">29800000</us-gaap:ResearchAndDevelopmentExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i32c2a84796d544b182e6e74ceb73a585_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy00LTEtMS0w_7562a8dc-2930-44ef-bed1-24e2053ef54e"
      unitRef="usd">83200000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i155a77df03774a34b4015dc1801c5b18_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy02LTEtMS0w_211a088f-033c-4cea-b821-949be6f0fcf6"
      unitRef="usd">111600000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="if30550b7dd2b49b4b69c045354a6a07f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy04LTEtMS0w_7e2a8c75-d865-44f3-96e3-a6591ee7432e"
      unitRef="usd">260400000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i0e159ae1bc03421c808cd526f3c49fb0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfNy0xMC0xLTEtMA_3b1502aa-b704-4c27-a2ab-66c849cb875c"
      unitRef="usd">349300000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ae24fdf2ba43769cc7901206518a12_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtNC0xLTEtMA_47c594f8-3a6a-42a1-ae16-87b4c92198b3"
      unitRef="usd">-4700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e4206c910554d81af805977f3002947_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtNi0xLTEtMA_1b6ca553-eded-46e6-9b40-2522db3685a9"
      unitRef="usd">-4600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09a1e9f85cf481ab3cc770922ba3391_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtOC0xLTEtMA_f1455444-f792-4572-9173-ca813a5b8084"
      unitRef="usd">-17300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f74bf2738be48258c23b0dcbdaa12ea_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTAtMTAtMS0xLTA_1effb4f0-4234-481e-9c8f-47d3725ff3ac"
      unitRef="usd">-16200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f86c58c4b574796881d49e37d000bae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtNC0xLTEtMA_358ae22b-b410-4e56-b4c4-4350a56687a5"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice9e38a9d51f4fbaa964316765d51ca0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtNi0xLTEtMA_642284cf-ef21-4da8-b0fe-bc08d9f96f6a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i424392c0a0484adfafb25cbcffa01a84_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtOC0xLTEtMA_fb956469-b99f-4cc1-81ff-506944013e86"
      unitRef="usd">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife607ecedd0549008b720df4da98fba3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTEtMTAtMS0xLTA_60bdf886-c9bf-4c26-a1e3-fb83f6c77009"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i524b4d40e946437f9cc3badd5234eca4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItNC0xLTEtMA_151f086f-4c77-4986-b9e2-84f64fa8c50b"
      unitRef="usd">49800000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i249d2b86432a4c65bd64b122b30b44a1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItNi0xLTEtMA_7e98a21d-f587-4d76-bed4-100a4d0bff3e"
      unitRef="usd">38000000.0</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="icd85c66a10c44e869a10593d3b0aae6e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItOC0xLTEtMA_93a75ebb-c78e-4fd7-8267-12db21d795e6"
      unitRef="usd">136700000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i903692403a774f48bb520b2c3aaa8879_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTItMTAtMS0xLTA_4225e2a8-84be-42a7-9d62-0d7aa0548c26"
      unitRef="usd">120900000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i11c8625c815b4033956a9b3202d3f56e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtNC0xLTEtMA_8f92827c-f8f2-4bb6-935e-13cfeacffc76"
      unitRef="usd">14500000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="ie1288473dda949c38b342de4f098cc6d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtNi0xLTEtMA_dd070612-f61e-4e52-84e2-6bc618ebca7e"
      unitRef="usd">3000000.0</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i125e5e85d95a405e8280fe383b98b6c0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtOC0xLTEtMA_802b51c5-7436-42ce-bcf7-39e229c731c2"
      unitRef="usd">39200000</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <regn:ReimbursementOfSellingGeneralAndAdministrativeExpense
      contextRef="i3725af6673294f5aa8ee78886c09a9af_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTMtMTAtMS0xLTA_030f0875-dd56-449f-875a-c9c28137238c"
      unitRef="usd">7000000.0</regn:ReimbursementOfSellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9269fb1edbc04cd1ac5f2238658e8872_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtNC0xLTEtMA_098ed103-353d-4a5f-b903-3f9a951925dd"
      unitRef="usd">31500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i789f27d056fe4015b571c9fc45b1bdc3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtNi0xLTEtMA_76ba87b6-5d99-4132-a8ca-c34defdeea33"
      unitRef="usd">20100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4bfa0b97e54d49f7a24ff6f66c316d8b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtOC0xLTEtMA_5da45898-7eb1-462f-9c2b-3537b88725f9"
      unitRef="usd">86500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i89320920064f41bf969faeb62c0e0007_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTQtMTAtMS0xLTA_b6899adb-aa17-4b14-bd16-195dfa352cab"
      unitRef="usd">51500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncome
      contextRef="i7075e6f52bc44235a553c88375786049_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtNC0xLTEtMA_ca6fd9b9-5016-490e-bdc7-5bf3c2dd02f3"
      unitRef="usd">20000000.0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i5f314f4872f04da6b2b01389f0883f09_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtNi0xLTEtMA_0369dcd9-52b6-44c1-a1d2-4a6f11ca7f37"
      unitRef="usd">18500000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i2cd6be8d9b3e4d459a816ed46de88b98_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtOC0xLTEtMA_dda28939-f0a6-4bd4-8319-ccaed8cb8fc3"
      unitRef="usd">57000000.0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="if734d160735a4b25bcf2df8175aebb38_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjI4ZjY3ODE5MGNkYjRjMzJiMzQwZGM4MzVhOWM4YTRjL3RhYmxlcmFuZ2U6MjhmNjc4MTkwY2RiNGMzMmIzNDBkYzgzNWE5YzhhNGNfMTUtMTAtMS0xLTA_cd4acc1d-4ea9-488e-8f4a-f87efab75e13"
      unitRef="usd">73800000</us-gaap:OtherOperatingIncome>
    <regn:PercentageOfTrialCostsBorneByCollaboratingParty
      contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDUzOA_0e34b4a1-e713-4c68-97ee-3bc536514d36"
      unitRef="number">0.80</regn:PercentageOfTrialCostsBorneByCollaboratingParty>
    <regn:PercentageOfTrialCostsBorneByEntity
      contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDU1NQ_03277c11-421a-49a7-9a73-63bfd16a3a88"
      unitRef="number">0.20</regn:PercentageOfTrialCostsBorneByEntity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i585fe77826e544afaaba8b754a15fd8b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIwOTQ2Mjc5MjUwMTQ_8883698c-27be-426c-ba4b-8231ccb89140"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived
      contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk1ODU_1e8629dc-438f-4036-b485-c39db6bb2059"
      unitRef="usd">1000000000.0</regn:Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk2MjY_122e92ca-837a-41f6-858d-9202bbea9599">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels
      contextRef="i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzOTMxNjI4MDk1OTk_d1e3020e-0c10-4e72-81fa-a84b9bd366b0"
      unitRef="usd">200000000.0</regn:MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels>
    <regn:ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTYzMTA_89fb03e0-b6fe-4b55-8276-7b2998f0327c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable - other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable - other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</regn:ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i647137868b2d4017a026a60b257f74d9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMi0yLTEtMS0w_3d16af4d-5ecf-4582-94d9-1b27b5520240"
      unitRef="usd">453200000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i82b9876c37a342a39a55d03fb7cd497c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMi00LTEtMS0w_c7f6b155-d4a3-496e-ac91-b7ed336bef97"
      unitRef="usd">272700000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i647137868b2d4017a026a60b257f74d9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMy0yLTEtMS0w_ac7233d0-aca0-4561-9817-17086c46dfc5"
      unitRef="usd">433600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i82b9876c37a342a39a55d03fb7cd497c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjM4YTc3MTNlMjM1YjQyYzE5OThlZjgzYzhhMzJmZjU2L3RhYmxlcmFuZ2U6MzhhNzcxM2UyMzViNDJjMTk5OGVmODNjOGEzMmZmNTZfMy00LTEtMS0w_dc93b195-efd9-437c-b9a4-fdbf900f975e"
      unitRef="usd">328800000</us-gaap:ContractWithCustomerLiability>
    <regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates
      contextRef="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNjgwMA_4bdea737-5e65-461c-a8f7-24e30c1b826d"
      unitRef="number">0.05</regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates>
    <regn:PercentageOfRoyaltyPaymentThatCanBeOffset
      contextRef="i768f3f67a5ad413cb73fbc810de0d72b_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNzkyMg_065cdc8d-efcb-4c24-b20a-17d28d314cd9"
      unitRef="number">0.50</regn:PercentageOfRoyaltyPaymentThatCanBeOffset>
    <regn:LossContingencyPercentageOfDamagesResponsibleFor
      contextRef="iae5e5290e8774b0c9acd7d63220a0d1d_D20200401-20200401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfODAwNA_54465ded-0fdd-4adf-b882-c80b423f4f55"
      unitRef="number">0.50</regn:LossContingencyPercentageOfDamagesResponsibleFor>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMi0yLTEtMS0w_ab787d91-6b9d-4327-9f5f-0635ea8a9c84"
      unitRef="usd">4500000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMi00LTEtMS0w_0b299b60-92e9-4662-9743-f8b0107ade58"
      unitRef="usd">16700000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMy0yLTEtMS0w_ee89babf-b13c-4855-a2ed-6b71306885a1"
      unitRef="usd">13600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfMy00LTEtMS0w_0e6c768c-31fa-4e93-a63a-7785df64cccc"
      unitRef="usd">9400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OtherLiabilities
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfNC0yLTEtMS0w_f8529c72-326c-4179-ba6b-9ebca410489e"
      unitRef="usd">441800000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="ibcdbc69b1cfb4c809d8f1bde183015c3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjdkNDdkYzVjNGViZjQ0MTdhODZjYThiNTFjZjZiMGIwL3RhYmxlcmFuZ2U6N2Q0N2RjNWM0ZWJmNDQxN2E4NmNhOGI1MWNmNmIwYjBfNC00LTEtMS0w_d688a391-5deb-4fcb-bc04-bc4489e08c27"
      unitRef="usd">558600000</us-gaap:OtherLiabilities>
    <regn:UnsatisfiedObligation
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTE1MzU_1406b577-0f83-4b07-b99f-4a89e8384c95"
      unitRef="usd">951000000.0</regn:UnsatisfiedObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ea0893a48f488d8f88308c3e9ee61b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi00LTEtMS0w_cf302205-e140-4722-bbb0-35ade1237e20"
      unitRef="usd">287900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2ac5fc163d3459aa29a0f7e270b195c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi02LTEtMS0w_9c34ba9b-492d-4e12-b376-24b400bf9b73"
      unitRef="usd">275000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62eefa1863e47f7a276818d52328f65_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi04LTEtMS0w_7d66321e-a392-4c92-8971-1cd64dde8e9d"
      unitRef="usd">772600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a032ed700df48e8b4754328ea168c43_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMi0xMC0xLTEtMA_33443449-a87c-456f-985c-22f03307dcb9"
      unitRef="usd">793300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa95e30f69814af0a60388d1bb9f88a6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy00LTEtMS0w_955dfca7-92ab-4029-838e-43344dfcbd24"
      unitRef="usd">12000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbd823974b604b1390f3616a69d17bd6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy02LTEtMS0w_4a349ee6-e157-4324-9f0a-3beabff51da9"
      unitRef="usd">18600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc38fd53dce24fa3abe9de323809035c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy04LTEtMS0w_797b2bf7-cda0-4e2b-9e31-63a2da7afb6e"
      unitRef="usd">52900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33902f27fb464f2788858727dc0f48f4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfMy0xMC0xLTEtMA_5857c0fd-c792-47b2-9804-3fcb6cf08aa5"
      unitRef="usd">41500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ibd88b5df537c46f0a7f3172ab2b40960_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC00LTEtMS0w_28fedd43-bfbf-4062-8d75-a910a69c48a3"
      unitRef="usd">11500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i2e78e3764fb346d9abe7fb4037bb0528_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC02LTEtMS0w_a4bf2b1b-dad4-4d33-8074-0df5f0f92cdb"
      unitRef="usd">5000000.0</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i5aef510b4bff453f8d176f79acb15431_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC04LTEtMS0w_469566b8-9edf-4ef1-9612-ab7c6240b73c"
      unitRef="usd">34300000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="iba52ce52c05f40beba9639ea3d78c7d3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNC0xMC0xLTEtMA_bcfc279c-dbd5-4fd8-b447-72978844d8ff"
      unitRef="usd">15600000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia7e6521a7a684a99872680a1548d3d37_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS00LTEtMS0w_6ac8ba05-700b-46e7-90fc-c1e5b2c06ad4"
      unitRef="usd">12900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i01db19eff4ba44168b83edd0617cc0bb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS02LTEtMS0w_4a7f3fca-34cc-4dc2-b8ad-c64ad752e229"
      unitRef="usd">7000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8f67f970eb284b439ef2084a5ddf0c4e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS04LTEtMS0w_2170ef48-deda-48d6-b366-b91c64ae5d00"
      unitRef="usd">26300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc03aab082174d41aa16b8adf809207e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNS0xMC0xLTEtMA_16427b29-776c-446a-954a-7c0803476838"
      unitRef="usd">13600000</us-gaap:ResearchAndDevelopmentExpense>
    <regn:ReimbursementOfOtherExpenses
      contextRef="i042578dd0f7942d0837b6e77eecbd085_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi00LTEtMS0w_c65c9533-ede2-4c1f-bdc7-6771615fb52c"
      unitRef="usd">2000000.0</regn:ReimbursementOfOtherExpenses>
    <regn:ReimbursementOfOtherExpenses
      contextRef="ia17ddd9842744aaea31d03825f513ff8_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi02LTEtMS0w_1f41d730-1ccd-4cf9-b826-592273b79b12"
      unitRef="usd">3700000</regn:ReimbursementOfOtherExpenses>
    <regn:ReimbursementOfOtherExpenses
      contextRef="i4e0d66d038e84724bc6951ccc43d25a5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi04LTEtMS0w_487cbeec-ea5a-40a1-95d2-3de4517bda44"
      unitRef="usd">5300000</regn:ReimbursementOfOtherExpenses>
    <regn:ReimbursementOfOtherExpenses
      contextRef="i0b24fd379cb345f092d697825567373e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmIzNWIxZjM1NGJhYzQ5ZDNiYTFjODk5YzcxZjFkZGY0L3RhYmxlcmFuZ2U6YjM1YjFmMzU0YmFjNDlkM2JhMWM4OTljNzFmMWRkZjRfNi0xMC0xLTEtMA_7d9b2522-a594-4145-b4eb-35aa208ec4fb"
      unitRef="usd">16600000</regn:ReimbursementOfOtherExpenses>
    <regn:RevenuebasedonpercentageofannualsalesinJapan
      contextRef="i796be097beaf45008b0b52db759c841c_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIyNDk_4dccc00a-33a2-4177-9cab-35d9ccc61143"
      unitRef="number">0.335</regn:RevenuebasedonpercentageofannualsalesinJapan>
    <regn:RevenuebasedonpercentageofannualsalesinJapan
      contextRef="idab077eab2b448d4bc8e7af35fdefa59_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTIyNTY_9ac88637-eb5f-421e-9dd5-ebfa5a686ae2"
      unitRef="number">0.400</regn:RevenuebasedonpercentageofannualsalesinJapan>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="i5351df69b749490991f52fb2919ecaa6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMi0yLTEtMS0w_f988f7d4-4276-4825-a2ac-d047a7898b1d"
      unitRef="usd">299200000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="if1febd6b0737446ebac35bb01d092f15_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMi00LTEtMS0w_bf67ca46-2a32-4746-8065-42812a9f18db"
      unitRef="usd">311600000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5351df69b749490991f52fb2919ecaa6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMy0yLTEtMS0w_70795f4f-3325-4774-91ce-b0a455a430bf"
      unitRef="usd">122100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if1febd6b0737446ebac35bb01d092f15_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOmQ5YWQ1ZWM0YWRmOTRkZGZhMzg0OTExMTE1NWE5OTJiL3RhYmxlcmFuZ2U6ZDlhZDVlYzRhZGY5NGRkZmEzODQ5MTExMTU1YTk5MmJfMy00LTEtMS0w_6b508f78-a7c5-4acb-9ee3-0cd35fcdc0df"
      unitRef="usd">123000000.0</us-gaap:ContractWithCustomerLiability>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi00LTEtMS0w_fc9279f5-a3bc-4f36-93e6-9a93c567079b"
      unitRef="usd">25900000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i7058246a9659451f88d94beb0d3ec13e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi02LTEtMS0w_7a952c69-70e1-4e94-ad69-d7a8d49571f1"
      unitRef="usd">34200000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i0ae545194ff24904a88dd0e9092398b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi04LTEtMS0w_27926c0c-ec4c-41af-8515-e08eea4afb66"
      unitRef="usd">82100000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ibe3f67d977694fb89ca3de52695ce285_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMi0xMC0xLTEtMA_c99f13f1-eb9c-4095-b225-5c7c12f8f2d2"
      unitRef="usd">102900000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:OtherOperatingIncome
      contextRef="idf58477014064d2aa4d6dc03bb6963ed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy00LTEtMS0w_2b8f0b75-cf31-4e1e-865a-d3c8f288a505"
      unitRef="usd">17200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ic85be8c3176d432ca84c44b9cab50dde_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy02LTEtMS0w_3310c870-7925-4c62-acbc-087f614a484b"
      unitRef="usd">22800000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i64bf72d6126149e4abf801ce66065da4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy04LTEtMS0w_28e02546-38ba-4803-a827-014a12babc0d"
      unitRef="usd">54500000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ic184b458c91d499fa1a5711477b97f68_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjhiOTlkZTFhOGI2YTQ2MDlhN2E5YjllZTQzZGNhZTE5L3RhYmxlcmFuZ2U6OGI5OWRlMWE4YjZhNDYwOWE3YTliOWVlNDNkY2FlMTlfMy0xMC0xLTEtMA_cf6ec5a5-c2ef-4591-bc34-90630de65248"
      unitRef="usd">68800000</us-gaap:OtherOperatingIncome>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMi0yLTEtMS0w_38b2e504-7cf4-4a33-b4d1-a44effb759f6"
      unitRef="usd">26600000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:AccountsAndNotesReceivableNet
      contextRef="i36638689867843109daff532397d136a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMi00LTEtMS0w_d4650ebe-509b-4da1-af83-6829698ff8a8"
      unitRef="usd">21200000</us-gaap:AccountsAndNotesReceivableNet>
    <us-gaap:OtherLiabilities
      contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMy0yLTEtMS0w_5652d9d0-3fc2-48a1-a932-577dbc1b55d4"
      unitRef="usd">61000000.0</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i36638689867843109daff532397d136a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RhYmxlOjljNmI5MzBiZDZmZTRiMTNhMDFlYzk4NjY1YzI3MWY2L3RhYmxlcmFuZ2U6OWM2YjkzMGJkNmZlNGIxM2EwMWVjOTg2NjVjMjcxZjZfMy00LTEtMS0w_e8cc66a4-4479-4a90-afcc-f774bdd2f5f4"
      unitRef="usd">114400000</us-gaap:OtherLiabilities>
    <regn:UnsatisfiedObligation
      contextRef="i478c123cbdf04a5693d39fe47d38ee54_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTM2NTM_920ee32d-4a91-48aa-a87f-465a91ab165d"
      unitRef="usd">130300000</regn:UnsatisfiedObligation>
    <regn:CollaborativeArrangementUpfrontPaymentMade
      contextRef="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUxNzY_84c9e19d-134a-4b7f-b19a-9c83c8bd5656"
      unitRef="usd">70000000.0</regn:CollaborativeArrangementUpfrontPaymentMade>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUyOTc_fab32658-d3a3-4300-a128-3ef6dbc4c35e"
      unitRef="shares">925218</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i3e329e6feefb45cf9ed05530b0d0a61d_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTUzNjc_659310ba-8706-4616-b7e8-7d0f10adcc8e"
      unitRef="usd">30000000.0</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTU0NTA_b5cbc141-7388-415b-a94b-87ceae82201c"
      unitRef="usd">15000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <regn:PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty
      contextRef="i6e8b16b9d02f4c5db91ce70d178e3e91_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfMTU4MDc_bfd06ea7-be4e-4bf5-b9b2-e02180c8ee26"
      unitRef="number">0.80</regn:PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty>
    <regn:MaximumTransactionAgreementPayments
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF8zNy9mcmFnOmM0ZmUyN2Q3OTI5YTQ1Y2Y5Y2IwNDYzMmVlYmM2YTk2L3RleHRyZWdpb246YzRmZTI3ZDc5MjlhNDVjZjljYjA0NjMyZWViYzZhOTZfNDk0NzgwMjM0MzU0MQ_95128095-2fe7-44fa-9b7b-0f5a294bc8b6"
      unitRef="usd">450200000</regn:MaximumTransactionAgreementPayments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzg1_4e56942b-68e2-47ea-b24a-fff1cda862a0">Net Income Per Share &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's basic net income per share amounts have been computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive, include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzky_528d453a-aa90-4223-b954-3faa242c0dcd">The calculations of basic and diluted net income per share are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.900%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;669.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi0yLTEtMS0w_49a6e178-28a5-4ae3-8ae7-275589249cba"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi00LTEtMS0w_3aa85e40-b4ad-48fd-b682-80cc2abb660f"
      unitRef="usd">669600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi02LTEtMS0w_0ffc34b8-aed4-4766-b5b0-07994bbeb0d1"
      unitRef="usd">2364000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMi04LTEtMS0w_222b42bf-dc84-4d59-b75d-c399fcc64ba9"
      unitRef="usd">1323800000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS0yLTEtMS0w_f6981412-e0a5-4324-8e2b-e731118c2987"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS00LTEtMS0w_57091313-a9da-4700-aa97-d3c84d99dd84"
      unitRef="shares">109400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS02LTEtMS0w_459ab687-9f2c-41ee-a95f-a34080275346"
      unitRef="shares">108300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNS04LTEtMS0w_2534a12f-558c-4239-9802-4b039ed2a633"
      unitRef="shares">109200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iffa227b8deba441693b33a2fbafddb8e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy0yLTEtMS0w_15a8dd81-78a9-4092-8077-e372ade81dc9"
      unitRef="shares">7800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2ab2a78eec84461897d6a611b6915df8_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy00LTEtMS0w_8e30ead8-e75e-46f9-85ac-32c693863c24"
      unitRef="shares">4800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia9825a846e164e5ea7cfe55e771e11b5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy02LTEtMS0w_70f3d513-99c4-404a-b941-8d1e49e9efd8"
      unitRef="shares">7300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic7f5db47717d49e1844b3f7b3174f1dd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfNy04LTEtMS0w_98f4c1e5-e7bc-4818-a879-43f3bb99609a"
      unitRef="shares">5500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ife0ade14d07348fea114a6a08fedda5a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC0yLTEtMS0w_1093fad9-63b4-4f28-a5fc-f64054dd2b89"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9f33ed3e59d44118a5a40e3435d58ef8_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC00LTEtMS0w_4f5ce628-183e-4b49-83fa-44066c55e0f8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iff9d9e2ee1494f5f9a4f9463de7838e6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC02LTEtMS0w_1b2dc336-5cfb-4114-94f5-99b63c768d8b"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i66510b4d5ffc47b6a9f4b37c4c429ca3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOC04LTEtMS0w_c068f51c-ec9c-44a3-94b9-364cbec65a56"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS0yLTEtMS0w_17d8d3f9-d847-4be2-a719-e68c18824d25"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS00LTEtMS0w_cdfea998-08c1-43bb-9123-72260aa85f91"
      unitRef="shares">114200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS02LTEtMS0w_dbfc10b4-dae0-4e8e-bf26-f1383f431394"
      unitRef="shares">116100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfOS04LTEtMS0w_5a80aa04-9ee1-4787-a95d-f8512e8ec771"
      unitRef="shares">114700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtMi0xLTEtMA_039aed97-1e89-4612-89c4-3d31733e9a70"
      unitRef="usdPerShare">7.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtNC0xLTEtMA_4e347043-02f3-4044-8728-9ef1ca4e2b55"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtNi0xLTEtMA_fd7eac92-a076-478e-bb83-28ea9c09acec"
      unitRef="usdPerShare">21.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTEtOC0xLTEtMA_71073d6b-39b5-4567-a87f-a66d99a424c4"
      unitRef="usdPerShare">12.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItMi0xLTEtMA_3b934267-5cae-4ed0-b2e3-2337c62a23fc"
      unitRef="usdPerShare">7.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItNC0xLTEtMA_6216e80b-d152-4750-9add-a84ac881f894"
      unitRef="usdPerShare">5.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItNi0xLTEtMA_1bff6f55-574a-4ac8-87c6-fc77e8b88593"
      unitRef="usdPerShare">20.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjU3YTA3MDkxOGY1ZjRlMTY4NTVkYTNmMzgwMTFjODg3L3RhYmxlcmFuZ2U6NTdhMDcwOTE4ZjVmNGUxNjg1NWRhM2YzODAxMWM4ODdfMTItOC0xLTEtMA_8f0ce353-882c-4a68-a071-587329a72ba2"
      unitRef="usdPerShare">11.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RleHRyZWdpb246OTJiMmIxODA3ZjVhNDk3YzgzOWExYzMyMTI4ODlhZTdfNzg3_ff30ba46-a168-4bf3-b0d3-c25c68e16167">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive, include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.964%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib54c03b4823b4871926f13634d87caab_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi0yLTEtMS0w_86de6484-5d85-45dc-be14-379ce94748e0"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9207f4bbca3f4cf89c0781ee2963e848_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi00LTEtMS0w_a05513a1-e386-48a7-b42e-57f15f2cd679"
      unitRef="shares">18300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icafbbe3c8ece417ea95836d71b2b8d9c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi02LTEtMS0w_c8b108ca-be71-4b5d-8b27-d21697f503db"
      unitRef="shares">2600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia323b61d6ca54592b8470bc4a3c536af_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMi04LTEtMS0w_c57e916e-33bb-487f-a4ca-cd90c3750342"
      unitRef="shares">18200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i78f643a7609c4ebfbb43b0e1032cdde6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy0yLTEtMS0w_2fe251fe-0f7e-4b02-877c-a727d730fc2b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60c6215466c64dd8a803be94b251edda_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy00LTEtMS0w_df928c5f-5e82-41c6-b8bc-dddb5a324d00"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id810e98c23264dd7862faff8c51896f0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy02LTEtMS0w_6a79d869-c649-47bf-8899-59a9b5bbf895"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if92d56f793334c729cbf51da9cc2bb80_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80MC9mcmFnOjkyYjJiMTgwN2Y1YTQ5N2M4MzlhMWMzMjEyODg5YWU3L3RhYmxlOjAwMjk3NDUwYjQ3NzRmMWFhMTk2NmY1MTNiOWFlZDJlL3RhYmxlcmFuZ2U6MDAyOTc0NTBiNDc3NGYxYWExOTY2ZjUxM2I5YWVkMmVfMy04LTEtMS0w_3de6dc70-428d-4426-8175-8928cba5ee07"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1Mg_55d23157-fda5-4db1-bcf5-2330dd13e9f3">Marketable Securities&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities as of September&#160;30, 2020 and December&#160;31, 2019 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,508.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2020 mature at various dates through September 2025. The fair values of available-for-sale debt security investments by contractual maturity consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September&#160;30, 2020, realized gains on sales of marketable securities were not material. For the nine months ended September&#160;30, 2020, realized gains were $28.5&#160;million. Realized losses were not material for the three and nine months ended September&#160;30, 2020. There were no realized losses on sales of marketable securities, and realized gains were not material, for the three and nine months ended September&#160;30, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to marketable securities, for the three and nine months ended September&#160;30, 2020 and 2019, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities (as described above).&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1OA_ba57d6b4-24c0-4b8a-a93a-f79a40056ede">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,508.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,206.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi0yLTEtMS0w_bc224c04-60c3-448e-8497-c4d7d760d63b"
      unitRef="usd">2796600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi00LTEtMS0w_aff25c92-db44-4be8-80ad-53ee60278dff"
      unitRef="usd">40100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi02LTEtMS0w_8208a845-21d0-417b-b2c6-0c77aae40a75"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6371d5d148549828b6707ade5b5f0ea_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMi04LTEtMS0w_16e17ae5-85c2-4741-b74d-e062385ab2e5"
      unitRef="usd">2836000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy0yLTEtMS0w_23a971b2-0013-4649-abac-dc34dda84b86"
      unitRef="usd">133500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy00LTEtMS0w_45da744d-9392-403a-868e-0e2c81730d5e"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy02LTEtMS0w_5f34c7ed-ed0c-495c-9e57-95c2117cdad1"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id99617e0fbe44be4ba82c4083676868b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMy04LTEtMS0w_1dfc23b3-60e2-46f0-9aaa-c8a49a7cc4d3"
      unitRef="usd">134700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC0yLTEtMS0w_a09eaa1b-50c3-44f0-8beb-46bf6c69a702"
      unitRef="usd">65400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC00LTEtMS0w_4cbe6d27-6c1d-4cac-bb30-804f11e980a8"
      unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC02LTEtMS0w_f1af3fdc-7943-4971-b785-d2dbe530d647"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2f12ac6d96642d3afe120dc2407f7e9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNC04LTEtMS0w_d8c8c86a-7585-4ec6-9047-a0f668d5fd67"
      unitRef="usd">66600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS0yLTEtMS0w_ef7832a4-2b1a-473e-8add-13d239e6afa0"
      unitRef="usd">390400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS00LTEtMS0w_49260689-545a-488d-8d47-e2563c2c77ec"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS02LTEtMS0w_7d42a829-471a-48c4-87bb-d860adc57321"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i911314304b514431af13b55d5a2dc5ca_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNS04LTEtMS0w_c4ea5e71-2d74-478d-bd54-f7e4116988d5"
      unitRef="usd">390600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi0yLTEtMS0w_c54c7974-767d-47a7-a15f-3aa08fa79bab"
      unitRef="usd">122400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi00LTEtMS0w_9f46754a-bc07-4419-8a01-b9e527b01d1f"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi02LTEtMS0w_147c74ef-57fc-46dd-a7c9-569c417b6354"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a25246f43da4ad1b8d8e5b7d20dfd3e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNi04LTEtMS0w_312763a5-5eec-4d3e-87e3-b1fb9fcd838f"
      unitRef="usd">122500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy0yLTEtMS0w_c2edd589-8e4b-4618-afb0-2deaa3d028e2"
      unitRef="usd">3508300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy00LTEtMS0w_aa5e6834-7c63-42d4-a069-1cc24b9ba6ed"
      unitRef="usd">42900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy02LTEtMS0w_f2c9ed1a-4f48-43b2-b98b-11993a392c4e"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfNy04LTEtMS0w_1591fb6b-ccd5-42b0-931f-4e5627bd7c9c"
      unitRef="usd">3550400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtMi0xLTEtMA_3034a7af-77d4-43d6-b40f-5bdff9163ebc"
      unitRef="usd">3960500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtNC0xLTEtMA_f97ed72f-72f8-44f0-a241-d1da9885681e"
      unitRef="usd">27800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtNi0xLTEtMA_95f73b76-b5af-4e7d-8a09-b2fe2873b266"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d63c24f0218414e9990379ad00300cd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTAtOC0xLTEtMA_d9e0f885-5f4c-4247-899f-110feb1742e6"
      unitRef="usd">3988100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtMi0xLTEtMA_3e299a8b-7e7f-499d-9c73-f69c318ed62f"
      unitRef="usd">54300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtNC0xLTEtMA_24b8679e-0c09-4435-a913-8007e7a47a5b"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtNi0xLTEtMA_127b2df5-c768-486a-bf27-71437307ddf8"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c8ceb313d6d4253941c222abbdda87d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTEtOC0xLTEtMA_b99589ee-00ab-4065-b6f8-d7a94607807c"
      unitRef="usd">54400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItMi0xLTEtMA_381f6891-66ca-4fb2-b2a2-6bb2a475af36"
      unitRef="usd">26900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItNC0xLTEtMA_4e386c68-ca83-4cda-855a-7972c768a1c8"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItNi0xLTEtMA_2164f30c-d412-4b7a-b4d8-14527cd6bd11"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d45dd2344b9435d9aca4a3a8a97973e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTItOC0xLTEtMA_18b3f5c8-8f06-4df9-a14d-dfb1491156f1"
      unitRef="usd">27300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idad0c140dee94620bf61713792c263c0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtMi0xLTEtMA_2397fb3c-098a-4775-a8be-191f9724314c"
      unitRef="usd">92300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idad0c140dee94620bf61713792c263c0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtNC0xLTEtMA_f81bf4f9-b0fd-4c9f-9e43-5503cee7a530"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idad0c140dee94620bf61713792c263c0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtNi0xLTEtMA_9a0d7f35-225e-4b7c-bd9f-2cc6cab39b99"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idad0c140dee94620bf61713792c263c0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTMtOC0xLTEtMA_6d45c7e3-d519-4476-9975-aacb7e519060"
      unitRef="usd">92300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtMi0xLTEtMA_067de385-4363-48c1-bfaa-faa59fecc84a"
      unitRef="usd">72300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtNC0xLTEtMA_2be8bd64-e09b-4042-b334-905f8ea8694a"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtNi0xLTEtMA_18170bfb-5c0b-46c1-935b-ae4cac3fb847"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96c5c5c10a764aa7a44e809bc6909b5a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTQtOC0xLTEtMA_10f06e0e-6767-4212-8bc9-b70b3ae3e5b5"
      unitRef="usd">72400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtMi0xLTEtMA_6cd784c8-cae6-4888-b285-f5e1f74c55a1"
      unitRef="usd">4206300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtNC0xLTEtMA_7aeea5bf-3208-49ca-9ffc-950f88b9975f"
      unitRef="usd">28500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtNi0xLTEtMA_c618b874-d0de-4c05-9034-8d50da9fd259"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjM4NDQzNjgwZDAyMjQyYmE4OTNlNTM3Y2ExNGI4NjIxL3RhYmxlcmFuZ2U6Mzg0NDM2ODBkMDIyNDJiYTg5M2U1MzdjYTE0Yjg2MjFfMTUtOC0xLTEtMA_38c81f0e-6ca0-45b8-8c66-ece16d3170b5"
      unitRef="usd">4234500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ2NQ_bef4f88c-db60-454c-b113-10e5e7cb3d76">The fair values of available-for-sale debt security investments by contractual maturity consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMi0yLTEtMS0w_ac37617b-2e0b-426e-9b8f-fb29711f78a8"
      unitRef="usd">1452900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMi00LTEtMS0w_1c679924-d36d-45ec-9608-e457c073fb68"
      unitRef="usd">1596500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMy0yLTEtMS0w_130d47f1-a037-484d-9ffd-6eff15313799"
      unitRef="usd">2097500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfMy00LTEtMS0w_9bfa3e20-bf2a-4df0-ac63-88902d4255ac"
      unitRef="usd">2638000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfNS0yLTEtMS0w_d7ee0960-c18f-4af4-81bc-baa53a9be510"
      unitRef="usd">3550400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjg4YjE3YzA1MTVlNDQ5NTdhNDc3ZGUwYjY1ZDE1YzEzL3RhYmxlcmFuZ2U6ODhiMTdjMDUxNWU0NDk1N2E0NzdkZTBiNjVkMTVjMTNfNS00LTEtMS0w_6a9d2592-68fe-4274-a28e-7cbb30f46bc5"
      unitRef="usd">4234500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTQ1OQ_1def1142-a0de-4a8c-b9f9-6ab8a8f20d4e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0xLTEtMS0w_9b020b6e-342d-4de7-a6c9-f9fa4d22837b"
      unitRef="usd">560500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0zLTEtMS0w_3d8c90e8-b129-42dd-a5f1-55bdfd8d24c3"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi01LTEtMS0w_d68d2987-0238-4425-aae0-b3caa49dbae2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi03LTEtMS0w_65c04b9a-2151-4cd0-8328-893ec4886986"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi05LTEtMS0w_b6e3ce3e-dab3-4bdd-96e3-e70a3f814f53"
      unitRef="usd">560500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i20d30029d14449749b125424cd027e65_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMi0xMS0xLTEtMA_8cd0e5ab-784a-4a80-acd1-96edf9bf1713"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0xLTEtMS00MzM3_3cbd2af5-8c5e-4232-8aa4-7e34eb1dc731"
      unitRef="usd">45500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0zLTEtMS00MzQz_11455d62-7e22-4abc-8b29-af5e0c2b1e84"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy01LTEtMS00MzQz_f6635596-5c45-4920-9d6d-f089118ea8fb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy03LTEtMS00MzQz_80b8e055-16ca-40dc-962f-2cbd2c1e9af0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy05LTEtMS00MzQz_5f0ce256-3bbc-4aae-bce6-331e01a6c4eb"
      unitRef="usd">45500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if71c780a8fb44eb3a2cfd3e811018adf_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfMy0xMS0xLTEtNDM0Nw_48f61464-b052-4c92-9857-f3a85428ed0d"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0xLTEtMS02MjQ5_12777726-50da-4ae5-820f-55886984f752"
      unitRef="usd">606000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0zLTEtMS02MjQ5_5644751e-fd20-4081-b7c2-4177615abc64"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC01LTEtMS02MjQ5_09a3d7a2-c7c1-4933-85d3-5d6fa7eef484"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC03LTEtMS02MjQ5_0f34a777-3a3a-4b72-99ad-43d0e2751038"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC05LTEtMS02MjQ5_e3be4efb-23f3-42cf-9496-d4a2fdc71099"
      unitRef="usd">606000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNC0xMS0xLTEtNjI0OQ_d33bb72e-e66c-4038-9f5f-fed4582ffb7f"
      unitRef="usd">800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0xLTEtMS0w_af59aee3-9a02-4ee7-9ce4-262660a93109"
      unitRef="usd">257200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0zLTEtMS0w_fff6ae9a-323c-4d7a-a46a-1b2d0b7d9109"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS01LTEtMS0w_cb73cb3f-2216-4d04-b5d1-f735340f2fc6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS03LTEtMS0w_f425a2df-0354-4a79-82fd-6556dc3a5bbe"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS05LTEtMS0w_a7a0a6c9-eb02-42c6-93c8-6a321c174019"
      unitRef="usd">257200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib8cc65a8a19c4e8cabd9a049b3a6ce24_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNS0xMS0xLTEtMA_8f88dfee-2489-480b-a6db-175113eec6b8"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0xLTEtMS0w_51467151-080c-4a19-8869-56ec304d8fc2"
      unitRef="usd">17300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0zLTEtMS0w_3e0ca3f7-a949-4fbe-815a-d172bc03bf7a"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi01LTEtMS0w_c15699c6-8d21-4bff-8ed7-ce0d8b04bc14"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi03LTEtMS0w_3a140942-339b-4a4c-bb27-448deba72615"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi05LTEtMS0w_941b6946-e496-4262-812e-ee0c79cf2a75"
      unitRef="usd">17300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iae6ef393ea1f41409b5056fb005e2f77_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNi0xMS0xLTEtMA_bf7944b1-5c97-43b9-a909-f343a8f912b2"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0xLTEtMS0w_fd406e06-fe62-4db4-a0ee-414f1b6c8387"
      unitRef="usd">274500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0zLTEtMS0w_1fecf9d4-2248-49b6-8bff-b7644c127d9c"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy01LTEtMS0w_9eb47902-9f3b-48a0-a891-374c2c553d4a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy03LTEtMS0w_0d3d6756-57c0-4a28-8fd7-302d97dec13f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy05LTEtMS0w_1587a70b-a435-458e-88b6-f5dfb1ab8acf"
      unitRef="usd">274500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RhYmxlOjNlODliMmFlYWRiZjQyZGJiNjgzMjI5YjUyYTYwODA1L3RhYmxlcmFuZ2U6M2U4OWIyYWVhZGJmNDJkYmI2ODMyMjliNTJhNjA4MDVfNy0xMS0xLTEtMA_4eed56ef-010c-4a20-bba8-ecded8af88ab"
      unitRef="usd">300000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTAyNA_28441ade-0d34-4db1-bebd-0595fff0ad2f"
      unitRef="usd">28500000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTA5Mg_695d82e4-2e0b-4800-8bc7-9301432dd55b"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80My9mcmFnOjI1ZjY3ZmM4MDgwYjQ2YzE4NmNkYjI5MTRlMjkwMDIwL3RleHRyZWdpb246MjVmNjdmYzgwODBiNDZjMTg2Y2RiMjkxNGUyOTAwMjBfMTA5Mg_d1c5f41b-181d-4ee1-a65e-34a24012c6c0"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTMzMQ_b6d94ba9-f075-4283-a8fd-11d49447c7b6">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,328.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain restricted equity securities as of September&#160;30, 2020 which are subject to transfer restrictions that expire at various dates through 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020, we recorded $37.5 million of net unrealized losses and $133.8 million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2019, we recorded $15.7&#160;million of net unrealized gains and $58.4&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2020 and December&#160;31, 2019, the Company had $60.6 million and $55.6&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term debt (see Note 8 "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;" for additional details) was estimated to be $1.929&#160;billion as of September&#160;30, 2020, and was determined based on Level 2 inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTM0Mg_d18b205a-f81a-412c-ad39-066e1639e2f8">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,836.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,328.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,988.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,853.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57ac96ed0be24de7b4d78a4154650332_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy0xLTEtMS0w_912ea7ac-5347-458e-ba75-4518571935ed"
      unitRef="usd">2836000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3a8bbfcd7a24b5b824f96ad7338a054_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy0zLTEtMS0w_5c0dac2e-cdcc-4765-a9d8-16cd4461816c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i713f9254ad4e48be9e5d986625994aa4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMy01LTEtMS0w_fa810c44-910b-46d5-bc9a-5e28817dd7f6"
      unitRef="usd">2836000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13644cdf2ce34c7c8c816531c17bffac_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC0xLTEtMS0w_9b9a26a1-6827-4d85-b075-e9912c918f59"
      unitRef="usd">134700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cbc42470c77425ba7013c4d8b733291_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC0zLTEtMS0w_9b7c2189-8474-46cd-81b3-95200bd5de96"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife4de3948dc24c89953087647ee69972_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNC01LTEtMS0w_a223bf10-8e2a-4f7b-bf89-c9e17aa1ddde"
      unitRef="usd">134700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if88b69bb3d8246e492ef775636b3be4e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS0xLTEtMS0w_050f4aae-a3d5-47b8-8516-1796114caa5d"
      unitRef="usd">66600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40e7fa786500484f9ecd6a1394da0446_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS0zLTEtMS0w_8bb94fd2-84bd-4212-9914-b91066a80839"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9dbf1de37814cc591de5f5dfd7367a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNS01LTEtMS0w_1ccd0929-5a85-46e6-9b60-cc5ce091f9fc"
      unitRef="usd">66600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d60d80740cb4c3d8c3264e5a536bb75_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi0xLTEtMS0w_f38a4768-f3e1-41b2-a3c8-60f036ae5642"
      unitRef="usd">390600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45c4643a0fbe4860b2b92747ba930b68_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi0zLTEtMS0w_722b651b-aca1-4204-a6ad-d491e286d5ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdbc67414a3f4b75a4caa66eca345086_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNi01LTEtMS0w_16b1ec33-7888-44fa-ba0b-25960be652e6"
      unitRef="usd">390600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb5b3e8bce4a477b86a941cc7530a23e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy0xLTEtMS0w_87f5b52c-c429-4607-8785-f7667a53a935"
      unitRef="usd">122500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie06ce8aa5e2b4cc09ea1c19bd54664cc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy0zLTEtMS0w_6e29668b-9a96-48e9-864d-5660a2da8066"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73ca96a034d34a608df2c5923fa76c90_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfNy01LTEtMS0w_34281c87-b807-4e3a-b6d1-3dcdbb30d112"
      unitRef="usd">122500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i40d96bb16db141e2a860d5637be2962e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC0xLTEtMS0w_1bfefff1-2409-4403-ab48-c57e060cd3cc"
      unitRef="usd">41300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if2506ac5a2034c828fe5038d9beb37ee_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC0zLTEtMS0w_dc4e296b-cff9-411e-8bd5-2228b1ff033f"
      unitRef="usd">41300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i541eacb289b24268a93f9d97ac19b713_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOC01LTEtMS0w_84d55a29-12e0-4dc8-9a60-9e9b8b68186d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id6e6ac37be9848dda98174ec211537bb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS0xLTEtMS0w_fcdb6c63-af05-4fe2-ac2e-bad0708572c7"
      unitRef="usd">736300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia9c906750bd44ebfa1472014377a3aa1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS0zLTEtMS0w_d754f54a-71f8-4d0d-a249-65e680c804ef"
      unitRef="usd">720000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i358f15a0dd6d48b29acf4a71f823027f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfOS01LTEtMS0w_cc970b9f-36c5-4b20-89eb-70b22da582a3"
      unitRef="usd">16300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i4c52905678f44008a79f2f04de098ce4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtMS0xLTEtMA_885cc521-e81f-4eea-a830-2b25eda7c3d9"
      unitRef="usd">4328000000.0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i52447f425dcf49d6b1e10676a99f4280_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtMy0xLTEtMA_bf380caa-a7f8-4443-8c09-adb4271d3cfe"
      unitRef="usd">761300000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i28b2946c537042c89d7783ab07d85448_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTAtNS0xLTEtMA_d4adc954-c4ae-4561-8b92-9ef6d02628cf"
      unitRef="usd">3566700000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0579df393aca4a968868c9bb40a1ab0e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtMS0xLTEtMA_9fb89ffe-909a-4cbf-9f0c-245fa4f2855a"
      unitRef="usd">3988100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68f420c9c13e4e23a601c1b506fa4a4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtMy0xLTEtMA_230b65c9-6ba3-492d-be64-3c126b08fbf7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19e0aead3d7445da8371fd938402c091_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTQtNS0xLTEtMA_811cc567-cf49-47d7-8737-143d35bdf1d4"
      unitRef="usd">3988100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e14cefc3db84553880f64ccb1fa43bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtMS0xLTEtMA_21a30101-beb9-4ab8-8bb3-88165f13efbe"
      unitRef="usd">54400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86accf19d5314b94b2f97f98ad733968_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtMy0xLTEtMA_b17ae861-2a5e-4cea-8554-7bf3755857e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e0b94218008446f83e54c839d26d417_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTUtNS0xLTEtMA_22d23ad0-8c36-425d-b057-53685c115b32"
      unitRef="usd">54400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d5e6f8e04c640e9a3a58b970d0b5099_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtMS0xLTEtMA_0cf29101-e92f-41c1-885a-84d902da422a"
      unitRef="usd">27300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i322b98f3dc874456add467767aaa4162_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtMy0xLTEtMA_0b92671e-fa13-41a0-b344-80fbd658de58"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i278d21029b334fdfa0462d06cf1f3130_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTYtNS0xLTEtMA_e403da01-03e6-497a-96d0-0a8e70260a52"
      unitRef="usd">27300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e8ef1954ceb4ec99864b1fe9544ceef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctMS0xLTEtMA_0585637d-18bd-4b3a-b6ad-d8fc08869d7f"
      unitRef="usd">92300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7feff46efcfb423cb246abcc1bb4d36a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctMy0xLTEtMA_f916f3f5-4618-4e68-8db3-dce0f488e1d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18805c870e4245d592672c40510db7b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTctNS0xLTEtMA_bc09bd66-cf69-4215-a812-3dbda83bcd77"
      unitRef="usd">92300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie8876032e074445d89ddad2131dd29fe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtMS0xLTEtMA_b9c8632a-8773-46ad-a09c-3ca90ae2eabe"
      unitRef="usd">72400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45fd969b6c884737a5442b5de99684a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtMy0xLTEtMA_629f9c94-5909-4cde-a7f6-f1da064090ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8593ca7502ee42d499fd89567506b6c1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTgtNS0xLTEtMA_ff96a303-9be5-4d17-a6b5-5b9e33e25180"
      unitRef="usd">72400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib31d2a9dd29b41c98f55f6c5305d8e3e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktMS0xLTEtMA_2f554497-31cb-451b-87de-6798bc8d4b65"
      unitRef="usd">61600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8532b49a5daa42f2a3875d2512dbd140_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktMy0xLTEtMA_42177700-8a03-4f55-8cad-245c7a10079a"
      unitRef="usd">61600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic3c2c6d2774a4997916504acf5a44d4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMTktNS0xLTEtMA_7287d166-26e5-4b0b-84ce-0eb958a52bea"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifbb07d4899f3445b83edd542e47de881_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtMS0xLTEtMA_f6399c14-5b2b-4e90-b654-02a7294e369f"
      unitRef="usd">557200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i490a6a8ff60443ed968309024d4e02ed_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtMy0xLTEtMA_820249aa-444e-46e6-a3b0-24982d54ef41"
      unitRef="usd">557200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9093b35e7b624c38a7f019c21a2e9a5b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjAtNS0xLTEtMA_51a2599c-8ba0-49f3-8aa6-48e6d0021ecf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="ifc12bd1bc93d4447ae534aa38c459530_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtMS0xLTEtMA_98baa00e-1557-48c7-b61d-db9f9318c59a"
      unitRef="usd">4853300000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ia0e42d73bc9440fcb7dfe671ce0e5ccd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtMy0xLTEtMA_b82ef7be-8cac-4395-a483-0ab239b1564b"
      unitRef="usd">618800000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i771b1c5b394f47639c3f9bdf6695758d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RhYmxlOjBmZGY0ZGM0MGI4NzQwZDViMTNiNjNlZDVmNDYyMTc2L3RhYmxlcmFuZ2U6MGZkZjRkYzQwYjg3NDBkNWIxM2I2M2VkNWY0NjIxNzZfMjEtNS0xLTEtMA_ec56398b-67ac-4a15-8072-40ef910ad5d9"
      unitRef="usd">4234500000</us-gaap:MarketableSecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfODY1_6670e409-3892-4ec9-bdda-3eb88cc2df2b"
      unitRef="usd">-37500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfODcy_50b6d84a-7d5f-406b-8be7-f62a4463679c"
      unitRef="usd">133800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfOTk2_e38a4760-c6ee-4274-9ed6-fe4e9086c585"
      unitRef="usd">15700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTAwMw_9804e89f-e90b-4db9-b1da-62242e63d73d"
      unitRef="usd">-58400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTE3MA_33eb8029-85c1-4681-a39e-05f301d8d413"
      unitRef="usd">60600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTE3Nw_58b72aff-cc28-47a6-a98d-11945489f030"
      unitRef="usd">55600000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80Ni9mcmFnOjg0ZmE0YTJhNTIyMzQyYWM4NGViNTU2ZTE4Yjk0MTQwL3RleHRyZWdpb246ODRmYTRhMmE1MjIzNDJhYzg0ZWI1NTZlMThiOTQxNDBfMTIwOTQ2Mjc5MDc4NzI_dc91bd7f-89fd-4fa1-9559-aa1ae05e9d79"
      unitRef="usd">1929000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RleHRyZWdpb246MWJmMmFhMDYzMmU4NDQ2NmFmYWQ3NzRiMzFkMTA2ZjVfMjMx_580bafc3-d2ef-4b6c-80df-7cd59b984da6">Inventories&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred (see Note 3).&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RleHRyZWdpb246MWJmMmFhMDYzMmU4NDQ2NmFmYWQ3NzRiMzFkMTA2ZjVfMjMw_3f1898b7-a5e7-474c-aef7-b52387049c82">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMi0xLTEtMS0w_a4623781-deed-40e0-96f5-b0288af83576"
      unitRef="usd">400400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMi0zLTEtMS0w_bdcc74b9-c85a-4d38-a49e-3edb82415330"
      unitRef="usd">216300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMy0xLTEtMS0w_5da2187d-de5a-4f5b-8a7e-b99a19d60787"
      unitRef="usd">715400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfMy0zLTEtMS0w_29083808-e0c8-4714-8626-87e7edd14b11"
      unitRef="usd">727700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNC0xLTEtMS0w_91f3f1a9-a761-4ac1-9b1d-68775e538db7"
      unitRef="usd">132100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNC0zLTEtMS0w_dc7bc3e8-1372-4282-a52a-108140378e7e"
      unitRef="usd">70600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNS0xLTEtMS0w_edbd8fd2-37d6-416a-98f5-162196ee0afc"
      unitRef="usd">553700000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNS0zLTEtMS0w_7bc6bdf4-59a5-49b8-96eb-5f0e0a2521a4"
      unitRef="usd">400900000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNi0xLTEtMS0w_be1efed4-f7e1-4cee-9822-778fe73d8209"
      unitRef="usd">1801600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF80OS9mcmFnOjFiZjJhYTA2MzJlODQ0NjZhZmFkNzc0YjMxZDEwNmY1L3RhYmxlOjAyNDU0ZGE3MTJlNTQwMTk5NTdjYzlkMzUzZmZhYmM4L3RhYmxlcmFuZ2U6MDI0NTRkYTcxMmU1NDAxOTk1N2NjOWQzNTNmZmFiYzhfNi0zLTEtMS0w_8596f320-39e8-41dc-a90a-d176cf4443dd"
      unitRef="usd">1415500000</us-gaap:InventoryNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTQ2NA_984df62a-521d-4b25-8fc8-454d3dbe5ab4">Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Loan Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 10, we purchased shares of our Common Stock from Sanofi, in connection with Sanofi's secondary offering of our Common Stock held by Sanofi, with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $1.5&#160;billion senior unsecured 364-day bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $750&#160;million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above. The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes accrue interest at the rate of 1.750% per year and will mature on September 15, 2030. The 2050 Notes accrue interest at the rate of 2.800% per year and will mature on September 15, 2050. Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes for the three months ended September&#160;30, 2020 was $6.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes may be redeemed at the Company&#x2019;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes also contain certain limitations on the Company&#x2019;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8d06b9c5853e400a9847d748ae198625_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMjkx_8bba3f3e-d09f-42eb-bcc3-09db42a6d4f7"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie7c14da02ab04b15a697c1f976f6c63b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDg4MTg_c144c130-4d4b-414b-bca8-1750c413c5e3"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ied42ff47bb2e4f48ad72135de84e2827_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDg5MDc_84e82512-8241-475b-bd8e-734fbdc00600"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie7c14da02ab04b15a697c1f976f6c63b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDk0MDE_418e4fe9-6e54-4d6d-aa0e-4c114b249f41"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ied42ff47bb2e4f48ad72135de84e2827_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTIwOTQ2Mjc5MDk1MDQ_0a0d9cf4-a1f5-4928-85c7-504f874c23b4"
      unitRef="number">0.02800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="ie7b56bd9207547a3a35c46fed3f56b79_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfMTI2NDQzODM3MzEyMDA_99cc90fa-fed4-4060-9963-67393f8c1573"
      unitRef="usd">6400000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfNDk0NzgwMjMzNDAxNg_7a44ac75-04f0-4909-9fef-d70c7b53f7aa"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage
      contextRef="i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81Mi9mcmFnOjFkN2NmMzAwYTM4YTQ4MWQ4NjBhYjEyNmFhYmFiOTlkL3RleHRyZWdpb246MWQ3Y2YzMDBhMzhhNDgxZDg2MGFiMTI2YWFiYWI5OWRfNDk0NzgwMjMzNDAyMg_73dc0a71-55f5-4209-95b7-4a36f37fcf35"
      unitRef="number">1.01</regn:DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfNDk0NzgwMjMyNzg0OQ_1a46e65a-6da0-4a9d-bc7f-68df972a1ce5">Income Taxes&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 15.6% and 12.9% for the three months ended September&#160;30, 2020 and 2019, respectively, and 8.6% and 14.0% for the nine months ended September&#160;30, 2020 and 2019, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's effective tax rate for the three and nine months ended September&#160;30, 2019 was positively impacted, compared to the U.S. federal statutory rate, primarily by federal tax credits for research activities, the foreign-derived intangible income deduction, and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, partly offset by the taxation of certain global intangible low-taxed income and the non-deductible Branded Prescription Drug Fee.&lt;/span&gt;&lt;/div&gt;The Company believes it is reasonably possible that its unrecognized tax benefits as of September&#160;30, 2020 may decrease within the next twelve months, and, as a result, positively impact our effective tax rate, as a result of expected settlement of audits and statute of limitation lapses.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTMx_20bed819-7eb6-47c9-9e55-39079e11436f"
      unitRef="number">0.156</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTM4_6dbff6e7-c2c4-459d-922b-bf9c82672e06"
      unitRef="number">0.129</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfMTk3_bb67990c-6112-414a-a655-2e5d807c6139"
      unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81NS9mcmFnOjFiYzg4ZWUxNTAzOTRkZWY5ZDUyMjQzMjY1Y2ZhYTYyL3RleHRyZWdpb246MWJjODhlZTE1MDM5NGRlZjlkNTIyNDMyNjVjZmFhNjJfNDM5ODA0NjUxMjI4Mg_bfe1cfa4-3d37-491d-9700-b339d05e25d0"
      unitRef="number">0.140</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjgyMQ_43de4ce7-7d14-46a1-bfce-30f342d00ce1">Stockholders' Equity&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. The share repurchase program permits the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#x2019;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the&#160;shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company had $372.7 million which remained available for share repurchases under the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Funding of Certain Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 3, effective January 2018, we have agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments by selling our Common Stock directly or indirectly owned by Sanofi. The table below summarizes the&#160;shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dupilumab/Itepekimab:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares purchased (in cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, 279,766 shares of our Common Stock remained available for sale by Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments incurred in periods through September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Stock Purchased from Sanofi&lt;/span&gt;&lt;/div&gt;In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5&#160;billion (the "Stock Purchase"). See Note 8 for additional information. As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (which Sanofi has used, and may continue to use, for the funding of certain development costs described above).</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie00da91153ab4285948986d4a8528f33_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMTU0_caae9c17-0a72-4b86-b310-1fd18a880239"
      unitRef="usd">1000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfNDk0NzgwMjMyOTMwMA_2bb27795-69e2-429d-82fc-04ec983308e5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the&#160;shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The table below summarizes the&#160;shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:21pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dupilumab/Itepekimab:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares purchased (in cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMS0yLTEtMS0yODY3_011d16e8-8bbe-4188-80e1-69ac0d28fd94"
      unitRef="shares">179824</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMS0yLTEtMS0w_9e6b3e11-69e3-4c92-a11a-6cfa63d54f82"
      unitRef="shares">898991</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i766ccbbedd874a76b4de80e70bc4498b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMi0yLTEtMS0yODcw_fe2a1085-91f4-4514-a9af-2a517d5bacd9"
      unitRef="usd">100400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i49ceb6461ac94b90af0809b219a440c9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjFkOTIyYTFkNDUxZTQ3M2I4NGY0MDExNDQzNjhkZTk1L3RhYmxlcmFuZ2U6MWQ5MjJhMWQ0NTFlNDczYjg0ZjQwMTE0NDM2OGRlOTVfMi0yLTEtMS0w_cfa63f5f-ed95-46a5-9b08-a5696215b121"
      unitRef="usd">373300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i8c5a33a1ef064741af1b75d4df1e7b8c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfNDM5ODA0NjUxMzk0NQ_f03b3761-e9fd-479c-a371-c6e42428ab2e"
      unitRef="usd">372700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy0xLTEtMS0w_d5b3ad98-9e54-48b4-a680-1ad1a1c48ba1"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib14491178e814761b044424a9d90cc57_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy0zLTEtMS0w_5a748173-330a-4a61-919d-35f67bd88b6a"
      unitRef="shares">103761</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy01LTEtMS0w_d61723ce-c2c8-480a-98cd-23a482d057d0"
      unitRef="shares">77677</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfMy03LTEtMS0w_d4edc703-8a62-4a33-a8a7-ea078287c179"
      unitRef="shares">210733</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC0xLTEtMS0w_ec9d25d1-3d29-4fb7-a6b1-709126efc455"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib14491178e814761b044424a9d90cc57_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC0zLTEtMS0w_19c7debc-c9f7-45ac-b2e2-e9e101aea10b"
      unitRef="usd">29200000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i43852af6ae12405fa47ec6553ebe4ce8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC01LTEtMS0w_c99bc10d-6c95-49ae-b219-63850798b570"
      unitRef="usd">41700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if6356cf1100a4e688622570ae9f99fe5_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNC03LTEtMS0w_c64b2a12-56c4-414e-b7ad-79ed80d1640e"
      unitRef="usd">73300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy0xLTEtMS0w_2f7b7f96-a45f-414b-931d-24a67bd516f2"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy0zLTEtMS0w_642344dc-814e-4960-8ac2-f3516a65d88b"
      unitRef="shares">69143</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy01LTEtMS0w_56a35008-d74d-4434-9044-b09268e67a15"
      unitRef="shares">171471</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfNy03LTEtMS0w_1e51bd38-398e-4edc-9a08-d65bee5cd97a"
      unitRef="shares">93286</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2ff67089be2745209aeae2740f6ae270_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC0xLTEtMS0w_ce43e54d-f8bb-4932-b047-15642811f31d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic10bdc86ea514afbb3e21403f202d699_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC0zLTEtMS0w_d9792f18-a130-40b9-a686-c7c7fe6dd871"
      unitRef="usd">19400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="icf5c04a6930e42e99e4d26e0ebc60b41_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC01LTEtMS0w_1608b234-1c45-4a36-b71b-49536d0859c1"
      unitRef="usd">93300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i63c7968e3cb5438bb50705035b77f8b5_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RhYmxlOjNjMDVhNDcxOTQ3NjQ2MDNiMTkwY2M0MTZmYmM0NGZkL3RhYmxlcmFuZ2U6M2MwNWE0NzE5NDc2NDYwM2IxOTBjYzQxNmZiYzQ0ZmRfOC03LTEtMS0w_8a8a5969-3b5a-4b16-9165-53e4b42f6cd7"
      unitRef="usd">29400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <regn:Maximumsharesthecollaboratorcouldsell
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMTkwOA_5d9776b6-9eed-465e-9094-a2c39dbdeda9"
      unitRef="shares">279766</regn:Maximumsharesthecollaboratorcouldsell>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i136244d2dc724edcbda67477d4375855_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjIwNA_eddba0d6-46b8-4a49-bc73-4784f23ece73"
      unitRef="shares">13014646</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7fb343771e004b36a23994024299f080_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjM1Mg_7c64b122-af2b-46de-b4dc-b462b71d650e"
      unitRef="shares">9806805</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7fb343771e004b36a23994024299f080_D20200501-20200531"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjQxOQ_0b3d5feb-b676-49dc-a56a-4c9ae1f19c7f"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id7a7a7f0ec7b41ccb9e296ec34a49d62_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF81OC9mcmFnOmNjYWJhZThkYmYxZjRkYmViZGYwZmY1ZGVlMzU4NzFmL3RleHRyZWdpb246Y2NhYmFlOGRiZjFmNGRiZWJkZjBmZjVkZWUzNTg3MWZfMjU3Nw_0ad345b4-2df2-4256-913c-85a36eefaed9"
      unitRef="shares">400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzYy_abca14d2-7b28-49c5-b49e-97e364fce184">Statement of Cash Flows&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included in accounts payable, accrued expenses, and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzUy_9bacf486-9f5e-45dc-9dca-d9d940be1d36">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNzU0_e8d00293-e69a-4f44-bd27-124adb8b1d65">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMi0yLTEtMS0w_d0f1dbd0-69ae-4555-839f-1cefa7a89d02"
      unitRef="usd">1573000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMi00LTEtMS0w_3d5ea15e-81f3-4d3a-ace8-4be94d23d94d"
      unitRef="usd">1384800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMy0yLTEtMS0w_0bc097b6-d85e-4983-ba57-385128ea3372"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfMy00LTEtMS0w_21737ee2-817a-4ee0-8ba7-e7465cb39bc2"
      unitRef="usd">12500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfNC0yLTEtMS0w_9fb5cac8-05b6-47e1-92c9-7da085c1a708"
      unitRef="usd">1586600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOmNkMTExZGQ0ZTRiYjQ0NzliZWJhZGNkMDc4NTM4ZDhiL3RhYmxlcmFuZ2U6Y2QxMTFkZDRlNGJiNDQ3OWJlYmFkY2QwNzg1MzhkOGJfNC00LTEtMS0w_4d22686f-c447-462e-9c81-fd9baaee66d9"
      unitRef="usd">1397300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RleHRyZWdpb246OGM3NTFiOWFiNjEyNDA1MThlMDlhNjA2OTNmNzE1YThfNDk0NzgwMjMyNjM2OQ_826a5ccb-0060-4977-9406-37d163fdc38b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included in accounts payable, accrued expenses, and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi0xLTEtMS04MzIx_1e97403c-752b-4fec-af46-f9fb4d3ed422"
      unitRef="usd">100400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic76fb63f2f534fd586e297b9d26b3169_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi0zLTEtMS04MzIx_183e3396-602f-4838-92f8-88a0a87c6cef"
      unitRef="usd">133700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0d509e43524b46db858b6d36d8865013_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi01LTEtMS04MzIx_19df2f17-b192-4de0-8443-d3d0a704cabd"
      unitRef="usd">100500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i75a462a19f724c93b0ad3e5e3df53fa2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82MS9mcmFnOjhjNzUxYjlhYjYxMjQwNTE4ZTA5YTYwNjkzZjcxNWE4L3RhYmxlOjI2MzMzZThkZjYyNzQyZjI4ZDU2ODFiMGYxZWRiMGE3L3RhYmxlcmFuZ2U6MjYzMzNlOGRmNjI3NDJmMjhkNTY4MWIwZjFlZGIwYTdfMi03LTEtMS04MzIx_9a117a56-185a-454d-b0f2-3a76fef958ea"
      unitRef="usd">54500000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNDk0NzgwMjM3ODU2Nw_5fbdf5c4-f83c-4a22-8368-f9a5ad9bcfa6">Legal Matters&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company's business. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2020 and December&#160;31, 2019, the Company had accruals for loss contingencies of $132.2 million and $100.0 million, respectively. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to '287 Patent and '163 Patent&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to patent infringement litigation initiated by the Company involving its European Patent No. 1,360,287 (the "'287 Patent") and its European Patent No. 2,264,163 (the "'163 Patent"). Each of these patents concerns genetically engineered mice capable of producing chimeric antibodies that are part human and part mouse. Chimeric antibody sequences can be used to produce high-affinity fully human monoclonal antibodies. In these proceedings, the Company claims infringement of several claims of the '287 Patent and the '163 Patent (as applicable), and seeks, among other types of relief, an injunction and an account of profits in connection with the defendants' infringing acts, which may include, among other things, the making, use, keeping, sale, or offer for sale of genetically engineered mice (or certain cells from which they are derived) that infringe one or more claims of the '287 Patent and the '163 Patent (as applicable).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 25, 2013, the Company commenced patent infringement litigation against Kymab Ltd in the English High Court of Justice, Chancery Division, Patents Court, in London, asserting the '287 Patent and '163 Patent. Following a trial to adjudicate the claims of infringement and counterclaims of invalidity of the '287 Patent and the '163 Patent, the court issued a final judgment on February 1, 2016, finding that the asserted claims of the '287 and '163 Patents are novel, not obvious, and infringed by Kymab's genetically engineered mice. However, the court invalidated the '287 and '163 Patents on the ground of insufficiency. On appeal, the Court of Appeal (Civil Division of England and Wales) reversed the English High Court's decision and held that the '287 Patent and '163 Patent are both valid and infringed by Kymab and subsequently issued a final order, which enjoined Kymab from infringing the '287 Patent and '163 Patent (subject to certain exceptions) and required Kymab to destroy or deliver to a third party all products and antibodies and cells engineered to produce antibodies which infringe the '287 Patent and '163 Patent (subject to certain exceptions). On June 24, 2020, the Supreme Court of the United Kingdom overturned the decision of the Court of Appeal on validity and held that the '287 and '163 Patents are each invalid on the ground of insufficiency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8 and July 13, 2016, notices of opposition against the '163 Patent were filed in the European Patent Office (the "EPO") by Merus N.V. and Kymab and Novo Nordisk A/S, respectively. The notices assert, as applicable, lack of novelty, lack of inventive step, and insufficiency. Following an oral hearing before the Opposition Division of the EPO on February 5&#x2013;7, 2018, the Opposition Division upheld the '163 Patent without amendments. Kymab, Merus, and Novo Nordisk each filed a notice of appeal of the Opposition Division's decision on February 9, 2018, May 25, 2018, and June 26, 2018, respectively. On January 7, 2019, Merus withdrew its appeal of the '163 Patent in the EPO in connection with the previously reported global settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Praluent (alirocumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and seeks a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that two claims of the '165 Patent and one claim of the '741 Patent were not invalid. The jury also found that two claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit has been scheduled for December 9, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United Kingdom. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 25, 2016, Amgen filed a lawsuit against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi-Synthelabo Limited, Aventis Pharma Limited, Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the English High Court of Justice, Chancery Division, Patents Court, in London, seeking a declaration of infringement of Amgen's European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, by Praluent.&#160;The lawsuit also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On February 8, 2017, the court temporarily stayed this litigation on terms mutually agreed by the parties. On October 22, 2020, the court lifted the stay upon application by the Company and the Sanofi defendants, and the case will proceed in due course.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Germany. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 25, 2016, Amgen filed a lawsuit for infringement of the '124 Patent against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the Regional Court of D&#xfc;sseldorf, Germany (the "D&#xfc;sseldorf Regional Court"), seeking a permanent injunction, an accounting of marketing activities, a recall of Praluent and its removal from distribution channels, and damages. On November 14, 2017, the D&#xfc;sseldorf Regional Court issued a decision staying the infringement proceedings until a decision of the Opposition Division of the EPO concerning the pending opposition filed by the Company, Sanofi, and several other opponents against the '124 Patent (as discussed below). Following Amgen's request to reopen the proceedings in light of the issuance of the Preliminary Opinion (as defined below), the D&#xfc;sseldorf Regional Court held an oral hearing on September 11, 2018 and ruled on December 10, 2018 that the infringement proceedings would be reopened. On July 11, 2019, the D&#xfc;sseldorf Regional Court found that Praluent infringes the '124 Patent and granted an injunction prohibiting the Company and Sanofi's manufacture, sale, and marketing of Praluent in Germany (the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;"July 11 Decision"). Amgen subsequently enforced the injunction and, as a result, commercialization of Praluent in Germany has been discontinued. On July 12, 2019, the Company and Sanofi appealed the July 11 Decision to the Higher Regional Court of D&#xfc;sseldorf (the "Higher Regional Court"). An oral hearing on the merits of the appeal to the Higher Regional Court (originally scheduled for April 2, 2020) has been rescheduled for November 5, 2020. On August 5, 2019 and October 31, 2019, the Higher Regional Court denied the Company and Sanofi's requests for a stay of preliminary enforcement of the July 11 Decision pending the appeal on the merits. On November 3, 2020, Amgen filed a motion withdrawing this lawsuit without prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;France. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2016, Amgen filed a lawsuit for infringement of the '124 Patent in the Tribunal de grande instance in Paris, France against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi Chimie (subsequently added as a defendant). Amgen is seeking the prohibition of allegedly infringing activities with a &#x20ac;10,000 penalty per drug unit of Praluent produced in violation of the court order sought by Amgen; an appointment of an expert for the assessment of damages; disclosure of technical (including supply-chain) and accounting information to the expert and the court; provisional damages of &#x20ac;10.0 million (which would be awarded on an interim basis pending final determination); reimbursement of costs; publication of the ruling in three newspapers; and provisional enforcement of the decision to be issued, which would ensure enforcement of the decision (including any provisional damages) pending appeal. Amgen is not seeking a preliminary injunction in this proceeding at this time. On April 10, 2017, the Company and the Sanofi parties filed briefs seeking invalidation of certain of the claims of the '124 Patent, and Amgen filed a response on July 28, 2017. Oral hearing on this infringement lawsuit (originally scheduled for February 12, 2019) has yet to be rescheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Netherlands. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2019, Amgen initiated a lawsuit alleging infringement of the Dutch designation of the '124 Patent in the District Court of The Hague in the Netherlands, against Sanofi-Aventis Netherlands B.V. and Sanofi-Aventis Groupe S.A. The Company has not been named as a defendant in this action. Amgen alleges, among other things, patent infringement based on the production, importation, and commercialization of Praluent (alirocumab) in the Netherlands. Amgen's requests are made on an accelerated basis and include, among other things, a request for a permanent injunction, damages, an order for customer information, a recall order, a destruction order, and an order for costs. A trial has been scheduled for February 12, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Italy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 20, 2019, Amgen filed a lawsuit for infringement of the Italian designation of the '124 Patent in the Tribunale di Milano - Enterprise Chamber in Milan, Italy, against Sanofi-Aventis Groupe S.A., Sanofi Chimie, and Sanofi SpA. The Company has not been named as a defendant in this action. Amgen alleges that the production, importation, and commercialization of Praluent (alirocumab) in Italy infringes the '124 Patent. The writ of summons filed by Amgen seeks, among other things, a declaration of infringement, a permanent injunction, withdrawal of product from the market, and damages. On June 24, 2020, Amgen also filed a preliminary injunction motion against the Sanofi parties. On August 12, 2020, the court denied Amgen's preliminary injunction motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Spain. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 20, 2019, Amgen also filed a lawsuit alleging infringement of the Spanish designation of the '124 Patent in the Juzgado de lo Mercantil No. 5 (Commercial Court) in Barcelona, Spain, against Sanofi-Aventis, S.A. The Company was not named as a defendant in this action. Amgen alleged, among other things, patent infringement based on the manufacture, offering for sale, introduction into the market, use, and importation or possession of Praluent (alirocumab) in Spain. Amgen sought, among other things, a permanent injunction, withdrawal of Praluent from the market, seizure and destruction of Praluent from the market and in storage, and damages in the form of lost profits and costs and expenses. On May 12, 2020, the court stayed this lawsuit until October 30, 2020 on terms mutually agreed by the parties. On October 30, 2020, the stay was automatically lifted. On November 2, 2020, Amgen filed a motion withdrawing this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;EPO Proceedings. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The '124 Patent is also subject to opposition proceedings in the EPO seeking to invalidate certain of its claims, which were initiated by Sanofi on February 24, 2016 and, separately, by the Company, Sanofi, and several other opponents on November 24, 2016. On December 13, 2017, the Opposition Division of the EPO issued a preliminary, non-binding opinion (the "Preliminary Opinion") regarding the validity of the '124 Patent, indicating that it currently considers the claims of a new request filed by Amgen in response to the opposition to satisfy the requirements for patentability. An oral hearing on the oppositions against the '124 Patent was held on November 28&#x2013;30, 2018, at which the Opposition Division upheld the validity of the '124 Patent's claims in amended form. The Company and Sanofi filed notices of appeal to the Technical Board of Appeal (the "TBA") of the EPO on November 30, 2018. An oral hearing before the TBA was held on October 28&#x2013;29, 2020, at which the TBA ruled that the '124 Patent claims directed to compositions of matter and medical use were invalid based on a lack of inventive step.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Japan. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 19, 2017, Amgen filed a lawsuit for infringement of Amgen's Japanese Patent Nos. 5,906,333 (the "'333 Patent") and 5,705,288 (the "'288 Patent") in the Tokyo District Court Civil Division (the "Tokyo District Court") against Sanofi K.K. Amgen's complaint alleges that manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) infringe the '333 and '288 Patents. The complaint further seeks a permanent injunction, disposal of product, and court costs. The Company has not been named as a defendant in this litigation. On January 17, 2019, the Tokyo District Court upheld the validity of the '333 Patent and '288 Patent and ordered a permanent injunction against Sanofi K.K. to stop manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) and to dispose of all product. However, the Tokyo District Court stayed the enforcement of such injunction pending appeal to the Intellectual Property High Court of Japan (the "IPHC"). On January 30, 2019, Sanofi K.K. appealed the Tokyo District Court's decision in the infringement proceedings to the IPHC. Following an oral hearing on October 30, 2019, the IPHC affirmed the Tokyo District Court's decision in the infringement proceedings. Sanofi K.K. appealed the IPHC's decision in the infringement proceedings to the Supreme Court of Japan on November 12, 2019. On April 24, 2020, the Supreme Court of Japan declined to hear the appeal filed by Sanofi K.K. in the infringement proceedings and the injunction issued by the Tokyo District Court became effective. Sanofi K.K. subsequently complied with the injunction and, as a result, the commercialization of Praluent in Japan has been discontinued. On March 31, 2020, Amgen filed a related lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the finding of infringement of the '333 Patent and the '288 Patent. The Company has not been named as a defendant in this damages action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Dupixent (dupilumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation filed a lawsuit against Amgen and Immunex Corporation, a wholly owned subsidiary of Amgen, in the United States District Court for the District of Massachusetts seeking a declaratory judgment that the Company's and the other plaintiffs' Commercializing of Dupixent does not directly or indirectly infringe U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. On May 1, 2017, the Company and the other plaintiffs filed a notice of voluntary dismissal of this action without prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of the '487 Patent. On July 28 and 31, 2017, the same parties filed two additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). On October 4, 2017, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a decision on the first IPR petition and declined to institute an IPR proceeding to review the validity of the '487 Patent. On February 15, 2018, the PTAB issued two decisions instituting the Company's and Sanofi's Additional IPR Petitions on all claims of the '487 Patent for which review had been requested. Oral hearings on the Additional IPR Petitions before the PTAB were held on November 14, 2018. On February 14, 2019, the PTAB issued final written decisions on the Additional IPR Petitions, invalidating all 17 claims of the '487 Patent as obvious based on one of the Additional IPR Petitions while declining to hold the challenged claims of the '487 Patent invalid based on the other. In April 2019, the parties filed notices of appeal with the Federal Circuit appealing the PTAB's respective adverse final written decisions on the Additional IPR Petitions, and oral argument was held on August 5, 2020. On October 13, 2020, the Federal Circuit affirmed the PTAB's decision on the Additional IPR Petition that invalidated all 17 claims of the '487 Patent as obvious.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. Immunex is not seeking an injunction in this proceeding at this time. On June 21, 2017, the court denied a motion to dismiss Immunex's complaint previously filed by the Company and the Sanofi parties. On June 28, 2017, the Company and the Sanofi parties filed an answer to Immunex's complaint and counterclaims against Immunex and Amgen (which was amended on October 31, 2017 to, among other things, add an inequitable conduct allegation), and Immunex and Amgen filed an answer to the counterclaims on July 28, 2017. A combined hearing on the construction of certain disputed claim terms of the '487 Patent and the Company and the Sanofi parties' motion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for summary judgment on the issue of indefiniteness of the '487 Patent claims was held on July 12, 2018. On August 24, 2018, the court issued an order denying this motion and construed the disputed claim terms as proposed by Amgen. On February 28, 2019, the court granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#x2013;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. The original patent term of the Immunex patents is set to expire in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#x2019;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis also filed a patent infringement lawsuit in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), treble damages, costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended. The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Proceedings Relating to fasinumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. A trial has been scheduled to commence in late November or early December 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the oppositions against the '048 Patent was held on November 29&#x2013;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. An oral hearing before the TBA has been scheduled for July 29, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to REGN-COV2&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Allele seeks a judgment of patent infringement of the '221 Patent, a judgment that such infringement was willful, and an award of monetary damages (together with interest), treble damages, costs and expenses of the lawsuit, and attorneys' fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. An oral hearing on the motion to dismiss was held on October 7, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, is evaluating this demand letter.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMjgxODk_f3fc9873-74b3-449d-ac15-ede78e7f6c7e">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i00959df13c4a47889ab1b2afc9be2d60_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNTcy_5ad98fb1-2e44-41ab-b135-c55d2ca5ede8"
      unitRef="usd">132200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i934dd0ac4fc14622bde3e0ed5f0d5b9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNTc5_eea6a69e-dac3-40f8-afd1-e2d695f95592"
      unitRef="usd">100000000.0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib4162e2d3ffa40cab347875d0e8141e1_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzM0MA_9f57c55a-58a2-4568-ba0c-4e1981cfaa93"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i76ec0cbb09134d05af796df3d6121770_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzM3Mw_439709c1-d31d-45e2-a92d-5f5f2c2d82af"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <regn:LossContingencyClaimsInvalidNumber
      contextRef="ib4162e2d3ffa40cab347875d0e8141e1_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfNzQ0NA_75bda83f-28cf-43cf-92a7-f40188a16b4a"
      unitRef="claim">2</regn:LossContingencyClaimsInvalidNumber>
    <regn:LossContingencyDamagesSoughtPerUnitProduced
      contextRef="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTEzNjA_76406eef-adf4-4d94-be63-e30eee48f920"
      unitRef="eur">10000</regn:LossContingencyDamagesSoughtPerUnitProduced>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i7538d1ad0d1a4c09817c10388a05a332_D20160926-20160926"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTE2NDI_1bb89f51-a380-408a-8642-08f06ea075b4"
      unitRef="eur">10000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <regn:GainContingencyInterPartesReviewFiledNumber
      contextRef="i00e0c80c71e941b48916ad1f5287ba31_D20170728-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTg3NDg_59ffa07f-98c3-48fc-a45c-062b2c269eec"
      unitRef="claim">2</regn:GainContingencyInterPartesReviewFiledNumber>
    <regn:GainContingencyClaimsInvalidatedNumber
      contextRef="i841077884f1e4957adca717303635407_I20190214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMTk1MDM_1eaa218b-daf3-4372-ace0-3c49e9c7a588"
      unitRef="claim">17</regn:GainContingencyClaimsInvalidatedNumber>
    <regn:GainContingencyInterPartesReviewFiledNumber
      contextRef="i4b28b11bf97045e493c30eaae17baf6a_D20200716-20200716"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF82NC9mcmFnOjFkZTYyNTg5ZjU2NjQ2MTQ4N2Y2ZGM0ZTA5YjBjMGY3L3RleHRyZWdpb246MWRlNjI1ODlmNTY2NDYxNDg3ZjZkYzRlMDliMGMwZjdfMjY3MzU_2dca5b6b-9807-4e12-acdc-60a80b4f66eb"
      unitRef="claim">2</regn:GainContingencyInterPartesReviewFiledNumber>
    <regn:Maximumsharesthecollaboratorcouldsell
      contextRef="ie52e1228322949d0906b14737878fbb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJhYjY0NzA1MGJjMjQ4ZTM5MzAxNjM1MzFhMWQ1N2Q4L3NlYzpiYWI2NDcwNTBiYzI0OGUzOTMwMTYzNTMxYTFkNTdkOF83OS9mcmFnOjM1Mjg5ODIzOTczNzRmMTI4MDg3MDAwNzcxODgzNTNhL3RleHRyZWdpb246MzUyODk4MjM5NzM3NGYxMjgwODcwMDA3NzE4ODM1M2FfMTIwOTQ2Mjc5NDMzOTQ_5d9776b6-9eed-465e-9094-a2c39dbdeda9"
      unitRef="shares">279766</regn:Maximumsharesthecollaboratorcouldsell>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589343921656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGENERON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3444607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">777 Old Saw Mill River Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tarrytown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10591-6707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock - par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">REGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,857,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589364385512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,573.0<span></span>
</td>
<td class="nump">$ 1,617.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,452.9<span></span>
</td>
<td class="nump">1,596.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade, net</a></td>
<td class="nump">3,092.5<span></span>
</td>
<td class="nump">2,100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable - Sanofi</a></td>
<td class="nump">460.8<span></span>
</td>
<td class="nump">260.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts receivable - other</a></td>
<td class="nump">486.2<span></span>
</td>
<td class="nump">425.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,801.6<span></span>
</td>
<td class="nump">1,415.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">230.6<span></span>
</td>
<td class="nump">273.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,097.6<span></span>
</td>
<td class="nump">7,689.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">2,875.1<span></span>
</td>
<td class="nump">3,256.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,138.3<span></span>
</td>
<td class="nump">2,890.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">804.2<span></span>
</td>
<td class="nump">824.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">168.8<span></span>
</td>
<td class="nump">144.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">16,084.0<span></span>
</td>
<td class="nump">14,805.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">443.1<span></span>
</td>
<td class="nump">418.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,303.0<span></span>
</td>
<td class="nump">1,211.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities - Sanofi</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,337.8<span></span>
</td>
<td class="nump">2,096.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,978.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">716.5<span></span>
</td>
<td class="nump">713.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">454.0<span></span>
</td>
<td class="nump">317.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,958.5<span></span>
</td>
<td class="nump">3,715.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">6,592.8<span></span>
</td>
<td class="nump">4,428.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">9,743.8<span></span>
</td>
<td class="nump">7,379.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, at cost; 15,741,824 shares in 2020 and 4,860,123 shares in 2019</a></td>
<td class="num">(6,242.0)<span></span>
</td>
<td class="num">(739.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">10,125.5<span></span>
</td>
<td class="nump">11,089.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">16,084.0<span></span>
</td>
<td class="nump">14,805.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">409.3<span></span>
</td>
<td class="nump">310.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">367.0<span></span>
</td>
<td class="nump">482.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 67.0<span></span>
</td>
<td class="nump">$ 77.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253173688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock (in shares)</a></td>
<td class="nump">15,741,824<span></span>
</td>
<td class="nump">4,860,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">1,848,970<span></span>
</td>
<td class="nump">1,848,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="nump">1,848,970<span></span>
</td>
<td class="nump">1,848,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">120,516,837<span></span>
</td>
<td class="nump">113,288,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250176808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 1,743.7<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
<td class="nump">$ 4,694.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">684.6<span></span>
</td>
<td class="nump">526.0<span></span>
</td>
<td class="nump">1,990.5<span></span>
</td>
<td class="nump">1,897.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">326.9<span></span>
</td>
<td class="nump">304.4<span></span>
</td>
<td class="nump">1,042.5<span></span>
</td>
<td class="nump">890.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(171.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,240.9<span></span>
</td>
<td class="nump">1,005.2<span></span>
</td>
<td class="nump">3,664.6<span></span>
</td>
<td class="nump">3,160.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,053.1<span></span>
</td>
<td class="nump">738.5<span></span>
</td>
<td class="nump">2,409.6<span></span>
</td>
<td class="nump">1,534.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(28.5)<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
<td class="nump">218.3<span></span>
</td>
<td class="nump">28.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(26.3)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(42.1)<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(54.8)<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">998.3<span></span>
</td>
<td class="nump">768.5<span></span>
</td>
<td class="nump">2,585.8<span></span>
</td>
<td class="nump">1,539.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">156.2<span></span>
</td>
<td class="nump">98.9<span></span>
</td>
<td class="nump">221.8<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 669.6<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
<td class="nump">$ 1,323.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 21.83<span></span>
</td>
<td class="nump">$ 12.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="nump">$ 20.36<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">105.5<span></span>
</td>
<td class="nump">109.4<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
<td class="nump">114.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 669.6<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
<td class="nump">$ 1,323.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on debt securities</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gain (loss) on cash flow hedges</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">837.4<span></span>
</td>
<td class="nump">670.3<span></span>
</td>
<td class="nump">2,373.7<span></span>
</td>
<td class="nump">1,352.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,482.2<span></span>
</td>
<td class="nump">1,238.3<span></span>
</td>
<td class="nump">3,945.8<span></span>
</td>
<td class="nump">3,548.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">131.0<span></span>
</td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">312.3<span></span>
</td>
<td class="nump">253.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember', window );">Collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">454.5<span></span>
</td>
<td class="nump">289.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember', window );">Sanofi | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">353.3<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">869.3<span></span>
</td>
<td class="nump">232.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">293.6<span></span>
</td>
<td class="nump">825.5<span></span>
</td>
<td class="nump">834.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember', window );">Other | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 158.6<span></span>
</td>
<td class="nump">$ 36.8<span></span>
</td>
<td class="nump">$ 433.6<span></span>
</td>
<td class="nump">$ 78.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589242728456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Class A Stock</div></th>
<th class="th"><div>Common Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">111.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 8,757.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">$ 3,911.6<span></span>
</td>
<td class="nump">$ 5,254.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="num">$ (12.3)<span></span>
</td>
<td class="num">$ (396.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">140.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(10.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of Common Stock</a></td>
<td class="num">(54.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">114.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">461.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">111.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">9,444.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,160.9<span></span>
</td>
<td class="nump">5,725.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="num">$ (444.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">111.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">8,757.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="nump">3,911.6<span></span>
</td>
<td class="nump">5,254.3<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
<td class="num">$ (396.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,323.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">112.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">10,504.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388.4<span></span>
</td>
<td class="nump">6,587.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="num">$ (488.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">111.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">9,444.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,160.9<span></span>
</td>
<td class="nump">5,725.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="num">$ (444.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(29.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">109.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">193.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">111.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2019</a></td>
<td class="nump">9,755.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,263.6<span></span>
</td>
<td class="nump">5,918.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="num">$ (441.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of Common Stock</a></td>
<td class="num">(48.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">112.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">669.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Class A Stock to Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Class A Stock to Common Stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">112.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">10,504.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388.4<span></span>
</td>
<td class="nump">6,587.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="num">$ (488.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">11,089.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,428.6<span></span>
</td>
<td class="nump">7,379.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="num">$ (739.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">817.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(155.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of Common Stock</a></td>
<td class="num">(336.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (336.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">108.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(30.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">12,133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,211.4<span></span>
</td>
<td class="nump">8,004.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">$ (1,073.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">11,089.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,428.6<span></span>
</td>
<td class="nump">7,379.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="num">$ (739.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">2,364.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">120.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">10,125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,592.8<span></span>
</td>
<td class="nump">9,743.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="num">$ (6,242.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">12,133.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,211.4<span></span>
</td>
<td class="nump">8,004.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">$ (1,073.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">1,355.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,355.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(416.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of Common Stock</a></td>
<td class="num">(5,071.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,071.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">897.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">119.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">9,057.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,263.0<span></span>
</td>
<td class="nump">8,901.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="num">$ (6,142.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(80.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of Common Stock</a></td>
<td class="num">(100.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">842.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">120.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 10,125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592.8<span></span>
</td>
<td class="nump">$ 9,743.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="num">$ (6,242.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Value, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253940040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 2,364.0<span></span>
</td>
<td class="nump">$ 1,323.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">174.2<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="nump">310.5<span></span>
</td>
<td class="nump">330.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="num">(111.3)<span></span>
</td>
<td class="nump">113.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">117.9<span></span>
</td>
<td class="num">(110.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in Sanofi, trade, and other accounts receivable</a></td>
<td class="num">(1,275.3)<span></span>
</td>
<td class="num">(464.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(402.4)<span></span>
</td>
<td class="num">(227.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in prepaid expenses and other assets</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">166.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">80.8<span></span>
</td>
<td class="nump">328.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="num">(976.9)<span></span>
</td>
<td class="nump">318.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,387.1<span></span>
</td>
<td class="nump">1,642.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable and other securities</a></td>
<td class="num">(2,642.7)<span></span>
</td>
<td class="num">(2,834.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable and other securities</a></td>
<td class="nump">3,330.3<span></span>
</td>
<td class="nump">1,306.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(453.2)<span></span>
</td>
<td class="num">(290.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">234.4<span></span>
</td>
<td class="num">(1,819.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">1,981.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bridge loan facility</a></td>
<td class="nump">1,500.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of bridge loan facility</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Common Stock</a></td>
<td class="nump">2,471.1<span></span>
</td>
<td class="nump">163.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments in connection with Common Stock tendered for employee tax obligations</a></td>
<td class="num">(652.5)<span></span>
</td>
<td class="num">(40.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of Common Stock</a></td>
<td class="num">(5,465.7)<span></span>
</td>
<td class="num">(29.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,665.2)<span></span>
</td>
<td class="nump">93.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(43.7)<span></span>
</td>
<td class="num">(82.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">1,630.3<span></span>
</td>
<td class="nump">1,480.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 1,586.6<span></span>
</td>
<td class="nump">$ 1,397.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245368152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Interim Financial Statements</a></td>
<td class="text">Interim Financial Statements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2019 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, we changed the presentation of cost reimbursements from collaborators who are not deemed to be our customers from collaboration revenue to a reduction of the corresponding operating expense (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, either Research and development or Selling, general, and administrative) incurred by us. We also changed the presentation of amounts recognized in connection with up-front and development milestone payments received from collaboration revenue to other operating income. We made these changes in presentation because we believe the new presentation is preferable, as it better reflects the nature of the Company&#8217;s costs incurred and revenues earned pursuant to arrangements with collaborators and enhances the comparability of our financial statements with industry peers.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation has been applied retrospectively. The tables below present the impact of the change on the Company&#8217;s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company&#8217;s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company&#8217;s previously-filed Consolidated Statements of Stockholders&#8217; Equity.  </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"/><td style="width:46.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Balance Sheet Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (current)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (noncurrent)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(766.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,048.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,159.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.</span></div></td></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"/><td style="width:46.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Flows Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable, accrued expenses, and other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245144312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ProductSalesandConcentrationRiskTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.461%"><tr><td style="width:1.0%"/><td style="width:42.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,422.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2020 and 2019. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.847%"><tr><td style="width:1.0%"/><td style="width:45.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ProductSalesandConcentrationRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Sales and Concentration Risk Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ProductSalesandConcentrationRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589246792296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Other Agreements</a></td>
<td class="text">Collaboration, License, and Other Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize product candidates and utilize our technology platforms. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are entitled to reimbursement of all or a portion of the research and development expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred. In connection with the commercialization phase of our collaborative arrangements, we may be obligated to perform commercialization-related activities on behalf of the collaboration. If we are reimbursed for all or a portion of costs incurred for the commercialization-related activities, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are obligated to use commercially reasonable efforts to supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator; however, recognition of such cost reimbursements is deferred until the product is sold by our collaborator to third-party customers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for such quarter. These estimates are reconciled to actual results in the subsequent fiscal quarter, and collaboration revenue is adjusted accordingly, as necessary.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.449%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8 and Note 10 for information regarding Sanofi's sale of our Common Stock during the second quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the companies' Antibody License and Collaboration Agreement (the "LCA"), following receipt of the first positive Phase 3 trial results for a co-developed drug candidate, subsequent Phase 3 trial-related costs for that drug candidate ("Shared Phase 3 Trial Costs") are generally shared 80% by Sanofi and 20% by Regeneron. All other agreed-upon worldwide development expenses incurred by both companies are funded by Sanofi. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Refer to the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section below for further details regarding the Letter Agreement and Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products developed under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. See discussion below related to the development and commercialization of Praluent </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective April 1, 2020. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $200.0&#160;million in additional sales milestone payments from Sanofi.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 is the last quarter for which Sanofi and the Company will share profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). The IO Collaboration is governed by an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), and an Immuno-oncology License and Collaboration Agreement ("IO License and Collaboration Agreement"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into the Amended IO Discovery Agreement, which narrowed the scope of the existing discovery and development activities conducted by the Company ("IO Development Activities") under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. If Sanofi exercises its option to license rights to a BCMAxCD3 Program antibody or MUC16xCD3 Program antibody thereunder, it will co-develop these drug candidates with the Company through product approval. Sanofi will fund development costs up front for a BCMAxCD3 Program antibody and we will reimburse half of the total development costs for such antibody from our share of future IO Collaboration profits to the extent they are sufficient for this purpose. In addition, we and Sanofi will share equally, on an ongoing basis, the development costs for a MUC16xCD3 Program antibody. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the IO License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab), an antibody targeting the receptor known as programmed cell death protein 1 (PD-1). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. Pursuant to the Letter Agreement, the Libtayo development budget was increased and the Company has agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to the Libtayo development and Dupilumab/Itepekimab Eligible Investments incurred in </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods through September 30, 2020 by selling certain shares of our Common Stock directly or indirectly owned by Sanofi; if Sanofi desires to sell such shares, we may elect to purchase, in whole or in part, such shares from Sanofi. See Note 10 for additional information regarding shares purchased by us from Sanofi during the three and nine months ended September&#160;30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States and the parties equally share profits and losses from worldwide sales. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $951.0&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.422%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. In addition, the Company and Bayer share the funding of agreed-upon EYLEA development costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company and Teva entered into a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan. The Company is also responsible for the manufacture and supply of fasinumab globally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:33.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.606%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2020 was $130.3&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2016 agreement, the parties agreed to a target selection process, whereby the Company may obtain exclusive rights in up to 10 targets to be chosen by the Company during the collaboration term, subject to various adjustments and limitations set forth in the agreement. Certain targets that either we or Intellia select pursuant to the target selection process may be subject to a co-development and co-commercialization arrangement at our option or Intellia&#8217;s option, as applicable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gene edited products. In connection with the agreement, we made a $70.0&#160;million up-front payment, which was recorded to Research and development expense in the second quarter of 2020, and purchased 925,218 shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, was also recorded to Research and development expense in the second quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">e. Biomedical Advanced Research Development Authority ("BARDA")</span></div>In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement ("OTA") with BARDA, pursuant to which the U.S. Department of Health and Human Services ("HHS") is obligated to fund 80% of certain of our costs incurred for certain research and development activities related to COVID-19 treatments. In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished REGN-COV2 to the U.S. government. The agreement could result in payments to the Company of up to $450.2&#160;million in the aggregate for bulk manufacturing of the drug substance, as well as fill/finish and storage activities. See Note 2 for REGN-COV2 net product sales recognized in connection with this agreement during the three months ended September 30, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245399800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's basic net income per share amounts have been computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.900%"><tr><td style="width:1.0%"/><td style="width:42.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive, include the following: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.964%"><tr><td style="width:1.0%"/><td style="width:33.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589247581656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of September&#160;30, 2020 and December&#160;31, 2019 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2020 mature at various dates through September 2025. The fair values of available-for-sale debt security investments by contractual maturity consist of the following:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:29.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2020, realized gains on sales of marketable securities were not material. For the nine months ended September&#160;30, 2020, realized gains were $28.5&#160;million. Realized losses were not material for the three and nine months ended September&#160;30, 2020. There were no realized losses on sales of marketable securities, and realized gains were not material, for the three and nine months ended September&#160;30, 2019.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to marketable securities, for the three and nine months ended September&#160;30, 2020 and 2019, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities (as described above).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589246846680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:48.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,328.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of September&#160;30, 2020 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recorded $37.5 million of net unrealized losses and $133.8 million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2019, we recorded $15.7&#160;million of net unrealized gains and $58.4&#160;million of net unrealized losses, respectively, on equity securities in Other (expense) income, net. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2020 and December&#160;31, 2019, the Company had $60.6 million and $55.6&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt (see Note 8 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" for additional details) was estimated to be $1.929&#160;billion as of September&#160;30, 2020, and was determined based on Level 2 inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245347112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred (see Note 3).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589246767240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Loan Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 10, we purchased shares of our Common Stock from Sanofi, in connection with Sanofi's secondary offering of our Common Stock held by Sanofi, with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $1.5&#160;billion senior unsecured 364-day bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $750&#160;million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above. The underwriting discounts and offering expenses are being amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes accrue interest at the rate of 1.750% per year and will mature on September 15, 2030. The 2050 Notes accrue interest at the rate of 2.800% per year and will mature on September 15, 2050. Interest on each series of Notes is payable semi-annually in arrears on March 15 and September 15 of each year until their respective maturity dates. Interest expense related to the Notes for the three months ended September&#160;30, 2020 was $6.4&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes may be redeemed at the Company&#8217;s option at any time at 100% of the principal amount plus accrued and unpaid interest, and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes also contain certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well as customary events of default.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589342939704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 15.6% and 12.9% for the three months ended September&#160;30, 2020 and 2019, respectively, and 8.6% and 14.0% for the nine months ended September&#160;30, 2020 and 2019, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate for the three and nine months ended September&#160;30, 2019 was positively impacted, compared to the U.S. federal statutory rate, primarily by federal tax credits for research activities, the foreign-derived intangible income deduction, and income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, partly offset by the taxation of certain global intangible low-taxed income and the non-deductible Branded Prescription Drug Fee.</span></div>The Company believes it is reasonably possible that its unrecognized tax benefits as of September&#160;30, 2020 may decrease within the next twelve months, and, as a result, positively impact our effective tax rate, as a result of expected settlement of audits and statute of limitation lapses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245471496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. The share repurchase program permits the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"/><td style="width:46.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company had $372.7 million which remained available for share repurchases under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3, effective January 2018, we have agreed to allow Sanofi to satisfy in whole or in part its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments by selling our Common Stock directly or indirectly owned by Sanofi. The table below summarizes the&#160;shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"/><td style="width:50.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupilumab/Itepekimab:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (in cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, 279,766 shares of our Common Stock remained available for sale by Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments incurred in periods through September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div>In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5&#160;billion (the "Stock Purchase"). See Note 8 for additional information. As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (which Sanofi has used, and may continue to use, for the funding of certain development costs described above).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245450584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text">Statement of Cash Flows<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:26.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245471496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2020 and December&#160;31, 2019, the Company had accruals for loss contingencies of $132.2 million and $100.0 million, respectively. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to '287 Patent and '163 Patent</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to patent infringement litigation initiated by the Company involving its European Patent No. 1,360,287 (the "'287 Patent") and its European Patent No. 2,264,163 (the "'163 Patent"). Each of these patents concerns genetically engineered mice capable of producing chimeric antibodies that are part human and part mouse. Chimeric antibody sequences can be used to produce high-affinity fully human monoclonal antibodies. In these proceedings, the Company claims infringement of several claims of the '287 Patent and the '163 Patent (as applicable), and seeks, among other types of relief, an injunction and an account of profits in connection with the defendants' infringing acts, which may include, among other things, the making, use, keeping, sale, or offer for sale of genetically engineered mice (or certain cells from which they are derived) that infringe one or more claims of the '287 Patent and the '163 Patent (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2013, the Company commenced patent infringement litigation against Kymab Ltd in the English High Court of Justice, Chancery Division, Patents Court, in London, asserting the '287 Patent and '163 Patent. Following a trial to adjudicate the claims of infringement and counterclaims of invalidity of the '287 Patent and the '163 Patent, the court issued a final judgment on February 1, 2016, finding that the asserted claims of the '287 and '163 Patents are novel, not obvious, and infringed by Kymab's genetically engineered mice. However, the court invalidated the '287 and '163 Patents on the ground of insufficiency. On appeal, the Court of Appeal (Civil Division of England and Wales) reversed the English High Court's decision and held that the '287 Patent and '163 Patent are both valid and infringed by Kymab and subsequently issued a final order, which enjoined Kymab from infringing the '287 Patent and '163 Patent (subject to certain exceptions) and required Kymab to destroy or deliver to a third party all products and antibodies and cells engineered to produce antibodies which infringe the '287 Patent and '163 Patent (subject to certain exceptions). On June 24, 2020, the Supreme Court of the United Kingdom overturned the decision of the Court of Appeal on validity and held that the '287 and '163 Patents are each invalid on the ground of insufficiency. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8 and July 13, 2016, notices of opposition against the '163 Patent were filed in the European Patent Office (the "EPO") by Merus N.V. and Kymab and Novo Nordisk A/S, respectively. The notices assert, as applicable, lack of novelty, lack of inventive step, and insufficiency. Following an oral hearing before the Opposition Division of the EPO on February 5&#8211;7, 2018, the Opposition Division upheld the '163 Patent without amendments. Kymab, Merus, and Novo Nordisk each filed a notice of appeal of the Opposition Division's decision on February 9, 2018, May 25, 2018, and June 26, 2018, respectively. On January 7, 2019, Merus withdrew its appeal of the '163 Patent in the EPO in connection with the previously reported global settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen has asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and seeks a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also seeks a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that two claims of the '165 Patent and one claim of the '741 Patent were not invalid. The jury also found that two claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit has been scheduled for December 9, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2016, Amgen filed a lawsuit against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi-Synthelabo Limited, Aventis Pharma Limited, Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the English High Court of Justice, Chancery Division, Patents Court, in London, seeking a declaration of infringement of Amgen's European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, by Praluent.&#160;The lawsuit also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On February 8, 2017, the court temporarily stayed this litigation on terms mutually agreed by the parties. On October 22, 2020, the court lifted the stay upon application by the Company and the Sanofi defendants, and the case will proceed in due course.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Germany. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 25, 2016, Amgen filed a lawsuit for infringement of the '124 Patent against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi-Aventis Deutschland GmbH in the Regional Court of D&#252;sseldorf, Germany (the "D&#252;sseldorf Regional Court"), seeking a permanent injunction, an accounting of marketing activities, a recall of Praluent and its removal from distribution channels, and damages. On November 14, 2017, the D&#252;sseldorf Regional Court issued a decision staying the infringement proceedings until a decision of the Opposition Division of the EPO concerning the pending opposition filed by the Company, Sanofi, and several other opponents against the '124 Patent (as discussed below). Following Amgen's request to reopen the proceedings in light of the issuance of the Preliminary Opinion (as defined below), the D&#252;sseldorf Regional Court held an oral hearing on September 11, 2018 and ruled on December 10, 2018 that the infringement proceedings would be reopened. On July 11, 2019, the D&#252;sseldorf Regional Court found that Praluent infringes the '124 Patent and granted an injunction prohibiting the Company and Sanofi's manufacture, sale, and marketing of Praluent in Germany (the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">"July 11 Decision"). Amgen subsequently enforced the injunction and, as a result, commercialization of Praluent in Germany has been discontinued. On July 12, 2019, the Company and Sanofi appealed the July 11 Decision to the Higher Regional Court of D&#252;sseldorf (the "Higher Regional Court"). An oral hearing on the merits of the appeal to the Higher Regional Court (originally scheduled for April 2, 2020) has been rescheduled for November 5, 2020. On August 5, 2019 and October 31, 2019, the Higher Regional Court denied the Company and Sanofi's requests for a stay of preliminary enforcement of the July 11 Decision pending the appeal on the merits. On November 3, 2020, Amgen filed a motion withdrawing this lawsuit without prejudice.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">France. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2016, Amgen filed a lawsuit for infringement of the '124 Patent in the Tribunal de grande instance in Paris, France against Regeneron, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A., and Sanofi Chimie (subsequently added as a defendant). Amgen is seeking the prohibition of allegedly infringing activities with a &#8364;10,000 penalty per drug unit of Praluent produced in violation of the court order sought by Amgen; an appointment of an expert for the assessment of damages; disclosure of technical (including supply-chain) and accounting information to the expert and the court; provisional damages of &#8364;10.0 million (which would be awarded on an interim basis pending final determination); reimbursement of costs; publication of the ruling in three newspapers; and provisional enforcement of the decision to be issued, which would ensure enforcement of the decision (including any provisional damages) pending appeal. Amgen is not seeking a preliminary injunction in this proceeding at this time. On April 10, 2017, the Company and the Sanofi parties filed briefs seeking invalidation of certain of the claims of the '124 Patent, and Amgen filed a response on July 28, 2017. Oral hearing on this infringement lawsuit (originally scheduled for February 12, 2019) has yet to be rescheduled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Netherlands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2019, Amgen initiated a lawsuit alleging infringement of the Dutch designation of the '124 Patent in the District Court of The Hague in the Netherlands, against Sanofi-Aventis Netherlands B.V. and Sanofi-Aventis Groupe S.A. The Company has not been named as a defendant in this action. Amgen alleges, among other things, patent infringement based on the production, importation, and commercialization of Praluent (alirocumab) in the Netherlands. Amgen's requests are made on an accelerated basis and include, among other things, a request for a permanent injunction, damages, an order for customer information, a recall order, a destruction order, and an order for costs. A trial has been scheduled for February 12, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Italy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, Amgen filed a lawsuit for infringement of the Italian designation of the '124 Patent in the Tribunale di Milano - Enterprise Chamber in Milan, Italy, against Sanofi-Aventis Groupe S.A., Sanofi Chimie, and Sanofi SpA. The Company has not been named as a defendant in this action. Amgen alleges that the production, importation, and commercialization of Praluent (alirocumab) in Italy infringes the '124 Patent. The writ of summons filed by Amgen seeks, among other things, a declaration of infringement, a permanent injunction, withdrawal of product from the market, and damages. On June 24, 2020, Amgen also filed a preliminary injunction motion against the Sanofi parties. On August 12, 2020, the court denied Amgen's preliminary injunction motion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Spain. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 20, 2019, Amgen also filed a lawsuit alleging infringement of the Spanish designation of the '124 Patent in the Juzgado de lo Mercantil No. 5 (Commercial Court) in Barcelona, Spain, against Sanofi-Aventis, S.A. The Company was not named as a defendant in this action. Amgen alleged, among other things, patent infringement based on the manufacture, offering for sale, introduction into the market, use, and importation or possession of Praluent (alirocumab) in Spain. Amgen sought, among other things, a permanent injunction, withdrawal of Praluent from the market, seizure and destruction of Praluent from the market and in storage, and damages in the form of lost profits and costs and expenses. On May 12, 2020, the court stayed this lawsuit until October 30, 2020 on terms mutually agreed by the parties. On October 30, 2020, the stay was automatically lifted. On November 2, 2020, Amgen filed a motion withdrawing this lawsuit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPO Proceedings. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '124 Patent is also subject to opposition proceedings in the EPO seeking to invalidate certain of its claims, which were initiated by Sanofi on February 24, 2016 and, separately, by the Company, Sanofi, and several other opponents on November 24, 2016. On December 13, 2017, the Opposition Division of the EPO issued a preliminary, non-binding opinion (the "Preliminary Opinion") regarding the validity of the '124 Patent, indicating that it currently considers the claims of a new request filed by Amgen in response to the opposition to satisfy the requirements for patentability. An oral hearing on the oppositions against the '124 Patent was held on November 28&#8211;30, 2018, at which the Opposition Division upheld the validity of the '124 Patent's claims in amended form. The Company and Sanofi filed notices of appeal to the Technical Board of Appeal (the "TBA") of the EPO on November 30, 2018. An oral hearing before the TBA was held on October 28&#8211;29, 2020, at which the TBA ruled that the '124 Patent claims directed to compositions of matter and medical use were invalid based on a lack of inventive step.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2017, Amgen filed a lawsuit for infringement of Amgen's Japanese Patent Nos. 5,906,333 (the "'333 Patent") and 5,705,288 (the "'288 Patent") in the Tokyo District Court Civil Division (the "Tokyo District Court") against Sanofi K.K. Amgen's complaint alleges that manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) infringe the '333 and '288 Patents. The complaint further seeks a permanent injunction, disposal of product, and court costs. The Company has not been named as a defendant in this litigation. On January 17, 2019, the Tokyo District Court upheld the validity of the '333 Patent and '288 Patent and ordered a permanent injunction against Sanofi K.K. to stop manufacturing, selling or otherwise transferring, and offering to sell or otherwise transfer Praluent (alirocumab) in Japan (as well as importing Praluent (alirocumab) into Japan) and to dispose of all product. However, the Tokyo District Court stayed the enforcement of such injunction pending appeal to the Intellectual Property High Court of Japan (the "IPHC"). On January 30, 2019, Sanofi K.K. appealed the Tokyo District Court's decision in the infringement proceedings to the IPHC. Following an oral hearing on October 30, 2019, the IPHC affirmed the Tokyo District Court's decision in the infringement proceedings. Sanofi K.K. appealed the IPHC's decision in the infringement proceedings to the Supreme Court of Japan on November 12, 2019. On April 24, 2020, the Supreme Court of Japan declined to hear the appeal filed by Sanofi K.K. in the infringement proceedings and the injunction issued by the Tokyo District Court became effective. Sanofi K.K. subsequently complied with the injunction and, as a result, the commercialization of Praluent in Japan has been discontinued. On March 31, 2020, Amgen filed a related lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the finding of infringement of the '333 Patent and the '288 Patent. The Company has not been named as a defendant in this damages action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation filed a lawsuit against Amgen and Immunex Corporation, a wholly owned subsidiary of Amgen, in the United States District Court for the District of Massachusetts seeking a declaratory judgment that the Company's and the other plaintiffs' Commercializing of Dupixent does not directly or indirectly infringe U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor. On May 1, 2017, the Company and the other plaintiffs filed a notice of voluntary dismissal of this action without prejudice.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of the '487 Patent. On July 28 and 31, 2017, the same parties filed two additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). On October 4, 2017, the Patent Trial and Appeal Board ("PTAB") of the USPTO issued a decision on the first IPR petition and declined to institute an IPR proceeding to review the validity of the '487 Patent. On February 15, 2018, the PTAB issued two decisions instituting the Company's and Sanofi's Additional IPR Petitions on all claims of the '487 Patent for which review had been requested. Oral hearings on the Additional IPR Petitions before the PTAB were held on November 14, 2018. On February 14, 2019, the PTAB issued final written decisions on the Additional IPR Petitions, invalidating all 17 claims of the '487 Patent as obvious based on one of the Additional IPR Petitions while declining to hold the challenged claims of the '487 Patent invalid based on the other. In April 2019, the parties filed notices of appeal with the Federal Circuit appealing the PTAB's respective adverse final written decisions on the Additional IPR Petitions, and oral argument was held on August 5, 2020. On October 13, 2020, the Federal Circuit affirmed the PTAB's decision on the Additional IPR Petition that invalidated all 17 claims of the '487 Patent as obvious.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. Immunex is not seeking an injunction in this proceeding at this time. On June 21, 2017, the court denied a motion to dismiss Immunex's complaint previously filed by the Company and the Sanofi parties. On June 28, 2017, the Company and the Sanofi parties filed an answer to Immunex's complaint and counterclaims against Immunex and Amgen (which was amended on October 31, 2017 to, among other things, add an inequitable conduct allegation), and Immunex and Amgen filed an answer to the counterclaims on July 28, 2017. A combined hearing on the construction of certain disputed claim terms of the '487 Patent and the Company and the Sanofi parties' motion </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for summary judgment on the issue of indefiniteness of the '487 Patent claims was held on July 12, 2018. On August 24, 2018, the court issued an order denying this motion and construed the disputed claim terms as proposed by Amgen. On February 28, 2019, the court granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019. The original patent term of the Immunex patents is set to expire in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), treble damages, costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended. The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Proceedings Relating to fasinumab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. A trial has been scheduled to commence in late November or early December 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the oppositions against the '048 Patent was held on November 29&#8211;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. An oral hearing before the TBA has been scheduled for July 29, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGN-COV2</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allele seeks a judgment of patent infringement of the '221 Patent, a judgment that such infringement was willful, and an award of monetary damages (together with interest), treble damages, costs and expenses of the lawsuit, and attorneys' fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. An oral hearing on the motion to dismiss was held on October 7, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. The Company is cooperating with this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Demand</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, is evaluating this demand letter.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250054456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2019 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and nine months ended September 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various collaborative arrangements to research, develop, manufacture, and commercialize product candidates and utilize our technology platforms. Although each of these arrangements is unique in nature, such arrangements involve a joint operating activity where both parties are active participants in the activities of the collaboration and exposed to significant risks and rewards dependent on the commercial success of the activities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements involving multiple goods or services promised to be transferred to our collaborator, we must assess, at the inception of the contract, whether each promise represents a separate obligation (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is "distinct"), or whether such promises should be combined as a single unit of account. When we have a combined unit of account which includes a license and providing research and development services to our collaborator, recognition of up-front payments and development milestones earned from our collaborator is deferred (as a liability) and recognized over the development period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, over time). In arrangements where we satisfy our obligation(s) during the development phase over time, we recognize amounts initially deferred over time typically using an input method on the basis of our research and development costs incurred relative to the total expected cost which determines the extent of our progress toward completion. We review our estimates each period and make revisions to such estimates as necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are entitled to reimbursement of all or a portion of the research and development expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred. In connection with the commercialization phase of our collaborative arrangements, we may be obligated to perform commercialization-related activities on behalf of the collaboration. If we are reimbursed for all or a portion of costs incurred for the commercialization-related activities, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. In arrangements where we:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">are obligated to use commercially reasonable efforts to supply commercial product to our collaborator, we may be reimbursed for our manufacturing costs as commercial product is shipped to the collaborator; however, recognition of such cost reimbursements is deferred until the product is sold by our collaborator to third-party customers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share in any profits or losses arising from the commercialization of such products, we record our share of the variable consideration, representing net product sales less cost of goods sold and shared commercialization and other expenses, in the period in which such underlying sales occur and costs are incurred by the collaborator; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive royalties and/or sales-based milestone payments from our collaborator, we recognize such amounts in the period earned.</span></div>Our collaborators provide us with estimates of product sales and our share of profits or losses, as applicable, for such quarter. These estimates are reconciled to actual results in the subsequent fiscal quarter, and collaboration revenue is adjusted accordingly, as necessary.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Matters</a></td>
<td class="text">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245149944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Reclassifications</a></td>
<td class="text">The tables below present the impact of the change on the Company&#8217;s previously-filed Consolidated Balance Sheet as of December 31, 2019, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2019, and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2019. The Company&#8217;s previously-filed balance sheet has been updated to reflect the addition of the caption Other liabilities for the presentation of up-front and development milestones paid by collaborators that are deferred. There was no impact on the Company&#8217;s previously-filed Consolidated Statements of Stockholders&#8217; Equity.  <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"/><td style="width:46.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Balance Sheet Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (current)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue - other (noncurrent)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities - Sanofi (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(766.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,048.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,897.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating (income) expense, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,159.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,160.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In addition to the reclassification of certain amounts in connection with the change in accounting presentation described above, the Company also reclassified certain immaterial reimbursements that were previously classified as collaboration revenue to Cost of collaboration and contract manufacturing.</span></div></td></tr></table></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.578%"><tr><td style="width:1.0%"/><td style="width:46.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Cash Flows Data:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As Revised</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable, accrued expenses, and other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589356292936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of product sales</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.461%"><tr><td style="width:1.0%"/><td style="width:42.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,422.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGN-COV2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,548.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.847%"><tr><td style="width:1.0%"/><td style="width:45.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589249654600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of collaboration revenue</a></td>
<td class="text">In arrangements where we do not deem our collaborator to be our customer, payments to and from our collaborator are presented in our statement of operations based on the nature of our business operations, the nature of the arrangement, including the contractual terms, and the nature of the payments, as summarized in the table and further described below. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Presentation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits or losses in connection with commercialization of products </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and/or sales-based milestones earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's research and development expenses </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Research and development expenses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestone payments to collaborators</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of Regeneron's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction to Selling, general, and administrative expense</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of collaborator's commercialization-related expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation to pay collaborator for its share of gross profits when Regeneron is deemed to be the principal</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front and development milestones earned (when we have a combined unit of account which includes a license and providing research and development services)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.449%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.210%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.301%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.422%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer collaboration revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with the Teva Collaboration Agreement are as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"/><td style="width:33.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.606%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock', window );">Summary of contract balances</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:58.333%"><tr><td style="width:1.0%"/><td style="width:48.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.053%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:65.935%"><tr><td style="width:1.0%"/><td style="width:54.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable - other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer and Collaborator Asset And Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589247580376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The calculations of basic and diluted net income per share are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.900%"><tr><td style="width:1.0%"/><td style="width:42.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive, include the following: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:60.964%"><tr><td style="width:1.0%"/><td style="width:33.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589247581656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Debt Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Marketable Securities, Based on Contractual Maturity Dates</a></td>
<td class="text">The fair values of available-for-sale debt security investments by contractual maturity consist of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Unrealized Losses of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:29.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589344058216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"/><td style="width:48.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,328.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589246908728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245398136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Shares Repurchased</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the&#160;shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.631%"><tr><td style="width:1.0%"/><td style="width:46.169%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The table below summarizes the&#160;shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.134%"><tr><td style="width:1.0%"/><td style="width:50.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.314%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupilumab/Itepekimab:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares purchased (in cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589358194696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Summary of Non-Cash Investing and Financing Activities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.836%"><tr><td style="width:1.0%"/><td style="width:26.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589335055128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Financial Statements - Schedule of Balance Sheet Data (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,303.0<span></span>
</td>
<td class="nump">$ 1,211.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities - Sanofi</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">454.0<span></span>
</td>
<td class="nump">317.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">409.3<span></span>
</td>
<td class="nump">310.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">367.0<span></span>
</td>
<td class="nump">482.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 67.0<span></span>
</td>
<td class="nump">77.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,086.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities - Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities - Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589333582808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements - Schedule of Statements of Operations Data (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 1,743.7<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
<td class="nump">$ 4,694.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">684.6<span></span>
</td>
<td class="nump">526.0<span></span>
</td>
<td class="nump">1,990.5<span></span>
</td>
<td class="nump">1,897.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">326.9<span></span>
</td>
<td class="nump">304.4<span></span>
</td>
<td class="nump">1,042.5<span></span>
</td>
<td class="nump">890.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(171.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,240.9<span></span>
</td>
<td class="nump">1,005.2<span></span>
</td>
<td class="nump">3,664.6<span></span>
</td>
<td class="nump">3,160.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember', window );">Collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">454.5<span></span>
</td>
<td class="nump">289.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember', window );">Sanofi | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">353.3<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">869.3<span></span>
</td>
<td class="nump">232.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">293.6<span></span>
</td>
<td class="nump">825.5<span></span>
</td>
<td class="nump">834.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember', window );">Other | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 158.6<span></span>
</td>
<td class="nump">36.8<span></span>
</td>
<td class="nump">$ 433.6<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,693.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,159.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Sanofi | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Bayer | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Other | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(999.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(455.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(999.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Sanofi | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(766.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Bayer | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments | Other | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (199.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253565144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements - Schedule of Cash Flows Data (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="nump">$ 112.3<span></span>
</td>
<td class="nump">$ 166.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">$ 80.8<span></span>
</td>
<td class="nump">328.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589254050664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Net Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 1,743.7<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
<td class="nump">$ 4,694.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,482.2<span></span>
</td>
<td class="nump">1,238.3<span></span>
</td>
<td class="nump">3,945.8<span></span>
</td>
<td class="nump">3,548.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,482.2<span></span>
</td>
<td class="nump">1,238.3<span></span>
</td>
<td class="nump">3,945.8<span></span>
</td>
<td class="nump">3,548.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,318.3<span></span>
</td>
<td class="nump">1,187.7<span></span>
</td>
<td class="nump">3,604.0<span></span>
</td>
<td class="nump">3,422.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Praluent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | REGN-COV2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | ARCALYST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_REGNCOV2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_REGNCOV2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589252835512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details) - Gross Sales Revenue - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossSalesRevenueMember', window );">Besse Medical, a subsidiary of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossSalesRevenueMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossSalesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossSalesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_BesseMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_BesseMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589254050136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,294,000<span></span>
</td>
<td class="nump">$ 1,743,700<span></span>
</td>
<td class="nump">$ 6,074,200<span></span>
</td>
<td class="nump">$ 4,694,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfTrialCostsBorneByCollaboratingParty', window );">Percentage of Trial Costs borne by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfTrialCostsBorneByEntity', window );">Percentage of Trial Costs borne by entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived', window );">Levels of twelve month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels', window );">Maximum amount of sales milestone payments if total sales achieve specific levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Sales-based milestone earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember', window );">Praluent Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates', window );">Royalty percentage to be received on net product sales outside of the United States</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyPercentageOfDamagesResponsibleFor', window );">Percentage of damages company is responsible for</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi | Praluent Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset', window );">Percentage of royalty payment that can be used to offset litigation proceedings</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of twelve month sales upon which sales milestone would be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyPercentageOfDamagesResponsibleFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Percentage Of Damages Responsible For</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyPercentageOfDamagesResponsibleFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Royalty Payment That Can Be Offset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfRoyaltyPaymentThatCanBeOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfTrialCostsBorneByCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfTrialCostsBorneByCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfTrialCostsBorneByEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfTrialCostsBorneByEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for Achieving Sales Target for Milestone Payment, Rolling Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage To Be Received On Net Product Sales Outside Of United States</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589249888488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,294,000<span></span>
</td>
<td class="nump">$ 1,743,700<span></span>
</td>
<td class="nump">$ 6,074,200<span></span>
</td>
<td class="nump">$ 4,694,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(684,600)<span></span>
</td>
<td class="num">(526,000)<span></span>
</td>
<td class="num">(1,990,500)<span></span>
</td>
<td class="num">(1,897,600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember', window );">Regeneron's share of profits in connection with commercialization of antibodies | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">212,800<span></span>
</td>
<td class="nump">94,200<span></span>
</td>
<td class="nump">555,600<span></span>
</td>
<td class="nump">105,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember', window );">Sales-based milestone earned | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember', window );">Reimbursement for manufacturing of commercial supplies | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">94,300<span></span>
</td>
<td class="nump">85,400<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">143,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember', window );">Reimbursement for manufacturing of commercial supplies | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember', window );">Reimbursement of research and development expenses | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">45,500<span></span>
</td>
<td class="nump">60,200<span></span>
</td>
<td class="nump">174,400<span></span>
</td>
<td class="nump">216,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember', window );">Reimbursement of research and development expenses | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">49,800<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">136,700<span></span>
</td>
<td class="nump">120,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember', window );">Regeneron's obligation for its share of Sanofi research and development expenses | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(17,500)<span></span>
</td>
<td class="num">(10,200)<span></span>
</td>
<td class="num">(59,100)<span></span>
</td>
<td class="num">(29,800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember', window );">Reimbursement of commercialization-related expenses | Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense', window );">Reduction of Selling, general, and administrative expense</a></td>
<td class="nump">83,200<span></span>
</td>
<td class="nump">111,600<span></span>
</td>
<td class="nump">260,400<span></span>
</td>
<td class="nump">349,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember', window );">Reimbursement of commercialization-related expenses | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense', window );">Reduction of Selling, general, and administrative expense</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">39,200<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember', window );">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="num">(31,500)<span></span>
</td>
<td class="num">(20,100)<span></span>
</td>
<td class="num">(86,500)<span></span>
</td>
<td class="num">(51,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember', window );">Amounts recognized in connection with up-front payments received | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">73,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Regeneron's share of profits in connection with commercialization of antibodies | Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (4,700)<span></span>
</td>
<td class="num">$ (4,600)<span></span>
</td>
<td class="num">$ (17,300)<span></span>
</td>
<td class="num">$ (16,200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Selling, General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253950632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 460.8<span></span>
</td>
<td class="nump">$ 260.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">453.2<span></span>
</td>
<td class="nump">272.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 433.6<span></span>
</td>
<td class="nump">$ 328.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250003208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable, net</a></td>
<td class="num">$ (460.8)<span></span>
</td>
<td class="num">$ (260.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable, net</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 441.8<span></span>
</td>
<td class="nump">$ 558.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589246933176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_UnsatisfiedObligation', window );">Unsatisfied obligation</a></td>
<td class="nump">$ 951.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UnsatisfiedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsatisfied Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UnsatisfiedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253367832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 1,743.7<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
<td class="nump">$ 4,694.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(684.6)<span></span>
</td>
<td class="num">(526.0)<span></span>
</td>
<td class="num">(1,990.5)<span></span>
</td>
<td class="num">(1,897.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Product and service, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">293.6<span></span>
</td>
<td class="nump">825.5<span></span>
</td>
<td class="nump">834.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Regeneron's net profit in connection with commercialization of EYLEA outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">287.9<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
<td class="nump">772.6<span></span>
</td>
<td class="nump">793.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">52.9<span></span>
</td>
<td class="nump">41.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Reimbursement of development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Regeneron's obligation for its share of Bayer research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(12.9)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(26.3)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Outside United States | Bayer | Reimbursement of other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfOtherExpenses', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245172888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Bayer Narrative (Details) - Bayer<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RevenuebasedonpercentageofannualsalesinJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="nump">33.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RevenuebasedonpercentageofannualsalesinJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RevenuebasedonpercentageofannualsalesinJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RevenuebasedonpercentageofannualsalesinJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250358424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts receivable - other</a></td>
<td class="nump">$ 486.2<span></span>
</td>
<td class="nump">$ 425.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts receivable - other</a></td>
<td class="nump">299.2<span></span>
</td>
<td class="nump">311.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 122.1<span></span>
</td>
<td class="nump">$ 123.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250067496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - Teva - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Reimbursement of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
<td class="nump">$ 82.1<span></span>
</td>
<td class="nump">$ 102.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Amounts recognized in connection with up-front and development milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="nump">$ 22.8<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
<td class="nump">$ 68.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250598648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts receivable - other</a></td>
<td class="nump">$ 486.2<span></span>
</td>
<td class="nump">$ 425.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndNotesReceivableNet', window );">Accounts receivable - other</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 61.0<span></span>
</td>
<td class="nump">$ 114.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndNotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndNotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589343929720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Teva Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_UnsatisfiedObligation', window );">Unsatisfied obligation</a></td>
<td class="nump">$ 130.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_UnsatisfiedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsatisfied Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_UnsatisfiedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589254043832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Intellia Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 684.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526.0<span></span>
</td>
<td class="nump">$ 1,990.5<span></span>
</td>
<td class="nump">$ 1,897.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember', window );">Intellia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_CollaborativeArrangementUpfrontPaymentMade', window );">Upfront payment made for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember', window );">Intellia | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Shares purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementUpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment made under a collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementUpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchCollaborationAndLicensingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250041224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - BARDA Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_MaximumTransactionAgreementPayments', window );">Maximum agreement payments</a></td>
<td class="nump">$ 450.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember', window );">Other Transaction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty', window );">Percentage of research and development costs to be paid by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumTransactionAgreementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Transaction Agreement Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumTransactionAgreementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Research And Developments Costs To Be Paid By Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589333494168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income - basic and diluted</a></td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 897.3<span></span>
</td>
<td class="nump">$ 624.6<span></span>
</td>
<td class="nump">$ 669.6<span></span>
</td>
<td class="nump">$ 193.1<span></span>
</td>
<td class="nump">$ 461.1<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
<td class="nump">$ 1,323.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">105.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">109.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
<td class="nump">114.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.83<span></span>
</td>
<td class="nump">$ 12.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.36<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250108856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive weighted average number of shares (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive weighted average number of shares (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589333727752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 3,508.3<span></span>
</td>
<td class="nump">$ 4,206.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">42.9<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,550.4<span></span>
</td>
<td class="nump">4,234.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">2,796.6<span></span>
</td>
<td class="nump">3,960.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,836.0<span></span>
</td>
<td class="nump">3,988.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">133.5<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">65.4<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">66.6<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">390.4<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">390.6<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">122.4<span></span>
</td>
<td class="nump">72.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 122.5<span></span>
</td>
<td class="nump">$ 72.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589250361848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 1,452.9<span></span>
</td>
<td class="nump">$ 1,596.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturities after one year through five years</a></td>
<td class="nump">2,097.5<span></span>
</td>
<td class="nump">2,638.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 3,550.4<span></span>
</td>
<td class="nump">$ 4,234.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589339869720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">$ 606.0<span></span>
</td>
<td class="nump">$ 274.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">606.0<span></span>
</td>
<td class="nump">274.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">560.5<span></span>
</td>
<td class="nump">257.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">560.5<span></span>
</td>
<td class="nump">257.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589247212648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain (loss) on sales of marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589335285368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">$ 3,550.4<span></span>
</td>
<td class="nump">$ 4,234.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">761.3<span></span>
</td>
<td class="nump">618.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">3,566.7<span></span>
</td>
<td class="nump">4,234.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember', window );">Unrestricted | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">41.3<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember', window );">Unrestricted | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember', window );">Restricted | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">720.0<span></span>
</td>
<td class="nump">557.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember', window );">Restricted | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">4,328.0<span></span>
</td>
<td class="nump">4,853.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Unrestricted | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">41.3<span></span>
</td>
<td class="nump">61.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Restricted | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">736.3<span></span>
</td>
<td class="nump">557.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">2,836.0<span></span>
</td>
<td class="nump">3,988.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">2,836.0<span></span>
</td>
<td class="nump">3,988.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">2,836.0<span></span>
</td>
<td class="nump">3,988.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations | Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">134.7<span></span>
</td>
<td class="nump">54.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">66.6<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">66.6<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds | Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">66.6<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">390.6<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">390.6<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">390.6<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">122.5<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">122.5<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Estimate of Fair Value Measurement | Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities:</a></td>
<td class="nump">$ 122.5<span></span>
</td>
<td class="nump">$ 72.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_RestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253771384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on securities</a></td>
<td class="num">$ (37.5)<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 133.8<span></span>
</td>
<td class="num">$ (58.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Securities owned not readily marketable</a></td>
<td class="nump">60.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt fair value</a></td>
<td class="nump">$ 1,929.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,929.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245284056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 400.4<span></span>
</td>
<td class="nump">$ 216.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">715.4<span></span>
</td>
<td class="nump">727.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">132.1<span></span>
</td>
<td class="nump">70.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryNetOfReserves', window );">Deferred costs</a></td>
<td class="nump">553.7<span></span>
</td>
<td class="nump">400.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventories</a></td>
<td class="nump">$ 1,801.6<span></span>
</td>
<td class="nump">$ 1,415.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589249914008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage', window );">Redemption price with change-in-control provision, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember', window );">Bridge Facility | Common Stock Held By Sanofi | Bridge Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member', window );">2030 Notes | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member', window );">2050 Notes | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_CommonStockHeldBySanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_CommonStockHeldBySanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245311672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253476056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="nump">9,806,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
<td class="nump">$ 5,071,800,000<span></span>
</td>
<td class="nump">$ 336,000,000.0<span></span>
</td>
<td class="nump">$ 48,700,000<span></span>
</td>
<td class="nump">$ 54,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_Maximumsharesthecollaboratorcouldsell', window );">Maximum shares the collaborator could sell (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">13,014,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember', window );">Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_Maximumsharesthecollaboratorcouldsell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares the collaborator could sell through September 30, 2020.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_Maximumsharesthecollaboratorcouldsell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253308088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="nump">9,806,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="nump">$ 5,071.8<span></span>
</td>
<td class="nump">$ 336.0<span></span>
</td>
<td class="nump">$ 48.7<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember', window );">Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589254052744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Sanofi Funding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="nump">9,806,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="nump">$ 5,071.8<span></span>
</td>
<td class="nump">$ 336.0<span></span>
</td>
<td class="nump">$ 48.7<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentMember', window );">Libtayo development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,677<span></span>
</td>
<td class="nump">210,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.7<span></span>
</td>
<td class="nump">$ 73.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_DupilumabREGN3500EligibleInvestmentsMember', window );">Dupilumab/REGN3500 Eligible Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,471<span></span>
</td>
<td class="nump">93,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.3<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_DupilumabREGN3500EligibleInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_DupilumabREGN3500EligibleInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589249720280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,573.0<span></span>
</td>
<td class="nump">$ 1,617.8<span></span>
</td>
<td class="nump">$ 1,384.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in Other noncurrent assets</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 1,586.6<span></span>
</td>
<td class="nump">$ 1,630.3<span></span>
</td>
<td class="nump">$ 1,397.3<span></span>
</td>
<td class="nump">$ 1,480.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589245246008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
<td class="nump">$ 133.7<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140589253804808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Matters (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 26, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 14, 2019 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132.2<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=regn_Amgenv.s.RegeneronMember', window );">Amgen v.s. Regeneron | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyDamagesSoughtPerUnitProduced', window );">Loss contingency, damages sought, per unit produced | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember', window );">'165 Patent | Amgen v.s. Regeneron | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyClaimsInvalidNumber', window );">Invalid claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember', window );">'741 Patent | Amgen v.s. Regeneron | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember', window );">'487 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyInterPartesReviewFiledNumber', window );">Number of IPR filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyClaimsInvalidatedNumber', window );">Number of claims invalidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember', window );">'631 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyInterPartesReviewFiledNumber', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_GainContingencyClaimsInvalidatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Claims Invalidated, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_GainContingencyClaimsInvalidatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_GainContingencyInterPartesReviewFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Inter Partes Review Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_GainContingencyInterPartesReviewFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyClaimsInvalidNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Invalid, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyClaimsInvalidNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyDamagesSoughtPerUnitProduced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Damages Sought, Per Unit Produced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyDamagesSoughtPerUnitProduced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=regn_Amgenv.s.RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=regn_Amgenv.s.RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  */F51K*<\)Y$%  "&%P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+58WW/B-A!^OOX5&J8/[4P(E@PQW"29(1RY8YH0#G+M7#M]4&P!GK,M*LLA
M_/==V6"1G%F[G;D7\*_]]&FU^G:UEUNIOJ5K(31YB:,DO6JMM=Z\[W12?RUB
MGI[+C4C@S5*JF&NX5:M.NE&"![E1''68XUQT8AXFK>O+_-E,75_*3$=A(F:*
MI%D<<[6[$9'<7K5HZ_!@'J[6VCSH7%]N^$HLA/ZRF2FXZY0H01B+) UE0I18
M7K6&]/W(]8Q!_L7OH=BF1]?$3.5)RF_F9A)<M1S#2$3"UP:"P]^S&(DH,DC
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M43JV!>X3UH@H9A91OY?G2)I]^*85U%H>SBO2O<J5WD@4>K(=--7/J%<8JK*
M%$!A/MA2H#"H!0:L#<0*:R06H_^#7]JA8_(,A8.D'(AN% 9VX3,4Y@#9,&!M
M0":Q1B R9A2?<Q4J6>RIM3-69)IN=YG<%.>F;Y+<(:FUVTVCQIA9C9DS==WX
MHTR-P+!,7<,^R-2(,5.F9HT08^($.;_H>/(@R.(TS\]*]5UX6Y=MD\IGC09B
M9@WT+<ED&$=_%[%;=D'6H8[A5&= ^:I(+A?[+%(1+HD8%"=?!8QF&^C OAA
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MR\N-#)<R*P#Z]U6:JL--T<'Q0Z/K?P%02P,$%     @ "CYE48](E929#0
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MU$@B'99$PREN=2V&WTG)DO_905^8F!@L#\^@EEJ)2 -=8V#E9E-.VMDAFUE
M)J'3^NL1']J(*!T6T?G[J2"FT9*O19:9[8-8A).LD+&585<L(=V[AQB;G0MM
M1$^/25MO'8=[S _2XN9P-DB(=E\.>H'?.L14A"QV-)RUB)>$IJW7UBE7Z^)M
M?HZ*_JQ\UUL_K7\QN"S>DQ\]O\*G\_*]?S--^3/$#5.P5SE*^ JF="8SD Q5
MOMDO;[3<%B_'EU)KF1:7&\Z@2AH#^'XEI=[?F 7JWU<N_@-02P,$%     @
M"CYE46@NJ[5P"P  X!X  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM
M66USV[@1_BL8]:9U9F1:I%XLY9+,V+YDFK;7I'%RUYE./T D9.%"$CH M*+^
M^CZ[ "G*EGRYS'V1^ +L/MA]=K$+OM@:^]FME?+B2U76[N5@[?WF^<6%R]>J
MDBXQ&U7CS<K82GK<VKL+M[%*%CRI*B^RT6AV44E=#UZ]X&?O[:L7IO&EKM5[
M*UQ35=+NKE5IMB\'Z:!]\$'?K3T]N'CU8B/OU*WRGS;O+>XN.BF%KE3MM*F%
M5:N7@ZOT^?6$QO. G[3:NMZUH)4LC?E,-V^+EX,1 5*ERCU)D/B[5S>J+$D0
M8/P:90XZE32Q?]U*?\-KQUJ6TJD;4_ZL"[]^.9@/1*%6LBG]![/]JXKKF9*\
MW)2.?\4VCAT-1-XX;ZHX&0@J78=_^27:X6LF9'%"QKB#(D;Y@_3RU0MKML+2
M:$BC"UXJSP8X79-3;KW%6XUY_M7;VBNK*_%&U[+.M2S%K9=>P>S>O;CPT$#C
M+O(H[3I(RTY(6X@?3>W73KRN"U4<SK\ L@Y>UL*[SIX4>*LVB1B/AB(;9:,G
MY(V[Y8Y9WOB$O'?V3M;Z?Y(8,10WIG:FU(4,!*D+\=XJAZ6'!V9UU"SB/U=+
MYRWX]-\G$$TZ1!-&-/F#'/#MTL2U=-K1J@Y6^7&MA([38) " :>*GFEP<U0:
MY'Q0=ZI6%D+>KR5")%>-U[DLW5"\K?.$+:HQU#5+IPLMK59.G VZ:<.!&-R8
M:B/K'5UN%?TV#K\T<V :.W@FUO)>B:52M4#6V4@+/)JB.3>V "J%@/%KX7D5
M<$O#T>Z$-X+"5J2C\W^QN"L+;*7"@PB]*8,!;L__G8@KEJ?KNW(W)&$[41A1
M&P^A>=D42LBRQ'7(@BU;"NWRTK@&YA2URI5SR&L"8X0DL =,(H!QK7]Q8M59
M=&.<#FS$!*02-BQRKN69L"0IRJ5;BQ42J*.UYX9Q:+\+:R=;-+4'>&@%7KTI
M 8AM#-0[>J\V/MB-8'RJ-=VQ+UG=507OYS*!UWB V>@ZPJYDC=Q,'F>S.-6#
M[O9D0"JE/,M6JLE&)1[EC;4$2A:_()&%@;0:X+$-6/+(9BNI[5[J8ZOE'3WS
M/CV/(B*)KLG7 J;4IG )$_VHC8/V>M>%09@BP#6F0 M3ES2D@*5H)VGAM2))
M"-VO&MA@IZ0-&G_ Y&JIK!BGE,72Q:D@NY8ET_F6]V(\DV*K@*  F'M:I365
MD$VA3RUY*):-/T;;/DVM^K71%$/+W1_(FX^GF>'6IBFAC@PEBTC?7YHZ;,I=
M[!Z=2V3!8J ,0ZQ"2&.N1Z6QQQ3)\><_S;/T\GLGKNH:U$)X;XP%@^HN"?R]
M<Q#Y1BC:H!X[)Q$WRI(&HF\IG=,K=C>Q9)^(*@G+ @VL!IDM6RHR)B>>&*#[
MU5$D$*/#4#"YGQT2\7JU4ER=B+])P$<\I&''&X("(E_+^@Y@2=##K)(;YP%5
M5\O&NI;Y1!34!:5<&C#<6">V:].QN5 85Q!,^ 0I-E89RCZ:&>JN>U4WO%J)
MFR*DUY;[R)D M &AB40QHG"EOFR(X>),Z$0E8BB4)@_"+0[&1U!R]H3HTFQ"
MJ%MQB\H,<X<M 4/FDP6*'DW;+=GG&?&:;,G\;1#4/Q/%G7G22*UGX%)SA]U?
MM32L58^%S>8<ZP>6A]@JC;#PIH9@N6O37:[V07G28H87O3<+P,/0##I0B,,F
M0.?,?H!\J7+9X/V66%=JB.75U:AT#\9IIM,*2I:E@M4@R6.&1RYK\[(+,Z5'
M#GB05KO((2JYO7W)"G$I3L!I%',;D*R1, FQP5J"'>S!!CRD',U7]9I2FHM<
M@3Y@U"5M7)2 P;VC8<_2D&C!2X3"1H&:(9<&2STRU!I+YKB4FPWL1+B]-6X3
M8JK<A<F>S$,#L8VV\T/9 %QYM]M$'>9X>L&\>VT:5^[.5Z#%DRE<<HY\E&*&
M4?#13>"VO_F].]RA:)I?6Z5"7D06%%6HMD,RNZ5D'52-6E4T\FO5W5"1\8:+
MC%;=UR@)UOU-0RVC;4*KV;FLV00D8%1;0Y!B613Z(-'(#=^^XX@J=: 1E9,M
MU(=!_]OA#)!2<R(Y9*Y?2\_9LJ"@0BSP"G&_!>C:='SY%H8<UL^WWN2?UZ;$
M%N^B /$:^[,'91_7#8?LHF[ON;AR5,Q'A7'7@YJK7L6%(1\P@GQ_1847_F-Z
M#D$:DE2[0_5-^QVVH=%\ELSI*ILD,WZ2I6DR ;Q@FR[=G8M;69N5%F=1U#.,
M'B^FR13_9_-I,N('Z0@/CDP.*/IST\4LR6@NJZ8GERD@/&; $<ULS.Q[S"'%
M[=\3F&M3]U1/1XODDE1/YEG G5WBP6G8A]-33!_3]'&:7#+PR]\ WI^_Q\[:
MN_\P?S_R@:LR.&K$%F;HXY00?^1TT>_)Q3\II ^>G,HYW\2PWS4Z+O_X_HEU
MCR:! 5FV2#*V[&5PYV(1'70YFR4+=M X T^OY8ZX?$+>>)0QE\^BM&PQ9D[/
M9W.6>C8>AQ?S\00#@\'WT]/1.$EI&'2.F<PA-+++>20JH6)_ST'RC\9S%Q2W
M4(P;CB9SA XIPLIX9#J\G(QY*=/A#' 6# ]RYO1V@F<3Z#Q9-GTG9K-Q$)F.
M+Y,)DS<+1,B&X^DX1-]D.@U62H?S!7'Q:VHMTH_LSHC2%'',2P;P24@#D]9H
MT\L@?+X8 >L-5:1<F?:=P$TL2$>G)M13-BM<--P=GJ6,#(F!/9HF:1M#LZB0
MUY!.HJ/GBRZ8]I7562BMGK6I;8@RR?="Z6PZ"@:/%[TWZ654V5X%QSTJ9D,^
M'(^B27HN'(VF3(#),)TN(L-:%XZ'Z6P$0]$JT5UW^QKVN] \'G89;+G8@;1E
MZY%:U1\40P=]7&\7+)3+K5Y2,;<T]VK8WZ]"U;Q73SUUU*NK2E(?S.P]Z"QX
M9^2F=+_+B9X$Z4[7PK^7%\F13-6K4+XE.=WL3U&X;M^[F,^&.9,^IY,K=*J.
M+5L\S/AP*%(0NS@#$WAO2&>4!_K3HD.HP-C%HOS!SCOL;;T/MMP8<RR>]&5S
MW']R7+>_=EY7W'U_#"4/5=0M;X[6TD>.BXXT^,=/ N)9@>L= I$G*_E9"=4A
MX<SA7%-MXL$;ET_<T892KNN^HG=BYWZRXR<PS%&"P^U_*#'5%Q\1;-<Z#T%P
M\^ZGMS^<HSC"^$)5.@>ZG2B .O=8(&I#.K")=VWAAKYCV3BPR\$/>QATNA2/
MXD+S<^RH",W66M^M(:VINT#%:-<L?^$5MZTH=WET3*51W;6-J:$5D*[#GN/Q
M*LBC@'G:RK&P[ZI2F%QT81NE4P=*_?WO.#4+/0L)_Y:.(QM]+]9FBUBQ1'G?
M< H)9LSY&*C0((8-X>?7QCTD4E@2^7"Y;XSC.O8C8?-5P[UL=[CW >5R34Z^
M*@Q3^FI/:10X=2%MX?BTX*GWG[@;H7)[=IZ.A[V#[[=\MAR,="YNX%$TV?\P
MSE'*^!&!#S1=(]5_RV=01\6<#:YN/[6Z!L^&T?@/CH 2T1NU#TE9"Z(28IHB
M,NB/M(V'')QK<EIJ'O"4 0\YMF7NG@-Z#VP8#P_)-$C,A8K''=P_,THH1_XP
M6VY'.-X/SAD",#JOC95JZSG._P=@.HSA.*H]?4CHV$[(>ZE+TGH.S.=.EM22
M+;UP=+(<\F4XN:F1>4L^USF0'C8\%[W;LUV+W46U9#-;<)!:T]RMN7@(%04;
MA@XN ;U+)'P.QN8)^<WZH#QN<>%;Q+T*6Q#@(0.T/2KO52'QG\-R]3D""'F1
M'$Y1JVWH44VARI#UF*]=)XSTTZVGT'PZ&LXE'T=_3"%'PYQ/VYT&3ZCP@,+#
M.7P.7H>4Z*TI77+L0]=%[ZMCI>P=?UOE0*]]^ #9/>T^WUZ%KY;[X>';[X_2
MWL'0HE0K3$6%-AT(&[ZGAAMO-OP-<VF\-Q5?KN$596D WJ\,4FN\(07=1^U7
M_P=02P,$%     @ "CYE46NV[33* P  :P@  !@   !X;"]W;W)K<VAE971S
M+W-H965T."YX;6R=5FUOVS80_BL'=>F PM.[8SMU#-A9]H(E61"G'8IA'VCI
M;!&E2(VDZF:_?D=*UIPNR5Y@@SZ2=P^?.][Q/-\K_=%4B!8^UT*:\Z"RMCF+
M(E-46#,3J@8E[6R5KIFEJ=Y%IM'(2F]4BRB-X].H9EP&B[E?N]6+N6JMX!)O
M-9BVKIE^6*%0^_,@"0X+=WQ76;<0+>8-V^$:[;OF5M,L&E!*7J,T7$G0N#T/
MELG9*G?Z7N$]Q[TYDL%YLE'JHYO\6)X'L2.$ @OK$!C]?,(+%,(!$8W?>\Q@
M.-(9'LL'].^\[^3+AAF\4.(77MKJ/)@&4.*6M<+>J?T/V/LS=GB%$L:/L.]T
MTSB HC56U;TQ,:BY['[9YSX.1P;3YPS2WB#UO+N#/,MOF66+N59[T$Z;T)S@
M7?761(Y+=REKJVF7DYU=W&I5MH6%-1-HYI$E2+<1%;WYJC-/GS&?P;62MC)P
M*4LL']M'1&7@DQ[XK-(7 =?8A)#%(TCC-'X!+QO\RSQ>]@S>'7Y"V:*!7Y<;
M8S4EP6\OH.8#:NY1\_\;M?]@#C=4>DV_8OQ*H2CIC06U!5LA;)6@VN%R=P;W
ME49\%'.X(? O5@CP\1%<>J!WDEO:7UMF:=%%F(9D=B1=?KBZ7,+K5\DD?PM?
M03+*DFF8>2F93L()2=GH-,[#V$MYFH8)7/&-90_J8#9)PE/()S0DLU,W)N,P
M)4),M"CM02N?AF-X [,Q@;ZAS]WE]S??7/S\/H4\)O77KZ9IDKY]/%G>72RO
M/JSO#Q@9H6=$9484D]BS2T;Y-"43)Z59QST;S?)Q./72F,Z-Z;C+[1;]@P#+
M1G-!VCX*(Q^G"U4W3#X -V"40/% SX]IW*5LA+L.[;5*2BVAFMHYQ61)MU;7
MJ O.!/^#^2>'[F]P^\DK<&8:"Z5+ _)O:?!/YB&L*1ENE$7(/*MMJTE)$S/+
MN*#]^R-G*E9^@6\5%*A)5?8O#6I:K!BY4Q2JE>XD!ULKC6Y=4I!/?%(JRP3L
MM#)F@-1=H0W1L3Y3G8/2)6C=)2CZ!*4BMUAOB.FATKVBR\"PSUCBAJRH^A(P
M>,20T1<:BC3%A?K&H4IZ/[\V+])CY H!="5E_F5!/54I*S3$ZAI+7C Q(D:F
MW1A><NILCM&2J'*C6F*Y0KU#2?QTHW27&.,83F \<4-ZD*Z+GPA2/5;,<MHY
M&C(X>>KYBHX:0.V.<VW.O2-TB5TO&%:'3KKL&LA?ZET;OF9ZQZ4!@5LRI:(:
M!Z"[UM9-K&I\.]DH2Q?BQ8K^#:!V"K2_5920_<0=,/R_6/P)4$L#!!0    (
M  H^95%J<4AQT!<  *E3   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MU5QI;]M(D_XK#6WF'1N0:1V6CR03P'&RV+R8S 1QLH/%8C^TQ);$"<7FL$DK
MVE^_=70WFX=D9<:9W06"6 ?9755=QU,']7*KBR]FK50IOF[2S/PT6)=E_OS\
MW"S6:B--I'.5P3=+76QD"6^+U;G)"R5CNFF3GD]&H\OSC4RRP:N7]-F'XM5+
M795IDJD/A3#59B.+W6N5ZNU/@_' ?? Q6:U+_.#\U<M<KM2]*C_G'PIX=^Y7
MB9.-RDRB,U&HY4^#V_'SUQ=X/5WP[XG:FN"U0$[F6G_!-^_BGP8C)$BE:E'B
M"A+^/*@[E::X$)#QAUUSX+?$&\/7;O5_)=Z!E[DTZDZGOR5QN?YI<#T0L5K*
M*BT_ZNV_*<O/#-=;Z-30_V++UUY<#<2B,J7>V)N!@DV2\5_YU<HAN.%ZM.>&
MB;UA0G3S1D3E&UG*5R\+O14%7@VKX0MBE>X&XI(,#^6^+.#;!.XK7P$WJ9SK
M0J*,AN+G9 $"5T,ALUC\6JY5(6Y7A5)P#*5Y>5["CGC?^<*N_II7G^Q9_4:\
MUUFY-N)M%JNX>?\Y4.K)G3AR7T\.+GBO\DA,1T,Q&4U&!]:;>O:GM-YTSWH?
MU8/**B66A=Z(.Z"U #6!(RC7XHZ$#P+XS]NYH<__Z\"&%W[#"]KPXCO)^^E6
M%[\IL98/2L ;5:A8)%FIQ8,L$ET9L:A7@DMD4<AL9>^#JPIEE"P6ZR$8P ,8
M=CX$G<RJ)0BI*NQ^"[T!Z2T2F2;_K41>Z+@"T2[@JR26I3)T454F]+6N"E&J
MQ3K3J5[M1)[*$AV.B<1M6JYUM5H+)1=KH9<"V# MBA(CJBSY \XQR40FF093
MP?7-R[('G2(WXG<-S KP;,A?MF+?D)0[L049*3'7</ZY+,H$R80/V'?P1XLD
ME[P:DN)NQ2N9N%!TZ': 2_4UUP8D#)(SR2I+E@F(H11%8KZP& JUE45L0)K@
M;&.%M&5V+2=$Y&>AC-^EWC<2[[(FH\S%5HE8BTR7L*S:D(AKTG2!U,Q9\@NK
MZD/@<.</&0DCN^C<B2+)40= <U!OZ I3PJENB/:E$ZW.#/G,V/'#AT-7P"WS
MRH "(T_^\F'K,F*UYFT(NRW2*L9#8_FPR58@(-#BC6'=ZZ[A&(/OC8U H'>Q
M.\52SE/%'%<%&4JLS*)(YG#)'"-7)'ZA]<X_[7):] ,O*.Y#MG^MV?[ \F$E
M^*A6*E.%SGZ$S=>2R0*36"8@:A!HJHU1I%+ 4&8#%GFAT(IX+;X3C<F(AKV#
M%K$S^ZB2S;PJ#),%=A08)PH.5FCH59ZGJ+Y[%M,[F;(A9/$YK&5DJLP9G^HF
M@=>EAC,$\RPR^.08BF#_4"#.F9#XK3^AZ\!LT'T9N!K9Q05!+3\><7F]N)ZG
MR8J)04&@O/T!A#I])!V'KQ"?\S.P&/B@?8$75,/"0@*.6/V@%#N*<E8H\*(J
MWB/&>P!"H Q#04O(E U'QH Q$@QWY/#JG?^41(^@Z2G( &Y JDT7U2%M58"-
M>9L##QE8)080])'LHL$IDL< 6T%?GX).&Q+W2FOPT4:G\1$'[2WBA/;:VF K
M42CS!+^ D$7+RL5"5W#K=IW X;-_0W,3*8=OV@,(?TC([>U54Z.*![C#G-I0
M7X<W6!/<.X6).OQS-,2O-X!@DQS\'S.(-FZ7PFTWB:GE H[8+%51\"?MP#!$
M-C<03,#)PN&BLRU)ED" RIWW"OWV$$^"J*7P;K<#'FUX03$8!7$7M"8\\A.1
M1"H20SRY00R: CN4@],A$N]6) !@5T1%T%6*SKP^ $FK@P2 ]=9A1.*WO_G4
M^N59J(4&P.!$5SFU\U[D<?WK#^&D\?8D3R33+>< QLK=J84DM#/&2/T TL13
M"S<"Y4IT7!\$7P3YVND!/&+@],QR1^34IWD"*AMS:.KLLH8X4Z]-"N8I$W*#
M1X"J#!*2:;JK>?*WB'*7 ]S"+Q%M -8#<\_R"D0%:J(],H& EA@'3/:>U@)<
M >ZWJ&@7<F?HH>#P"$;H$OP%NJL%>CF\VBI(K!">(-JA"]77TB$EV [4!.S2
MH X@#D1E W-$T42(TB&*8GJ+5\+9)AM"SVPO? A(Y49^X2L-P0^$FJC_]0UP
MR( L8!?(O6OU1N\(E"1ERB9=M&,,2 Z-2HI<%Z$%/QXMRS58_U:QM,!N8E60
M(352%'N>!6(V39;/^S,>\^?+'IFYA7<L4V*03P39<*="^M?&44TP[;"45:]E
MRS[:*0_[-0@Q<^^$6%I $:8I!P)=F!YD</]:ILO>1 &H7KH#\8<04QSK.X*6
M(N)EO2SV$/*=A/Z9#GBABE(F7DON0)-EMOO1B%96Y./0T*>&!"QMZL@!ES^Q
M@F>*$8_O]BZ-,$J2A>V(N@-!W0%_C&AR84]@C]]Z+O[Q+]>3R>4+6K2A 94)
MA0Y.IE#2Z(PDJ99P+*6U10#9NQ!V.Z[WAE''=4,5\-(FF+='8?K63C#L)7G.
MI#953A<OQ%IOP7"[8<:?<=,=F$;4 "5)4BO4>CL$1_-=;[)9KI,B/L,<>N<S
M3O/"BY:16H(9\ZXG-X)\C=PWA;-^:W:4N_0H5'3*4!T6Q-NQT$&G!)[")+%R
M#LE##]PL4V5+/5-TTXLN($2UI?7C'L+P2\THQSK'X4'S(E^9[I "WE4OT(4Z
MTVA:GK.'YM'BM4ZR( *%+JTX*I6KL44O<FB%8*ZR]+H,QA^1^+6U@K&P"$"7
M8>=<!ZDZN0W<0>/L.II!&;W$'':!YSDD.R&R_JA UU01B4]4,@I"8<$L@"NP
M8<^6$.#D 0M[1DPU-^J/BK+HQ "(<$NZ"E=?K@M6(./?0;_)Z:+R(<+<#5L!
M6$;B7F; B[BUT@L0ERVI^-J":147>@H%K0B&5]'G=A/VAN":4U?1>+ZW='&7
M GRG(A4M_VD-OKI1R!6_ )!I?H+U6/AO?!.\N@4CFNMX]_QP_>/8JH?DY5!_
M+5/]!_!,3,:3Z!K^WEQ$$_@SF\VB2_@['LW@_7VOTENP_,C"LU$T(K,:3UZT
MW_[)JLLC.P(+4_AS/8LND+&K&>P(G%Q,@<%./>!;*BE4/GBDX/!,7,RB&?RY
M')$@QU<73,;X$CX^MBA@.7R"\LHS<3*^BF:G] )(HA>SFVA,+R8WT?5I5RC?
M5!A!<K^E(@$G,V71C,>D8Q,0%8IH>G$#!_=NLZDR?0:.ANK:>PSA&ZM_/R?S
M4NX0-I08N,A3?8;@C>I;DG][1*=.+J*K4_Y[>6J%.N47ERC4[Z/)H^@F,)W+
MO9;S??3XAAS"])K-9WH97>'?"1+U=VO,^()L:DJD3&](?:[@S0%[8M&&.N.4
MX'-T'[5J6SWE*CC:Z=@:#O#,]G)]:3^9T5?]8:BMD=T*A$47\;ZJ$]C$B*5^
M37S/KNC=%7JP>P@LO^A2B6L2&;T<C]B%9-QQ9B5:20JC@2# B[O$#3*!#5QU
M7^K%E["08##$QRYFX]48FR(?EQ 7N#0"PS9#4T0#8I7J.1XD'9]:)8N66H>A
MM;\?UFV!+2O,#]85&), >O4BA3PA#</:"5(]\.0U:NF#4^%R+(M^@6RXZ<>:
MG9^#RE.S#N^[?G:+G^]NL5BVA(OTELM3<(AYZ<#Q,BE AW)M$M+=#Y0F3R%9
M2@*01*DI$')F>085B(MJ5;?XAB& :JSA#8KA+&>OLFS=+TX&]PRIW<V?B !4
M< /R0%.P)@>"M>C[>O0#(F('>S*$)O2)-R_L*:86CU,>&I]5.9ZI+M)XBQZU
MU^6$>)L:A/X(B)!EE=GDE+>.Q-OE4G'?\)_@/@'T(2JZ'H;)*]%G26VT824D
M&F7I" Q/CC_V!PIBZ%KI$!$Y.FKB$8P(;K&=-1"57M20*HXIZ0.A(OW<E+ 9
M?%"YX#(76I4&^\J3%'1X3K1#U,G5EP3?GJ"%,,.(=HG:-^[B\W?UA6_!M268
M>;W+'@!]D1<9G$9P0$M5N$1UX&+GKS9VPB?&LDCPE92F;M8ALC6!H\ UVK+J
M^)B _7YW0SH%CJ$"VR; .,<J(B=&]M@"?U,24,9-,L3'&\;'BO3B7N6 M>=
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MHAVA]NN[][<L\3=3JV_XT5=\^P%'@^1F<%K#X_>?[\:7K>OIL]8-Y;J@.+^
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M7+POJ_OFK7EU:\<M9,%19W*.J9"SN$.FN@E7#:=7_O:)ZP7NLOYU*7'*-VR
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M41U\1[?&^=K.!:#TSHU9O[.I&;>^BQ096Q6*#S U!^NVG\1KN*VHV$^0"F(
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M%:AM*4XVY#S-M).P+4OG(TZLQ<1Y??T1C"*@V5]TV531A]%O(X+!D?"'XJZ
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M%L]]F<*FY:$$]F_0%/YC-0E+_3BK"Y3TK.7/XAYJ;5FLE:77-SJA4,Q56LZ
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M%;.@\"@6 VN>Z>G)($\QF5"F4^\1:7^XA$7Y+#1)XHI]<-95-)X'(8Z*,<J
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MZJV<3B^2^"3@+BT2IPA(>/,U>J$!V<#F.1L##D_.@"52\HL*:C6 @D>W@Y(
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M!H04_ZR4A /1 CQ?6AOZ"SH@?Q_UYK]02P,$%     @ "CYE4<BFH%,@!@
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M01;:?XGQ ZLJ^OHQ4=:J@B[G@F="NP6X/U7*+@=.P>ISV,5_ %!+ P04
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MA45\1B'I%1*/NW/D4;[GCJ^71K?,T&VT1@L?JM=&<$)14;;.X*E /;?>.NX
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M^&2#TY OZ>$C*0O*)[BF(<N_P:'$Z@I8IXS3J"2+&41!7/SB'V4C&@019YB
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MQ%YRR'&:;CHU/0^PH0_:S1]WFLD<*]C4LBMO#5705^8*VI %[9[B]VK#I-U
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M)5'-D4R]>).!A8Z64F?8H84[J@U?/;B-Z=Z .&;%L\!>CNQQGN:]GO8#1#I
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M+4J ^G[-N7S^4#;0_MCAZC]02P,$%     @ "CYE45T[BBRC @  W08  !D
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M89.4927DE138N[)X/Y&:0>MQ\']K,&P=#?]9#6JF9*\&O<&G"G08A</>J+L
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M#G56<I!7 T'/=<9>$[;JPJ:VYXY1$[;NPMRI[XYA"6LD.2F3G#R3I"18!'N
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MNMM%?NZ3WRB>9 <;&ZX4C[/+/<$A$0:@?]]RKIYN3(#R]&WQ'U!+ P04
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M\<#I.22$)<T3/1/KSU#ZTS%\@4B4_2?KTM9S2) K+=(2C#M(&2^>]*6,PQ8
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MJF:[\[#:!Q><Q"K@K.TT,_]^;2"$@,N@SLN\)&#.N;[WW&MSS>A V1O?8BS
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M;)*1-_!(#&N:<_,H=Q^@C*=G^2+)M?LEN](V\$B4:R/3$HP*4B:*)WTN\W
M0)YZ0%@"PE- ]PR@4P(Z;_70+0'=MWKHE0 7NE_$[A(WHX:.ATKNB++6R&87
M+OL.C?EBPO;)TBA\RQ!GQI^P%>]%)%,@"U!DF5 %Y#U98C_&.0<BU^16&!8S
MGMN*DB5$N6*&@2;SYXCG,<3D3LF43&6:Y8:ZZE_,P%#&]24R:<NH]P\FR /C
M'(WTT#>HWZKPHU+KI- :GM':(0]2F 0]"W1;@Y\UXZ\;\#[FK4I>N$_>)&PD
M7$+6(IW@'0F#,*C1,WTSO'U=%\[?>9__L?>C9'2J3NHXONXY/B.C)R(S\[*X
M1WS=BJ_K^#IG^%YMN_5IVV&OSJD23&ST03-_^XC$Y-Y JK\WR.I5LGJ-81[)
MVKGO$&JA6U#X624B3U?H&964#7^!'5\L+^L:OO U<+[L)WT[#EKMH;\];**7
M-NU!JW-L-'MI%+;ZQS;S6J*P,CI*1[]*1[\Q'8^@C6*1S8&V#="0X:N*\NI_
M*OR@DC7XAX4O?/4."W]2]D%-:W1/JOXJR[R9I4B$?S ^4E ;-[<UB60N3/'_
MKTZKJ\&MFX@GYY/VS;1=<S[#JT0Q^7_3%_>0!ZHV3&C"88VN@M85QJ**V5YL
MC,S<\%I)@Z/0+1.\#H&R!OA^+:79;ZR#ZH(U_@502P,$%     @ "CYE4329
M4-[F!   E!<  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULO5A-;]LX
M$/TKA-%#"S3Z(&59+AP#B8/N!FB H$:ZA\4>:(NVA4BBEZ2=MM@?OZ2LB)(H
M,0H<Q =;DF>&CS-\CR/.GBA[Y#M"!/B9I3F_'.V$V']Q7;[>D0QSA^Y)+O_9
M4)9A(6_9UN5[1G!<.&6I"STO=#.<Y*/YK'AVS^8S>A!IDI-[!O@ARS#[=4U2
M^G0Y\D?/#[XGVYU0#]SY;(^W9$G$P_Z>R3NWBA(G&<EY0G/ R.9R=.5_6:!0
M.106/Q+RQ&O70$UE1>FCNKF-+T>>0D12LA8J!)8_1[(@::HB21S_ED%'U9C*
ML7[]'/UK,7DYF17F9$'3OY)8["Y'T0C$9(,/J?A.G_XDY83&*MZ:IKSX!D^E
MK3<"ZP,7-"N=)8(LR4^_^&>9B)J#'_0XP-(!#G5 I0,J)GI"5DSK!@L\GS'Z
M!)BREM'419&;PEO.)LE5&9>"R7\3Z2?F=Y@]$H%7*0%+LCZP1"2$@PNPE.LE
M/LBG= -N\R/A0M9.<)#DX.J(D[3PD(D$2RPO;LA*U/T_WLB82<H_R4@/RQOP
M\<,G\$'YWB5I*JO'9ZZ0X!4$=UT"O3X!A3U EV3O .1]!M"#7H?[PNY^0];2
MW5?N_K3I[LJ457F#5=Y@$0_UQFO,^+/.RH7DU@576?G[FW0"MX)D_!_+D*@:
M$A5#!CU#7F64B>0WB<&"<@&N,4\Z\WB*,BFB*!8?YVCL10Z:N<=ZODRS 'IA
MS:P!,JA !E:0#[D4D[1 ^8<4D4Z IPA18V1GVH)G&L'(&7>#&U?@QD/!?:.<
MDTYT8V/@"\^)6N@ZC7I2%U;H0BNZKSAAX =.#Z0+5FB,B,9CSPE:P$RS **@
M+W&3"MK$"FU!V9XR+ A8T3SFX#^@4LD%2]:"Q):U'54#1.]%IVDUY/1-Z#0U
M%^)D&CIA*_&F&9J&7E_B?4_KLW<VH<H0C:I[CM]"V&$%)[65W018VT#\\TE5
MQF@19M)&V&D%>Q!JJ?;A&<0JG<<-I4'M\I96S?I&42W)37!:U'V[JC\X2P=L
MZ9&P7.VP .=QXW9+\O4O0%=ILL6J\7D%^7PMVG[P7O3SM1C[=C4>2D#?%%L?
MH1JSR@J99N.@3Y-]+<J^794'\<]47=_8;SN,^M>V%F;?KLS#V#?IXI6A#R]8
M-1%J9?>C<]@7=10W,)7!-)/%#7JPZ2W M^\!2T4TV>GGK]W7H-9OZ+T7M:#6
M9&C7Y*'4@J;@AF,G\&J?]BKI<(%AK7MK(JZUTW:-'D(S:&JP7V-0B<\T\OH6
M"M0J#5]0Z2$T*V/4=Q*OC<YFTL2FQ1O:6VX[P:#92(>A,Y[6/VV0';WWI$])
MH=9[:-?[!<TRPM8)3L$>[PE[!=NT6L/PW=BF-1C:-7@PVTR!15.SA>\PF\+>
M]&L=AG8='L0P4V8]DV'1X#6LA1C:A7@8OZ8O\\MFTGSKU@J.[!VXG5_([*I5
M4=O]8X=9?U&1%GID%_H%D2MODZSEJQE71S4QV5.>B.'40EJAT?N=>-2./-[H
MS .96P.$!K4ZS";]5= *C,X_]$"FJ)HMV M&37A:>-$;''N4,6SDLIHTL6G!
M1N<<>I3.DU99VZU_AYDL:T\;<P+JUHY,U7GU'69;63F0DHV,(5]-Y2S9Z0CX
M="/HOCA%75$A:%9<[@B."5,&\O\-I>+Y1AW,5@?Q\_\!4$L#!!0    (  H^
M95$7.QJ2B0(  !<&   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;(U5
MRT[C,!3]%2MB 1+3I'GP4AL)VAD-"R1$AYG%:!9N<]-8.'&P;UKX>ZZ=- I#
MB]@T?IQS?.[QHY.MTD^F $#V4LK*3+T"L;[R?;,JH.1FI&JH:"97NN1(7;WV
M3:V!9XY42C\,@C._Y*+RTHD;N]?I1#4H107WFIFF++E^O0&IME-O[.T&'L2Z
M0#O@IY.:KV$!^%C?:^KYO4HF2JB,4!73D$^]Z_'5++%X!_@M8&L&;68K62KU
M9#NWV=0+K"&0L$*KP.FS@1E(:87(QG.GZ?5+6N*PO5/_X6JG6I;<P$S)/R+#
M8NI=>"R#G#<2']3V)W3U.(,K)8W[9=L.&WALU1A494<F!Z6HVB]_Z7(8$,;Q
M 4+8$<*O$J*.$+E"6V>NK#E'GDZTVC)MT:1F&RX;QZ9J1&5W<8&:9@7Q,+WC
M^@F0+R6P!:P:+5" 8=_8@HY+UM"HRMD<ECB<O:'8,D9[,%,5:MJ(ADMVQ]'.
MOS*R09CC.:D*:4Y(ZW$Q9\=')^R(B8K="2EI_\S$1[)O3?BKSNI-:S4\8'4!
M]8A%P2D+@S#80Y]]3I_#BNAC2Q]?OJ?[%%J?7-@G%SJ]Z(#>;;4!@W2@T9RV
M$?$J8]^?&QO"(*V_UTOC4OKWR:)1OVCD%HT/;A?N=+<""\I35<!>@>M]>;9:
MYT[+7N=-.HZ3<$35;X:Y[8$EEV>CI(>]LQKW5N.O6N4Y@NZ=,BRT:M8%R^D"
MNY&]AZ%5OQBX"H/+\X&KUGP+2X:PL^ABO_6DMYY\:OV70B[W>4H^)!4E23"*
M__/T$1:'4?PA4']P;>V327=Q+2K#).1$#$;GI*/;9ZCMH*K=35XJI'?!-0MZ
MN4%; ,WG2N&N8Q^'_K\@?0-02P,$%     @ "CYE44Y06O#K P  Y1$  !D
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M(,KH]!,5OVD;4#M!7?N2G&ND O?#DGHV&)= ZPNM<3-Q OV_0/H'4$L#!!0
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MFQ!L)Y7EI$4/>+ABG'OCX&+R4"^U&Q90%HSY+FPOYV"7<X#F7*]72*! L[)
M/\A[_:!CXB/5X;MWXD.$)W;I";00?Z<FC.TZS[[85609UJ@U0=M.IFHTI/#'
M[("9&R5\-5;-R.0N4WD&9!2IB=J]DQHBLNDNO>DYD4T=&(P+,98'S-PP;)WY
M'K1]#\WVDRU';K)H;FRU?I#?7WA^37'\(7+TH:_[%*W-'U\WD?G>PJ^:8X^,
MN^0:HNS"%$?H06OW\=[>B1ZV!GWHT'XP2'K0V'U^!GK;.7B-BW>(#@O9SPVZ
MNH^W]9LSKSEHTKX<)#7H[;XZ S7E()'4X::<)<>Y'-,C[*"]^WA_[\ .6W$4
M6C7UALB.0D.G_N^SJ^:H8_&%TR^KJ!,6':UMTUO:>6XB>[Y7GL@TG^ZT <6J
M!#V;LD%BA,Y.\<WW+VY@JMGJJ )&U2'0P)5)Q5D-_'ZVT.9I2YL_A>JOZ"16
M0VCP5 P2,@@!Q;?KIZU5><K>IB'J^-Z&@A+0%B4X!>SIS1BK&O1^.ATB5@8:
MP?#M_$E8JSGV3A.9VX,;PA !92 3#)>)ZS1;IUE!=I8FB_PL.R &*L"&Z=;4
M[)I^_!K6NI-%0_:S!;%@N%ATA8EMB1@T?S9(]X:!#C!\H]\5IG!(4<7$(4_7
MR&%3I<;^$:@@#@P7!Q=J74"QPD!W9X,T<1BT>H9O\[N2FYY$KL'U0<@%T/\#
MO/^[Y'K=]0;0](-!FCT!Z$* GQUTY%W-VL([<.T?E#>(1=!B (UOQV29/N@L
M*5$6U:H_7>ID_IVDLSA:AL779>=1VZ#FXP_2)0I 00+\]*$K]G;?" W9SQ;D
M),#EI#_<F!X'(!S!(.VE &0GP$\JNN)VO22?!8Y)WQ#&@]I79OM)@Q0%N!1U
MH7ZB8'-0%CY(]XF#PG#\M*(C6M[@1S6@;0@[CI:#ZG!<=;J@[571.4@/'Z2/
MQ4%[.'YJTO4#X3I5C1\(-PSY0-2^CL;UZ+: KZ-E<L:38P[ZP@=I6W$0&(Z?
MF71E*EOE&@W9SQ;4AN-JTQ4F)L8<9(,/TJP2("D"/UGI"%.XOI008SZM_QQ>
M\> .H?*8]RQ <@0N.2[?$V57@$"(0=I5 F1 ]&)75;/^$D1W" (19$+@,N%"
M[%5@!4B!&*2Y)6K7)O5B;HF&ZX_:T+M#$/2@)J+-YUJM=#:/PIBLP[7.SJ*V
M N1!#-(#$Z @HA</3+@>V*':HB'[UY^!G,@V[ZLC34QN)8B!'*3#)4%*9"\.
MEVSRKKSQH<75$#:EQY:H!'F1N+PT0#U18R4H@!RD225!"60O)E4U:RLY-PPA
M!^H@<75H(->KL,K:E:J#=*DD"(/LQ:62KOW4R-L-0WB#6$A<+*YU9J*[:&[Y
MY@7@A5ZG>=1*]"1-52 ":I VE0*94+W85 J[(&K+%0W9SQ8T0^&:\;M0T>N]
M0034(*TF!0JB>K&:5(/51&GMHNX*K!LFZ3CP:C]'ODA2(#$*EYCCH$^46P7"
MH 9I,BG0!]6+R:3<ZZ ::;IAI]*LW2&!"\AQFKU*L *Q4(/TIJ:@(]->O*EJ
M5MGR&6@(:_L,3&KW]A4W5GX(LV64Y"36=W8.;USLXK+MO8K;)R9=E[?[S5)C
MTE7Y\%Z'"YT5 ?;_=VEJ?CXI[B#<W3%Z]3]02P,$%     @ "CYE49T:@#[X
M @  HP@  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULI59M;]HP$/XK
M5K0/K;22D!#>!$CE39LTJJJHW8=I'TPXP*IC,]N!=K]^YR1D@:84J5^([=SS
M/'?GRQV]O53/>@-@R$O,A>X[&V.V7=?5T09BJFMR"P+?K*2*J<&M6KMZJX N
M4U#,7=_SFFY,F7 &O?3L7@UZ,C&<";A71"=Q3-7K$+C<]YVZ<SAX8.N-L0?N
MH+>E:YB#>=S>*]RY!<N2Q2 TDX(H6/6=VWIWVK3VJ<$3@[TNK8F-9"'EL]U\
M7_8=SSH$'")C&2@^=C "SBT1NO$GYW0*20LLKP_LTS1VC&5!-8PD_\F69M-W
MV@Y9PHHFW#S(_3?(XPDM7R2Y3G_)/K-M>0Z)$FUDG(/1@YB)[$E?\CR4 ,A3
M#?!S@'\*:+P#"') <*E"(P<T+E4(<T!X*:"9 ]++=+-DI9D>4T,'/27W1%EK
M9+.+]+I2-":8"5M8<Z/P+4.<&4PI4^2)\@3(#*A.%&#5&$UNR!U5BMIK)U=C
M,)1Q?8VGC_,QN?IR3;X0)LB,<8[EH7NN05<LH1OELL-,UG]'-B S*<Q&DXE8
MPK("/SZ/[YS!NYB"(@_^(0]#_RSA'+8U$GA?B>_Y7H4_HXOA]4Y5.)]3GWQ.
M?7H>/H8(X?4J^%$N@Z*F@I0O^+BFQDQ'7-JRTN37[4(;A:WD]QF-1J'12#4:
M[VC<8<]-!+92SO["DJRQA9(K5,(BQ7ZE(4H4,PPJ2S-C;J7,MO'N!C=!JQ;V
MW%WYPM]:U<-:Z]AH7&$4!+7VL=6D0C!LUQJ%U5$&PB(#X=D,S(L8B=P+S(&0
MAMC9PO@K=@CUC!_M@D-5 C+B=LF?IE=KGH1VB=$T?!-9&):,C@)K%H$USP;V
M0XKUC0$5XX18&+*RU;2SU5052D;5+%] Q^^<A/*!4>:E6VJB,:AU.NXTB60B
M3%;[Q6DQ46_307)R/JQW1_6*\W&].\D&YG_Z;'S/J%HSH0F'%4IYM1:F564C
M,=L8N4U;^$(:' CI<H,W#<H:X/N5E.:PL0+%_Y+!/U!+ P04    "  */F51
M0:Q9!9H"  #X!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R-E4M/
MXS 0Q[^*%7$ :<D[#: T$K1"RP&IHLMR6.W!32:MA1-G;;>!;[^V$Z) TN[V
MT/@Q_YG?C%])P_BKV %(]%;22LRMG93UC>.(; <E%C:KH5(S!>,EEJK+MXZH
M.>#<B$KJ^*X[<TI,*BM-S-B*IPG;2THJ6'$D]F6)^?L=4-;,+<_Z&'@BVYW4
M TZ:U'@+:Y#/]8JKGM-[R4D)E2"L0AR*N77KW2QB;6\,?A)HQ*"-="8;QEYU
MYR&?6ZX& @J9U!ZP^AQ@ 91J1PKC3^?3ZD-JX;#]X?W>Y*YRV6 !"T9?2"YW
M<^O*0CD4>$_E$VN^0Y=/I/UEC KSCYK6-O8ME.V%9&4G5@0EJ=HO?NOJ,!!X
MX1&!WPG\_Q4$G2 PB;9D)JTEECA-.&L0U];*FVZ8VABURH94>A77DJM9HG0R
M?:@.4$G&"0ATB=9JD^1["H@5:#ASO@2)"147RN9YO43G9Q?H#)$*/1)*U6J(
MQ)$*1KMTLB[P71O8/Q)X#;6- O<;\EW?G9 O3LN7D"FYI^7>]6>YHTK0U\'O
MZ^ ;?\$_ZO".ED1DE(D]!_3K=B,D5SOM]XD(01\A,!'"(Q&><*,63@(GF$[6
MJY7'1JX/WR$-7=<.$^<P+,O8RO=F=M!;?6(+>[;P)-N+.FJ7I+JL.<M 3-*U
M#JX&<6,O&M%-6/FQ'4_313U==)+NGE1$[? <;1G+)^&B45@O\&WO"]S8*G;M
MZ'KXFP:=]:"SDZ!+*(!S!9HQ(2=!9R.$* H&]6E!QU9Z)QR!BWNX^"3<#R8Q
M'9[J*;YXM+N\*]>S9U\ )\Q"M1NB+X3.X%[2;\(CYEM2"42A4$+7CM6*\/:>
M;3N2U>:JVC"I+C[3W*FG";@V4/,%8_*CHV^__K%+_P)02P,$%     @ "CYE
M4=BF<E]@ P  3 P  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULM5=;
M3]LP&/TK5K1)($%CIQ<*:BO1=M.0!D)4; _3'DSRM;%([,QV*4C[\;.=D)0M
M=4$3>6A\.^>[V#[Y.MH(>:]2 (T>\XRK<9!J79R%H8I3R*GJB *XF5D*F5-M
MNG(5JD("31PHS\((XT&84\:#R<B-7<O)2*QUQCA<2Z36>4[ETQ0RL1D')'@>
MN&&K5-N!<#(JZ H6H&^+:VEZ8<V2L!RX8H(C"<MQ<$[.YF1H 6[%-P8;M=5&
M-I0[(>YMYR(9!]AZ!!G$VE)0\WJ &62993)^_*I(@]JF!6ZWG]D_N^!-,'=4
MP4QDWUFBTW$P#% "2[K.](W8?($JH+[EBT6FW"_:E&L'O0#%:Z5%7H&-!SGC
MY9L^5HG8 AB>=D!4 :+7 KH5H/M:0*\"]%QFRE!<'N94T\E(B@V2=K5ALPV7
M3(<VX3-N]WVAI9EE!J<G<[C3Z!A=42FIW0%T, =-6:8.S>CM8HX./AR.0FTL
MV?5A7+%.2]9H!RM!EX+K5*%//(&D!3_SX[L>?&@BK,.,GL.<1E["\_6J@[KD
M"$4XPFW^^.$+* P<[X3/_?!+^K3#^(M@NO6>=1U=;Z<WG F);KF">"TA05="
M@_(0]VKBGB/N[B#^:OI(+-',D#*-/M.894P_H1]NXD)#KGYZS/1K,WVO_S>0
M0%ZX:U](%L,1*D#&P+41FK:SYF<C&'<P_NCQ:U#[-7B37^8JZA3%*>4K.&;\
M.#9G4IH;6DCQP*SP[7/<;XY@LL?QD]KQ$R_3!=<@06D$C^9[H-I\F94, \=@
M/P8/DT$/VV<4/K28'M:FAU[34\F2%31'Y3>:B3PW&5QH$=^C+Y E:/J$%I2+
M)3.S?ZWW!']:>W#ZGH>6X$8IL3=4*Y5']F3PF!4T0S07:Z[;U* BVDXVZ>/J
M:<\WV1)LXG4CPEU<WGB3SC=+ 8D:.]&[YK51,^*7LU?G=5H1O<AKU/?GM=$^
MTGO=)3(?PM;;O =/.B=]WV4FC3P2OZ)%N/\_.]S('1F\ZPXW\D3\^O2&'?Y7
MID[V;'"C5,0O5?LWV(^/.L-VM0ZWRJ\<Y,J5L0K%-LBR$JM'ZU+YW!6(8;.\
MK+,OJ5PQKE &2P/%YD@%2):E:]G1HG#%W)W0IC1TS=24^R#M C._%.9X5!UK
MH/X#,?D#4$L#!!0    (  H^95$='J +3 (  +T&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4W+GAM;*55VXZ;,!#]%0NI4BM5,0&RW40D4A)2=1]6BC:]
M/%1]<& (UAJ;VD[9_?O:AM T(A>U+V"/YYSC&>-#7 OYK H C5Y*QM74*[2N
M)ABKM("2J(&H@)N57,B2:#.5.ZPJ"21SH)+AP/?O<$DH]V:QBZWE+!9[S2B'
MM41J7Y9$OBZ B7KJ#;U#X(GN"FT#>!979 <;T%^JM30SW+%DM 2NJ.!(0C[U
MYL/)*K+Y+N$KA5H=C9&M9"O$LYT\9%//MQL"!JFV#,2\?L$2&+-$9AL_6TZO
MD[3 X_&!_:.KW=2R)0J6@GVCF2ZFWKV',LC)GNDG47^"MIZ1Y4L%4^Z)ZB8W
M##V4[I4690LV.R@I;][DI>W#$<#P] ."%A"< J(S@+ %A+<J1"T@NE5AU )<
MZ;BIW34N(9K,8BEJ)&VV8;,#UWV'-OVBW'XG&RW-*C4X/7O@J2@!?28OH-#;
M!#2A3+V+L3;<-@.G+<^BX0G.\(3H47!=*+3B&60]^.0R?GP!CTU-76'!H;!%
M<)%P ]4 A?Y[%/B!W[.?Y<WPX;BOG/]37_VS^E_-"+M3#AU?>/6444)5RH3:
M2T#?YUNEI;FJ/RY(1)U$Y"2B,Q*K/ =WZ1%MQ+01DT1#W[=TF6HX&MSY;_K.
M[ HN&(Q[<<EEW/T9N=45N6C@G^*:UN&C^UB"W#DC5"@5>ZZ;0^NBG=?.G<6<
MQ!?#R7+8$T^,-S=6^H>^,?9'(G>4*\0@-U+^X(.Q"]F893/1HG)NL!7:>(L;
M%N;_ M(FF/5<"'V86('NCS7[#5!+ P04    "  */F51C,-D(40$  !T$
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RU6%MOHS@4_BL66FD[4J=@
M(%RJ)%*;7I+1MJJ:F=F'U3XXP0FH&&=LTS3[Z]<& KF D]6J?6C!G.\[WSFV
MS[';7U/VQF.,!?@@:<8'1BS$ZMHT^3S&!/$KNL*9_+*@C" A7]G2Y"N&452
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M]-@GZ@4A<@U/]VJ8/'=S@;(HR98GI=E'TES-1H--[8:.?DZ53_"*5SF;Q_+
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MCB\"2,NNK9QPLE0]P(QPT5&H82(:742E@?@^)X1O)M)!W3KW?P%02P,$%
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M@O>/L*5_IB^"^3G]7;ZX1:HSSX:D E"\5J&L7J"FB!<7LZ(AV2X_M2^95'>
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  H^95&LISPGD04  (87   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  */F51!_W?7RD'  !C(   &               @('5#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ "CYE4<^X5MZ/ P  <PX
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M965T-RYX;6Q02P$"% ,4    "  */F51:[;M-,H#  !K"   &
M    @(%F00  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M"CYE46IQ2''0%P  J5,  !@              ("!9D4  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  H^95'SGI<='P0  - )   9
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M970Q-"YX;6Q02P$"% ,4    "  */F51,89B>4P#  #""   &0
M    @($/=P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M  H^95%:H-X;V 4  )P.   9              " @9)Z  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ "CYE4?7T1T5R P  'P@  !D
M             ("!H8   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  */F512+AR2 PE  #G@@  &0              @(%*A   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  H^95$I*A9]G P
M "LE   9              " @8VI  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ "CYE4<BFH%,@!@  : \  !D              ("!
M8+8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  */F51
M6P[B$;P#  !D"   &0              @(&WO   >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    (  H^95%H.>W^>P<  !H;   9
M      " @:K   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ "CYE4;2Q>*&$ P  :@@  !D              ("!7,@  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  */F51%?A:I?8$  !)#0
M&0              @($7S   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    (  H^95%C12#Q8 0  *4*   9              " @431  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ "CYE45JD.8Z!
M @  -04  !D              ("!V]4  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  */F51AC6.+S<#   8!P  &0
M@(&3V   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  H^
M95'[/I.Y>@,  .@*   9              " @0'<  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ "CYE4?0NS\[>!   7AD  !D
M         ("!LM\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  */F513]_Z>A@'  "N*   &0              @(''Y   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  H^95%#5TIG)P,  %X*
M   9              " @1;L  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ "CYE4>?/U7D8!   %Q(  !D              ("!=.\
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  */F51ARI
M9MT"  "D"0  &0              @('#\P  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    (  H^95&D0@N;;@0  %00   9
M  " @=?V  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M"CYE4;J4SA]J!@  ^"   !D              ("!?/L  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  */F5173N*+*,"  #=!@  &0
M            @($= @$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    (  H^95&Z>!_OQ@(  'P'   9              " @?<$ 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ "CYE40P0 ;PM @
MA 0  !D              ("!] <! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  */F51[[LVG]$$  ")$P  &0              @(%8
M"@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  H^95%?
M/5'P90(  %T&   9              " @6 / 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ "CYE4;8>Y9>6 @  N08  !D
M     ("!_!$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  H^95'43:]$JP(  (X&   9              "
M@?,@ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ "CYE
M4>R+XHIP!   E!$  !D              ("!U2,! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  */F51I;I01/("  !L"0  &0
M        @(%\* $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   (  H^95$TF5#>Y@0  )07   9              " @:4K 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ "CYE41<[&I*) @  %P8
M !D              ("!PC ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  */F513E!:\.L#  #E$0  &0              @(&",P$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  H^95$?/SR]
M:P(  !$&   9              " @:0W 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ "CYE45:24U(>!P  /3H  !D
M ("!1CH! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  *
M/F51G1J /O@"  "C"   &0              @(&;00$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  H^95%!K%D%F@(  /@&   9
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M970U.2YX;6Q02P$"% ,4    "  */F51+,)Z0/ #   J#P  &0
M    @(&Q50$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M  H^95%KF'1HU0(  -0'   9              " @=A9 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ "CYE42('VZ:A @  V08  !D
M             ("!Y%P! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    "  */F514*WG"J\#  #*#@  &0              @(&\7P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (  H^95$'!9E)8 (
M +8,   -              "  :)C 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  $9P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>377</ContextCount>
  <ElementCount>290</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Interim Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatements</Role>
      <ShortName>Interim Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Collaboration, License, and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</Role>
      <ShortName>Collaboration, License, and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2126104 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2130105 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2136106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2140107 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2143108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2145109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2152111 - Disclosure - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlows</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2156112 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Interim Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsPolicies</Role>
      <ShortName>Interim Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Interim Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsTables</Role>
      <ShortName>Interim Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/InterimFinancialStatements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/ProductSales</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Collaboration, License, and Other Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables</Role>
      <ShortName>Collaboration, License, and Other Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/NetIncomePerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/MarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Inventories</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Statement of Cash Flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsTables</Role>
      <ShortName>Statement of Cash Flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StatementofCashFlows</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Interim Financial Statements - Schedule of Balance Sheet Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails</Role>
      <ShortName>Interim Financial Statements - Schedule of Balance Sheet Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Interim Financial Statements - Schedule of Statements of Operations Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails</Role>
      <ShortName>Interim Financial Statements - Schedule of Statements of Operations Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Interim Financial Statements - Schedule of Cash Flows Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails</Role>
      <ShortName>Interim Financial Statements - Schedule of Cash Flows Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails</Role>
      <ShortName>Product Sales - Schedule of Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails</Role>
      <ShortName>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails</Role>
      <ShortName>Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Bayer Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422415 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423416 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Teva Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2424417 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Intellia Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425418 - Disclosure - Collaboration, License, and Other Agreements - BARDA Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - BARDA Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435424 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439426 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2444428 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/IncomeTaxes</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449430 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450431 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Repurchased Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2451432 - Disclosure - Stockholders' Equity - Sanofi Funding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails</Role>
      <ShortName>Stockholders' Equity - Sanofi Funding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails</Role>
      <ShortName>Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="regn-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2457435 - Disclosure - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMattersDetails</Role>
      <ShortName>Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/LegalMatters</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="regn-20200930.htm">regn-20200930.htm</File>
    <File>regn-20200930.xsd</File>
    <File>regn-20200930_cal.xml</File>
    <File>regn-20200930_def.xml</File>
    <File>regn-20200930_lab.xml</File>
    <File>regn-20200930_pre.xml</File>
    <File>regn-ex101x09302020x10q.htm</File>
    <File>regn-ex102x09302020x10q.htm</File>
    <File>regn-ex103x09302020x10q.htm</File>
    <File>regn-ex311x09302020x10q.htm</File>
    <File>regn-ex312x09302020x10q.htm</File>
    <File>regn-ex32x09302020x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "regn-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 377,
   "dts": {
    "calculationLink": {
     "local": [
      "regn-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "regn-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "regn-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "regn-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "regn-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "regn-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 416,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 26,
   "keyStandard": 264,
   "memberCustom": 44,
   "memberStandard": 30,
   "nsprefix": "regn",
   "nsuri": "http://www.regeneron.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.regeneron.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126104 - Disclosure - Net Income Per Share",
     "role": "http://www.regeneron.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130105 - Disclosure - Marketable Securities",
     "role": "http://www.regeneron.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136106 - Disclosure - Fair Value Measurements",
     "role": "http://www.regeneron.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140107 - Disclosure - Inventories",
     "role": "http://www.regeneron.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143108 - Disclosure - Debt",
     "role": "http://www.regeneron.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145109 - Disclosure - Income Taxes",
     "role": "http://www.regeneron.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Stockholders' Equity",
     "role": "http://www.regeneron.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152111 - Disclosure - Statement of Cash Flows",
     "role": "http://www.regeneron.com/role/StatementofCashFlows",
     "shortName": "Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156112 - Disclosure - Legal Matters",
     "role": "http://www.regeneron.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Interim Financial Statements (Policies)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsPolicies",
     "shortName": "Interim Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Interim Financial Statements (Tables)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsTables",
     "shortName": "Interim Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Product Sales (Tables)",
     "role": "http://www.regeneron.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Collaboration, License, and Other Agreements (Tables)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
     "shortName": "Collaboration, License, and Other Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Inventories (Tables)",
     "role": "http://www.regeneron.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.regeneron.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Statement of Cash Flows (Tables)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsTables",
     "shortName": "Statement of Cash Flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Interim Financial Statements - Schedule of Balance Sheet Data (Details)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
     "shortName": "Interim Financial Statements - Schedule of Balance Sheet Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i5a4cbb6fa8714d64ab778e6b541f91ec_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Interim Financial Statements - Schedule of Statements of Operations Data (Details)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
     "shortName": "Interim Financial Statements - Schedule of Statements of Operations Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ief6c24330e2a4fca9f1e273a3a438e44_D20190701-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Interim Financial Statements - Schedule of Cash Flows Data (Details)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails",
     "shortName": "Interim Financial Statements - Schedule of Cash Flows Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i4fbdf688cfd5412f9290fda4c7f3b304_D20190101-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
     "shortName": "Product Sales - Schedule of Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "icf58700054b74965a4154a14e0348fc2_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0e0f96f1723947e68a27075b552c4719_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails",
     "shortName": "Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0e0f96f1723947e68a27075b552c4719_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00efecf4b4524604b364d7d6ed7c3b8f_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "regn:PercentageOfTrialCostsBorneByCollaboratingParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i7440ca289f91448e86b7140c31a5c495_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "regn:ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i647137868b2d4017a026a60b257f74d9_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ie52e1228322949d0906b14737878fbb8_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ie52e1228322949d0906b14737878fbb8_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UnsatisfiedObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ie52e1228322949d0906b14737878fbb8_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UnsatisfiedObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "role": "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
     "shortName": "Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i18ea0893a48f488d8f88308c3e9ee61b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i796be097beaf45008b0b52db759c841c_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "regn:RevenuebasedonpercentageofannualsalesinJapan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i796be097beaf45008b0b52db759c841c_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "regn:RevenuebasedonpercentageofannualsalesinJapan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNotesReceivableNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i5351df69b749490991f52fb2919ecaa6_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:ReimbursementOfResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "if64b70e28fec43aeae989aeff73c25c0_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:ReimbursementOfResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNotesReceivableNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422415 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i478c123cbdf04a5693d39fe47d38ee54_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsAndNotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i478c123cbdf04a5693d39fe47d38ee54_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UnsatisfiedObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423416 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i478c123cbdf04a5693d39fe47d38ee54_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:UnsatisfiedObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424417 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic92360f27f254c5cb8b7dbf9f12ca77b_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:CollaborativeArrangementUpfrontPaymentMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:MaximumTransactionAgreementPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425418 - Disclosure - Collaboration, License, and Other Agreements - BARDA Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - BARDA Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:MaximumTransactionAgreementPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "iffa227b8deba441693b33a2fbafddb8e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ib54c03b4823b4871926f13634d87caab_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
     "shortName": "Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ib54c03b4823b4871926f13634d87caab_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ibb4b7ed63ac34f4c80f58df725b8c4a0_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "id1dbcf1c58b04386b0b8628caf87d9d6_D20190101-20190331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
     "shortName": "Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435424 - Disclosure - Marketable Securities - Narrative (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails",
     "shortName": "Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0126a8d85658467b9eb1fafad1f2cd63_D20190701-20190930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i52447f425dcf49d6b1e10676a99f4280_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439426 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "role": "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444428 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.regeneron.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i0338183dd78a412ebf3ab3d3a5ce298c_D20200801-20200831",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Income Taxes (Details)",
     "role": "http://www.regeneron.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i3934cec4df5c43409018d2fbd7f3cc38_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i7fb343771e004b36a23994024299f080_D20200501-20200531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449430 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i136244d2dc724edcbda67477d4375855_D20200501-20200531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i7fb343771e004b36a23994024299f080_D20200501-20200531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450431 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "role": "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails",
     "shortName": "Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i7fb343771e004b36a23994024299f080_D20200501-20200531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451432 - Disclosure - Stockholders' Equity - Sanofi Funding (Details)",
     "role": "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails",
     "shortName": "Stockholders' Equity - Sanofi Funding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "id4d35d6f56e64ee1a99667d6373d1e25_D20200701-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ia4ef2b2657f94ef8947c83514aa3cd1b_I20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails",
     "shortName": "Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457435 - Disclosure - Legal Matters (Details)",
     "role": "http://www.regeneron.com/role/LegalMattersDetails",
     "shortName": "Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "i00959df13c4a47889ab1b2afc9be2d60_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Interim Financial Statements",
     "role": "http://www.regeneron.com/role/InterimFinancialStatements",
     "shortName": "Interim Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:ProductSalesandConcentrationRiskTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - Product Sales",
     "role": "http://www.regeneron.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "regn:ProductSalesandConcentrationRiskTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Collaboration, License, and Other Agreements",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements",
     "shortName": "Collaboration, License, and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20200930.htm",
      "contextRef": "ic25dd8d16149485ea5b47dc05ecf0939_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "regn_A165PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "'165 Patent [Member]",
        "label": "'165 Patent [Member]",
        "terseLabel": "'165 Patent"
       }
      }
     },
     "localname": "A165PatentMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A487PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "'487 Patent [Member]",
        "label": "'487 Patent [Member]",
        "terseLabel": "'487 Patent"
       }
      }
     },
     "localname": "A487PatentMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A631PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "'631 Patent",
        "label": "'631 Patent [Member]",
        "terseLabel": "'631 Patent"
       }
      }
     },
     "localname": "A631PatentMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A741PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "'741 Patent [Member]",
        "label": "'741 Patent [Member]",
        "terseLabel": "'741 Patent"
       }
      }
     },
     "localname": "A741PatentMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_Amgenv.s.RegeneronMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amgen v.s. Regeneron [Member]",
        "label": "Amgen v.s. Regeneron [Member]",
        "terseLabel": "Amgen v.s. Regeneron"
       }
      }
     },
     "localname": "Amgenv.s.RegeneronMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "label": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "terseLabel": "Amounts recognized in connection with up-front payments received",
        "verboseLabel": "Amounts recognized in connection with up-front and development milestone payments received"
       }
      }
     },
     "localname": "AmountsRecognizedInConnectionWithUpFrontPaymentsMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ArcalystNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "Arcalyst Net Product Sales [Member]",
        "terseLabel": "ARCALYST"
       }
      }
     },
     "localname": "ArcalystNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BARDAOtherTransactionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BARDA, Other Transaction Agreement",
        "label": "BARDA, Other Transaction Agreement [Member]",
        "terseLabel": "Other Transaction Agreement"
       }
      }
     },
     "localname": "BARDAOtherTransactionAgreementMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BayerCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bayer Collaboration Agreement [Member]",
        "label": "Bayer Collaboration Agreement [Member]",
        "terseLabel": "Bayer"
       }
      }
     },
     "localname": "BayerCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BesseMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Besse Medical [Member]",
        "label": "Besse Medical [Member]",
        "terseLabel": "Besse Medical, a subsidiary of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "BesseMedicalMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BridgeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bridge Facility",
        "label": "Bridge Facility [Member]",
        "terseLabel": "Bridge Facility"
       }
      }
     },
     "localname": "BridgeFacilityMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ClassificationOfInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.",
        "label": "Classification of Investment [Axis]",
        "terseLabel": "Classification of Investment [Axis]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentAxis",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ClassificationOfInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides general categories of investments for which information is required or determined to be disclosed.",
        "label": "Classification of Investment [Domain]",
        "terseLabel": "Classification of Investment [Domain]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentDomain",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationandContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and Contract Manufacturing [Member]",
        "label": "Collaboration and Contract Manufacturing [Member]",
        "terseLabel": "Collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CollaborationandContractManufacturingMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborativeArrangementUpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payment made under a collaboration agreement",
        "label": "Collaborative Arrangement, Upfront Payment Made",
        "terseLabel": "Upfront payment made for collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPaymentMade",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_CommonStockHeldBySanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Held By Sanofi",
        "label": "Common Stock Held By Sanofi [Member]",
        "terseLabel": "Common Stock Held By Sanofi"
       }
      }
     },
     "localname": "CommonStockHeldBySanofiMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer and Collaborator Asset And Liability [Table Text Block]",
        "label": "Contract With Customer and Collaborator Asset And Liability [Table Text Block]",
        "terseLabel": "Summary of contract balances"
       }
      }
     },
     "localname": "ContractWithCustomerandCollaboratorAssetAndLiabilityTableTextBlock",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "regn_DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage",
        "label": "Debt Instrument, Redemption Price With Change-In-Control Provision, Percentage",
        "terseLabel": "Redemption price with change-in-control provision, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPriceWithChangeInControlProvisionPercentage",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_DupilumabREGN3500EligibleInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dupilumab/REGN3500 Eligible Investments [Member]",
        "label": "Dupilumab/REGN3500 Eligible Investments [Member]",
        "terseLabel": "Dupilumab/REGN3500 Eligible Investments"
       }
      }
     },
     "localname": "DupilumabREGN3500EligibleInvestmentsMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EyleaNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "EYLEA Net Product Sales [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EyleaNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_GainContingencyClaimsInvalidatedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Claims Invalidated, Number",
        "label": "Gain Contingency, Claims Invalidated, Number",
        "terseLabel": "Number of claims invalidated"
       }
      }
     },
     "localname": "GainContingencyClaimsInvalidatedNumber",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_GainContingencyInterPartesReviewFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Inter Partes Review Filed, Number",
        "label": "Gain Contingency, Inter Partes Review Filed, Number",
        "terseLabel": "Number of IPR filed"
       }
      }
     },
     "localname": "GainContingencyInterPartesReviewFiledNumber",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_GrossSalesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross Sales Revenue [Member]",
        "label": "Gross Sales Revenue [Member]",
        "terseLabel": "Gross Sales Revenue"
       }
      }
     },
     "localname": "GrossSalesRevenueMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_IntelliaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intellia",
        "label": "Intellia [Member]",
        "terseLabel": "Intellia"
       }
      }
     },
     "localname": "IntelliaMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LIBTAYONetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "LIBTAYO Net Product Sales [Member]",
        "label": "LIBTAYO Net Product Sales [Member]",
        "terseLabel": "Libtayo"
       }
      }
     },
     "localname": "LIBTAYONetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of twelve month sales upon which sales milestone would be received.",
        "label": "Levels of twelve month sales at which sales milestone payments would be received",
        "terseLabel": "Levels of twelve month sales at which sales milestone payments would be received"
       }
      }
     },
     "localname": "Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswouldbereceived",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LibtayoDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Libtayo Development [Member]",
        "label": "Libtayo Development [Member]",
        "terseLabel": "Libtayo development"
       }
      }
     },
     "localname": "LibtayoDevelopmentMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LossContingencyClaimsInvalidNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Claims Invalid, Number",
        "label": "Loss Contingency, Claims Invalid, Number",
        "terseLabel": "Invalid claims"
       }
      }
     },
     "localname": "LossContingencyClaimsInvalidNumber",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_LossContingencyDamagesSoughtPerUnitProduced": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Damages Sought, Per Unit Produced",
        "label": "Loss Contingency, Damages Sought, Per Unit Produced",
        "terseLabel": "Loss contingency, damages sought, per unit produced"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtPerUnitProduced",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LossContingencyPercentageOfDamagesResponsibleFor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Percentage Of Damages Responsible For",
        "label": "Loss Contingency, Percentage Of Damages Responsible For",
        "terseLabel": "Percentage of damages company is responsible for"
       }
      }
     },
     "localname": "LossContingencyPercentageOfDamagesResponsibleFor",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels.",
        "label": "Maximum amount of sales milestone payments if total sales achieve specific levels",
        "terseLabel": "Maximum amount of sales milestone payments if total sales achieve specific levels"
       }
      }
     },
     "localname": "MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_MaximumTransactionAgreementPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Transaction Agreement Payments",
        "label": "Maximum Transaction Agreement Payments",
        "terseLabel": "Maximum agreement payments"
       }
      }
     },
     "localname": "MaximumTransactionAgreementPayments",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_Maximumsharesthecollaboratorcouldsell": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum shares the collaborator could sell through September 30, 2020.",
        "label": "Maximum shares the collaborator could sell",
        "terseLabel": "Maximum shares the collaborator could sell (in shares)"
       }
      }
     },
     "localname": "Maximumsharesthecollaboratorcouldsell",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "regn_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "McKesson Corporation [Member]",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NetProfitInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Profit In Connection With Commercialization [Member]",
        "label": "Net Profit In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's net profit in connection with commercialization of EYLEA outside the United States"
       }
      }
     },
     "localname": "NetProfitInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_OtherCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Collaboration Agreements [Member]",
        "label": "Other Collaboration Agreements [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationAgreementsMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "verboseLabel": "Reimbursement of other expenses"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_OtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Revenue [Member]",
        "label": "Other Revenue [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRevenueMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Research And Developments Costs To Be Paid By Counterparty",
        "label": "Percentage Of Research And Developments Costs To Be Paid By Counterparty",
        "terseLabel": "Percentage of research and development costs to be paid by counterparty"
       }
      }
     },
     "localname": "PercentageOfResearchAndDevelopmentsCostsToBePaidByCounterparty",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfRoyaltyPaymentThatCanBeOffset": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Royalty Payment That Can Be Offset",
        "label": "Percentage Of Royalty Payment That Can Be Offset",
        "terseLabel": "Percentage of royalty payment that can be used to offset litigation proceedings"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentThatCanBeOffset",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfTrialCostsBorneByCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.",
        "label": "Percentage of Trial Costs borne by collaborating party",
        "terseLabel": "Percentage of Trial Costs borne by collaborating party"
       }
      }
     },
     "localname": "PercentageOfTrialCostsBorneByCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfTrialCostsBorneByEntity": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate.",
        "label": "Percentage of Trial Costs borne by entity",
        "terseLabel": "Percentage of Trial Costs borne by entity"
       }
      }
     },
     "localname": "PercentageOfTrialCostsBorneByEntity",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "label": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "terseLabel": "Period for achieving sales target for milestone payment, rolling basis"
       }
      }
     },
     "localname": "PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_PraluentCrossLicenseAndCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Praluent Cross License And Commercialization Agreement [Member]",
        "label": "Praluent Cross License And Commercialization Agreement [Member]",
        "terseLabel": "Praluent Agreement"
       }
      }
     },
     "localname": "PraluentCrossLicenseAndCommercializationAgreementMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PraluentNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Praluent Net Product Sales",
        "label": "Praluent Net Product Sales [Member]",
        "terseLabel": "Praluent"
       }
      }
     },
     "localname": "PraluentNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ProductSalesandConcentrationRiskTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Sales and Concentration Risk Disclosure [Text Block]",
        "label": "Product Sales and Concentration Risk [Text Block]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "ProductSalesandConcentrationRiskTextBlock",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "regn_REGNCOV2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "REGN-COV2",
        "label": "REGN-COV2 [Member]",
        "terseLabel": "REGN-COV2"
       }
      }
     },
     "localname": "REGNCOV2Member",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regeneron's Share Of Research And Development Expenses [Member]",
        "label": "Regeneron's Share Of Research And Development Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi research and development expenses",
        "verboseLabel": "Regeneron's obligation for its share of Bayer research and development expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementForManufacturingOfCommercialSuppliesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "label": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "terseLabel": "Reimbursement for manufacturing of commercial supplies"
       }
      }
     },
     "localname": "ReimbursementForManufacturingOfCommercialSuppliesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfCommercializationRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "label": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "terseLabel": "Reimbursement of commercialization-related expenses"
       }
      }
     },
     "localname": "ReimbursementOfCommercializationRelatedExpensesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfOtherExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement Of Other Expenses",
        "label": "Reimbursement Of Other Expenses",
        "terseLabel": "Cost of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "ReimbursementOfOtherExpenses",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expense",
        "label": "Reimbursement Of Research And Development Expense",
        "terseLabel": "Reduction of Research and development expense",
        "verboseLabel": "Reduction of Research and development expense"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpense",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses [Member]",
        "label": "Reimbursement Of Research And Development Expenses [Member]",
        "terseLabel": "Reimbursement of research and development expenses",
        "verboseLabel": "Reimbursement of development expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement Of Selling, General And Administrative Expense",
        "label": "Reimbursement Of Selling, General And Administrative Expense",
        "terseLabel": "Reduction of Selling, general, and administrative expense"
       }
      }
     },
     "localname": "ReimbursementOfSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research Collaboration and Licensing Arrangements [Line Items]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsLineItems",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Research Collaboration and Licensing Arrangements [Table]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsTable",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_RestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted [Member]",
        "label": "Restricted [Member]",
        "terseLabel": "Restricted"
       }
      }
     },
     "localname": "RestrictedMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RevenuebasedonpercentageofannualsalesinJapan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.",
        "label": "Revenue based on percentage of annual sales in Japan",
        "terseLabel": "Revenue based on percentage of annual sales in Japan"
       }
      }
     },
     "localname": "RevenuebasedonpercentageofannualsalesinJapan",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "label": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "terseLabel": "Royalty percentage to be received on net product sales outside of the United States"
       }
      }
     },
     "localname": "RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales-Based Milestone",
        "label": "Sales-Based Milestone [Member]",
        "terseLabel": "Sales-based milestone earned"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementAntibodyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Antibody [Member]",
        "label": "Sanofi Collaboration Agreement, Antibody [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Antibody"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementAntibodyMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementImmunooncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "label": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "netLabel": "Sanofi Collaboration Agreement, Immuno-oncology",
        "terseLabel": "Sanofi Collaboration Agreement, Immuno-oncology",
        "verboseLabel": "Sanofi Collaboration Agreement, Immuno-oncology"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementImmunooncologyMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement [Member]",
        "label": "Sanofi Collaboration Agreement [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi [Member]",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofisShareofLibtayoU.S.GrossProfitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "label": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "terseLabel": "Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits"
       }
      }
     },
     "localname": "SanofisShareofLibtayoU.S.GrossProfitsMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SeniorUnsecuredNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2030",
        "label": "Senior Unsecured Notes Due 2030 [Member]",
        "terseLabel": "2030 Notes"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2030Member",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SeniorUnsecuredNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2050",
        "label": "Senior Unsecured Notes Due 2050 [Member]",
        "terseLabel": "2050 Notes"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2050Member",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareOfProfitLossesInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "label": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits in connection with commercialization of antibodies"
       }
      }
     },
     "localname": "ShareOfProfitLossesInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase Program [Member]",
        "label": "Share Repurchase Program [Member]",
        "terseLabel": "Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock in connection with 401(k) Savings Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_TevaPharmaceuticalsCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "label": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "terseLabel": "Teva"
       }
      }
     },
     "localname": "TevaPharmaceuticalsCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UnrestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.",
        "label": "Unrestricted [Member]",
        "terseLabel": "Unrestricted"
       }
      }
     },
     "localname": "UnrestrictedMember",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UnsatisfiedObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsatisfied Obligation",
        "label": "Unsatisfied Obligation",
        "terseLabel": "Unsatisfied obligation"
       }
      }
     },
     "localname": "UnsatisfiedObligation",
     "nsuri": "http://www.regeneron.com/20200930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r111",
      "r119",
      "r205",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r111",
      "r119",
      "r205",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r111",
      "r119",
      "r205",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r179",
      "r269",
      "r273",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r288",
      "r289",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r399",
      "r445",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r288",
      "r289",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r399",
      "r445",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r179",
      "r269",
      "r273",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r176",
      "r269",
      "r271",
      "r400",
      "r444",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r176",
      "r269",
      "r271",
      "r400",
      "r444",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r279",
      "r288",
      "r289",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r399",
      "r445",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r279",
      "r288",
      "r289",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r399",
      "r445",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r124",
      "r125",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r141",
      "r206",
      "r207",
      "r306",
      "r320",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r141",
      "r206",
      "r207",
      "r306",
      "r320",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r107",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r124",
      "r125",
      "r141",
      "r206",
      "r207",
      "r306",
      "r320",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "As Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r269",
      "r272",
      "r447",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r269",
      "r272",
      "r447",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndNotesReceivableNet": {
     "auth_ref": [
      "r20",
      "r180",
      "r430"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable - other"
       }
      }
     },
     "localname": "AccountsAndNotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r415",
      "r437"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r180",
      "r181"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable - trade, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r51",
      "r106",
      "r367",
      "r368"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "negatedLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable - Sanofi",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r58",
      "r59",
      "r60",
      "r433",
      "r457",
      "r461"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r107",
      "r108",
      "r110",
      "r334",
      "r452",
      "r453"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r306"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r290",
      "r292",
      "r307",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation charges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive weighted average number of shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r165",
      "r168",
      "r174",
      "r201",
      "r332",
      "r335",
      "r353",
      "r410",
      "r431"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r54",
      "r102",
      "r201",
      "r332",
      "r335",
      "r353"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r185",
      "r213"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r189",
      "r191",
      "r425"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturities after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r189",
      "r190",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r183",
      "r186",
      "r213",
      "r414"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities:",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r294",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Facility"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r35",
      "r91"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r91",
      "r95"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r354"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "verboseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r100",
      "r102",
      "r128",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r147",
      "r201",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration, License, and Other Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "netLabel": "Common Stock",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r72",
      "r420",
      "r440"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r179",
      "r350",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r179",
      "r350",
      "r351",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r179",
      "r350",
      "r351",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r154",
      "r155",
      "r179",
      "r350",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r152",
      "r154",
      "r155",
      "r156",
      "r350",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r179",
      "r350",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r258",
      "r259",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r258",
      "r259",
      "r270"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r258",
      "r259",
      "r270"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "netLabel": "Corporate bonds",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r76",
      "r400"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of goods sold",
        "terseLabel": "Cost of goods sold",
        "verboseLabel": "Cost of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r153",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r411",
      "r412",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r197",
      "r217",
      "r220"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Value - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r197",
      "r217"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r197",
      "r217",
      "r220"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value - Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r197",
      "r217"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r195",
      "r214",
      "r220"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Fair Value - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r196",
      "r215"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized Loss - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r194",
      "r216",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Unrealized Losses of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r89",
      "r163"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of product sales"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r73",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r126",
      "r128",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r421",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r73",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r421",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r113",
      "r122",
      "r125",
      "r144",
      "r205",
      "r245",
      "r252",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r200",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Securities owned not readily marketable"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r339",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r338",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r341",
      "r342",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r286",
      "r287",
      "r339",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r286",
      "r287",
      "r339",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r343",
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r216",
      "r218",
      "r219",
      "r220",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r105",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r321",
      "r323",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r124",
      "r125",
      "r164",
      "r312",
      "r322",
      "r324",
      "r443"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in Sanofi, trade, and other accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r69",
      "r162",
      "r362",
      "r364",
      "r422"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r79",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r222"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r52"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r222"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r222"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Shares purchase price"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r465",
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares purchased (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Marketable Securities, Based on Contractual Maturity Dates"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r408",
      "r426",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r98",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r102",
      "r169",
      "r201",
      "r333",
      "r335",
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r102",
      "r201",
      "r353",
      "r413",
      "r435"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r102",
      "r201",
      "r333",
      "r335",
      "r336",
      "r353"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r39",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r46",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r233",
      "r236",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r233",
      "r236",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r225",
      "r228",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r233",
      "r236",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Total marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r42"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on sales of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r87",
      "r90"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r62",
      "r65",
      "r70",
      "r90",
      "r102",
      "r112",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r134",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r201",
      "r353",
      "r418",
      "r438"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r141",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r317",
      "r318",
      "r319",
      "r320",
      "r401",
      "r402",
      "r403",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Interim Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gain (loss) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r68",
      "r71",
      "r245",
      "r355",
      "r360",
      "r361",
      "r419",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryNetOfReserves": {
     "auth_ref": [
      "r53",
      "r221"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Net of Reserves",
        "terseLabel": "Deferred costs"
       }
      }
     },
     "localname": "OtherInventoryNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r43"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities - Sanofi"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other operating (income) expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payments in connection with Common Stock tendered for employee tax obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable and other securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Sales or maturities of marketable and other securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from bridge loan facility"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Product and service, other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBARDANarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofBalanceSheetDataDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r224",
      "r436"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Repayment of bridge loan facility"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r309",
      "r493"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r95",
      "r409",
      "r432"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in Other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r252",
      "r306",
      "r434",
      "r456",
      "r461"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r113",
      "r122",
      "r125",
      "r205",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320",
      "r452",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r179",
      "r268",
      "r269",
      "r400"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of collaboration revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r128",
      "r132",
      "r135",
      "r137",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r109",
      "r117",
      "r118",
      "r121",
      "r122",
      "r124",
      "r125",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofCashFlowsDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Reclassifications"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r95",
      "r409",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r100",
      "r145",
      "r146",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Shares Repurchased"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r152",
      "r154",
      "r155",
      "r156",
      "r350",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/InterimFinancialStatementsScheduleofStatementsofOperationsDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Unsecured Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r291",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Sovereign bonds",
        "verboseLabel": "Sovereign bonds"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r100",
      "r102",
      "r128",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r147",
      "r201",
      "r245",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r50",
      "r107",
      "r108",
      "r110",
      "r113",
      "r122",
      "r125",
      "r144",
      "r205",
      "r245",
      "r252",
      "r303",
      "r304",
      "r305",
      "r319",
      "r320",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r144",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r18",
      "r19",
      "r245",
      "r246",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Conversion of Class A Stock to Common Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r245",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r50",
      "r245",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of Class A Stock to Common Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r252",
      "r293",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r102",
      "r182",
      "r201",
      "r353"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:",
        "verboseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r252",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r49",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury Stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r19",
      "r245",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchases of Common Stock (in shares)",
        "terseLabel": "Treasury stock, shares acquired (in shares)",
        "verboseLabel": "Number of shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r253",
      "r256"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury Stock, at cost; 15,741,824 shares in 2020 and 4,860,123 shares in 2019"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r245",
      "r252",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchases of Common Stock",
        "terseLabel": "Cost of treasury stock received",
        "verboseLabel": "Total cost of shares received"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquitySanofiFundingDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r280",
      "r423",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "netLabel": "U.S. government and government agency obligations",
        "terseLabel": "U.S. government and government agency obligations",
        "verboseLabel": "U.S. government and government agency obligations"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r494": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r495": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r496": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r497": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r498": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r499": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001804220-20-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001804220-20-000030-xbrl.zip
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M-,YU;_\#Y0>CR93SF)?#H_'H'>5GXQ'?_&F?)ALG:7#,B?2C\>AP_9 /W_^
M53O?/SW?YG1[S*\.*)V?^IC>#.^^P.&H]!^,!@.,H_'L!^MOQD0M8E115G#B
M(X/3#B(2"IN55BGDR$);M9%1/V+@'9GFTI53,WU0"TLQ0C(NI)RS\Y)DU,XD
MVT(RM=D]G:<K7R/4=6>9\V*4+\2BUUN-Q0,*%2RB\G7EW0A1:=U"1K74/:T
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MHRY>HW(J):T3)F$,@$*P0G46I35%Q40%.XW:%**^H2&-1\/)^6B29?O4)72
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MR>'A\7 T&J;18/1F+H3]BU[&%Y>Z-1J^_!X=?]8XFC<;<$EK$!&P-:0@67Y
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M4J?HV!DD+T4FD9V*'5.N@2G?O:1,_;M/Z0T.-F:W^ LGM8I,9(=%4BG/3BI
MR"((&R4X%B7.EQA]IT"64X"_%AT24X[)ABA3B9"\"-D7&3-)KX4T27<Z9-E@
MSU&-2$\H?- (OH#W#+5GF'W2%(BLC-T#%$;]/I[2^.N@7W-M9(NF9T\B?[:+
MS95.9$Y-?%KY7(94'=>6I-59UQHWJH"B.%).1!E,ZI[+=(:P8$-8TH10JX@*
M2F]U7;[6H>(\1/HZW5[Y8DU7BNP,80D180F+.:+0BK(3M3^*)Q_!&6 ;()36
M)^A:I72&L(R(L/B'4XC!D!;%!B\!BT K]&R=Z!@X6T#;Y0A+-81Y-PEJD3TL
M:47*F+W2P4&L3VJE#J)H*RW:D*6+V7:I0F</-RECB$G[DHW.J:Y]@1HCA4Q:
M:2^"T&>I<Y<Q=/9P4Q('S1%!%>5*! O\K_?>,%5=3J+4,FN7.'3V<)/R!Y9+
M/II<C'8)+.</KFCI%$85000KNOSA^NVA(?WY&]00:DG=(<EYTH[C0M1@<V"M
M5..$T"Y&852W0FAG"S>F]:1!*D:*"+$4,+IX3I]M<0%3E 9TM]!19PLWIJ]E
M1*,2\1]A"HA($8/5@5!GYY/+W<.&SA9N3--,=&2-DNC0>L 0F*+6"^28X+/.
MVK4@7_@NQ&]H2./1<'*^8-5/@=Q9YBH_;1 R1QF()5)$ &E]]+HNWV&E2TG$
MV(*,H;.&%;2&Y>0,OEA7@A,4E8<(+)&*$APE3,Y%)&A#N_K.&E;0&I:3-7
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M%(O&J+-&DT@%G\YQ]!<XW@#SG@.._NHX?FJ//X$C"9$QU+[,&$%Y$\"S2,R
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M+L"=$G"O%8BH% $EWB"7^ZUP#Q:NCOF(VT87"4V1:5 @^#*G^N%='TN?IWM
M\'T<6'@Q-*+M=6#T_4;I[O14FL/E6FQ>+,6:]V<G9^U\_KH14\NW2H>9R;CH
M1J=HRHU4DC,P8:1'/'(\5"(BH](R%O,Z+JV:9<79PY6(T@*JCAB>@1)1,#Q]
M#%_K$]99I[1(2*4D$#=6(L>T0]+@J",/,86PM*J6F3+UP?#S\DA<RWNC6_60
M]-V3TUX\BIU^Z^_8:'7@]UB\$X_:07)D$:IN=>NC2[!5K<";;K_?C(.=M&>_
M%D::B)%NM)F6/GB#F4/**HJX(@%IYBSR0KLDG?$)YS;3N/@E%A.RT^HJ62#[
MR) =.=5@+C<7"$@(DQ /2B,;M48F225<TL#! %E*'GZL43./Q,,B[B]4CZ?J
M1=F+MG_6.[\,L;<#F(G^H(Z]'BZ'.A)?4R)K)H+K]D\B:];.#_8.\?;QYR]P
M'=O)>:;',):]=S WA_#O7Y^W]S;/X3Z?__?;EOCDO:8^"(*(DOD(,T8 NY-(
M<>IE4LJ+J)96B0"SGRQKRN^,*;Q_1-<L^D$4F:N+S'WX^LG1Z+&';<4(+A&'
M7059QAWB3G@.-&.Y3=GKK25>AF7_N<@]TY"N%_5RS=[ 5XDKN1>\KHTF8WBT
MRFOD8[*(PS(!5#Q'D5D.&A-31I%\GDLY7?DQ[/NW$N^U"*B=EN54H/EP:%X;
M1]@IXY,C2#"OA@6#@$@)DBP93FEPBN.E5<7,BJD',!>^*^M>=V#;\*4_]F9]
MB!?UN?;IGH&N,-I&=[-:J$)($Q'2NU%=(>=!!!X5LB172>#.(^.%1]9R)I*6
M7.!<)BAKTO/2K_L)/+#/%>XS./$M<'\XW*_U#QVQ\4$Q) P8!%Q$C2RV"@7,
M,)?1)L%CSH1:QMJL_)AX5T>XS]1[^W0:2KME7:O=&K1R FXGC*6Q_&H*'D9;
M]9JE_WZ\AU\,KIZ!:O;F6D;7.J$P]P.9^\.-1E&:"A9"1-[Z?!(NP'+T7B.L
M>6[FG<_5/#"W!.;FMWAU[A><4P]%[1=.G\)RA>5FJ9$6EILVRUWKIXY2L#B)
M0T3%B'@0&#EB+6BJ1NA@(R-" ,OQ98W%"IT+EKO03R]'<2G8M.*PVRGPER;I
M"%M>CYW!Z$+WS+7C#X,?XT:/^YVW*NED#"_]Q7<-G9(_^[IJ?>@*4S?IVT<@
MA]X3>?'5[?K\46S UMT]@>\^S\TK.MU!5NI[\'*GT8+Q'O:JC-/>H-%-C0%\
M/+4ZMN-;E:/2#N()/%1_Y8:85Q/\^\#"U%P>98Y$FEQ\/\^QK:?=?I6'];(7
MVW;0^CO^\:45!D>75#MRU<6DX^M+K -PG WNON2'F9_]CD'SF.C-4]TQ1KCZ
M3]?[??6[P^"1O_,M*C9WUDFNL,#.4ZXC X692"88L20(%?0G8I8N+SKJ7</K
M,"+7B_8SL@F^]:5M?['G_:7?;PSNI-5!HVOU_33?.9DIW6<RS1AS.003;(7=
MGJUD # :>_E3,"1;EZ$TCGIY^_^O7Z^. @!FE&1HK6?- :#TS]_MZ@\"<[=8
M_/3-L05NAK130>+]YNO-YN;[G6;C[;_6WF^OK6]^V-M:7WNSN]S8:JZO3 R8
M68]_?:>YL=G<W=QHP$^[.V^V-M;VX)?=/?AG>[.YM]O8>=78>;OY?FUO"S[0
M6&OF3VZ_?;_Y+[ALZZ_-_)@[VYNU?] 7'SKV++0&,?Q6A[%6=WR94W5;?IS1
M;W4:\$5MP&=_N1&_^@A[]FGL#:-N&L$.[-V/=6)[AT"!%QM/9L"+5[*N(6[;
MV;,.5<'YIFX"S]^VI_WX\O*'/T*K?]JVYR];G6K,U46W:&W7E+N"A[1[H;5<
MW/_B[97JK>\4S.%[W*QPS>]\&Z^0>[XGV-U?^K,K?S98 K<UXKD/EMUSO19I
ML!*SL6[["W?[-"T.\\-';_'/U%+![\78V(;/'?4;FZ"CA$:E*.P"%<83!US(
M\/*=T07/8(*:\,I$\S-#H;O5S/VE6Z#F$YX]^V,(W%A/_-QF;B1"^''%:NYF
MYF$R-16!FKLY^TZ:9A1>]Z0/O7OELLHV]P[8 I7UWA]'>.X=M#/&/:;&=F60
M4\%XC48XHYB2)PTF?Q__CIVSV']Y+QR.&XA?[K%8]WB":AM/BI)F'#1.>]UP
MYH$U;#L^RJXUR>2-':3PI-,V?IS";8]8[RR<":(1',9!JL"\98'3%*Q3Q&GN
MF' D:9D^;50Q5PH3-(7R9A6?O^IU3_*Y1A[=Q];@:/VL#U,5>YM???LL3_%:
MOQ_A3ZA3F8.=W8M(A>/]K]M[FW3_X[]/]ND[W-QXEZ,,1(Y.@-?Y/H51[6V*
M?-UUI,(AW]EHMP\^[O.#G$NZ\?YD^]B+YNN#H^V]+=+\YL_W3V"\'_?%]Y$*
M.QMP[<>_V@?'1R?;&__^W'R]?][\]AD?G&Q^W3[^P)K?_MTZV#B"]]NIN8[/
MJRB%7?SEDZ?,V(0CDBJW6/&)($N-1S$Q$J2AFKH<C;7,-7UXF$+]^H$6PEI0
MPO)2.BF)2-0E3AC77DC+A%;!6N^(SX1%S 5AP0^%L&I-6/B*L%S /%+#D(G$
M(NZL0HY[B6C0!*1$)DQM)BS*],J/*?.%L IAU9.PHG+1&T.LD)PG&HPQFC@?
M<1#*6&XO-"Q2-*RY("QZ15A:6!%S/1E'K$;<8($TIP(%;90WR6#*@+#8LN'B
MB8N_%<(JA#5!&@ZG5'+L*0Z4>XZU\-YZ3FRNX6ZPN]"P2-&PYH*P^!5A*>F\
M2%P@KFU /&J)+',)&1:8C$EXA4TF+,'UP_-SZM=O?FX\>KNVTTVM1A48YBXB
M21N](5(>U16^F#5I)J"^0$(@H)3EOI_ @@)V<A&(<_""<%KR,;QAA=]FRF^[
M(RZOI$UN'^>09I$"R1&.G.39^>65X=P133WPFV /MQ]+8:GZ@M@KXGGP5!JK
MN G9-61@ZS-"6Y+PT*7]"P]1 ?&,07SM!K*<.&N)05JEW#$HYA;SRB'"6$I!
M>459SJ]38FHIQ 7$-00Q@V4&<T.RY#@G--GH(R>*8!]4U!J/X34I()XQB*]=
M(R&28!C#*.8BCYP(C(S-Y7<C_!<(UH30I54M3=F)%QG$BOO@N1<F@ IMD[,B
M4$<ML004:AG#&)Z$ N(9@_C:71"<X&#U>.2UX@#B7"$_.HXT-S%A'I//>:24
M3:'E9OW*0<Z-L^!/>U[UV)F6K^#)NW[,"[EI3XA("6S-"+8EME8'G:1)7,O$
MA2^^@MJ16VO$5\""E:!72@36A@&]Q#MDE(@H")Y;DWK.901R,[>5N9W[HYL"
MXDL0<TV3H)82HBAW4AA-<VUR)BC%+&E9? 7U _&UKR#W$):$"R0(58@;8I'Q
M"126(*S0EF(5: 8Q>^+>P@7$C[L3$X:9#TI;P[ASP2JMHY <]F0?Q?# LO@*
MZ@7B:U^!M<Q0X@(BB><R6MXCZXU%.D8;&.%8D;"TJJ=8W+F N(8@#DX[30/8
MEE;QX*1C!E1K2;,C24>"BZ^@?B"^]A5X%9,&C0E%DWMK,\J0IEPA0_*)'$[$
M*@4@9KQ6D5#/+;"@:BQ9(@EF06<)2ZV(8RD)P37&UL7H% [82:J-&B>OIM#9
M3.GL?,0[8$!SU(%1A!EGB!-OD;,:(^X4=]X+14T^A!3ZX89%.;^H+XB-8Y:K
MR)6#G0M,2LN4\4Q@ 9:E<[Q$$M00Q-?> 4$):)  8B,$19P3C6Q0H),DEZR7
MAFL&A@63M3J^*!B>,H;!AF2")LJP)US0J WV7A+N-6S#2K/B'*@?AJ^= [D_
M9&+2(I4B;,22!&2SA\]2' WG,0GEEE8YFX*'KX"XOB!FB4A)B% R<*Y=S%Y[
M)9F1.D,WT>(<J!^(1P()(B<,DX@TV#^YI1-#5FJ.;/2@7P/K<J.75I5^N(.O
M1G$$CUI/Z&D:OLT-6QC&??0\).$YXQB(00>:7%")><]TJ6DQ/T2R,UK3@DKG
M/'$1$>,%F.52@380/0J<4.M$,L;FB*1E:J;08.CQ6L,]^4G",^8&3*C,D3I"
M"LVE<B8Z BJF#:!%^"!9*1\Q5]QP;>TSH')/,$72)H>X40(Y'@6*1'D6&9;,
MJUP^0G%6Y[:1A1N>,'&(BA!TR"$EAFL1K7!<!8]%] F(P)1*#7/%#==>!),B
M8]HPQ**TP TQHMQL!0F5#// #8FRI56YC!6?6BVLP@T+Q0TX"&PB9X)RQV5P
M6F@G Y-!:RDP8:4HPEQQP[5S OL(MB%+2!(5P:8@&%E)-2*<>RDIB\#_2ZM\
M68)-0>:%&^[1T:_VQ5X?K\YT&>1"#'*Q*M7?OF-M?CV-G?Y]2V+/TD59[E&?
M>SRW.+?WL1]MSQ\U;"> $O9W;'=/<WN'$O)6<[?[]WKP<!G7.F'C>A$O*+!H
MO!-HO-M9VVU=][ F2AFK+ I":\1]/E47(B+'(M9&.RZT!'M8\W*JOLB G8(O
MO #V\0#;7+\"+./)!)8/OACUB$LL$*R21$P39JW345@P4@65I2C.(@-VM@[J
M@N4I8OEZ\V564>:X1I3PA+@R%#G +Z+666L%37YX4&4,KE5 3$'S7+N4"YJG
MA^:=D9U91,6EH$BG'-M&K82=V0&:-=6,,2\J59HL:Z-JI4P_MS(YN[$-+QXN
M-PYC)_9L>[GR#=APTNJT^H-<-^?O4B]GOMP#%TOZ>KB@P&QK-U:SD-M]R&UK
MU$^ A4N<!XV"UQ3(C8*J(I1&D:H4J, X*;ZTRL#L*$5R%ABY4_<3%.0^"G)'
M' ;)4DEC-,@1[K*'3R$;640F\)1 57$VYE+8F*_P@MS%1>XL'08%U(\#ZA&W
MO2,V":,0CPYL#0^VAL-"P79,B)',$Q]IMC4PIZ56SB+#>@J>@X+=&6!WQ$\@
MA)$F 6Q99 &!_4.028HBX[525"OFK%Q:U09/+<BL%,B9'(/KW?Z@T4V-PVXW
M]'/,42@A S7O/GV3R/("[J37>?F Q79C[^^6C_U=6,A"7A.1U_:H'X!YV'!(
MCA*0'A0/+%BNI$&12%JD: 2\F9V<C)3CQT5&ZQ1:+Q>T/A):1VQ_*Q06AALD
M)/: UAS1'BA UE 2<*#6!0YH)>+A7KN"UOJB=0I]APM:'PNM(SYV[$*B&&23
MYOP3E@C2B1'$M3*81<G 8%A:98265CF+C-8I--TM:'TDM(Z8\1&V5AJD02"1
M8,;SP)'6/" A M/*.1H8H)4*5JNB<L_ML/_2C/<WNN+D W]_D4_9@.\X2_##
M60\>L!S\/RJU59W\E-,26YZ4U"E2P4T(1G"FI2I&_E-1V[M1(Y\K$YUSH'Y8
M#(J(5Q(9J@4RL'@A&8IYRD8^9[7J#5[0.NV>?31)$HT7SF(>)+-*L)"D,MYA
MZ:,K1O[3H77$R(]8 )LJCA3G%/&(+;(Q260]S@W(?*+: 5JQ*:UO%AFMWA#'
M8B+:6C#I [?<)8"ME[#R1NE8C/PG1.OUWDJ$)-)ACQ@L06Y499!U/AOYPN.@
MK G,+ZURP<NY_2*C-;"H'?.$PK;)C?&@ "M/A- Z@33PR<_M"UJGAM81(]];
MV$)-KAU'#4=<P'(8F01B BL9HU2:*3#R=;WVUN=V5C]L9M,]C=F\[QPV7K0Z
MOGL2?VO$8;3*<J,39Y7Q/X>T]>(I0_>KM=NY7+JM:N$N@HR:<5"X:R+N^C!J
MQ8,F(7AT"0DI4K8+#'*"4J2]B%PQDP@GH&G<EMG_VQVL5>_S@@6'WM1C[POT
MI@J]$9/<X*2C5Q0E&B3B+G)D>6#(LF!##(R3 ":YP+>4GYT]] K"IA@C7Q#V
MF B[WMPT!@HTB2+BDD<\*8R< X1Q325-W$E"4XY#$[=4<2T0>\)-;-KQZ@5B
M4X78B.V;8B!1Z(18+I#,K7%(*V.1PY9:2T$6<IPZ4>26./7'A%AIQU(O^->T
M'4MVB&57V&6=S$(%$U'!_HWL;^F"Q10(0&,'NZW@R&"OD=<\&2<252S'D2X#
M*4PM_[M435\HZ,^RVTJ!_@.A/V+*:N45,8P@G+NF<A$L,L9IQ"QA6 J@;EG5
MJ,+X-E6[0+] ?Z:IYP7Z#X7^]:X?@H]"*(,T!BN &^J1(<Z#$A"38)H1[\$
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MUG^(2TDF(9!0W*+,.4B#XH.25RIJI[4P;&F5XA56"*@0T+P1T&.[PPH!W8^
M1AQB.F$?F6!(:^J!@*3.GGF"A%:,&JNHLW1IE9 5P6M$0%,)B/R%L[[<H]SC
MSGL\!X_LQ^J7&!H61F4/X] GVV]TSP;]@>WDYWA0G.+S;D)^YW8ZG.7'SNV^
M7-RUX=HVSTY<[.VD:EOM[URO\,T3IY)S,,X&^V[4PYFDT803BF+N3\X9Y4A'
MZE!4C!"B/35:P0:+IU!;IGX:?L'P8^9+%PP_)H9'O(1"84,88<B: %:ZPAA9
M:Q0*S&L>C E!YU-C;%;JI"07#$\?PU,OO%@P_*@8'JG!(HQU4BMD4C9T28R
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MWZL(%7O>.%T;:@S7*_^O;CM/[6M8^*Q&['1VKU9]K=?JPUL;\&OG\"U,0S>
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MV6IFMK>;RF2VMXP2H\0H,4J,TB:AM(K"7'O.@17F/2K,A>1#+-:$(+4P-:*
M+(N(D4P3G,752($2Q$U2F-S)\*E.AF_+L"</TNF<N\O:&AH;O_GC'X-7^+9]
MC>G@YR,<<=,")]$9)4:)46*4&*7M1^E+!(DGU+[T8LW0A0Y94C[TY+R6X7L:
M41W.N@1A^;Z2?/_U2H X&9URR47(5%R3[Z:*$+06#=5D4ZA.%[.S'[D%:-N(
MS.:646*4&*6'@](J(U5LL%"T(ZP)8K0!9:B6DL[D2T3)TF5CI<OE,"5I"E##
M3V2IJP!OLVBZ4XEJ50('4&KMN>T]8.GRU1)Y;6D$)O(]$WEQ:Z&OJ0)*@1J:
M#P+!B.2;(U+0&2>#MHC8]X?<?E82]R_<(6WG[!&I9]?:%;E,KPWR(4[>$+<;
M</*;46*4&"5&B5'Z"E#:D'KR@_&C=N7Z)\"CWL?S=/083X8S/)H7^Z3KQ3XO
M^VS&Z7!&KVCR=ICI3->_I#Q^,YJ_RUSBLYY?2<__=B6G  6D=H5$SK7I^5*S
MP%BMJ-Y5#\K(:DK3\S(NF7+,G-]HSK-E9I08)4:)46*4-@FE#:D\9RVZ$5IT
M(;8L2]"4N_A,N0H 'P2F6D4 [3Q*;4#AYFE1+E*_3O#G-.OS\L?'Q!7G7,3
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MP^[?C.BQV'XNY106+,W\X<HI/.D@7XM^"S#7CV#(-2>)@&G+0XTW_O>X_16
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M"2?P4D82F4-:)0T*D#?(*L%1T-HFR;23VBRM"BI+L=2"/L\&?1XWF*  T]R
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M=E6"*T^$T#HY3_CMST +[,P/=J82,XTU-)J((M4*M!\; ':,1I%H%H3Q(#7
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MACST,Y4%7G+LF^49:E)@9S4O'^7\Y6_;W:]Q&/)?-=DG0TUCE% Q/&9#L'*
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MA^+Z&!@?T/FP'F+JY6>,)[:<,X#KXT/@;^"Z,$:G8<YM,^.S @&U[[<=7.(
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M,.>XB+=9N)<F 6=-\<5(0*%%BDII*J/@W"9KG=5."6Z)2$&[ZYR7K$C QY6
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M#C=^G><?8)5J3B9/^NJ2W;@P*7W/PIA;K$O)LJ#8573]O"#\?!5,R:[*5%J
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M3>][472IFJ1]_Z\]._]G4:QA_N6O)G]/;Z]G\9V/!\.Q+;>]>*W-KV]-]99
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MBE(7G6[W3E"5I6">TCQ:Y1M+D"W'SK\ED*%5C=D"Z0,:GP-YEF]1QW7?'XX
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M*S_$K-4B<HP<MP%QG0)R4E.DL??4.B<E3AO;4IJFV&X#8C\[B#U&Q$V#;_>
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M7)4P@Z+G]]ZUBZ=@3DH[&V: $Y811R255(B#:B+MO$$.5)G9R*)PHN;9BQ0
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M4$C.E2 1I4 QXE@3Y)0'QD>4DD18YV5]T*(7/6ZD) J\ #Y4#F<6'1W(!73
MQK*@+$5>>8*X80QI$1@202:K0 EX/H9]@]D!!29>%TP43O$@U& 742,Q;L&Z
M0LPRL*V<HL@8&Q!G 4<*; ,S_291HUA7K]VZ6CCCJIQVS0/?Q 5\B\Q%'I-#
ME"6&./4)&6XD"MS2%+PB.'>E*[ZC@FZO#-T6SW=4S@(?PU-^?A9X ,_S<3<P
MYH#$112E](@#>T,FB812#%QHFI)3Z47XB,:GA)-1C&7;U"@V[VB 6UQCYF&O
MZ>0RCSN44991EE$.+^G_*RF.>K]BZNO1CVNIDUQ+G9A[]2E_@@:FY1KE&H]Z
MC3EE&B\(&LRW5/)MXQ47[H%O;YA=]XB+;7[=P?IRVGLIK+;$>!ZUMRX8B[EQ
MS$H?*;^YP60)65H40^SS3-ECFX2Q,3($JT@1CU$AXR-'5%(IL36,8+.T2H5:
MH:\OPKJ@U$M"J;LXB183IHK[Z$&H-2U4#)(K;306,<H\XD%99+FTB#@:L%/!
MU*B%K\&LDL6]L/K]).I= H467<NG18>]4\P[EA"E1(*68XZ<" 0EQ03C.-'D
MYU="M*A[4?<2\//LVC\M()PX%9:&A# 3''&K#-(T!22%D,$S*YR+KUC[BVWR
MDFR3A3--2GC./-!H6O+7*HOK?E#193\)]1(9YC62EE'BB>*P9L5/4K!H 9YM
M\?PD)9CF,7RXLT5ZD]8AQ8@HUP9QC1VR,CA$E""$Q>BETPOD#WGJX_+0_CZY
M]O@2*'_^C_,ROC-E>U]<@5YXN/NEC[QNF]%&&1,S+%J2..'8.(&%3 YC$6E2
MJAQ4+3[(S?;G%(1+E5O)8(US)2 "YJ"6!@D9/<,\Z.3ITBI1*VQ.H=$+% #]
MRK7Z+H1E,=6Z4)D':?E,!\J(O65)(6LX$)GD(M)$6!2(HLYCYI*R#ZT.5/3[
M->[:Y6!GT;5\YF"'"&F,ET@'2A!W*2$=@T(^XJ =YLZ3N6=_%W4OZEX.=IY/
M^Z<'.\SFE>84,68<,'GND7-4(<YUB,XJ*HDHVE^T?TY<OIR$S$-]IR<AAA,G
M#9<HYM1D3B4%BIYS^("Z*^,3M4H40_Q%ZN[B&>+EY. QG&HS)P=@4!O.'4'"
M&]B"F3-@>F.#$N/,Z@0+Z.@"&=P/3:VYZ\GF.!=P-(CKT@%OS"M^[>4'YC]!
MBXV-=X!&PW@(V'J>P(Z5E+H06<0QB(2#<,:6HX?%1\G3F:.'%#B6$4N4(I =
M'AQ'%L>(8-M+P(6\9EHMK5+%Y]:%8'Y:M>"1(P5?"[[>G7LN)L 65OH@O)T>
M I$4?3*!(TJY1MPXB73V$3LE.?>$JF!\YJ17#<P[1[.\&J"]2[+ (X/NXF'+
MDT!+.8!:=(29'D"9Z+@RF"*3F$-<6XRL-@0QQ3WU0K# [;QS"PK4%*AYL5!3
MN,V#D&=Z^(4#"U()B83R&'%+-=(I*,0P#4;!,A.6"O(4:[)8DXL/P^44\JEQ
M='H*28165N4\!\X$XD)'I#48BDF$Y(AUVOI4?'(%10N*OBJ?7#D/?HR3CIGS
M8!YAR61,"),ZS8)BY)S5*/H0@[9):^M>C>^M/DW^QS#+UWDBU>BIFL>'H#)^
M]+<?&4MUWM6%9+*QLG !VG0TEL4_^A$$L?T]_O.D'8;[$SXR\ZWQ ^/I5ZR#
M9SL>WOR5F<?R$92N__2 0/.8B+R8=G:+(:[^R_7_L7HI6VWFW_WSJME'=B\B
M!_K]#=D$%_C#=D[LZ6#I'Q?N<]CN3L9D\J O3]F-$Y/2?2;&W&)>?E8;]U]V
M4892[?<S4/]7VUDGN<(".T^YCLPP3"03C%@2A IZ5RVMMK).Y*J^V5$ RSGX
MUS_LZI6UOWF%?[80CU6EN);03QL?-IH;G[::U7_^=^U38^W=QI?6YKNUOSXO
M5YO-=RL+,LKF5FOC<]7:JMYM-=<WFI\WUO-OG[?^VEQ?:\$?[S>;:\UWFVM_
M59];\$)CH]GZ7/WVI;GV97T3WO_]Z1ZCON(?[2%HMK_%@_WVI=N)@T'5&^['
M_DE[$*MN#W;E98#V3L?V!U6[6\% .CF#=;F*/WP$Z#Z*@ '[MA^K8(?V]^NP
MXA(*C[9U+HD7&M1)!,5)2":X&!2U0E&AK:47,?30]O< .\;HJ^$!QZ_D_45?
MY*@'QX-A.YT^$\H"UZE@_N#__1BKP]H15T50Y%!]AOFJJVR/;!B&<ZEM"O].
M:%&U9]M=F'\8-%"@NC W/.:W6&]RU>"<6%4GL5\O#KP-6-NVG95J<M\NC.A^
MMZTO^O_NP!H]%2'H0"3AAFL1K7!<!8]%] D;9G;7ZV8>!!-TFYYNW>/#T!N.
MW[_,+!OG\S#EEY_&X_\ PW\-U+$3__?3Z<[7<.0HEXV#OP^;!^%P^VP/:.*?
M[>;ZSD&CM4>WZ:<V?.='\\.7TZW6VDGCX,_4:*V=-M=VJ>:<V! 1#HSG4!>"
M7'0!86$$<#9L \UFM;[1JAXK]THUF=FJ ]-ZG;SEA9L1\YSP?FO!6ZE:^_EZ
M]47OTCLF"&PB9X)RQV5P6F@G Y-!:RDP85G<B!F+&_QR2=PVF^\OR!LHN,\R
M=P)$=1"[#Q(X_/8$3C3V=J410=-<<#CB?!*',=+.*Y1)"6<T!"'<W;J?$2JM
M#EI(H;E4SD1'DDTVD$1]D),E5F6)GVJ) ^S2B1.'B"8AEY@FR$H1$0/KDL-R
M>>GQTFJW=P51KKPPW6[&H/++;6ZYQI7K=JE9*%J^/Q81LU)5-QI%+X=S?&T/
M]V&>!D?1#ZMA[Z;9? !FUY_.$P9K<M@[!IL"[N<[=C!HIS9\+?5[A]6,)V?$
M(4&Y#X_Z<3]V!V!3 WV$O_,/&.)6_?YO\<<1O!E_'[^W7'7C<+3$M24.%X+/
M7I* /)1K1,A.O$T(GA/EEP$9W'"6-OUF!_#:P/?;P#4KZWK?X^^7K(KK70:U
MYO_2].)RZ86(T?7\7ZY,MN.Q!V4.=.\BXKZW[?[?MG,<U]L##VMX#$+;@AO\
MV>GY;\\,L,WV!&#W\,[A!M[.?K;6YFGC[./I]M<&;W[XN]UL?:$[K0V^?? -
M-UH?KP#LUOJGP^W6I_W&X09I'&R>-==AS&=PO:^;I-G:Z31:^^VMUL<?S?4,
ML(VSQL==H#"&.VM0PDH@3C5#5J> " DPS5QYY>1HEP21C&$M[VQ28:6]QB)0
MPJ/1+E$2'3<X2L.4UTL5"+D]RHZ=_G$$FP2FO:KGO6I$FV?]<.06N.POF]6$
M:ZVV7]_YXD@9ALV:QB@% ]VAT9G @@:-@1=33.:<'3RZQ*T!8 P'X\</6]U/
M&1;Z[>[>6C<T>]W^Y,\_[: ]J#TH;U@P<;WS:T>QL"C!>B$.6SVR@1F$I8R
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MVP)L '6ZMFWW_[:=X[AVV#ON#M\PM]I@C;5=EMT&F!J4VR<@+C5!EIF(L$@
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M)I=AH?'UWX>-0QC'^O99X_ +;ZY_I,W#]X?;7S^RYMFG-HSQ6P.NNW/P=VK
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MSWB?!!,RRV!H]8KS)F9D%/T,#SR:CI-T.B3!SR<3.J;?0-($RC$\D*6S8(/
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MS<:E?):5G'W@?!B!_&<*PMJP>J(7..L4.05=?-B@%_SR3SBU<=;PX@A6-<,
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M>[_J[IW5=!L$#@:Q:"=1"R/6[3V^G8IY/5TN!@2C@\HO,O_*(KH+'48:+UX
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M>&-Y9<*-$4,GM;ZPF/F-&17)-1,LH+F,,SHB-02-<?J!V&(X"D65K[LK_S5
MBA&6&69&1A.&F# S><S08G"WK>G[X9M]\PT<AE=D)"JFBHP0UH YXLD4(]:
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M4- -YL\TJKX@'%5WP06'P(5X)\,$ AX35'38"6W)F8>6P(([)EBCL')K"K>
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M0LPO8J9IT2/TD] /40($#.\$L^E.F^+V@1T(_?7?8XX@#GCOI.\:F+XH:#5
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M(V<\=W7P]HY]4?UMTNB>:6:J^U!$I"PR3@JZH[@ J8'\6 FTQ);9_4;712K
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MZ<A"6>V35$RJRLA-' .7P@-NZ!.0&)[(]/(EH@G:W2*K5+9+SDMG1%4J@BM
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M+O%+NL1)ZXQO<@TN\0*)I+7=H(_HC-ME?PHR74G"I1NOROS=.+UR-/B0C2[
MM?K$)XNF9 .-.;'&DO,,ZKQ%DJ^+K/C8=DX?*[92;/7<;'4,Q2"1D_!-$9YY
M3H30)V-(-<EZ3O*E00<VY45TVBD@KL/#5=_P6^YPSW7^ZFO^#*-Q[A2]:%,K
M\/.<9+DA)B:D@+4:97_*PL5=Z%2W1,&\)98[';"CUP'>4/%<E7ANO'L=@&(Y
MQ7*/JY_JUP"W0?%<E7A.;_</*>>.#926DD>;$TJCA.&Y'[@.USCS'&XJK-K=
M)69[W[+_$I4SU9Q&JIUM)<BDCE+Y:73PHZ3<7AO<7M9\$GJ^R/7"/"08,IPR
M(Q"Y9^XTY>G2_'"QL%/>K2>=\:#UN)JFK25-I_JKYW/)%3J[U<42&_=4&Y6R
MTVC4;_44C<I-HX[J[%5^(NF][B$=]L<0*Q? B:ME-8=2I@MG7E2$@;O]X9/#
M3^0DH53%5JH;>?7A>-_V.8J\Y2?O:-16Y*TO>3N]\9.CO3X5>8^A&\G5?!XZ
M;M-U\(.W>V;K%560"XSQ?#EF:I*UF.1+VP.5<5OF9.O9KN_SXLEZ'ZQ)P):N
MYH:!;YE\'=3A$0[#XW;VG_9:PX,TU%+D*4B>@2)/><FC#P_4CT[1IQA]!JW.
M4?0+K(PRH&*8RJV_G4?:.S<&5Y&72J2(*#*],)D&*H99=A(=_"0=3Q1SQ:&H
M@IE/K&MW6Z.=56T5"*D 8??Q02C"5H"PNKZ']T)1M@J4W<?OH<*63Z9K2.A$
M(P.=Z*U )[Y@.>3C&+QTF[QSK63Q]9?[8'?[W7T3O$LCMQ4K*U:F[+B]4ZP5
M*RM6+M/"1X.QDLJ*E>O RIWNWB!(+V4^1!,I85/$]$K5-U_HF[E696?X:&3A
M&G4)3(6CGW3:!?L$GKN>: 6%FP@T\@FGSP@]3_0 #',S ?W0F$7-,?"7EI^T
MPL 'X)5S&$KD#*3M;-%6R@D\; *6R2\XHG:"VSK(K-5SE7K917I4 )O<628,
M"ZQ$S ,SX3"O.0LHWQ3[I,3)IY@]&L%%NEZ4BSKUW/E#4)%Q%[,Y,AYP(V6Q
M6#Z<N:B_W5O\N\_CKT?MXH A#<L6W5:0'>$-.!.A+2 K5UKI98>4S>A@"0O7
MBR:5OP@X(\Q$BF ;/P,/"W"]O801L%6:P7V?><N6MM:M9L?VBOBB,6/.+34(
MS&SN_CB<#W1ME T+&]08T?1 ]CDH.V1[Q8MP87W'K8N^#RMJT%YK-JP:G@".
MA;\W:+8.,-]*VQS)2'1*M/N99<P:&M_4[DZV*'1<V'?8!+%\W%%8M:1$>M"<
MO: =W-KZ[M0'ND2=9BP'.&\N'IIPV[U_U=*^8@?(5)]&+YU;Y1=.KD*>236M
MW+BQU)Z(&$GZ,8FI;QVZC^AK)+ -<3(R4X$OF-B "$D; KWMB'NI[Y'H%YAN
M!DODMSRSB5TXEYH!_.S"M%7?M)3@Z_55WS35-ZW*?=,Z^V Y;Y2;D9QJI"0H
MW&UN>#O3KID'DJDKQ?<K<9_^D]_]8!XC\1/.4?S]0&T4A>N;HOV\#MO>JM_J
MCMI[M;<:M<;MS7]^1%^C_N Y^AKU>UTU6379?F^HVENI]E8OLD&JO54FGT2U
MMRJP2ZH/D6IOI=BJ5#MWX/96FT((X_)4Y*W;35GS:*U#];$5XSV09KIW4F4=
MHN)/DF.;V8C![K'A@R0O-?1>IS5XCAJ2Y\U5+C]//=WZR\U"P_ZP[O!AQ\[*
MSU*"4!$)V6WH?;U52'%55ZZZ<HM<N6-]U.H]3I]_)I2-7FL-8X-^=3"4C9R@
M2C9')@JQ:(_0C)\N970EU>MHSNEN.U&1@]KI=EO# Q<YU9"AGFKUY68>[!3W
M^*J0;1M0G43Z&C+Q\4K% 2@ONI**2BKN)14[[9T;!;R,5%0>]0<P[D#S-OD=
MM]T%_9-_7W!'0-\F^>])FJC(V66.P46Z4UJ37["E&'$"6T):_ N@WNY(RD@8
MEQ\A 4[4N$@H6T%JKD)+M/? ^2F14[+^K#WHM/J*M?=A[5Z.3'@)UBZ+'ZM4
MM^ANB<$/5>Z4PL]UI.[HG3:B(O9<1^^T1J6"\JD#.SW1XLO-.N->J_/$)?85
M]7#5CX&/5A[V^_T]\V$4.QVY/$2??RD%8OD!1UX<A>-8/ZC\G(_),F#P_V,A
M/^:(LUN>7Z^I\HZ5+R:Y$W;M ?(TWIA#+/7/RE6W1T!,L8=BC\WLL2N$G6*/
M8V*/_I%R1UGL&?7H7D"&+Q8&4@B'\;0+(AS^:KL39J\;+6E+)V/>1*!PA&88
MIX (4"\)^R9!V++@-81^AB X-O.#^$E$WR+,LBB5!#^%3YTCHIJS%/:9F09'
MV]*"68P!5MUMLBJQFFA8H@TW=T$P,WG +-N7Z&6$DN=QF#<7:'*/67/NKL>S
MN(?O8+:-'>+($FM/X/& H7K'5T'%JH8*N15>Z0R1UWS#LR8("(C+E0AW)^=I
M0[VA?; ,S$L2-O@GHMA9!)#G:TWM60[7GM"6$>KC,\]IZPQ*MR6KF)Z'V)23
M+9"):6DD$/^XO=0$+*QOX6F,L#73Z7("RG6;D)$'.M,-O@7_1";'/V2@'AMQ
MJMT3SB!J2B]!.3,S$>?IWK)M3-_+; +3^G_6/'?)[&"IP9!B9M0/</C6?T"H
M1=]<7WH-,%VOI(Q&",A8W!/\YRHC<>8YW!2;+-$H$<0MP:@4CT\M#RZ.G_KM
MJ+1 8MF(C6VB%F$BO@WW ]?A @E6D*.AA0M$%+X%#KI%+%GF. C=&E,DE6&R
MD2;:J;A^$(,SHN KC7\'JX)^]Y/>:FL3.27\&K %_ ,!6N^Y?<>;!,JJP32M
MJM!W1^'U"UL"B3-7DG:STBUI^WK[V?7VL^M]5AR^L=[J#GO[X/#U.RU]]"PX
M?'NB^VV;[+@U5'-5<RTX5X7!EQ)Z"H-/8?#M<$<J##X%EE8"L#3%5HJM% ;?
M2V?22+M_:@6%JQPN?_]P>;;9_"PA]MTJ&]<M.[-F4&6=T;"U9SZ.@BI3K%RF
MA7?VZ#JK6%FQ<@E9>3CL* !)Q<JU8.7Q[FWM7XJ556WV P@G11O-'5L"_P-U
M;3DYEA5,I=0[#ZA3)2I,K<F.CQZX]9]OQ^N]L?W. T:NVMC]-K:GM[9G7%<1
MB.P0&_G5#> ^%<D2V4([;R59H@PZ^%$KX%72OCOC\9.[]VIA12H.K@P'=Y_<
M%:(X6''PRZUZU.D_H"0I#E8<7&H.[O9:>Y;=E@W%97_/P@N-\31P*6J*M9OB
M0R6DJE+TT)6BYZXG2HZH],-P_2"+!1[FEF3ZH3&+RH'PEY:?5(_B _#*.0RU
MCL CRI><P&-&D/72U[CJ\7GSJ:AX+)S#XJG8B I:WZP4D6[<-KV;W3?ZMZI4
M4145:JZJ4J6L.;RJ4D55JJA*%5524)J=4Y4JBJV.IU*E9-UEA7F4@T^QT6!2
M%2BE[@:]NA<509P'!;]D_<454U6?J;KM5D<QE6*J)TU/:.CMSIX]L15;*;;:
MS%;8L>YQ.NLQ5"L4[%,@@+\>4&9+T4=N)19X3&=YY\VHR&'NP@W1+U=_<,56
MU6>KSFB\ISZKV$JQU>9D+WVPI^VMV$JQU98<PO[*)5@6'VRI]-ET]2WHLFFX
M8OY]@3C>V9PB43%D.1HS,&>(.087Z2]IU7C!EF+ ">P(J<4OT+RJMCW8P3 ;
M/&\/]CIO74=MW5Y;U^NV>FKK]MNZSBK7*5=*=8#J5 _A)]<HMVQ$1;1)@JU3
M+:D5.STA=)QB)\5.3PC?IMA)L=,30JB5LMMCZ7N[U_^#RHM6U)3)Z52_<[ZC
M:OJ^;PQT>*2->15[%&(/U=5;L8>2'HH]E/38N>O[QJI^^6(/2TS6$15DH:TH
MT$V]):O9V\DK; +V4QAL?B6OR/V%-X?  7J#K'Y68(H_4S7GBEJ7^N_,2[3=
M6]Z<>)Q]:[(I#/"&V?=LZ9^\SD("6$XSO>^K6[9Q8Z;3?3;F060*V!?!T"9B
M2I"[_@VUB1:(&7]C99F*-O/X].\G?[(F;#+H#=O]]L3H]$:\.^ZV]4&WW]69
M;O:'YNC_AB<_?R4$!5#@S^&#V,;Z;Z]9+A$KB7$A8OH"!&1#M^ 'PBTMF1<
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MMH\&BNVT4PKRX<%B?ULTIYZ+O<O84G3+3C5;LRV#VDZ*WJ>9;JBW'A?=M5\
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M3_:?R.VF?](Z;@DZ_>B@58#Q#:\Y<*\YT-=$).SJXLS05;:V@QL)7YPM&=4
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M0$UT_(\?%.L;U/JCD:@<1WS8<)FD6,SLM'CT^^#3P(_9XC=LN ;+AU(&%%@
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MHDWJ$%5&4+S7.HR)-/^#FYM1\1]_&#X!OL^\E=!OJ76^,M( !Z4":XFO+5N
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M52=PGH^N#1ZWA/J.4-E;0BC:OGCGN6'2!SJZ*KR)*86 9QC7281)W8?&'H_
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M GL9?7R[LF=8*TR7ES:=HSG(QXDH7L/]99P710,B>/(L^0<Q9)Y;+ U]2ZA
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M>H#W*_RQA-J?L2>(V>4(4*MMT /EN[AP+BLNX/4FAX;JR!1$T]2?^ 71DHQ
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M@8\VJ(\9!"A;OP!"7FA1H/ERK1#M8=XA?4XN&G)]&T"5D.*. FUONQI"/4N
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MXQ^$#>.&'-72T?CA@XFH'9]F/PG,A@"T[8*(+5.8=R.2902U[-U&=L-^EY*
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M,S!A@WDH9.,SY5#V(N2^_L]05P']/+0O?H$4>%3&]4I!,&$+?#<O(0.L1D.
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MWU:YR/V3G68_>-<12LI7DF5V(==W;7:2G(5_J]+2BL2:$$=01U+1=<V<@JL
M8;>3]Q)96-A%T@*,_F8<D$=%VK!>+>0M(-T2IX\P=8:MW1^=%]@QFSR4FCP+
M$F9O$U)[2%J[2Y)F; "ITXDPRX3:7X!/@L@F\.UE^/-L551]'*#H(=ESY%$8
M^0'ZQ!@& +SF6V"?I>47_54T?A1YW(9OXU;FF<3K\/YY%%.8"@-Z1Y+X+KL
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MP\9[X0/-!L6"X@XKDW.G&44WD=J$AV\'<QDR\SH@1+&I'QI2<!T0 @$A\/B
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M0SD[Z1 R616K .=/!43).8CHBNWBQ+_*":9QK$$,L4J(L)=;,MQ((&]LI_"
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MY2M@1%L&#EQTKZJMIDZ+KG.MJMJ(1"!G5R@_G4^' 1;8$R^,P'A'C$Z28)I
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M?]I0Y! U'**&.Q@UD%&;-%\?($AX+S_F;CA[MW3P7XZVAG7,51J:IE!'D5M
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M@K<,"AP3_E0N.HL3YDG$%L_>/#W[?]E/5>.?RK]Y!8'Q"\-!&I<U9/V20^*
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MK7^A(I5.PM9(B"FC'31FVOJ<F3+,_M_ E(^C*;7E1_3323)EZC1E=O:?L62
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MR/8D!=41 TBR%R8$&73.)N3MW"$!YG2^<44R'6#\PWPQKJ!T(1+HZC=&?,1
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M$"YMU0[9UA D14N1/%[5OU#B!@X? )/(O0*D3WVOZNFU&H%;"OY(96V8*V6
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M&0-/?J)6?K(ZW!78&3=&GCKH?%L1>.37;T?40U]GD"+B#M77:=T@?.JS8K%
M,()X(']]IR28W5;"X4CXSHH5?LP6![X$EP2ZXK+$L?SD=4H^G;D'P=J;U9^@
M/Y(?NUU..V0MG+4.8O^3(5C.QR4^0+C =+Z+85+:(AA [,S5ERM> .60]>$;
M@N\/R(/N<[ ^OQ6U&N'8^XRC*X+H!-(",[XGOD^PJF=_0,^]BRIDO0XW )6N
MQCY$_BB@3%WNB92604"=:0N[;?@&/3*3USL?,_D,=*X>S9"8S#F\-PK?PG%;
M<2AT$3?2KY"^<-=T7D 6K?KEQ8M(CC#7ZS0]KG0UOE!YC CS>TH8BQY9%^*7
MUB<<%)*'J17YQ:/K^AENC:YT0<CSX@F7LO3_O7$;^.*_PK6P&<$,A4_?Y-JT
M.:*2XXOR,5W& NB*Y$64=2/YW&T[D$<!7Q03ZJA9QY]Y9 [AG4B5QHB_B)65
M*X-=4'[:51XR+C36<J9(A!D\B3Y,0R>0B\M/(N@P+O"]@+G*-HCGQ<<[<R6U
M&](#A;88J% 8B!L!>L>0'E?ZBL]XJ;E8MQ@ZDHK,#5]G#Z(FX)'D-^1<VV(K
M7PSV]56AX)4:5SKK?3(''D^XV"&Y@T(#$+W):F4M ^X%G"%7N.%7+#\#K-H9
M^0MS+[A+]NQ)#H&,PHE/Z,BOY@SA![_SA*O.=T_%,1S*&GA,HL"$XW<KZ2UY
M?53I=MRBHE:?,VY4Y&T *GU23^ #^8'/U$XKGPJ_&+\>B5"'!)[+A!)R#:\@
M].99(E'] VR6%(14"\SQ%3,A0C9&PB6,/#2)Y)DSIYS1!G/X4_.=.\@8?!(4
MA)WI33%K9.GV%ZX+D5:N!^)4,:*?G#F>TJ>N'(%ZJ'J1/NKGJ $H?3)Q4V#U
M+>K8#:M+N;=!J>SA+1^FT^2@QICV,'V7?YW.9= .1K";]C5<%D7F#9<!5(7
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MF1'I 1%Y#D0F'K-)"JAHX@L> M6G@K ")ZKIO^["P+EDU\B)T5-XQCQ6+06
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MLL=4%_Y1DR_F;/DC8%'[C[_]7U!+ P04    "  */F51;<ZF,3M[  !#704
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M_:)0E@6+'E:3P,-=*(\^@6]/Z3:P,K_G40^LSXYEA48/TPH7Z8 $KCVNV;'
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M0A@2I'<$_]]+GS)EKDF[OF[PCBHIJ!>A]V:?5V&CN<XL(,V>7<X_3:;EOF!
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MA18:<3^L$]&*BK)ODA-Z>\D#'H5B6@D2=<DFX(82;S20[%16GAHO9),Q\NM
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MM(@_U?N@:M D?7;K@8<R F"1.0(\QA*24@1M*D.4"#E;;:@WA[:K3\\BJ$5
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M9@F3I2),L$B\S8%P+HP(^ G4-4D1.H[<]W;<K=_-[R7X%ET0[RQUP 4$0Z/
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M&6QIJHR.!G?.:N&"X^+!VKB<MK)4IV>##K6*V"]MQ!>3\1<4"S)2BK>&\]G
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MANE2-M,D._=1M*^JJDDUNE/U8:M!#'J+/)81 ):<!U=:7RX*L(H)&(1#XBD
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M*JIBB($3YCSJ,J-H@>D02&;2:^&M@-@EH:138/;K4X_R'J87AY-]95DY\KX
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M&0NP/X/:]\14(O L/$LA)4:W=V)1J<@4VA+ IR1\DPOS=;H+QA.6/GPYMKN
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MF3-G0C&)>U&VH^,O(-_^ RF:1%$XQWW=@58;B_&OQ5O\ +/\]LN[VHX EY^
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MGAVPH)[<J+5"AY!Z\W=CT/$Q@.W-K.E6X@A92-#%FP!1@ 6?,!@5+3_;AG(
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MYN;CS?W-^Z_@^O,[\/7^]NW_^K?;C^_>?_GZ3^#]__YV<_]W.]O*> BDB,.
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MQ>H+E)U<#W74N=(/K!0$] 7\K'4$6?X+6*L)-GHZ/)@; 'VG9W,NY1OW>&X
M9 ].Z(;HXW)O,1T%KI.@WLJ/1?YP+\HG?6 X\SWBIR@)8(@]3V?2\V&JPPQ0
MA"(<\C1AV+,Y"CC?Y=2,OUV?I*R56?LJS)744(GP!+B2N[_WUPGHS:C8+: #
M$^PNEC=;6'Y<8_FN"\N+_+FZX1G*@>M$KZ_FL=6-0I>+UIDW>V8$W$T*INEO
MYL4D#HB(841%"%$L(TC\.($A][S8B]* ,&9C/![I8VHV8&M=U/.BS9-6Y):&
MX#$HS4CD0H &9HV--;5C@SE,ZG=:?:>9_(YT,V[ZOM-Z'N3LZWC4_C3I?;[0
MQU*<JX]%=5=4:C[]O]GSVX*+61C2*$DXA@'7&T7&&:1Q&D*?TB1&-/0"LY2?
MW=U,S:AH) 6MJ%>@$18H:8$6U_Q0J0/9\\=*;O :>/;WA<KJ;.D\$A><+G4T
M/MKYTGD%MT^8#)YVF@6O]C@X3+'F<1K3"/LPPD)M/A .(4U1" /BBP '6'JA
ME3.85>]3HPR+''A.\MZ=&!,S@V(PI <FFZZL=ZVGUFLDO>O&;82<=R<$F$+*
MNVYL##/>G6GD8G^+]LA^AHGO,2XD%")2.QL?4TA$ZD./,9]Y292D ;?9V1QV
M,;6-37.XS=K;H=Z)YXY@:7TWWP.A\6[A%;$TX@UR\;ZG^D!7[*M>7NLR?4_+
MCFOS_2=[Q)-=(YS<D85JI?76DXQB7WH,RD"[KOLAAY0&4ADOC%&?RQ!YS#@X
M;+_UJ5DC_Z3D XV %B$_!YAUS^&+D1AX^FZ!<#X)DP$:%M%,EZ R4FB2%3IV
M\46GM.\,%CIX:;S(GU/R[H3QG'RH[^6.>"89;ZLL7.>\+L/0I!Q9FR,\%LB7
M$J*0<HAHRB")U :+RXC*(&$,)5:.G@9]3HW(6I'7:7*W(OM71@NIY;>]WSF/
MOND%CU-,![_A:>!LQ:W1; JT-!(/8.98 .3VCN=\MR-?\ACC<'C+8_YJSX,?
M]BCX<BYNY?NR+,JWA6J4U7<<JK>Z7E>S$=O<CF\5GKK7 2TSJL8AQHQ DGHQ
M5&2I@^_]!%(_"-1_G'")K4Z#+A9I:ERVTD@?3-0Z@2VEZJFX4QEMHQC8J2)7
MZV9HR#@<7\.3I5%';>CCIE$&S/X4RAG&3H^F+I=JW/,J9R@>'&*Y:_EB5]$O
M8MX4 ;TG/_Z6+1ZU(WJ6/^CP0YUZ[0VI!-?5==3"TFYK$B^1?IK 1#6MPUM2
M2!!)U(:9IB1)"0K4-GF[$*J--Z*M-$9<<+;\J^,"4YM:-G7QTU)PL'Q6OQ,_
M1,FRJF:+JOY[\;QA"IU,3!]7JS\J>19EQG0,<?.<5!PBGI[GQ8L08$%^@(+.
MLX<^/@:7C+P9P0\]FB,QNQ80ZKK?7)=]J'GZNBQU+)_^_@JLR@/48Z/T UL*
M@MOU\ SB-=H7UX&<1*W%>2V?T+ZX=;B ]FZRYZ% \U&L5/M?Q"HIYJUL2*?F
MG%G ?)G$G,%4YP)$,?$@IEX"&2(A2R*?4!3,#BJ"G]_&GNVY!Q>?*GSNMK#P
M2MI5Z<2>]ZP&V!N>"+B!<J0#@5;8FN<VXAI#:7\<8(R.T]. \[V.>QA@C,+!
M68#YFSV-Q_I881UBBS%'6#()J0Q3'=^<0.PG&,91$/) ,L82J^*LN\U/;8M^
M_?7K^_NOEC;7+F"&9E1O& 8FA$:P02*-C^OLU&K9[6%<0^2H=@>VQ?&GW+MK
MG=K>H91A/Y#0$XF$*$$A)%Q0G<HKX2SD(B8N"I=VB#"U*;\=YK"SNZMW94W<
M/?F3E+P"#VJ#H'=M2[WMVXHOR7*=V4WG\WI635MNV7H,HN%1W*!#,\8&K6I=
MO=;.76>W;4WF+;4V2I$MEJ7#=%O]T1S+_VL*N['^*-EX@CG=>VT<:K\^BOE<
MMTCREQE)HS 040())@0B+XG5=ZF B#%?$,9]+(SN7H\W/S42;+VX:Q%!*Z.M
ME_L.?-T4=3DH ]./%1X]7-F/J7VQ"_M.HR.[KA]3Z-!E_>A3/;*?%-]%N3:X
M8R8Y0S2 E!(.44PIQ%CJ@NS$BP*1")P$QBE/MEN>VB2MA3.QS,\ =GYN]H9A
MX&EIC(!=YI)CVEZ2KF2GO?%RE!Q38R<QR=$'[*??N]9![5Z].A-8R#!)U>Q#
MS-?G QP2$D3J"T]IY"?4,\NYO]_PU";?2C:@A3.?>3M8G9]X?1$8>-Z9*6\U
MZ8YI>L&<VVENM"EW3(GM&7?T[_WV^E^$KDPF^'M2YLH:KJZ9:GI9WTZ\$S)C
MV6(FO2BDGK)1)?*Q6@AU<NXH9C#AGI0L\B,1A39[^_-=3FV2KB0&HA79;BMN
M@+'9UMLM<@-/[C5H*VG!SUOR@E9@A_'<YNBXW#H;]#KJ5MD<A?VML<6;#LK5
M-R<QU^P?RZP4?(:Q%S$<I3HZBD%$/ EQ'%'(9,I\&B=![,L>]X\=7?[7NW@$
M/V<YJ&HE3D\;:^2]B,<LP00F02@ABE*UQ6&1!W&$8F6%^8GTK<)M+X5\1%Y?
MB=KXRURUV +2BCL,WJ%/TU"@"/H!TY]TWU=XJR\IIK&R0#B-/6F7X]<1XN.D
M]?V\U%$.M3-3@W:Y_L /!+C9VNH(Q($7U?4G]FOSB6T$O0(K4=VMI@9XN%Q&
MN[H;=?TTT'M_X31YI4>HX2?VOT15%?G;HGPNFM1 ;<08C>+ CWT!:8ABM6(2
M'Y* "^C[0NI,FTG(C<HK='<S-;9>"0JV)+6(NSL-9S=!N -I8&XXAD^? ,73
M0%E$*CH!;*20Q7[ V<4NGL6C,XCQ]-OC13.>U6 GK/'\TSVS*RA+?/Z)+#3A
MZ,KJ1:[=GT7.,E&M"ZG/0D:E3",?>C+U(>(LA"EC7/T829Z$2# B+.LHF/0[
M/6NK%ANT<EOF7C!"VLRX<H[>P%2Z UOM9[\C,OA="PUJJ5V63+!!R6DR!Z..
MQ\WO8(/%0<H'JY?[$=%G\><U8\6R;OJN+'+U+:O=1:K;\NVC]AVYR;>?R%3W
MSW/Q,<O%S4(\5;,@D(PG-(0\8BE$GI_H&NP1C+'$H4RP3WUDL_&^6**I&7Q*
M(;"1%^RJI.NT-TH!M6G<>:S5"_RN-0.U:I9QC9</KADOCCID W/F**-ES:G.
M$';)MY<+-2H7.\-PGZ?=-6Q?KO 3^8^B?+NL%L637B5^9-4L#9(48Y3H<A58
M68V)VE8+YD&?QU&H=MFI$$8>'\>;GQJ[KH0#OVOI+&H5'D&NF^TNQV-@ZC*%
MPJI0X6F-+ZU7>*3ET<H6GM9JNWIAQU,]#L+J M:U7^:G3'VW*/)5J4S$XHBF
M"B"6^@2B* D@9K$/>2+3)"8B1I'Y0=C);J8V<VM!6W?EIY6H]=UTQP&P#:P&
M!V).P!IX6C<XU4*"M91]3L1.(V5Q(N8$L9%.Q(XBY^@D["P.G2=AI]\>[R3L
MK 8[)V'GG^X9I5-?--PN%]6"Y#IZ>!;X- ZQ2&&$O4B7YL,ZJ7H*4R].0R2"
MD(=L]ES[NW]=D')AMJT\Z,?F\[K?VW ?V3?B(<NUWP)X0^9UX$WOR\1#9$F@
M^H\$AE&4<(A"M5^G(O;4YU-@3H,D27C:(OL^-\Q?X0#755_#H?J^EFP(2,TV
MR!>!-/3RTMZ];DGG,"[HE.).PWX..ADWJN>4C@=!.R<?[)TD48JR%$T1U3KV
M9R8Y#[E(0@4391!)A5;J^TA?'D@B<,)8:EGRZJ"/J=F1:Q%7W@3_]Z^>#YY)
M";YK<?\'"+TKSZO_OW:-62X>BS+[3\'_1UT42[U;9T[<# V (.\R%HP'Q(P@
M+H1Y8(HX0+@-.&P"T)PF0SR%@N/DAP?=C)WL\)2>1Y(;GGRT'VM\^[IR]+C.
M^5]UT$/^M,GB&[,@XK'D,.1J%XH(]6":D "*T//C)$Q%P*PBH#M[FQJ3?/OU
MZZ_@82UDS0G;/^J[EY?^Z:>ZD2>2((H"#A.!E'%&"(-I*)5Q)DB*I"^$3ZG=
M9:\S[,>YY'U5])D7QXRA&/I<?=J1% 1B*I5][)%8>#%-$4:S7!AN-BY'?NVQ
M._2&XU51-UL<G7V.!UXFOWT%:\=&#>-&5(=N.%:@N%PUNSL<=?TTTGU_)35[
MJ7^\W_]>DE(M4O.7+^*Y*!<S/_19$ <IU&XZZ@N.E"7./"AY(!/FT81'PC;T
M;Z^/J:V?ZT"XM9R@$=0^(G ?S6ZF<(31P/Q@#T^OF,$3 #@(']QO>?1(PA.J
M'0LJ//5H/Z-Y*X'8'2EORZ\Z(6V3;N-.--D.9Y&((QPS :,$Z]RP$84T\BB4
M"='AA;&RJ*VVW@9]3HT ML-\KC9;\/K C1?S.2DK\"S*9AMN>?9F,@1F]H1C
M8 =FC5U,E<#:":41N=F'ZP3;302%.^O" B*7-H9)MZ-:&A8X[-L;-J_V(Z5/
MI/Q#+'1&[*^"+<NZ-M0L8!XCH4*7!I[.2*CS?7B>A''L^3A)(H:1L"G2=JP3
M*]H9K4S;TUI24*U%M>.8HXB:D<JE. W,(AOQP-?SX%CS19?V+@GB:#^C,D*7
MIOL4T/ELSXKSNK:)SA%4BD>15]EWL:EQ_5DL;N4]^7&G[!VU4[]>+,J,+NO^
M[PO%0<HJ6F>YX5+Z:1@RR!.4ZD3),:04^= /0S\.$\^CD977KB.YIF;0--5_
MV+9>.I]A7<=]KNNX7X%<+'08Z(+\^(MEQ7M'0VG&3Z\P0 -36C,V.RJ!FW9L
M/C9C\[D9&Z6:+KU=*P>VM=.UAQO]!DGIZAASET3J2K11N=<QGOMT[;KY"QA^
MJ]KG9X5-6W.-2H&8/I5&02HA\@6')) $,DHDCV*?RLAJAWFZJVGR<+Z6KW\M
MW@YX+8CT8M!&X<:="KT;.1T37"<6SCGK>&_CTU"GUD>9I?N-?F3QKKT=;HA*
M\5.305NQU<PG <<"8<@B71XS#C#$W!.0>#Q.)4K"6!I5]#W?U=3(8B5I72RH
M3_W+#E3-.,(-5D,?1Z]@:HTF7<=G5>=22>J.)<ZCX9(E.GH;E27.:[W/$@9O
MN#LH6M5QI6$<B41$,.$80>3Q!!*=]SY*/!1Q&BM3PVHCV-'7U'CBTS '1G85
M<AWA]1K'1P.4PS5 8^CCI%<I?VN@M\GATF7E;FL__X\W;^ZO_WZK2.>N+/B2
M+6K'_]9?0^*02"_A, H0@RA,"4S#1,(@UC5L$^9[9LFDS_8T-:KXF-$%>2DL
M@FTZ<>RF!J?H#$P,K9CU24LK**@E[1.@U(F918R2*^Q&"E.Z $.[F"437#K#
MECH;&"]RR42/G> EHQ?ZV58W^7?U"2G*E[\5Y1\WN6J?B?:XZ(NH1/E=5#,_
M8;J"D ]Y?2<7J:T80;%B41;Y@E/,,+.J$F;0Y]0(5$L*LQP^-[+:65DF&)M9
M6XZ1&YA<U])> 2VOSCG12KP^VEY)[<X$LX#(I2EFTNVH)ID%#ONFF<VK%]>P
MOB^N.<_T"D7F=R13N\>WY#E;D'GM8D#WZP!]T46[JFRAK,;R>\9$4SCHBV#%
M0UZWTL8188J"A'LP0DD,$:L/C@($8\^+$A8CC#RCP@5C"3PUOJO]/MK@=K:E
M#6!*R0?;;>;@PVW&GE,:Q(&I]_KNYJU!1;6;?*L0]MNB6H MG08I?STH\ /5
MR!Y&YM<JI#WH"'14VQZVWPNM7WTV'B1JG0C#&'JQSN<KX@2FGDBA"$.2L-2+
MI8=[F;D3O&-8R69]8KB+F.0B#5$$/1X'$/EI BE-8TB%A[D?>-*CD8VS7F_$
M1G/2<X.;I;$_K7N7+:O>Z37+,74'L=!'OTHYIME)F_ORZY(O0C6U%!^4'#KG
MIO;I^%NV>%PE@GK_@\V7.D9<7\^H__@]^3%+9!Q)X<4P0+&GMOCJ"Y5Q"GW,
M29"PD%!JM<7O(</4*+)5P;K*D#WX9G0P,*0#LT8K/="S ZSD!W\J!<!*@RNP
MU@&LE-"WNBYK$_6&T&VQ(GLQ1JY>U!NGPW)&_9OJ1W\?2%;6MN&G.ERRWNE\
M*)4UJ2.!WQ5/),MG$<<!\:B$/(V\NCPZ)"((H"2!I&$8IEP:9:RSZ'-J]+8E
M*5B+"GYOA+5,U&L"N1G).09RZ&OE?AA:\Y8%*BYYRJ3;47G) H=]'K)Y]0+'
MUVTS;NMT/^0T]$D<P<#'.CV#AV&*40AEF& 2Q'&4D-3:\_5X7U/CF;6;%BLJ
M6T>V+DC-^,014 /S2./NNKNQ&N9VQ  /YRZO)[H;W^>U6^^C3J]G7NGAH/+^
M92[(<1<!WX\"(CQ=>R"@VCTE@6G,$,1!$$O$(RQ\\SRZI_N9&D.\__O']]<6
M;A8="':3@D-<!B:$&A(W3BD=:%FXI+A!;22'E-5>DR]+O9=4\Q@TF3J!FJ/9
M=[46U;M0 JIGP3*9J5\\MS#/=?6#GVOX?[D"1*K/OWI)_TFW1)Z?YQFKW0C5
M"]^S2B<4JN].>%;5^?&K*U"*Q;+,ZV\H66@WP^;.C!+VA_I!/=G$WNC;-"GT
MW^O<??424-49?TO1%.=M.U9]_.K(@^;\,';ZSW2\/I[WS'D==GQG#![OP>)-
M@S);W.1J6YN+>ICJC6WQI+:U+"/S[#]WB@6F0<@"WX/45_M,%,8>5!M0 B7E
M*2/*"&38*/:I5^]38_POXD'DHBSR?ZKJ^-/G6AGM'\+6ZC1G0VQ?(6T6->RH
MLUUF7-33^UN>+>KTCGK"69"C]3 :+#!##L[ RTZ[X.BQN-%U^-9C\;?ZG.Y@
M+'HL1]:(6RQ20R(_TM+E? 3LUH>^"':N&M:-CK>6]-5W9X7IW4C?7$Y*+WV2
M6M^29]4?=ZH/_<E\$/XL8CB.O)! /Z(>1'[BPU3&,8R"D# <(!$AJ_RG79U-
M;579D1642M@K;?>UXMIF:^H V>SHP15T W/^+FI?:M3NSJ/6(R73>3C<YF+J
MZ&_D)$SG-3_,OF3PCGVRQ_?Y(EN\?,CFHBD /_-8G) DPI![J3)+DT! [.,8
MHHCY0:K(Q ^H:9;'_<:GQ@^-?$ +"!H)S?,Z'@#7S0&7PC'T\8(Y$E8I'$^I
M?$'NQH,F1TO:>$J9[6R-)Y_IM[2_)Z6NG5*M$JR]R^9+M:_YN*YGZ?$PYLS#
MT,.ZTE:0QI#0R(,\2:447NAQ8G5O>:[#R4WA5MY-SL KT,I\!>@+:),-OIT3
M'6-PDZ_<">[_+)I?@D]B\5CP"XJ2GATC,^O )?)#L\6HH%L;%J9(NC0NSO8Y
MJH%ABL"^D6'\GGU=SZ_B0>^6_RJ*AY(\/V:,S%L_ (;3F/F^#UFDO6QY'$'J
M,PICS%."HH@GU+B\Y\E>IL9;VQ):^EATH]E--LXP&IAA[."QJO]Y5OU+RX">
M[F"T:J!G==PN"GK^X9Z%\/39JVYYLQ(*'$@_"21D6)<$B6,!4Q)&T/<C2I-8
M,I^%-M;*81=3F^=K"2\P,(X :6927 ;/P%/<$AG[2FTGE7=:JNVPEW%KM9W4
M\J!8V^DG>\YO]BCX<BYNY;7:]'!M*F3?MW)W-)Z<@C>>GD_/R^:H_%;N6QGW
MXL?BC5+JCQGV>)2$1$#"<0A1ZGN0A#2%/" >\\.(LL#**\J]B%/CEVV]3!(A
MCS62A@3UJN,S-,&URND+RA/#!%8*KKS@URK6MYH'VRSP^WWM:Z#5!;6^+@ES
ML,%P2KCNI1R7L =#^8#PA^NIAW]$[3S7WN &(4DC&@K(8WW&+!77IX$OH%!6
M8)3B. QX9%89;K]IF^D_3A&X+R)[HDNU$-2FCIK5C5^/^*'C6JU<$[81[*;7
M2U 9F!0;Q]8>;@+;VEMX /1$8:3+?4,T[*[LCZC<>1N__?QX%^U'I-RY0S_V
M]QZT4Z>M:,JZOEOYV:EO:S_ )H"\C@%X__0\+UZ$>"-R(;/%G1JE61+Y#..4
MPSBB B),*21(2NC'<2*BA%/L&QFC%\HQ-8M3*Z&+CO^VX[>HB&V[KD_M HD\
M_^<_?@%?R??&BE'-6$SX"T;.@!W'&8_!M] :ZD:+W[;4 (T>H%%D7=UXI0QH
MM1EQ1"P8>YR1&8G@!QTANV7A<EP[5Y$+FA]OT;D<@YTURD%S?;.4-%EZWHGF
MWYO\(-6RJ&:2>))PF< HY1(BY E(?8PA%ISX28"Q\/$L%P_:M?S>)HN)0>=&
M<W%=$WA/A.'FXW8F=?N$'2:@FQU\N,-PK!0?;5JHGU<2_Z*=LX]D7'>;N<\"
M);>904PZ'CEEB 46A[E$;%[NZ86J+_9O9<V)[5TD$I12*2+HZ7)<*/1CB&G
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M@LS-;B+,N[:BX;4 PTT'[5C#E.CZ)*&6'="7K1R-9"VXW;V$Q5B874T,@_#
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MKAU\]^[H$L%1%*<QQ '6W@0)@10C#--$AD(B$@O"^_H5F(DP-5(ZN+1F^VK
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M9,F74J>N*=4Z;.5#VP&X :V[@G'P0ZTM,<&M;#.2K"1U!9B5D[$;X$8BY[X
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M:\'TCOQ8%/OP[P?+\B9N_UC$SMT&1+\OM8MBI^#\[,$5QGF]KYSYB3 %A35
M 2H) H)!"')$*\IR1@N*T[@KC@<?F[GJ<>*6NTJXIJOICM\G)N=:G\9UD+^]
M?V-8M%,Y/JY#_=_)"7)B?O[='2+G)R_>.7+BG2-QE)S7UM]ITO&./JKK'X2M
MYX@Q;' %L+*6!U*% ARB'"@!#=*(<\F]]J^8P<>V?QW79,\.ZK:G+)8?5WZM
M)WA[WJL\RM_W6X\M K;ARMF_:76V"&3""M0G22S8IMZW(>^DI#D4I>6M0B"
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M5.TRU:8@BG$-$*P00"6RQH:&.8!*5H4TFG+I%0GA-=K8+(RV0NM6R"BW=#?
M?HL^&6P],T P8N$5\WV02%HXOW/ 8>OG^^A^5$;?ZZ$X[KA;/>J%>^-"/UHN
MFOS4V_[Q[_GR\;?I_(__H]6#_AN?S-P_WAJ[;K]I.>7+Y<1,9.T\M%SV@_]Y
MGY>F* J& &.L D@9::T((8 P"-M#36ER[=6$N@_AQL9,+EJ.3R?_JU7V8*7/
M?IE:^7]U[4KK/A7&JI8].MT";9*D$^I';6\U33TS8:U6MJ=7UBB6_>*T^/4F
M<]IE3KVLUN\F^UL]E>UON5,S.]2SMJZLIND(M0_\4_)O4OD&I>L^D#UD]U[&
M"(\Q:L^6K[ 0/R:KJ;X7@FM3E@)(S Q 4C+ C2Q!52(AE,O-))5OG-'AR\=&
MQK50[M8!%K^(7]?^$\\@RI/H=3/GM9CTS'RA< 1%(9W3^XI(I*-7#A:-=$Z9
MW8BDLY^);9=H>6$^<VX+/9.O7UUWG]G#^RF?/"V_O-39'J5$AN#< %)  A"#
M C!4:4"X*'):\IS2H"8EEX<<VX)N1<QD+6-HW\2+ /O916EAZWG-.V&S'6EO
MLC6&C< W62-RRM:*OO"D;;-X<=2!6R[ZHG#<?M'[R3BF^;9)YZF+F[:I9$Q#
M+8N26VN@8@!1A0"7C(!<"VG/=U0H&N1/.CG*V/AD*V2V=%*&,<II(/U(Y&IX
M>N:-'62:$KCIJD-[09"2&TX/-"@==.IZR #='XZMW]*V>OYM,ILL'[6J(S^^
MZ%63\[#XZ6Z+!(6*YAI0901 G!: 5AJ!'%<5QYIQPH(HP&/,L1'"6M(FFBNT
M*LMEB/W((3%P/5/%3D/X#7RUP-:VT'70UUKHE/56O!%*6V/E\K #UU7QQN&X
MEHK_H_%%*#_-+)?5.7M?[%=HTP.>HTHB 3 M+-%@J !GN !&V?^E6E"$O/H[
M71IH;.Q21W%L!;7KPWXXL@W\67#]*"8%9#WS2B1:484ANZ!(703RY%B#%WSL
MTOA4<<?.SX?QPW*QNO_=DL[3RU-K,Z.B*C54"A24:'OXT 2XOO! 060DEE 7
ME?0AA*,WCXT!6N'\EOHQ3MUK^RKM>U[,K5P)CQ%GM>U8K_:9G;5J_W:X3H]?
M.LC"/*O+>B6>_T!D;(FT&_[+5-^9]5W$]Y?GYVE]'<VG.T60#DM%"U,(B3&H
M*'<AKO8GD5,,2*E%64F[IT,4%'42)\?8EO7WEZ<GOGAUMNZ7^0S4]X=-+1OG
M:7,W@];(XC/I_G;K6EE'5)*.G3(_>V" B>B98=8:N$G87.#>9+MJ[!==Z['6
M])5H)HV2B11EV/B9Z_ ZBJRY\G41=8WJ=@]WYNMB;B8KY\+5R[HX9=M3JBY/
M.7]ZT@LY<>$A]>5NNZD7ND"$E @H9BJ C'*<BHB[EI4YHY((4WK7-(J78VR<
MNNFD]I=EMG1:N87]7.MULF&7/%3+?9[/5A,Q5]YD>^U<=I/M@#/4-]G6$W)G
MLD:-)C9&+W^UNUZVU:7NVI4=:1-3_.Z*.0FH9#3,W Q4Q:CG.0JK870]LIWU
MBZYX_7"UBZ['8*]N48+7Q::9+)Y=>KE^-W>9H^ODE7:Y8:D0M>=XP"M2 %1"
M#82[5T382(&,J9@)BE+H'&ULF]9&V$Q8:8/S3KIPI4I1:D0%<%E1@*H2 D:1
MB]XR1>X*'Y!"A!8W2(3L4/4->L.VX+E6*B\!PZZ8=V$(8$(50%?*,,PA)06_
MG^G54+AN"ABL_GTQ]3MW)OL.]FSP;(%R@NZD8O9P,>Z%2=KTJJX!!\ZU\M#]
M./'*YZ&PS:ZNB;IXO?_[]WLJM(:FL@>T I8 Z9( 07@):%4207*&!/?R3F]?
M.;9MZ^]?/OWX^"'[_N/VQ\?O?B2P@T_W2H_3NN?E[*>P]\H]UK$C[+7]<+,\
MV[\<KLR=%PZR_(X56*^Q$[^YUN6\C6]Q[IG;6?V'2X+ZR:<N_VGKNZQ,CB@C
M!BB*7%',"KIRSQR4Q!H\1C!%N9=KY H9QK94UX*[CN,NK:AV=3H/<_W#C@:Q
MWF7_V0GU+/>"><]$X0WW0/[D8 S[\27[B_%&?N1@G,[[D,-?%1N76[<"V[:^
M,46EF4(5T$0A@(BB@!E>Q_L390I>(*K#3GR'0XSOD+>6,+!"S!%VS$BJ-$2@
MJG(#$,P+0 EE@&##+9I<53BH%L\UR VS+33R13=A.D+0C]VOP:5WZO:')")X
M^;3>:>.6#\88.&3YM(;'T<IG/I>NZ=K6Y)"0:EHR"(BIC.O_X9R+%%L$<4E%
M;BINQ+5=UT9K^NUT#_M=<R?K4[BAUXVOWZ)/AEK/#'"NW5HO-IH7*'UW7'LC
MN\M+=Y^>:ZELJ2]ZY:RTKXOYSXG2ZMWKWY=:?9K=K2M#;8-P-OM=+F&.I(1
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M)$ZTIO!_-M:R^&A?^F -EK\MYG_88:PIPV>O]XQ5N"H* HR!!"!>$4"9= 5
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MK9#9LY,RW'MQ#*3"S%1,8XMA[KP_I )4(>3.A+G,4:41(:%52*^$<IBRHWV
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M=WZ\H3/@+FI^(O/M\C.1&6_S1=U;=O4;GRSJ"F.;'[:#M6Y#C46A*H$ 1UH
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M9ZWHO32[#4<L<;TYW]&'KCX7B,J)6G2A;[@BRGBGP/C[=L\VDL!"D )0"G.
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MWP[7>_< @ZQY+QW7Z][OPQ$>ZL\3L>*O\P_NP#Q_WLL6( 9318$DN3W58DX
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M<E 9S #"0@)>8 BP9@J5I*P*&!07Z3'FV$YA'MTKXZ(F??#WX\O$J/;,BBD
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MQ70YOWP^RSARJ'S&XH"+0NQ@,1!=D<"]*F@]#ZE39_814K:"CGU2T.E.](-
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M :^%I@9IL%_C)5ANT <),M3! 8X'\"4XX-D@N;HJ&'L4FWTH]WY' 5I'^AC
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M<?YYG'!U>")QG)!+,*7.&L5"#HD0IE9Y:"WKY#:S30D,??XU>X3^==L6>8B
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M#N]97MD*2$TU?WLO.T@)>^/HT^K@I14S7W9T\-T6T$A(C)8E"5$;LDW)38;
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M>_..# ]JV[8\6X]:@6&2U^H23AX]K01O)2/S4Q<?VXP&'\*V_8@;>3I_OLK
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M%J>@YA 5%KR)H5$V_O$.S1'//J"O,[Q6#=SJO424GFABB#S9J+)OXD@\1M3
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M?!\VNKT7?R@IX^N5J2F(TED&O%3?.-?$CV0T1.]ET<$'T69&\Y;T';YA?=7
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M1F#[:O7ND=NYB/M&SE7_HN>UH&@3=3FI ;AS<E+KN//->OO*ZX9'6F9"% R
M9)W2@9 4>-2&Y"A%R4YCU'$K&.U)0._MQ+K U#&$/XQVIC>[=D99^_62M2M#
M'2;+ZP*)+(,6(0?D7 K5=2?3W=O>]M,U9A\;JQ,Y#P,G][3N-.3BNE2[A(=(
M[DTA=XE65X;@HU"V!$UL=0R6P;>]W4FQ6[6]W47*?9]9J[K79V&!^;<QO5K.
MIE?EKSP$6;+TH%*=/QZU!&^1 TNH2P[TF[C=J?3@(WH'PJ&ZFW4NR &X5M]M
M@523(XM5O%Y0UL1)S\ Q.C$#:BTQ662Q2;5>)_W+FJ5#-_/V.]5'W]O-MP3<
MT_)A3E;9REE]-IM/\=GE-8=@>O8VD#\ZXD)+J6D1ZAS)_ ]HP0M:F,GK@CHR
MR^5V$<L='SS(^XL]53X[DOP'C:UUK'C$0G0^U9)6JVNEF[5U;JDA$?*</;,V
M*'TXGM8/&V3TL36&]I#S ,Z\?3KSE22**4* 2ZM^Q)*3XQC)<>2)\Z)3YJY)
M8E^KGHK']M$.0^*Q--?WIO::^)LL9F7Y!TX^XSFQ^'&Q&L^\_./C.*U?GU\9
MG)_"Y2JQYX_9Q83VZSDF''_&/-*)]FPF%.1<79PH+02;/>B@BC6H= [;]2#O
M@II!FFD=;(M'UU3?T*1S8#S+O\SF)R1S_$R+;#.J>GZ&2_KQ5S_H[9K9=V1>
MT)O(1ZIW"UAX+LZ!URF"LHY<+$NODD,1I8A"L^T*; ^AHM_FV4U/Z.-HIF\(
M_A:^C,\OZF76Q71Y6M9=PV\QMWA5/LR68;+ZY5H@^/X3IG$9I_6:':EBF"KU
MDH&MIH_X4"?:!-#DM^>2;.!ENZ$=W="S%2S-TX-E#]KJ&Z#O9I=ALKS\9C)_
MF#W#=YO=_G1ZJ^']Z<5R,<Y8[V['2\RKN8^T($.6)KH$K&@Z$U06$+Q($&3,
M4KG"E=AR>L3AQ&P%3?OTH'EL/?6-R^L^W!7OZP7XX6-8/@_39_2+LL":4RLT
M2C*68U$D4HNZ1B\+%,,CQ^Q4$%M>3F[[R*TPYIX>QMK(O&\DO9XM%M7S(OL!
MI^GR.I,OPCE]7[S#Q:?9=#&.$R3;8Z04*\IR#[(.)Z5UD<$'+Z&N'A&5-Y&%
M[9R1'9^\%:[\T\-54PT\\2J?M:U! DBSLVE-CGHU_3I->59./^'Z[Q=_C)<?
MUUDIS0N ]B?IF+5!'0GNR&5#@>E$]F $R;2HTZ,,.*4C[9Z&.V.T1M:D=&80
M94,!I?<Y 0^J-A-P#'PB 81HR2H1Y+W=WE?_43:T.VIV*QO:024]YXP\/&.>
MH3>9V0C)()FUD@XG.I<D>.\ME\PHG[:9';15SLB#5 SR/FX/)<^ZEGC?L'EP
M&GU)07'#,@@>ZB _C."R,&"21R<S+TIO,S]C.]@\1$5_&28=:7?6M:@'<-GV
M9C;]_6JVG]>>C%&R/5TB^E6("IS.$M 5R[5"EGB3*3W7:.@1(]UH=-:->(>1
MM'@S-T\Y[E'2CEILU#4W+T&4/)!6D00DC6:X3:>IMLFM/140[7GL'"SG8>#D
MGM2]H*)40BFBFMQFQ>N02-I3 7GQQ0JCN-MF+_FADEMW4NQ6R:V[2'D A\V&
MD6]\K/S<JZGSJ:C$:O/\4&JK%<D@R&K]!RZLBD*RU*21W6-$]0Z@0W5^MQ"L
M&P7T'>A\_Y$D>%J(GS)>UI@;+EY-R:^<XJK-T\JSO%ULLF&3R9!XE!XTUI[8
MW+C:$SN %-86KE.P>KO\B_UIZ+UNK",0S(ZOD=Z!]V!F>5;*BZ@=8/"B]G7T
M$')0P#(KW&@T=\HYFJ3HMRP-:P&;3N39-RK>X?@\7M!'51>BYG2$Z44):7DQ
M'T_/:M^Z*^"_O_CT:3+^.DT]D8N9E,O =2U)B$%#,(;<3\$=LYQ;$N)VM\G[
M$=!O+F(;1!U#%X/"6_5%%DC$?"1)OJAI&;-/]><OOWRJUPE7_#'NC2(_A#R3
MR$%)9! %6M!D-$@>H\VWVX9N@[7M'MYOFN$1<-9 !_UC;'-;M=@<[5MQF#$I
M@\22*[1V%&H.,?@ZO\HR'JS!%+>;>[G7X_O-(6R%L]9ZZ!]I-U;2'3/Q'4["
M$O,M#GWFVFMCR$RL'*[#:8A@B7'AHRA,FGWVL^T>WV]:X%%VM 9ZZ!MIZ\OQ
M]4*:E=?CN R7L]___/[/J[&S:]_EBJ]H(ZT@*8D1SRM?Y)4XYB";R(RO>_?M
M.8B/]A/9ZJ']9O2ULO#;R+QO+-V3E''3W?W]TR^T:R^O<FFO"I"U(PF2=VNP
M3L[FJPD#F5A,,;%<I ]J.S-LO^?WF\_7!F%'T,0 @J<MFDJAU*:V5H&(BGR>
M8&CO=JR0R^W(&!7,8+F53_JTV\OUU/IDC]NAH6A] ,"_V9/(,-19TID0,#-0
MHI8*2E_ "1&Y9#GRL$V+G7^TESL $X^VE]M%07V?X3OT/F/.VYB$@5Q*O;T7
M&@)7 NA%;5,:2[#;%7X\S?9R.VEUS_9RNXAXR,AY=7Y^,9VMYI',SJZ8TV3
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MTRH$0YAHDABT)[V=JJ4A:%I72\>07 ?A@?MEOII?SE)=TNQ;_BW'JXO9>L;
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M4*+>V1:)66#236:]C;:"CI7S$.2]H)R/).$.[B2WY:A'$XLV(=/)0L:Z*BE
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M4^!MIJ\.([-KA34$1]O[!8\NK0Z,]_O5?<S$K%F\S&G+.N\U<PA<:L- )Z]
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M33OY^@CX&8//[<NJ;GY0/P1<YO_]O_X_4$L#!!0    (  H^95'><(4XW?L
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M?MC>3:^Q[UQ'5>=;[>0?_W-]4#L].#\ 7Z?NN.$ Z,7Y6NU6FU7G+S_73C_
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MXT3\JO[CX\!/QH$[^=4/Z7WTI8^@:RB<*%,#:326":#S#]6CPV/, :5P*NE
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MPLNHAOIF./1EH4+S7G!E N(^?_)Q _2CVC,\N'5S .=PL>\D0GQ/<&P6T$/
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MZK<H %&]4955>*'%'@__"LP(6-JO!QN"TUCMCA-IEL9PI#?[ZL;]1#/)7*]
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M%KO>I*+2[X1'+\M%[FP -\]@=J@PDW:&P 2VWDJ!?%/?$,D1]0PSF"B;B89
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M86'S"*B-$#Y0-&+%\&RQA2G35=-K\4T8@209:?H,],M5:P67MW,]<HBQUFQ
M"6AJ-T"9C+')Q*Y@]L,'!-*\R^\,4==R\+[$>18"9WZ6=F(]<%?<NRONW7IQ
M[]'KP+&]#5EFXX)@"B54Q6*-&PP9*,Q1*A<D""$);(JX\ZI/2WI7+,(T(BX*
MG$ \2.-.SK/(CZ[ K$DTR*/\,+P/#MX-[UC?Z^E/:'YF \R)H/&KT3JP:4@B
MC_"W,/6" I$@+"Q@3';=)9(^YF80IW*2;Q![ IC53&\%2R9S"Z!W%6H. V#R
M2\"'C.)Q1&$16J7<&6>*X)3]1,9D,(QCCCO.8]K-0(\3[@V^C_JI;,A-C>U,
M[1^WC=\4TK8$),_WSW/K2F(U0M&3I['M58\:CA[PLE$6*/MOS%W9H+6H*(M:
M75G'P .F-8'NOIDFG@*[:K$:\:/:"KAYR)HKP*@O:<B4BL_=ZGX!O?XC<V,@
M;: \MNV8*.6E&N B3*OSX+.$66+C(SOF]C<O5A1TBHG[+9WTGK]?%M?M0[5.
MYV"$6I?9T[YM@_@F>=>^?F9LZS/:UD.A;:*E/&,O)*:'CX _-R*#4GV-.B^I
M%I+IR(II:(<MU:1'MC/IAJK3PAB\ J>+QAAY4-.W!R!K,4"KYPC(K)L$*Z/^
M".[KUD;S$G1;6VMO1-F#;GNUIZCVD/Y9Z?6UI:GVM'I$SN-S!MHVCJE!1?$X
M[DI"3W@I6@+HW.'PAN1>(?#+[LRG( (4'BVX6*X")]3U>4S]KXH@<'YN25=%
MDB?'1+K;HLIZ:63I\5'UD,(S'1K @$B8D]S5%5[UHY!AVA'"WZ%M^U3B?PV7
M^%:3Q7M'._FSP#'=<">!0!W)*+_V4';,&E,3.F%?Y:9W:% )+G- GTI731+J
MQ ,(-8Q./9'3W&#K8-EKO?>.=^2YF'HTOJ$'SGZHTY\!CLU%!)T8@5I#!N15
M#BOF^+6M^.\HBT,L9'/:N3H(GP8@)8G=H(!!>S0&QQQDY0%)IMB"0@=2K6(U
M0YP;_]660*"PMN]8,J%>7)%^N(R%IGX:%+'%\M"?H&"+].OVJ/JD5.J5R%J.
M$I3!#T%E+;)9,"'0&9E%QX'A M%@\)HP-[-)..>Y[NA"]>'GU>,MFE!^J?Q1
M.HA/6+F-G%S@CO;5W_+>J!P.+Z-0C(PDPY+HH6JC6I=IF$ 4_GHF]%$QZM)
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M=R*E^85JXH0KA^J.(Q^CLK=F@,8,\574 &86D?@0AM:2(RBP.\.>!../QJK
MHT(HIVR26HD8.D0+/%).E6;+V$@)J> JQGZ^PRE<\E)I2#=:L-1WSV8&+IN_
MOJ"D?5] _"!%ZB1!_- BIQQSP$U=992L6E*XO.BDRAU1: '_CE,=IJ=%JH+.
M0#=!DG>&0VPE5W%\7] @.+L:SQJ3HJ>E8^XX0';,Y*1I@9D4,WE0#Q1"FW,4
MA7=R.K5MC=BSAJ8GV>0:42MJHBX/263;9L27KHJP]*NU_<YRIE+<GHJ0C#(
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M/ 8[EP#V1SBDE3UQ(#4RHS6-FU952PUC,//.C0>!FMP<$G70@ E-A;)GF$O
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MNF0]I_5R$A+U@27P5"0>C/[CEY1A9,FQJ3G-QDFUBB[G6&C3D"HYJ"LKJ3L
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M6-)_Z<=4 $;),Q1)FSX^M>U(\=![GU(F'S')_GC2D(<TKJ$[L()0,<7-1G.
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M_Y@IXI>+A%0DA(07/:VA2K4%7J  SU-DPH%7IG<H9Z!X99A$I8./BAR9)W.
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M>L[ZL'6I24()$U%^Z]0P:Z8DQ IFN7I9*EU&SRA>FKM8=#Q%7R$^XA23P'5
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MSK;<H!;- YRJ9UG.:4)J!60.1,@F^IT4XV6>4IC(F<8S4RFJ>OK/W P_I_S
MK1_\@-8;@,,#P$OD%>*B:JY/N5PXX&*R"T._%UG7Q!'E3N ."CF*$'-L!;[=
M*UGX804A[3TPWJ>P#QI:$4T0K;>:79X8#^4%L0HTM7I=>LW$:JH=FMP*&)
M*5_9 #ND@FC+AWQ)?0AAGM%#F5,#6+2@$H+ ]?$?Q229S_&_,(=?%-F(:=0<
M-,<]/_ K-\,\8:8/U^"P. #.W>T5DH* E>LK:49,("Q+. [)&VQRSY\<=W^
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MA/B4A0YM'D#2=(WVV@G+7-N'<9^,<G.<+V/V9&C?-=I."]ZJ LE$EY&.(;6
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MF'WSQ1(ARDUE:WZ0K>FT[R:B/.QCJNA&V%VE]\C\D?28'_4*'(JLS4MN#,.
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M,Z6_;$ 'L#<76.F#[>LF!R/KI2'V(2H<T#X^_R/?B!Z37T*0!52*BNF>PKU
M]F!N$)ID"QR(\2C+N; 44&:QC#&:YU"/4I)*ASG?.1_L:FM^N_NN=W2LXS+#
M5"\S_0H(H7?=T^?@9K>T83^Q14-Q*CTEY]!*=#-12EN\G4\WYS>=;7?MEX\<
MF4ZRQW1H!/"D%$OK;U@KC:TOV#E52;:X@(IGE$Q>9K1;<WJ_MT>FGO/K*K9&
MU9BLC59*?HA=<J7'8\G4Z.J>4C?;WQ=0QDAB 7<Q%_E02M'HDW'%XEXYF\)P
MU6,C0P*97>F! C15BLX;$6EBH1*])>@0M6[80U0L%%,UFZW%W6%)+<7\PR31
MCC1?"H\S8/(; <L\>H5)\05I=N&O3DO:1G=FT]K;EL-=O_;\+7MF.L^V[TX!
MWP23%B?"<D$5P')_'$,W0JKHN1 ,Y;U=0_?L^Z]JM,15C$L5.GX ^)8(0Z/-
MWI3/?G4?39<1DV[X]QKI2T,Z-AUQ9&+8GM#),0!!)'C&N\R@"Q*30D_L!.'-
M)>1@"EX5NDN,V\(C:!%]T9MTO=/H]59VFQ;V[V80_\!!I"AA^V:U72O(6QFE
MU<T23%%0/Y3!H/]'H#W=3[]]TI[NWKO3T_4915\I.-T2ZUW]@CM/BGE6(%K:
M8H+0:[Q6!8)_J2 QRJ-Y((YQL7T[6R)JQ+? T(^B6'ITZC?&1[='O5U/XSR;
ME5:3"R8'OFT=-<ZG68']Q^6%AFN9UG64,E&SONJ_ :"<D"&>J<4DB]DBQS+4
M<,+75-R?C25^>3ZM-<O/9!,'_^H&U^^OKM_?O+^X[=\.+B]N@O[%>?!'__JZ
M?W$[>'^SP5)ZJX;DAIMZ>J?=O1Y8+:..E#&(_X\HSV&-D<@",EP1VGZ](3IX
M)?Z*MKF*#=$=XA:C7#0DO*8!HSU% _M  VNZC:DV)JT,""T'3 -1:X[U18@.
M88%*696K4\X&2OQ _94%<::'*81?8\40.C7NDPQH5"A+AC>S8IJ@F0&B@WR[
M".G@'SEIQ8TF^J,)%"[1;XK8]=1K)U40R0 Y#$0\ALX&CVOR&S%7&UMJBVH7
MAX#%/#(,PHIE0SVQO""_(7?P BW<%>NPE1MX/_@(S3@T5J^\/5N=,VC8C%]'
M:HXX<7VNZIU73!]M@PA439(T!!* ><-^!0&H G<+;]7'4*Z$<F$080%"6"6X
MF0!YCN(>.<#=#4\2UKFCAQ#^"'69)0F%&MFSD-B-T-?,<,=3)QB#0#EZ\?-F
MC@":OI1TCR4I)T;@1PQS<KJ;'&6..>(X1VK%-0\ZCIW0]D9-IWJE<7L6)X]-
M.U7=MB0WA) ##0-L>M* 1Q&(H*91,J,1Y\$U(P^C.%,Y2*XMHJ&1,'(_'B<+
M)'(D0 _)6>@(-H<^+O#7WC $[<40'+YA"#:!(3A\PQ X7K]V^C\.^K\./@YN
M_R>X_!#<_OY>1UC7?T9W?Q_8.K5K#^X8K)&/"1O537H-M?F)>D*'+7D,@)%G
M])EXY4YZU<D:-K<&HT=!$0!%[B0CF6)#=C+3QVP$?4C6XP=AI+*FG7Q@_ULD
MWX0)47'43Q),H5.##@-!W&5P"0>!A_]&$28\XAONVG@G4M-[E#+R(B.VND@/
MF7CJ#ZDOWNW=(D%>*O^B^"#(K4Z%Z 7KA16%>TWC<6"/=K1HOMK#1*'#4E#_
M-3QH2,\8FH(]7S_*$V*=1-B*#F+N] )43,+G>&>*O$ANG1A%E/B!H&J\U+.+
M4FK@H:T9AAS\5#9D/SC'47V+-BAIS<$[[7R(N8?0I(@-D0+Q-1!8F[T&6$6H
M;4J:@.<8DE_,"47!0X!()@VUQ=$"9P(@+^03N_YA<3,FQG2!.] 9<9NU(5@@
M&D-^A]R/"_-SSEDJ;W=@&S,8N$[]3F'#J><%?7S8B?+D@!H ] TUZ/-E_E[4
M[";*/%QD"ZA>%2*G0Y5Q;: IN<'Q H_E(D^&2U:8)H6;29+'NQ1\&%N 3Q(Z
M5D"Y+!9Z!.%,C#$H0Y5%_*K$)FMSN[YHE[<UM0 ;_2!X#_-9<$#[8L_A95GD
M)@O0T!2P96 F1M(%49KJ,:/$UH,9L:F,&%*IJP6L7U#?&^HC'(YKY%I 7112
M*T=XO!$6J7:(#1\#C^YQAJD&L^W]/0H9NCO.)>(C82)/ F_'-S%YR+*#L^X.
M^+F<Y<.@S[WM&U_LIUMK8JDSMW328-J,F(DD=QM16!72OVH,@G\*.M0 B^R9
MH"8_N-RO5??:WJA!RNZ,-I#;0>WP4R%O%845!*:4^F  Z8W1!&*&U"(V0CJ&
MTWGT*!0>8[W_BV]J16S=J.V;47/\?^L<-+D$>DC7&8+CIB%P^\5Z2#NXK0$X
MZ&!#>S6O2M9X7:1 :VW,TT;UJ"DQ9<L8+W Q#G]T8'_]>AFDD%G ^),,*QN6
M,&#F,I<>?9RDVI* A;'>!D'2*:F!,!BIK%FZ+ ?)CC[UC!4)(Z@(GD7%A$@@
MQ,]&O:;=+WHW^7]'WQX[(F=$1X@!^J/!J-<0N^BC9\(!B]<H:7G3,H2,4/UB
MA*QK^,C$/8!!"258D)\%RI[8%Y,"E/\!<9G&"](CD10O!'G](.?[4YG00;=I
MZ_WV_N+]=?]C<'5]^<_!#2 C-@D^;H$=ZG7W&A/D']2ZF8W7[#9KD]7QZ.?8
ME:.MJ$,%BVI2@>.L0%N659T*QDIQS\DXP6"'T@-$<$:H.UOD1'*1:HR#!.Z(
M50:>$N# Y(?A7Y/M4:Q<-5;*4<!:P319PZ*#+6_J+EL016]F5#O JIG_!*/S
MRJF )_RW=NR4_::=0O[_G[PS\R)SPGRLXL.'SE(DYCJ(NI<IMK>#E$'*[*GZ
MZ'L 2GO@5GWD/84"I6YN'T[5T!S[R/)+6/^1WA=WPM_J)QS@22C0H(S].%I.
M%TYTAOLY06!"5/H917_X&HB8H!.<"P'%<LCYR^KE-YP-;\%6.&C:"O*EWQ5V
M[%4/D#=LP7?%%IR\80LV@2TXVI8P0#W,O54' 3@A$][^(D-E_LW5UD(Q_+T&
M# D>3@JI8Q5+=>->I8G47PR5JG9/L&<Z-G4,\S/N ,,S1/^&HL2,&Y#Q 68J
MDL9C^%4^S]7":=G?(,3R!TCY]B#E>Z. N7E+P(@M-6XT)A_0:;\GI@>N3)BL
M<,T:'JI1-J-B90*<0CHXSZ7L!USN&"E SA.)N +HK"_B9,3U.^QBFT[5'11&
MEZE*D?T7L\?Z@O=9$H?UE.PD=K=4A@>X0AL,&6X@J2BB)+9O0,G%*T&'XBNF
M&54O"V<9U/ERQ$+,3 3P6M1Z3^\BJ5X0WYU$Z1T+7>K12;.9#DJ&*E40%]40
MVV=N(6;=+?@3E5WT'CPBN=/@4_2_:FW&V-=+ +9J#^KH8APE4U!#A)K>+"D*
M3K9)B8%#:\R\0=#.F)42IA[]>H.IKUEX9HG'\ =]MACWOO)5.)LH%P=7M;E&
MWA)(W,T\-0"WH70!@J%0P!)^S@3AZC'CP 7#^<S0$_+Z=WNEJM(381W/1\3,
M:[]ES&C1%Q8R'KM"AL-&6/Q%B-V ?2/TV'+@I]C^*K)VP\?2SR,C34QH)?Y"
MALH .4"1A)A=^F9)HS=G<FJZ!OP8 B^5C>EY@.J$_JM8Z)GD/TXS>3&E+SKY
M]S+ZPM^RW"GPKX<HI__(U5!-I\;:)2"MF=-NXR\DF2VS )X\*J1W8^Z91K1P
M=:O1TK'@5".1"LTCU;=YND&@;YE39KG(2%5<_XUQZ6CGT2^G$N1H!,_)R[>&
MWX4N/2/P.R@"XTW^E$[+L1#R9_ECT!_K*<J_<Z/6#Y"G<4FU>6T+[PZV&<0H
M*\A_+=,UC,&:6<+8^3('B1!9BA_TGB3B[GQY%_1CX%N 9"FK*ISW.]Q<S^T=
M6<J$WN9N1,*#=>(TF>GGT(L=-;OU*&GS1YN'K1*9($K20.-^Z"C85JCVNS;=
MB6H>M5T;(II#VE"HHP3]9"0;C-LO=]2X _U"<@M8<)CVO=?/C.EBO0BP5\:7
M)89XQJDS6?DIYSJ<-TM<KU/?F\=(&D_H]T/]FIFI6;%-Z@;ON=6_MG_F\K;O
MG')@493^._6AD.6K4*@+NS];IZ='>\-EDYIJ9:OVV*U?3N16?A)S=AT2)KTI
MW.E77Z$0#OZ"J[E.D3! 4V)P.&2;HC*VRG4TB]=VUP;3/:Q'9?M\H=7MX4VV
MUQ'OV_K>4?< O6WBG9&IC(2Y#W;OG5T$>I,#DG)9%-B39LHLJ(VN79A4NU:3
M9&XU"T96)F"2/6#^0CM>,^75EY"Y!@GGS0)"BZON$NFC=YX!+1/).H6VT$/;
M%R)6DC9/"UBJA7T2<*>I%@369-?4E.#FNT, BD*,2Q"I=>6!#YM0C:U:;?NM
M6FV8^]>3P7(7$$00!X.9>R;6PR,%#I<I\B]P/85<R.<8$3?N&$?%8A=0E5^H
MDU/(;PIO/<Z46A!MI</M15)=2<;$S.@RW&?:B\8^#Y2-P3M S !I:6E+@*,]
MFG..S[Q-;$_:TLUW"J7P5/[-M9HL3OA(<=%[;5YC#)RN9*S@2S= ?+Y$;8XX
MH8!'Y#W F2$_Z-<$I#B24;&N\D;C*F\5N&;GH)6KW->2@VE%PIG"T8CTC)MP
M/B)+23:B<-*(MJJ"'<8/K/'*E*O($U*P._>MT]JJE,G.88NG%4_)FB-REJ7)
M@HD48:8 AK5,6:4/I=2F.J10*7>,+[1-T <65P28YF@!50#X ANC;SZ3VN5<
M[AS]@/-*D^*Y*=H(!Y!_YB STL?,0@X5C"N L0"!UDCW(_3Z;F,+_>9;I[==
M\?G.<8NGUU4-_N\E)>OZVBO-\;2EL)&WIH,C0DP]1MW&I716!QIH)+D.+3:<
M#FY2"/^0J"E>]2R:2XYU1ZS]^YG**8_X6;M#?29@B02BJ8_["$N"?0JU018\
MTV-9=$(342,J"QFK\&^+#"G3J%OTI8F@'^2(.&GQ6I.3W\8S:$AJ\RJ8N!DA
MTM7)M3O6IB%9 1]QUF2C*=/6=K?UNGLGP744)QG9W"KQW ;*33]&3ZM#PDB9
MFS*M*#/[.[U!M\EBJH+>7G#VX1K&EBAI':E-[84"GWHQ405E56-8>;PB2Q$3
ML, HZ\3JR]OV@6-)N;Y/M?D#\:(LOXM2,7Q]8OSLG9X<_EE7]3L])GK"AM +
ML C.+_IO:+.-H\T.]M[09IM FQU_#[39BTCB#FN$?'^ _'S%M!.J1_^;BSY2
MA0(3NRP8=^:9$U=QMGPPF*2]J1M'BY*LRX,:0@"T;;IAFI)8OQI5Z?X3ZT3P
MK;_\UV2QF./S8;X:_^?AX>&PF\7=-)ETM0=/Y&K#:)L<M<'.A0CR# 3)C6?Q
M[RJ:ZKGXVU]/>[]<#'[7__?@%TP,HL*;(=ZE2N3 S'CIU @^95,U C3$BIS?
MRWH2UR@EM_)D/17AAMBA@\?A_$P[Y6,TA.6$17BLXFZ4(*6>6*E5YJ;<6FZ;
M"QSW$0(::BN2-D#D0B!XC-Z?\RR7FK>%P J1HU1I$I?N44_),(EC$F-@Q)'#
MB&2ZD=C 3>VT4?&]$%4A/0#:S0P>M)$L,L #&APA<9T0*R3T;RQ4:K/S[*)^
MOB$)[4]<;O DOBG<4%,1U0YYR>A8GT568%%=(H0H+/-"LYYM]<Z(H;S#LAC?
MRV(6G#KVG),!G =FO'%="Y;I]'JUE^$G*@ 3!=FMJ5HL2 ;#[9^_RH$"9X[&
M3<>N"\"M97DW@,3HW%+)^M"#H7/P\/5(EMS,.$*R,,V23!7TGZ:[Y3.L'N(Z
MFB)T#223&/'), 5'FQEQ9;!TN_JAK?AP  )E]0Z,/&W3Y]&BZ1-]ZZ:/'#Q<
M_1?X"%YU^AZ<'AU$AVTY?6?Y;-2-9BJ.NY%>@UW]/*P/%JNOW=%X]K>_'A_\
M OYVHH?RN/>++,[_"UDO1MQWH]$RS_ZO ];8YNEM=S2G%TFM(HKO827&;BT2
M7W6>W&> ,S1H($LA3R@ADI'BCT-!$2E8[]'(?(#82_TTN(7E;T8.$(V ["A2
M2]/_A353H%N+YUF22J::S+A< E3@"39J::$9H@K%#+BPMCWL<XH"M:G'2CX2
MK"X*&\)FA(H\ @ 7P6\ KW(.URLALO742KQOG\E+UG]7ZF!,B&TMHP-MPL-)
M"."LF@@H(YHA1/Q >3QQ,,9XHG'9S?C%._L]3)$ O+703L7>[GZOMZZ#]5-A
M%GM[3WE3O^/"OED.X4C:1E:N58B,Z_*!;ORDVJ"-K0(/'IY;U#H-SL$R723$
M)/&Y>]/US_75!_O?"SG%]3W,-QTK&_*TU7TF/]WY_?KJLL.6ACLCC$=2 \([
M/#)[)C@\[@9_/.WUK';X2H/S#!?)&783!A,H_*6.$HQ%N-HG AH@](XIRA-L
M-KI+K^ F;=1%@N]/,JIB":,1G1]YG?N$DU!UH1 D_JT9A9_1IYGHZ&BK;LS&
M5!B:$FRM/,MZC6?9TCW+^GJA0_L7R'XNAQ 5C]9E&OD3'&QZ8U<M7<%^*)GL
MR Y@80;P&8?;=L^V5SNYZH?A[1C3QUAHWP#I,G[D4RUX.]9>K_/U1SU:]MT3
M!=>I%^=^BM(EZ,^0;.&5Z5?:&?WVZ:JSR?3SCR'-Y8_/C<%CE0#48B:FD';A
MIB."0QE<"(E:C]T$BL%.<7(&4@.5=  R\Q>(W1P]!M/,3Z!@7Z23,/ [&D F
MOG 4AL5D+9Z]$EZ0E @&8TM&/%.NN.HT&2O/L-E$/("*"FJGL(@Y> 1)I<S<
MYPREQ8ZJ S& ];]$=VQ7T0!+<H@(-9P&5#+'E*NW^+DHOE=Y(8WZW&G'Z3%@
M6Y<>752V'SW*6\A==IQ+\8UP[%AB-+&LB7H([5M36GX2W2N$:0).[V"O$^AE
MH&#!!7'T6-B3"8<3WZ5\+S@3G%M1#JSANV_*1NW%@QR\X4$V@0<Y>5,V\KV#
M VC\MJW&:&QOH#4 :GAP-'"OSY^<HN\/9(65.D?H=A@25VTAW:EP\I@\/D0G
M4?%%8M""!G;(S5!PV-QQ _(B^YIX)W6.TZ(@(^!")F$N[!_.4->3$!GG20'*
M$T2IFTVY"*I$VV_G[/RL$P;GADG"07K 5SE9KO+[!&+!G?/??[_I2#C"Q5B\
MY!2\!_[A((6.1KR^_67_ZO?!C;X51L_^_?IW.8CK+>!(VOE\<][77R-'BL/-
M4+\Z*'6XHPG HK VK;N/7L?) 81C;M<PA5,C_3Y#9;VN$D#)7>5%6'*AS*5#
MX20!:N0ISPIOEA%T&T-Y;*&(K"A-@$KTH_Z&,';QC.,T\WK B0[-(JC[#+T[
M_3;3:"X?VR6B'_1!3;&#+W%BP6@HJ +O&=D["F4TLB%#)=BOJ=OKP1\<.H+W
M5H]EZH[BD<4QD59D$<WQ__[Y%(VT'3T,SI>+Q]T/H)'Q7F_ 39*.[^\[*!WF
MI-_M'0 #\+:Z(:)-=T/@%?\S 9:;T3/[(_1H]6!DSF%[)RTHW/<+,DJ"5N(,
M$7?-;E!3L)ZFX+1N+6U1X*#7P:'0-X'$199"-S7^H?<+D@^RTNM"S9!@9)I8
ML(Y+$%((AR$02RM+UX*\0_!'BI]'<H^7-RRU;/SV[?AI\YA!2[O*\P3S 0(L
M2[&/^V:ACZ["'UOX^&B//Z+X]!R.DX3 "V<Z,)L-DX@.J:NE/@*SX#H993_-
M\!V8X7NOSYB$<^"D).(.U%/;U7O)D_W:@\M_[_TM&O#$O/6Y*O03(F('Z0V
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MKT/J@S?V([IOY>"O!6!!.5,VZJ.K"!52[D+#U<5IC#/MI$\0-"F!(C4-+%N
M;=9<V(E?B/J\X;MB"BC<$:FB40M!W]C?N([.U<S0-M*(#2J(-_#L82QZ,B_4
M%*$OM7<KT)#"5_CF1P$.W15WTM,&3B(5QZ3R,?:S[:YMI??8ER_QA_L.095\
MC25<W]3YFM/J4@<%T?"H+/ &PN\*PZ .QH?55":]IOAD!W\I(PM?"V>C,]T
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MWN#WG]3?"N<:6TD7*S'=/"LIZ8H$GMB80LC/B8O+FW:+F6:"H%.+&F^&N*[
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M+L%U$-0>\#E'XEZF]6AJ1LS"RVBC%P+66QZ;6 5I!_$UU4;!VFYD^JLJ)HI
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M"L5(P9"V%A-^?:JE4>87L?(DK5 U<EIU: I!@F:H@+S+Z)('SJ&P=6!;P6)
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MM_7N;>MME5VCTN\P?B,(5X;GDA .F>5I&(>^L#8I-+?NS,20$EE]1&\3P5#
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M 2J%\,U/CJ^BM4W[!N.;]"%1D4PU(EII7!KP/B!5,O7NW7V+]@' .[Q$;SX
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M617JW@&QDF-1Q8#5/6GV!B5QBX"P.16)(';V0F5'_#,V ^">0/$8H(ZQRX*
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M[M=0:7WZQBJMTTY(!:BLJQ>KLFX8SY63S,U-A]]<7[<[T+NNQ\A^1"^>@Q"
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M4$Q(U)34S.XA8M<;GRPB,I5$'02 -S89 %QW,:!MUYN7]/9__./\I'34=0@
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M/8_S$0^R'+,G09),NYA>_<*;%&DD;X[^.&>GL$<2_>''V$-,=;),RPMO9M2
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M//GEY[V#5Z^/+D^.V-%8B:Y"X]D;*^\)#7;Z5:89*J,:&]B00&8=!8<W9-;
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MH_YVMGW4GZZYR>,O*I]ERSVPOBRP7:N#ZA+YLL#/LBSPB@C2P!,D75])IH$
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MPA/T!-S)L.0&2'4ZD3-\S311I#S%;"1',$+0E) $L8U??M[?>?5B^W]O6I6
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MI#4O:#ZV^+#Z(5G$9<\6W4\I;%^.T(SOF$$3IXP^'XVX5&FM.)ZT1:>$+ _
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M9J2T('J,M\6A2NW>L.M5[]=V_V#/[%>I<^%Z8%BV[AMI2/BWSWD#32\:%>M
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M:K*.'I$2[K[><_OZE17@:9JC/('*+2&BJ/TQIUD0(Q *SZ7E>;2YL !CKM^
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M<T0F*ZY2&.8<7<13$G@EQA9KN<XQH*A?,A$#<2JL!+XC_9$L$-_V/5U;8V5
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M'9O3*&N"C>(=S?.4[FA$>E(%H)^4W<!NZM_W5MJ@HT.HSV=3]RJMWC)3S('
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M0=L&$K^G!"R'A8WU9GA]!LM],A^Z)K15BL3UJ0[VV#,#/\1:JA$&>K/Z<C2
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M(-/8EZJW3J7(%MI6(=&+MOV2J7,2]!+(&DD*!'\/ND\2'!&)3J?&)9CD2;8
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MONGM/K(RRB^94E^L"=L8M@&L*N1_>78>%#ZV9N"J8T!LC!C<QV4#G62S(]4
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MBBMJW%OKZH'SU_N6$!\Q:O_\*%#[;VP#<G85#5"IU]+H_&A@_!_3R6528"<
M7%TX0(0!ZZ5<PE!=S,(S4F-$'?^\!-[I>'WJ)?3&29W!%\E!*29>LI1]]5;N
M97O*12 6']!CSA:=7[-YJD1$)X$Y\#HW@R]DG!)3\:;*;,);8$GJ3&H56FE/
M]F 4A(+C&7:26G0GFD0YA?U<$&D5IV;=@VP9I1NH";GJI1VYB,JJR)KXEP9U
MF7>#5P04$@!5\-Q^L16<:7<6:R15:0<< GD;+AOYMEK-\8<"(KE.:K__L9>9
MAC.]6@Y.^->B5C?3PUIB"Q W/[TB )8#60YQ.:Y:#HJ4[UUM72;7(QF!,.W'
M^.UI[FD]5;@.NUR#SU;B'<= &[8&9;T?OQL=1P3#!QDW!@7+H,!8PH#@-@/J
ML+O;O>MX]CZ7CX(!$_+-W;WJ"!K8G!H:*<;9SSCMSCN(O,)@*<6/2<<C:KZP
MIW08XC>Z*>=,ERE=429)/L'84*:(,'P9L0-FHSMU3AV-!:J,5*83.'\FEHH4
M-C+S,;;?/AS%CS=%(_39;#DHN=N[L$*)JGR[#[3%HDGP1)W.^';Z<T5#N4JO
M,C!&&2OW?4#U^<R3T-$*P(]MR97JN$VMBBOFA"59LG5<LSR5RG!T/W)!=-0M
M+@/#0EQB%PRB7BD'R7R.?3&:5/U>>HM0385<@E3A+&)FB4M\Q#X]>?B#*S<F
M-IKW&=?8X23E2#W\61YZ%03DL8'[5C_A^G5BY%E_$R,/ZBR(4V#<>:UZ-2],
M5]187PB#/T@D>B#HL(V6NJ*$2C 9<%5:2J4 '@Z*;;I*C1/3+Q9&],C"HF&_
M,((8%'8LQ_1^.3+(4[C*^3K6#$9P&%U.3%!RQ,6Y!C_?R>*[FY_E?#EI^(S/
MQM&8YY\-WARYK=K2KAMLU4U5",KF)?,-3;.#J;;?TTD)7GTNS>=]P^!P>BTT
MI&U#L91R4%*8YW<MLU9R"[)T'W;>QH4[J*6WP\CNSM;;8N6)X&?2,2NMIKKD
M2_&0'LLM.&K;;@\UO6%:3QKZ5C7T*FKE:^\Q+#F:KU/,O6S5F'O4@)L')]>,
MMDJD@,Q_?29OCE>V[11BV:JZA$3,/=8*WM:@3PX8=&@-YH)LCD.''>Y6LY&$
MV%!BN:>BV[AFFY6:],J+CJ5*,L,?87]AB"BG4[AKM73DZCJR2KOM,,0N[;;U
M.H;+D149TBEO?N?V34 A&YU<8'#?@0P.7]$G<,T;I/TPZ6S,(&.11%)-9;7Q
M$AB4E<8AE865HVV-6')^P6_3"N-#IZI6,G?;<Z+VBJM;2K*-S>BP94]/=\*!
M!_B^4K,5#^06)8_U(;OG9^>X$WHYW.+1$^U#"&%Y<Y*_X\AD'TN5[C]1:-Z
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MT:I2MQ-1)\X882('*JO!:X^N&)IH$UX1##%+;R3,SL@C-/OIA%:LL7Q81IS
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MG[59 FO=:>P@6H8JO.E<)/@=B._<U.08/^TZJ],^B9:0N\@JU1/%Q>DDZ7!
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MW;R$T+SE450,.G=0+::EGC53[42,=BSN84L'W]HY/54.;JP<#!;JT10.1FO
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MCL;6$=UO#.RKW1478G?A/I(83Q=97;7#F8:S*,KG8C!4%><9PWT_=.!(6F-
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M%J=5\R6+-^2ZWY1 7Z6JP!'^_CJ>,JL69X<QTH_"S''/&81>KTTXN6Y^?D9
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M!%E:/V_WDB%JYK&NEG2=6<7\9T"Y=Z:1VO%O!2$^XZ%F)*'02[@XKP/C>I6
MR /)WG=0 &@6M>3*&MDQZ$X<WY QM\7D,.B59A>L,!!'369X/FG2'"88,,,L
MO(PDM=;XMH,B$U(YR^^R ,U(510M?6OJWP5PF,8BW=NK&<W8Z^O5>>J3D\K=
M40MOID5(US997@F_30K:1!B $IG1ML3$,W1HMF5-=6KE_A>V\*:7HV*NGF@(
MMM=-8D,#T3B:EP;0*/>0,!#R/2'N&$_<A9(XE$C].+SJ,Z$'LMP_%O*,NBUV
MCMM+A#2TG1LM,D LX]A1$]!WW?;5NNBV;EW[5 *Q,V\XE(M?BI_X%Y?$8%M3
ME)08IJHJ=XYQNM,FM,RD(FG;2QTV3Y!1S S+[29%X\F0)W7&3C7K17W:"V\!
MC[*=]VA%CXV2%G"ZG%0D\^L+6V(YK"9L=J+?PIU-86>Q]2=A8!;VQT\YPIK,
MP6T&\K_,KIADL%$@<93ML#)JB-X[]U@HR>M-F\]O%#5:/"0T@RX.M[!E54^Q
MB8NHV9,DYKL;LY1P93(S-XJPW\J5MN#'NX;GTTSA",TA0EC $")GR5 \P6F2
MK*RA,<"5TG-<;KB+X.0E%*3S#(7&XH>MJ\]3C=:6-B2X&(7T_L%3;2+@"X07
MU_E)D+U/R&V9-3F3'<B4!E(6!3[<N*V5V_K-QFV]U%2!;EN-I( %PRQCXYE4
M.IH-J#^,#L#Q6W!.&J;;6W.K=LKZSK^^-OD8SWAOH@1^\-WID$@A)]J: KND
M\CD"TH9K9;OIZ[$A4^J1$,(C5,F)7&.,+[R9T.*.P-BO6]MD3G5]*0X-*BY
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ME.#$#CA'C.94,D5&E.S2-I7(,>(D:(PQ N$F7SBJKM72<RYP'IIEXU%>U*A
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M36C@LR0@/C)%9M55QQ;Z@2D=CP+R88W<,%2.6R0N04X+#_Q%HI:23CVD:Q/
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M37D*S^'C;H)'7L3M=\+^B]W57@G[>SAVM\*=T[KJJ)O"SZ)<EY)%%!L;8PV
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M/&H8S[8U?*!1KA]-#8VCNYTRVQECP2)S4M$-7Z46NY3&&$M!/I(VEY-+(14
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MO?X?PVQ\!_^Y+F?3__?_ 5!+ P04    "  */F519?-I#Y@(   ;+P  &P
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M.R';V?=_Q]\PY5NSV6I7U\;]!?;3_P)02P,$%     @ "CYE4?HDL2B2"
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M"^AP9P ]9^JK,4]+1V<4;A''=+@S1J#,!I4(W;$%,?O'S9+101<-0:K&"]-
ME?;QL;=)'7Q>6Y#JCK^]<V+!3,^[U2C\', >ASP:X#6B+]H9],WIU$=W'26T
MGZ]$GRM9 >$3Z).2O@K#4A,*EC+L@_XR92S>T#DD>C$ANJ@.C-C^6N48$ :9
MK=2KS,0>2[B#!SJ3R,NY+0?>DH2;N00A&G20%Y'+#\[[BKNG+)5W(JU.(5;J
MUW_#A#PWP'=JVS9X\=LV=W(9S59%?<%31)O+*%U0%J'M"4)D3>+"* Z!:Y4V
M\ZSO7J"S+)/6"K$Q$00*BH)*(@F;7/-]H!B\:XC7\9\$]FRYB5]+"9/= BMS
M]_N!.7C%.[(W>YW#]NGZY_L4T@E2SOU2!\-HFQM*@3!5B7.^09D(?D>9T$LI
MEPN="'1GF+.#G2<%O]I+^*.!#43#(S0T8LXS&X!2B4941LRA[>H^$1MD85-F
MB \FR;E1\?C&PZ]7G62#QT./G!9K+*TZ B$<#R"4[A"XBGG=)PF9CU4Z%I0I
M<CZJSK)U11TB*U(U%2B=),KS!7^ *"#@-R;-YJ-Q6?G)'T+?'3H._09Z+-8N
M <P:5I%L+YKP !OITJXW^<:] ?^9Z%G/!6:H$0#/=PT>P\$A3R=\:FJ_YW6%
M%7!N^F73N@W9?#8T=G$-0#+EA1'#V9=3,'^1\NE0Y@Y8KM'IF)(%I$;5)4:I
MC#\Y:1ZUC\A^"Z-M-.N^<JWI7&O9:+ULT.RV^X^6MIN=1\N^UFL/#7N/-]W%
M;K>;A):;7S_'B)4I>/ZNUJLM(.C(:-@M[EGG8?R)GU8#Z(%3^PJFNDL,Y^Z_
M#+O-[F[<BW'KY1)\M2%WS^;Q&:?H1WCW$;R8!:#&0=U=KIH[^?SN;84 E^,J
M &Q"Q0^9)N]B1"+ Y?2A.YBB6K7S-WO]HU/C/M=N13P9,6V:T"<NQ =MGJWJ
M_T]P:^=_A.U%ANWJ7H0E"3'V3VPJV8W&CH$4<;VZ NBU^44B1;Q^*?"/&+^(
M&.]_Y5[GP3/$L.54YX[KWN-![WMT[\EQ\Z3]>/$&S;>R\^FYR=H\I95W"R0Q
M]U,AVSMT?Z??,>4[L]]J^5OC[O[Z^7\!4$L#!!0    (  H^95'?XNV4(04
M /(:   :    <F5G;BUE>#,R># Y,S R,#(P>#$P<2YH=&WM66USVC@0_GZ_
M0B5S;3*#7X&0&,I,CZ1SG4G;-*'7N4\WPEYC36W)E40(]^MO)=M (4W3=J[M
MW< 'L*W=U>ZS;UH\?'3V>CSY\_*<9+K(R>7;WRY>C$G+\;QWG;'GG4W.R.^3
MEQ>DZ_H!F4C*%=-,<)I[WOFK%FEE6I>1YRT6"W?1<86<>9,KSXCJ>KD0"MQ$
M)ZW1T#S!;Z#)Z)?A(\<A9R*>%\ UB250#0F9*\9GY%T"ZCUQG)IJ+,JE9+-,
MD] /??).R/?LAE;KFND<1HV<H5?=#SV[R7 JDN5HF+ ;PI*G+=:/ITD8]&BO
MW^MU^_V AG$7H!>F<8HW0?!7@$IZ2%[Q*+W,X6FK8-S)P.P?=4.WWROU8,$2
MG46![__:LJ2C82JXQOTD\E>7E9A=853.4-Y4:"V*R,C2<*L=FK,9CZR1K4I8
MPQ"+7,CHP+>?@5EQ4EJP?!D]F; "%'D%"W(E"LJ?M!4ZQE$@65H1*O8WH):X
MB;U=U$:@G)QQ:(P*NETTX_PV8U.F22?\V((-W3<TC1%LD/^ZJOT[51V#U"QE
M,34Q2$1*+B7C,2MI3LYO(9YK=@/D=8H4( GER<;Z<\8I7N)5LWXYEVI.T0@M
M?GK#@Q/RUKUVQRZYAM@:'W1Z?ONGU_N9(L\249H$_R_!W8!\ZA^;*-,9D&LJ
MIY2#<E[?YK DSV)M5D+?__*LN:-:W%LGZB=:E.;V!U6)%YS$@O,:F 73F87E
MS9Q*M"Q?DBLHA;2@7,$,.$@DN\RH+&@,F)@QS56;O."Q2PX-X^.#3G<P%D5)
M^=)>'Q%D>"YD00+?>4-2(>T&'U8;E*BX2 CP!*/I&C"HBBG(QP?!L3_H^.VJ
M15!%4I8CP4I#].5<8M-"*$Q%.+^-,\IG@+VE*)A2MI!P2YE@(R(92$ ;UCI6
M=E4JMLD%8/.3N#]F8ISEP%*0;?+2/7/;:*W]017N*TMU/-6FMZU25P(MT>3<
M)1=X*Y=;0G9KU[80H'%F59\N25P524"XRW7.D4^4$+,3K5-TD_R+4J!M. S)
M%)1]F#%%WG.Q0$_, %<SB@CV3@9?'?6#DB8)GA"<'%(==8Z;]LDP&KB.G.#D
MAV7&87#4F/7]M_\8EV.WTS4X3- 5=3ZF\QQS)\9 R4T*K-)"PH<YDV#.3LIX
M;!T4AQ1349*@=Y@<K5R_3J)5 M7^#TX[7?3MZ<!&\O_2P>%/Z6#&L486U5$(
M2[.FR)G@4^NPQON4V=(I01E'M\TRS7.";*@,%A1<*-'SJFVYTE6A08&)/>E;
MKR+5/*_B1& 9MGNJK2+D/M3W0?BIGO;-C5'3:0X-_53(!*2#;LIIJ2!J+@8)
M4V5.EQ'C%FS+-+@Q51.;5-VP469]UN^$;L<_-<=]C<KII!%?3P*NG00\G>RN
MG9ZXI_ZGEWTW6*UY5G8E'_54".C35J?5,-0Q$(7E+0D^GAQ,6&PK7T'4N@>]
M<#OA0C?<3$([C]0/OW_6(6B5B0G$HHJV:(YU0!JJUNCQ0;<_4/;[SGZ\-8CM
M\;T#W];HLR>9/8P/@?$2:R,S+<H6RG'&(-T]].VA? B4A_<<FX^^&4)B?FNC
M'XKFCT#AE;BQ@PWI52/-RO -DQN=&L:Z^]T+@V] V/>;;^PWVY/:/K,?$M-[
MU+X&M741_ -+(%EUFG;]AP!LM)R=OPCV$']AR]E!<-]RUB9[=DC:&,H>,K!M
MO3HI1?7N*)*04Q/6.R]3UI.;C1]_S4*G2N1SO<ORF?<O]7?U-LB^EQK] U!+
M 0(4 Q0    (  H^95&F @.#.Y,# /#2*0 1              "  0    !R
M96=N+3(P,C P.3,P+FAT;5!+ 0(4 Q0    (  H^95&X+](\H1(  %_%   1
M              "  6J3 P!R96=N+3(P,C P.3,P+GAS9%!+ 0(4 Q0    (
M  H^95%?45))HAT  )$W 0 5              "  3JF P!R96=N+3(P,C P
M.3,P7V-A;"YX;6Q02P$"% ,4    "  */F51;<ZF,3M[  !#704 %0
M        @ $/Q , <F5G;BTR,#(P,#DS,%]D968N>&UL4$L! A0#%     @
M"CYE49&+\M1EQ   F^X' !4              ( !?3\$ ')E9VXM,C R,# Y
M,S!?;&%B+GAM;%!+ 0(4 Q0    (  H^95%3YIW:9HT  -]L!@ 5
M      "  14$!0!R96=N+3(P,C P.3,P7W!R92YX;6Q02P$"% ,4    "  *
M/F51WG"%.-W[   ,70< &P              @ &ND04 <F5G;BUE>#$P,7@P
M.3,P,C R,'@Q,'$N:'1M4$L! A0#%     @ "CYE4;W21=R^<@  MZH# !L
M             ( !Q(T& ')E9VXM97@Q,#)X,#DS,#(P,C!X,3!Q+FAT;5!+
M 0(4 Q0    (  H^95%H3#7=)$D! #$(#0 ;              "  ;L !P!R
M96=N+65X,3 S># Y,S R,#(P>#$P<2YH=&U02P$"% ,4    "  */F519?-I
M#Y@(   ;+P  &P              @ $82@@ <F5G;BUE>#,Q,7@P.3,P,C R
M,'@Q,'$N:'1M4$L! A0#%     @ "CYE4?HDL2B2"   &B\  !L
M     ( !Z5(( ')E9VXM97@S,3)X,#DS,#(P,C!X,3!Q+FAT;5!+ 0(4 Q0
M   (  H^95'?XNV4(04  /(:   :              "  ;1;" !R96=N+65X
I,S)X,#DS,#(P,C!X,3!Q+FAT;5!+!08     #  , #\#   -80@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
